<SEC-DOCUMENT>0001558370-23-004401.txt : 20230323
<SEC-HEADER>0001558370-23-004401.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323074808
ACCESSION NUMBER:		0001558370-23-004401
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40886
		FILM NUMBER:		23754493

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cgtx-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/22/2023 5:54:08 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: acb56c24-fadc-457c-b9de-3fe88b8667ac -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cgtx="http://www.cogrx.com/20221231"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" xs:nil="true" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_JrDevPImqEyKBMb6BdEzvg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" xs:nil="true" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_7BjTKF9n-EG_gf6RvGM8aA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityCentralIndexKey" id="Tc_0d2CGQKJrkiYj5T9E74Uxw_2_1">0001455365</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentFiscalYearFocus" id="Tc_TiEClwaiqECyC-pFc-FDtw_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentFiscalPeriodFocus" id="Tc_PcxGfAKvf0SNUwtCpOCDEw_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:AmendmentFlag" id="Tc_0KWXnOMw10CM2diY9L7m9Q_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_Oi4h6fGa2US3JbBF6tZnLQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_Q5OFgkJEGUOCsvg-cFO3Fg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_MxgYh04ftUq-sNwdNmvJAg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_O5E8uWbUck6gpmHBRiqGIQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" xs:nil="true" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" name="us-gaap:PreferredStockValue" id="Hidden_ovgd2fX3ZEaWm0wcmsqVsg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" xs:nil="true" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" name="us-gaap:PreferredStockValue" id="Hidden_5TBw3xjUxk-WxRkuRpVO-Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden__HQWsjBkFkmBXhs8jgM5nA">22230032</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_4NRuDtMjt0WCqOwgWiie7w">28991548</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_7_1_2021_To_7_31_2021_NSbC4L6Dt0mqcQAgorA4fg" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_nQx1SsH8n0-iTW-hmt6Uqw">0.3092</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_zrVKOEsWWUen0jAD0vBoIA">22230032</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Y0sKS617cUG-4b1iHZkpJw">28991548</ix:nonFraction><ix:nonNumeric contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg" name="cgtx:PurchaseAgreementTerm" id="Hidden_EOZZ9ib9PU6NThp6PBR4OA">P36M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cgtx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k0Fx52yg8EmU-X-cmYFt2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_enLCj8Q1xEml8KVpBZ04bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesaConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TaoGs-evLUaQbSnfNKRUJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_uKNBRS7LKkeAraJh_fQoTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YhglPqSICEOHSV_IdZw7eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_1ng_kk66vUmNmQ2gIQxa1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0haQ0rDcjEC7Lpsh3ZXY1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_66gOUrgOGkmMATI_UYMUcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-15</xbrli:startDate><xbrli:endDate>2022-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_7_2021_To_10_7_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_J1qjrKQ97UC4V1Qbkn0BVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfSimpleAgreementsForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-07</xbrli:startDate><xbrli:endDate>2021-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_NSbC4L6Dt0mqcQAgorA4fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wzhq5N306Uqh98sS1Rmuwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ALOa0B34YEu4wK2K83rlug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ob1HFOSlEUyTfi6gKd0HIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmHMF32sz0KA3893X1KYUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EjDdvR-xQEuO4zQmEOjdDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DVOWTmYar0GNsT5vClx9zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p9uGeWcXbEizrgTa2nWZiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OJPY2v-8HEm6XwyhP4ZZqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_G6KN4NQzqUuxhlJs_8voKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SFKIrluacUKxgPM0Dk_COA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFWuF54H3UCI_hJ6ZrtvQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_XYAfduBLiEyYZK5YwTJYpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_Mm4HIB07WkaEjnsTACDzAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Osz1MgsDcEWWlW4jGAr1bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DVoBTPqoMkip6hYlwzicaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_1pumPUEKZU2T8noHh3EBSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_NPy6437bOUm5rmu1Uvq-zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_LRRxx2Dlh0uhljHR9SnyHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_yahv0OkpPEaYE1i-7KtT_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_7A9Z0eNU2kGCYq5FHtJgjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6lpHwpsw-EWJo0Zgq6rNcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_oXjUmgTrE0eWw47O5kihsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_kLTU2zUbVEic1iFZs3Jr4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MFx5PzsB3EiVmUbOAvS2KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_J2XBpl_S60WJ_31CJUKMPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-GYnhwP-wE6fE3kPKJhleg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_zSXdcVC8VE-7xnTJfzdRMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_NdALTKUy0kmXAWKzuRjFpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_aO4rFi4jSEyn8DSa70-4Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rCOlfsot3EiDxI_jxFLXiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rdiZqGOI80qH1SRFtNcStA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_0h3qCBEleU-V3fVtO2hK3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_OuQa9AV1Z0aOm013SYiWPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4BX_LYCjYEOG2mey0sSEjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_Z7obri4_Hk2MEqxX8hrVuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_cFNoQhYPU0-zSAcDylTH8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_FHzzyuPXwUKyBLXHpnwHPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_AE0FpwKs-EOageu6dOfl8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f9FhQl3y6EiSdHDswe6MEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_YEX4tFts9UqlH27hYh2GNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_5Llp0meHlE2FcF9C5kq5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_uHgL9nAXWUGXP88TL0_l4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_XP8oKPKT_Ei7TjXFOpwjtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfSimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_-IP8DBZpCUSLq5j3zp66OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkBqUzrULkqvOk4_Dzd2oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_N1dAezJ1BEmEY5K2pYrnWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_sct--jfhGkOI2iY08mN67g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_n6-tqTA3EkmAO2tyD5S7NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_Sm3lzM60aUOPdd-qCWli3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_2SLhlXLD40WSZNvO2Kvf4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_XL_cLPnem0WdnDFZvFsDSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oSyBIfvMNk2jXeReNnXygw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hNnv6GZ7IUi4mGR9CBNWEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_t-1Qw68sI0aC5oM3AVvG-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_Ht59q_5JiEiVhpo-kC0tEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_RcqZUt4qD0CDmwKu-H5W3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_JWuAV66_FkKYy9ml74D0OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_nwX8yS5_AE26RPa_9Fo2wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_b88oSDVpj0-qGHOfTzZbKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_96iu6bqRR02okgqdFfwfwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_x9O6RRV7-EqAHJFc8zyb0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_BBPnWdc1jEC6JJ6WU38FKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_aYLK7DBMgEenBoD_1pqp7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnder2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_JbPg3qBfrkinytQJRc8rBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_Vt-R9TT6a0-mHF1vBUv27Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_GOEFjr5HT0K3IfUrhIxbaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnder2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aM0FMO2TMEaf1Fu_f9Yn8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2QI15J_3YUCTGyt7KkvUew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_At8s-OhSw0yRFbaWfIbeww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sWlYGe9ixUe9X9WZ9DcihQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_Kc3nx2ZzNkm9H6jyKJJoMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2023_V_7yKkzdtEiNANBLG-zv0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_T1dodM-JUE2PyHPTE4fWQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_raLm_xXRuUiTAX_TParm5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_Ew7Kbm3OAEy6EtEDlHqmug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfEquityFinancingOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_vyxTfLKJxUW9zuhqZTsSFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfDissolutionEventOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_1ncZ0wDVjUaMv3n8bW5Qww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponImpliedReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_MxmsAkGlGk6Tkcg1-sC0nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponConversionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TIObl80f7UWIvJjeNn-tkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_HuWBldoXiEChJl-DHcYigA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_iqb3nfvhzUGG9vyRKPjbLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_O1QXNgSInE2t6P_Ih0REuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfEquityFinancingOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_QoK-U_gP1Ua8QKYjkoygBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfDissolutionEventOccurrenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_h4s2HAgDWEyJ3_wpwJxxJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponImpliedReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_ngpHUyNFakCau2ySwCxAGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponConversionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2021_To_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember__NxCd_fmOkGpRip87LsWsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-15</xbrli:startDate><xbrli:endDate>2022-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-10</xbrli:startDate><xbrli:endDate>2021-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_QGjdHn6BlEOiqD30uxaG1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_aWodb89n40ua9F3TL8eTqQ"><xbrli:measure>cgtx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_KVexRmvX6US-liK6aNll8Q"><xbrli:measure>cgtx:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_0QdZH6dU9kC3NWhic3Tuew"><xbrli:measure>cgtx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:0pt;padding-top:1pt;text-align:center;text-indent:0pt;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_292ff956_8645_4e15_aa66_ea5db447277a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentType" id="Narr_kZH7V6z-AUiVFin3qas7hw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentAnnualReport" id="Narr_kXcCUEdUZE-gUyAMJN9-ew"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">For the fiscal&#160;year ended</span><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentPeriodEndDate" id="Narr_i0OgEx1LKU6ohATcVBzkMw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:CurrentFiscalYearEndDate" id="Narr_8voNyipXc02b7m6TiiYaWw"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:DocumentTransitionReport" id="Narr_Hhm4EBAmHUKyIU3vkwYGWQ"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For The Transition Period From&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityFileNumber" id="Narr_t79Mcio5gUO73pEIa1XfwQ"><b style="font-size:8pt;font-weight:bold;">001-40886</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityRegistrantName" id="Narr_nbZIah3rqES1T1KVeYBRqw"><b style="font-weight:bold;">COGNITION THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_0bd4c4e5_d908_49c7_81ef_291d7e378540"></a><a id="Tc_ICamoSU7qEe_Gwlz0Ln_jw_2_0"></a><a id="Tc_wzg2XmuYnES4z14Ple3V7w_2_1"></a><a id="Tc_wLS8pK3LpUytFr60d7PNqQ_5_0"></a><a id="Tc_1c6YPE_18km0VzvcyewoQA_6_0"></a><a id="Tc_Fmmg2ukTKkqp-Rmg_tHEig_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityIncorporationStateCountryCode" id="Tc_vvBw0A8aXUeZZiPc_okyNg_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityTaxIdentificationNumber" id="Tc_fDt4tWkcS0i1Estzb70MUQ_1_1"><b style="font-size:8pt;font-weight:bold;">13-4365359</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityAddressAddressLine1" id="Tc_jbY8gwHwtk-DEf8Ujr6n8w_4_0"><b style="font-size:8pt;font-weight:bold;">2500 Westchester Ave.</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityAddressCityOrTown" id="Narr_C-NQYGx5VUiSPyGEuipQ9A"><b style="font-size:8pt;font-weight:bold;">Purchase</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityAddressStateOrProvince" id="Narr_z7FsRDtq5E6MgDclOPjoUw"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityAddressPostalZipCode" id="Tc_zW6s0TS1QkqB7ixjDB6XZg_5_1"><b style="font-size:8pt;font-weight:bold;">10577</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code:</span><b style="font-size:8pt;font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:CityAreaCode" id="Narr_5gfjXDxi70eGJNaslLbg5Q"><b style="font-size:8pt;font-weight:bold;">412</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:LocalPhoneNumber" id="Narr_uc1Pva8_DECgOmjPme7jjg"><b style="font-size:8pt;font-weight:bold;">481-2210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_6a81bc1b_1939_4c30_9a32_7126c7b10385"></a><a id="Tc_brPb3X7ezk6uAlyetF3uAQ_1_4"></a><a id="Tc_XIwThy7jvU-PCq8OOQiFyQ_2_0"></a><a id="Tc_NF5GkMtmuEW2jABc12lWSQ_2_2"></a><a id="Tc_upgZ4DAsfkOcKHGeYJrxcw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:Security12bTitle" id="Tc_XYhic_2JLkymqjvtgHHvRw_3_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, par value $0.001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:TradingSymbol" id="Tc_kAej8D8wHU-EyBp3WtFMVw_3_2"><b style="font-size:8pt;font-weight:bold;">CGTX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:SecurityExchangeName" id="Tc_ISLYiNnZekKbMo0t60g3Dw_3_4"><b style="font-size:8pt;font-weight:bold;">The Nasdaq Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;<span style="white-space:pre-wrap;">of the Act:  </span><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_7R7n9awTXkSdXV9P-ONPGw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityVoluntaryFilers" id="Narr_NK-Owouxkku7EFJFIeqkuw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityCurrentReportingStatus" id="Narr_fpN1snkbYkm65f6GxAjPpw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityInteractiveDataCurrent" id="Narr_YNHad5w3XUe-_uxAlM17Nw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityFilerCategory" id="Narr_4R7-XV40UEqXNO-5mNbKpQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntitySmallBusiness" id="Narr_dGHPzo6jc02hipfcOwPfiw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityEmergingGrowthCompany" id="Narr_ojUJb2s33kCiHtg5Z-cTEg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityExTransitionPeriod" id="Narr_NhHTyZOieE2U_rx6jr1_KA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C.&#160;7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#39;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:EntityShellCompany" id="Narr_T1-52oTVhUixWO-oSwg4HQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The aggregate market value of the Registrant&#8217;s Common Stock held by non-affiliates, as of June 30, 2022, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_Kc3nx2ZzNkm9H6jyKJJoMg" decimals="0" name="dei:EntityPublicFloat" id="Narr_HEo4hbyPzUGVDoBkdBCSyw">38,225,874</ix:nonFraction>. Shares of Common Stock held by each executive officer and director and by each stockholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of March 20, 2023, was <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_20_2023_V_7yKkzdtEiNANBLG-zv0g" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_d5zj_4PfW0ah7HWFZWZH-g">29,262,587</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5dce0578_0c4a_4bcf_80c3_5e7777be47c2"></a><a id="Tc_OpnHIuhCFUKrpN7jR9UDlQ_1_0"></a><a id="Tc_1QWhlE_aRkGkTKiEuvDS6g_1_2"></a><a id="Tc_7dE9J1nu902WhbraEHPU6Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Firm ID:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:AuditorFirmId" id="Tc_nsphUVVh_kiha_LdH0FrQA_1_1"><span style="font-size:8pt;">42</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Name:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:AuditorName" id="Tc_DK0NNcjHs0m3yXHfzCJsjA_1_3"><span style="font-size:8pt;">Ernst &amp; Young LLP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Location:</p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="dei:AuditorLocation" id="Tc_3aK-jaG-bUq32lkWwrNdCg_1_5"><span style="font-size:8pt;">Philadelphia, PA</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd890168_2553_4957_931c_45dc67909ad7"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTI_883693"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1Business_571021"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1ARiskFactors_361684"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">49</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1BUnresolvedStaffComments_685711"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item2Properties_347022"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item3LegalProceedings_272268"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item4MineSafetyDisclosures_494562"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTII_331600"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item6SelectedFinancialData_500456"><span style="font-style:normal;font-weight:normal;">Item&#160;6. [Reserved]</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">105</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">117</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">117</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9AControlsandProcedures_434960"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9BOtherInformation_878908"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9CDisclosureRegardingForeign"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTIII_479695"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item11ExecutiveCompensation_635596"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PartIV_346291"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">143</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item16Form10KSummary_806161"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">146</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d94eedff_1fea_4a4d_8360_b9e6dedb457a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or Annual Report, contains forward-looking statements concerning our business, operations and financial performance, as well as our plans, objectives and expectations for our business operations and financial performance and condition. All statements other than statements of historical or current facts included in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements including &#8220;we believe&#8221; or similar phrases reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements. These risks and uncertainties include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical nature of our business and our ability to successfully advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which health epidemics and other outbreaks of communicable diseases, including the COVID-19 pandemic, geopolitical turmoil, including the ongoing conflict between Ukraine and Russia or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our dependence on the success of CT1812, our lead product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the novelty of our approach to targeting the S2R complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competing therapies that are or become available; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential scope and value of our intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic uncertainty resulting from actual or perceived inflation or banking stability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risk and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221; in this Annual Report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#8220;Risk Factors&#8221; set forth in Part I, Item 1A of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2e0abf97_19dc_4272_839a_e09b54a3a704"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SUMMARY OF RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects, and/or cause the price of our common stock to decline. These are not all the risks we face, and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Additional detail about these risks is included in Part I, Item 1A &#8220;Risk Factors.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:9.5pt;">Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs; Discovery, Development and Regulatory Approval of Our Product Candidates; and Business and Industry</span><span style="color:#ff0000;font-size:9.5pt;font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have not yet completed Phase&#160;2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">&#8203;&#160;</span><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third parties in the conduct of all our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and for which we receive approval and ultimately harm our financial condition.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales or affected products. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Our Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market price and trading volume of our common stock have been and may continue to be volatile, which could result in rapid and substantial losses for our stockholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Concentration of our capital stock ownership with our directors and their affiliated entities and our executive officers will limit stockholders&#8217; abilities to influence certain corporate matters.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d4c89985_b651_43a4_87b5_af94a4d4bc41"></a><a id="PARTI_883693"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_571021"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma 2 receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. We have initially focused on the development of CT1812 for the treatment of Alzheimer&#8217;s disease, or AD, by targeting &#946;-amyloid, or A&#946;, oligomers, which has been linked to the disease. We believe our evidence demonstrates that by binding to the S2R complex, CT1812 displaces A&#946; oligomers from their neuronal receptors. Based on this mechanism, we believe CT1812 has the potential to slow the loss of synapses and cognitive decline observed in AD. CT1812 is the first S2R selective ligand modulator to reach clinical trials and is currently in Phase 2 development for the treatment of AD. The direct healthcare costs to care for patients with AD and other dementias in the U.S. is estimated as of April 18, 2022 to exceed $300 billion. Approximately 6.5 million people in the U.S. have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35 million people globally. Among people with AD, approximately 50% have mild disease, 30% have moderate disease and 20% have severe disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are continuing to enroll patients in two ongoing Phase 2 clinical trials with CT1812: COG0201 (SHINE) and COG1201 (SHIMMER) in dementia with Lewy bodies, or DLB. Preliminary results from an interim analysis of the first 24 patients in Part A of our SHINE Phase 2 clinical trial demonstrated a statistically significant decline in the presence of A&#946; monomers and a positive trend on cognitive function as measured by the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate completing enrollment in 2023 with top-line data expected in 2024. We have treated over 220 subjects with CT1812 in our clinical trials to date including over 90 patients with mild-to-moderate AD. CT1812 has continued to be well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, in this indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health. Our awards include a grant award of approximately $81.0 million from the NIA to fund our Phase 2 START (COG0203) study of CT1812 in patients with early stage AD. We intend to enroll 540 patients in our START trial with mild cognitive impairment, or MCI, due to AD or mild AD who have elevated levels of A&#946; oligomers as determined by a clinical diagnosis of AD confirmed with amyloid biomarkers positron emission tomography, or PET, imaging and/or cerebrospinal fluid, or CSF, biomarkers. Patients will be randomized to receive CT1812 or a placebo for 18 months. In addition to cognitive and functional measures, such as the Clinical Dementia Rating Scale, or CDR, Sum of Boxes, or SB, and ADAS-Cog, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We are conducting this clinical trial in collaboration with the Alzheimer&#8217;s Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias, and we expect to open sites during the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We intend to expand our CT1812 pipeline to include additional indications such as geographic atrophy, or GA, secondary to dry age-related macular degeneration, or dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing distortion, loss of central vision and eventual blindness, for which there are currently no FDA approved treatments. The S2R complex is expressed in the retina in several cell types including the retinal pigment epithelial cells, or RPE, photoreceptors and retinal ganglion cells. We </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an Investigational New Drug, or IND, application to the FDA at the end of 2022; the IND was cleared at the end of January 2023. Our first trial in dAMD is a Phase 2 trial called MAGNIFY and we plan initiate this in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, we are developing other product candidates in the area of synucleinopathies. Synucleinopathies are a group of degenerative diseases characterized by the abnormal accumulation of the &#945;-synuclein protein in neural cell bodies, including Parkinson&#8217;s disease, or PD, and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are developing a pipeline of innovative, small molecule product candidates that are designed to target the S2R complex, a key regulator of the cellular damage response for diseases such as AD, dry AMD, geographic atrophy (an advanced form of dry AMD), or GA, and other conditions for which there is significant unmet medical need. Our current pipeline is summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:198.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:480.83pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mild-to-Moderate AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are currently engaged in two ongoing Phase 2 clinical trials, designed to evaluate safety, dosing and potential efficacy for CT1812 as a treatment for mild-to-moderate AD. These trials include evaluations of CT1812&#8217;s ability to engage with the S2R complex enabling the restoration of synaptic function as measured by quantitative EEG, or qEEG. In the largest of these trials, our COG0201 SHINE study, we are assessing CT1812&#8217;s ability to alter disease progression and cognition, with a target enrollment of 144 participants. We are currently recruiting patients at sites in the United States and Europe, with additional sites expected to activate in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Early-stage AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We plan to evaluate CT1812 in a 540-patient Phase 2 COG0203 START clinical trial to investigate the potential for CT1812&#8217;s use at an earlier stage of AD. In addition to cognitive and functional measures, such as CDR-SB (Clinical Dementia Rating Sum of Boxes), ADAS-Cog and volumetric magnetic resonance imaging, or vMRI, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We expect to open sites in the first half of 2023. This trial has been funded by a grant of approximately $81.0 million from the NIA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">DLB</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are evaluating CT1812 in a 120-patient Phase 2 COG1201 SHIMMER clinical trial to investigate the potential for CT1812&#8217;s use as a disease-modifying agent in DLB. We are assessing cognitive and functional measures such as Montreal Cognitive Assessment (MoCA), Cognitive Drug Research Battery (CDR), Clinician Assessment of Fluctuation (CAF), Epworth Sleepiness Scale (ESS), Unified Parkinson&#8217;s Disease Rating Scale &#8212; Part III (MDS-UPDRS3), Clinical Global Impression of Change (ADCS-CGIC), ADCS-Activities of Daily Living (ADCS-ADL) and Neuropsychiatric Inventory (NPI). We are currently recruiting patients in the United States. The trial has been funded by a grant of approximately $30.0 million from the NIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Geographic Atrophy Secondary to Dry AMD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are also evaluating the use of CT1812 to treat GA secondary to dry AMD. We believe that human genetic and proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. We are currently engaged in preclinical development activities for this indication, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an Investigational New Drug, or IND, application to the FDA at the end of 2022; the IND was cleared at the end of January 2023. Our first trial in dAMD is a Phase 2 trial called MAGNIFY and we plan initiate this in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Discovery Initiatives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are pursuing a number of early-stage discovery programs which are built upon our identification of five structurally distinct chemical series. We believe we have identified several structurally distinct compounds that possess advantages for specific disease indications and patient populations. A few of these next- generation S2R modulators have been identified for synucleinopathies and dry AMD and are being assessed as potential IND candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For example, one of our next-generation S2R modulators has shown activity in cell-based dry AMD assays, suggesting the potential to maintain homeostatic functions of RPEs, ameliorate lysosomal dysfunction, and prevent RPE cell death. It has further demonstrated retinal exposures above 80% receptor occupancy with oral administration and favorable PK properties, including high degree of bioavailability and high retina-to-plasma ratio, which we believe may provide us with a suitable next-generation molecule to advance for this indication. Therefore, we believe S2R modulators may present a novel therapeutic approach for these indications and intend to pursue development as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our objectives are to develop and advance our portfolio, beginning with our lead product candidate, CT1812, through clinical development for the treatment of age-related degenerative diseases and disorders of the CNS and retina and to leverage our understanding of the S2R complex and its regulation of pathways to pursue indications in other degenerative disorders. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance clinical development of our lead product candidate, CT1812, in mild-to-moderate AD and earlier stages of the disease</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Our lead product candidate, CT1812, has progressed through Phase 1 and into Phase 2 clinical trials. Funding of the Phase 1 and Phase 2 trials has come primarily from the NIA. We are evaluating CT1812 in earlier symptomatic stages of AD and MCI, which is a slight and noticeable measurable decline in cognitive abilities due to AD. Our START (COG0203) clinical trial in patients with mild dementia associated with early stage AD has been funded by a grant of approximately $81.0 million awarded from the NIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Pursue the development of CT1812 for GA secondary to dry AMD</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;We plan to evaluate CT1812 as a potential therapy for GA secondary to dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in indication and it was cleared by the FDA at the end of January 2023. We plan to initiate this Phase 2 clinical trial in 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leverage our understanding of the S2R complex to develop product candidates for other CNS and degenerative diseases, including synucleinopathies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to develop and advance other product candidates to treat other conditions, potentially including the synucleinopathies, which include PD and DLB. We are evaluating CT1812 in a 120-patient Phase 2 COG1201 study of CT1812 in patients with DLB, which is funded primarily through the NIA and are currently recruiting patients. Preclinical data published in February 2021 showed that the S2R complex may play an integral role in the pathology of PD and we believe these results merit further study.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our pipeline through internal development, in-licensing and acquisitions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;We intend to leverage our expertise in drug development and business development to evaluate additional product candidates as well as bring forward novel chemical matter using libraries generated with our Novel Improved Conditioned Extraction, or NICE, screening platform as well as other molecule generation and screening strategies. To achieve this objective, we may supplement our internal development initiatives through selective in-licensing arrangements, as well as investments in strategic collaborations, and partnerships which complement our initiatives.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Optimize the value of CT1812 and other product candidates in major markets. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We currently retain all worldwide rights to CT1812 for all indications. We plan to develop and pursue approval of CT1812 and other future product candidates in major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs. We and our key opinion leaders believe CT1812 also can be used in combination with other therapeutics targeting AD biologies and thus may have many partnering opportunities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to pursue non-dilutive funding opportunities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The majority of our research and clinical efforts have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA. This includes awards totaling $10.9 million in support of preclinical studies and $160.1 million for clinical development, the largest of which was the 2020 award of $81.0 million supporting our upcoming Phase 2 START (COG0203) study of CT1812 in early-stage AD. These grants are non-dilutive and allow us to collaborate with research institutions in pursuing the development of our product candidates for age-related degenerative diseases. We intend to continue our work with these research institutions and plan to seek additional non-dilutive funding for our clinical development when possible.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Team and Collaborators</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have assembled a management team with extensive experience with CNS and degenerative diseases, significant expertise in the S2R biology domain, as well as drug discovery, clinical development, general management and business development. Collectively, our management team has a track record of managing drug development programs that have received regulatory approval and been successfully commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, our management team has built companies that have initiated innovative technologies and investigational new drug programs. We augment the strengths of our management team with an experienced board of directors and scientific and medical advisory boards. We believe our team, with its deep scientific and drug development background, positions us to become a leader in the development of therapies for age-related degenerative diseases and disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date, we have received approximately $171.0 million in cumulative grants awarded primarily from the NIA to support our clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Approach to Treating Age-Related Degenerative Diseases of the CNS and Retina</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Age-related degenerative diseases are defined by an age-related decline of cellular function often resulting in cell death. Neurodegenerative diseases, perhaps the most prominent of these degenerative disorders, are a variety of conditions defined by progressive degeneration of nerve cells, or neurons, which often leads to neuronal death, causing decline in cognition or other functions, resulting in decreased quality of life and shorter life span. The two most common neurodegenerative diseases are AD and PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To our knowledge, no other biopharmaceutical company has focused solely on stopping the synaptic binding and signaling of soluble A&#946; oligomers through the use of small molecule receptor modulators, such as CT1812. We believe our deep expertise in oligomer and synaptic biology provides us with a competitive advantage and led to the creation of (1) proprietary assays that target the critical molecular step causing memory loss and (2) proprietary chemical libraries yielding highly brain penetrant small molecule drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Based on this expertise, we are able to discover and optimize small molecule receptor modulators like CT1812 that we believe represent a functionally distinct and promising approach to synaptorestorative AD therapeutics where neurons remain viable and functional. These molecules were designed to displace A&#946; oligomers bound to neuronal receptors at synapses and clearing A&#946; oligomers from the brain into the CSF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to neurodegenerative diseases, other degenerative diseases include AMD. AMD is a common eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. It is the leading cause of blindness in people over 60 years of age and afflicts approximately 11 million Americans, including an estimated 12% of all U.S. adults over 80 years of age. We believe that human genetic and proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. We are currently engaged in preclinical development activities for dry AMD, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in dry AMD. We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in indication and it was cleared by the FDA at the end of January 2023. We plan to initiate this Phase 2 clinical trial in 2023. Other S2R modulators are being explored, currently in lead identification studies, prior to lead optimization and candidate selection for IND-enabling studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Sigma-2 Receptor Complex</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The S2R complex is comprised of transmembrane protein 97, or TMEM97, a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1, or PGRMC1. The S2R complex is expressed in the CNS, the retina, as well as peripheral organs, including the pancreas, liver and kidney. Within the brain, the S2R complex is found in several areas, including the cerebellum, cortex, hippocampus and substantia nigra, and is enriched in neurons as compared to glial cells in the adult brain. In the retina, the S2R complex is expressed in several cell types including the RPE cells, photoreceptors and retinal ganglion cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The sigma-2 receptor (S2R) complex</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:241.5pt;width:271.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Internal and third-party studies suggest that the role of PGRMC1 and TMEM97, the protein components of the S2R complex, regulate cell damage response processes, including cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. In addition, the S2R complex regulates autophagy, the cellular process by which altered cellular proteins are degraded and removed. The aberrant activity of these processes, believed to be triggered by cellular stresses, is a hallmark of the dysfunction related to degenerative diseases. The S2R complex is a key regulator of processes that have been implicated in several age-related degenerative diseases and disorders including AD, retinal diseases, such as dry AMD, and synucleinopathies, such as PD and DLB. S2R affects diverse regulatory functions through specific interactions with the oligomer receptors and other membrane proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe the array of degenerative disorders which involve protein components of the S2R complex allows for the potential therapeutic use of proprietary S2R modulators in numerous indications. While a fuller understanding of the molecular mechanisms involving the S2R complex remains to be elucidated, evidence suggests that targeting the S2R complex may provide therapeutic benefit to a wide range of age- related degenerative diseases and disorders. We believe modulating the S2R complex to normalize cellular function may provide a restoration of normal cellular processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biomarker and Imaging-Driven Evidence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Biomarkers have become increasingly important in the development of treatments for neurodegenerative diseases for a number of reasons, including monitoring drug activity in patients, assessing changes in disease pathology during treatment and identifying responder populations for clinical studies. Given that biomarker-enabled therapeutics have a higher rate of success at gaining product approval, we elected to employ biomarkers in our programs to mitigate clinical development risk. To that end, in addition to a number of cognitive tests, our clinical trials use a variety of biomarkers to measure target and/or pathway engagement and assess changes in disease progression. For example, in AD, changes in cerebrospinal fluid, or CSF, concentrations of neurogranin and synaptotagmin-1 can be indicative of damage to synapses. In PD and other synucleinopathies, changes in markers such as &#945;-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain can indicate dysfunction in membrane trafficking and autophagy processes. Quantitative EEG and PET imaging agents as well as vMRI may have utility in several neurodegenerative disorders to measure synaptic function, synaptic density and brain atrophy, respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:213pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Novel, Improved Conditioned Extracts (NICE) Screening Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Chemical structures that we are currently evaluating as potential therapeutics for degenerative diseases originate from our NICE screening platform. The NICE screening platform allowed us to generate proprietary small molecule libraries derived from natural chemical scaffolds through a proprietary process which we refer to as conditioned extraction. Conditioned extraction, a process pioneered by a cofounder, allows us to eliminate undesirable properties of well characterized, biologically active compounds sourced from natural products, while retaining their biological activity. The resulting molecular configurations are then subjected to proprietary functional <i style="font-style:italic;">in vitro</i> screening assays designed to replicate the mature brain and its intricate connections and patterns of electrical signaling. Unlike most other screening assays, such as cells lines derived from immortalized neuronal tumor cells, our use of mature primary neuronal cultures provides us with information-rich measurements more indicative of normal brain function and predicative of functional benefit. We have utilized our NICE screening platform in conjunction with these mature primary neuronal cultures to develop product candidates for our proprietary Early Alzheimer&#8217;s Screening System, or EASSY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The candidate library produced by the NICE screening platform is predisposed to compounds with attractive drug-like properties such as low molecular weight, low number of reactive hydrogen bonds, lipophilicity and relatively neutral chemistry properties. These characteristics reduce the reactivity of the molecules and related toxicities, while also enhancing their ability to cross the blood-brain and blood-retina barriers. As a result, the NICE screening platform was designed to accelerate drug development time while reducing development risk. We believe this platform provides us with differentiated libraries which may lead to development candidates beyond CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our expertise in the biology of the S2R complex, synaptic function and plasticity, and our understanding of the role of toxic age-related soluble proteins, to construct a pipeline of innovative, differentiated small molecule product candidates that are intended to restore normal cellular damage responses. We intend to develop therapeutics with the potential to overcome diseases associated with age-related toxic protein buildups that disrupt key cellular processes. Our initial product candidates target diseases characterized by dysfunction or dysregulation of the S2R complex that leads to cellular degeneration, as observed in age-related degenerative diseases and disorders, such as AD, GA secondary to dry AMD, PD and DLB as depicted in the illustration below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:212.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:411.98pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Lead Product Candidate: CT1812</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the S2R complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. CT1812 originated from our initial efforts with our NICE screening platform which enables the generation of innovative leads. Leads identified through NICE were then evaluated using proprietary <i style="font-style:italic;">in vitro</i> assays designed to better emulate <i style="font-style:italic;">in vitro</i> synaptic activity. We believe the use of these assays allows us to identify functionally active structures which may impact neuronal behavior significantly faster than alternate screening approaches. We currently retain worldwide rights to CT1812 for all indications and are developing CT1812 as a potential treatment for a range of diseases including AD, GA secondary to dry AMD and synucleinopathies, such as DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CT1812 for the Treatment of Alzheimer&#8217;s Disease (AD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 was designed to selectively target and displace A&#946; oligomers bound to neuronal receptors at synapses by a new and differentiated mechanism of action. CT1812 binds to S2R which interacts directly with components of the oligomer receptor, resulting in displacement of bound oligomers, which are then cleared from synapses. In our preclinical studies, CT1812 has demonstrated the potential to protect synapses, facilitate their restoration and improve cognitive performance. These preclinical results are currently being evaluated through our ongoing Phase 2 clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of the Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">AD is a progressive neurodegenerative disorder characterized by cognitive dysfunction, memory loss, dementia and the impairment of daily living activities, along with numerous behavioral and neuropsychiatric symptoms. In the advanced stages of the disease, an AD patient is unable to recognize faces, use or understand language and displays a lack of awareness for their surroundings. Continued functional decline ultimately results in the patient&#8217;s death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Due to the size of the affected population and the current lack of effective disease modifying therapies, we believe that AD is one of the most significant unmet medical needs of our time. Nearly six million Americans have been diagnosed with AD and disease prevalence is expected to more than double by 2050. The direct healthcare costs to care for patients with AD and other dementias in the United States is currently estimated to exceed $300 billion and projected to increase to $1 trillion by 2050. Absent the development of meaningful intervention in the course of the disease, the number of people diagnosed with, and dying from, AD is anticipated to escalate appreciably as lifespans lengthen, since prevalence increases significantly with age. The Centers for Disease Control listed AD as the primary cause of death for more than 119,000 Americans in 2021. The disease is equally devastating worldwide, with the World Health Organization estimating that as of December 2022 AD affects as many as 35 million people globally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Currently Approved AD Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Only two disease-modifying therapeutic option has been approved by the FDA. Specifically, Biogen&#8217;s Aduhelm received accelerated approval on June 7, 2021 and the FDA granted accelerated approval to Eisai&#8217;s Leqembi in January 2023.  Aduhelm and Leqembi are monoclonal antibodies administered via infusion reported to reduce A&#946; plaques and protofibrils, approaches that are distinct from our small molecule approach to modulate the S2R, thereby blocking A&#946; oligomers from binding to synapses. The only other therapies approved for AD are indicated to treat the symptoms of AD: acetylcholinesterase inhibitors, or AChEIs, and glutamatergic modulators and an orexin receptor antagonist. AChEIs are designed to slow the degradation of the neurotransmitter acetylcholine, helping to preserve neuronal communication and function temporarily. Glutamatergic modulators are designed to block sustained, low-level activation of the N-methyl-D-aspartate, or NMDA, receptor without inhibiting the normal function of the receptor in memory and cognition. Namenda (memantine), an NMDA receptor antagonist was approved in the United States in 2003. These therapeutic products do not modify or alter the progression of the underlying disease and provide only modest efficacy in treating the symptoms.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Therapeutic Approaches in Development to Treat the Underlying Disease Have Shown Little Success</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Numerous therapeutic approaches have been evaluated to remedy the causes of AD. Those focused on reducing the aberrant production, or removal, of intraneuronal neurofibrillary tangles of tau protein have yielded limited clinical benefit. Development initiatives intended to inhibit hyperphosphorylation of the tau protein and related kinase activity, enhance microtubule stability or block tau aggregation have largely been discontinued due to toxicity or a lack of efficacy. Microglial activation and its role in AD-induced neuroinflammation has emerged as another potential target for therapeutic development as has the proper functioning of processes dictating synaptic plasticity, believed to be of central importance to neuronal activity and continued viability. These efforts have also not yielded meaningful clinical advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Among the more prevalent and targeted mechanisms implicated in AD, is the accumulation of A&#946; aggregates in the neuronal synapse where disease progression leads to synaptic dysfunction and dysregulation. The accompanying deterioration in neuronal activity ultimately results in neuronal death. As a result, the reduction in the levels of A&#946; aggregates at the synapse has been a prominent objective of a significant number of therapeutic candidates, including active and passive immunotherapies, designed specifically to target A&#946; aggregates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe a common issue with therapeutic interventions intended to limit A&#946; aggregate concentrations in the brain is that they fail to discriminate between different forms of A&#946; aggregates: fibrils, plaques and oligomers. Such efforts may demonstrate success clearing fibrils and the largely inert plaques but fail to address the specific neurotoxic effects of A&#946; oligomers. Conversely, as exemplified by Leqembi&#8217;s clinical results, we believe that preferentially targeting A&#946; protofibrils/oligomers has the potential to prevent synaptotoxicity. Our strategy of targeting the S2R to prevent A&#946; oligomer toxicity at the synapse is distinct from these immunotherapeutic approaches, but we believe may be complementary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Role of A&#946; Oligomers on Synapses and the Downstream Impact to Brain Function and AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synapses are specialized points of contact between neurons, where electrical signaling and communication takes place. It is well established that synapses are routinely sprouted and resorbed as part of the normal process of learning and memory. Each neuron is covered with an estimated 10,000 synapses and these synapses participate in a complex electrical circuit with other neurons. Neurons do not divide or reproduce as part of normal physiological function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Emerging scientific evidence suggests that A&#946; oligomers, formed over time through the buildup of A&#946; and its aggregates, bind to specific parts of the synaptic structure and interfere with the normal process of memory formation. This ligand-like activity confers to A&#946; oligomers potent synaptotoxic activity. In response, the neuron dismantles and resorbs the synaptic structure to prevent its abnormal function from interfering with what remains of the normal circuit behavior. If a large enough number of synapses are lost, the neuron dies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synaptic loss, however, is not necessarily permanent and synapses can be regained or sprout again once the oligomers are removed. We have observed this process in our research involving preclinical AD models. This observation leads us to believe that displacement of synaptotoxic A&#946; oligomers may enable synapses to recover and potentially slow cognitive decline. We are further encouraged by the numerous precedents which exist that demonstrate the therapeutic utility of blocking ligand-receptor interactions in the brain with small molecule drugs capable of crossing the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CT1812 Uses a Differentiated Mechanism of Action to Selectively Target A&#946; Oligomers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our proprietary CT1812 clinical candidate employs a novel and fundamentally different mechanism which through alteration of S2R activity selectively facilitates removal of neurotoxic A&#946; oligomers. Experimental evidence suggests that A&#946; oligomers likely occupy binding sites contiguous to the S2R complex. Binding at these locations is believed to produce structural distortions which inhibit the proper functioning of the S2R complex including its role in regulating critical signaling pathways. The preferential binding of CT1812 to the S2R complex produces changes that alters the binding affinity of A&#946; oligomers to their targets. CT1812 binding to the S2R complex likely modulates the conformation of the S2R complex, which in turn allosterically alters the conformation of the oligomer binding pocket on the oligomer </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receptors. Binding pocket destabilization leads to displacement of A&#946; oligomers from the neurons and neuronal synapse. Once displaced, A&#946; oligomers are unable to rebind as long as threshold concentrations of CT1812 are present and are rapidly removed from the synapse. Based on our preclinical studies, we believe that CT1812 not only prevents binding of A&#946; oligomers, displacing them from the S2R complex sites at neuronal synapses, but also slows A&#946; oligomer-induced loss of synapses and restores synaptic activity, which may reverse downstream alterations related to membrane trafficking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Use of an S2R Targeted Approach is Supported by the A673T Mutation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe the benefit of the mechanism by which CT1812 stops the toxic impact of A&#946; oligomers on cellular function is further supported by an analysis of the A&#946; sequence variant, A673T, which is commonly referred to as the &#8220;Icelandic&#8221; mutation. The A673T mutation is the first variant associated with a mutation in the protein structure of A&#946;, first identified through a genomic analysis of the Icelandic population. Importantly, carriers of the mutation are four-fold less likely to develop AD. The A673T mutation, which involves the substitution of the amino acid alanine for threonine at position 673 of the precursor molecule, not only produces fewer A&#946; monomers, but our research indicated that the toxic A&#946; oligomers generated have four-fold lower affinity for brain cell synapses. This reduced binding is evidenced in the results of <i style="font-style:italic;">in vitro</i> experiments, which are presented below. Whereas wildtype A&#946; oligomer binding is pronounced, the binding of the A673T variant is much lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Binding affinities of wildtype versus mutant A&#946; oligomers to synapses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(intensity in arbitrary fluorescent&#160;units)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Kd&#160;</span><b style="font-weight:bold;">(nM)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">B&#160;max</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">wt A&#946; (1&#8201;&#8211;&#8201;42) oligomers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Site 1:442 &#177; 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.98 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup> &#177; 0.29 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A673T mutant A&#946; (1&#8201;&#8211;&#8201;42) oligomers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Site 1:1,955 &#177; 502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.98 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup> &#177; 0.50 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Kd is a constant used to evaluate and rank the strengths of interactions for ligands and their receptors. The smaller the Kd value, the greater the binding affinity. Bmax refers to the maximum amount of a ligand that can bind specifically to a receptor. Intensity is measured in arbitrary fluorescent units.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:219.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:365.83pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that CT1812 is the only drug candidate currently in clinical trials that mimics the effects of the A673T mutation. As the images presented below suggest, both CT1812 and the A673T mutation similarly reduced the binding of toxic A&#946; oligomers to synapses. We believe that drug candidates like CT1812 that mimic the protective effects of the A673T mutation are more likely to succeed in the clinical setting in patients with mild-to-moderate AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:236.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:394.16pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CT1812 Clinical Results in AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have completed seven clinical trial evaluations of CT1812, in both healthy volunteers and patients with mild-to-moderate AD, with three clinical trials ongoing. The clinical trials we have conducted to date have enabled us to evaluate the safety profile of CT1812, as well as validate its mechanism through proof-of- concept trials and conduct initial assessments of its therapeutic potential. The following is the status of our completed and ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of our completed, ongoing and planned clinical studies of CT1812 for AD and dementia</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:218.09pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:408.92pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264.23pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COG0201&#8201;&#8212;&#8201;Phase&#160;2 (SHINE) Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our ongoing COG0201 SHINE study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to enroll up to a total of 144 patients with mild-to-moderate AD to evaluate the safety and potential efficacy of CT1812. Participants are divided in two CT1812 dose groups (100 mg or 300 mg) and one placebo group, dosed daily for six months. Endpoints include safety and biomarker evidence of disease modification as well as cognitive function, as measured by the ADAS-Cog 11-item version, or ADAS-Cog 11. ADAS-Cog 11 is a globally recognized cognitive scale that is used to assess cognition in patients with AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Preliminary data from an interim analysis of the first 24 patients from the COG0201 study demonstrated that CT1812 continued to be generally well tolerated. There were four serious adverse events, or SAEs, which were not drug-related and occurred in a single placebo patient. The patient was discontinued due to one of the SAEs. Treatment emergent adverse events, or TEAEs, were well balanced across all treatment groups. We observed mild and transient elevations of liver enzymes in three patients without any other indications of liver injury. These data were consistent with findings from earlier clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preliminary data also demonstrated a significant decline in the presence of A&#946; monomers and a three-point mean improvement in the rate of cognitive decline as measured by ADAS-Cog 11, in patients receiving CT1812 when compared to placebo. These results were observed in patients receiving CT1812 or placebo in addition to background therapies they may have already been receiving for AD. We believe these preliminary data provide promising evidence of CT1812&#8217;s potential cognitive and biological impact. These data also indicate that patients treated with CT1812 showed relative stability on a measure of cognitive performance compared to the placebo group. A mean difference in the rate of decline of approximately three points was observed between the CT1812 dose groups receiving either 100 mg or 300 mg versus the placebo group based on the ADAS-Cog 11 measurements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preliminary data showed a three-point improvement in cognitive decline in CT1812-treated patients.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:264.23pt;width:396.35pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Proteomic measurements were also performed of CSF and plasma from these patients, from which we have comprehensive datasets of whole proteome changes observed in AD patients given CT1812 versus placebo for six </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">months. From this, we identified product candidate pharmacodynamic biomarkers that could reflect processes of target engagement, pathway engagement and/or early disease modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The interim analysis of the SHINE trial (SHINE A) was not powered to detect statistically significant treatment differences. Nevertheless, p-values were calculated at the time of the interim analysis with respect to the clinical and biomarker outcomes to help inform on the potential importance of observed numerical treatment differences. For these interim analyses, p-values&lt;0.05 were considered &#8220;significant&#8221; while p values&gt;0.05 were considered &#8220;non-significant.&#8221; The approximately three-point treatment difference relative to placebo observed for the pooled dose groups that was observed on the ADAS-Cog 11 was non-significant (p&gt;0.05; p=0.1295), while the treatment difference relative to placebo that observed for the reduction in CSF A&#946; 42 protein at the 300mg dose was significant (p&lt;0.05; p=0.0178).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Proof-of-Concept Clinical Trials for the Mechanism of CT1812</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have conducted and are continuing to conduct a series of clinical proof-of-concept trials intended to assess target engagement and the impact of CT1812 on synaptic activity. These proof-of-concept trials are presented in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COG0202&#8201;&#8212;&#8201;Phase&#160;2 (SEQUEL) Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0202 SEQUEL study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of 16 patients with mild-to-moderate AD to evaluate the potential efficacy of CT1812 in restoring synaptic function in patients through qEEG measurement, as reflected by relative theta power. The trial is configured as a two-arm crossover trial, in which half of the participants will receive 300 mg of CT1812 daily for 29 days. After a 14-day wash out period, these participants will receive placebo for an additional 29 days. The other half of the participants receive placebo daily for 29 days. After a 14-day wash out period, these participants will receive CT1812 treatment for an additional 29 days. CSF and qEEG evaluations are taken periodically throughout the duration of the trial. We completed enrollment in the first quarter of 2023 and expect to report topline data later in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COG0105&#8201;&#8212;&#8201;Phase&#160;1 (SPARC) Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The COG0105 SPARC study is a randomized, double-blind, placebo-controlled Phase 1 clinical trial of 23 patients with mild-to-moderate AD. The primary objectives of the study were to evaluate CT1812 for safety and tolerability. The secondary objectives were to evaluate potential effects of CT1812 on biologically relevant endpoints using various imaging modalities, including PET imaging and vMRI as well as CSF biomarkers, and cognitive and clinical endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Participants were randomized to receive treatment with 100 mg or 300 mg of CT1812 or placebo once daily for 24 weeks. A preliminary analysis has been made of safety, clinical laboratory measurements, PET imaging, functional MRI and vMRI, CSF biomarkers and clinical outcomes in patients treated with CT1812 compared to those in patients receiving placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Seventeen patients completed the study protocol, eleven in the CT1812 arm (six in the 100mg cohort; five in the 300mg cohort) and six in the placebo arm. CT1812 was well-tolerated with similar adverse event rates across treatment arms. Most adverse events were mild-to-moderate in severity with no deaths and no treatment-related SAEs reported. We observed mild and transient elevations of liver enzymes without any other indications of liver injury in two patients in the 300-milligram group. The patients were discontinued from the study and the liver enzyme levels returned to normal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Topline results from the analyses of secondary endpoints demonstrated that after 24-weeks of treatment, there were no significant treatment differences on the ADAS-Cog 11 change from baseline. In addition, there were no significant treatment differences on SV2A signal change compared to baseline. However, vMRI showed a trend (p=0.0641) towards a significant reduction in the loss of composite brain volume in CT1812- treated patients (pooled) compared to placebo. A statistically significant (p&lt;0.05) reduction in loss of brain volume was also observed in three brain regions (hippocampus, prefrontal cortex and pericentral cortex) in treated patients (pooled) compared to placebo, as shown in the table below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:342.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:342.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:313pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COG0104&#8201;&#8212;&#8201;Phase&#160;1 (SNAP) Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0104 SNAP study was a randomized, double-blind, placebo-controlled Phase 1 clinical trial that enrolled three patients with mild-to-moderate AD to measure the effects of CT1812 on displacement of A&#946; oligomers. Patients were randomized 2:1 to receive a single dose of CT1812 or placebo. Patients enrolled in the trial had an indwelling catheter placed in the lumbar CSF space. CSF samples were collected hourly over a 28-hour period. Five CSF samples were collected before and 24 samples collected after administration of a single 560 mg oral dose of CT1812 or placebo. CSF samples from each trial participant were analyzed to measure the concentration of A&#946; oligomers over the trial period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results of this trial revealed an increase in A&#946; oligomer levels in the CSF over the 24-hour period following treatment with CT1812, but not in the patient administered placebo. These findings were measured using two independent methods, microimmunoelectrodes and western blots. This effect of CT1812 was specific to A&#946; oligomers, as no CT1812-related increase in A&#946; 1-40 or 1-42 monomer was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe these results provide the early proof of principle of CT1812 target engagement in AD patients. Further, we believe that they corroborate our mechanism of action previously demonstrated in preclinical studies, providing the first evidence that our preclinical studies translate to patients with AD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:356pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">First evidence of target engagement in humans, which mirrors that found preclinically; and we believe this reinforces that our mechanism of action extends to patients with AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:356pt;width:356pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COG0102&#8201;&#8212;&#8201;Phase&#160;1 Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0102 study was a randomized, double-blind, placebo-controlled, Phase 1 clinical trial of 19 patients with mild-to-moderate AD. Participants were administered one of three oral doses of CT1812, either 90 mg, 280 mg or 560 mg, once daily for 28 days. The primary endpoint of the trial was safety with a secondary objective of establishing the pharmacokinetic, or PK, profile of CT1812. Also included as exploratory endpoints were measurement of CT1812 in CSF, and protein expression changes in CSF and plasma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In order to gauge the impact of CT1812 on synaptic damage due to AD, we measured concentrations of synaptic proteins, neurogranin and synaptotagmin-1, in CSF samples from these patients using clinically validated standardized assays. Our evaluation of AD protein biomarkers in the CSF revealed that neurogranin levels, shown in the left graph below, in patients treated with CT1812 for 28 days was significantly decreased compared to levels measured in patients administered placebo (p =0.05, analysis of covariance). Neurogranin is a synaptic damage marker that increases in the CSF of AD patients reflecting its decrease in the brain. The lowering of synaptic damage markers in the CSF is consistent with CT1812&#8217;s mechanism of action as observed in our preclinical studies and demonstrates the potential of the CT1812 to slow A&#946; oligomer- induced synapse loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Another synaptic damage biomarker that is elevated in the CSF of AD patients is synaptotagmin-1. CSF levels of synaptotagmin-1 were similar at baseline and end of study in patients treated with CT1812, whereas its levels in the placebo group displayed a marked increase over the same time period. This analysis of CT1812&#8217;s impact on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.86pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">synaptotagmin-1 levels is presented in the right graph below. Consistent with our belief that targeting the S2R has the potential to prevent A&#946; oligomer toxicity, we observed a reduction in neurogranin and synaptotagmin in CSF, which are measures of synaptic damage, suggesting that CT1812 may have the ability to protect synapses in AD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Treatment with CT1812 was associated with lower levels of neurogranin and</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">synaptotagmin-1 compared to placebo</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:205.86pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:308.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 was well tolerated in the COG0102 study. All AEs were mild to moderate. Some of the participants in the highest dose group experienced lymphocytopenia or elevated liver enzymes. These laboratory abnormalities resolved in most patients with continued dosing of CT1812. One trial participant was discontinued from CT1812 prior to study completion because of elevated liver enzymes with subsequent resolution of this abnormality. Lymphocytopenia or elevated liver enzymes were not observed in either the 90 mg or 280 mg dosing cohorts. There were no SAEs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Phase&#160;1 Safety Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to Phase 1 clinical trials conducted in our targeted patient population, we also conducted a series of Phase 1 clinical trials in healthy volunteers designed to evaluate the safety profile of CT1812, as well as determine potential drug-food or drug-drug interactions. These trials and their results, which are summarized below, indicated that CT1812 was generally well-tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG0101 - First in human phase 1 clinical trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0101 study was a randomized, double-blind, placebo-controlled ascending dose Phase 1 multi- cohort clinical trial of 93 healthy volunteers to assess the safety and potential drug-food interactions of CT1812. The trial was conducted in two segments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The first segment was structured as an ascending single dose trial, in which participants received one dose of CT1812 with increasing doses given to each of six cohorts. In this segment of the trial, eight participants were enrolled per dosing cohort with six participants receiving CT1812 and two receiving placebo. The doses evaluated were 10 mg, 30 mg, 90 mg, 180 mg, 450 mg and 1,120 mg. A seventh cohort of six patients received a single 90-mg dose after receiving a standardized meal. All doses were administered as scheduled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The second segment was configured as a multiple ascending dose trial, that enrolled 39 healthy volunteers, divided in three cohorts of ten participants, with one additional cohort consisting of nine healthy elderly volunteers. Each </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">participant in this segment of the trial received a single dose of CT1812 each day for 14 days. The doses evaluated in this second segment were 280 mg, 560 mg and 840 mg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 CSF concentrations correlated to a &gt;80% S2R predicted receptor occupancy in brain</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:205.41pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:251.96pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following completion of each trial cohort, bioanalytical evaluation of plasma CT1812 PK was conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This trial demonstrated that administration of CT1812 in single doses of up to 1,120 mg, administered once, as well as up to 840 mg of CT1812 dosed for 14 consecutive days was well tolerated. Significantly, CT1812 concentrations detected in the CSF correlated to an estimated receptor occupancy in the brain of greater than 80%. There was one SAE in the multiple-dose portion of the study that was deemed unrelated to study drug. There were no SAEs related to the product candidate or TEAEs leading to withdrawal from the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG0103 - Phase 1 trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0103 study was a Phase 1 clinical trial of 15 healthy volunteers designed to evaluate the potential effects of CT1812 on select CYP isoenzymes: CYP2C19, CYP2C9, CYP2D6 and CYP3A4. This was accomplished by assessing its effects on substrates of these isoenzymes: 20 mg omeprazole, 500 mg tolbutamide, 50 mg dextromethorphan and 4 mg midazolam. The 15 healthy volunteers who participated in the trial received the substrates of these isoenzymes two days prior to the initial dose of CT1812 and PK assessments were performed. A dose of 560 mg of CT1812 was administered to each of the trial participants for the following six consecutive days. The day 6 dose of CT1812 was administered concomitantly with the four-substrate cocktail and PK assessments were repeated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A weak drug interaction was observed between CT1812 and midazolam and dextromethorphan. A lack of any clinically meaningful interaction was observed with coadministration of omeprazole or tolbutamide. Based on the small magnitude of change in PK parameters of the probe drugs observed in this study for the isoenzymes CYP2D6 and CYP3A4, clinically meaningful interactions are unlikely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development Plans and Future Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Our Upcoming COG0203 Phase&#160;2 Clinical Trial Fully Funded by NIA Grant of approximately $81.0&#160;million</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our COG0203, referred to as START, study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to enroll 540 patients with early-stage AD and powered to show a change in the rate of cognitive and functional decline. We intend to enroll patients with MCI, due to AD or mild AD who have elevated levels of A&#946; as determined by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:328.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PET imaging or as measured in CSF. The trial is being conducted in collaboration with the ACTC and will utilize approximately 50-60 sites including research sites associated with the consortium, as well as other qualified sites that are not part of the consortium. Patients will be randomized to receive CT1812 or placebo for 18 months. In addition to a battery of cognitive measures, we intend to use a variety of biomarkers to measure target engagement and assess changes in neurodegeneration and disease progression. We have received a grant of approximately $81.0 million from the NIA to fund this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to entering clinical trials, the therapeutic potential of CT1812 was observed in numerous preclinical studies. As is demonstrated in the images below, the addition of A&#946; oligomers to neuronal cell cultures resulted in synaptotoxicity as illustrated by the reduced expression of synaptic markers neurogranin, synaptotagmin and SV2A. The lack of immunoreactivity of these three synaptic proteins can be seen in the middle column of the image below. However, the presence of CT1812 blocked the A&#946; oligomer-induced loss of synapses, as reflected by the presence of synaptic protein expression displayed in the right-hand column below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 prevented A&#946; oligomer-mediated synaptic damage</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:328.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:328.45pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results showed that CT1812 also slowed the loss of synapses that is triggered by A&#946; oligomers. A higher resolution image of the cell culture exposed to A&#946; oligomer is shown below, before the addition of CT1812, which is presented on the left, and after the addition of CT1812, which is presented on the right. A&#946; oligomers shown in red bind to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 displaces A&#946; oligomer binding and appears to block the effects induced by the A&#946; oligomers, with the synapse numbers remaining at levels similar to normal.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:247.66pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812&#160;slowed loss of synapse numbers in the presence of A&#946; oligomers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k013.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:347.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The protective benefits of CT1812 observed in these <i style="font-style:italic;">in vitro</i> assays are supported by functional <i style="font-style:italic;">in vivo</i> assessments of CT1812. In one such preclinical study, the memory of mice was tested based on the subject&#8217;s ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below, performed significantly worse in both the fear and maze tests when compared to normal, non-transgenic mice, represented by the blue bars. However, after administration of CT1812, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal mice. We believe these results are illustrative of CT1812&#8217;s ability to restore synaptic proteins and numbers to normal levels and with it, the animal&#8217;s functional capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 restored functional capabilities in a mouse model of AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k014.jpg" alt="Graphic" style="display:inline-block;height:247.66pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:371.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CT1812 for the Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (Dry AMD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. Human genetics points to TMEM97 as a promising therapeutic target for GA secondary to dry AMD, as indicated via several large- scale, independent genome-wide association, or GWA, studies. In addition, unbiased pathway analysis of AD patient proteomic data obtained during our clinical trials provides independent evidence of a relationship between the S2R complex and GA secondary to dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are currently engaged in preclinical development activities for this indication, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:238.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> Early proof-of-concept studies with CT1812 indicate a role of S2R modulators in rescuing key aspects of dry AMD including maintaining homeostatic functions of RPEs, ameliorating lysosomal dysfunction and preventing RPE cell death. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in indication and it was cleared by the FDA at the end of January 2023. We plan to initiate this Phase 2 clinical trial in 2023. We believe that well-characterized clinical endpoints and a defined regulatory path increase the attractiveness of this indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of the Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">AMD is the leading cause of blindness in people over 50 years of age in the United States, afflicting approximately 11 million people in the U.S., including an estimated 12% of all U.S. adults over 80 years of age. Dry AMD is a progressive condition and accounts for up to 90% of all AMD cases. Advanced dry AMD, or GA, affects approximately two million people in the U.S. There is currently one approved therapeutic for dry AMD. Other treatments in development are primarily invasive, including intravitreal injections, stem cell replacement and gene therapy approaches. We believe the limited treatment options available for patients with dry AMD, coupled with newly implicated biochemical pathways, make GA secondary to dry AMD an attractive target for the development of therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">There are two types of AMD, the first of which is neovascular, or wet AMD, and non-neovascular, or dry AMD. Dry AMD, which accounts for approximately 90% of all AMD cases, is a progressive condition that involves a dysregulation of cellular processes, among which is the accumulation of lipid deposits, known as drusen, that causes a thickening of the Bruch&#8217;s membrane. This thickening disrupts the cytoarchitecture of the RPE, and this disruption, coupled with oxidative stress and inflammation, leads to the diminished health and function of RPE and photoreceptor cells, with accumulated damage resulting in cell death and visual impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The anatomy of the eye and the regions impacted by AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k015.jpg" alt="Graphic" style="display:inline-block;height:238pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:357pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations of Current Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Treatments for dry AMD and GA secondary to dry AMD are currently limited to vitamins and over-the-counter zinc. While there are no therapeutics approved by the FDA to treat dry AMD or GA secondary to dry AMD, there is considerable development activity ongoing involving numerous targets. Among the areas of ongoing interest are efforts targeting the complement pathway and its role in inflammation, as mutations in this pathway have been associated with higher risk of dry AMD. In addition, cell and gene therapy approaches are being evaluated to regenerate RPE cells and rescue the loss of photoreceptors. Small molecule visual cycle modulators are also under evaluation to maintain retinal integrity. Most of these approaches require invasive administrations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rationale for S2R Mechanism of Action</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Indications of S2R Involvement in Geographic Atrophy Secondary to Dry AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. First, human genetics point to TMEM97 as a promising therapeutic target, as indicated via several large-scale, independent GWA studies. These studies indicate a genetic mutation known as a single nucleotide polymorphism, or SNP, in the TMEM-VTN locus confers decreased risk for dry AMD. It remains unknown if this mutation confers a change in TMEM97 expression levels. However, knockdown of TMEM97 in <i style="font-style:italic;">in vitro</i> models of the disease partially rescues RPE cells from oxidative stress-induced cell death. Investigation of the effects of pharmacological perturbation of the S2R complex signaling is currently ongoing to determine if the rescue of cell death mediated by decreasing TMEM97 expression can be replicated by S2R modulators, such as CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unbiased Analysis of Clinical Trial Sample Proteomics Data: Top Disease Ontologies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Unbiased pathway analysis of AD patient proteomic data obtained during the COG0102 and SHINE Part-A clinical trials provides independent evidence of the relationship between the S2R complex and dry AMD. Analyses of CSF were performed to ascertain which predesignated functional disease ontologies may be affected by the administration of CT1812. These analyses identified GA and macular degeneration as two of the top indications affected, with GA presenting the most significant relationship. Subsequent analyses identified several subsets of proteins altered by CT1812 that are involved in dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In subsequent analyses examining the overlap of proteins altered in CSF and plasma biofluids of AD patients treated with CT1812 versus placebo, we identified a set of proteins, altered by CT1812 that have been previously shown by other groups to be disrupted in dry AMD or GA, compared to age-matched controls. Subsequent analysis identified several pathways in which these proteins are involved, many of which have known genetic or biological links to processes disrupted in dry AMD. We believe the collective insights provided by these analyses provide early proof of concept that an S2R modulator may be capable of altering AMD relevant proteins and pathways in an aged patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Support for Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We believe that proof-of-concept studies indicate a clear role of S2R modulators in rescuing key aspects of dry AMD. Pathway analysis of transcriptomic data suggest a key role of S2R modulators in regulating pathways involved in cell survival and inflammation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:329.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Mechanistic Studies Indicate CT1812 Plays a Role in Cell Survival</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">and Inflammatory Pathways in RPE Cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k016.jpg" alt="Graphic" style="display:inline-block;height:329.2pt;width:395.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Additional functional studies indicate S2R modulators may ameliorate disruptions in homeostatic functions of RPEs, including ameliorating lysosomal dysfunction and salvaging the ability of RPE cells to recycle photoreceptor outer segments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:325.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Working Hypothesis of Mechanism of Action in Dry AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k017.jpg" alt="Graphic" style="display:inline-block;height:325.55pt;width:293pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe preclinical studies provide further evidence supporting a clinical trial for CT1812 as a potential treatment for GA secondary to dry AMD. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration. Moreover, as is illustrated in the graph below, CT1812 levels recorded in the retina were similar to those in the brain, suggesting that the doses used to achieve potential therapeutic levels in the retina needed to achieve efficacy will be similar to the doses for AD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:256.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Similarities in CT1812 concentrations following oral administration in the brain and retina</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k018.jpg" alt="Graphic" style="display:inline-block;height:256.62pt;width:414.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Additional studies have been conducted to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD.&#160;<i style="font-style:italic;">In vivo</i>&#160;preclinical studies are evaluating the utility of CT1812 to impede the death of retinal ganglion cells. Not only is it anticipated that these proof-of-concept studies will allow us to further elucidate the mechanism by which the S2R complex modulators act upon the various disease pathologies, but the learnings from this may also inform appropriate patient selection, time of intervention and clinical outcome measurements to enable a successful clinical trial design. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Planned Phase&#160;2 Clinical Trial Design</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that an S2R antagonist, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in indication and it was cleared by the FDA at the end of January 2023. We plan to initiate this Phase 2 clinical trial in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We plan to enroll individuals 50 years of age or older that have received a diagnosis of GA secondary to dry AMD, with a best corrected visual acuity, or BCVA, score of 24 letters or more, with GA of between 2.5 mm2 and 17.5 mm2. The primary endpoint of the trial will be change in GA lesion area using fundus autofluorescence imaging. The secondary endpoints will  include change in the square root of the GA lesion area, low luminance visual acuity, or LLVA, and BCVA, low luminance visual acuity deficit and drusen volume as measured by optical coherence tomography. We will measure these outcomes at three-to-six month intervals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">S2R Modulators for the Treatment of Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Substantial cellular and clinical biomarker evidence demonstrate that our S2R modulators, including our clinical drug candidate CT1812, have a beneficial impact on the pathways impaired in synucleinopathies, namely the localization </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of &#945;-synuclein aggregates in Lewy bodies, which is a chief hallmark of PD and other synucleinopathies. More recently, human genetic evidence has linked SNCA, the gene encoding &#945;-synuclein, to the pathology of synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have conducted preclinical studies of S2R ligands in our library, including CT1812, to explore the potential of S2R antagonists to rescue the biological processes that are impaired in synucleinopathies. Subject to discussion with the FDA, we intend to conduct clinical studies in DLB, PD and potentially other synucleinopathies as outlined below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An Overview of Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Synucleinopathies are a group of neurodegenerative disorders in which the protein &#945;-synuclein accumulates  abnormally to form inclusions in the cell bodies or axons of neurons or oligodendrocytes. Two of the primary synucleinopathies are PD and DLB, which each involve motor and cognitive dysfunction. While the cell types and brain structures that are affected in PD and DLB vary markedly between the disorders, synucleinopathies share a characteristic accumulation of &#945;-synuclein aggregates into fibrils, the major constituent of the Lewy bodies that occur inside brain neurons in these diseases.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Increasing evidence suggests that &#945;-synuclein also aggregates into oligomers, and that oligomers are more toxic than fibrils. <span style="letter-spacing:0.2pt;">&#945;</span>-synuclein oligomers contribute to neurodegeneration through a variety of mechanisms including disrupting normal autophagy and inducing synaptic dysfunction and loss. Synaptic dysfunction and loss contribute to the cognitive and motor symptoms of these diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synucleinopathies are second only to AD in terms of neurodegenerative disease prevalence. In the United States, as many as one million people suffer from PD and an estimated 1.4&#160;million from DLB. According to the Parkinson&#8217;s Foundation and the Lewy Body Dementia Association, the direct healthcare costs for patients with PD and DLB are estimated to be approximately $25 billion and $31.5&#160;billion per&#160;year, respectively. For PD, these direct medical costs include an estimated $2.5 billion for medications annually in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations of Current Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Most approved therapeutic products treat the symptoms of the diseases and modulate dopamine. While some existing products provide meaningful symptomatic relief, they have significant side effect risks, fail to address the progression of the disease, and over time gradually lose their effectiveness in treating the symptoms of the disease. There are no currently approved disease-modifying therapeutics for PD or other synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rationale for S2R Mechanism of Action for Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">&#945;-synuclein is a protein primarily found in neural tissue that plays a role in neurotransmission. In synucleinopathies such as DLB and PD, &#945;-synuclein builds up in brain cells and forms oligomers that saturably bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and eventual loss. Our decision to pursue the treatment of synucleinopathies with S2R compounds is based on internal and third-party data, indicating that the S2R components PGRMC1 and TMEM97 regulate cell pathways known to be impaired in synucleinopathies, such as autophagy, vesicle trafficking and lipid synthesis; &#945;-synuclein oligomers bind directly to PGRMC1; and synucleinopathies share certain mechanistic similarities with AD, including pathologies related to aberrant oligomeric protein formations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As summarized below, we believe our preclinical studies provide compelling evidence supporting the use of CT1812 and our next-generation S2R modulators as potential therapeutics to treat synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As with oligomers of the A&#946; protein in AD, oligomers of &#945;-synuclein are highly toxic when bound to brains cells and internalized. This binding causes cellular stress, including three major pathway disruptions: upregulation of the autophagy receptor LAMP2A, dysregulation of lipid metabolism and a reduction in membrane trafficking. The S2R complex components, PGRMC1 and TMEM97, directly regulate these processes, activities which are compromised by the binding and internalization of &#945;-synuclein oligomers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Compounds that bind to S2R and block &#945;-synuclein binding and/or internalization are therefore expected to be disease-modifying.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Study Support for Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The results of <i style="font-style:italic;">in vitro</i> studies suggest that S2R modulator, such as CT1812, may have disease modifying effect on the synucleinopathies by reversing pathway disruption and dysregulation caused by &#945;-synuclein oligomers. In work funded by grants from the Michael J. Fox Foundation, &#945;-synuclein oligomers were found to bind to brain cells in culture and are internalized, indicated by the red dots in the image to the left below. With the addition of S2R modulator CT1812, the binding and thus internalization of the &#945;-synuclein oligomers is inhibited as indicated in the image to the right below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 blocked the binding and internalization of &#945;-synuclein oligomers the neuronal synapses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k019.jpg" alt="Graphic" style="display:inline-block;height:169.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:350.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The potential for S2R modulators to reverse the deleterious cellular effects of &#945;-synuclein oligomers is also reflected in the <i style="font-style:italic;">in vitro</i> analysis of LAMP2A expression presented below. LAMP2A is a critical component of chaperone-mediated autophagy, one of several processes that eliminate damaged cellular proteins. Its expression, noted in orange, is upregulated in the presence of the toxic &#945;-synuclein oligomer, likely a compensatory mechanism in response to the cellular insult. S2R modulators, which block membrane trafficking deficits caused by &#945;-synuclein oligomers, are observed to inhibit the upregulation of LAMP2A, as evidenced by the dark and light gray in the below chart. As these antagonists are selective for the S2R complex, their ability to reverse the effects of &#945;-synuclein on LAMP2A expression provides compelling evidence of the S2R complex&#8217;s importance in the regulation of this autophagy pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In vitro</i> analysis further illustrates &#945;-synuclein oligomers&#8217; dose-dependent inhibition of membrane trafficking. Importantly, oligomer-related inhibition was noted to be four-fold higher than that observed with high concentrations of monomeric &#945;-synuclein, illustrative of the significantly greater toxicity of &#945;-synuclein oligomers. The addition of CT1812 was observed to reverse the membrane trafficking deficit related to the presence of &#945;-synuclein oligomer, while having no effect on membrane activity when dosed in its absence.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">S2R antagonists reversed the effects of &#945;-synuclein oligomers on LAMP2A expression and trafficking</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20221231x10k020.jpg" alt="Graphic" style="display:inline-block;height:237.3pt;width:444.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase&#160;2 Clinical Trial in Dementia with Lewy Bodies (DLB)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are actively enrolling sites for our Phase 2 clinical trial studying the use of CT1812 to treat patients diagnosed with DLB. The design of this trial is a double-blind, randomized trial involving three dose groups, two active treatment cohorts and a placebo group. We are enrolling 120 patients in a six-month study, with equal participant numbers in each of the three dose groups, with daily (QD) dosing. Eligibility requirements include individuals between 50 and 80 years of age that have received a diagnosis of DLB and have a mini-mental state exam, or MMSE, score of between 18 and 27. Clinical endpoints of the trial include safety and physical activity measurements, cognitive assessments, and PK and pharmacodynamic biomarker analyses compared to baseline measurements recorded at the beginning of the trial. In addition, CSF will be collected and analyzed for &#945;-synuclein content and established patterns of differential protein expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Additional Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many degenerative disorders likely involve a dysfunctional cellular damage response mechanism and significant evidence is emerging which highlights the importance of the S2R complex and its components in regulating this response. The complex likely contains a number of relevant binding sites that may allow for multiple disease intervention approaches, making it an attractive therapeutic target. Accordingly, we are actively engaged in a number of earlier-stage discovery programs which are built upon our identification of five structurally distinct chemical series. From these series we have multiple leads which will be optimize each of our lead series. Each of these leads has demonstrated favorable potency with variable selectivity in early preclinical testing and each of the molecular series possesses distinct bioavailability and PK properties, including differences in half-life and blood-brain and blood-retina permeability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Proposed Synucleinopathies Clinical Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Subject to additional funding, we plan to study several next-generation S2R modulators derived from chemically distinct series to measure their ability to rescue cell death in synucleinopathies such as PD and DLB. We would also study &#945;-synuclein pathology and motor deficits in two mechanistically distinct <i style="font-style:italic;">in vivo </i>models of synucleinopathies. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">parallel, these studies will elucidate the mechanism of action by which S2R modulators are efficacious in PD and DLB and provide essential data to support potential biomarker nomination for PD and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Funding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Historically, we have sought grant funding to strategically advance our programs. To date, we have secured non-dilutive funds from the NIA, the Michael J. Fox Foundation and other groups to pursue our commonly aligned interests of developing therapeutics for neurodegenerative disorders. Taken together, the company has been awarded approximately $171.0 million in cumulative grants for the advancement of our pipeline programs. Of this, approximately $81.0 million in cumulative non-dilutive grants have been awarded by the NIA to fund development of CT1812 for the treatment of AD. As of December 31, 2022, we had approximately $89.3 million available from NIA funds for applicable expenses to be incurred in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Funding Org</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0101 Ph1b first-in-patient trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0102 Ph1b/2a Clinical Trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0104 Ph1 SNAP Study: CSF Catheter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,527,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0105 Ph1 SPARC Study: SV2a PET</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,795,774</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Study</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,848,329</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0202 Ph2 SEQUEL Study: qEEG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,445,051</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0203 Ph2 Study with ACTC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,974,766</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0108 Study: hAME</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,642,783</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,634,548</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG1201: Study: DLB</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,498,048</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NIH and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2010&#8209;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ten Preclinical Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,859,971</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 171,047,879</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Each of the grants awarded to us relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to CROs, research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for our eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIA Grants do not contain claw back provisions, the NIA or other government agency may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. To date, we have not been found to have breached the terms of any NIA Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, in the United States and internationally, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Owned Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of March 1, 2023, our intellectual property portfolio contained nine issued U.S. patents, sixty seven issued foreign patents as well as one pending U.S. provisional application, four pending U.S. patent applications, two pending </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patent Cooperation Treaty applications and twenty four foreign pending patent applications directed to the composition of matter of, pharmaceutical compositions of, methods of use of, and methods for selecting subsets of patients for treatment with our chemical structures, including our lead CT1812. Our current issued patents relating to CT1812 are projected to begin to expire no earlier than 2035, with the composition of matter patent covering CT1812 set to naturally expire in 2035, subject to adjustment or extension of patent term available in a particular jurisdiction. We will likely be awarded Patent Term Extension, or PTE, when CT1812 is approved as a New Chemical Entity, or NCE, that will extend the term of the CT1812 composition of matter patent by up to five years, and we anticipate pursuing additional patents to further protect CT1812 and to further extend the patent term associated with CT1812. We expect to file additional patent applications in support of current and new product candidates as well as new platform and core technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of six patent families that include several granted U.S. patents and pending U.S. patent applications, as well as granted patents and pending patent applications in numerous foreign jurisdictions, relating to compositions of matter and pharmaceutical compositions of CT1812, analogs of CT1812, and the use of CT1812 for the treatment in certain diseases, disorders and conditions including AD, GA secondary to dry AMD, PD, and synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The first of these patent families is directed to compositions of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD, and we are the exclusive owner of this patent family in the United States and certain foreign jurisdictions, including Australia, Brazil, Canada, China, the European Union, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa. As of March 1, 2023, this patent family includes granted patents claiming composition of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD in the United States (three patents), Australia, Brazil, China, the European Union, Hong Kong, India, Israel, Japan, New Zealand, Mexico, South Korea, Russia and South Africa. This patent family also includes a pending U.S. patent application and pending application in certain foreign jurisdictions including Canada, India, the European Union and Hong Kong. This patent family has a natural expiration date in 2035 subject to any adjustment or extension of patent term that may be available in in a particular jurisdiction such as PTE following approval of the New Drug Application, or NDA, in the United States or extension of patent term via a Supplementary Protection Certificate, or SPC, following EMEA marketing authorization. Upon approval of the NDA for CT1812 in the United States, the patents in this family claiming compositions of matter of CT1812, pharmaceutical compositions of CT1812, and methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD will be eligible to be listed in the FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. These patents complement the regulatory exclusivity by providing the basis for an additional waiting period prior to the FDA&#8217;s   approval of an abbreviated new drug application, or ANDA, or 505(b)(2) applicant. If  an ANDA or 505(b)(2) applicant were to file its application referencing the NDA for CT1812 before expiration of our composition of matter, pharmaceutical composition, and method of use patents and the applicant asserted that our patents identified on the Orange Book to be invalid or not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory 30-month stay if we sue for infringement, or a shorter period if the patent expires or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to patent exclusivity, under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that CT1812 will be eligible for five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety as the chemical entity in the CT1812 NDA. When approved in Europe, CT1812 will also be eligible for 10 years of data and market exclusivity which is extendible for an additional year upon market authorization for one or more new indications during the first eight years of the data and market exclusivity period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="white-space:pre-wrap;"> We also own four families of pending patent applications directed to methods for selecting subsets of patients with AD for treatment with CT1812, methods of modulating amyloid beta monomer and oligomer levels using CT812, methods of treating GA secondary to dry AMD with CT1812 and methods of treating various neurologic diseases including PD and synucleinopathies with CT1812, as well as a pending provisional application directed to treating certain subsets of AD patients with CT1812. Any of these applications, if issued, will have a natural expiration between </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">2038 and 2043, subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Additional Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of three patent families that include several pending U.S. patent applications, as well as pending patent applications in numerous foreign jurisdictions directed to additional product candidates, including CT2168 and CT2074, among others. These patent families have expirations no earlier than 2038 subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We oversee and manage third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if we receive marketing approval, we will rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the drug substance for CT1812 and with a single third-party contract manufacturer to manufacture clinical trial supplies of CT1812, and we expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of CT1812. We continue to develop a commercial route for CT1812 API and to meet all requirements for our planned clinical trials. We plan to transfer the API manufacture to a larger third-party manufacturer to support the commercial launch of the product, if approved. The current API manufacturer is able to supply all of our needs for the planned clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard organic synthesis or pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We have selected a larger third-party drug product manufacturer and will be executing technology transfer of drug product manufacture to a larger manufacturer. We will also maintain the current drug substance and product manufacturer as part of our supply chain strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Commercialization Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may to seek third-party support from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the geographic market for a product we develop on our own is limited or that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to establish direct sales capability until shortly before the products are approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We face substantial competition from multiple sources, including large and specialty biotechnology and pharmaceutical companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to the current standard of care treatments for patients with neurodegenerative diseases, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess technologies and product candidates in the CNS field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the biopharmaceutical sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retain qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2023, we had 25 employees, 22 of whom were full-time and 19 of whom were engaged in research and development activities. Seven of our employees hold Ph.D. or M.D. degrees. None of our employees are represented by a labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are dedicated to conducting business with the highest standards of corporate responsibility. Our goal is to build a culture of diverse and passionate people striving to positively impact patients, our communities, and broader society. Our human capital resource priorities include attracting, recruiting, retaining, incentivizing and integrating our existing and new employees. We believe that a diverse, equitable, and inclusive workplace allows our company to best fulfill our mission. We are committed to continuing our efforts to increase diversity throughout our company and foster an inclusive work environment that supports our employees and the communities we serve. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. During 2022, the Company has taken proactive steps to enhance and improve our policies related to employee welfare and engagement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#8217;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s good laboratory requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee, either centralized or with respect to each clinical site, before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA after completion of all pivotal trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including potential requirements to conduct any post-approval studies required by the FDA or the potential requirement to implement a risk evaluation and mitigation strategy, or REMS; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with the Pediatric Research Equity Act, or PREA, which requires either exemption from the requirements or may require conducting clinical research in a pediatric population.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <i style="font-style:italic;">in vitro</i> studies assessing the toxicology, PK, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial or drug candidate. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, or DSMB, which may review data and endpoints at designated check points, make recommendations and/or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the registration of ongoing clinical studies and posting of clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;One</i>:&#160;&#160;&#160;The product candidate is initially introduced into a limited number of healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Two</i>:&#160;&#160;&#160;The product candidate is administered to a limited patient population with the target disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning Phase 3 trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Three</i>:&#160;&#160;&#160;The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk relative to potential benefit and generate the data used by FDA and other regulatory agencies to evaluate suitability for marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Sponsor may voluntarily pause or stop a clinical trial, or the FDA may place a trial on full or partial clinical hold at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or concerns related to chemistry, manufacturing and controls. A clinical hold is an order issued by the FDA to delay or suspend an investigation Following the issuance of a clinical hold or a partial clinical hold, a clinical trial may only proceed after FDA has notified the sponsor that any deficiencies have been corrected and FDA is authorizing the trial to proceed. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Finally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move   forward at designated check points based on access to certain data from the clinical trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested by the sponsor. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug candidate and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <i style="font-style:italic;">in vitro </i>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NDA Review and Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product candidate. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with and approved drug and to enable patients to have continued access to such drug by managing their safe use. It could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission to and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drug candidates that meet certain criteria. Specifically, new drug candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the drug candidate and the specific indication for which it is being studied. The sponsor of a fast track designated product has </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">opportunities for more frequent interactions with the applicable FDA review team during product development. With regard to a fast track designated product, the FDA may also consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Any drug candidate submitted to the FDA for approval, including a drug candidate with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A drug candidate is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug candidate designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, a drug candidate may be eligible for accelerated approval. Drug candidates intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the drug candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA generally requires that the sponsor perform adequate and well-controlled post-marketing confirmatory clinical trials which must be conducted with due diligence to verify and describe the predicted clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such confirmatory trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct the required confirmatory trials or if such studies fail to verify the predicted clinical benefit.  In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive Breakthrough Therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;Breakthrough Therapy&#8221; if the drug candidate is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a drug candidate is designated as Breakthrough Therapy, the FDA will work to expedite the development and review of such drug candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Fast Track designation, priority review, accelerated approval, and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development, review or approval process. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our drug candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record- keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, untitled letters, Form 483s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on post-approval or Phase&#160;4 clinical studies, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under PREA, an NDA must contain data to assess the safety and efficacy of the applicant product for indications in applicable pediatric populations. It must also contain information to support dose administration for pediatric populations where the drug may be utilized. FDA has the ability to grant complete waivers, partial waivers, or deferrals for compliance with PREA. PREA requirements may be waived for applications for approval of drug candidates intended to treat, mitigate, prevent, diagnose or cure diseases and other conditions that do not occur in pediatric populations. Generally PREA does not apply for drug candidates which have obtained an orphan designation, unless otherwise regulated by the FDA. Despite this, separate PREA compliance or waivers may still be required for each product indication. Although noncompliance with PREA will generally not be considered for withdrawal of an approval it may be considered by the FDA as the sole basis for enforcement action such as injunction or seizure as non-compliance and may render the drug misbranded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off- label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five- year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. The FDCA also permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for an NCE in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. During the NCE exclusivity period, the FDA may not approve or even accept for review an ANDA or an NDA submitted under Section 505(b)(2), or a (505(b)(2) NDA), submitted by another company for another  drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. Any competitor who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must make patent certifications to the FDA that (1) no patent information on the drug or method of use that is the subject of the application has been submitted to the FDA; (2) the patent has expired; (3) the date on which the patent has expired and approval will not be sought until after the patent expiration; or (4) the patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not   approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the 30-month stay is extended so that it expires 7 1&#8725;2 years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. The indications the Company is currently pursuing for its product candidates will not be eligible for pediatric exclusivity because they are age-related degenerative diseases and disorders that do not occur in the pediatric population. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities  from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers  of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Corrupt Practices Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the SEC, and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time- consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not    to cover a product could reduce physician usage and patient demand for the product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law. This legislation contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. The Inflation Reduction Act of 2022 also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. Additional drug pricing proposals could appear in future federal legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, there are also new laws and ongoing ballot initiatives that create additional pressure on drug pricing and may affect how pharmaceutical products are covered and reimbursed. A number of states have adopted or are considering various pricing actions, such as those requiring pharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or to place a maximum price ceiling or cap on certain products. Existing and proposed state pricing laws have added complexity to the pricing of pharmaceutical drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February 1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. These regulations became effective on April 1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code, commonly referred to as the individual mandate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent legislation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. As of July 2, 2022, the 2% sequester reduction resumed. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act has also been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-indent:19.95pt;margin:8.44pt 30.65pt 12pt 0pt;"><span style="color:#231f20;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:0pt;margin:8.44pt 30.65pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:22.5pt;margin:8.44pt 30.65pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware on August 21, 2007. Our principal corporate office is located at 2500 Westchester Avenue Purchase, NY 10577, and our telephone number is (412) 481- 2210. Our website address is www.cogrx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-indent:19.95pt;margin:8.44pt 30.65pt 12pt 0pt;"><span style="color:#231f20;margin-right:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7247638f_8dc2_4fc0_9de5_8369f2b997d1"></a><a id="Item1ARiskFactors_361684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. We have listed below (not necessarily in order of importance or probability of occurrence) what we believe to be the most significant risk factors applicable to us. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. Some of the statements in the following risk factors constitute forward-looking statements.  Please see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses over the foreseeable future and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses were $21.4 million and $11.7 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $115.4 million. Our clinical trials have been funded by approximately $171.0 million in cumulative nondilutive grants, awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health. On October 13, 2021, we completed our initial public offering, or IPO, whereby we received net proceeds of $37.9 million. On November 12, 2021, we received an additional $6.3 million in net proceeds resulting from the exercise of the overallotment option held by the underwriters in our IPO. On November 15, 2022, we completed a follow-on public offering whereby we received net proceeds of $5.2 million. We have no products approved for commercialization and have never generated any revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have devoted substantially all of our financial resources and efforts to the development of our product candidates, including conducting preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating losses over the next several years. We expect that it could be several years, if ever, before we have a commercialized product. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially for the foreseeable future as we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">conduct our ongoing and planned clinical trials of CT1812, as well as initiate and complete additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">pursue regulatory approval of CT1812 for the treatment of mild-to-moderate Alzheimer&#8217;s disease, or AD, dry age-related macular degeneration, or GA secondary to dry AMD, and Parkinson&#8217;s disease, or PD, and dementia with Lewy bodies, or DLB, and other age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seek to discover and develop additional clinical and preclinical product candidates from libraries generated using Novel Improved Conditioned Extraction, or NICE, screening platform, as well as other molecule generating and screening strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">hire additional clinical, manufacturing and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">incur additional legal, accounting and other expenses in operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">scale up our clinical and regulatory capabilities; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval, including CT1812. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our candidates or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our stock and could impair our ability to raise capital, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have not yet completed Phase 2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We commenced operations in 2007, and our operations to date have been largely focused on developing our clinical and preclinical product candidates and our NICE screening platform. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We may also need to transition from a company with a research focus to a company capable of supporting commercial activities. Our inability to adequately address these risks and difficulties or successfully make such a transition could adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our operations have required substantial amounts of capital since inception, and we expect our expenses to increase significantly in the foreseeable future. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several years as we complete our ongoing clinical trials of our product candidates, initiate future clinical trials of our product candidates, seek marketing approval for CT1812 for the treatment of age-related degenerative diseases and disorders of the CNS and retina, such as AD, GA secondary to dry AMD, PD and DLB, and advance any of our other product candidates we may develop or otherwise acquire. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for the foreseeable future, if at all. If we obtain marketing approval for CT1812 or any other product candidates that we develop or otherwise acquire, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had $41.6 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents and income from our non-dilutive grants will be sufficient for us to fund our operating expenses and capital expenditures requirements into the second half of 2024. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including, but not limited to<span style="letter-spacing:0.2pt;">:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">progress, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs we </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur as a result of preclinical study or clinical trial delays due to supply chain disruptions or other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing and receipt of any future non-dilutive grants from the NIA, or NIA Grants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">macroeconomic factors such as inflationary pressures, rising interest rates, liquidity constraints, failures and instability in U.S. and international financial banking systems, supply disruptions due to political unrest, conflict and war or other factors, and pandemics such as the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We believe our existing cash and cash equivalents and income from our non-dilutive grants will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of C1812 and our product candidates. If we receive regulatory approval for any of these product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by recent volatility in the equity markets </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The economic environment may make it difficult to raise capital on acceptable terms or at all. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, the continued challenging capital markets environment, lower prices for many securities and concerns about potential recessionary factors may affect our ability to raise additional funding through sales of our securities or issuance of indebtedness, which may harm our liquidity,  force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or cause us to grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our product candidates or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, liquidity constraints, failures and instability in U.S and international financial banking systems, geopolitical tensions resulting from the ongoing war between Ukraine and Russia, heightened or fluctuating inflation and interest rates and the related impact on U.S. and global economies or other economic or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our stock to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to our product candidates or any future therapeutics candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on the availability of NIA Grants. Although we have applied for and currently anticipate receiving additional NIA Grants, we cannot be certain that our grant applications will be successful, that additional NIA Grants will be made available to support our clinical trials or that we will continue to satisfy the award criteria of prior NIA Grants that have already been awarded to us. If we fail to continue to receive NIA Grants, our ability to continue our clinical programs for CT1812 may be impaired and delayed, and we may otherwise need to seek additional financing through dilutive methods, such as through equity or debt financings. Such dilutive financings could have an adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be subject to audit and repayment of our non-dilutive NIA Grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In addition, in connection with the NIA Grants, we may be subject to routine audits by certain government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. Any audit by the NIA could require significant financial and management resources and may result in a material adjustment to our results of operations and financial condition and harm our ability to operate in accordance with our business plan. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, negative results in any of our ongoing and planned clinical trials of CT1812 that are funded with NIA Grants may result in our failure to receive additional NIA Grants to fund future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are currently focused on developing product candidates to address age-related degenerative diseases and disorders of the CNS and retina. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our lead product candidate, CT1812, in identified indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways and decide which product candidates to pursue from time to time and the amount of time and resources to allocate to each such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties with respect to certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the market of age-related degenerative diseases and disorders of the CNS and retina or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and status of enrollment for our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing, and receipt of any future NIA grants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">future accounting pronouncements or changes in our accounting policies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the level of demand for our product candidates, if approved, which may vary significantly over time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Discovery, Development and Regulatory Approval of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently have no products approved for sale, and our lead product candidate is in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of CT1812, currently our only clinical-stage product candidate. However, given our stage of development, it may be many years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The clinical and commercial success of CT1812 and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to complete an investigational new drug application, or IND, enabling studies and successfully submit INDs or comparable applications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates, if approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the convenience of our treatment or dosing regimen;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;white-space:pre-wrap;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or  in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:12.5pt;margin:0pt 0pt 0pt 36pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, the FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions. We have not yet conducted an end of Phase 2 meeting with the FDA to discuss the registration pathway for CT1812, and our current clinical development plans for CT1812 in mild-to-moderate AD may change as a result of future interactions with the FDA. For example, the FDA may not accept the results of the ongoing CT1812 clinical trials and may require that we conduct additional trials, including more than one pivotal trial, in order to gain approval in AD. Furthermore, any approval of CT1812 for AD may be limited to CT1812 in combination with the existing standard of care.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">A key element of our strategy is to build and expand our pipeline of product candidates, including by developing CT1812 for the treatment of GA secondary to dry AMD and age-related degenerative diseases and disorders of the CNS beyond indications in AD, and by identifying other product candidates from libraries created using our NICE platform as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">well as new molecule and screening strategies. In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We have devoted significant resources to discovery efforts through our proprietary NICE platform, and we cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable product candidates from other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development of pharmaceuticals is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are at an early stage of clinical development of our only clinical stage product candidate, CT1812. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our product candidates may not successfully complete preclinical studies or clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in our efforts to further develop our current and future product candidates. Each of our product candidates will require significant clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not be acceptable to the FDA or other regulatory authorities or demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may encounter substantial delays in our preclinical studies and clinical trials or may not be able to conduct or complete our preclinical studies or clinical trials on the timelines we expect, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:0pt;">Clinical <span style="letter-spacing:0.2pt;">trials are expensive and can take many years to complete, and the outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays in obtaining, or failure to obtain, regulatory authorization to commence a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">imposition of a temporary or permanent clinical hold by the FDA or comparable foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identifying, recruiting and training suitable clinical investigators;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining institutional review board, or IRB, approval at each trial site;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">new safety findings that present unreasonable risk to clinical trial participants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a negative finding from an inspection of our clinical trial operations or study sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">recruiting an adequate number of suitable patients to participate in a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">having subjects complete a trial or return for post-treatment follow-up;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">addressing subject safety concerns that arise during the course of a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining sufficient supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated or continue;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulators may revise the requirements for approving our product candidates or such requirements may not be as we anticipate; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval in some countries and not in others;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">have the product removed from the market after obtaining marketing approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">available </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapies, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new drugs that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications we are investigating; the severity and difficulty of diagnosing the disease under investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patient eligibility and exclusion criteria defined in the protocol;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the proximity of patients to trial sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competition with other companies for clinical trial sites or patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the design of the trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the study drug and safety concerns;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient referral practices of physicians;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting health conditions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">ability to monitor patients adequately during and after treatment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">availability </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and efficacy of </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medications or therapies, or other clinical </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">trials, for </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the disease or condition under</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain and maintain patient consents.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable and unforeseen side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Adverse <span style="letter-spacing:0.2pt;">events or other undesirable side effects caused by our product candidates or related to procedures conducted as part of the clinical trials could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the data safety monitoring board, or DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a new approach to inhibiting the synaptic binding and signaling of soluble A&#946; oligomers through the use of small molecule receptor antagonists, like CT1812. As a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to conduct additional clinical trials or post-approval studies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be subject to fines, injunctions or the imposition of criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the product may become less competitive; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">Preclinical <span style="letter-spacing:0.2pt;">and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain Phase 2 clinical trials of CT1812 targeting mild-to-moderate AD, we do not know whether CT1812 will perform in future clinical trials as it has performed in these prior trials. The positive results we have observed for CT1812 in past clinical trials may not be predictive of our ongoing and future clinical trials in humans. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. In addition, changes to the design of our current or future clinical trials may be necessary if there are new developments in the field of Alzheimer&#8217;s research. A number of companies in the biopharmaceutical, pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, some of our past clinical trials have utilized an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in a controlled environment with a placebo or active control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">For all of the foregoing reasons, we cannot be certain that any of our ongoing and planned preclinical studies or clinical trials will be successful or acceptable to the FDA or other regulatory authorities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have initially concentrated our research and development efforts on the treatment of AD, a disease that has seen limited success in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Efforts <span style="letter-spacing:0.2pt;white-space:pre-wrap;">by biopharmaceutical and pharmaceutical companies in treating AD have seen limited success in drug development. Only two disease-modifying therapeutic option has been approved by the FDA. Specifically, Biogen&#8217;s Aduhelm received accelerated approval on June 7, 2021 and the FDA granted accelerated approval to Eisai&#8217;s Leqembi on January 6, 2023.  Aduhelm and Leqembi are monoclonal antibodies administered via infusion reported to reduce A&#946; plaques and protofibrils. We cannot be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products. With the exception of Aduhelm and Leqembi, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. As a result, the FDA has a limited set of products to rely on in evaluating CT1812. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of CT1812 for the treatment of AD</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We will need to successfully complete pivotal clinical trials in order to obtain the approval of the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to market CT1812 or any future product candidate. Carrying out pivotal clinical trials is a complicated process that requires significant financial resources. As an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">organization, we have not previously conducted any later stage or pivotal clinical trials. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA submission and approval of CT1812 or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">We<span style="letter-spacing:0.2pt;"> may seek a &#8220;Breakthrough Therapy&#8221; designation for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA granted CT1812 Fast Track designation in October 2017 for the treatment of mild-to- moderate AD, and, in the future, we may seek Fast Track designation for other of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many small molecule product candidates that have received Fast Track designation have failed to obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have conducted clinical trials of our product candidates outside the United States, and plan to continue to do so in the future. For example, we initially conducted our Phase 1b SNAP clinical trial of CT1812 in collaboration with the Karolinska Institute in Sweden. In addition, the Phase 1 single and multiple ascending dose studies of CT1812 in healthy volunteers (COG0101) as well as the first-in-patient study (COG0102) were conducted in Australia. We have opened additional clinical trial site in the Netherlands and are opening sites in the Czech Republic and Spain for our SHINE study. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, any comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data are applicable to the U.S. population and U.S. medical practice;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the trials were performed by clinical investigators of recognized competence, or GCP, requirements; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Many foreign regulatory authorities have similar requirements. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;">Although <span style="letter-spacing:0.2pt;">a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that help restore normal cellular damage responses in age-related degenerative diseases and disorders of the CNS and retina. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate CT1812 and other product candidates discovered through our NICE platform in other diseases beyond indications </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">in AD, such as GA secondary to dry AMD, and synucleinopathies, including PD and DLB. However, we may find that while we have seen promising results in one neurodegenerative disease, that effect is not replicated across other indications with promising similarities. Even if we successfully identify additional product candidates, we may still fail to yield additional product candidates for development and commercialization for many reasons, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be unable to identify viable product candidates through our NICE platform and other molecule generating and screening strategies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competitors may develop alternatives that render our additional product candidates obsolete;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be accepted as safe and effective by physicians and patients.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the European Union, or EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of CT1812, our lead product candidate, which is still under clinical development, and if CT1812 does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of CT1812, currently our only clinical-stage product candidate. To date, we have invested a significant portion of our efforts and financial resources in the development of CT1812 for the treatment of AD. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for and successfully commercialize CT1812, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to CT1812, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, while inhibition of A&#946; oligomers has been validated as a therapeutic approach, the use of small molecule receptor antagonists, such as CT1812, to inhibit the synaptic binding and signaling of soluble A&#946; oligomers is an innovative therapeutic approach, which exposes us to certain risks. For example, we may discover unforeseen safety events or that CT1812 does not possess certain properties required for therapeutic effectiveness. Even if found to be effective in one type of disease, CT1812, or the associated therapeutic approach, may not be effective in other diseases. In addition, given our therapeutic approach, designing preclinical studies and clinical trials to demonstrate its effect is complex and exposes us to risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market CT1812 in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for CT1812 and may not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory approvals for CT1812, we will not be able to commercialize CT1812 in AD, GA secondary to dry AMD, PD and DLB or other age-related degenerative diseases and disorders of the CNS and retina, and our financial position will be materially adversely affected and we may not be able to generate sufficient revenue to continue our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of March 1, 2023, we had 22 full-time and 3 part-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize CT1812, our lead product candidate, or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth and we expect will lead to increasing costs. Our need to effectively execute our growth strategy requires that we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our clinical trials effectively;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identify, recruit, retain, incentivize and integrate additional employees, including personnel focused on research and development and, if our product candidates receive marketing approval, sales;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our future financial performance and our ability to develop, manufacture and commercialize CT1812 and our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize CT1812, if approved, and our product candidates and, accordingly, may not achieve our research, development and commercialization goals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, particularly our President and Chief Executive Officer, Lisa Ricciardi, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth or raise funds to support our growth could delay the execution of our business plans or disrupt our operations. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our current or future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">injury to our reputation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">withdrawal of clinical trial participants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">costs to defend the related litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">diversion of management&#8217;s time and our resources;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">loss of revenue; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the inability to commercialize our current or any future product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may explore strategic collaborations that may never materialize or may fail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may attempt to broaden the global reach of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations, we intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek to grow our business through acquisitions of complementary businesses, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could harm our financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may consider opportunities to acquire other companies, products or technologies that may enhance our manufacturing capabilities, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including: problems assimilating the acquired service offerings, products or technologies; issues maintaining uniform standards, procedures, quality control and policies; unanticipated costs associated with acquisitions; diversion of management&#8217;s attention from our existing business; risks associated with entering new markets in which we have limited or no experience; increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters; and unanticipated or undisclosed liabilities of any target.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired service offerings, products or technologies. Our potential inability to integrate any business, products or technologies effectively may adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant disruptions of information technology systems, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other  third parties on which we rely, are vulnerable to damage or unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, denial or degradation of service attacks, ransomware, hacking, phishing schemes intended to cause an unauthorized transfer of funds and other social engineering attacks, attachments to emails, persons inside our organization or persons with access to systems inside our organization. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss of confidential information or other intellectual property. We may face increased risks of a security breach or disruption due to our reliance on internet technology and the number of our employees who work on a hybrid basis, at home and in the office.  This may create additional opportunities for cybercriminals to exploit vulnerabilities. The costs to us to investigate, mitigate and remediate security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In November 2021 we were the subject of a phishing scheme involving a fraudulent email and wire instructions, resulting in the loss of approximately $0.5 million in corporate funds. We took immediate action to contain and eradicate the security breach, including the implementation of control enhancements in an effort to prevent a similar situation from occurring again. We also subsequently submitted a claim for the loss under our cyber-security insurance policy whereby we received net proceeds of $0.5 million. We believe this was an isolated event and do not believe our technology systems have been compromised. While we have not experienced any other losses relating to cyber-attacks or other information security breaches such as the one that occurred in November 2021, there can be no assurance that we will ever recover the funds lost or that we will not suffer additional losses in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">Moreover, if a computer security breach affects our systems or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personally identifiable information or clinical trial data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged.  We would also be exposed to a risk of loss, governmental investigations or enforcement, or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are subject to or affected by federal, state and foreign data protection laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section 5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. For example, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January 1, 2020 and grants the California Attorney General the power to bring enforcement actions for violations beginning July 1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Foreign data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects in the European Union or the United Kingdom. The GDPR went into effect on May 25, 2018. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to &#8364;20 million or 4% of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of European Union or United Kingdom data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal information, and honoring and providing for the rights of European Union or United Kingdom individuals in relation to their personal information, including the right to access, correct and delete their data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our current and future drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future drug development programs and product candidates, successfully defend our intellectual property rights against third-party challenges and successfully enforce our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, some of our product candidates are not, and in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. The patent applications that we own may fail to result in issued patents with claims that cover any of our product </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">candidates in the United States or in other foreign countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable, and vice versa that may affect the regulatory approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patents and patent applications that we own may fail to result in issued patents with claims that protect any of our product candidates in the United States or in other foreign countries. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may obtain. Even if patents do successfully issue based on our patent applications, and even if such patents cover our product candidates, uses of our product candidates, or other aspects related to our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our products and technologies. Other companies may also design around technologies we have patented or developed. Any successful opposition to these patents or any other patents owned by us in the future could deprive us of rights necessary for the successful commercialization of any of our product candidates, if approved. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any such outcome could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September 16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, and derivation proceedings. After March 15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, post-grant review or interference proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">Patents <span style="letter-spacing:0.2pt;">have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success will largely depend on our ability to obtain market exclusivity in the United States and other countries with respect to our drug candidates and their target indications. Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, certain of our product candidates may be eligible for marketing exclusivity. The Food, Drug and Cosmetic Act, or FDCA, provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. If market exclusivity is granted for an NCE, during the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, dosage forms or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and prohibits the FDA from approving an ANDA or a 505(b)(2) NDA submitted by another company with overlapping conditions associated with the new clinical investigations for the three-year period. Clinical investigation exclusivity does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of an NDA for the same drug. However, an applicant submitting an NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain such marketing exclusivity for our product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates including our lead product candidate CT1812 can be challenged by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non- infringement. For example, if a third party files an application under Section 505(b)(2) or an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed in the Orange Book with respect to our NDA for the applicable approved drug candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our drug candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Periodic <span style="letter-spacing:0.2pt;white-space:pre-wrap;">maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering any of   our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">issuance of a patent does not give us the right to practice the patented invention. A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Third parties may also have blocking patents that could prevent us from marketing our products or practicing our own patented technology. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The risks described elsewhere pertaining to our intellectual property rights also apply to any intellectual property rights that we may in-license, and any failure by us or our potential licensors to obtain, maintain, defend and enforce these rights could harm our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we may license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our potential licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents</span>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. However, while certain research, development and commercialization activities may be protected by the safe harbor provision of the Hatch Waxman Act, other activities may subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;white-space:pre-wrap;">cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside   the United States remain confidential until patents issue. Therefore, patent applications covering our products could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products that are held to be infringing. We might, if possible, also be forced to redesign products or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Competitors <span style="letter-spacing:0.2pt;">may infringe or otherwise violate our patents or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as </span><i style="font-style:italic;letter-spacing:0.2pt;">ex parte</i><span style="letter-spacing:0.2pt;"> reexaminations, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, or post- grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could harm the price of our common shares</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because <span style="letter-spacing:0.2pt;">of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution</span>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product including our lead product candidate, CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The <span style="letter-spacing:0.2pt;white-space:pre-wrap;">United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain   patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents covering any of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Because <span style="letter-spacing:0.2pt;">we expect to rely on third parties to manufacture our product candidates and expect to continue to collaborate with third parties on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants, independent contractors or we have wrongfully used or disclosed confidential information of their former employers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We do and may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Even <span style="letter-spacing:0.2pt;">if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In <span style="letter-spacing:0.2pt;">addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to rely on trademarks as one means to distinguish any of our drug candidates that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Certain <span style="letter-spacing:0.2pt;">provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, the NIA has provided grants to fund certain of our preclinical activities and clinical trials. If the United States or another jurisdiction decides that the NIA grant bestows rights to our patent applications, that could affect our ability to obtain valid and enforceable patent claims protecting our rights as they relate to our lead product candidate, CT1812, our other product candidates and our NICE platform. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries. Such a loss of patent protection could harm our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">Once <span style="letter-spacing:0.2pt;">granted, patents may remain open to invalidity challenges including opposition, interference, re- examination, post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may be able to make product that is similar to product candidates we intend to commercialize that is not covered by the patents that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we, or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or any collaborators might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patents of others may harm our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Should any of these events occur, they could significantly harm our business and results of operations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Even <span style="letter-spacing:0.2pt;">if one or more of our product candidates receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the safety and efficacy of our product as compared to other available therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability of coverage and adequate reimbursement from governmental healthcare plans or third party payors for any of our product candidates that may be approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">proper training and administration of our product candidates by physicians and medical staff;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">public misperception regarding the use of our therapies, if approved for commercial sale;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue and profitability that our products may offer a physician as compared to alternative therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">limitations or warnings contained in the FDA-approved labeling for our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any FDA requirement to undertake a REMS;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the effectiveness of our sales, marketing and distribution efforts;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adverse publicity about our products or favorable publicity about competitive products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">potential product liability claims.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to initially seek approval for CT1812 for AD, GA secondary to dry AMD, PD and DLB and other age-related degenerative diseases and disorders of the CNS and retina. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if we obtain significant market share for CT1812 after FDA approval, the potential target populations may be too small to consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">do not currently have nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which we may not be able to do on reasonable terms, if at all,, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We currently rely on third parties at key stages in our supply chain. For instance, the supply chains for our lead product candidate involves several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, if approved, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#8217; or suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, if approved, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial- scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates, if approved, would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;">product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that our third-party manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently do not have the ability to independently conduct clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting preclinical studies, clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to obtain </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">regulatory approval in a timely fashion, or at all, for   the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of product candidates for the treatment of the diseases and disorders for which we have research programs, including AD, dry AMD, PD and DLB. Companies developing therapeutics for similar indications include large companies with significant financial resources, such as AbbVie, AstraZeneca, Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, Pfizer, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early- stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of age-related degenerative diseases and disorders, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products   that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221; The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates, if approved. Even if we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates, if approved, or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved, and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">There is significant uncertainty related to the insurance coverage and reimbursement of newly- approved products. In the United States, third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs   and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially- reasonable revenue and profits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad    to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">currently do not have a marketing or sales organization. In order to commercialize our product candidates, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issue warning letters, untitled letters, or Form 483s;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose civil or criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend or withdraw regulatory approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend any of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seize or detain products, or require a product recall.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. The Centers for Medicare &amp; Medicaid Services, or CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February 1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. These regulations became effective on April 1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code or the individual mandate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction, or the Joint Select Committee, to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent legislation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. As of July 2, 2022, the 2% sequester reduction resumed. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="white-space:pre-wrap;">The Affordable Care Act, or ACA, has also been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken   to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Under <span style="letter-spacing:0.2pt;white-space:pre-wrap;">the Hatch-Waxman Act, a pharmaceutical manufacturer may file an ANDA seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications a paragraph IV certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents.  Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accordingly, if we choose to develop a small molecule product candidate, and the product is approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">False </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Claims Act (which can be enforced through &#8220;qui </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">tam,&#8221; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or whistleblower actions, by private citizens on behalf of the federal government), prohibits </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">person from, among other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">things, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly presenting, or causing to be presented false or fraudulent claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the government or knowingly and improperly </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">avoiding, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreasing or concealing an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">HIPAA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which imposes criminal liability and amends provisions on the reporting, investigation, enforcement,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">penalizing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;">for,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">things,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">executing, or attempting to execute, a scheme to defraud </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefit program, or knowingly and willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">falsifying,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">concealing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covering</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fact</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statement, in connection with the delivery of, or payment </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefits, items or services by a healthcare benefit program, which includes both government and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">privately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funded benefits programs; similar to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal Anti-Kickback Statute, a person or entity does not need to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual knowledge of the statute or specific intent to violate it in order to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">committed a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">violation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations, including state anti-kickback and false claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">laws, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apply to our business practices, including but not limited </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">to, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">payer, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including private insurers; state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government, or otherwise restrict payments that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be made to healthcare providers and other potential referral sources; and state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided to healthcare professionals and entities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicare,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicaid,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Children&#8217;s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Insurance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Program to report </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">annually </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to CMS information related to certain payments made in the preceding calendar year and other transfers of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers  of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nurse-midwives</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">similar </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data protection and healthcare </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governing the privacy and security of personal data, including the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union and European Economic Area (including with regard to health data</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">).</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">New <span style="letter-spacing:0.2pt;">income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-  money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our stock price may be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In particular, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to acquire, license, or develop additional product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">innovations or new products developed by us or our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with manufacturers, suppliers, licensors, future collaborators, or other strategic partners;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain additional funding;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our stock by insiders and stockholders;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, product liability, or other litigation against us; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including with respect to the financial markets in the United States and worldwide resulting from inflation, the ongoing COVID-19 pandemic and the conflict between Russia and Ukraine.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, the stock markets in general, and the markets for biopharmaceutical stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with the auditor attestation requirements in the assessment of our internal control </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be adopted by the Public Company Accounting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oversight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regarding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">firm</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rotation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supplement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">auditor&#8217;s report</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reduced </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosure obligations regarding executive compensation in our periodic reports,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">proxy </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements and registration statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to hold a nonbinding advisory vote on executive compensation and stockholder </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">approval </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">golden parachute payments not previously</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="letter-spacing:0.2pt;">, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we sell shares of our common stock in future financings, stockholders may experience dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because we expect our expenses to increase significantly in the foreseeable future and because, based on our current business plans, we believe that our cash, cash equivalents and non-dilutive grant funding, will be sufficient for us to fund our operating and capital expenditures into the second half of 2024. As a result, we may from time to time issue additional shares of common stock or other securities to raise capital. These issuances may be at a discount from the current trading price of our common stock. Our stockholders would experience dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders will experience additional dilution and, as a result, our stock price may decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">As of March 20, 2023, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially owned approximately 29.8% of our outstanding common stock. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions<span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Sales <span style="letter-spacing:0.2pt;">of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. Sales of significant number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We have also registered or intend to register all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be available for sale in the public market subject to vesting arrangements and exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates may in the future establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">In December 2022, we filed a registration statement on Form S-3 relating to the registration of our common stock, preferred stock, debt securities, warrants, units and subscription rights or any combination thereof. Concurrently with the filing of such registration statement, we entered into an &quot;at-the-market&quot; offering program, or ATM, which provides for the offering, issuance and sale by us of up shares of our common stock from time to time for aggregate gross proceeds of up to $40 million in sales deemed to be &#8220;at-the-market offerings&#8221; as defined by the Securities Act of 1933, as amended. For the period ended December 31, 2022, we have sold and issued no shares of common stock pursuant to the ATM. In addition, in March 2023, we entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, providing for the sale of up to $35.0 million worth of shares of our common stock. Any additional sale or issuance of securities pursuant to this registration statement or otherwise may result in dilution to our stockholders and may cause the market price of our stock to decline. Furthermore, new investors purchasing securities that we may issue and sell in the future could obtain rights superior to the rights of our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We are also authorized to grant stock options and other equity-based awards to our employees, directors and consultants pursuant to our 2021 Equity Incentive Plan. The number of shares available for future grant under the 2021 will automatically increase each year by up to 5% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. Currently, we plan to register any increase in the number of shares available for issuance under the 2021 Plan promptly following the effectiveness of any such increase. If our board of directors elects to increase the number of shares available for future grant under the 2021 Plan, our stockholders may experience additional dilution, and our stock price may fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of December 31, 2022, we had federal net operating loss, or NOL, carryforwards of approximately $36.3 million and state NOL carryforwards of approximately $12.2 million available to offset future taxable income. Of the federal NOL carryforwards, $17.9 million begin to expire in 2033, and $18.3 million can be carried forward indefinitely. State NOL carryforwards will begin to expire in 2027. As of December 31, 2022, we had a foreign NOL carryforward of $0.3 million in Australia that can be carried forward indefinitely. As of December 31, 2022, we also had $1.7 million of federal research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2027, if not utilized. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the &#8220;ownership change&#8221; provisions under Sections 382 and 383 of the Code. An &#8220;ownership change&#8221; is generally defined as a cumulative change in the ownership interest of significant stockholders over a rolling three-year period in excess of 50 percentage points. Similar provisions under state tax law may also apply. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change. We may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. Such ownership changes could result in the expiration of our NOL carryforwards and other tax attributes before they can be utilized and, if we are profitable, our future cash flows could be adversely affected due to our increased tax liability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, under the Tax Cuts and Jobs Act, or the TCJA, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, NOL carryforwards arising in tax years beginning after December 31, 2021 are limited to 80% of taxable income. Under the TCJA, federal NOL carryforwards arising in tax years beginning after December 31, 2017 may be carried forward indefinitely. Under the CARES Act, federal NOL carryforwards arising in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss and temporarily suspends the 80% limitation mentioned above for this period. The changes in the carryforward and carryback periods as well as the limitation on use of NOL carryforwards may significantly impact our ability to use NOL carryforwards, particularly for tax years beginning after December 31, 2022, as well as the timing of any such use, and could adversely affect our results of operations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and amended and restated bylaws each contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the required approval of at least </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">2</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8725;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;">3</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">%</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law, or the DGCL. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our third amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our third amended and restated certificate of incorporation and amended and restated bylaws, however, provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce this provision, if applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision contained in our third amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic or political conditions has in the past and could in the future adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;white-space:pre-wrap;">business is susceptible to general conditions in the global economy and in the global financial markets. Further, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the U.S. and China or the conflict between Russia and Ukraine, including any additional sanctions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities in, for example, Russia, also has in the past and could in the future lead to disruption, instability and volatility in the global markets, which may have an adverse impact on our business or ability to access the capital markets. A severe or prolonged economic downturn, including rises in interest rates, liquidity constraints, failures and instability in U.S. and international financial banking systems, inflation, recession or depression, or political disruption has and could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Key national economies, including the United States, have been affected from time to time by economic downturns or recessions, supply chain constraints, heightened and fluctuating inflation and interest rates, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies and overall uncertainty with respect to the economy. In particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#8217;s measures to slow inflation, the stock market has been exceptionally volatile.  In addition, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit  rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.  Most recently, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver.  Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;background:#ffffff;">our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general.  These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.  Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws.  Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The <span style="letter-spacing:0.2pt;">trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have incurred, and will continue to incur, significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We are subject to Section 404 and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are deemed to be a large accelerated filer or an accelerated filer, we will be required to include an attestation report on internal control over financial reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we identify any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could materially and adversely affect our business, financial condition, results of operations and prospects, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs and other third parties to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, increased costs and demands upon management as a result of being a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">a public company listed in the United States, we incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and The Nasdaq Stock Market LLC, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a3438a8_5fa4_43a7_b5b0_654ec873a156"></a><a id="Item1BUnresolvedStaffComments_685711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3db72d22_af62_4cbe_8fd0_6d8e4661a47b"></a><a id="Item2Properties_347022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. We lease approximately 6,686 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9049cae0_3007_4c2b_a385_352c655cb1d7"></a><a id="Item3LegalProceedings_272268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We are not aware of any pending legal actions that would, if determined aversely to us, have a material adverse effect on our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We may, from time to time, become involved in disputes and proceedings arising in the ordinary course of business. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations, and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_66b75b38_1d4a_4dcd_9fb1_40e2c954da12"></a><a id="Item4MineSafetyDisclosures_494562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e8777922_fff9_4825_9dee_b9b86cceff4e"></a><a id="PARTII_331600"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;CGTX&#8221; on October 8, 2021. Prior to that time, there was no public market for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of March 20, 2023, there were approximately 29,262,587 shares of our common stock outstanding held by approximately 256 holders of record. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We have never declared or paid any cash dividends on our common stock, and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our common stock may be limited by any future debt instruments or preferred securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Information about our equity compensation plans is incorporated herein by reference to Item 12, <i style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i>, of this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">There were no unregistered sales of our equity securities during the fiscal year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer or Affiliated Purchaser</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="display:inline-block;width:36pt;"></span><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our registered equity securities during the fiscal year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On October 13, 2021, we completed our IPO. Our registration statements on Form S-1 (File Nos. 333-257999 and 333-260128), each relating to the IPO were declared effective by the SEC on October 7, 2021. We issued 3,768,116 shares of our common stock at a price of $12.00 per share for aggregate net cash proceeds of $37.9 million, after deducting underwriting discounts and commissions and other offering related costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On November 10, 2021, the Representative provided notice to us that it had elected to exercise its over-allotment option in full to purchase 565,217 shares of our common stock. The Representative&#8217;s exercise of the over-allotment option closed on November 12, 2021, resulting in net proceeds of $6.3 million to us, after deducting underwriting discounts and commissions and other offering related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus dated October 7, 2021, filed with the SEC pursuant to Rule 424(b) under the Securities Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eb807afa_c6cd_444e_92a8_dc2b9fde5ee4"></a><a id="Item6SelectedFinancialData_500456"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;6. [Reserved].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f6902888_240b_47ef_b9b5_0552db8bd23a"></a><a id="_643054"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Item 1A, Risk factors, in this Annual Report on Form 10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the &#963;-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2007, we have incurred significant operating losses and devoted substantially all of our time and resources to developing our lead product candidate, CT1812, building our intellectual property portfolio, raising capital and recruiting management and technical staff to support these operations. As of December 31, 2022, we had an accumulated deficit of $115.4 million. We incurred net losses of $21.4 million and $11.7 million for the years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging, or NIA, a division of the National Institutes of Health, or NIH, and proceeds from our initial public offering, or IPO, completed in October 2021, proceeds from our follow-on public offering in November 2022, and the sales of our convertible promissory notes, convertible preferred stock, simple agreements for future equity, or SAFE, and stock option exercises. Since our inception, we have received approximately $171.0 million in cumulative grant awards to fund our clinical trials, primarily from the NIA, and we have raised approximately $108.8 million in net proceeds from sales of our equity securities, convertible notes, SAFE, stock option exercises, our IPO and follow-on public offering. As of December 31, 2022, we had cash and cash equivalents of $41.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, we completed our IPO, pursuant to which we issued and sold 3,768,116 shares of our common stock at a public offering price of $12.00 per share. Additionally, on November 12, 2021, the underwriters exercise of their over-allotment option in full to purchase 565,217 shares of our common stock closed. In connection with the IPO, we received net proceeds of approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us, which includes net proceeds of approximately $6.3 million from the exercise of the over-allotment option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, we completed our follow-on public offering, pursuant to which we issued and sold 5,000,000 shares of our common stock at a public offering price of $1.20 per share. In connection with the follow-on public offering, we received net proceeds of approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, we entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings (the &#8220;ATM&#8221;). For the year ended December 31, 2022, we have not sold any shares of common stock under the ATM.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of CT1812 for preclinical studies and clinical trials, as well as for commercial manufacture if CT1812 obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute CT1812, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Impact of COVID-19 on Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;background:#ffffff;margin:0pt;">Our business has been and could continue to be adversely affected by the effects of the ongoing COVID-19 pandemic, including, but not limited to, our clinical trials. For example, our ongoing and/or planned clinical trials may be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory authorities. Additionally, we have made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA and may need to make further adjustments in the future. We have also initiated our clinical trial protocols to enable remote visits to mitigate any potential impacts as a result of the COVID-19 pandemic. Many of these adjustments are new and untested, may not be effective, may affect the integrity of data collected, and may have unforeseen effects on the progress and completion of our clinical trials and the findings from such clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The spread of COVID-19, including the spread of new strains and variants of COVID-19, and actions taken to reduce such spread may also materially affect us economically. While the potential further economic impact brought by, and the duration of, the COVID 19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. As a result, we may face difficulties raising capital through future sales of our common stock or such sales may be on unfavorable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs. Following the completion of our IPO on October 13, 2021, we have incurred, and will continue to incur, substantially increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Grant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and consulting costs, costs paid to contract research organizations, research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension. Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0 million grant from the NIA to fund our Phase 2 (COG0203) study of CT1812 in patients with early-stage AD, an approximately $30.5 million grant from the NIA to fund our Phase 2 (COG0201) study of CT1812 in patients with mild to moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase 2 (COG1201) study of CT1812 in patients with dementia with Lewy bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in fair value of derivative liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Change in fair value of our derivative liability consists of changes in the fair value of certain conversion and redemption features associated with our convertible notes that are required to be bifurcated and accounted for as free-standing derivative financial instruments. The derivative liability expired unexercised upon the conversion of the convertible notes into Series B-1 convertible preferred stock in May 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in fair value of SAFE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;">Change in fair value of our SAFE consists of fair value adjustments to these instruments based primarily on the changes in the probability of occurrence and estimated timing of future event inputs in the valuation model. Upon the occurrence of our IPO on October 7, 2021, the SAFE was converted into 931,485 shares of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Gain on Debt Extinguishment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;">Gain on debt extinguishment for the year ended December 31, 2021 was the result of the forgiveness of the Paycheck Protection Program loan on January 21, 2021. There was no gain or loss on debt extinguishment for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Interest expense for the year ended December 31, 2022 consisted of interest expense related to the insurance premium financing arrangement with a lender. Interest expense for the year ended December 31, 2021 primarily consisted of interest expense from our convertible notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other income (expense), net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists primarily of research and development tax credits earned in the applicable period, as well as foreign currency transaction gains or losses, and interest income from interest-bearing cash equivalents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December 31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our results of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations Data: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,572</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,752</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,026</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,201</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,551</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,598</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,953</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,551)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,598)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,953)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,217</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,447</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,770</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,209)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in the fair value of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,236)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,236</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (88)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (443)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (893)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 865</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,154</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,272</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,397)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,716)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,681)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our research and development expenses (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,679</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,103</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,599</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,661</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,465</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,804)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,178</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 752</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities and other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 102</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,572</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,752</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $30.3 million for the year ended December 31, 2022, compared to $18.6 million for the year ended December 31, 2021. The increase of $11.7 million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $11.1 million in clinical programs related to increased Phase 2 trial activity primarily due to increased contract research organization spend; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $2.6 million in personnel costs associated with expanded research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $2.8 million in manufacturing expense related to costs incurred with contract manufacturing organizations for production of pre-clinical and future clinical trial materials associated with our most advanced product candidates due to the timing of the manufacturing of the pre-clinical and clinical trial materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.9 million in preclinical programs, facilities and other costs primarily due to increased sponsored research spend under grants.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $13.2 million for the year ended December 31, 2022, compared to $10.0 million for the year ended December 31, 2021. The increase of $3.2 million was primarily due to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.1 million in Director &amp; Officer liability insurance and other expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.8 million in compensation and employee benefits driven by increased headcount; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $2.6 million in professional fees driven by increased audit, tax, and legal services; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $1.3 million in equity-based compensation from stock option grants.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Grant income was $22.2 million for the year ended December 31, 2022, compared to $17.4 million for the year ended December 31, 2022. The change in grant income is correlated with the increase in eligible reimbursable costs incurred during 2022 as compared to 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of the Derivative Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Changes in the fair value derivative liability resulted in a gain of $2.2 million for the year ended December 31, 2021. There was no gain or loss for the year ended December 31, 2022 as the derecognition of the derivative liability occurred in May 2021 upon the conversion of convertible notes into shares of Series B-1 convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of the SAFE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Changes in the fair value of the SAFE resulted in a loss of $2.2 million for the year ended December 31, 2021. There was no gain or loss for the year ended December 31, 2022 as the derecognition of the SAFE liability occurred when the SAFE converted into shares of our common stock upon the closing of our IPO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income, net was less than $0.1 million for the year ended December 31, 2022, compared to other expense, net of less than $0.1 million for the year ended December 31, 2021. Overall, management believes that the change in other expense was not significant in either period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Gain on Debt Extinguishment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Gain on debt extinguishment was $0.4 million for the year ended December 31, 2021 as a result of the forgiveness of the Paycheck Protection Program loan on January 21, 2021. There was no gain or loss on debt extinguishment for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Interest expense was less than $0.1 million for the year ended December 31, 2022, compared to interest expense of $0.9 million for the year ended December 31, 2021. The change of $0.9 million in interest expense was the result of the convertible notes outstanding balance during the year ended December 31, 2021, which were subsequently converted into shares of our Series B-1 convertible preferred stock in May 2021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFE, stock option exercises, our IPO and our follow-on public offering. Since our inception, we have received grant awards primarily from the NIA in the aggregate amount of approximately $171.0 million and have raised approximately $108.8 million in net proceeds from sales of our equity securities, convertible notes and SAFE, stock option exercises, our IPO and our follow-on public offering. On March 25, 2021, we completed a SAFE offering with various investors, pursuant to which we received gross proceeds in an aggregate amount equal to $8.9 million. On October 13, 2021, we closed our IPO, selling 3,768,116 shares of our common stock at a public offering price of $12.00 per share. Additionally, on November 12, 2021, the underwriters exercise of their over-allotment option to purchase 565,217 shares of our common stock closed. The net proceeds were approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us, which includes net proceeds of approximately $6.3 million from the exercise of the over-allotment option. On November 15, 2022, we closed our follow-on public offering, selling 5,000,000 shares of our common stock at a public offering price of $1.20 per share. The net proceeds were approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On December 23, 2022, we entered into a sales agreement with the Sales Agents, providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in ATM offerings. As of December 31, 2022, we have not sold any shares of common stock under the ATM. In addition, in March 2023, we entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, giving the Company the right, but not the obligation to sell to Lincoln Park up to $35.0 million worth of shares of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;">As of December 31, 2022, we had $41.6 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that the net proceeds from the IPO and follow-on public offering, together with our existing cash and cash equivalents and income from non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the second half of 2024, which assumes no usage from the ATM nor purchase agreement with Lincoln Park. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 20.15pt;">Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to the COVID-19 pandemic or other diseases, macroeconomic conditions, global or political instability, such as the ongoing conflict between Ukraine and Russia, inflation, or other delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, timing, and receipt of any future NIA Grants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA Grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA Grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or other diseases, the ongoing conflict between Ukraine and Russia, inflation, liquidity constraints, failures and instability in U.S. and international financial banking systems, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our cash flows for the periods indicated (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18,533)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,631)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (171)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,546</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,201</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,159)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 49,532</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2022 was $18.5 million, which consisted primarily of our net loss of $21.4 million partially offset by net non-cash charges of $3.8 million and a net change of $0.9 million in our operating assets and liabilities. The non-cash charges primarily consisted of depreciation and amortization of less than $0.1 million, amortization of right-of-use assets of $0.2 million, and equity-based compensation of $3.6 million. The net change in our operating assets and liabilities was primarily due to an increase in grant receivables of $1.9 million, an increase in other assets of $1.7 million, a decrease in accounts payable of $1.1 million, partially offset by an increase in deferred grant income and other liabilities of $2.6 million, and a decrease of $0.9 million of prepaid expenses, other current assets, and other receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2021 was $3.6 million, which consisted primarily of our net loss of $11.7 million partially offset by net non-cash charges of $5.2 million and a net change of $2.8 million in our operating assets and liabilities. The non-cash charges primarily consisted of depreciation and amortization of $0.1 million, amortization of debt discount of $0.4 million, change in fair value of SAFE of $2.2 million, and equity-based compensation of $5.1 million, partially offset by a change in the fair value of the derivative liability of $2.2 million. The net change in our operating assets and liabilities was primarily due to an increase in accounts payable of $2.2 million, an increase in accrued expenses of $1.3 million, and an increase in other current liabilities of $0.5 million, partially offset by an increase in grant receivables of $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2022 and 2021, we used $0.2 and less than $0.1 million of cash, respectively, for investing activities related to purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $5.5 million and $53.2 million for the years ended December 31, 2022 and 2021, respectively. The decrease in cash provided by financing activities relates primarily to the IPO of our stock whereby we received net proceeds of $44.2 million and the issuance of SAFEs whereby we received $8.9 million during the year ended December 31, 2021. This is partially offset by proceeds received from the exercise of common stock options in the amount of $1.6 million, as well as proceeds from issuance of common stock in our follow-on public offering in the amount of $5.3 million during the year ended December 31, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our contractual obligations as of December&#160;31, 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3&#160;to&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More&#160;than&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 126</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,020</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 126</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,020</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we entered into an insurance premium financing arrangement with a lender. Under the agreement, we financed $0.8 million of certain premiums at a 6.85% annual interest rate. Payments of less than $0.1 million are due monthly from October 2022 through September 2023. As of December 31, 2022, the outstanding principal of the loan was $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have entered into operating leases for office and laboratory facilities under agreements that run through May 31, 2029. The amounts reflected in the table above consist of the future minimum lease payments under the non-cancelable lease arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, we entered into an agreement to lease 2,980 square feet of office space in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. The annual base rent under the lease is less than $0.1 million throughout the term of the lease. Total payments due over the term of the lease are $0.2 million. Additionally, on August 31, 2022, we modified one of our existing lease agreements with the landlord for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July&#160;1, 2021, we entered into an agreement to lease 2,864 square feet of office space in Purchase, New York. The lease has a term of 89 months and commenced on December 9, 2021. The annual base rent under the lease is less than $0.1 million for the first lease year and is subject to annual increases of between 1.82% and 2.04%. We provided a security deposit in the form of a Letter of Credit in the amount of less than $0.1 million pursuant to the terms of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with contract research organizations and other vendors to assist in the performance of our research and development and other services and products for operating purposes. These contracts typically do not contain minimum purchase commitments and generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable advance payments for research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for stock options subject to time-based vesting on a straight-line basis over the requisite service period and account for forfeitures as they occur. To the extent any stock option grants are made subject to the achievement of a performance condition, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Term. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected term represents the period that the stock-based awards are expected to be outstanding. As we do not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk-Free Interest Rate. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Volatility. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Dividend Yield. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected dividend yield is zero as we have not paid and do not anticipate paying any dividends in the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fair Value of Common Stock. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors has determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">See Note&#160;9 to our audited financial statements for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested time-based vesting awards was $6.5&#160;million, which is expected to be recognized over weighted-average remaining vesting period of approximately 2.0&#160;years. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">For a description of recent accounting pronouncements, see Note&#160;2 of the notes to our audited consolidated financial statements for the&#160;year ended December&#160;31, 2022 included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our IPO.</p><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As a &#8220;smaller reporting company,&#8221; as that term is defined in Rule 229.10(f)(1), we are not required to provide the information required by this Item. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_940b2e00_99b6_40ca_a0b7_54849e5deaf1"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><a id="_d6dc94fc_f996_41a2_85a9_0ecf12033dac"></a><a id="_Hlk130366833"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">As of and for the years ended December 31, 2022 and 2021</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42)</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4c7ba408_c68f_4934_965f_2234f8b186e9"></a><a id="ReportofIndependentAccountingFirm"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Shareholders and the Board of Directors of Cognition Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Cognition Therapeutics, Inc. and Subsidiary (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">March 23, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d09d1774_2905_4782_adbc_6cd8cd9d3114"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_54f3b420_0b09_47cd_9448_1231a4edc769"></a><a id="Tc_d8xrsfIpWkaJ7sOAH5eUpQ_2_2"></a><a id="Tc_0cYu09_Uh0G3x921RrH-dA_3_2"></a><a id="Tc_nBjEbK85ck6fWHeGDwqgGA_3_5"></a><a id="Tc_wCyNRyAMG0yXrbNZ3lsqiQ_4_0"></a><a id="Tc_kZdDk2cPNEqtzMCUTbqU7Q_5_0"></a><a id="Tc_PbnXvXIKS0qxcTxUvGfJhw_6_0"></a><a id="Tc_52UbA4y4l0uWjV_CFCi1bw_6_2"></a><a id="Tc_9s2mJo7UvkGE4Xnf0IW-qA_6_5"></a><a id="Tc_p_822MTtAk-IicuoKi811A_7_0"></a><a id="Tc_vujBVvZSeEaiw7foJFDqPw_8_0"></a><a id="Tc_PVbKrhnCw02JAQZgR1IClA_9_0"></a><a id="Tc_AIKgqvA6tU-hmA3MUznc6w_9_3"></a><a id="Tc_i4O6K2Z4d0CVqAqYK-6DPQ_10_0"></a><a id="Tc_6r3z3_XrIEiN1uLkddbLbQ_11_0"></a><a id="Tc_Zx9gT6J1LUybBXHiOu1k6w_12_0"></a><a id="Tc_0zmIDTrxgUWLiLZfuB8kMA_12_6"></a><a id="Tc_-sawTMCQPUuUbwMwJMNaGg_13_0"></a><a id="Tc_1G2b7WBinU27AdqAtQXr_A_13_6"></a><a id="Tc_wGxSnnem7EeAtuWfs_BFFw_14_0"></a><a id="Tc_qoE95vecx0CjKDN4U7yzrw_14_2"></a><a id="Tc_NA0QxFaJ20e1vs2NvDFRTA_14_5"></a><a id="Tc_fXjn66X9I0mbKwrXvEoyzw_15_0"></a><a id="Tc_FNGs0NvZ202enxokh9IYfQ_16_0"></a><a id="Tc_EKOylf0DREy1u_e-c7VlRg_17_0"></a><a id="Tc_yJSiM0_puUSyVe9kq1xXmQ_18_0"></a><a id="Tc_UcjfPeXcrUOEy4cb4nyjuA_19_0"></a><a id="Tc_cuVWtTmGakKXGoUOKtWXNQ_20_0"></a><a id="Tc_--5Bl8Ttl0OvL-kBi564Og_20_6"></a><a id="Tc_l8R3FN8ZIkiMDgtfbKoWdg_21_0"></a><a id="Tc_8ow18Uvdt0WGgJzZiq3qwQ_22_0"></a><a id="Tc_4dcnB5yMuEudAG7d0OZXEg_23_0"></a><a id="Tc_tZU2dF3TQE2TSIz86qLATA_23_6"></a><a id="Tc_8UQgUAY2U0mAoQODKX13-g_24_0"></a><a id="Tc_QLT82Eg_YEGTdF0Nd059fg_24_6"></a><a id="Tc__gMhmSMWeku7A4XXDli-ug_25_0"></a><a id="Tc_kMsAXjDqZ0qeYL05tq4m_w_26_0"></a><a id="Tc_eoySQZOJg0uHIvtkUZHK7w_27_0"></a><a id="Tc_k-nyK8oHj0SK4CjOkpvMsA_28_0"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_2"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_3"></a><a id="_62dad1d3_bd4d_44b7_b05b_41c8e40c5587"></a><a id="_62dad1d3_bd4d_44b7_b05b_41c8e40c5587_2"></a><a id="_62dad1d3_bd4d_44b7_b05b_41c8e40c5587_3"></a><a id="Tc_XS2qaN8FwU2g2at9n-oSWw_29_0"></a><a id="Tc_64ImZMOsX0G2zTA27ve5nQ_30_0"></a><a id="Tc_c-L8YMqor0WjmPCeR8DgVA_31_0"></a><a id="Tc__ou5_qbT9Uaq47L2oPtDgg_32_0"></a><a id="Tc_rOWM7RBB7U2N-EjFeE1RXg_33_0"></a><a id="Tc_zaxvz79DJk2Q_EmFdNtfVg_34_0"></a><a id="Tc_z3X3UBDv4UqZi_941qT90A_34_2"></a><a id="Tc_ZVGrYqXPqEC8qFf4qk24AA_34_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_32v469jtJkuRjf5fYnKK0Q_6_3">41,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LzE3yk4CdUeE72o_gJBbJg_6_6">54,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_lLz2VSzWGEOgbGk6qjyN4Q_7_3">3,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_iZE9tW5QHkSHqjQv38SieA_7_6">1,799</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_3utFbwpJP02yZ65QEt0e6A_8_3">2,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_I7XgPbDQ-EaLVDwRdWo5fg_8_6">2,005</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_p14wcYhyKUyfhpH19imK7A_9_6">467</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_2bQV-AsNtEqoLpc04aza9w_10_3">47,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_XSddKiZCCUmTWIuJPlXKNg_10_6">58,992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_cBm3r6Nk10ykhqcOOmt5Gg_11_3">233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_oN921YJjakeNpwxTDbihGQ_11_6">145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_f55yyE5ntUiPloVKQldX0g_12_3">813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="3" id="Tc_csgwQv0pN0mSJRXRoldZ8g_13_3">1,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_gOHuWVfIfU-ZyarGAGBlJA_14_3">50,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_FIGUnetbMkiNdMzUSTdkwQ_14_6">59,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_bpd53LzG3Ue5twneizeMtQ_17_3">3,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_kOb7Amj7P0a-GGdgAAt7Ww_17_6">4,168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Iu8EZ3M23UevkAvIV7KJNA_18_3">2,094</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_zPCBO5HaEUSoTuNZ7GaKWg_18_6">1,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Deferred grant income, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_TkgjTZ54aUuGNdOyLidajQ_19_3">1,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_Cpg-ilyPCkSpRAiHf-dFbg_19_6">753</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_NIs7nXWZhU-krqU27sB6TQ_20_3">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_6wg6uLhgIku9dmdPQbPXtw_21_3">634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_bLJ-u7LuPUeHwU-oV9DLcQ_21_6">1,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_-tmHBYdJ7kaa7c5i6EbF5Q_22_3">7,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_J5pP0sxvIUmjQu3q2SF89Q_22_6">7,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Operating lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_fTt5zLYmMEWkD7BUJiPmIw_23_3">695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Deferred grant income and other liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_nd_JXzy7aEOJSToML9erBw_24_3">1,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_gzlmfDS7rEal6fTV2Ww0qg_25_3">10,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_4qof0lbfQEmOb_X2gqFLNw_25_6">7,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FFwd-ub1zUGGLAqJyg_bBw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr__-WGWkiX1UCoMOjOHG6PNg">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_yzRnZV3R-ke8zRMgZc_HFw"><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_GfWmOHPjWk6iN2KT-qna2g">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December&#160;31,&#160;2022 and December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ovgd2fX3ZEaWm0wcmsqVsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_5TBw3xjUxk-WxRkuRpVO-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;">Common stock, </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_mIaB4bEur0-saeV8Z1L5pw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Jgp6rULfGUWYS1AIU-vQEg">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lEiAjkMZ70CxPbwuWQECXg"><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_cYrSL3bPUU610j2HEy2gyw">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized at December 31, 2022 and December 31, 2021; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_j4RY_z3Z80mAynSS-DURZA">28,991,548</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_wGt9_-HLwEmBS1Z9F3wEig">22,230,032</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden__HQWsjBkFkmBXhs8jgM5nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_4NRuDtMjt0WCqOwgWiie7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_lwkuSp18nUOZhLHWDLQhNQ_29_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_D1gvcFyAwkyuD6JnB1uHtA_29_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_IDDDW2GSxUaotsa8D62tPg_30_3">155,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_KJ_haXVKJ0-YivOUvd0OGg_30_6">145,453</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_hsBuddxQqUizHTuEyc6vzg_31_3">115,401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_1IiMRKeV00uTiF1hRrEiCA_31_6">94,004</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_PlKSjRSah0ernFGrtJoSNg_32_3">199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_rhlE9exrb0apuNXsRjRcyA_32_6">198</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GFlAV4SsxkqDc96K1WDNqw_33_3">40,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ROlrrJznJ0uUTEawB9H4Cw_33_6">51,273</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_SHL59Pf0w0CA1LecrslTpw_34_3">50,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_yRy-mDm5qUiJi-spylOUvA_34_6">59,137</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f68c2ed8_7e18_4388_808e_450f13cf32c0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_cbd2e53e_0778_4387_a69a_47f92c968321"></a><a id="Tc_BUOsUmWD0kmlV7XXXGgddw_1_2"></a><a id="Tc_ZuZDj6czwEmXSN5OVLKI-g_2_2"></a><a id="Tc_9JgetBX17kKIpvdwUxnv_Q_3_2"></a><a id="Tc_aQqsLvWuqkKLSRfg0qKLeg_3_5"></a><a id="Tc_bXemUtg6D0GblGNHBkq0SQ_4_0"></a><a id="Tc_TFxkuRmzy06n4d9_BJkILg_5_0"></a><a id="Tc_I_jBuR69oUucTd7WC3Jxrg_5_2"></a><a id="Tc_Jq718LXfgESDD23_6IZC3w_5_5"></a><a id="Tc_MJYc9SanRE6lntUG6Bv6BA_6_0"></a><a id="Tc_Qm-Y0z3JgUWTZ5xssAawGQ_7_0"></a><a id="Tc_Oe6xpzd9H0atHwD76rClcg_8_0"></a><a id="Tc_B8FJfbz7b0i4MBVsPA0_hg_9_0"></a><a id="Tc_gE0snCnStkWCWRN0Jwy2iw_10_0"></a><a id="Tc_g2j87-nkmU-tPrgf9tF_DA_11_0"></a><a id="Tc_KLUYqoveqEuMmQlSpsWJrw_11_3"></a><a id="Tc_kQBSVLmiSU2WrLe_Jx5r4Q_12_0"></a><a id="Tc_QPcuXMH6bkKb6E15fMGOeQ_12_3"></a><a id="Tc_zrpxDhIoTEOpahseVFjAgw_13_0"></a><a id="Tc_jE4e41NAckiTwztNCw82KA_14_0"></a><a id="Tc_OB-TLvsaPEK5q96ytjIpsQ_14_3"></a><a id="Tc_qsOtnIGxFkGCgrR7duQEgg_15_0"></a><a id="Tc_YSvuLGjYz0CqvwoBsbvDtg_16_0"></a><a id="Tc_1gbUR0zDu0asE3ze-GCJUQ_17_0"></a><a id="Tc_8PqlXCvY4UaevI8nIAU3pQ_18_0"></a><a id="Tc__A_RI2wZNkW8jlJfIMVhbg_18_3"></a><a id="Tc_sy_SV-_PykWqtfJEhJoDKQ_19_0"></a><a id="Tc_Iz3_dizatEOxANCnW2dEZg_19_2"></a><a id="Tc_QXGjzoCemEqQ6oirZhyEag_19_5"></a><a id="Tc_vL5Fm19D-UintugzYB7Rhg_20_0"></a><a id="Tc_PRD7JGu7K0uvnssDVOY3-Q_21_0"></a><a id="Tc_0TxVk74ja0SLq7SXTZ0s3g_21_2"></a><a id="Tc_G0kKfqkCwUuq9y0rM1BGLA_21_5"></a><a id="Tc_OhhfXuwtUEim0JzqC7r1iA_22_0"></a><a id="Tc__5vFMRmkRE-X9w8JFniFug_23_0"></a><a id="Tc_i-QsNRi-ckaXpz5rxB4ACw_23_2"></a><a id="Tc_7AlRo_nqgkyZiUT5duVt5Q_23_5"></a><a id="Tc_cN_SYC-Pek-lGl9Vz3ea3Q_24_0"></a><a id="Tc_y-mwTPT0S02tCp4UJzo3nA_24_2"></a><a id="Tc_ESWDH5Q-ZkykQeRU1zwW8g_24_5"></a><a id="Tc_w__n5vl2XEmbzrlSukWXtg_25_0"></a><a id="Tc_mmpbotvK60GRXw0USQfrZQ_26_0"></a><a id="Tc_GjwWGb88vUWJnHdIpVBe-w_27_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the&#160;Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_FmSuBEtWMUKTLmvUOtQ_tQ_5_3">30,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_zwh0C1ptz0Scpos7W54Ltg_5_6">18,572</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Dvd69gZhKkib3Q3HufvTbA_6_3">13,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_cja9nAEzCE6qX9jMiwNWbw_6_6">10,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc__4xSsaSmD0ml51MQS_cI9g_7_3">43,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc__z-XOwQbUUmzJSK3JV0V6g_7_6">28,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_6QsqJomi_U-R_-JhqcWeuw_8_3">43,551</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_5ecDsCuf-USWolKPB8kvWA_8_6">28,598</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Tc_OVAdpdTkskGvs3voKhAe8w_10_3">22,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Tc_oa2PJjuJjUua1jTn4ipULA_10_6">17,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfDerivativeLiability" scale="3" id="Tc_fVwttrnYr0qRD8nipxNHfg_11_6">2,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of the Simple Agreements for Future Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity" sign="-" scale="3" id="Tc_9Lkc0OLRM02Lo14SvxPPNg_12_6">2,236</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_Xw-QV1qiuUaIjdWb_j_nCg_13_3">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_bjUPxMbvgkK5_GqO0U2DXw_13_6">88</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_8sbYEdde8keidDizIafhIQ_14_6">443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_KbSJXIuNPUmpIUaP5f0_mw_15_3">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_AJo6ly55UkiuDKMl5XYl1A_15_6">893</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_mSEB7cm4ukSfbUm9Z4Fxug_16_3">22,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_nJk2ga04ak6ugGytm0JpMA_16_6">16,882</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sGO23BrOUUaHNt-YI_EU_A_17_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EYDju9ycv0-cGfP36XnKjQ_17_6">11,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cumulative preferred stock dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_rhl96dYxcEuI20wF1EDKxw_18_6">4,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_a88mctrUrUCP3JSCrehzDg_19_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_cYyRztOD1Uuyx1VAOf0WMw_19_6">16,248</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized loss on foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_CCfft4Bn4Uynl1mHRGKQgA_20_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_j9DJa48X_E6PE82MN-BHCw_20_6">11</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_L-sTA45_JkKYMHfnMme3WA_21_3">21,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_LOPIp_NmR0yLVb5uCrSWGQ_21_6">11,727</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_cnyJCAyEJki4YdPiviBCGA_23_3">0.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_VeMpxHXXA0OKeRlGKISBjw_23_6">3.13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_JTjEjUFgs0uW0mxu6-edUQ_24_3">0.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_PuJw6urKH0uVT9B6tOtwWA_24_6">3.13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_zGAT0Bsu1k6njs8Shz8r_Q_26_3">23,640,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_UC_EqmlO60GuhVccD1XzTQ_26_6">5,190,883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_UUAu-d4SEE2a3W61Qk3wmg_27_3">23,640,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_kHkZRVfbYUe1mQMGAfXEsQ_27_6">5,190,883</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4bf1c834_e569_45db_8032_b5091e22b6f9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofStockholdersEquity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f1d84c4c_1bc3_480b_881e_038b6f5c88aa"></a><a id="Tc_NmWoZRD3rkG4VTlQFgq-_Q_1_19"></a><a id="Tc_-DAYMKCGCUuo-EKbPXeIHQ_2_2"></a><a id="Tc_8KoHIBPC7EqS7hGqMitQxg_2_13"></a><a id="Tc_ZBLxcX09hUaDf_t64gzd-g_2_19"></a><a id="Tc_Z4pX0HTURkSzTIV4TBg82A_2_22"></a><a id="Tc_Z6-kiP2vUkOdlfVzsoNOig_3_2"></a><a id="Tc_7OqNbUvz4kqe5G4UqdT4ug_3_8"></a><a id="Tc_IeYQ_mIuNUqqxLD4CvQ2Lg_3_13"></a><a id="Tc_JVsfR3lfFUmPJSFm-EguPw_3_16"></a><a id="Tc_NZpwzeerI0KO6KE27F9htQ_3_19"></a><a id="Tc_p87Kq6H-kk614RBBMt8lKQ_3_22"></a><a id="Tc_OsQjmwblB0qGE2FucBngdg_4_2"></a><a id="Tc_9KPk50JsEkK-O5luYm13Qg_4_4"></a><a id="Tc_xWk332YnU0OL7yY2VRUJEQ_4_8"></a><a id="Tc_Ug8JfIkVVUWc0WS8mvdKFQ_4_10"></a><a id="Tc_tvLQ2qrLekyw_YvfAS8Vgw_4_13"></a><a id="Tc_eZbG7RHh60W9axOFdOuXrg_4_16"></a><a id="Tc_0hGhQ3870k-CsLNZR3pN-w_4_19"></a><a id="Tc_y7R1yN6IDEaz_rNmcaYKBw_4_22"></a><a id="Tc_er8zsrXc0ECxT-DHY0tbIw_5_0"></a><a id="Tc_sou7YHotL0WVquxuAbLO5A_5_4"></a><a id="Tc_SyZoZva7E06ijLN1_TlNIw_5_10"></a><a id="Tc_cTk7R--R90ukHtzIZLIkyw_5_13"></a><a id="Tc_Wstl5OthfUKRtdGGjvMwng_5_16"></a><a id="Tc_zUXls7LdGEey_y1Kqi94Ow_5_19"></a><a id="Tc_3Oi5WNdFA0WoGFvq8ieFaw_5_22"></a><a id="Tc_D_Tu_fxBLUaBw6JsrQrrrA_6_0"></a><a id="Tc_m2aJ0rEC4kOKfZpK_Spj-A_6_8"></a><a id="Tc_RsSPn22jrku8HNP4uD5rPA_6_11"></a><a id="Tc_Mb8vkrN8ikGdgsDG3J6xiQ_6_20"></a><a id="Tc_udDy7TLBekiNKB2GDaXtXw_7_0"></a><a id="Tc_24TSPU69VEK7Dc5CoUh2KA_7_17"></a><a id="Tc_p4tgp6im_EWvx1QbSOt5Sg_7_20"></a><a id="Tc_70wNbn8LaEGBCOFrRNw8ug_8_0"></a><a id="Tc_6PC-cN3kYEKLNYytLoUt2w_8_2"></a><a id="Tc_2YpWS0vbOEGhk0BRu_NxIA_8_5"></a><a id="Tc_frqa7TVm7UKXjslb8YVk3Q_8_17"></a><a id="Tc_o8MzhCYtuEGYFsSyGjCq9A_8_20"></a><a id="Tc_hNk3tsrfO0eALF5hUC0-Ug_9_0"></a><a id="Tc_67vlJKSU80uALiez8GoZBQ_9_2"></a><a id="Tc_4AKeT0j3OkiGBLdDQbiypg_9_5"></a><a id="Tc_6EShggBYpkurMzcbt5Cdzg_9_17"></a><a id="Tc__XyNsGX_M0a26Auaxe-ndg_9_20"></a><a id="Tc_5tOn8cCyXUmHXz08NUBG8g_10_0"></a><a id="Tc_vS9DrzHip06enxFJQ7W_Vg_10_2"></a><a id="Tc_KjOeCXo5_UaD7bgLB8MIzg_10_5"></a><a id="Tc_gBlBBGykp0iIoFOQrDcHSw_10_11"></a><a id="Tc_pvDekSUsfkuXIez_IJKEqg_10_17"></a><a id="Tc_1ilTu6F26USN8tceN5jTZw_10_20"></a><a id="Tc_U6bPs4Nb6kir-9M12psvsA_11_0"></a><a id="Tc_APXCKaEo6Ei1PxJ9TDhneA_11_2"></a><a id="Tc_v7XsUGJVSEmLlzB2z-XyNg_11_5"></a><a id="Tc_GWgJNVG4_Uac-3AEO8MUnw_11_11"></a><a id="Tc_8hiOI7scCE-0zDV9VRAn6g_12_0"></a><a id="Tc_Chka-K_WAEuKxsllCgl9yA_12_2"></a><a id="Tc_HwEcrKAQ002zXhxHGHpl_A_12_5"></a><a id="Tc_LTWSHMxu6k-AzuuqQ67t9g_12_8"></a><a id="Tc_9xr-Ffb8wky9QhsO4ia2iw_12_11"></a><a id="Tc_jLk8LRbPiEeG05mVnPF-UQ_12_17"></a><a id="Tc_L4LXO9sx-U-ZX3LCpjS3_A_12_20"></a><a id="Tc_wn6Sz6ez3E6ljzUC2HQjDA_13_0"></a><a id="Tc_BhGIUq-gkE27ouNWKB32lg_13_2"></a><a id="Tc_bLHrwucqqkGm5ka_yARj3Q_13_5"></a><a id="Tc_7a2yMA99pE2-jFq6QNqhwA_13_8"></a><a id="Tc_gukHQ4Q52E6ANQXdlmaZWw_13_11"></a><a id="Tc_q8b_X5zi9EyjWrYWl-ElSA_13_14"></a><a id="Tc__c5V5fOsxkmHAW8R-hg9IQ_13_17"></a><a id="Tc_-FER4lIDjkyoH7ryuqgkZw_14_0"></a><a id="Tc_U0UH4MB3wEymMrpWGakTNg_14_2"></a><a id="Tc_aTg3iFBx_0KWYIy98TxfEw_14_5"></a><a id="Tc_rRqewXcPZk-NRXV6gJjrMA_14_8"></a><a id="Tc_gSV6wWtITkWzQUOlwX-Qtg_14_11"></a><a id="Tc_BSd9ktIHVU6PmMlRsS2aDw_14_14"></a><a id="Tc_gMIEY317aESCwEmFHh9lng_14_20"></a><a id="Tc_m_9G3rAPdkGV1vyuiFkFhQ_15_0"></a><a id="Tc_ndGmgMxs5kOeZagS9Sdllw_15_2"></a><a id="Tc_0uD-iaZw8U2iPmEHQza8zw_15_5"></a><a id="Tc_Skk0HTEWA0-ASejZAjhazg_16_0"></a><a id="Tc_PGmjTTtrXUSmzSnsr07UXA_16_2"></a><a id="Tc_s_l2orUGV0qqt7N1Fv1W-A_16_5"></a><a id="Tc_DKa8ezgVGkymmeHiIBkX8A_16_17"></a><a id="Tc_P60AeqHYBkWQuJPyswaL3w_16_20"></a><a id="Tc_x2RsctmE-0iKwFbSGNtb6g_17_0"></a><a id="Tc_8WSVWsay8kiiqJW32F_Yzg_17_2"></a><a id="Tc_OUs7RXTMM02zXm8aU-AQig_17_5"></a><a id="Tc_2lr1PltDc0a1-gZv2aS6Xw_17_17"></a><a id="Tc_wPFS8i6YnEOQfvGd9Sc1Eg_17_20"></a><a id="Tc_rtv0LRjyJky9QxXTfFQ1cw_18_0"></a><a id="Tc_ZpS5nnNL7EGpGykAyREzXg_18_2"></a><a id="Tc_GP9jlYe24E6_rMlRpWBj7A_18_5"></a><a id="Tc_TA7am7L_f02eVd8zhKYMcw_18_8"></a><a id="Tc_dvqj8zyPG0GMdio7RM7uOA_18_11"></a><a id="Tc_yE91g-1HvE6bus-mgkxBkQ_18_17"></a><a id="Tc_fE5SXGkFNUuHXmaDxK961g_18_20"></a><a id="Tc_mgw21t4QrUqxkXiLHPURaA_19_0"></a><a id="Tc_hYDwkETHXEiTkEHByUZTzQ_19_2"></a><a id="Tc_9LW2_K58V0WAcATOJ2kAIw_19_5"></a><a id="Tc_LpdIdNAbP0qAxzLGsyJSnQ_19_8"></a><a id="Tc_cFGpHDeHRke9UY566td54w_19_11"></a><a id="Tc_5-1_X33wYUa9iIQeLkSCPQ_19_14"></a><a id="Tc_RQNtLp34ckqa3La5XmqnjQ_19_17"></a><a id="Tc_kZ1m-89C50iv-G8ZlorkaA_20_0"></a><a id="Tc_jq7M2HSelU2_dQBHe_8CmQ_20_2"></a><a id="Tc_vUDWbBQR8kaR4_GmNDLktQ_20_5"></a><a id="Tc_uKhMQSgNM02lCbfunjFVBA_20_8"></a><a id="Tc_bwrzBwMur0CJfUY0wYkNdQ_20_11"></a><a id="Tc_HjjcrQ3qtUazaBCsm0eW4A_20_14"></a><a id="Tc_cdLS7iOz5EOZbkolNUcYHg_20_20"></a><a id="Tc_-3Z71sXBm0mQmFgF77P-LA_21_0"></a><a id="Tc_iwd4bXB0Wkuvd1xcML4vGw_21_2"></a><a id="Tc_rAEqINjI_0eENmX195YgXw_21_4"></a><a id="Tc_lr9Lza_LDUGWw5Va5nKt5Q_21_5"></a><a id="Tc_Wjem3MgmJUe1HLh-XrLVig_21_10"></a><a id="Tc_pOvumsS7aECjAis-HPgStw_21_13"></a><a id="Tc_PhLHHuqz3k-vw9QVgmXIVA_21_16"></a><a id="Tc_-bvhB59uEUeRhAhSPIybqA_21_19"></a><a id="Tc_6LSKwJy6L0OItHxlQPTJLQ_21_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.2893448%;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_CizV4-yCUUSuOAnIGXoxzg_5_2">40,524,346</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_UHcg7FBjDEe8KlP5LU_J0Q_5_5">55,370</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zrbNgxCwDEKeP2fYOPqfjw_5_8">538,793</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BLa-H0zETUKETzDYZDjyoA_5_11">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OJPY2v-8HEm6XwyhP4ZZqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LwGSdNQdbk6BheH2-_cGqA_5_14">222</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p9uGeWcXbEizrgTa2nWZiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mwtgZ9Rbnk28kTXfYROlYw_5_17">68,220</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_G6KN4NQzqUuxhlJs_8voKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DWD-uroyGkyA5eVWtQLN3Q_5_20">187</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__1lY-xV9XEabX_cFhLYRIg_5_23">68,184</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of Series B-1 convertible preferred stock upon conversion of debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw" decimals="INF" format="ixt:numdotdecimal" name="cgtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" scale="0" id="Tc_D9Y0_cClu022jUUFGsZuSg_6_2">10,926,089</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" scale="3" id="Tc_0jGwuvvnHU-Hr7HgmBG7_w_6_5">29,391</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" sign="-" scale="3" id="Tc_9oPWeIGpMkCHH7XdakpgBg_6_14">397</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" sign="-" scale="3" id="Tc_LKnTsfy68kiEZuD3Qh5Wow_6_17">14,068</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" sign="-" scale="3" id="Tc_EvdiASS_e0y8QpSeDYf-xQ_6_23">14,465</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Conversion of convertible preferred stock into common stock</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw" decimals="INF" format="ixt:numdotdecimal" name="cgtx:TemporaryEquityConversionOfStockSharesConverted" sign="-" scale="0" id="Tc_euUMp_RUFU-cx2OqhL2Bkg_7_2">51,450,435</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:TemporaryEquityConversionOfStockAmountConverted" sign="-" scale="3" id="Tc_rzymLBrGkkOForQy_vgcRw_7_5">84,761</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_JQgiEJ6RfkORb29Y4T1-Gw_7_8">15,906,537</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_PvJU5M5dxU64unIFCn718A_7_11">16</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_7OeUn9Xm-02u6Cnu-akeMQ_7_14">84,745</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_ANqDpdbhA02W8ascxbJtNA_7_23">84,761</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock in initial public offering, net of discounts and issuance costs of </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_R7grV6xRSU6sJnYuuYh8VQ">7,783</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_fEJAxn0610ylgoycDocr_A_8_8">4,333,333</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Do0mwrypnkewLTiuX9M7vw_8_11">4</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0haQ0rDcjEC7Lpsh3ZXY1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_INSMIpdTz0mGa7T4rJ2Gyw_8_14">44,213</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_7W7yfqT9I02k5VJjUTHGBQ_8_23">44,217</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Conversion of SAFE into common stock</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="INF" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" scale="0" id="Tc_w-R-bp6EJ0mMEpMO-X5ZbA_9_8">931,485</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" scale="3" id="Tc_8x9PYGTiGkKRlwE0EATSXw_9_11">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" scale="3" id="Tc_GrQmDkVjMkabQbJkFx3P6Q_9_14">11,177</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" scale="3" id="Tc_TWA6G5B6M022cVFyIfwCMg_9_23">11,178</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Exercise of common stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_-ztqhlP9sUmyT4qHoPIo3g_10_8">321,686</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_tjMuSVKl4UKnVi5z11QDLQ_10_14">276</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Fi0YN4XVz0e25h4vJl2k3A_10_23">276</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Exercise of common stock warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Tc_1e3x2Nnd0U6TvDi_Ydbw6Q_11_8">198,198</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_xx8LjVm0u0avlL8xVL1q4g_11_14">34</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_2qZ1uiTcpEqvQCvjJcouyQ_11_23">34</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XJo02Yv4EU23ou2Gam4JfQ_12_14">5,183</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_i-wg1Ypm4EC4FtOIrT7p2Q_12_23">5,183</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Other comprehensive loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rdiZqGOI80qH1SRFtNcStA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_ZApi04cgpk-5uNAFGiTKDw_13_20">11</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_zjnwgfQJ0EWJAHhreVhjIg_13_23">11</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wwOw8t8ExE6RdaKosX35mA_14_17">11,716</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-_KDV6BgIUC_lavfFNEJ5g_14_23">11,716</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0EsQ_iCF5U2yZq50BBevbQ_15_8">22,230,032</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YlunXD8jNEuX-TQaNetmlg_15_11">22</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EjDdvR-xQEuO4zQmEOjdDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_s9CfJKhLiE2TSccqDy27pg_15_14">145,453</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmHMF32sz0KA3893X1KYUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_fhuDfbOFAEKQssH8HUaI-g_15_17">94,004</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DVOWTmYar0GNsT5vClx9zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tol-sGKiKUKNvhdM9kRPaw_15_20">198</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BnS6JQH4N0SYCBCGVc3Xcw_15_23">51,273</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_PQSx3rJG4k-9hn2iC9k99w_16_8">1,761,516</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ms9rZF0pBUWs8MiD0wO40g_16_11">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_oQfZhRWUjkqgUPFoQPUFzg_16_14">1,616</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_5e786fqRD0u5gxaN7ZsO6Q_16_23">1,618</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Proceeds from follow-on public offering, net of offering costs of </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_P8O29jTjK0S7X3BCcqBvAA">816</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_c63kdjAqakOTWYXg9zjidA_17_8">5,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ScMJIS4X1EKDxvG6Li-Y8Q_17_11">5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_1ng_kk66vUmNmQ2gIQxa1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_93IzBTWBQ0SoYQb2y2lvRA_17_14">5,179</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__T4rW9ML1kWDDh2s8KIDYg_17_23">5,184</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_xXSL3T4j30WsqXSNjN_a3g_18_14">3,572</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UaMwymgJ3EulwEoOyEjzbw_18_23">3,572</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Other comprehensive loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rCOlfsot3EiDxI_jxFLXiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_XfUp-pNAnUmcyxvG_x0Y8A_19_20">1</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_PBa-j11DI02USj-SFlJrEw_19_23">1</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4BX_LYCjYEOG2mey0sSEjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7zpQE2zSik6cZ-dXPzxhvQ_20_17">21,397</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HlSwkpq4RUye7CFQSuxqTw_20_23">21,397</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MAMsQpzsWUe948NJareNKQ_21_8">28,991,548</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7I9eZt33h0KF9x7bWuWVoA_21_11">29</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ALOa0B34YEu4wK2K83rlug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iCo6ofTm6EyaEGUOgldBmQ_21_14">155,820</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wzhq5N306Uqh98sS1Rmuwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3baNiw1PCEaicFEeBZuhDw_21_17">115,401</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ob1HFOSlEUyTfi6gKd0HIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FDi_vMGNW0S5UCbO5CcrWQ_21_20">199</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BdoYLrQUukKZ3tWx5uYzeA_21_23">40,249</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ba4cb25_ccc3_48fc_ab41_0c5a803581b4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofCashFlows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bb87a9fc_583a_4719_a1bb_e1fbd8ec0021"></a><a id="Tc_nL23o2fJqk2VLj-SpAyHpw_1_2"></a><a id="Tc_tkDsLWtNdUCJetPyJmREZw_2_2"></a><a id="Tc_oWCGaXnbtEmgr1nNQVOO1w_2_5"></a><a id="Tc_vNsQCVnNl0qY2rLWHzYLsQ_3_0"></a><a id="Tc_wXTEt3qBqEqdTnJDLGtQ9w_4_0"></a><a id="Tc_wqL4yh6ioECJvIKvp-sO-g_4_2"></a><a id="Tc_dtOwfvibQk2sAPBcRAN5vg_4_5"></a><a id="Tc_HNsldC-98kin7-Az8Tzvgw_5_0"></a><a id="Tc_OOIAdIgKtUu_gxR_H10UmQ_6_0"></a><a id="Tc_-dSD38QlgkCOeO3qL18DwQ_7_0"></a><a id="Tc_AvM8z0ILmkmBbK3TRQY7aQ_8_0"></a><a id="Tc__gZzkEgiVkySuH_NRAk3qA_8_6"></a><a id="Tc_3u1phX8L0E-JG792pnC8eQ_9_0"></a><a id="Tc_FEQYZOeI7Em0xahAoLJr3g_9_3"></a><a id="Tc_f896EV8-KU6jftgMenRKGA_10_0"></a><a id="Tc__iobs0yKcUmnYhz7vfXttw_10_3"></a><a id="Tc_Kh2jBqsF1UyUxaEqJCj9rQ_11_0"></a><a id="Tc_jXY-Abu9VkGFIaQTjPqXLg_11_3"></a><a id="Tc_gqMlUuKxQUex2fLv2TE9MQ_12_0"></a><a id="Tc_zVwvxq7LiEafxdpsKM6_jQ_12_3"></a><a id="Tc_YJHqO3F-H0SbC3zYMe4WKg_13_0"></a><a id="Tc_8t2jLJo1SUCBteTSxvOZ1w_13_3"></a><a id="Tc_4eTFIeABK023GJ4v5EqUQw_14_0"></a><a id="Tc_Xq9scrqiZU-1xqysP0LnHg_15_0"></a><a id="Tc_QddqII_-QkmAYGaxLB0bVg_16_0"></a><a id="Tc_hU_vjhonP02TOgEl1EOI9Q_17_0"></a><a id="Tc_coqsVVN_4Ea8am8hkSbxWw_18_0"></a><a id="Tc_hDlkmn5eUkG_DVNZUZQ9jQ_18_6"></a><a id="Tc_T_vH3JnBoUq68xRCRq0bUg_19_0"></a><a id="Tc_ZCBf0WG3IkKv1MGeZ-XOUw_20_0"></a><a id="Tc_rLI3Q-BPfEC2dK7QoSxNaQ_21_0"></a><a id="Tc_3wBeXZw0TkqTlJsPUKUYkA_22_0"></a><a id="Tc_ZPppCEKMG0eyOOx3VrG2-w_22_6"></a><a id="Tc_oc6m-TxEPEmn3XITrUta0Q_23_0"></a><a id="Tc_NSFOHeXLI0uXSLtc0lRvHQ_24_0"></a><a id="Tc_DNTNZd29L0KPEOx_V8SZEg_25_0"></a><a id="Tc_5w2NV_e04kCgTzOKPhG98g_26_0"></a><a id="Tc_dOJRuUhtV0u4ajMA8qtKpg_27_0"></a><a id="Tc_-rfS_1j7A0mayRcr5_XkHQ_28_0"></a><a id="Tc_joQxt0xl60qjGtFU-og-Tw_28_6"></a><a id="Tc_rTf7rF2U4kullBoOGDdX7Q_29_0"></a><a id="Tc__ufkqBQhBkaxhy3eUWWftg_30_0"></a><a id="Tc_dOHHfFigfEWCJNOxhoK9eA_31_0"></a><a id="Tc_N6fazbX8Pk-258jZpjs5kA_31_3"></a><a id="Tc_sv2dXITPAU-zzL9UBtm2kA_32_0"></a><a id="Tc_PNqu1tuhRECjM_i_QcW8iw_32_3"></a><a id="Tc_hDYjmYiUKkOGh0A_D5AOag_33_0"></a><a id="Tc_7CB3C_Rj0k6dXWh-nAWpfA_33_3"></a><a id="Tc_uj9jhlHJ50i0wcw_NjUnVg_34_0"></a><a id="Tc_04GRG_yu1UiiQmIBddvurQ_35_0"></a><a id="Tc_CNYo89tTBUKZiGBugZxEXA_36_0"></a><a id="Tc_BkvrPrfPuU-FYZdA9sVf7A_37_0"></a><a id="Tc_aauEKVfX_Eml6aXiVhskAA_38_0"></a><a id="Tc_hlFbd-JNv06F4dxEgN86jg_39_0"></a><a id="Tc_scoQs5A4sEWg8TXL1qF7hg_39_2"></a><a id="Tc_eMBAbqdWDk-0YYHAkLkaOQ_39_5"></a><a id="Tc_Qemsfw2-30md-JZ_Q4eegA_40_0"></a><a id="Tc_qBLgiUqcpEyXo5i0e11Y1A_41_0"></a><a id="Tc_cQPUbdT2dk2jPlod8nDlMw_41_2"></a><a id="Tc_V45VDh3RSkePXnOnbjcDLw_41_5"></a><a id="Tc_SlbEP_0Ba0mI4cLvgrgmhQ_42_0"></a><a id="Tc_r0BOd1Llv0ai-8yFR-azJA_42_2"></a><a id="Tc_fWmhEdjagkqqBHJgxbBm1Q_42_5"></a><a id="Tc_IbuIwvjRIEqZ91FeSMr0JA_42_6"></a><a id="Tc_FMbav8flXkizCrcBtDb6xg_43_0"></a><a id="Tc_cDnpMNLTwEuLPQYzTQVPLA_43_2"></a><a id="Tc_w69gOYRu3EqZeFjo9cfKSA_43_5"></a><a id="Tc_7x6lNIbSq06dHhII6bLm4w_43_6"></a><a id="Tc_Vp5dscmIWUCIo5bz5D3JSw_44_0"></a><a id="Tc_Pl-2OOz_7kqimEiVXnTT9A_44_2"></a><a id="Tc_LpmgIYbV20u3yDJHqcPuuw_44_3"></a><a id="Tc_FASw34wGLE255zSh3kT90Q_44_5"></a><a id="Tc_70GZLg71JUy7SKOTYkTICA_45_0"></a><a id="Tc_bPjVvflcmEa3q7O448Q1MA_45_2"></a><a id="Tc_0L5nWQqBY0avRxRb8AXgHg_45_3"></a><a id="Tc_R2Qw_I9YO0yCNDsf0zvWNA_45_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jEMFZZi6Kk2ydLicgDroPQ_4_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VvlO1i04akKam8cNGyLqJQ_4_6">11,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_XzWKZtu31026hS8LLpjQMQ_6_3">83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_dN7n7puBwkqbWw9B_cW59A_6_6">93</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_WlJ1d3ROnkevfBvPPTm6WQ_7_3">3,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_D1vvusQl20ekNe8dmsW82w_7_6">5,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_fxL9TZMXDUqpXWOrf2ltiw_8_3">152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_ZOj0t7aKX0yTGuVLhNh4UA_9_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_7_WO8XdSF0mOuBqHGISUzA_10_6">352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfDerivativeLiability" scale="3" id="Tc_LfQlVizKrE6k8nSslfzoXw_11_6">2,209</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Change in the fair value of the Simple Agreements for Future Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity" sign="-" scale="3" id="Tc_QJcxV3vtck65Nc0X94NWiw_12_6">2,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Gain on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_2NA17UCKeU-Kj5x2GMD0zQ_13_6">443</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInGrantReceivables" scale="3" id="Tc_94a0zuHgVE2MC_b47u1ckg_15_3">1,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInGrantReceivables" scale="3" id="Tc_6E8-Rb5OZUeM9Jp8dK0I1g_15_6">1,235</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_UQuVUpKgcESmomuVsLsYdA_16_3">430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_-BZaj-ot_0yOKb4oZP6aew_16_6">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="3" id="Tc_VyZLlR4jMUa9Gwn9Xvx3xg_17_3">467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="3" id="Tc_mO7scI9CSEyVz-G98OwFdA_17_6">121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="Tc_YF8E0rugNU-Zn7rKy4ko6A_18_3">1,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_G9rgKhv1gkC2qv3IBsNkDw_19_3">1,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_25QYdMUQE0SBYvqdpA4wug_19_6">2,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_YuDFPtcJP0SP3K3KqE11Rw_20_3">343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_cZPG1ALaqESjke23nbEAKQ_20_6">1,269</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Deferred grant income, current and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" scale="3" id="Tc_E0GTjZyX1kiYVQftm3ejIA_21_3">2,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" scale="3" id="Tc_73gtV6edGEi73t7637-CHQ_21_6">501</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_OxWLr20RqEWI8s2qdPPclg_22_3">121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_BTIJc22Iy06yeHfPPtO6ZA_23_3">18,533</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_bV-zhlUlmUi8vrTq9tvx1Q_23_6">3,631</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments for property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_IiglOzzMXUKFUJs33NShVg_25_3">171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ZNxRaxWil0Kj3BFQZf7B3A_25_6">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_DSQheS-e9k23NaRV5kh1UA_26_3">171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_qaRA797ul0yqipBT2G0xVw_26_6">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from Issuance of common stock in follow-on public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_beCTDa6HvkGhjgoPOTA8yg_28_3">5,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_oIEifU5PO0a25ErLNUg2vA_29_3">1,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_wFtErnWcAEy27Hba6BgrMw_29_6">276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments on loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_YClK_cSWekiaMrFN8vtKzQ_30_3">1,396</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_ZeuYCMpNiUWS08_8v2lWgg_30_6">268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock in initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_sGjuosKl1k-AfOcE7uIzPw_31_6">44,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of Simple Agreements for Future Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromSimpleAgreementsForFutureEquity" scale="3" id="Tc_n9JYl74T40qeaZD9-WtslQ_32_6">8,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_8RlyEGW1fk6M43Jed3zpKQ_33_6">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ntpPQieB5Uu6bqddHA2lXw_34_3">5,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_kTMbhP0Wc0ScXClD49MZiA_34_6">53,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_OBYHXbc_wkKRQUyYxtke4A_35_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_oS7DqBkTD0WXBIakxy8YTg_35_6">11</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_ltnS3qGWxE6g0iQntIImVw_36_3">13,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_cz91tyNVlEmxp1vVWWiyFA_36_6">49,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZlZUkKxG-0SxGDFOffcxlQ_38_3">54,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_HGLSGsl_iUSAJ__L_xo7Hw_38_6">5,189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hfr65AlDpE2EvnAYcTQytw_39_3">41,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_xSgwz8-igki7rnn3Uf86yg_39_6">54,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prepayment of insurance through third-party financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_Ei1V46xA60GAQGi8BVbDNw_41_3">838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_eekv-6ZUpkqS-N_wj_ZlBQ_41_6">1,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Remeasurement of right-of-use asset and operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_FaCSuZ5l3kG0WQbdC3CQxg_42_3">349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Deferred offering costs included in Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredOfferingCostsIncludedInAccountsPayable" scale="3" id="Tc_TTXoDA3DxUa7lzIXtUisGg_43_3">140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Conversion of convertible preferred stock into common stock in initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="Tc_euizZmPjsUWFk3dcAItIiw_44_6">84,761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Conversion of Simple Agreements for Future Equity into common stock in initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" scale="3" id="Tc_OFIWtfkREEufNcAlcuq7Yg_45_6">11,178</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5b4ad96e_86e1_4b28_a2dd_b0eb177d912e"></a><a id="NotestoConsolidatedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY<br />NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS<br />(in thousands, except share and per share amounts)</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_3sfv-SJfwEqDXNVT2ibWqA" continuedAt="Tb_3sfv-SJfwEqDXNVT2ibWqA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August&#160;21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies for central nervous system (&#8220;CNS&#8221;) disorders. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July&#160;14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#8220;Subsidiary&#8221;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at&#160;year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the&#160;month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholders&#8217; deficit. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) of <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_V21sIwIxfE6V-AX0_mQ3Ww">3,768,116</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFWuF54H3UCI_hJ6ZrtvQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_csjCJVsVo0OwsOBUdiYz6A">12.00</ix:nonFraction> per share. The gross proceeds from the IPO, excluding the overallotment exercise, were $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_y_Q04RUzx0OMQuN1VgAHhg">45,217</ix:nonFraction> and the net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Narr_s-Em8XcAPESz9rT_Jt1BoQ">37,909</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Upon completion of the IPO, all of the Company&#8217;s then outstanding preferred stock was automatically converted into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_hBZQ-Oe1c0uyfod2aeXMVw">15,906,537</ix:nonFraction> shares of common stock and an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Narr_zGUnXyPiiEeNNGPO7aacbA">8,942</ix:nonFraction> of simple agreements for future equity (&#8220;SAFE&#8221;) was automatically converted into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_ukDg0yFlKkeKpB2ljTnetQ">931,485</ix:nonFraction> shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 10, 2021, the representative of the underwriters for the IPO provided notice to the Company that it had elected to exercise its over-allotment option in full to purchase <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_T0oUh1yBbUi5zUIZcP5g8Q">565,217</ix:nonFraction> shares of the Company&#8217;s common stock. The representative&#8217;s exercise of the over-allotment option closed on November 12, 2021, resulting in gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_8i0DZu0YjkGId-G8Lh6-Xg">6,783</ix:nonFraction> and net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Narr_T_5-aIcKqkigdhXqbSnP_g">6,308</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering related expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, the Company closed its follow-on public offering of <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_teIkya7aNk2bMYq6Zu3mRw">5,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SFKIrluacUKxgPM0Dk_COA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ukXy4RGGIEmaFnuU26_FMA">1.20</ix:nonFraction> per share (&#8220;November 2022 Offering&#8221;). The gross proceeds from the November 2022 Offering were $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_av3R367pV0iTl-iwyaWnqA">6,000</ix:nonFraction> and the net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Narr_uexMUjpwtEG43se5R321XQ">5,184</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Additionally, the Company granted the underwriters in the November 2022 Offering an option to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_66gOUrgOGkmMATI_UYMUcA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_JoJio7LjO0yOmIvqGogosA">750,000</ix:nonFraction> additional shares of its common stock at the public offering price, less underwriting discounts and commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_LWiPboIUzEeAsuLKTowSkw">200,000</ix:nonFraction> in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_xSLyHPLaJ02AVZPaFJ_vvg">40,000</ix:nonFraction> of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company held cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_tmsK5gJjDEiJqCCIyIfuSw">41,562</ix:nonFraction> at December 31, 2022. The Company expects that its cash and cash equivalents, including the net proceeds from its IPO and its follow-on public offering, will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3sfv-SJfwEqDXNVT2ibWqA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_BMASJtCJpkCJY7KgNRNEJw" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_ZEy4tDRVPUiKXi3KHIpwFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:UseOfEstimates" id="Tb_uRy5-avr0UmNNTvMIVgPvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_ycqCCCBC7ESSvE7R-mLwsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_hmH_YpikbU2cNBS4ShBq6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt-sec:numwordsen" name="cgtx:AllowanceForCreditLossGrantsReceivableCurrent" scale="3" id="Narr_yk07746wTkeS2bZijnFCjw">no</ix:nonFraction> allowance for doubtful accounts required on these grant receivables.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_VKh_bkzKz022NBKIk0_9mg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_IZwaffecFkOCkeGesRQAWg" continuedAt="Tb_IZwaffecFkOCkeGesRQAWg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_J2XBpl_S60WJ_31CJUKMPQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_nI6KLxb_SkGnigACNAO8uQ">5</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MFx5PzsB3EiVmUbOAvS2KA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ogizgEhlREKzarxJM9l2sw">6&#160;years</ix:nonNumeric> for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2022 or 2021.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont1" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont2"><ix:continuation id="Tb_IZwaffecFkOCkeGesRQAWg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:ConvertibleInstrumentsPolicyTextBlock" id="Tb_Th91FmEBC0y5T1TcNa8YOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">ASC 815,&#160;<i style="font-style:italic;">Derivatives and Hedging Activities</i>&#160;(&#8220;ASC 815&#8221;) requires companies to bifurcate certain conversion options and redemption features from their host instruments and account for them as free-standing derivative financial instruments should certain criteria be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company also follows ASC 480-10,&#160;<i style="font-style:italic;">Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a)&#160;a fixed monetary amount known at inception; (b)&#160;variations in something other than the fair value of the issuer&#8217;s equity shares; or (c)&#160;variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:GrantIncomePolicyPolicyTextBlock" id="Tb_gd4A6geI_0COkyTu-PrykA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2022 and 2021, the Company generated grant income of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Narr__DZS2aZMmUqwwmYbLMst4A">22,217</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Narr_OHnm-hYN3U2rzjCFde5UNw">17,447</ix:nonFraction>, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_pQWi8HP5gUKdCMU0ONxszw">1,702</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Narr_tUjGLjd65kGOpUKhyqAbZg">1,686</ix:nonFraction>, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2021 of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_Ui-VGuCNhkKdld0VuywG7Q">753</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Narr_E5sVNV0f4k-zUB6q3tbSFA">0</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_xKJFxVyp40ScjBY_juKVyQ" continuedAt="Tb_xKJFxVyp40ScjBY_juKVyQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company is involved in research and development aimed at the development of treatments for a variety of diseases related to the central nervous system, with a primary focus on Alzheimer&#8217;s Disease. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_9bXoTqIcQ0uGOlhl9WZ9zg_1_1"></a><a id="Tc_LoiAcZtnvkaKLB_AKekNTw_1_4"></a><a id="Tc_tfyQRKaK8EaAJai4MZ8gsw_2_1"></a><a id="Tc_2OEL9t_HH0qKjC9jnHxo2A_2_4"></a><a id="Tc_H1UMHVTz6k2WUF8aDly9SQ_3_1"></a><a id="Tc_vCp_-L3UREa8kbB8gOuKMA_3_4"></a><a id="Tc_zyYih0ZxbEy-qX9pgY-75w_3_7"></a><a id="Tc_eXlD-rgV7k69I-fY-0YOrA_4_0"></a><a id="Tc_iyJceDfRj0qJRFUEkYju6g_4_1"></a><a id="Tc_pwjsTgtqbUizS7BlPIXWZg_4_2"></a><a id="Tc_qmdvKWZfVUGr7DJynfILOA_4_4"></a><a id="Tc_JwJyYvi_PEmnqvEZBHn9pA_4_7"></a><a id="Tc_T_WMNwsCc06U4fflNjt3vQ_5_0"></a><a id="Tc_WkSRdjKu8EGfhAX2HRtuWQ_5_1"></a><a id="Tc_-gcbS4dIbkWt7CICnKNMGw_5_4"></a><a id="Tc_jW2VmfC8HkiRWXiA5dB49w_5_7"></a><a id="Tc_BG5tjv3n00WseKEJ4YaXTg_5_8"></a><a id="Tc_9GWj0oenJ0WHnuha7G_QVg_6_0"></a><a id="Tc_ht7GO5XaHEmoShlb6hMQOw_6_1"></a><a id="Tc_KP9VkIsXzESXZ6Rs5ZtnPw_6_2"></a><a id="Tc_mBbzArmWLk64JMSaBBBRoQ_6_4"></a><a id="Tc_Vj6O4YbK7kqbwR8Dqyumhg_6_7"></a><a id="Tc_l03m3UFIyEmxkDUAggB23w_7_0"></a><a id="Tc_OHeuLI11BE6ojV3UyQ2dIg_7_1"></a><a id="Tc_4lkzNjomkUucWnxo56fO6A_7_2"></a><a id="Tc_IlXpwXpRU0a4pt8iz9Wz7Q_7_4"></a><a id="Tc_nHkNjfjXP0i-fXUe4o_wHQ_7_7"></a><a id="Tc_P69cLPAVDEeB5npUvyy74A_9_0"></a><a id="Tc_Cyth9Ok9VE-L5CcedcmLEg_10_0"></a><a id="Tc_MVin-aM_mES_4Tv2UsGNog_11_0"></a><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont2" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont3"><ix:continuation id="Tb_xKJFxVyp40ScjBY_juKVyQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_wdigME0q-kG4oJBani_4vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Narr_-Bl0PBAgPEKzeF9n1jaJqw">616</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Narr_GJbIaGNLO0WBQBz9vLu4kQ">130</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Narr_MhK73cZzLEWz0AtC-iRK2A">486</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. The Company will continue to report financial information for fiscal years ended before December 31, 2021 under ASC 840.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Tb_rrAupAMvVE-QMlW0lrYRMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_2kEua8umX0eRzaul5dzOIA_4_5">616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_avK-ybi7lkecfJdDqR1Stw_4_8">616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_5Llp0meHlE2FcF9C5kq5gQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" scale="3" id="Tc_XzuZjR28NUautDMZnemn3A_5_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" sign="-" scale="3" id="Tc_nw-qnrQJYkql8VDw1v5ISg_5_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_U-nDG4aiykSRgSx2TJxZUA_6_5">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_zd01b8Ah5kW1cDbaIJO0Fg_6_8">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_GHSn6klXkEGRhfeux2dIiQ_7_5">486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Z9TT7RU89ECsDxL3RL_i-A_7_8">486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_MSqUJbwlSU2z-7lOQrrIIw" continuedAt="Tb_MSqUJbwlSU2z-7lOQrrIIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont3" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont4"><ix:continuation id="Tb_MSqUJbwlSU2z-7lOQrrIIw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr__W1ntDxmykitutUHgApvBA"><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_B2NgQKYgQkiecFOZafMjDQ">no</ix:nonFraction></ix:nonFraction> uncertainties as of December&#160;31, 2022 and 2021 that met the recognition threshold.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_vuUNc9qB4UWUJ8GExE85wA" continuedAt="Tb_vuUNc9qB4UWUJ8GExE85wA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_xM56a7lpQkmP2n51JMV4UQ">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont4" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont5"><ix:continuation id="Tb_vuUNc9qB4UWUJ8GExE85wA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_MGGVewFWn0qSW4H2c0EH0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_grE2YiiueEiimwmcOoCS2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. In addition, the Company records its warrant liability, derivative liability, and SAFE at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_sXdrYoeek0i3ukWLx2pX8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Narr_SqnraH5sMUmIs1qJpG0KPg">1</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Narr_7BGFFHBTX0OpSMyIMj2b3Q">11</ix:nonFraction> in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The Company presents comprehensive loss in a single statement within its consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_sKlVElPsLUWU9Di_DZLAfg" continuedAt="Tb_sKlVElPsLUWU9Di_DZLAfg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Basic net loss attributable to common shares is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss attributable to common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont5" continuedAt="Tb_BMASJtCJpkCJY7KgNRNEJw_cont6"><ix:continuation id="Tb_sKlVElPsLUWU9Di_DZLAfg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the impact is anti-dilutive. The Company&#8217;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_FqR_EpOMmkimZX224pLnrg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages <ix:nonFraction unitRef="Unit_Standard_segment_0QdZH6dU9kC3NWhic3Tuew" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_KI0RUBIR5UKPoYyc8a3ftw">one</ix:nonFraction> operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:EmergingGrowthCompanyPolicyTextBlock" id="Tb_46voZ798N0mAGjFmSK-mdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_wVmY2Kwaw06ri7QWS68q4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (ASU) No.&#160;2016-02,&#160;<i style="font-style:italic;">Leases</i>&#160;(Topic 842). ASU No.&#160;2016-02 requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company adopted ASU No.&#160;2016-02 on January 1, 2022. For additional information on the adoption of the new leasing standards, please refer to the section titled &#8220;Leases&#8221; above, and Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, <i style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for all entities. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material impact on the Company&#8217;s consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In November 2021, the FASB issued ASU 2021-10, <i style="font-style:italic;">Government Assistance (Topic 832)</i>: Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The Company adopted ASU 2021-10 on January 1, 2022. The adoption of ASU 2021-10 did not have a material impact on the Company&#8217;s consolidated financial statements. For additional information on the Company&#8217;s governmental assistance transactions, please refer to the sections titled &#8220;Grant Receivables&#8221; and &#8220;Grant Income&#8221; above. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:ReverseStockSplitPolicyTextBlock" id="Tb_X5HqJQdFZkuNg096qRr4YQ" continuedAt="Tb_X5HqJQdFZkuNg096qRr4YQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In July 2021, the Company&#39;s board of directors approved an amendment to the Company&#39;s second amended and restated certificate of incorporation to effect a <span style="-sec-ix-hidden:Hidden_nQx1SsH8n0-iTW-hmt6Uqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-3.2345 reverse stock split of the Company&#39;s common stock, which was effected on October 1, 2021 with a filing made with the Secretary of State of the State of Delaware. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMASJtCJpkCJY7KgNRNEJw_cont6"><ix:continuation id="Tb_X5HqJQdFZkuNg096qRr4YQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shares. The par value of the common stock was not adjusted as a result of the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of our convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. All common share and per share data have been retrospectively revised to reflect the reverse stock split.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d11d9ff2_a834_4232_af98_d34c9aa23701"></a><a id="Tc_NeVSJvxMoEK6JHwJOMugaA_1_2"></a><a id="Tc_HEaOnG1zYk-aQt0FtzVCUg_2_8"></a><a id="Tc_BOpfDeSeRkSx9hsxfEBrDA_3_2"></a><a id="Tc_du-TMUPiz0aN0IMPqgYr-A_3_5"></a><a id="Tc_VMYw5B1j2kiahubokxDiDg_3_8"></a><a id="Tc_a4b_jQlfFEmAIHWVpxCw-Q_4_2"></a><a id="Tc_xHCeKKrqiU-KBSAwBmwOYg_4_5"></a><a id="Tc_OXoKknRpOk6cFOaWuppFhg_4_8"></a><a id="Tc_Ow2oUBJDW0SVjbLlYC4Dcg_5_2"></a><a id="Tc_h4W_8IW_Akq7HrEjutIiZA_5_5"></a><a id="Tc_0RwpCsI_zkOk5VsDzjJPBA_5_8"></a><a id="Tc_Q7JikSKtuk2Jo0Sh9w3rjA_5_11"></a><a id="Tc_FrY94D1Ux0idTkI9l3CXcg_6_0"></a><a id="Tc_G7QzJkQDgU2HNTdSu7-AiA_7_0"></a><a id="Tc_6DDaIJcQzUm-m0XUFVgXfQ_7_2"></a><a id="Tc_EJ9IIi_VkUuC5Wx60Z98bw_7_5"></a><a id="Tc_aJQIH0KX20ae3eA3ubWAnQ_7_6"></a><a id="Tc_iD70sx7Qo0-OD85cTX-ONw_7_8"></a><a id="Tc_FS2YTlbXu0aYFkcwdXHGaQ_7_9"></a><a id="Tc_-inoCR_RyE-n7fCrorZxxQ_7_11"></a><a id="Tc_v3Oz23Aqw0WmTnZAfEWY3A_8_0"></a><a id="Tc_MGUyt1Om50W_V139VB6k_A_8_2"></a><a id="Tc_PbaX4nMr00KisHA_A4ztBw_8_5"></a><a id="Tc_2Qd9F9XXdEGkgAgQdfg2VQ_8_6"></a><a id="Tc_vRBufq40_EOlTrRqV_p_8Q_8_8"></a><a id="Tc_96E3oNZYKEuYpwJsJ2iF3w_8_9"></a><a id="Tc_LvKeMiWA-k-ZzXnustdOaQ_8_11"></a><a id="_69c15f46_951c_49d5_976e_9ebc5ba4826b"></a><a id="Tc_JY27ZaqeVEamAT3adECs-Q_1_2"></a><a id="Tc_rthAdYeJ0UGDGD8JV3GSPw_2_8"></a><a id="Tc_eKwQsTT6vU6t35hu5xc9wQ_3_2"></a><a id="Tc_S60tBg1pvESyPTVc5L8erQ_3_5"></a><a id="Tc_6sr9BZM9iUKXDzx0qCNo_g_3_8"></a><a id="Tc_PgfK_sM3uU6rlUY1edrhpg_4_2"></a><a id="Tc_r2X_Storu0KU8xSxhFQLNA_4_5"></a><a id="Tc_w902AlH_EEWsg48fU0A0Fg_4_8"></a><a id="Tc_j7Qs1ZTjtkabc5je0Aq_VQ_5_2"></a><a id="Tc_9CjqtGZYi06vix1TuFc-zg_5_5"></a><a id="Tc_2XoumhikUUGt722f9y8Gzw_5_8"></a><a id="Tc_mckxQghFMkikNvt_RwQIjw_5_11"></a><a id="Tc_Am2uVHJLnUiHSzhkxpZ72w_6_0"></a><a id="Tc_4G6PRKxib0i6jJJNBayzkg_7_0"></a><a id="Tc_5T0b_F3HwkGQgZ-7aH8N3A_7_2"></a><a id="Tc_S2Mj8dDSmkaM9PwOmAl9wA_7_5"></a><a id="Tc_N6alPo4VnE2neNcl2MGQpw_7_6"></a><a id="Tc_PRjB4LdLvUiZBxor27KcfQ_7_8"></a><a id="Tc_3sCyJczxJEqYJt6UzZlyDA_7_9"></a><a id="Tc_SVN_fJnRVkGIuHtQUy9U3w_7_11"></a><a id="Tc_afHoW_SH6UCjnem2g9yOrw_8_0"></a><a id="Tc_8xHKYziv00-VsrFWXZzZ1w_8_2"></a><a id="Tc_ENea04Qrh0G9rykcUNPaLg_8_5"></a><a id="Tc_2d8GQ8JC1UerCYXgbTFimQ_8_6"></a><a id="Tc_8oDguJZ1_EO0E9FHB53rNw_8_8"></a><a id="Tc_ZbrVPVm1TUGZHKEPX45e9A_8_9"></a><a id="Tc_ezHR38TDgU2o4XswjAP9aw_8_11"></a><a id="Tc_BwzHUPfgSEKN_x8RWZLc-g_1_2"></a><a id="Tc_U_OFH9CPuU2LBz_uMFE6EA_2_5"></a><a id="Tc_2Vj0Yokx2EiXrxi8V9CFUw_3_2"></a><a id="Tc_3P1TzoVKd06Cfm36-rDTZg_3_5"></a><a id="Tc_5TTPXfou8EGvIVRpshnjOw_3_8"></a><a id="Tc_Zt7Xaj-19EmOlqS30lufMw_4_0"></a><a id="Tc_CXsFvP7lpU6_401XvZfhLQ_4_2"></a><a id="Tc_0xhto8wxJE-Vs3ZrzSIFsQ_4_5"></a><a id="Tc_k9hPU0FvdE6K9dA7vtYV0Q_4_8"></a><a id="Tc_gBVtI3KpEkOd9svjlKhULg_5_0"></a><a id="Tc_XI6Y_4EY-Ea0RlxL3nQnEA_5_6"></a><a id="Tc_8CyrKbPCk06FUWmJB5dndA_6_0"></a><a id="Tc_YNi7XTGG9E2Bhg88iFYr3Q_6_3"></a><a id="Tc_FdPLY2zMHkyxSvMXSQWNdw_7_0"></a><a id="Tc_HzscAEMptE-zHnYUog3pGw_7_6"></a><a id="Tc_IjjCeCfdoEOS35xrl4V9gg_8_0"></a><a id="Tc_xbXpv0hdNEuwre9hGn4S6w_8_6"></a><a id="Tc_V8armkmXb0WZWgMMhC5mNA_9_0"></a><a id="Tc_kU-K2HONbEW-basN6VaacQ_9_2"></a><a id="Tc_rH5Zn7yxSUCDJoWNys34Gg_9_5"></a><a id="Tc_4Q9y9kZkXE2IflfT-mMoNw_9_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_JUCF3w8DHEysL0CI-VZwLA" continuedAt="Tb_JUCF3w8DHEysL0CI-VZwLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_JLMKkWvsMESTL0H8UVt4wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oSyBIfvMNk2jXeReNnXygw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Gv0CyJ5jxU-kUY5gCU3P-w_7_3">37,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hNnv6GZ7IUi4mGR9CBNWEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_vLZBIAW9DUCnh9Ge1HtaGQ_7_12">37,479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_RcqZUt4qD0CDmwKu-H5W3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4993jqkGQ0qELNKI2TODaQ_8_3">37,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_T2UqkgAY5ESys8dB3tOsdg_8_12">37,479</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_t-1Qw68sI0aC5oM3AVvG-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Hj91V5J52UeV7XcGiMqXsw_7_3">46,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_Ht59q_5JiEiVhpo-kC0tEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_EikLu5WySUuS7dGaYKR5_w_7_12">46,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_JWuAV66_FkKYy9ml74D0OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_BhNUgpB2J0yKP708bBKFiA_8_3">46,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_1aKfUI7VvUCMHFU3jUdSGA_8_12">46,687</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2022. The following table sets forth a summary of the changes in fair value of the Level&#160;3 liabilities for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_5d2bKe0p1Ea-mQno3JQOJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SAFE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_YEX4tFts9UqlH27hYh2GNg" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_b4wFk7bKyEKEjEHdtJ-b0w_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f9FhQl3y6EiSdHDswe6MEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_NMnXP7C6aU-4Hn11VFSxvQ_4_6">2,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_j4pvfSykykSSUFnoURQ5sA_4_9">2,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon the issuance of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_tueCY50SO0eqlailL8rt7Q_5_3">8,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_AoY1YKKaKEGg7pzxmISf-w_5_9">8,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_QGjdHn6BlEOiqD30uxaG1Q" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfDerivativeLiability" scale="3" id="Tc_bsqSl_Bl1Um6o8LrdPhCOw_6_6">2,209</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfDerivativeLiability" scale="3" id="Tc_P5R_mOavjUmPsdRUGN9rxQ_6_9">2,209</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity" sign="-" scale="3" id="Tc_MhiZD1SNFUO3fRSu0VqKRg_7_3">2,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity" sign="-" scale="3" id="Tc_nA0ojTCshUu2tqhBGiDNJw_7_9">2,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon conversion of SAFE into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Tc_uiFqp3bXo0iA_WcRix8mFw_8_3">11,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Tc_BocQ-3FLqEuyl1iv2uRAmw_8_9">11,178</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_AE0FpwKs-EOageu6dOfl8A" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_iJj0zIiPCES5iFxI1Mb3UA_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_FHzzyuPXwUKyBLXHpnwHPw" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_GoqltU9TIEKsmFb7klWl4A_9_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_QSoMt9G_HUS8I4_gcMCT9g_9_9">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Derivative Liability&#160;&#8212;</span>&#160;The Company recognizes derivative liabilities as a result of the issuance of the convertible notes that contain conversion and redemption features that are required to be bifurcated. The fair value measurement of the derivative liability is classified as Level 3 under the fair value hierarchy as it has been valued using certain unobservable inputs. These inputs include: (1) probability of occurrence of future events (such as a qualified financing or a sale), and (2) discount rate for implied return required by investor. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of the derivative liability was determined by calculating the fair value of the notes with the conversion and redemption features as compared to the fair value of the notes without such features, with the difference representing the value of the conversion and redemption features, or the derivative liability. The conversion and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_MpuYUHoExkCTT2qWibp7YQ_1_2"></a><a id="Tc_iw7lX6cWkkCI9vicgwVXAg_1_4"></a><a id="Tc_YPecCwD4VEuzd851CFlceg_2_2"></a><a id="Tc_cZiMeR5fL0ezmBmO0SQZnw_2_4"></a><a id="Tc_n6b2zYqrskqFDiQsddzunw_3_2"></a><a id="Tc_RiUnIBNHck-3VpzvLf7aLw_3_4"></a><a id="Tc_cH0HaSF2lkOvkmaHTLgWnw_4_0"></a><a id="Tc_dPNVt5BE7UWVMUWUREIyHg_4_2"></a><a id="Tc_E8ttWETbBkmXf3Ud_J73GA_5_0"></a><a id="Tc_2ygutLGVnEyqfDvbDWAJLQ_6_0"></a><a id="Tc_CkBcMs6tlUK9_bkm9N7MRQ_7_0"></a><a id="Tc_yMaV4_Gpx0G1K7HOr2zcsg_8_0"></a><a id="Tc_GWMkefYIBk2RF37QmmadxA_9_0"></a><a id="Tc_wMdhPinSW0SsHDWbls-2xg_10_0"></a><ix:continuation id="Tb_JUCF3w8DHEysL0CI-VZwLA_cont1" continuedAt="Tb_JUCF3w8DHEysL0CI-VZwLA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">redemption features are measured at fair value as of each reporting date and the change in the fair value for the period is recorded in the consolidated statements of operations as a change in the fair value of the derivative liability. The fair value of the derivative liability is based on Level 3 unobservable inputs. Changes in fair value are recognized as a gain or loss within other income (expense) on the consolidated statements of operations and comprehensive loss. The derivative liability expired unexercised upon the conversion of the convertible notes into Series B-1 convertible preferred stock in May of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Simple Agreement for Future Equity&#160;&#8212;</span>&#160;On March 25, 2021, the Company entered into SAFE with existing investors, pursuant to which the Company received gross proceeds in an aggregate amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_3_25_2021_To_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember__NxCd_fmOkGpRip87LsWsA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromSimpleAgreementsForFutureEquity" scale="3" id="Narr_PnLdHaHUx0SvD5I0cd2mvA">8,942</ix:nonFraction>. The fair value of the SAFE liability is estimated using a fair value model that includes inputs such as: (1) probability of occurrence of future events (such as a change of control or public offering), and (2) discount rate for implied return required by investor. The Company recorded a change in fair value adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity" sign="-" scale="3" id="Narr_RQA2vsMtwUi1DodLU5io-A">2,236</ix:nonFraction> in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2021. Upon the occurrence of the Company&#8217;s IPO on October 7, 2021, the SAFE converted into <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_10_7_2021_To_10_7_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_J1qjrKQ97UC4V1Qbkn0BVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_-Q5DwhgnXkO13eDjSFRH4A">931,485</ix:nonFraction> shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of the SAFE was determined using a probability weighted expected return method (PWERM), in which the probability and timing of potential future events is considered in order to estimate the fair value of the SAFE as of each valuation date. Management determined the fair value of the SAFE using the following significant unobservable inputs:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_fgLiHxsGP0uXE9jzjas5Uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">October 7,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 25,</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Conversion)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Issuance)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_KVexRmvX6US-liK6aNll8Q" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TIObl80f7UWIvJjeNn-tkA" decimals="INF" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_uT4RsB85EU6D7J6Ihiq7AQ_4_4">0.35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon conversion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_MxmsAkGlGk6Tkcg1-sC0nQ" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_bztRM48Bdkep9KdH0EfXwQ_5_2">20.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_ngpHUyNFakCau2ySwCxAGQ" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_woXIhuJk7UKLhS_moiK8vA_5_4">20.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon implied return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_1ncZ0wDVjUaMv3n8bW5Qww" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_XPD278HWL0mhVBV6oH-gXQ_6_2">18.9</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_h4s2HAgDWEyJ3_wpwJxxJg" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_THgzKtzz50moGjLX7ki4cA_6_4">18.9</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of IPO occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_raLm_xXRuUiTAX_TParm5g" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_lg0-n3MmUkC9DQdqZZLojA_7_2">100.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_iqb3nfvhzUGG9vyRKPjbLQ" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_Eg23mIYqpkS0x8H1i_9E1Q_7_4">45.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of dissolution event occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_vyxTfLKJxUW9zuhqZTsSFg" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_hTjQAtCFrkaa-R9N0nyhgw_8_2">0.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_QoK-U_gP1Ua8QKYjkoygBw" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_qua8UH1qg0uJKv8GOXXVOA_8_4">15.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of equity financing occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_Ew7Kbm3OAEy6EtEDlHqmug" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_btl8ggaF5E6UYDPoi5GXFw_9_2">0.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_O1QXNgSInE2t6P_Ih0REuA" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_ju2feHBvMEOClcta9tLQbg_9_4">37.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of change of control occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_T1dodM-JUE2PyHPTE4fWQg" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_fDE_6FHB60OXx2PHUcKO9A_10_2">0.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_HuWBldoXiEChJl-DHcYigA" decimals="1" format="ixt:numdotdecimal" name="cgtx:SimpleAgreementsForFutureEquityMeasurementInput" scale="0" id="Tc_SH1togVTsEWtKqhMIFd_LA_10_4">3.0</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In addition, the Company recorded the Series B-1 convertible preferred stock within mezzanine equity at fair value on the date of issuance, May 1, 2021. This non-recurring fair value measure was based on level 3 unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In April 2020, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Narr_rob-4UnbmUukLcAQbm-q_w">443</ix:nonFraction>&#160;unsecured loan, bearing interest at&#160;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_T5T795wE9kGTs0g6v6hUBw">1.0</ix:nonFraction>%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). The PPP provided for loans to qualifying businesses for amounts up to&#160;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw" decimals="1" format="ixt:numdotdecimal" name="cgtx:PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" scale="0" id="Narr_F6_MQMdB2k2P6YSFGhW9ZA">2.5</ix:nonFraction>&#160;times of the average monthly payroll expenses of the qualifying business. The loan and accrued interest are forgivable after eight weeks if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The amount of loan forgiveness may be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over&#160;<ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw" format="ixt-sec:durwordsen" name="cgtx:PeriodOverWhichUnforgivenPppLoanPayable" id="Narr_VFQkMFDYtU-xifq2R5SeBA">two years</ix:nonNumeric>&#160;at an interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_f0FeNir8A0WhKppxAs82pA">1.0</ix:nonFraction>%, with a deferral of payments for the first&#160;<ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw" format="ixt-sec:durwordsen" name="cgtx:LoanDeferralPaymentsPeriod" id="Narr_XeMTPrcMzkCpO7KdQdpDsw">six months</ix:nonNumeric>. The Company used the proceeds for purposes consistent with the PPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On January 21, 2021, the Company received confirmation from the SBA that the PPP Loan had been forgiven in full, including all interest incurred. Accordingly, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_cFNoQhYPU0-zSAcDylTH8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Narr_BPJIngi5w06sL2WUOn9XAw">443</ix:nonFraction>&#160;of income for the debt extinguishment pursuant to ASC 470-50-15-4 for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JUCF3w8DHEysL0CI-VZwLA_cont2"></ix:continuation><a id="Tc_boSFRJSmukuqSkiGGvjOIw_1_2"></a><a id="Tc_BDtQ2Zya0USpe8bX3R0CHg_2_2"></a><a id="Tc__fA0ESLG3E-xmhfPeUSVgg_2_5"></a><a id="Tc_kL-P18s440q7FWP_0REuJw_3_0"></a><a id="Tc_duyp-8GXjke2PqeVjjQHmQ_3_2"></a><a id="Tc_B9_nqLCXNkGKQw6Xwj08sg_3_5"></a><a id="Tc_gJ_z1TRzyECLeLZAX2JM9A_4_0"></a><a id="Tc_8phrDPGrxkS-1O6SdubQBw_5_2"></a><a id="Tc_Luxa7t5yYU6cyLOAacNKqQ_5_5"></a><a id="Tc_giN6C86qUk-XUTbfOjMcLg_6_0"></a><a id="Tc_qGnxTdDAXkO8M4LD-vM6ug_7_0"></a><a id="Tc_cTZ3M8-zN0as8NvZv75xDg_7_2"></a><a id="Tc_MeG68kj3a0SuLecT5lPRjA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_Gv_uMtgvIkuaopriRsHKwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_-8XC0xGvf0qxnc7E7EYv7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_zSXdcVC8VE-7xnTJfzdRMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_kOV7Bo1VyUGoazXyHPm3ag_3_3">1,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_aO4rFi4jSEyn8DSa70-4Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_89CX-O-SnEertb7Qd8-Lyg_3_6">1,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-GYnhwP-wE6fE3kPKJhleg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_o1JqiN7jnUWBMoHvnXey8g_4_3">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_NdALTKUy0kmXAWKzuRjFpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_tczQgHup_k25b9nnFi6YTQ_4_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qWvN1g_NnUC1FsLJCflOyw_5_3">1,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_MSOlyJK7WkafoEAuYwp3OQ_5_6">1,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_MQBfTaJ0yEaLhVhAuERuEQ_6_3">953</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_Cpc29J_v7UaWccW3DuzCNg_6_6">870</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_MLPLU1LWc0q-k63IGKVhWQ_7_3">233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QKeMGtkFbE-Dy4Yzt-_AZQ_7_6">145</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_udPTuXyqPkKaXa9dioG1sA">83</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_reIOU8NDMUSTJddHXZAuoA">93</ix:nonFraction>, respectively, which includes amortization expense of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="3" id="Narr_oVyLWCdtYkeIcRMNOujSEA">2</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="3" id="Narr_R9aO5HZXykmtBUkaqS_Jbw">38</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_GK_sEZ62UUifBT3tgFoSoQ_1_2"></a><a id="Tc_4DTozLGGnUeRaVE27Or9Rg_2_2"></a><a id="Tc_UsQOgWo3eUeHLdvXNP73Rw_2_5"></a><a id="Tc_AJeZuxJ2bU2-dir5nxpI0Q_3_0"></a><a id="Tc_OzHlk7dNRUGKuNnB4HvEWw_3_2"></a><a id="Tc_p2CiHWz9f0GEv46qvYtTMA_3_5"></a><a id="Tc_Sy3p0kCqHESVWHnBHnH-XQ_4_0"></a><a id="Tc_WjOHktzdZUiKygu1sPwADw_5_0"></a><a id="Tc_1gQuDVJWlEuV5x2KoDAhYQ_6_0"></a><a id="Tc_H_QnQmB6QE67z-5Jy9HCDw_6_2"></a><a id="Tc_5xlSRkr7WEu_c0vXfuBrbA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_j_j6hjecqUWKtcYcpg9j7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_pameAXwS8E6zgxF2e_dq8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_RQSdMuXRnkO4yNMOFd1dWQ_3_3">870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_n9yNu-KAYU2fk5VvAUQ5Zg_3_6">1,285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_zrkGgkokP0-yub9HBhCYhA_4_3">900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_tuDJMgxXGUKmuYTFRKyecw_4_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal reserves, professional fees, and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent" scale="3" id="Tc_lem7sFGNdUS4MdFA5Dcqag_5_3">324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent" scale="3" id="Tc_s5S5MRJA70CLPUyheRVbvQ_5_6">216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_EJi_TguLAEGtBMq7MVjsnQ_6_3">2,094</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_f-OSJfKCZ06se6lYwK4skA_6_6">1,751</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f7a7ff03_795c_4f06_a876_a6f8a02a849a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:OtherCurrentLiabilitiesTextBlock" id="Tb_4_PkVu-K3kyf0KmFPkHCBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_o9pqSCH9S0quhv-OqZaHrQ">838</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_EWVlgr5r8EC_L4Ho7--lRQ">6.85</ix:nonFraction>% annual interest rate. Payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_uHgL9nAXWUGXP88TL0_l4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_sadx5Y-jWEiiUEJEyselnA">72</ix:nonFraction> are due monthly from November 2022 through December 2023. As of December 31, 2022, the outstanding principal of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Narr_bkIhYmZevU6wvLmfVAOTcA">634</ix:nonFraction> included in other current liabilities on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In October 2021, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_JvssCYPdjkyIHws7kOP5kA">1,453</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_0zcQS88ZpEKn9dv4z9bArg">3.25</ix:nonFraction>% annual interest rate. Payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_XP8oKPKT_Ei7TjXFOpwjtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_MUIUetZns0-uOi5KDeIYxQ">134</ix:nonFraction> are due monthly from October 2021 through September 2022. The loan paid in full as of September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_rgbDy3ss10qBgjKOlipX-w" continuedAt="Tb_rgbDy3ss10qBgjKOlipX-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy <ix:nonFraction unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_nwX8yS5_AE26RPa_9Fo2wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_lpBVVLiO3U-4zI0xR3ygiA">2,864</ix:nonFraction> square feet of office space under a lease that expires in May of 2029. The Company also leases approximately <ix:nonFraction unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_b88oSDVpj0-qGHOfTzZbKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_ecn7_F-bE0SI_JhIAM69HQ">6,068</ix:nonFraction> square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_96iu6bqRR02okgqdFfwfwQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_ma2rToQhAUmjjWqxR5u96A">2,980</ix:nonFraction> square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of <ix:nonNumeric contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_Z7obri4_Hk2MEqxX8hrVuw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_XDbUWts0vU2crjlR5bTvcA">45 months</ix:nonNumeric> and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified <ix:nonFraction unitRef="Unit_Standard_lease_aWodb89n40ua9F3TL8eTqQ" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" scale="0" id="Narr_Ai5d90cXQUqbI7Qj2BjYcw">one</ix:nonFraction> of its existing lease agreements for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_LQ20bH7lykG3YbuhQGEovA">3,706</ix:nonFraction> square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gdxdeiOnZEaz3-Zymnde0w_1_1"></a><a id="Tc_CX_hCLQxTUK2_RBE2KBCOw_2_1"></a><a id="Tc_8ZUDFHHIBE-Vco9PhPcdtQ_3_0"></a><a id="Tc_bDhKCfHThUqp-ONfOUx_ig_4_0"></a><a id="Tc_2K6DeRddqUCFC3vqpftEzw_4_1"></a><a id="Tc_JvTgRqHyXUGL1yksf22ARQ_5_0"></a><a id="Tc_ONEgXR8lHk2s4ZheHQkHBw_5_1"></a><a id="Tc_r8QpvIiCH0aYvo9tG5Imvw_6_0"></a><a id="Tc_sGHUiDS_rEaNC5s9WL0CFw_7_0"></a><a id="Tc_jxtbXx3UUEGwrjw8TTMiyA_8_0"></a><a id="Tc_AOfGd1ze7UKiUcAXRSrjPA_8_1"></a><a id="Tc_2zGGSzCQs0Kb0lTeEA0ZzQ_9_0"></a><a id="Tc_sIQ_Sdk9E0iL7TzaoI0_MQ_10_0"></a><a id="Tc_7cHilvwGZ0CTCzkY0CwbUg_11_0"></a><a id="Tc_HEvFxnM02U-YSja0l_XV8g_11_1"></a><a id="_922b3997_28c5_4b68_9e9c_0737a2d9c5b8"></a><a id="Tc_N4Sk-7Rn7E-uHJKsQ0zQRg_1_0"></a><a id="Tc_uTnWKt87q0WWFJCE99zGcA_1_2"></a><a id="Tc_bV9-vmETuEGVZGqCP-IY7A_2_0"></a><a id="Tc_hWEw7_U9bkinDu3P4UxzdQ_2_2"></a><a id="Tc_MmP3o70jkUyOD23gCflIbg_3_0"></a><a id="Tc_lf-3jW_rzUKh7PAlKI4RhA_4_0"></a><a id="Tc_-VatTFUqFEObyQr3vUx3Pg_5_0"></a><a id="Tc_SAJ4fKgJzkmqSsc2U_-lQQ_6_0"></a><a id="Tc_cf-l_D0GwkiKwedKYCscpA_7_0"></a><a id="Tc_fGRrV_ngmkiDXM69m2kppg_8_0"></a><a id="Tc_0lvvzeywW0eb0GDaX3wTXA_8_2"></a><a id="Tc_2ibqQA55w0SIfviXyIUmrg_9_0"></a><a id="Tc_AZ9u7-xY9EGC-zQobD5Mag_10_0"></a><a id="Tc_K7noxCA7aU6YsPG4q9iMzA_10_2"></a><a id="_5cd29646_248f_4e6d_8182_c84b5c23c9bf"></a><a id="Tc_60fKeIUuEUGuvAZbpVdhFA_1_1"></a><a id="Tc_bAGPxVE9dEKYsDVGBeG8_w_2_1"></a><a id="Tc_Tdq14yhXzE2q9K35y7VTCA_3_0"></a><a id="Tc_NUEh3_cMSES8m5D4mdsVqQ_4_0"></a><a id="Tc_oJ97fMW1602HIOTUWirVQQ_5_0"></a><a id="Tc_49yKLs1GeEyVzNCkCwFQZg_6_0"></a><ix:continuation id="Tb_rgbDy3ss10qBgjKOlipX-w_cont1" continuedAt="Tb_rgbDy3ss10qBgjKOlipX-w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2022 were as follows, in thousands:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:LeaseCostTableTextBlock" id="Group_6-XPdodKVUqolN4a2JQTBQ" continuedAt="Group_6-XPdodKVUqolN4a2JQTBQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLeaseAssets" scale="3" id="Tc_Kn1Ei9x5vkqyVhVrcBBybA_4_2">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_EwW2UN8cckqkYRv7DUjWgQ_5_2">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_jNNqlkOoF0ikAJbaK7PZQQ_8_2">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_iYDvOM-W5k-RI7XtAutzsw_10_2">695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_M6G_bq7ZBUePK5k5dwVzFg_11_2">844</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_auSOfrk73UGf8prOT74NTg">203</ix:nonFraction>. Rent expense was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_83bFHNW5nUy3ew9VgP2MoA">163</ix:nonFraction> for the year ended December 31, 2021. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_tz1zbV39IkKrHKdou5Sgtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_9ktvMSqJGEyKijLJVsd6vw_2_3">209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_kPx9WhSJY0S8btTdIFoXjA_3_3">221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_nP2ztAHZFUu8RABLQ2F0Tg_4_3">222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_efwNkoF7IU626Tjx_31VKw_5_3">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_JTnvlWBtwEqTVYy1MbTgxQ_6_3">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_adJVq1UZTE2VFNZMYyZ-ww_7_3">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_XCUF6qpLVkq7fbu03hmnww_8_3">1,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_7o_VzPl4FUOnmmk75XFaww_9_3">176</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_8vbx8iZHOkK5U75SgZ6MEg_10_3">844</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:continuation id="Group_6-XPdodKVUqolN4a2JQTBQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_js0GYZStjEao7o3FRMU_7Q_4_1">5.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_RA2XhUlsRUm_MLhIR0JaIw_6_1">8.1</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_VSgJWU6UpEmEIRHmZZHDqQ">172</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rgbDy3ss10qBgjKOlipX-w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2022 and 2021, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_8mGGEu-O7UiVBvu_Ogngdg_1_2"></a><a id="Tc_ASq7Pfp5tEOwU66ksjMRog_2_2"></a><a id="Tc_VZbnwmZp-EmEWwBdxkXtDw_2_4"></a><a id="Tc_SQjYjqZQnkOBZKO_ztcDFg_3_0"></a><a id="Tc_BIgFq8prdUqREA2Q_MgWFg_4_0"></a><a id="Tc_54pqVgTsbUyaahdkRu03kQ_5_0"></a><a id="Tc_cCRYcNCKVkKcxwD2wr7suw_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" id="Tb_NJNMVwxkBESjLd0COC-ieA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_astV6RG0N02PQZjh4hkZ3A">250,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_877D-dW31EO1hsoW00zheg">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ehcgtF-SMU6uSAARc68shQ">10,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ADrj0ktxNUW9bP0ZDZ0q3w">0.001</ix:nonFraction> per share. As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_G09Qmz_rEEuHNoNOIRH5Bg">28,991,548</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_tn17Xy4CSUyYEvmUuMAgeA">22,230,032</ix:nonFraction> shares of common stock <span style="-sec-ix-hidden:Hidden_zrVKOEsWWUen0jAD0vBoIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Y0sKS617cUG-4b1iHZkpJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, in connection with the completion of the Company&#8217;s IPO, <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesaConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TaoGs-evLUaQbSnfNKRUJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_LOtYLqly0kiSeFbfWPa7NQ">2,819,027</ix:nonFraction> shares of Series A convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YhglPqSICEOHSV_IdZw7eA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_A-Di9OP4i0iE0C6BKAPA8g">3,730,366</ix:nonFraction> shares of Series A-1 convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_uKNBRS7LKkeAraJh_fQoTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_IQHmnl1SVE2pVIda9aZQ4Q">3,565,063</ix:nonFraction> shares of Series A-2 convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k0Fx52yg8EmU-X-cmYFt2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_zjmRhKEms0mWVxAnmWixug">30,409,890</ix:nonFraction> shares of Series B convertible preferred stock, and <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_enLCj8Q1xEml8KVpBZ04bA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_ViiCLS-r-EGSGgk2bfoH4A">10,926,089</ix:nonFraction> shares of Series B-1 convertible preferred stock automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_bLCSVmRZekeyhHdm7au9-A">15,906,537</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2022, <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="3" id="Narr_gbDH_7aUoUexdPtbkFkU5w">no</ix:nonFraction> dividends on common stock had been declared by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of December 31, 2022 and 2021, the Company has reserved the following shares of common stock for issuance as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfStockByClassTextBlock" id="Tb_UCUl7csCDEC4QZT6_aIA-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_-IP8DBZpCUSLq5j3zp66OQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_b-EA8DzqX0yWYxilJF6Bhw_3_2">3,679,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_Sm3lzM60aUOPdd-qCWli3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_DmRJkWBRQka3KRpB7l41FA_3_4">5,640,438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_N1dAezJ1BEmEY5K2pYrnWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_vJl71nafWkm_GNWfdcFbJA_4_2">2,561,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_2SLhlXLD40WSZNvO2Kvf4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_BiBL3JHq80Ou6cXSge_nIg_4_4">1,242,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_sct--jfhGkOI2iY08mN67g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_eCgoxHVBtkSQXmf7WjivDQ_5_2">209,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_XL_cLPnem0WdnDFZvFsDSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_g-riIXWMT0Kh2ve9W3PLlA_5_4">209,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ukGpJxePwE2csPRGpV6fFQ_6_2">6,450,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_jQxzhupxJkmZfydKsnKRmA_6_4">7,092,241</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_k04wlCQ0-EmNIO6tHSOtIA" continuedAt="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the aggregate number of shares of common stock of the Company that may be issued under the Plan is <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_iEOmeOWnWUeEVW0qwLtJJg">2,561,085</ix:nonFraction>. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2022 pursuant to an evergreen provision therein by <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_n6-tqTA3EkmAO2tyD5S7NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_F3NSiDSoTU-VP_etUBF1CA">1,111,502</ix:nonFraction> shares, representing <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_NPy6437bOUm5rmu1Uvq-zQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_rFNBnZqrukmiWGqw2AobeQ">5</ix:nonFraction>% of total common shares outstanding at December 31, 2021. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_1pumPUEKZU2T8noHh3EBSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_C-8NqfSLakGv5d-R5uO8ow">5</ix:nonFraction>% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s Board of Directors or the compensation committee. No more than <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkBqUzrULkqvOk4_Dzd2oQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_8aR4WWYeO0Cdd9Cl6xmcvg">7,543,185</ix:nonFraction> shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw" decimals="INF" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" scale="0" id="Narr_SNLI1-vwTUeD3xkiMMjQLg">4,334,131</ix:nonFraction> shares.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_DzcxxBQ-U0-j3QrmvoiSEg_1_2"></a><a id="Tc_i6630SP1UkqjFwi4F1wBnQ_2_2"></a><a id="Tc_G3nwJGR4S0GweqjZgd8U7Q_2_4"></a><a id="Tc_FqxsuJHsrE2euCJRdrJmHw_3_0"></a><a id="Tc_W9mZ-umQBEmtThZjP7MIZA_3_2"></a><a id="Tc_-MR7j8kDwEiSxQTqHPH7YQ_3_4"></a><a id="Tc_DnHWw8MXYUauafjKHdDe3A_4_0"></a><a id="Tc_fJ_wj-RCnkugWTBmdmXgiw_4_2"></a><a id="Tc_XQvk0CDsS0eD2ZbRT6DJyQ_4_4"></a><a id="Tc_L-RkzusAD0OINJWwpsOpYA_5_0"></a><a id="Tc_WnpAkgi-6k-LH3iB5Q8fOg_5_2"></a><a id="Tc_MogdIhiU7EOEU5OOwCAAxg_5_4"></a><a id="Tc_tQoUO7BsaUqoSPcmD6IT4g_6_0"></a><a id="Tc_o1wLVoGymE2Dd5TfjgfELA_7_0"></a><a id="Tc_un0bhb854EWG5FLA7vV9XQ_7_2"></a><a id="Tc_duo8uZmS7kmnZ3gSm3anDA_7_4"></a><ix:continuation id="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont1" continuedAt="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_yahv0OkpPEaYE1i-7KtT_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_uQb93s24yU6wb-7V4mrlvA">4,334,131</ix:nonFraction> (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2022, a total of <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_LRRxx2Dlh0uhljHR9SnyHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_pyhNX1A_lEWC9uRokyTaJQ">209,532</ix:nonFraction> shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_hxVnFPmIVUOw6ds7o7K_dg">1,000,000</ix:nonFraction> shares of our common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_JLSmhOtMMEyvsABqAAR4zA">1</ix:nonFraction>% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_-K212FCHr0qteLAy0uDpyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_XYAfduBLiEyYZK5YwTJYpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_lJS9WZo82EKuX_pjNjHvjQ">1.72</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_Mm4HIB07WkaEjnsTACDzAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_i4jVeHL0CEmS0lufhmlcRg">3.05</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Osz1MgsDcEWWlW4jGAr1bw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_Cf1h5ESEQUmHZw4NBaLplA">1.75</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DVoBTPqoMkip6hYlwzicaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_BLIKJJvv00mkkBka0p4HJw">6.15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_NWSVc2ApeEyeocBS5ljQeQ">91.09</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ECnC1Xy4WUidcX9WSWA53Q">92.73</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_kfUO_Zt4Qk2_dM2uZ47z9A">100.82</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_doXD5O25l0WQz1gMOLFMlA">101.83</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_oIZ4GUCuM0-dE9ABTRvn0Q">1.87</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_lA3rllV8YkWQAa6ZRxyMUA">4.22</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_yc0dcU_QwUKHfpsEqVEhfQ">0.67</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_8_6iQW_3GkWfOsXs9ZGpkA">1.06</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_2YtABIE9nkmRtllMyc55ZA_6_2">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_CNi8szm7nUiWZcJySleFvg_6_4">0.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_7A9Z0eNU2kGCYq5FHtJgjw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_GrEkMuHglkawbUgJd8Q9mg">5.50</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6lpHwpsw-EWJo0Zgq6rNcA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_YAOfTegJsEqFyFGEr6etBw">6.40</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_oXjUmgTrE0eWw47O5kihsg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_VpI5Ibn6nU2v4d7Dy8P-BA">5.00</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_kLTU2zUbVEic1iFZs3Jr4A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_lmMbSMs4OUihHshdiBNYiQ">6.22</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_2c30OJkJPUSSWINNi82rnA_1_2"></a><a id="Tc_bnpgXgyjCUuy9WFS9NlXQA_2_10"></a><a id="Tc_233xL8LDeUKf_M97I9v_og_3_4"></a><a id="Tc_9XuP8CFqQEW0CI9bNPCVXQ_3_7"></a><a id="Tc_cts5ZEX-KUGpSfATQmJ0dw_3_10"></a><a id="Tc_M-Z9xroRi0uIfm6nVroVBQ_4_4"></a><a id="Tc_ofMEdZ3Ny0WPlcvXeD6Drg_4_7"></a><a id="Tc_Ma2gXpZXv0GP33w1iBYmfg_4_10"></a><a id="Tc_M5-g7DI-nkydSQgONUwY1Q_5_2"></a><a id="Tc_DkjY2ghouk-1slH-lB_1Ww_5_4"></a><a id="Tc_rAG-i-gIXUKbYiGraTqC1w_5_7"></a><a id="Tc_sBXTjWj3IEGYDsx_FtSd7Q_5_10"></a><a id="Tc_KqY1PPwdy0O1upmRfUhDSw_6_2"></a><a id="Tc_Tp6yRyqLtEKghQkaG4skcw_6_4"></a><a id="Tc_woOEgi9sP0SNLMp5IT7hCw_6_7"></a><a id="Tc_v1i0UxbEe0mAZgKYj_qkUg_6_10"></a><a id="Tc_G7NdGVDVzE6KiOmR_1F58w_7_0"></a><a id="Tc_FHqL773jV0epPqhfKuVaBA_7_4"></a><a id="Tc_iqTiu5zUxEmD50HSdcRGTw_7_7"></a><a id="Tc_xu4vNo8B8k-LSPhfGDBCqw_8_0"></a><a id="Tc_YUIGJL8yRkaM7DTScU6wWg_9_0"></a><a id="Tc_pFlqOaE5KEKcmkBDbhn3hA_10_0"></a><a id="Tc_e_TiMkXaKUqim7cTuQF5mA_11_0"></a><a id="Tc_j76TIPvXm0yVwueE72GgOQ_12_0"></a><a id="Tc_-boPq1sL9kSFOl-Yz8vlUA_12_4"></a><a id="Tc_NyQm5r7_7kWpYx4UtCoxwg_12_7"></a><a id="Tc_Ba6XYwhDREuVJHwnNY3EMA_13_0"></a><a id="Tc_Ili4SgwnwkWFj6jW4oNTBw_13_4"></a><a id="Tc_PLO-_TA8UUyy8jJSsLrtSA_13_7"></a><ix:continuation id="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont2" continuedAt="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_DZ6deQUzl0epB5ABUzs-bw">zero</ix:nonFraction> as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Common Stock</i>&#8201;&#8212;&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_5WaUJ5A6rkqBgfCU7iKUdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_NrfJ4c-ICUGfZBlFljDGLA_7_2">5,640,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Q8At0JJ5_E-CSXrBFay7yA_7_5">4.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc__odr_-rRHU-zyH8JtY5CgA_7_8">12,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc__m7d0m8IZES0PdW_QpNnUg_7_10"> 8.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_IJbUu_nrf0q1ja7Bra0_RQ_8_2">524,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_2t2u2Ie9r0Wujzu7uKrTgA_8_5">2.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_sj8FAvZw8ke04qr6e4BYKg_9_2">1,761,516</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vjEQRjNx80WNqwypjJOcew_9_5">0.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_jzGf0vrEOEWq9R8KnbTW_A_10_2">646,072</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_NfQWDD4iBUmF9v33HqGJyw_10_5">5.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_Qme3aOuaAkWJlYIbJfagRA_11_2">77,752</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_OSoCtOA840mUKLMU3Feqrw_11_5">12.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_aiDctbNDP0eW4fsuoxXkfw_12_2">3,679,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_pXSqCUgFlk2802CrdPzPIg_12_5">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_DSZbefkaZECw0hxg2JuvDQ_12_8">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_qJIdMUC7BUK5kv8yxGG0kg_12_10"> 6.7</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_n04EZCxXSUqZF1_j91_8Gg_13_2">2,253,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_rCHH46avxkKADt4uoyf7Og_13_5">4.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_pk6mw7k28E6xiM0sbhPhKQ_13_8">1,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_O1DfG3KaHkioDh5zX07KLw_13_10"> 5.5</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_RMTtHouqw0CO-vY3AEibBA">1.83</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_fin4Dac24kOVa2L-J-5gvA">9.09</ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively. There were <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Beytv4R0qkq8uGJ1KNoEDA">524,370</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_8BOfBJuXq0-SU4bCCK3sEQ">943</ix:nonFraction> for the year ended December 31, 2022 and <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_KfqvI5ERA0OkTzH8VWBVmA">1,697,076</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_rJyc4ARFE0eI1gNngSWwGQ">15,424</ix:nonFraction> for the year ended December 31, 2021. During the year ended December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_PteIQZh4DUKHQ6HCkshc5w">1,761,516</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_yrLm3pCZkUy7zf3cJcoqzg">321,686</ix:nonFraction> stock options exercised, respectively, with an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_TRcwDco8HUC4EUWdTWH7pw">1,325</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_U7pkZOiQuU-FRuwdK2pOeA">188</ix:nonFraction>, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_WCrqMwLOvkCyiHyYazkS1Q">2,738</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_ocuHpEqxLkyf1pRUjt7hhQ">1,610</ix:nonFraction>, respectively. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_218cjZ2Szk6A6_9Msy41vw_1_2"></a><a id="Tc_Dp4tIzxe7kOnRW9RP2CY1A_2_2"></a><a id="Tc_w3GEVXZk0E-iE9nz0rB8hw_2_5"></a><a id="Tc_CJYmjntjNE2xW9SVjRNtCQ_3_0"></a><a id="Tc_fIUzryKH4kS9v9KD8c0rHQ_3_2"></a><a id="Tc_YebQSVPmw0WbmbOSkFGMAA_3_5"></a><a id="Tc_w5FSZeGCPUao24ZpR12jGA_4_0"></a><a id="Tc_4h61KMqWdEyZJOsDzIkQuQ_5_0"></a><a id="Tc_rsfKHFyWcEKhIWUXyufSaw_5_2"></a><a id="Tc_VSjAWDi9cUaqKpspkcQ_Wg_5_5"></a><ix:continuation id="Tb_k04wlCQ0-EmNIO6tHSOtIA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to incentive stock options and nonstatutory stock options as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_GNK_OHQfNE2aprQBh10VMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aM0FMO2TMEaf1Fu_f9Yn8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_oCcAh_lLSkasH-tItRXU1g_3_3">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_At8s-OhSw0yRFbaWfIbeww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dcAb1isjBUaGJMU8xp1Zow_3_6">877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2QI15J_3YUCTGyt7KkvUew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HbeXGZpD50iNjtg7uMlMkg_4_3">3,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sWlYGe9ixUe9X9WZ9DcihQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Yk2_EPovmkuPJN4STJWUzA_4_6">4,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dKw-vJsxCkC_JGo6hgQ2pg_5_3">3,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0Qsh-kA0bkSSeBQslMxFqw_5_6">5,183</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, total future compensation expense related to unvested awards yet to be recognized by the Company was $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_31Jt8SoqtkmthGVFwSHF-Q">6,501</ix:nonFraction>. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_jfBxq-REkEeb3AT5s6aDYQ">2.0</ix:nonNumeric>&#160;years.</p></ix:continuation><a id="Tc_Kr4plU31xUKedc_LURYXUQ_1_2"></a><a id="Tc_PW93wNPwgkCmC-E4YlWKhA_2_2"></a><a id="Tc_aS4j7PPcT0i-iPv1JFkv8A_2_4"></a><a id="Tc_AhzgCumxwkqX8beRxHv6Fw_3_0"></a><a id="Tc_BmUVjLc_2060bQgECO-OYQ_4_0"></a><a id="Tc__ape87OiG0iYcL-L7hdGdw_5_0"></a><a id="Tc_wRS8crIPPkCre-wGPagrtQ_6_0"></a><a id="Tc_WlQ-Gt3yjkO1cfkTMwCn2g_1_2"></a><a id="Tc_f7G_1mw5OEOZeo592DNWyg_2_2"></a><a id="Tc_0jNqojK2jEOBfmmK99K-Kw_2_5"></a><a id="Tc_P3abdEV-3UqYrZozEQhB5g_3_0"></a><a id="Tc_M0qnHZDcl0-HUv3GqUUbsQ_3_2"></a><a id="Tc_RdfSd5t-kEST1BZVynu8cg_3_5"></a><a id="Tc_S5PAt7ultUG9yl7O3K-Vkw_4_0"></a><a id="Tc_hhZWIfGGT0mu8rVKre8BVA_4_3"></a><a id="Tc_DA1RRAfKJU2n9zI7y158Mw_5_0"></a><a id="Tc_sRnil41ciUqayTsy-XnM9w_5_2"></a><a id="Tc_gDZhoVFNjkOQjIXONrV-lg_5_5"></a><a id="Tc_OmroobSuUUy4857l1HXlpw_7_0"></a><a id="Tc_F31i0Etm9E-AAyQFQ-NS1g_8_0"></a><a id="Tc_2l0URIz68UOJmq1ERLmKxg_9_0"></a><a id="Tc_XeFaKOcEWUKEM-U29zmv6Q_10_0"></a><a id="Tc_3YeQQNpfh0GJ6Uy3JE77Fg_11_0"></a><a id="Tc_0_xke8juSkabcBz5EzXnOw_11_2"></a><a id="Tc_bcWMY7FY6UWz5tqtFkKX5g_11_5"></a><a id="Tc_xZyp8vCYUkGXlZzDFI3i-g_12_0"></a><a id="Tc_qOZluVXnLEuCGKv3cc80aA_12_2"></a><a id="Tc_SxM_RFvHVUSUzvsKF0fCBg_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_JicjruPBDEyRXmMxMtA27g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented due to their antidilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_C8nIoJ2ZCkGo_4gl4EBBuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_x9O6RRV7-EqAHJFc8zyb0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_mnWQJNlnEUmUeGzbhdqrQA_3_2">3,679,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_JbPg3qBfrkinytQJRc8rBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_hRFfFbYr_kiEAH_OSFkI3g_3_4">5,640,438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_aYLK7DBMgEenBoD_1pqp7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ILtzk6wRV0iXnjkepteUbA_4_2">2,561,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_GOEFjr5HT0K3IfUrhIxbaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_09_86tSqHECLvApCHiB1mw_4_4">1,242,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_BBPnWdc1jEC6JJ6WU38FKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_X1gXKcrM4UGPinShytNgrQ_5_2">209,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_Vt-R9TT6a0-mHF1vBUv27Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_eEC4F6JCxEygliiMlrq-fw_5_4">209,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ysqLYlD1ckukD7QmnmRHJA_6_2">6,450,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__3NA7JH7I0OquFUICHR88g_6_4">7,092,241</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The basic and diluted net loss per share attributable to common stockholders has been prepared as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_fHtA4hW6rUataDF5pwuU1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mhUzJnuQZ0i_uAEDmhaUTg_3_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4b3-5U0yDUeH-xRQDhf5ZQ_3_6">11,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cumulative preferred stock dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_KEUq0zUgXkqiD9IRaqpmkg_4_6">4,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_vNtgiYC9pkGpWedLHTfU4A_5_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_wxv08s32-Uaet3B9JE07Fg_5_6">16,248</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_QDUhCdmQJUGn4SlP35kHsg_8_3">23,640,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_m5qF8NDSjES-SDq-U_V2Sg_8_6">5,190,883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_9Mj5mvUmakmKzqsIMc8eRw_9_3">23,640,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_t24xAUhCZkS3oYzik6tn4w_9_6">5,190,883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_D6MpqlHtSkGuoJT0jaDlNg_11_3">0.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_EIdSDc0K9kuR887QTEvWkw_11_6">3.13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_1UmAfGfLNkiUbbsQy2STHQ_12_3">0.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ePFce-0W10-guU8csQVu1g_12_6">3.13</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;font-style:normal;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_0zWOqmJjNU-wGsFg-Cj5Ig" continuedAt="Tb_0zWOqmJjNU-wGsFg-Cj5Ig_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_vFikY3UU6k6UkfuWLvpq2g">6</ix:nonFraction>% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_Fwae4JVppEuyA4-lkF5bqg">156</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_DUj44FNAIkCDZBTB1K8Muw">113</ix:nonFraction> for the&#160;year ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0zWOqmJjNU-wGsFg-Cj5Ig_cont1"></ix:continuation><a id="Tc_rXCN1wuZ606rWqnu5SjNsQ_1_2"></a><a id="Tc_iDg1yvU3MEGHHCB3ep1kxw_2_2"></a><a id="Tc_7l_J8-qQ3UaArj_VXRZ-_A_2_5"></a><a id="Tc_8uXLMTd1H0mBdy0y8k-igQ_3_0"></a><a id="Tc_Bi2HBIAn3E-D8TamCWR5MA_3_2"></a><a id="Tc_00dDRkcRW0izo4KRNyY2hw_3_5"></a><a id="Tc_vTn1dOOTkkWrOinJ4dp68w_4_0"></a><a id="Tc_I9AkxShD2kmV2-ysSpLnpw_5_0"></a><a id="Tc_F44r0Txj5kicRfuWefhH7Q_5_2"></a><a id="Tc_4nes63_YakOht41hXm6fSQ_5_5"></a><a id="Tc_pBNelRU6C0CVncn74JlhtA_1_2"></a><a id="Tc_708_-EM3d0ecU7Iz-EygbA_2_2"></a><a id="Tc_DDMWbYQy7Ea-45wl99cFlA_2_4"></a><a id="Tc_IJ0p-xeQTEqNOcmygrSYpQ_3_0"></a><a id="Tc_JULEbr8hlkmAY-GH5zQ6xw_3_3"></a><a id="Tc_LJd18de9kUO9EXjLvXWlvA_3_5"></a><a id="Tc_g71Bbq8wF0C5eITamxjm2Q_4_0"></a><a id="Tc_AEh9VTS5fEaOicewYOZd1Q_4_3"></a><a id="Tc_blzdSbnLEUORpI4dIZUEpQ_4_5"></a><a id="Tc_slFPT74oVkSLHZmTy-QJTQ_5_0"></a><a id="Tc_m4i7jzq2VUill73xr097DQ_5_3"></a><a id="Tc_cf_qBHDCAkWwHLwgMcXnsQ_5_5"></a><a id="Tc_2173lmS9BUmRQpF4dKYPJQ_6_0"></a><a id="Tc_R95oC3f2N0mpFnPoi37tIQ_6_3"></a><a id="Tc_9kxjRUHfqUiR9XwN7lTVcg_6_5"></a><a id="Tc_dtn_EQ9deE-eG7YkQBq9Ig_7_0"></a><a id="Tc_93hU3EauYk2beqKbWmM_eA_7_2"></a><a id="Tc_zUEaE_-iQE6Q1S_LcUyypw_7_3"></a><a id="Tc_gi8OGI_mSUiZrXNlE_N_7Q_7_5"></a><a id="Tc_sr_ms283c0GgmRr8ptme7A_8_0"></a><a id="Tc_LEtMGNBvkk20TupQAPFpag_8_3"></a><a id="Tc_2ZkK-vZcc0KLUDguOwieOw_8_5"></a><a id="Tc_3W7g_uNr8UGbIUQWEhxzuQ_9_0"></a><a id="Tc_MTo3CvPfx02P2nFUeQntBQ_9_2"></a><a id="Tc_OhZ8dZj5GkeHMAkJbnLRYQ_9_3"></a><a id="Tc_tX1803ZRTEaO8UX2jizmvg_9_5"></a><a id="Tc_JMlwBJh7lUyneE6Bn-XXTw_10_0"></a><a id="Tc_U4BHbg172EOekxxfXl4dTw_10_3"></a><a id="Tc_kZHH1KNRAkug972-M9hbaw_10_5"></a><a id="Tc_hUVo1CLaKkuElIbWzfq6qw_11_0"></a><a id="Tc_GDqpPNzFBUWES5pJHg-Nhw_11_2"></a><a id="Tc_EmHeN5z7vUaq26oimRlBLA_11_3"></a><a id="Tc_pdiqIWh2gk-_P2g5ytF--w_11_4"></a><a id="Tc_VFk361-zvUW1HddiKYjSUw_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_3uiTDQ8QQ0yIQPNT-awbAw" continuedAt="Tb_3uiTDQ8QQ0yIQPNT-awbAw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_RcwALMhT50-v6h7CRkTQgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_FZ0l5EV4vEyoswf5Lc-szw_3_3">21,384</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_QWQicsnTD0iCv-JopSnawQ_3_6">10,910</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_sOy-vsml4Ey8VPaxw5SBZg_4_3">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_iE3oulWy3kKCciy0mglycw_4_6">806</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dWKH365LhEGrJoDsH0X1Ag_5_3">21,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VDUJTgGrMkaeqCUjgig2bA_5_6">11,716</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2022 and 2021, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr__aeli2oE_UWDTwozDMLqTw"><ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_KVRxpjDxjUWDcZ4L_NjH0g">no</ix:nonFraction></ix:nonFraction> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) is the excess of a U.S. shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. This results in a material increase to the Company&#8217;s net deferred tax assets. Furthermore, since the Company provides for a full valuation allowance against U.S deferred tax assets, this has an adverse effect on the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_dF4liTa_mkKlcHl05EaeLQ" continuedAt="Tb_dF4liTa_mkKlcHl05EaeLQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_tjvO2NE5k0KnwwCubB_nww_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_YuBJhPBee0eEocgNWmOGTQ_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_D69IU39rzkGb8GKbrhea8w_4_2">15.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_DZafbukqkkq_IRo0HEVXsA_4_4">4.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_W8CV5hnp9U-ImlPHYBCXWA_5_2">12.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_xBoqpxjr0U2gp8ffc7lA5w_5_4">32.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_cBFoXVEwMECzVjpZaWgx8w_6_2">15.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_B7bVZ6Gcaka9BKOR4ZVz0w_6_4">11.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="cgtx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent" scale="-2" id="Tc_a84S1QlghEGl9KN3Oxo5Lw_7_4">4.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-deductible stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_Fn76wdl-kkOQQxx6tH7j7A_8_2">1.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_omaZ36BEAkKUStzaXJLEIQ_8_4">5.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="cgtx:EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" sign="-" scale="-2" id="Tc_vE6dNkm_zkGePnZPSf1lHQ_9_4">3.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_Fuoh_AAO8k-R9zOGXAKi6g_10_2">0.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="Tc_s1w_Fu4YdkicXSNjUL4HDg_10_4">1.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_XdKsnh3e-0y_eya5LuYo7g_1_2"></a><a id="Tc_MR6-t0irgkOZ4Q3vJ2zW5A_2_2"></a><a id="Tc_eIUzhoBAjk6KfN4-uvMADQ_2_5"></a><a id="Tc_o5CQtK5WI0ONpt0XeoSVGA_3_0"></a><a id="Tc_G1uphH5b9Eqhnh3AuldAYQ_4_0"></a><a id="Tc_NbFm9kB_9kWtZHP4gFFCWw_4_2"></a><a id="Tc_NW33r2fqyEW2597JLPiC3w_4_5"></a><a id="Tc_ZnXQdw5Awkm3MgxmprZ6zA_5_0"></a><a id="Tc_gOhZmAP2E06-CMXbBIHSZg_6_0"></a><a id="Tc_4UtOHrrpAk2tyjWjkOn84A_7_0"></a><a id="Tc_T9bCUa1dN0mCOp8oHUVKBw_7_6"></a><a id="Tc_5IdAh_H4HkGHM-E6cohlNw_8_0"></a><a id="Tc_wLysO8vbsECsKbdz_aZqxw_8_6"></a><a id="Tc_YyjX7Z2HUUyYVPwDuQCslw_9_0"></a><a id="Tc_iVOEyRFpvUydCxOP_HkHnQ_9_6"></a><a id="Tc_-73NJfek7E6nscE4Gw13hg_10_0"></a><a id="Tc_ZMpGoNjWqEiVgsIyJXZ4Sg_11_0"></a><a id="Tc_d6iZmaImgkS6btXYnSQsCw_12_0"></a><a id="Tc_qdgsRInseEOBQLuL8NHqMw_13_0"></a><a id="Tc_ktsvx8KXUk2b6s-F3swdgA_15_0"></a><a id="Tc_0fDG1c3mI0i_lY6HPeVnVQ_16_0"></a><a id="Tc_YLVo2SfuiUOlqlf0IHfd6A_17_0"></a><a id="Tc_ZZBWC3HAlkmg-rkjqBH-mA_17_6"></a><a id="Tc_oIp2qtlaYESQk_BzYu9PgQ_18_0"></a><a id="Tc_pVcEbhUAeUi8inNwQ2ygKw_20_0"></a><a id="Tc_8zStKxYLb024ACwlZue6Ng_20_2"></a><a id="Tc_5heprwSlf06z1FEm7YxLeQ_20_3"></a><a id="Tc_G7ZXLXXseUW7d3ExJWzomA_20_5"></a><a id="Tc_cIpP4wgJM0q_9M_tSAD2PA_20_6"></a><ix:continuation id="Tb_3uiTDQ8QQ0yIQPNT-awbAw_cont1" continuedAt="Tb_3uiTDQ8QQ0yIQPNT-awbAw_cont2"><ix:continuation id="Tb_dF4liTa_mkKlcHl05EaeLQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_JgBZMQRDU0-m9YwGeV6a5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_wc0pLrWIh0qmLTZTkPF1lw_4_3">8,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_eqgKcvwAsU6h-I7KmsKsMw_4_6">13,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_OLUyxj2fAkWMgTA3FXNtjQ_5_3">1,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_KG8kUIgcM0WuwWewMJCeyw_5_6">4,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_jW9nN-Lmj0G8-zHTBi7FBA_6_3">307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_k5uZo62bxUKbhtFtSbMLew_6_6">545</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_fL0QcLzK60OiqF7E8LKKcQ_7_3">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_fjAxzYpI6UWouRcIeDotuQ_8_3">5,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_gtpm-MIBMkquej_v83WGGQ_9_3">354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_vguSSmkoBUSPyDt1Sqdz9g_10_3">165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_U3WfLqYhy0iFZ8ELYEY_pA_10_6">316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_M3pDP-AFokq1kgPKg3nzZQ_11_3">16,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_TkJCMUZ7WEuYfl7i-zfT5A_11_6">19,058</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_rbJ8SlFrgUu4QlWwsmcRXA_12_3">16,435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_7Q-UDftodkWgqIAjacG7GA_12_6">19,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Zo7gmu9ebESchfpOSOXTMw_13_3">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_fGrQ_en3VEm5rEsWkllGlw_13_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_wJY37lx46E2LMRlnf_e79w_16_3">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_u5Qd3CQWQkOTOFHDEjpgIA_16_6">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_FRCj4_FdCk2KMwK2RyKZxg_17_3">171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_RVFzaLLO80GVZJV66QEKWg_18_3">178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_TpY3Vts2XkWeXgc7yyvTbg_18_6">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2022 and 2021. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2022 and 2021, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2022 and 2021. The valuation allowance decreased by $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Narr_Urnkx8DE20Cj6iJXRt1DOg">2,610</ix:nonFraction> and increased by $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_PtbZ8wB-S0-0VzBEudPvbg">3,866</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively. The decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures, while the increase in 2021 was primarily a result of operating losses generated with no corresponding financial statement benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company is in a taxable position as of December 31, 2022 and has utilized NOL generated in prior years to fully offset their current income tax expense. As of December 31, 2022, the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_fdTtC9XpB0-ScJOa4IRFVg">36,272</ix:nonFraction>. Included in federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_v6fG8Yhu5kCuxgRpUFoeqA">36,272</ix:nonFraction> is $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLossCarryForwardsSubjectToExpiration" scale="3" id="Narr_qyBpIcvXJEiDVPdAsLGSYA">17,930</ix:nonFraction> that begin to expire in 2033 and $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLossCarryForwardsNotSubjectToExpiration" scale="3" id="Narr_YtquUIKE8E-NgqYoS8eMkA">18,342</ix:nonFraction> that can be carried forward indefinitely. As of December 31, 2022, the Company had state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_0h3qCBEleU-V3fVtO2hK3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_BtwFS2HVwE6liH8vhJk2LA">12,248</ix:nonFraction>, available to reduce future state taxable income, which will begin to expire in 2027. As of December 31, 2022, the Company had foreign net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_OuQa9AV1Z0aOm013SYiWPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_Cz3PAQChDki1T1PbmPfgYg">314</ix:nonFraction> that can be carried forward indefinitely. As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ResearchAndDevelopmentTaxCreditCarryForwards" scale="3" id="Narr_99kNpWEflUSUhexkkPnV-A">1,728</ix:nonFraction> available to reduce future federal tax liabilities, which will begin to expire in 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3uiTDQ8QQ0yIQPNT-awbAw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, <ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_r86VYS_0W0WTzM_aM7xtOA">no</ix:nonFraction> amounts are being presented as an uncertain tax position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue from 2018 to present; however, carryforward attributes that were generated prior to December 31, 2018 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_jdQGUHl_nEC2766aCY4YzA" continuedAt="Tb_jdQGUHl_nEC2766aCY4YzA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Subsequent Events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, the Company filed the Shelf (File No. 333-268992) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_0kLhgTvdj0qjXHF1f1YyBA">200,000</ix:nonFraction> in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_JnhWm1ntOkCHK3VEhr29nw">40,000</ix:nonFraction> of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_1zxg5AToSUenAu3Kh89EPQ">35,000</ix:nonFraction> of shares of common stock at our sole discretion, over a <span style="-sec-ix-hidden:Hidden_EOZZ9ib9PU6NThp6PBR4OA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">36-month</span></span> period commencing on March 10, 2023. The Company filed a supplemental registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rVfHQbNc80GA_eeXLO2dFw">189,856</ix:nonFraction> shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b44da88f_e641_432f_9d6d_01025588c259"></a><ix:continuation id="Tb_jdQGUHl_nEC2766aCY4YzA_cont1"></ix:continuation><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_91356089_6547_4863_b2fd_b1e0e5e982cd"></a><a id="Item9AControlsandProcedures_434960"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Our President and Chief Executive Officer and our Interim Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report. Based on this evaluation, our President and Chief Executive Officer and our Interim Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Controls over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Interim Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our management, including our President and Chief Executive Officer and our Interim Chief Financial Officer, does not expect that our disclosure controls and procedures or internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met and cannot detect all deviations. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or deviations, if any, within the company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a7ccf425_98c0_4294_8c00_a2f703bd2b89"></a><a id="Item9BOtherInformation_878908"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6b7fa45b_c6f4_4f87_8ddd_4e35b861ea59"></a><a id="Item9CDisclosureRegardingForeign"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d8b661c1_39e4_4431_918e_5bba7dac470f"></a><a id="PARTIII_479695"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our definitive proxy statement related to the 2023 Annual Meeting of Stockholders, or the Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><a id="_46d825f9_2ac3_4f86_a8d8_a2581ff6b9f2"></a><a id="Item11ExecutiveCompensation_635596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_44722d66_acad_40d2_bc93_ce01760d9481"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_465b17fc_5b3e_43b3_9b50_db61095da236"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c6c0ac90_f8e9_4acf_ab3a_4966629c5255"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aa455286_8c03_4326_975c_845a0ab85aeb"></a><a id="PartIV_346291"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">(a)(1) Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42) </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">(a)(2) Financial Statement Schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">(a)(3) Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The following is a list of exhibits filed or incorporated by reference as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_271d4d07_102a_4ad4_bfbb_8cc2d1b94bae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc.</span></a> </p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/14/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/14/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837022004672/cgtx-20211231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/30/2022</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indenture</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease Agreement between RJ Equities LP and Cognition Therapeutics, Inc., dated July 1, 2017</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Office Lease Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between 2500/2700 Westchester Avenue Owner SPE LLC and Cognition Therapeutics, Inc., dated July 1, 2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2007 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Stock Option Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2020, between Cognition Therapeutics, Inc. and Lisa Ricciardi</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2020, between Cognition Therapeutics, Inc. and Lisa Ricciardi</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922115489/tm2226999d4_ex10-29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease Agreement, dated August 31, 2022</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268228</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/07/2022</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employee Restrictive Covenant Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Board of Directors of Cognition Therapeutics, Inc. Nomination Letter of Mr. Brett Monia, Ph.D.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/14/2016</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 09/08/2018</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/28/2020</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 02/03/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/06/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/10/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Controlled Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Sales Agreement, dated December 23, 2022, by and among the registrant, Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.36</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.37</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP, independent registered public accountant</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.16%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bd897cc0_5d64_4a02_ba83_766ea39ed6b8"></a><a id="Item16Form10KSummary_806161"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8df5889a_b597_4b30_901d_4ff653499abb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 23, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC..</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Lisa Ricciardi</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer) </i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 23, 2023 by the following persons on behalf of the registrant and in the capacities indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.1pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.05pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer, President and Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Andrew Einhorn</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Interim Chief Financial Officer</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Andrew Einhorn</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Jack A. Khattar </p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director (Chairman of the Board)</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jack A. Khattar</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>cgtx-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"></td></tr><tr style="height:8pt;"><td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:bottom;width:2.18%;border-bottom:1px solid transparent;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership percentage</b></p></td><td style="vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.8%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of incorporation or organization</b></p></td></tr><tr style="height:10pt;"><td style="vertical-align:top;width:39.12%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Cognition Therapeutics PTY LTD</p></td><td style="vertical-align:top;width:2.18%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:14.83%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">100%</p></td><td style="vertical-align:top;width:2.05%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.8%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Australia</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cgtx-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the incorporation by reference in the Registration Statements: </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-260686) pertaining to the Cognition Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan, the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan, as Amended, the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan and the Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan, </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-263968) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan, and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-268992) of Cognition Therapeutics, Inc.:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of our report dated March 23, 2023, with respect to the consolidated financial statements of Cognition Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cognition Therapeutics, Inc. for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 23, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cgtx-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Lisa Ricciardi, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: &#160;March 23, 2023</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Lisa Ricciardi </p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cgtx-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Andrew Einhorn, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">. JK</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 23, 2023</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ Andrew Einhorn </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Andrew Einhorn</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Interim Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cgtx-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 23, 2023</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cgtx-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 05:54:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 23, 2023</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Andrew Einhorn</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Financial Officer<br>(Principal Financial Officer and Principal </p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Andrew Einhorn</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cgtx-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &- \,# 2(  A$! Q$!_\0
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M_P#"4O\ _P"-4<K"S/2J*\U_X7OI/_0N>,__  E+_P#^-4?\+WTG_H7/&?\
MX2E__P#&J.5A9GI5%>:_\+WTG_H7/&?_ (2E_P#_ !JC_A>^D_\ 0N>,_P#P
ME+__ .-4<K"S/2J*\U_X7OI/_0N>,_\ PE+_ /\ C5'_  O?2?\ H7/&?_A*
M7_\ \:HY6%F==XKAU&:"P&FF0.+R)IO+;;^ZS\V?4>U;8Z5Y#XA^.D4D-I_9
MN@>-$<749F(\*WO,6?F',7_UZU?^%[Z3_P!"[XS_ /"4O_\ XU19V"S/2J*\
MU_X7OI/_ $+GC/\ \)2__P#C5'_"]])_Z%SQG_X2E_\ _&J.5A9GI5%>:_\
M"]])_P"A<\9_^$I?_P#QJC_A>^D_]"YXS_\ "4O_ /XU1RL+,]*HKS7_ (7O
MI/\ T+GC/_PE+_\ ^-4?\+WTG_H7/&?_ (2E_P#_ !JCE869Z517FO\ PO?2
M?^A<\9_^$I?_ /QJC_A>^D_]"YXS_P#"4O\ _P"-4<K"S/2J*\U_X7OI/_0N
M>,__  E+_P#^-4?\+WTG_H7/&?\ X2E__P#&J.5A9GI5%>:_\+WTG_H7/&?_
M (2E_P#_ !JC_A>^D_\ 0N>,_P#PE+__ .-4<K"S/2J*\U_X7OI/_0N>,_\
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M /\ &J7*PLSTJBO-?^%[Z3_T+GC/_P )2_\ _C5'_"]])_Z%SQG_ .$I?_\
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MU=SX7>SB9HI=2D6T4XZ*?F<_]\J?SK;^''B-M4\*Z==R!GE:+RY<#I(ORO\
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M8;FSV''J:Z/0O!>I>.M6U#5+\2Z=IEU<-*H3Y9YTZ(!_<7 '/4]JGLO#FJ>
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M_P#7H_X9B^*G_0BZS_WX_P#KU^LOVZU_Y[P_]]BC[=:_\]X?^^Q7;_KCC/\
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MMUK_ ,]X?^^Q1_KCC/\ GU'\?\P_U+P7_/V7X?Y'Y-?\,Q?%3_H1=9_[\?\
MUZ/^&8OBI_T(NL_]^/\ Z]?K')>6KHRBXAY']\5C^#;./P[X=MK"XNK:2:)I
M"6CD!!W2,PZ^S"C_ %QQG_/J/X_YA_J7@O\ G[+\/\C\M/\ AF+XJ?\ 0BZS
M_P!^/_KT?\,Q?%3_ *$76?\ OQ_]>OUE^W6O_/>'_OL4?;K7_GO#_P!]BC_7
M'&?\^H_C_F'^I>"_Y^R_#_(_*_PM^R1\3_$6O6>GS^%K[28)G"R7M['LBA7N
MQ.?T[U^C?P:^#>A?!;PG#HVCPAI6 >ZO74>9<R8Y9CZ>@[5VWV^U_P"?B'_O
ML4?VA;?\_$7_ '\'^->%FF>8O-(JG47+%=%?7U/>RK(<'E,G4IOFD^KMIZ%B
MBJ_]H6W_ #\1?]_!_C1_:%M_S\1?]_!_C7S=F?3<R[EBHKBW6X3:W2F?VA;?
M\_$7_?P?XT?VA;?\_$7_ '\'^-1.FJD7":NF-22U3""SC@'RCFFW&GQ7'WEI
MW]H6W_/Q%_W\'^-']H6W_/Q%_P!_!_C7,\%0=/V3@N7M8KVCO>Y+%&(D"CH*
M?5?^T+;_ )^(O^_@_P :/[0MO^?B+_OX/\:ZHPY$HQ6B)YD^I8HJO_:%M_S\
M1?\ ?P?XT?VA;?\ /Q%_W\'^-59BYEW+%%5_[0MO^?B+_OX/\:/[0MO^?B+_
M +^#_&BS#F7<L457_M"V_P"?B+_OX/\ &C^T+;_GXB_[^#_&BS#F7<L457_M
M"V_Y^(O^_@_QH_M"V_Y^(O\ OX/\:+,.9=RQ15?^T+;_ )^(O^_@_P :/[0M
MO^?B+_OX/\:+,.9=RQ15?^T+;_GXB_[^#_&C^T+;_GXB_P"_@_QHLPYEW+%%
M5_[0MO\ GXB_[^#_ !H_M"V_Y^(O^_@_QHLPYEW+%%5_[0MO^?B+_OX/\:/[
M0MO^?B+_ +^#_&BS#F7<L457_M"V_P"?B+_OX/\ &C^T+;_GXB_[^#_&BS#F
M7<L457_M"V_Y^(O^_@_QH_M"V_Y^(O\ OX/\:+,.9=RQ15?^T+;_ )^(O^_@
M_P :/[0MO^?B+_OX/\:+,.9=RQ15?^T+;_GXB_[^#_&C^T+;_GXB_P"_@_QH
MLPYEW+%%5_[0MO\ GXB_[^#_ !J2*>.?/ER*^.NU@:+,=TR2BBBD,QO$VA/K
MT%E&DRP^1=Q7!+#.0ISBM@<"L7Q5HD^N06*0.B&"\BN&WD\JIR0,=ZVAP*?0
M!:***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*C+EL7**0$, 0<@]Z*YSB%HHHH **** "BBB@ HHI,T +1110 4444 %%%%
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MI]IJ<?BW5;B=W.F20PK;H9<J& ._"]NW/>MZFP"BBBD 4444 %%%% !1110
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M"BBBL#C"BBB@ HHHH **** &2Q+,A5NE>9_$[P=836-QJ;2&RO;6)G6ZBZD
M?=8?Q ^_X5Z?7!?$O1+_ ,2Z;_9EDZPB>11+,_1$!R<#N>G%?#<6X6E6P$I2
MI\TMD>GE]25.O%J5D>)P7RL($FEC2ZE0,(]W)^E=[\)_"UGK$$>LW;F[OA(R
M+'(/DMB#@A5]?]H\_2NET_X2Z1!H4EE+:"Z\WYI;B;F9V[-NZJ1VQTJ#X?\
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M#R/]1ZO_ #_7_@/_  3\8]I]OSHVGV_.OV<_X5WX6_Z%O2/_   B_P#B:/\
MA7?A;_H6](_\ (O_ (FC_72G_P ^'_X%_P  /]1ZO_/]?^ _\$_&/:?;\Z-I
M]OSK]G/^%=^%O^A;TC_P B_^)H_X5WX6_P"A;TC_ , (O_B:/]=*?_/A_P#@
M7_ #_4>K_P _U_X#_P $_&/:?;\Z-I]OSK]G/^%=^%O^A;TC_P  (O\ XFC_
M (5WX6_Z%O2/_ "+_P")H_UTI_\ /A_^!?\  #_4>K_S_7_@/_!/QCVGV_.C
M:?;\Z_9S_A7?A;_H6](_\ (O_B:/^%=^%O\ H6](_P# "+_XFC_72G_SX?\
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MM/M^=?LY_P *[\+?]"WI'_@!%_\ $T?\*[\+?]"WI'_@!%_\31_KI3_Y\/\
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M^?#_ / O^ '^H]7_ )_K_P !_P""?C'M/M^=&T^WYU^SG_"N_"W_ $+>D?\
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M_K_P'_@GXQ[3[?G7<?"'X0:]\9?%L&AZ)!GH]S=N/W5M'GEW/\AU)XK]9/\
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M7_G?WL/;5/YG]YO_ /"Q/&7_ $.WB?\ \',__P 51_PL3QE_T.WB?_P<S_\
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M:*/5;G10UH5*G*I%Y)*9]=@Z<UYS)\0=9N$N4N6M+V.YF6>1+NRBE4R!0H8
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M;D!R8(R?NIV)ZGVK[GA>6)CB.:$K4UOV/L^&JU>EB5*,K4UN?!OPJBUKQ/\
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M_NG\J-C?W3^5?='_  RK\+?^A5C_ / RY_\ CE'_  RK\+?^A5C_ / RY_\
MCE'^KU?^=?C_ )!_953^9'POL;^Z?RHV-_=/Y5]T?\,J_"W_ *%6/_P,N?\
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M&_NG\J^Z/^&5?A;_ -"K'_X&7/\ \<H_X95^%O\ T*L?_@9<_P#QRC_5ZO\
MSK\?\@_LJI_,CX7V-_=/Y4;&_NG\J^Z/^&5?A;_T*L?_ (&7/_QRC_AE7X6_
M]"K'_P"!ES_\<H_U>K_SK\?\@_LJI_,CX7V-_=/Y4;&_NG\J^Z/^&5?A;_T*
ML?\ X&7/_P <H_X95^%O_0JQ_P#@9<__ !RC_5ZO_.OQ_P @_LJI_,CX7V-_
M=/Y4;&_NG\J^Z/\ AE7X6_\ 0JQ_^!ES_P#'*/\ AE7X6_\ 0JQ_^!ES_P#'
M*/\ 5ZO_ #K\?\@_LJI_,CX7V-_=/Y4;&_NG\J^Z/^&5?A;_ -"K'_X&7/\
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M_P#@9<__ !RC_5ZO_.OQ_P @_LJI_,CX7V-_=/Y4;&_NG\J^Z/\ AE7X6_\
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M117WIX84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8WB:#3IX+(:E,T*+=Q-"5)&Z4'Y1
MT-; Z5C^)K&QOH+);ZZ^RI'=Q21G<!OD!^5>?6M@=*?0!:***0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX?KW-M!_U]P?^C!7N"?='TKZ;A#XL1_V[_[<<>;;4_G^@ZBBBOT<^>"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#'\2Z5;ZK#9)<70M1%=1S*20-[*>%Y]:UQTK(\2Z(
M-<@LT,XM_(NH[C)7.[:<[>O>M<<"GT 6BBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8EAH]M;>*=4U!+L27-S%"DEMD?NPH.#Z\Y[UMUAV'A
M\6GBG4]5^T*YO(88S"%P4V \YSSG-;E-@%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *0]#2TAY% 'B=C_Q_P"N?]A6Y_\ 0A5VMJZ^%5\;Z^GM/$+6T=S<27/E
M-91OM9CDC).:K67PNU]K93=^)HTN,G<(;"-DQDXP3@],?C7XO4R',^>35!M7
M?VH=_P#$?7QQN&LO?_!_Y&=16Q_PJW5_^AI/_@NB_P :/^%6ZO\ ]#2?_!=%
M_C4?V%FG_/A_^!0_^2*^NX;_ )^?@_\ (QZ*V/\ A5NK_P#0TG_P71?XT?\
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M)4:UNH88XXPQ+*4!W$C&!G/:MZFP"BBBD 4444 %%%% !1110 4444 %%%%
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M[?\ ^.U^>-%'^JF6?RO[V'^MV:?S+[D?H=_P\:\!_P#0O>(_^_=O_P#':/\
MAXUX#_Z%[Q'_ -^[?_X[7YXT4?ZJ99_*_O8?ZW9I_,ON1^AW_#QKP'_T+WB/
M_OW;_P#QVC_AXUX#_P"A>\1_]^[?_P".U^>-%'^JF6?RO[V'^MV:?S+[D?H=
M_P /&O ?_0O>(_\ OW;_ /QVC_AXUX#_ .A>\1_]^[?_ ..U^>-%'^JF6?RO
M[V'^MV:?S+[D?H=_P\:\!_\ 0O>(_P#OW;__ !VC_AXUX#_Z%[Q'_P!^[?\
M^.U^>-%'^JF6?RO[V'^MV:?S+[D?H=_P\:\!_P#0O>(_^_=O_P#':/\ AXUX
M#_Z%[Q'_ -^[?_X[7YXT4?ZJ99_*_O8?ZW9I_,ON1^AW_#QKP'_T+WB/_OW;
M_P#QVC_AXUX#_P"A>\1_]^[?_P".U^>-%'^JF6?RO[V'^MV:?S+[D?>_B/\
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M6"XD_P"65RO6.;^,8%:4;-<X)-S=M))YV;1?(DEECZ/&/X+R(?ZR+_EJN37
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M+J,>F+&[XB09*O*ORHY )VD?4@US7A_PO/KUCJUZLJV]EIEN)YYG!(RQVH@
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M;F1HEN3V\LRHT?J#CU&='_A0/C._N(H]#TF?Q"C6EK=/+8J $,\0D6,AB"6
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MK_4KJQ>&-%;$B1^:7R1P,%E.#U_"NVI4K6;@OY4KKN]7\D^_0X*=.A>*J/\
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M7W'S/3HY'B;<CLC8(RI(.#UZ5]+?\._/B?\ \]M!_P# U_\ XW1_P[\^)_\
MSVT'_P #7_\ C=+^V\M_Y_Q^\/[#S/\ Y\2^X^9Z*^F/^'?GQ/\ ^>V@_P#@
M:_\ \;H_X=^?$_\ Y[:#_P"!K_\ QNG_ &WEO_/^/WA_869_\^)?<?-<$\EM
M,DL,CQ2H<J\;%64^H(Y%,)+$DDDGDDU]+_\ #OSXG_\ /;0?_ U__C='_#OS
MXG_\]M!_\#7_ /C=+^VLM_Y_Q^\/[#S.UO82^X^9Z*^F/^'?GQ/_ .>V@_\
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M_P#SVT'_ ,#7_P#C='_#OSXG_P#/;0?_  -?_P"-T?VWEO\ S_C]X?V%F?\
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M?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\
M@:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z
M/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_
M /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$
MON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+
M?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V
M@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_
M /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AW
MY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_
M .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H
M_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_
M .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\
MX&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOI
MC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^
MPLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__
M ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?
MGQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GM
MH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\?O#^PLS_ .?$ON/F
M>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\ @:__ ,;H_MO+?^?\
M?O#^PLS_ .?$ON/F>BOIC_AWY\3_ /GMH/\ X&O_ /&Z/^'?GQ/_ .>V@_\
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M.*68*H83"&V"0);M]N8S)!9DY2WD(_UM@Y_U-R/FC8@'&*ZP? SXL967^SM
MCO0#*+R'5&1XKOI]KB7R=J/(.)4^Y)UP*='^S]\4+N5+>.U\/Z%$^ MW;W[S
M-8AO]>D*-%@V\@R3;ME0QR"*?UG#[^UC]Z_K\/E>ZDOJV(V]E+_P%_U^/SM;
MEY;2O#NN>/?$I\-Z%%-#J4NQM3N;_P#>26,2?<%T1C=/'P89XR2ZD9XKZ_\
MA[\/=+^'&@+INFJ\CNQENKR<[I[N8_>ED;^)B:A^&7PRT7X4^%X-%T:':BX:
M:X?F2X?'+N?Y#H!P*ZVOD,QS%XI^SIZ07X^;_1=#[#+<N6%7M:NLW^'DOU?5
MA1117AGNA1110 4444 %%%% !1110 4444 %%%% !1110 V1MB,>N!FL?P=K
MDGB/P];:A+$D+RM("D9)4;9&7_V6MB1MJ,<9P.E9'A'6(]>T"WOHK9;-)&D
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M4.[^]?Y':?\ "UO"/_0?LO\ OO\ ^M1_PM;PC_T'[+_OO_ZU<7FC-'^M6/\
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M "P^Z7_R0?V90[O[U_D=I_PM;PC_ -!^R_[[_P#K4?\ "UO"/_0?LO\ OO\
M^M7%YHS1_K5C_P"6'W2_^2#^S*'=_>O\CM/^%K>$?^@_9?\ ??\ ]:C_ (6M
MX1_Z#]E_WW_]:N+S1FC_ %JQ_P#+#[I?_)!_9E#N_O7^1VG_  M;PC_T'[+_
M +[_ /K4?\+6\(_]!^R_[[_^M7%YHS1_K5C_ .6'W2_^2#^S*'=_>O\ ([3_
M (6MX1_Z#]E_WW_]:C_A:WA'_H/V7_??_P!:N+S1FC_6K'_RP^Z7_P D']F4
M.[^]?Y':?\+6\(_]!^R_[[_^M1_PM;PC_P!!^R_[[_\ K5Q>:,T?ZU8_^6'W
M2_\ D@_LRAW?WK_([3_A:WA'_H/V7_??_P!:C_A:WA'_ *#]E_WW_P#6KB\T
M9H_UJQ_\L/NE_P#)!_9E#N_O7^1VG_"UO"/_ $'[+_OO_P"M1_PM;PC_ -!^
MR_[[_P#K5Q>:,T?ZU8_^6'W2_P#D@_LRAW?WK_([3_A:WA'_ *#]E_WW_P#6
MH_X6MX1_Z#]E_P!]_P#UJXO-&:/]:L?_ "P^Z7_R0?V90[O[U_D=I_PM;PC_
M -!^R_[[_P#K4?\ "UO"/_0?LO\ OO\ ^M7%YHS1_K5C_P"6'W2_^2#^S*'=
M_>O\CM/^%K>$?^@_9?\ ??\ ]:C_ (6MX1_Z#]E_WW_]:N+S1FC_ %JQ_P#+
M#[I?_)!_9E#N_O7^1VG_  M;PC_T'[+_ +[_ /K4?\+6\(_]!^R_[[_^M7%Y
MHS1_K5C_ .6'W2_^2#^S*'=_>O\ ([3_ (6MX1_Z#]E_WW_]:C_A:WA'_H/V
M7_??_P!:N+S1FC_6K'_RP^Z7_P D']F4.[^]?Y'06GQC\/RZ_?VTNIV,5A%'
M$T-UO/[UCG<.G; _.M3_ (6MX1_Z#]E_WW_]:N+HS3_UJQ_\L/NE_P#)!_9E
M#N_O7^1VG_"U?"/_ $'[+_OO_P"M2_\ "U?"7_0?L_\ OL_X5Q0/-:%ICV'X
M=/\ ZU;4>)<?5E:T%\G_ /)$3RZA%7N_O7^1TO\ PM3PE_T'K/\ [[/^%'_"
MU/"?_0>L_P#OL_X5G0@8P0H&,$-T'L?4>AJTJYZKNR<8;C)[*?1AV/>O<IYG
MCYK>'_@,O_D_Z]=#BEAZ$>C^]?Y$_P#PM3PE_P!!ZS_[[/\ A1_PM3PE_P!!
MZS_[[/\ A563G!&6).0P&"Q[E1V8=QWJ$$ @@A>K!D7/'=P/3U6J>98Y?:A_
MX"__ )/^M.C3(]A0[/[U_P#(FA_PM3PE_P!!ZS_[[/\ A1_PM3PE_P!!ZS_[
M[/\ A6?@#/RJ@ P1U"J?4]T/;TH(!R"N?X2K'IZ(3_)JG^T\?WA_X#+_ .3_
M *[:-)^PH=G]Z_R-#_A:GA+_ *#UG_WV?\*/^%J>$O\ H/6?_?9_PK/Z_P"V
M2>.,;F'\G'ZT<#!!YY8.J\GU=1V]UH_M/'_S0_\  7_\G_7S39["AV?WK_Y'
M^OO-#_A:GA+_ *#UG_WV?\*/^%J>$O\ H/6?_?9_PK/X7^ZF!UQN 4]_=#^E
M!4#*E0H'RLC'(4=D8]P>S=J/[3Q_\T/_  &7_P G_7R=CV%#L_O7^7]?=?0_
MX6IX2_Z#UG_WV?\ "C_A:GA+_H/6?_?9_P *S]NXXVF0DX*D[2S#^$GLX['N
M*/O8(.\D[E95P78=64=G'<=Z?]IX_P#FA_X#+_Y/^GIUCS'L*'9_>O\ +^OO
MMH?\+4\)?]!ZS_[[/^%'_"U/"7_0>L_^^S_A6?D !@54 %A(JY 4]74=U/1E
M[48"D@A8\#!!^;:I]?6,]CU%+^T\?_-#_P !?_R?]+7^;E/84.S^]?\ R/\
M7W7T/^%J>$O^@]9_]]G_  I\'Q.\*W,T<4>NV322,%4&3&3Z<UF8Y*E>>%,;
M'GV1F]?[K5%=V<&HVTMO<0K<P3 J\;# <]P?1Q^M#S/,%LX/_MV2_P#;G^5_
M*]DQ4*'9_>O\OZ_+OP<TM>;^&?$DW@^Z@TC5KAKC2)CLL-2D_@](I#^@8_0U
MZ17T>!QU/'4^:.DEHUU3_5/=-:-:HX:U&5&5GJGL^_\ 75= HHHKTCG"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!LA"HQ(R .E9/A'4K;5] M[JSM19
M6[M(%@  VXD93TXY()_&M:0@(Q(R,<BLGPE>6%_H-O/IEN;2R9I D14*5(D8
M-P">K G\:?0#8HHHI %%%% "'I7@>DZC::1X7:]O[J&RLK<2237-S((XXU#'
M+,S$  >IKWP]*^2/B^D<G[.OC!)5#1-I\ZNK="IE (_*OSOBN'M*^%@^O,OQ
M@>_EDN6G5EZ?J>B7GBG1=.TZTU"[UBPM;"\DCBMKJ:Z1(IWD_P!6J.3ABW8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 #K6C:=!^?%9PZUH6G;_/^37?A/C,:OPFK#P >  .O4#_%?Y59
M P.0/[N'/Z'V]#5: XVD'IR"H_4#^8JPORC@JN!]0 >_NI_2OM:'P_U_7]=M
MO%GO_7]?U][9!N)'S$L=N&X9B.Q_NN.Q[U$#N/5CD[OW8P3CN/1O4=ZED'#
MC QM(<\ =@Y]#V:HCER00S9.""<'(Z*3V<=CWK66_P#7]?UM>_-FOZ_K^O\
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M?:5W%03@]1GT]JKR:/I\TD<DEA:/)&NQ'>W0LB^@)' ]A4/]KW'_ $ ->_\
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M[SN^T+;1B3/KOQG/XU;**S*Q525^Z2,D?3TK/_M>X_Z &O?^"Y_\:/[7N/\
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M $ ->_\ !<_^-3?R?W,=C2HK-_M>X_Z &O?^"Y_\:/[7N/\ H :]_P""Y_\
M&B_D_N86-*BLW^U[C_H :]_X+G_QH_M>X_Z &O?^"Y_\:+^3^YA8TJ*R9M>D
MMPIET36XPS!07T]ADGH!SUJ3^U[C_H :]_X+G_QHOY/[F%C2HK-_M>X_Z &O
M?^"Y_P#&C^U[C_H :]_X+G_QHOY/[F%C2HK-_M>X_P"@!KW_ (+G_P :/[7N
M/^@!KW_@N?\ QHOY/[F%C2HK-_M>X_Z &O?^"Y_\:/[7N/\ H :]_P""Y_\
M&B_D_N86-*BLW^U[C_H :]_X+G_QH_M>X_Z &O?^"Y_\:+^3^YA8TJ*S?[7N
M/^@!KW_@N?\ QH_M>X_Z &O?^"Y_\:+^3^YA8TJ*S?[7N/\ H :]_P""Y_\
M&C^U[C_H :]_X+G_ ,:+^3^YA8TJ*S?[7N/^@!KW_@N?_&C^U[C_ * &O?\
M@N?_ !HOY/[F%C2HK-_M>X_Z &O?^"Y_\:/[7N/^@!KW_@N?_&B_D_N86-*B
MLW^U[C_H :]_X+G_ ,:/[7N/^@!KW_@N?_&B_D_N86-*BLW^U[C_ * &O?\
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M?$4O./#_ (@8% /GTYB2/[AY[=FZTO;T_/[G_E_7;641^RE_7]?U]S-@')#
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MPW_X++C_ .2J.1ARL^I,48KY;_X:&^('][PW_P""RX_^2J/^&AOB!_>\-_\
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MRX_^2J/^&AOB!_>\-_\ @LN/_DJCD8<K/J3%&*^6_P#AH;X@?WO#?_@LN/\
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M>3P\H@G2X79IEQRRG(!_TKI5_P#X:&^('][PW_X++C_Y*HY&%CZDQ1BOEO\
MX:&^('][PW_X++C_ .2J/^&AOB!_>\-_^"RX_P#DJCD8<K/J3%&*^6_^&AOB
M!_>\-_\ @LN/_DJC_AH;X@?WO#?_ (++C_Y*HY&'*SZDQ1BOEO\ X:&^('][
MPW_X++C_ .2J/^&AOB!_>\-_^"RX_P#DJCD8<K/J3%&*^6_^&AOB!_>\-_\
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cgtx-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO8GHJF^L6$<'G-?6RP[_ "_,,RA=W]W.>O'2I[>YAO(5E@E2>)NCQL&4_B*
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M1=,UVXOKF:"5<K801,BJW5P_F!MX!8Y4<$#%?;7@P:;_ ,(U8-I(46+Q*\>
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MI:>//#-GJMJR?O5(=$<-M8'!Y'^>:_)[QW=W^H^([NSU"66"WMDG,=TI9TN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYGR(^?\ Q?\ "S7M6U'6]*U66_\ $<6IOI'DZR=BM';PWH:6-D5%1'CWM(K
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M%+FG3<8M];[K3J:<C2YFC4HHHK@$%%%% !1110 4444 %%%% !1110 4444
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MDO;%,I!>E+8M!@J" ^>0C-$W&>/FXK[SV%+&.+JP6D8WT:<M?^'M9.]VCO\
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M<HN$G&6Z/)V"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK&C2FWAN!L)/S#9.G/KGTK9M]2M+N>2""ZAFFC +QQR!F4'H2!TS0!9HHHH
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M_'Z5\KA\15NZ:?Q'T5:A3LIM;'SW\6OASKESK][J-IIHNY=S1M]FC+_+T
MSD;CQQQBN1^#_@C4/#WBI-1U!Y[.RLANG\TE6C)R-I'7+<\>@-?:_P 6_#.C
MZ-&)M2NVTV$QRR"^A.TJJ#+;_;&,U7U3PYX8\': ^MZE:1VMBL7GFX?YO/*(
M3NQC).T$_K6\LKQ,:DH6VZ]#*.8T)04K[FS\+]#N]1B']I%I%8&:'> 6@5D
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ML^(!;G^UVT2RLC<&1S^Y\^Y?9MSM W#/3/7U-=C0,**YOQ=XRM/#=O(KR@7
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M#82C1IJ,4?IWX1^(UM=Z5%=W;-;VCQ[P9<DH.W/7\#7GOQ8^.T'AR&9VRKH
ML=O))Y9,C#*J?3"\GJ?I7/> KW55TJ")9UNK>U@Q=-)\_P"\"@X&.A&W\S7F
MO[0O@G4?$>M">UM%O5C'F18;EB<9)'K\O4^@KIJYEB*F'5-R_P""84\!0A7<
MTCG/%WBZP^+,=I%K\5K-)@@K'/YI"G."-P."02,<CGKFO/\ XG?!BXUG7+7[
M.(4T6WTRV2V:$10RRD)&0'&_[RL@7&3N*@94Y88FB>!=>NO%$3>7<VQEF#O
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M,GN%'2O2Q=>E0KM59632_KY:?>SAPU&I6I)TXW:?]??^AS_[(/CRU\.>,Y]
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MP:;N[OK\[_F?3?Q<OAH&A/9V5PZ6.F10VT<;/D>6%5CD]V8%1D_W<U\+:_\
M$+5K:[N-1NK>WFO99"A"@L\?J02>.."1Z5]RZGIB^-;"[57AOK"ZA*2.>1'*
MGRG>.OW64?A[UX;XG_9_M-8\0&"#3[Z+4"&=2FW[/+@DY+E?PZ@]*Y,=*IB*
MSK-:2V_0Z<'&%&DJ2>VX[]F_X@+/HU_?7,=TB*WS.6W*J]?E[]<9'T/>O:]9
M\%#Q#HTID,<]LKLUM)(GRLCH'56[C <#(]*Y'X9_!F^\/M:VTD$<.GI\]S&@
MRTTQZD'T'0#_ /77TOHNCII^D"VF1'W<NN,C'0#\  /PKT,MRZ6,4HU%9=&<
M6/QT<,XN&K['R+%^SW;ZMJ,UT^E0:1)'.&E628N+E3RVT$X ./;J:]L^&GPK
MGT9Y9KJ8SF8@JV!MA4<!4]L9_.O3X]!T^1MQM5P!M"[CM'X9Q6FB*BA5  '&
M!7O87(J="HJE25['C8C-YU8.$%:YFZIH=EJ"1B6'#QXV.A*L,=!D=1['BJT'
MA&R699Y 9) VX9 &/;@<]>];F,TM?0RP]&<N:4$WZ'B1KU8QY5)V$50@ 48'
MI1M!.<<TM%=!B%%%% !1110 4444 %%%>?\ Q?\ %.J^$K30KS2V8JM^)+R%
M(][S6L<;R3(@[N41MO3YMO(J)R4(\S+C%S?*CT"BO'D^*FJ1^,=<2RCBUFSN
MTL%TBU:;RH1O>\21_-1')#?9MP^4]A[U=G^,6L&9XK7PO;RRV\UM;72S:H8]
MLLTK0J(\0MN4.C$EMA"X.W<2HR5>#5S1T)GJE<MXAT_6;7Q'9ZUI%M;:@%M7
MM)[2XF,+$%E971\$<$$$$=#P>,'CH?BGK[W-S?G1[+[%96T_]H6O]HMF%H+V
M>W=X6\C][N\DD!O+[<U>O?BGK<<$DUKX>T^=7O+ZVMDDU259)5M97C=BJVS[
M22F0HR,'E@>"G6IR6_X#5*<7L4=;^&OB+Q'KMKJ6I7-LUPUM:Q&2S=56RDCN
M)9':/?&6.4=!E2I8QC=P>.E\"^#;WPWKFIWER\317-I# @0Y.Y;J]E.?^ W*
M?B#7.-\<YK6UO-5O-!2/0;0[)9X+TR7._P"P)>D"$Q!2NU]N?,R2.@S77>"?
M%FI>(GNH-6TB'2;N&&&Y5;>\-S&\<N\+\S1QD,#&V?E*X(PQY"Q3]DYWB]?F
M7/VJA:2T.I/(KP+QM;Z+\:-7N+/PSX@:V\1V" RV4BO;R.J-E)HF(R&5OXOF
M4@D$<YKWZOG;Q7X9M/AU\9?"E]IS74YN]6:XF5\R&%+A9DE /4)DJV.@*]J>
M)=HIRVNK]+:JS)H*\FEO9VZ]#G?A5K$\/Q2U'PSXMO9)/^$DT/\ L\^<V$DO
M8'E2XCP#@.5;=@=1TZ52T[P=?>#O'-]X1UW1YM9\*>([R.8&'Y+G3;S"QFZA
M;O&P52V.5(Y'7-OQ]\'FU?7/$&J_VD]T;_5/M<=K;Q,)8-VT1SQO_"\9 .!U
M /->M?"_QMK6M?!ZPU'Q1836NO@R6,BE,-+(KF-90.P8 -[9-<%*K2=U*5^3
MK>]UYG94IU%9QC;FZ;6?D>"Z'X9\2>.='OK#PW%"UE'>R2SW<CB./SGLHD5L
M=@1*[G'<5:M?#I\#?$1-&UZ9K[0O$MVMC-J$4?RI?^7^YNAU'[Q=T3KT)JGX
MR^+>G?#6S;1=!6V@F<A!YSE=PC C,C[<%F.T#.> .]1^"OCFVK:U:6$EI:W\
MTCKO9"3&''.[:^>GKP>^/3YMYM14HKDVLF^ZV>A[JRVJXR?-O=I=GN?4O@/X
M::7X#\$KX7A+7NE@R_N;GYD578DQJISA!G 7G KQ;X8^%-&LOBA>>)=0C>WL
M='L1;Z9-,0L3;IKD9Y^\5B*KGL&KUZ7QU(-&"I&!>.=H9S\H7^)OJ!V]2*^0
MOBS\;;Z#63IEM+=6,@'F2M:1@&-02%4$\*< GC/7FO3Q^:TZ"IRHZNWX'!@\
MNG5<XU=$=O\ $/P;IEIX]MO%%CI@U[0X[N&&]MHAYC-9RM^\1U!R1$^)%/8$
MCM7TO\1?!=MX]\,OIEU=3VUL)$G?[/@F0)R%(/49P<>PKXK^%GQZO/$'BJRM
M(]6S&WRLUQCS&4<G!'4_7%?5%QXWO4T1HX&BD1D>02H<G"CE /4EDQ[;O:N3
M YM3E&HJZWUT_+^NYTXO+9J4'1>W]7/,O@7H$/@Z]UG4];CG:&]LU2W2[8&:
M7SV,LNX<<X\I.@^Y6#XG\)W/ACQ3H_BWPXL^I+9:S9SLD*?O%1F,-QN /.82
MN2.I7.*\J^)GQKU276Y+8O?6T-J!+</:W!B5V(W-R 2P!('H>U;OP0^-EUXJ
M\4I%-JLHA5-WERDN[ =!NZ],<<]_2O+_ +7J<T=%:+T_JYZ']F0Y9:N[6I].
M_'/X<3^.+--2?Q(-%TK3K.9Y"(/-V[E.^4<@%O+R!GIDGFO-_A)X'TS6?"'B
MJ4D6\"R0:9:+<$NS1VZL"),<D$RR1DX_A->C:OXGM;_P;>V%^HO=-FA:1GA;
M "(29$)SQRJ_]]'TKY[\7?'Q=+U)=)T@V%I%'(9;C?O 4N=Q 1<?7GJ>I%>Q
MB\UHQ<9PC=M._P SS,-EU62<).R3T.Z^!277PU^-<V@W8+6FOZ:+:.=LC?-8
MC$9&0/O0R<^\=+^U;XELK[68]*M86?5K"!3"Z#YI+IW0QQ ?Q 1B4MZ*]97P
MM^*X\:Z[;1_8T<6C&XCF#[@C%2,KGYE)]C7M7C3_ (J3P=>-96=LNKM)##-<
M.BK((2R^8P;&?N!AP>@/TK7!8^.+H2H/2WY;V_1&>*P<L-659:W_ #[_ *GS
M%XQT35=2^#_B"UMI)KS3;:Z>&PA9RY1%%O/<6ZL>PQ* /]DCM7K_ .R)?64N
MJ?$B(%3?S:I#>QOGF2R>WC%N1[ K(/K5_P )ZWI/@;P%HWA34!87MZ-US<^<
M5Q/,\C2-(H9E/+,<&F_"_P *C0?BI!K6FSVT6BSZ5+97%N,+(CB<R1# X*J&
M90<]*Z,/C:#K0C&=V[+\%U]4OQ,:^%K>RDY0LO\ @_Y-G-?$>XO?@-\3;CQ!
MIJ07%IJ%L;66.Y4ND<4DV]'*@@X24R \_=D'I7&_&WXD7?C[PW;+/ID6EZC;
MO%HMQ:HV^(W$US&V5/="D&X?[U=_\<?AGK^JZ[?:WJFI6XTJYN8((88RS2>4
MAS'&JXP/F+.QSSMQBN6U_P"%]QXP^$]C,LPT_7=5E-^;>9MCVK*Y>U+9Z%4^
M1AU^<_W:VK5'1<E)VC>]GZK;YW^1C2A[5)Q5Y;77I_E;YGK?[-_B75?%T'C*
MYO[Z2[LK+5VTJUBE()3R$59&/^\Q)Q7@WQ&6XT#XDA-9++-9"X\Z786!CVEE
M=0.H*$' ^G:O5?V;'U#PYXY\2Z#J,1A?4K2'62H4A#.#Y,[*>^XK&W_ JX[X
MZZG!K_Q0OWBCDB%E97UMYDJX#M':EMPSV#$C/^S7VW#$X3E*I>_[JI_Z3J9)
M2I8B4+67]6-/XZ>,SI_@C38_"6J_:9M9LHFMKN [FWR3Q1Q;,G R3)[C;7KO
M@SQ7;?&7PK?7QL&MO[,OYK6)DDW"5XAM9E.!P267\*^9_%^B7OAOX<^#_%-I
M9-+:0RP:O'!U_=1W4\K(!VPDZN!_LGTKW']DG4X5\$ZQX?5BTNDZG,ZL>KP7
M!,\3_B'(^JFOC,-"#DZ;BE&5]/DO^'+Q$I)*HI-N/7YO_ACE])T[3O'UV\NE
MWTUDMO'#/>V(0K\L@R P/"G(8?4,.U2:SHGACX>R6+20I:,+NW2&"<;WW32
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MTQ2(4.22=S')YJX1D8-+179&$8+EBK(YI2<W>3NQ  !Q2T451(4444 %%%%
M!1110 4444 %%%% !4%Q96]W)"\]O%,\#;XFD0,8VP1E2>AP2,CL34]% &,_
M@W0'MEMSHFGB!$BC2-;5 $6)F:(+@<;&=BN/NEB1C-/L?".A:7;K;V>BZ?:0
M*4*Q06L:*"C%DP ,?*22/0DD5K45/+'L5S/N8EUX)\/7LR37&AZ=-*A9@[VJ
M$Y:3S6[<YD_>'U<!NHS4M]X2T34[<6]WI%C<P!I6\J2W5E)E),N1C!WEB6S]
MXDYS6M11RQ[!S2[F?;^']+M0H@TVTA"R"8>7 JXD"",.,#[P10@/7: .@I-&
M\.:5X=B>+2M.M=.C?&Y;6%8P<#"]!T X [#@57M9Y6\8ZG"9',*6%HZQECM5
MC)<@D#L2%7)]AZ5LT<J["N^XR:58(7D?[J*6./05\Q?&SXQQ^&D>\NEBCN'C
M C8@GJS;%XYP-I8@>^:^E-72632[M( #,T3*N[IDC%?(?QI\%S>,K6TEMIDB
MC\K 5^ DF0&^8],9;C([BODN(:E2,(1B_==_T/I<EA"4I2>Z/.M)_:$NK*<%
M[NTN+QG\P9M! R9]&'/U)(R.Q[_3.E>([C7O#]E<73!6D*M<>2X_B&WMP3R.
M?I7P[<_!#7'\20B^AC@N)9 (Y/,5E8+Z[2<# SSZU];?"?PS_;%K;K")DL+>
M-K/8VY/.+)M+$>G3![5\AAG4G45*'VM#Z;$*G"#J2Z'B/QA^&^M:EXDO=1L[
M**ZG5F/[E,G9P0 .H/SDX[_A7GWPM^'6H:%XNAOK[S;.VLF\RY,A(,9]AUR>
M>/K7WMXR^%QU58XI8I)8QG;>6N!(AXZCKS[9_"HM ^%=@7@ TH*JJH>XF1E:
M0J, L&4$FNIY7B?:<G+K_7]7V.=9A0Y.?FT.;\-V6H#1/MT[23699)DA/(BB
M*;#[X!*D_0GM7A'Q4^#EUJ&HW4\6HK;W#.QC-XVP,IQD!L'C&>G.2>*^Z=+T
M6WTNU,*(K*1@@@8QZ?2N:\0?#:SULE)(X9[4Y)AG7.#U&#VYQ7M8C(ZOLH>S
M=Y):GE4<WI^TESZ)['PA\-/A+<^$M?DU1[1[R>TPJP0*2LSG)7:2.@ SG'<5
M]4:3X/FTW1_/,;R>?D73+G"&10HP/7*CZ<5Z9I?@F2&2)K@6ZI&N%2- 2N.@
M!P.P':NHM[&"V@,*1@1GJ,=:>#R*3O*L[!B<XBK*DKGP-\1_@@EQ>2[M3&FW
M$CG NE8K*I8\!E')Z8Y[<TSX6?"6_P#"&HRW=OI\T]](_D!678J@$;I>?Q ^
MGO7VMJOP]M-0F+XCD0?,D<RYVMG((;K5O3/"7V:7S+F83G'0*!S]<9-<JR"O
MS\KV[F_]LT>2ZW['E5SX5DT;P^;&%1Y-S%*%:0?*\S 9R/3!_G7QY\0/A1KT
MT][/;:?]IBN7*S-;J2V3R6.!TX_/-?I;J&BVFI6BV\L2[$8.F!C:?4?F1^->
M7>)?A!%J&IK=R12CRB&,EJ>)0/X6 YK3'Y+5@TZ"YD1@\UIRNJVC/CCX!^$+
MGPGJ,M]=R,BS@6]NFX[I')4X('88ZGO7TIXAN-2T#P/=+<7[R7D"*C-*V/E\
MP-CW)!XSV%>D^'OA=86]QYK:7!9!22JH.F3DXX_SBH?B+X(-ZDB+$LMA<P>7
M*7&0LBYVDCW!Z^V.I&>-95B:5"55KY>1U?VC0J5HTT_F?GCXE^(>KQ:A=:E=
MP07%\\K* !O>,$8)!/0@<9%>V?LV_$$7.FZE>W<=TJQ$,7WY"KC)VCL>.G?@
MU8\2_ &SU?71:1:;=Q:@V\QS1$&"3J068KQZ?EUKN?AG\&+WPY);6YMX[>P4
M^9=HHW/-(<YP?09X ]:\:G3J2DN1:GJ3J047S,] \<?$>33?"2SR!7M$96CN
M7'S@%2V_!'R[1QGUS7RQ>_M%RRZK)?+>>19$F."VDLTV$9XRS98__7[5])?%
M+PA/-HUYI.YXG 652BEOW1&,8[X(;W^6OD/QC\#]5WM*9;:XL(R6/ES*S(<X
M("C+<=,XKMS"==UN6L]4DCEP4**I<U+9ZGT_\#OB+<>*[#[=));-+&WE0LC_
M #+@\_3KTST/I6)\?-4_MGQA;S.IC,NDW%O.F<%24DC?'IT./PKFO@K\/YM+
MTZ/0 KK),GVB:Y52%1<#8F[^]R"?QI_QO(FUN]\H/%+]AE!9LY+?O%#?4@+7
MZ#P#6G]=J4G\+IS_ ".',:4+JIU1VB?&G18HK'0OM$[6FFP1Q)(;=GMU**%'
M.\ D>NWZ9KLO@B?#>G^(M8US1[M_+U.VM;6>WS^YC,.\(5[@X<@@^@K\^-0N
M-6L/(M[.:Y:X4@R>:S9?'W1G(/\ C7U#^S]XAU;3_!=K)+;132O-A80FTN,\
MDG';GGOFO@*&85J5956[G;7P5*I2=-*QZ7\</A;I_AQ+?4_#NG7-YKE])=SK
M.\AD"N8VD(7T=V*\]=JL,X-:?BSP)X-U_P $Z-X=N?/233K*"&*6)XP?,C :
M-B2V0V\$YQ_$WK5?XL_$6Y\'Z A*[[.W\Q55?F943[JY]2<+CT')X-?*[_M!
MZI;:BU[<:IJ$4UV?D@EE A5>XV= !R,>W0]:]?%YMR5)0HQ5M/PU_/4\O#9;
MSP4JKUU_K[CZ(^'EAJ>@Z'\5- O+"X@LTFL]8M6?(21V5&G\L]" \6XX[MVS
M7A=M>PP3:/)=VAFL[33;C[6Y3*&V_?EHSZEG*X'7*U[?X#\>S>*/AG=W%QJ,
M5Q)/!)M"Y&T $8 ['MCO]#7"_#S0K'5K6)]3O1;VEFD<YB) !*3K+EB?X?W6
M#[$BON\%C88GA7$2J:<DX??9I&$L+*CB'&&O-K_F7_BGX&U+0;?P?;WY?<EA
M]CGE?EA]HLUMQ)GUCD7:?0./6OH?]G#Q#%J'P+\,&=5M9M(LETR]0C:(YK8>
M5)]!E,_0UPMW\:-$\=6]W97&K6MQ9OF%E:/8R>I1FC7G.._IBNU^!WANV\/V
M/B6#^TTU:UUC5)]1C1H]H19  T9'?D'ZYKP,#CJ%:O)4W\7?_A_-G!B\)6I4
M8N:V['S-XBNM&\1>-M2N-)A:U6_G$ME&@VM'-]JCCM)E'\+,2^/]D =JM?M%
M:;=G6/$-@L1DNKBWN7PP_P!;-'<I<&,^SP*F/88[5[3XR\$:'HGQ*LO$K2V%
MA8Z9*EXEI!$L:N8X9$S*>  K2;@?50.U8=_\0/!GQ,UJ'4;B^LII(951)()6
M5HRNX#Y61=WWFSDDX/I7%B,11P\G3E+7FO;IMK^9UT:-6LE-1TY;7Z_UH>]:
M=XLL;SP-;^([-'N-/>P%[%' F79-FX*JCOVQ7RK\-HWUSXN:;]IL7L-7N];.
MJF +C[-B*5[A5_V</ K'H6:OH;X16MGX'^'FGZ,VJ+?V>GQ.([Y_E#1;BP##
ML0#CT./PKR;Q/XJT3X=^)]3\3QO-=:U(DT"R=9 LLBR>6J]  $C!8\_*,9KT
M<;C:$(4ZSEI?9?)_\#YG#A,+6E*=-1UMO_7]:'*?$VUG\&?%/2=4NH<)H?B%
M=8DVC(GMI9)(W?W*BX4_4&OJ;QVYN/!>JPV]U':W%W:R0V\TAP [(0#Q^?X5
M\N7/Q@TGQC9O9:]9R?Z=$\#P7"(2 Y'\4>"IR!Q^>*]F\0:VFI>'[2UB1BT%
MDX#$Y8#8 <'^]MZ>]>;1S6A&C5C3O?=)^?H=U7+JSJTW/T;7D>2P:WX.^$-T
MTEG ]SJMU>37"W:V_G3CS#AF&"-@P-H_BVCZUN^&?$/A;Q3X[T75_M4@UK3;
MB6XB,2F,R&5 DBR*2<]!D@]:^1?B0^HV>N7UT9KK<Z[8%;.R/:-H&/P)]\@U
MTG[.&K:W;^*9WNBK1Q0%VDE0MQZY.>O(Q_A7RT,PQ$)J2EM]Q]#/!49Q:<=S
MZL^-^JF^T;5+NW#@J\85X_F)PN5R/[O+?C7P?X@U'7--D:"*^NY+OS6WM([8
M(YZ<\9YQ[&OT$T32+KQ;IDT\\!M\QLDT,9^;Y7PKCZC.0?[H]ZX/5O@S'KNH
M.EQ:::MD5<+J(MP9HCG(&,8'/<8SS3Q4*U::KM?'J+#SI4H^R3^'0\W_ &<O
M$>JVGA:\N9K6*:4RD*A3#R,!DJ6QSC!Y]R.U?31\"1ZSX;\R.V9T9V;8A_>0
MEL$[".>,D<<\5@> _@W%IM_:W<,OVA;:,0QQK@1X_B8CID]2>O)KV^QLUTVQ
MC@0E@@Y)ZDU[F598ZT9.NO=:T/)S''JE**HO5;GAUI\)(#*IU!;S5KR-]\<\
MI^>)2,;2#_GBO3?"'P^L?#,$:00)#&,-Y0 Y8="3ZUU<.2"3W]JDKZ+#93A\
M-/G6KZ'AU\RK5X\CT1'*I? '2GJ-J@>E+17M'E!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_1JU]JU^Y^'G^ZXC_$OR/R?C/\ WBCZ/\PHHHK]:/SH**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9?W<CJQ568'[H.S\;_V+K;XKW\B:5K.B^&=%?PZOAR.P/A6TN9;&$2%B]K<
MI)&=IVA&+H,LP7<01ZW<? ?X>W?BJS\2S^$=,FURS\LPWLD.YU:,!8W.>&=0
MH"N06 X!H ^>/!O[;'BO6=1\"76J>%=)@T+Q/?\ B2Q46ES*]S'_ &5#<2[^
M1M_>>2%VXXY.3D 8.I_M_>+M)^#^K^,W\"QS2)H6F:S9)+9:A9VZO=7L-NUO
M)+-$JR868,LL)97*MT Y^M;+X2>"=-_LK[+X4T>W_LF:ZN+#R[*-?LLER&%P
M\?'RF0.X<C[VXYZU@Z=^S1\*M*LM6L[;P!H*VFJK$EY ]FLD<J1R+)%'M;("
M(ZJZH,*K#( - '@WQX_;+\8? &RO7U?1_#>JZGHVDV^JZOI&D+J5S+")KQHD
M5IE@\BW4Q $/*X+." F"I.7/\8_'-QKWCB'7]7EGT_3/B[IWA[3$TFY>RDAM
MFBMW,3L@_>18D!*MDL2^3C&/IKQM\ _AS\2=:;5_%/@S1]?U![<6DDU_:K+Y
ML2L65'!X<*22NX';DXQDU97X*^!%U[5-:_X133&U34[R#4;RX> ,9KJ'_53D
M'@2+V<#/ YX% 'SIJ'[;/B+3M$T/QB_AK2G\%^(=<U+0--M1=2#5XI;>.<Q2
MSQ$;55FMG\Q0=T89/O9X[#X&_M*>+/B/XU\!:3XA\/:3I-KXO\#?\)E;?8+F
M2:2W >V01N6 !WBXW\ %>%.X@L?3D_9[^&L?BR[\3#P1HIUZZ:=YKUK12[-,
MK+.V#P&D#L'8 %@?F)XKHM*^'WAG0KW2KS3M!TZQNM)TT:/836]LB/:V64/V
M>,@?+'^[C^0<?(OI0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cgtx-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &K SH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H[@E8)"#@A3@CZ5)45S_Q[2_[A_E0
M!YO_ &Q?_P#/[<?]_6_QH_MB_P#^?VX_[^M_C52BM2RW_;%__P _MQ_W];_&
MC^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52
MB@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&
MC^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52
MB@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&
MC^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52
MB@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&
MC^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52
MB@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&
MC^V+_P#Y_;C_ +^M_C52B@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52
MB@"W_;%__P _MQ_W];_&C^V+_P#Y_;C_ +^M_C52B@#U#3W9["V9B68QJ23U
M)P*P_%FKW>F2VPMI?+#JQ;Y0<]/45MZ;_P @ZU_ZY)_(5S'CK_7VG^ZW\Q6:
MW)1F_P#"5:I_S]?^0T_PH_X2K5/^?K_R&G^%9-%:60S6_P"$JU3_ )^O_(:?
MX4?\)5JG_/U_Y#3_  K)HHL@-;_A*M4_Y^O_ "&G^%'_  E6J?\ /U_Y#3_"
MLFBBR UO^$JU3_GZ_P#(:?X4?\)5JG_/U_Y#3_"LFBBR UO^$JU3_GZ_\AI_
MA1_PE6J?\_7_ )#3_"LFBBR UO\ A*M4_P"?K_R&G^%'_"5:I_S]?^0T_P *
MR:*+(#6_X2K5/^?K_P AI_A1_P )5JG_ #]?^0T_PK)HHL@-;_A*M4_Y^O\
MR&G^%'_"5:I_S]?^0T_PK)HHL@-;_A*M4_Y^O_(:?X4?\)5JG_/U_P"0T_PK
M)HHL@-;_ (2K5/\ GZ_\AI_A1_PE6J?\_7_D-/\ "LFBBR UO^$JU3_GZ_\
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MAI_A1_PE6J?\_7_D-/\ "O//"'Q.T7QS;^'[G1Q?7-GKFE_VQ9W9LI5@,&4
M#R%=J.?,4A&(8@,0,*:ZVBR UO\ A*M4_P"?K_R&G^%'_"5:I_S]?^0T_P *
MR:*+(#6_X2K5/^?K_P AI_A1_P )5JG_ #]?^0T_PK)HHL@-;_A*M4_Y^O\
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M[0GB9_&_BG1_"7AG1-4L_#,T=K>OK.OII]Q=7!B29H[9"C*V$D4!I'0;\@D
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MYXEN=:^#'BKX2:EHWB?Q!J=YXHT/6Y=6_MK4I;R*YEBTMKR.00N?+C83(/\
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M4RF'.WS F<[<\;L8S0!>HJA<Z]IEGJMKIEQJ-I!J5TK-;V<DZK-,%^\40G+
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M =1110!Z?IO_ "#K7_KDG\A7,>.O]?:?[K?S%=/IO_(.M?\ KDG\A7,>.O\
M7VG^ZW\Q41W)1R]>6^%_A;JNB?M#>.?'D]Q9OI&NZ3I]A;01NYG1X#)O+@J%
M"G>,88GKD"O4J*LH^9O$?[)E_JDWQ-\*6&IV>G_##QI%#JD=BA(N-+UE)ED+
MQ1"/8UO(8H6==X).X #.X]1\//AO\1[?QWI6K>)%\#>'](TM)E:T\*6)EFU1
MW0HK2RS0JUN%R6VQ$DG@L5R#[C10(^9OA/\ LZ>-O!/ACX=^'=5O= GL?!?B
MF[U2WNK.:?S;NSE2\P71HP$EWW0^0,5"J?G)Z]#KWP&U_5/V<+SX?Q7FFKK$
MVHF[6=Y)!;A#J7VK!;9NSLX^[][VYKWBBBP'RWK7[-/C63QOX\O;%/!-_%XH
MN;FXA\4ZS;23ZSI$<L*QK:P(T;(T:%-RDR  R,=AQANT^!?P2\1?#;Q+:ZIK
M=]I]WL\%Z-X=D^R2R.S75HTYE?YD7,9\Y=IZG!RH[^X44 >-_$/X;>.;/XJ0
M?$'X=7VAMJ$^E?V1J>B^(6FBM;M%E\R&82PJ[+)'N=0"A!#D<=:X2+]F#Q?!
MX3T&\DU7P[JGCO1/$.JZTC7]M*VFW\-[([2VTBG+Q*V8R"!(4,:XW@<_3]%
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MI+X8?%_2?BC#>10:?JWA[6[#8;[0-?M/LM]:!\F-G3+*5<#(9&8=B0P(&?\
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M3BYT^WDNYI;>P+*RN;>%W*1$JS E ."1WKT.B@ HHHH **** "BBB@ HHHH
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MG ]A2>'/%%KKNDZ;<O+!;W5Y;I/]E\T%EW ''J>H[5MU<8T,0XUTDWT=M?\
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MI84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_*I:CN?^/>7_ '3_ "H \KHKM(O!-D\:,9KC) /#+_\ $T[_ (0>Q_Y[7/\
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M>C_A!%_Y_3_W[_\ KT707.2HKK?^$$7_ )_3_P!^_P#Z]'_""+_S^G_OW_\
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MI_[]_P#UZ/\ A!%_Y_3_ -^__KT707.2HKK?^$$7_G]/_?O_ .O1_P ((O\
MS^G_ +]__7HN@N<E176_\((O_/Z?^_?_ ->C_A!%_P"?T_\ ?O\ ^O1=!<Y*
MBNM_X01?^?T_]^__ *]'_""+_P _I_[]_P#UZ+H+G)45UO\ P@B_\_I_[]__
M %Z/^$$7_G]/_?O_ .O1=!<Y*BNM_P"$$7_G]/\ W[_^O1_P@B_\_I_[]_\
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M_$C3]7\0W.BSE++4!,8[6%I-S7*K;P32,.!C:)U!'X]\"CIOQBT34=7U"%)
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MSG_A!/%]E(VEZ7XILK#PV]T;DM_9[OJ,2M-YCPI*9MF#EE#&/*@]">:P-)^
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MHHH *0D*"2< =2:6J&O:+:^)-#U'2;Z/SK&_MY+6>/<5W1NI5AD$$9!/((-
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MZR;,UB/K$JZDT[K67K:UK)-[J^RZE7X:_M;^&_BEXFATK2M%UJ.WD9XSJ5Q
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MV$>6;NW'=[ZMWE=+M:+ZW:V/:****] ^/"BBB@ HHHH **** "BBB@ HHHH
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M;=0C6_S?NB,8*?,WR]/F/K3[_P +:-JBW2WFEV=TMTZR3B6%6\UU4*K-D<D
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MZYK_ "I__+Z/^N?]:9I?_(.MO^N:_P J?_R^C_KG_6@">BBB@!.M"J$4!0%
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M=];WW_K?8WITX4TJ5KKJ?7'P^_:L\-^,]:L='OK.YT+4M06W>RCG_>+-YJ9
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M77<%7'S!OXN,\<<]!BO::_ ,7AJF#KSP]7XHNS/G)P<).,MPHHHKD("BBB@
MHHHH *JR?\A2W_ZXR?\ H25:JK)_R%+?_KC)_P"A)0 FI_\ 'LG_ %VA_P#1
MBU;JIJ?_ ![)_P!=H?\ T8M6Z "BBB@ HHHH **** "BBB@ HHHH YCXF>*+
M7P9X"US6;U9WM;6U=G%L@:3&,< \=^_%?E[;:E);3G5]+@,=S-?0W42:I;&<
M3I*7S(KN ,DJ1A>/W;D9VC;]X_MGZ@^F?!>]ERT]N[^3+8H_EFX!!(PW4$$<
M##9)'!.*^$G^Q:-/9:3X?:!KE8//BNS?L7)5,RQLH"*Y5OD4!EP.N2=P_>.
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MQQPA1110 4444 %%%% %?4/^/&?_ '#5BJ^H?\>,_P#N&K% !1110 5'<?\
M'O+_ +I_E4E1W'_'O+_NG^5 !;_ZB/\ W1_*I*CM_P#41_[H_E4E !1110 4
M444 ?./[:?B&^TKP99V\-E'-92"22>Z:-6:#[L8P6/R[A(RY )R1TZU\NR:1
M?S:AH\T5T)VU%8IH\PK%%@HT<:DE3D($3+ G<4)R&&ZOJ#]KC6-%6/1HGN[5
MM5LC)(\#LV];=E'F]" IV D$\Y"X/.#XWI/BC1XSIU]':/>V!WV+PJ[%) LC
M!6,3(H+KN0*FP;@Y)?*9;]KX>G+#Y33E"EJ^;IO?;?TTM^ES\XS9*ICIISTT
M^7]?UV/3OA-\!KB1K.\:^FF2"5";H3.H0ISM7DY&_<Y7D;B,L<$'ZE4;5 ZX
MKP_]G/XBWVHZ8OAW6([N6ZMHTDAO);98DV.#MC8AB&?*2$;=PVJ"6)//L.N>
M(--\,Z=)?ZM?V^FV4?WI[F0(@X)QD]^#Q7YIG,\96QLJ>)?-);6VL]K>OWGV
M>7QP]/#*5!676_ZFA17*:1\4?#.OZ]!I&FZK!?W4T#7"-;L&0J&VD;@>N<\>
MQ]*T=&\8Z/K^J:CIMC>QSWVGOY=S ,AD.<?B..HKQYX>M3OSP:LK[=-OS.Z-
M:G/X9)]-SP3]JOPA<6SGQ&=8N8M/U$6VF7-E%#Y@1%,C"0;?GSE@,ID_-R",
MX^<]"^-;^'=6GOO#@O(M2AM4ADO-1D0VK,X895&#,A)4C[Q&U.W%?=?QA\(:
M?XS\ ZM:7[&(16[S1W$:@R0LJY#)Z-QQ7Q=:^![J76HI=)CDTFUU.TQ#<75O
M)'++,K@2RS1\CA 6VX*CY<%22:_5>&\9AJ^7RI8I7Y--=%;SMOHGWT6Q\!G6
M&JTL9&I0T<MK;W_34^Z? NKWFN>#M(U#4$$5[/;(\RC& V.>A(_*OSX_:0\4
M6?COXLZTOA^.31Y(&>"XDN$ %TOEESY88E=Q:,M_ QW'DYS7Z%^%K4:=X;LT
MG(5C&&D);Y<GT[ >W;I7YV_M$V]AX+\6ZQ;RK;ZA<+"Z22K)M69)"3"N-G7>
M$8DD?<8%F&W/)P)*A/-:MOC<7RI;6OJ[=4M%KU:/U#!Q<?BZ(\U\0ZWH^G^)
M=7U/0YY9;2#4FA2YN,RS>2Q<PED?"DQA6X<=AU&:T-+THMXIU35(P^GWEM#+
MJ8AU L09HI&58RP)5F+YY.5!8<@9:L72]%$^K:=J%S)%.D;0&\MQ;/.L\;,S
M1*8V!QN5&+JI^7D?,3QI^(%M]/NYM.MK:/2M:2U4/9B3?8^6VP[P!D*&VKE@
M!PNXAL$5^Y8F4/9^QIW;<;7?;3?;3K>UE=;'K1BTSZQ^&L%]^T3\*K71KB\C
MM]3T[,B3D,!-$Q9&1V Y^8/]W(Y'7@GYSOO#<'_"0S>'5A\JP(#7-S#+O#L@
MR,!L*I7D=CUKZ\_8MT6]M?!-]JM]:Q0OJ;I=*T4GF*-ZAV56VCJS,V,?+OVY
MXP/1?%_P#\)>*K&:*/3XM,NG;>+FVC7/T*G@KP./88Z5^*PXBI9-F>(PR7[G
MFTM;W7U?G9]-M-#B6(5*4H]&?GVGAJPDGTY5UB2>2RMY9FEEG(2X0[@OW02S
MY#')& % R=P![[PWX6\16-VNG026VI6EUN_L^.XML. RF,/YAZXRQ"G)'!'-
M>OZC\&4\#?%CPI9C;%I^H%[..YLW,4LD> S[@.A!V8]!G'4U]*:+X+T/P\D(
MT_2[6W>(8658QO\ ^^NIKHS7BQ4H1^KQYU43=W;35K:VZ:=_N.BMBXJ*Y5<^
M _$/PXU>TU&ZT*ZN/,U(WBW-P\N$"[4*995&TJ-@ !.,,N3P=N+96FD>%[R'
M4KC3Y+299&A=[4NRQR,W#9&YL ;<@G^+C/S8_1_4_#VEZRDBWVGVUV)%VMYT
M2L2/3)%?./A7X,:5XB^+'CVR#"SMM/O;61$2%&W(48E,L"1UZ@@]ZC <6JM1
MJ?6864(INSWU4>VF_G8F&-4D^==#S?P-X<A^(>MZ'''*UUIUE>6\DP\G:D[!
MRI"X )"AF(. <Y)SP:^V])TBRT+3X;'3[:.TM(1MCAB&%454\,^$])\'Z<+'
M2+..SM@<[5Y).,<D\G@ ?A6O7Y[F^:2S2MS\O+%;+_/S^1YU>M[:5^@4445X
M1S!1137=8D9W8*BC)9C@ 4 .HJMIVHV^JVBW5K()8&+*KCH=K%3^H-6:F,E)
M*47=,;3BVGN5=+_Y!UM_US7^5/\ ^7T?]<_ZTS2_^0=;?]<U_E3_ /E]'_7/
M^M4(GHHHH **** "BBB@ HHHH **** "O/?CUXTTOP+\+]8O]6@:[MY(S EL
MBY,KD$[>JXX4GJ.F!R0#Z"&#$@$$C@@'I7E_[1N@QZ_\-YQ-+"(+.9;V:";;
MB>) =R#<0,\@C/=1T."/2RU4GC:*KNT>97Z=2X*\DC\[[C4;*/0&G@,L6E/;
M2#3@I1I&//WV;]YM7#*I(*CYLMN-8,>M6<$FHVGV<F"_MF,8@;]VN]<KND!R
M%$LH/ *Y5>Q:K'B?Q%ICRZ/I&DZ)N669Y[6]N6552V9-\B_(6(VERP4$ [P"
M.@$OA#PWIUK9W\J%-8MGB^U:?;21O!.EN<!IPP1N%8J.,@X<\8)']<0=.E1Y
MY)Z[=]]'?9/2^MNI[FLBYX.^V>&],35-)U,^4VKF'?(B1E@%4_+(YQAC&@P2
M,C/'WJ^M_&O@L?'3P5'XR-TD+V$#6]_;2*4!>(@,ZJX&#P?O8R I!P17QEIL
MMH\AL?#MPUYIBS_9OLE^$CN'1Y=I()=L%?.V*Q3((Z],_IK\%_#,-O\ ";3M
M,OM.$:2QL)X9T \TD\L1SP>WMBORWB_&?4*E+&TM*G.[/1-QLKIJWH8UY>R4
M9+='YZ6_AZWUJ/4+=T&BZ98$-#- RDF1LC>K,<@?>;(Z?+QSS<A\*0:CX@$G
MVTI);645JY>8@S,^T*%C7VV'=@9)/]RONKQI^S9X9\36\8LXET^X0Y,DB>>&
M^H8\FO&/#WPMGT7X[1>%KY)-+L=0M'>86$VU;J)-PC;CE0V'!''ISC-3A^+<
M/BZ4IPO&4$Y<NG3>SZWW_JYO3Q<&V_P/./"_@KQ/%=FR2[M;YKHLE@)H<80L
M45@Y&&. 3]0>^,T=?^'5T6NO#FHW)DG2_3SGO&(8.$"-D+E2 J# 8E<%<G-?
M?>C>!M \//$^GZ3:VTL2[%E6,;\?[W6I]6\)Z-KPE&H:7:7AE7:[2PJ6([<X
MS7R*XTK^V=1TE;\;WWO;\#E6.M+1:?B?G$J:#X?E76K[1&MTM2SN=-4KDDY7
M:N25)7! W;>.#DUW&AZ3!\2#:6-OJKBVMKD2W%T8]JMM .R(;5D(V@+@C[Q)
M /WJ](T_X,V7BGXP^--&TVX.CVVG&V9%">:CJ5((96R"1DX/49/K7T;X*^'.
M@^ +26#1[(0&9MTLCL7=S[D\UZV;\3TJ=-0I1;JM)ZO2*E%2Z[O7T[[(VJXN
M,4G'=V+WA7PUIOA;1X;33+**RAVAF6)-NYL#D^];%%%?D3;;NSQ&[N["BBBD
M(***Q_$'BS2_#$0?4+I(,] Q )]N>*SJ5(4H\\W9%PA*I+E@KLV**Y:7Q8E]
MK&A0Z=,)(+F23SAMYVA"1S]<?I74U%*M"M?D=TO\D_U*J4ITK<ZM?_.WZ!56
M3_D*6_\ UQD_]"2K559/^0I;_P#7&3_T)*W,A-3_ ./9/^NT/_HQ:MU4U/\
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MJNC2?:/#MS+HUM97L,K:-:I(!+"W[MEE((#'?Y2[A\Q# ;3@*F9<0WUI9QW
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MR;?+;31QY=.Y]SC\T^O4,$XJTHS5W\35FK-W];GJFN^*O%VI?!R&6PEEBO\
MRP?,+AE8[<,W.,$,3UXXSR,UX/I/@GQ5\1M)UZVU[3H]1OHE6:W%P"S2% =A
MD<'<RJ"IVDG(^[C (^G?AGXC?Q#HOQ4TR_=-.O+6_N)H'"[HK> 1+''W^\!$
M'*]UD0]&K"TWXBW%ZW@V:SMX=)C@U1;6X8MOM[K<GEE. O 2?S<=/W>>>#7X
MSE4L;D^.HX["U[2C;OJDTFO1Z=O+4_5ZF,IU*<X>S_JU[^I\V?V1>^$]7ET^
M]MX;K4-4N86DCBM"C1C#+,0V0Q4@(<DY/H.:]%^(7@[PEX6\%WDNI6SWE_K(
M=+:YD3"QQ[. S)SMR[XY /''6O7O&>N:+X<\8>*=/O+)=1O;*);RU2. ,&B8
M;FB;_: 4@$#/*J2"1NJZ_HFE^-_A;X6U'7K6&R$[K87-PX5X(IES$9",Y57=
M ./N\$G )KZ3%\4\0U\7]<C52<.7W(MI2Y6KW[7MK9K3[Q0JX9J,9)Z]?EH>
M5_L[>,_&MOIN@PQ>*6U/0;.8F;R80JKM<&0LVS+J4(!!Z,Q;=TKZ T']J#0?
M$?BD:39/%-N<JAC)<OC.>1TZ'GV]^.8\!^'_  ?IVHZUX5T>]9I8+ WD<L8W
MQ% S+*%=,#H!]2X(R *X+1?@3X<\/:[9^,DOG@TZYG-E;R/EU+ERC*H !4Y6
M0$<[<$]!7@9QG>;YG6CB)4HP;;NH126_7<N%'+Y.7,_O_3N>P?&3QCI5AXZ^
M'%]-.OE07,S2 N%V;O+4 Y( .01SW%>PZ+KMCX@T]+VQN$GMW&0Z,"*^0/VB
M_ U]>ZG:Z;9W44CZO'BT=''>12)%;=T(. 3Z'-==X?T#Q1X-^$-S;VM\9=0A
MA%NACVD*R_,V]AT)!Y&1QCOS79C<SKT:6$=2GI[.3?DU4J+_ "^\Y/J%&K3]
MR?5)>=TG^I]-QWMO-*8XYXWD SL5P3CZ?B*\I^&B/%\;?B>K A7:RD7W!1A_
M2OG7X#>(?'>F^+;B/5?M'D.C"$NQ^9\[BQZCH&Y/'0=:L^*OVA+_ .'OQ@UV
M[A@ CU*=+:5%4DL8@ #D=!\S=NX'7FKRO/*=7!XR=2-N6">FNGM*:_5$U,IG
M3FH0E?F_X?\ 0^W:*\5\?_M"KX,\"+K*6+7-PY\I HRK2$' QU !')(Q]:H?
M";]IBW^(.C7]TT*>= WEH@<#<_8 8SW_ $/H:YO[8P?.H<VZO>VAQ?V9B>5R
MY=CWFLG6O%&F^']@O;CRV<@!%4LQSTX%?)EE^U]K%W\3XM'EM/)LIKCR58 G
M:!P22"003D@8&.F353]H#P9XI\?:I9ZYH5Q+&L\>^&/8YR3\VY1@C)7'#8],
MY!KS*^?1=-O#QN[]>W<]"EDTE-*O+3R/HSXJ?&*R\ >#CK4"&^0@$>41QD@#
MUZYZX.!DUY1\.?VBC\7--U?3>8I498SYCY).<E4.U<G"\<<_CQH_#[P.VI^
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MP><IDG@D=< _*Q!!R17R/XG\,S^$_%FO75Q?6M@L#F32+A95>7"DDRQA,$$
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M2'&23YZH<M_ 3@\!:P/%_P /-3@D\2V,]]:65R^H07MG:VTYC@)SO<0AE&"
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MG&SMOT.:.*Q-&FG;2+N].O74\Y^&?P6T;X:ZO9WMWK-O';:W,( \C$[SM=P
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MSN3G@<4O$_B#Q%X]OC>Z=87#:K/;-:&/3HF@N+:)XY1)'<+(VT[98U 8':2
MP)&",O4?&_@[6=6TS1)+Z>&^TS$-E?VK$^2YE9H]BGJR,4.3_='/4&3]I+QS
MXET^XBO-!M"RS*4N6CB^<HI/E@D#H3ELXXW>AKG_ +0PN'HM45?79:?.]O\
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M.EZ+9Z-9+:V4"6\*C 6,8%70,  4M%>K&*@E&*LD>?*3D[R>H44451(4444
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M>0_&?_D=O"/_ %Y:C_Z':5Z]7D/QG_Y';PC_ ->6H_\ H=I7IY;_ +U'T?\
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M %%%% %72_\ D'6W_7-?Y4__ )?1_P!<_P"M,TO_ )!UM_US7^5/_P"7T?\
M7/\ K0!/1110 E+110 4444 %%%% !1110 4444 %%%% '!_&O\ Y$=?^PGI
MW_I9#7&UV7QK_P"1'7_L)Z=_Z60UQM?18'_=_F_R1\5FW^^?]NK\Y%/6O^0/
M?_\ 7"3_ -!->K_#?_DG?A;_ +!5K_Z)6O*-:_Y ]_\ ]<)/_037J_PW_P"2
M=^%O^P5:_P#HE:C,/X,?7]#7)_\ >)?X?U.CHHHKP#[ **** "BBB@ HHHH
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MPS7FWCKQMK4WQ)L-3&HRQ3:GX;TZ.2:XMXPEBKWL\4DJQH77&4R&+NN7!+%
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M%=.V6!;<N "'PM\'_$EI\0[?Q+J=S9B)-7;46A^VR74NPZ:UIM+F) 6W;6Z
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MN]&%5J*].I"-6/)-:?Y'@T:M3#U/:4WK9K77>S^_0Z__ (7)IO\ T"-:_P#
M5?\ XJJFI?&&5X2ND>';V>X885[]TMX5/JQ!9L>P7\JYNBN98.@G?E_$[I9E
MBY*W-;T2_P""4[:VNIKZ?4]4NS?ZM<J%EGQM1%&2(XUYVH"3QR222235RBJF
MIZG%I5MYL@>1V8)%!$-TDSGA40=R37;OHCRV[7;8"Q7Q%XFT30@HD$TXO+E,
M9 MX65F)]B_EK[[J]YKBOAIX,G\.6MUJ.J+'_;FHD-.$.X01KG9"K=PN22>[
M,3Z5VM?/8VLJL^6.R_IGV>5X:5"DY35I2U]%T7Z_,****\\]D**** "OE?\
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MT]8^J@97@8KSL7@%5O4HJTNW1^G9GOY9G<L/:ABW>'275>O=>>ZZWW7O])D
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MSGQ'\)6\7>--:O\ 4-5O+;0M1TRTT^?3[&8(+Q$DG:6.?*$A")5 *,K8,@R
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cgtx-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X MT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ )ZFL&3_@G?J]U^Q1)\"9_&-E]KAU8:G::Q'9OY?^LW%'C+9[L,@^E?<-%
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MP@\2_#*WT_4'\'Z_=+?W5G->%V2Y 4":-R,JWR)ZCY1QUR ?#?[27A;6=/\
MAA^Q991^+=0O=2U#4-*FLM1U"WMW;33)%9B..-(XT5XXC@@.&8]&8U]0?\$_
MOC5XX^(7B[XW>#_&?B*?Q6O@[Q$;/3]3O(8H[AH2\R;7$2*I_P!2#TZL>V /
M1+_]AGX;ZIHG@K3+V?Q#=Q>#Y4N-'FGU>1Y8)4V"-]Q!Y411JH^Z @ %=?\
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M=FS ,Y,<+*<D$=>*T3I6G6^BQS"5EOP )8E^0NQ/ 'K]: /MW5/^"Q/CC1C
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MI!>1N@\I#GY=C=^* /T8A_X+3:%<,53X3ZN2 3_R%X?_ (W3F_X+1Z$L8?\
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M@32QJBD7K6%O("P<)O\ *XZ''7TK%O[AO*'D@ -EF(]:D-Q$44>6&^7#-G%
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MM;^T\,Z*=1U1H[B2>UM$,@BB"G#>G7IS7FXUW4='N$$L#F2%PGE7,?)(XP:
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M">Q,KQZ7?,JW050S% >U5+K&K7-[<[4MR6+K"G0 GHOL*FM_^)-;EY0'F)P
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M_P"PK<_S% 'V_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD/DQJN5VGJ#ZGVKX"\5?$+P_)K4+R>!-"L-2LT: 3*&$4IVA59D'\0(W9]:
M/._%NO\ B*>\U&RU74+Z]DNS'<:@\SD[I<81GS_$!BN3@O)[>VFM#=,\#2;W
MC&-K,.AJYXW.H'5LW#S232JDLC,I4R;NA/K[&L%IG2&6)85#"08([#TH LW$
M<5Q<))\J@?+CISZFJ2S.)8(X$>64$LV>5X]/PJ*XMW$=P[2 -@!(C]XU507&
M];78RS@C"CK0![AX/N=8\*>%-69I+74;2^A59+68'S(]W(= >X'>O*=3CO99
MV0&5[8J7B4MM0^ISW-=I\1)]0L=(T2ZFN(5,UFJHMN20!TVN>Q]JP]5CTVVM
MH(EUFWORD2Y1%8(I(R<$]QWH YBU=Q)!*H<3Q## =23P!7MGC>#5]"^$_AS0
MXY@VF/*955@4_?$992>_:N3^&EY'XO\ %>B6^LQ01Z;8NHVK'L$B YRY')^M
M=K^T_J-MXE\=S)X:U+[;X5AFV6+C(17P/,$>>HS0!E62>'O&7PXU!W>W\-:S
MI48C+*26U(]>?0CIQ7EVFZ)>Z?';WDUN_P!DO(]_('SJ&[5VO@?PWI:P17.I
M2W,EZWF+':F,@2X. 4/>M_X[Z6= \1WUM#H=WIVF/##Y?VU 3$VT%@"A*X)/
M0=* /)/$FHVU]J]Q-:Q1:?9MPD"+G8/\:J66MS:+=+>V02VO(<%)!R1[CWJ"
M^E@F+[LH@7$809W-WR?2J-L&CG;]V) RDE6&<"@#Z"_9Z^(<^L>.M&T;4[2V
MOXM4F%K<R7,F-T;YX;/&,G.>U<G\=/A_;_"CXCW>E1W8;=<,X,"_NC$3QY9Z
M$#I7G-K='1]LOD@%E(61<A@3T(KTCP=?CXC>%8_#^M:C"UY!.(M-:8[IV+<[
M">T?]: /-KBP:ZO?(B+R!Y"P9S@Y/K2W1<0);DF':<AEZM[&M3Q1I2Z!J<UC
M]H=M025H9HL<1[3C&>YJ/0+:?5Y#I")"]Q-RDMP=NW';)Z4 4A=R&W5G!582
M"A/4M^-:FIZI'KT,4EU<DW:\2RG 0*1P !5+^Q+^^U9--F\F*Y=Q$K2R!4SG
M&2W3'O5'5-/>PNY;>YDC,EN[0L8"&7(..HZ_6@#>T#4TAAET*.WMVM[E@3+*
M!OW=!ANPYK.\0:&/#VK2Z:\AN)[=MA=""C'U!'45%97\%E;R0W%BMU<DHT<D
MA(* <D8[Y]ZLRZHFI7DLLL<.G2R.'BBACQ$H Q@>E %<7$=WJ$0GG^P0HA5I
M84S@XXX]3ZU2BAN=CW&)2F=OF8XW=N:=<_:FGD9D/[TY#,, CUK6AUSR=)ET
MZV,K6TSJ[12,,>:!C=^IH M>!_ MQXX\2:?I]SJ%MHEM=SK$;^].V-"3R6-1
M>./!]KX,\6ZCI U:#58;2X,(N[0[DF .-R>U07<<MO8QGS6GCZR,#D*WTK%D
MY/F EB>OJ/I0!M^!2!\1_#(A)"#5;8 G@D>:O6OZ1D^XOTK^;GX?0._Q$\,N
MA+@ZI;#H>OFKUK^D9/N+]* '4444 %%%% !7BO[:W_)H_P 7O^Q9OO\ T4U>
MU5XK^VMQ^R1\7O\ L6;[_P!%-0!_/=/$0D?!4^4O#]1Q5.'>FX9.&^\:NW%X
M]Y&@D?+!%YQR>.E1(SBW;8@*YQSVH "D:P@]@>2*<(Q+,0F=N,@DXJ")&</\
MN0/TJPQ,;JI RHQT]: 'QM''''A,D@\D]:MVNFF6 2HAGC7#2HO4<]JL6.B0
MM;W<EW.('C0-&AZL2>@K4T34!HEQ;M;-]HG/RE$_B!ZC% &EIVNZ%#J]S&L=
M_I>EO;DBWMVWLTNW #$]5SDUSVMZ2^A:A"\9=H;A1-%(W *FNCU"SO?$^M-;
MZ3H\D<HRB0JFYV)[&O4$^"?B'Q!\,[&TO%D7Q#;7"1VMD8?^6#9+,7]1Z4 <
M!)X4UWQ%I5C) HNK10!*(&#;?J/I5_Q'X;'P^T*W31=75[F_?-PL<OS!1T4@
M>^:U["\N/#6O+H6AVLMY!8@G4I&.U9<?>'K@5R.L:-;ZWJ=U>:=*+=2^5@=N
M2#V7/I0!8G\&W/\ :5B+E66:YC67>1G<#WSZU]R_LO\ _!/N#XH:='K/BA[[
M3/#VT-;"(A);AO[W3A:^4OA5KNF:9XOME\8W=W)IMO$5_P!'3S9%;'RJ >V:
M_:_X!^/O#?C_ .&>BW7ANYBEM8+9(7@3 :%@,%6'8T ?FI^T[^QCKG[.;:EX
MDT.?^U?"UTK0M-)$&DMPW9N./J*^3+!!H,<SKK$.G2+";B-V&\32#HH'8U^U
M_P"VE<6G_#/WB.TGFMTDN4"1K.V-QSGCWK\2O%4$=I"((6CE5.<;,G/O0!Y]
M?7E[+ RRS32)<R&67<>';U/O56TC+L80&);A0.YK4D(%BC;AYPD(,;>GM4>E
MG=J2(72%7ZLYQ0!%JMNEI,B,8V/E@X4]#Z5E-#)>7 6&,!NI K>UA52:>)$4
MJY'[S'( JIY"+;-,K>6PX;L30!0,-R&6/YMO3@9I6TV6*1XYU:%E&=KK@U>T
MU;M[V$6[H65@57/.<\5T=YJ-QK4UU/J[P[@_[S;@2MVP* .:TUXHI0TD+2VW
M1NWY&EO+:87"B""7RILF&/;]Y?:MDI9VB?8Q-LM91YFYAN.X=!QW-1WGC&Z_
MMNSO+-ECDLXEAAPF!'CVH R;;2'N+?S'D6##[3$_#'W%2SZ-/+N>&"7[.J@N
M[+R*^]/#W_!/B\\??LPVWCZ/5GM?$<]O)J+P%-Z2QC+  #H37PO?ZUJ2(^FS
MN?W+$%.A!!YS0!+:>'+[Q// NEV7G)&@1C&N!N_VCZUE:M$(QY<EOY=PKE'P
M.!C@BM:P\2ZAH]O&L$QACF^<J!C=CIG%00W1U"\WDK--O#!47(SGDD4 1Z!X
M9;6KK9 Q920%1N'=NR@>I-6-*\$ZMJU_>V(L)(9[:7;*LHQY6.H:O1--\,6;
MW<FH:K#+INGV3I-'=RDQ!GZD =23VK<^)WQQTSQ1<@Z?H</A]#$!NB.)9FP
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M\5Z']MOC:>3IUK>6ZMB8@C>0W( R/KFOE[Q%J&M>*]434+AW:2Z8F,KP!D]
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M:K-IPTT%7OKEG98QG.-HXV@CI0!2\00Z+86FJ:-IFG0:_+#<K,NM1S,N4/\
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M+2_#FGV\\C3RSDSI+%]W8WMV(/:@#D[/4(+2^L[6>>:*Q282N\0RP/J!ZU]
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M#P/9Z]\+]7U6YSYT,!9'V\*1T!^M7?"&N:+\19K7PYK%W)<7(ACBANI?E1$
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MCGID]JP/):\,>G65X5MT/RI)P-WK6I;:/XBT[1;R1_.GTH/^]6%_EW@<'\J
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M9([EU/RMD$C@5JW,NDZ9IT,MNTMW.ZXE5U 4-Z#VK"U?6Y]2=$<>0B@(L<?
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MMDM6M[?:6%@23G(.=P^E?J=_P2+_ .35N%V#^U[KY1VY'% 'VW1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^,O_  5+E6W_ &SI
M9#G</"=H%YXYDFK]FJ_([_@H%!X3N/V]POC1KQ=$'A"V9Q8Q[I"P>; ZC H
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MR  ?*:\6\4^%?^$=UZZT3[0U_  ABV X$C*&V#MD9P:J7FDM-)8PZC/]FM$
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M>[FWU_6M?FTW4;&Q>ZLX&3:C,7)P"#R *U;/Q;X9T+5?$&DVT8F\*FU6UO\
M4)QB:2Y'#D1GG((/S4 8?@OX,S>.? 6HW\/A]K"YU#/VB[4[S/DYSSTJ?PK^
MPI8>*]-NK&[CGL-5F=1!?KR(4!^8;?<=Z^M/V6/%_@CQ%\-X-(\.:Y%J4L.[
MSH7^69"3T*GG\:Z>+3-7\.>*%:"-IK-Y/O,,X!ZXH _([]K#X"WOP!\6_P!B
M6MO<S:-G=#=,-IG? R<=QFO$KN/5/&EY;W.K.J/*8[;S6 7"+A0!ZX%?K[^W
MS\*-+^(GA'3+R6[CL=0L7"^=(^TB%B-VT=SQ7P%<?!GP9J/Q"MQJ7B#[%X<C
M3R]/L]/B>ZGGVCDR%>%+')]LT >3^+/@<?#%O_:<\LO]AS3&WM[@R([2.,9P
MJGIUYZ5R-_=VJ_;+'1I'%@DB(-T&'D !P[=QSGBOH/XJ>%KGQ?I<7_"&>$+K
M2+&R!@D"AFW@?\M&)/'J<5YDGPZ\0^'9)M3DOM/MX;=([1KF%U907'.['< _
MK0!Y3)9&(22B+S,G"G9QR>H%:*^';B[O+.RB#SSRIAE"$F/TXKZ+TGX>^!O!
MNBIXH\1Z[;:K:PVC;=,M&+2&3) (/8' (S7%W'Q,ATOP_&=*M+&WO]27>UU&
M2]W%&#PK-T4D>E %GX-:'+\*/$VCZK.]Q+>7]_%8P+;1[E12Z%G8_0_A7[Q+
M]T?2OY_/"7C#7O#GCS2K?3K[S++5=0MD?< Y56E3(!/0\<D5_0$GW%^E #J*
M** "BBB@ KQ3]M;_ )-'^+W_ &+-]_Z*:O:Z\5_;6_Y-'^+W_8LWW_HIJ /Y
M[=/D%NR$,RMM'S'@CBM[Q%IEC#)9?V1<&\+P[Y<(>'[C'M7-1Y,2KN)&T9S]
M*LVMS=V=R)X)#%(H(!0]!C% #8VA19A*CM/UCQT![YIH,DBAD)$B]1CDBM&W
M33S]GN;ARP+D/#&?F/X^]5+V[A2^E>RB>&(\(KODB@"K+)*3L.Y>>A&*D2%Y
MW89 YP><59>_:_95D15DX&[IBG/:6[^6T$SLY_UF\8&?;UH 9+9[54%T*K]X
M Y%6;+56TRZ%PD,4N8R@65<J,]Q0NFS08NPIFM$<!R@R,9Z'TJ]J5C::A?%]
M/BD@M9&(A@N7&5X[GZT 0:=((73[5:O+;.=QC'!.>XK0A\$R6FI6WVQQ;VLI
MWJH/[P ]/EI]O';I8QV[._VW)7=(WR1 >GK4WB*&U@T&&:ZEGN-9F*BWGBE'
MEA >=XZ^F* +&M:3-H=XUH_FM K[XY V4D^G8U-%<"SB9[O2YI51#F-U(V ]
M&Q6/X@U3[/<-9_O)!#"B@22[MA/)*D>]9$^NZG>2ES>7#NR!&9WZJ.@^E '0
MK:WMR(99XC;6C' EF?:'Q6FOCC^R+6:QM DMM(_F2V[(#'G&,J3S7$+>7TMG
MY3S/+&/X&Y J_80PSVIBEA>.X(_UN>,#T% &VGABTUVTBO1&VG6>,;GY3?\
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M3XBL;S[639Q.<[EEQQRO;UKSC0OB=KVKLGA^*ZN-;AU6)T@T^69W>T<] O\
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M5-KH6&"1FI8;=Y%1&4*K'A\\_A0!;T769-'9D+,]O,1YL6>' -=<-!AU6/\
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M>&HY-LTH8LR,^W.4[ =N/6L?5+S49[J;1+(2"!7\Y;"U0N6.WKQU..M6-?\
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MK)RK75LT-L\6'"AN"&)Z@\\U]R:C^S[X8\56,.CF_O=/N87:*U\I\I&"N64
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M'3H0UM)--*("R%8ANY/KG':LZ2Q+RLQ8JBC=D\#\* -FSN(;RRE-Z'DN4'(
M& .V*R9X6:5004B'S-@=J1=0>)O.1UC4D*_=F%=SX:L=#UNZ*ZQJ<T&EK:L_
MG0P[F27^%& Z#/>@#A[JVAC:0PS%D! 5B,9_"H[*^N+"[9B^UL8<]>*ZWQ/H
M6C^'=3']G:DNN:0A %V$V[F*@G"GG@G'X5QM[(AO&$>?++<,>N* -JSO[?5;
M\)J<["'&V.=0-RGMGVIFLZ*UA=I'!<17P+861&X85[[\>O@Y\+_"?P6\&>(?
M FLSZOJUW"KZPLI!$+D#@8Z'.1CZ5XOX;\=0:;X.NO#J^'["YO;F[6Z&LS$_
M:(XU',*]MI[T <]KFH2:C>*&@BM.%4)",* !C-:>BW;Z9#,L+)<._P CD$Y*
MD5F:K>F^F8R0Q0JQ/EJG\ STS6SH41TRUN2DJAMORLZ=CU- '/:B6 =5R5;(
MRW7IS7[-_P#!(/\ Y-/B_P"PK<_S%?C#<)(%=XQ(P!/[PCY<^U?L]_P2$);]
ME",GDG5;D_J* /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K\:?^"G]L+C]N"'/G!5\+V98PDA@/,F[U^RU?D-_P %#A%-^WFE
MO<W?V.R?PE;O,^,[@K3L%_$@"@"3X(6/@"PU7P9-XDUC3M+\,:5<-J=XFHL\
MTT!&-BE@#G>W. .-IS7*?M2?M<R_%/XU:UJ7ANZ":;HJ?9]!GQA9 HQYF,=V
M+$9[$9KPO6?BU=S1W,-SIUEMF5!&UNIC>#'H0>3CKFJ=K,;/1XI8=.%VMP#+
M<R%-P*#./F_A_K0!]-ZA\6?AQ\ -<^%?BSX=^(+OQ1KMS<Q7WC"TNI'D<2"(
M"0 N!M8,\F ">@KVR;XO? [P1\?-6^-/_"R8[Z:YLO,M_"L=K+]I6Y= ""V-
MN,=L]S7YM:Q<V<=I&L4 CNH\']X23(&YW8[8Z46&MQI9W,5W;I.L^%4'_EGS
MU7TH ]G\7?M1:]K_ (IO-2;4I-7MSJ#W5E8Z@@D%N9'+$*Q_@&< >U?I=\8=
M'T;X@:M\'+?5->MK+4;:V35CHD-F6N[]5C1ML,@P$4,!N!(&,5^2=AX+M;G1
MX);*];S9W4I#);MLA8G&#)TY[5[/XF_:7\5MJ.GV'BS7;DZKH=FUE:O#!'$Z
M1,@&U74#C*IG.<XH ^\O'G[4/P>\#_&NSO;WQM%!=7'E6>J6VUC'8^2LC(TA
M"G/S2%?E)YKEO@-\=_AKI?Q(^*$]]KUO-X<\0ZI]OM-0F5O*N H4J N,]LCC
MM7Y3ZQJNH>(KB3[3OOYYY&:)@V2ISSGVKW?X)>-9_AAJO@2[\4Z?;7OAS4;@
M_O<@RHH.UB,>GH>M 'V3\)/VG=)U#XV?%Z;Q1J<&E^%M7L!<:7>7*,0T7,(P
MR@E588.#BOA#QM'H?@;Q"L^H3IXHLK:;R(HK%BL<UMDLJE\#CD]LU[7^VK\'
M]1\-Q6'BSPI-!'X?U=B?(LP0R+G,:R>_).*^6]9UR75HFC$0MYH(AYR@;E,J
M\$J.Q.>: /0KWQ+\%[JQOIK7POK8U>\14M4DNT2*PESR^1RP["N=OO'MF]K=
M65])'=;5%MO<&6?;_P ]%8\ C&!7,2^ -?&MZ5I\NBW*3WWELD.#NE#C*GV!
MJ+QE\.-?\!:J(=:LGM8V.\<;A@'H6% $FC_$_6+7Q3:ZC=W!UJ*T8>7!J/SH
MR*,*&'L.U?:O[,WQ]\*W>I1V/Q#NM/U&:]<PZ4PL<G3R5PS$XX11QCFOAK4-
M#FN8#+90K>6K+YXN(E(V#H5/I@UVG@EO[,TX:K:6]LMQ92X::28GYNH/ICCI
MWH ^W/BY^SMXF\=^$[V6_P!<LKZ1B/[+9+8064,1?Y!'@=6'7BO(?#6C7O[+
M/C6XL/(M_&&F3V!-[#<EO)D8+N>WC]QWR .*W/A-^T*VJ:X-7U6^;0O"\VQ+
MM6E+*N!RL:'LQ';IFO:/B9:V/Q'\"Z-XAT/17T;[4TRV=W%%O=H=ARLASR6(
M^]V!H ^?(O$?@KQS:I_PEMG%X8T^*W:6QOK&V!CRQRUJ2!GC(P_;%>8_%30=
M3\-V=G'H^JRZG9R!)(4L%W,H;/#,./SKGOCY!XDT>XTS2M4MUM+18"T4-M(7
M1R>KYQQGTK;_ &-/&<WA;XOZ"VJW2OX>DNH[>[M[@JR$G[O#=!GO0!]B_L1Z
M+;^&OAKJ.F>*O$MKIEKKCI>:>&#I<H^<8E;' ''&<5YC^UQI$&C?%;1_%5O>
MVLFE#_19/*C,,EP\;8?S"/O%N@;H17U18:)8^,FTW3[?0[3^SY;MENK49*VT
MI8MN5ASAA@XZ 5\W^-O!LGAGXLE?%&IZ?J6GW<TMM#I=QN,D1C?*E,^N0,'K
MB@#N?&GQ@_X1'X%^++3PQ#;"VV12+$T:B2W,FW@$C$@&2,#TKX4OKK37-K?#
M5W2[-RTM[!<P".*+OE2.N?2OT9^,FI:)X>\#GP/X@\*VNIO>VW]K6[6TP@2*
M-1P&(&0>N/6OS8^)M[#XMU^?2],TAM'BBVBVM)G)=<=1D]<]: .OUCQ3X%O-
M<@O+6"X6&5%,[I<9!.,, ".,GFONG]CSX<^ ?#(U1Q>BXFN$241N-^S*Y#*P
MX/6OS/T'0CH\4WVV+SEF_=30 @.0.N,]/K7U_P#!;XDIX4L9/$19;>VAL?L%
MA;Q\!&;Y1N4=R>YH ^BOBO\  K5]'\8:=K&G7[R03W27+M$Q.P9 /'TKE/VG
M_@?\-9;K^T[B^BT?5]2B:.UCU/>0\_\ = &0@).>G>MGPCXPA\1^#-0A\6WM
MX;JYFA^S6Y=HWMBO(+'C )_E7S-^TI'KOQ*U73KN&VO++8V(O.N=QU%PY'G#
M'";<8_"@#P7QAX2N?!NMQV-U=+K=_:S>2]I;LPCC;L,D#/6CXTZ WAMM.L[W
M0H]/NI+))"@FW-O.3O7'52*YW6UNK#Q;/!<W@^TI-Y<I60R ,#@L6[BO:?'F
MAGXS65K<Z/JEOKVMZ;"FC6T5M V^>)$!R.PQN//4T ?+\=W*]BR&/,:.&#?W
M37I_@ZTLXO"FK3+JZ66H7$(9'OHNNWJ$<9.?:F^&_A%8W.K7FEZSX@CT26RM
M9)KM98BQ69./)Q_>X^E8]W\0$TRPMK32])ABBA#1I<3J'9L\%B/>@ \&6%U)
MXQ\.ZE;1--8'5;5))M_!D\U<\5_1*GW%^E?SC^##&WC7POLED\QM7MF90?D(
M,J\@=J_HX3[B_2@!U%%% !1110 5XK^VMS^R1\7O^Q9OO_135[57BG[:_P#R
M:/\ %[_L6;[_ -%-0!_/U8:?'96*7$B1W*3+L7:WS(V!U%=9\&_$?A/PK\6O
M#>M>-;*^U#PWIMVEW<6>G*CS2E/F50&95(+!<@D<9K@+8#$>TLPVCY<]ZD6'
MSG &5;=C+<4 >\?MH?M(1_M0_&"?Q1IL5WI_A^QM8[+2[&[51)&@Y8E59E!+
M$]#T J_XF^.7PK3X*_#G3O!OP_FT/XH>'[R&[OO$4D<>RX>-]W^L#[W!(7AE
M&.E?/DABMF94D+*#CV-1)G*X8,A;G'6@#[_O_P!N;X*>)?BGH/QA\0> _%)^
M)ND6(B^R6C6_]FS7(0JLA8R!R!DX^7C/0XKXO^*'Q$U'XU?%'7/%^K+MU#6+
MLW#QIR$' 51]% 'X50EUDZ9HEUI1L;5A<LK_ &J2/=,G^ZW85GZ3;2K'<WJ9
M582N6'?/I0!^J&H>'?#/B#]@3X+6_BSP7XJ\7Z=96YOVB\+K&YB$1<D3EV&(
MV'!(R:\+^-'[;GPN^,MW\+?$TWA;Q/HOB;P5?0M'96_D/9>0LB%U#%PS-M0!
M<A>>IKYT^&W[4OQ'^&5AJ&EZ%XBN#I-[926)LKN1I888F!SY:$X4\GD>M>;;
MI%LY5GA1)G&5)YSGG(H ^S9/V]M \/\ [;]W\7;#3-;D\(ZA8+8WFFE(OM+K
ML ^[OV'# '&ZM+1_V[]%U7]N-?BS?Z/K7_"*QZ:VE:=IJ+$;F-&4 $J7" EL
MY 8U\'X=XOO$.O52.WK76?"W[!=_$+PQ9ZK<[-.GU*W6Z<?PQF5=W/;B@#UO
M]JSX3^+="\?ZOX_U/PKJFCZ-XBOY[^W>\B!"H[;E#%20&P>F:^=VNGCO6DA(
M@+]53I@U_2;XS\$^'/'/P]N="UVVM[S0I[/RS]I *JFS ;)Z$#G-?SM_%3PK
M9^#_ (C^(]&T^Z34-/L;^6"VN$Y#H&.#GOQ0!R4D[LRJ[&1$Y&*6:42+DD\G
M)7'/US4_D3WX B3=(IV^6BX)%-G0JC1A2LB<LI'*T 2W,,MW96[I))+(@P4(
MX4>WM50*[3%0F9 .B\UN:'X=UC7\QZ9!-=R1QF9TMT+$1CEB0/2J^E/=Z5=M
M>V;A1$&7>RYX/!S0!0@ARW+A?ESM-6H-+>ZL'NB\2Q1L$&YQYF3TXZD>]7M)
MT2^\67UII^BVESJFM7A8-900Y8XR?EQUXY-+?Z:5"R!E1H/W4RE<&-@<%3[]
M: (ETAXHVB,T-Q$1NW(V3GV'6KOA>TN+_4(P'4+;N"!*<*0#WSVKMO"7PBO=
M=\,W7B;3;:[U"PM'$-Y+$F(X PX);MSVK5\,:E8Z+X;UNQN-!CU+597C2VOV
M;:8-IR<+W!XH \\\6^2-?OE81B<MA8X5^12>U5M>LM,N-*TA=+O);G4F1S?6
MWED+$1]W![Y&:V/&>GSZAK:S QB>XD#RF+E58XX%:WCC26\/Z_8'3[.#0TN[
M)8W@C?>^5X=WR,J6SG% '#6'AK4-0T)]3M].+V=LXBEN ORJQZ9-.MK^^T2T
MFAMR]I'=1&&X;&%F7.<9[\@5N>'=172]1T^#4(+V?PO#>*U[!;2;1<*#RN>@
M;%=%^T!XV\'>,?%T][X#\*7.@^&! D-K9SR[C'(!\SGW- 'EEC((KI7XV0MN
M*GH:U=8N;+5+0W=NBB[>0*;>--JJ!T/XUC%"/*&UC(_W@*T_[.;3%:"Z\^QN
M%*G]Y'C:#SD]Z +LL6O^(X[?3$\UK?<3%91@JN>Y"U1CE717N+5[=;BX9#$_
MFK@QG/;T-.37;S2+J*ZMM0=I3DB8-\P/MZ5 ]PFIEY76;^T&/4#.\]R?>@ T
M^3[7-#;067[S/[Q]I8X[GZ5>B:ST^[EBN[J2>R8%/]&ZGTZ]LU1M+R:S=DMY
M'BE8["T?WFR,;?QJ.>SDTZ.07$)CF#[61N63ZCM0 KK<S:>]M'-MME9G$?3G
M'WC7[)?\$@_^33XO^PK<_P Q7XO37*F%X\ON*D*>Q^M?M#_P2#_Y-/B_["MS
M_,4 ?;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7XU?\%/[/[5^VXC')6/PM:-CL?GFX-?LK7XV_P#!4E+^T_;#DNH;"^N;67PM
M:0L]K 7!/F3<9H ^/]3@?3[^6.\AVMN^Z/X<]*T=$\57>EP3VT;LEK<(%D@8
M_(^.F13)[R=KUG;PSJEY&%P#-;,"<"LVZ.H7,JR+X:U*WY'R+;L0!C^= &]=
MV=IJMD':[']JY"&(C"%,<8;UJWH/A/5/%0AM-/TQKN>WD(F5%X13W)/3O6==
M[()M+GLM(UR23RPUTLME@1R>BX^\.G-;'_"?ZI'=V*6OAK6;*TRIOVC1@]TP
M)^8\>AQCVH ]?\*Z]JWA+PGJG@:<'4-&U&+,"/"-J2 _?,F,G:?0XKD;;X.:
M[XAT6[UN?3;BY@AG&GQ%2P>ZDV[C(K'^$*ISVKJ-/_:GU3PGIEW8V/A*^UTM
M:&"SGU#3@!9DG)"KW^IKE=3_ &EO'%_H%A8+I&LPSV8=$E2$B,(_550# QD\
M^] '=Z!^SA]K9OL5U;6&O1*G_$B@O4EN)H"F3+NS@$''R]>:N_"O]DKQ#;?%
MO3+;Q!O71M/(OV)_?0K&OS$,0<)^-?-=AXH\2:1XCAU.UT75R89?,#&)U=AW
M!(]:]6^&W[4GC?X;ZUXCO;30]9GL]7@>W;3)49H@K>Y[B@#["^"_CJW\.>/O
M$>@>)[>UUKP)<W4BVQO("J(S9+. _P V !QC\*\STSX<Z%X8\<ZGK]UX875M
M!MA)K-OI%L/GN83(44,3]Q3UP?:L'P%^WQ=Z#X,^Q^)OA3/XMUE[@I)<W-OL
M)M<?*@<#.0>];/QI_;J@\;:#<Q>%O!>I^'M1-M#]FF33LF-EP?+8_P 2C'4_
ME0!N^$_VUO /@KQ!!=Z9\*HK&XN9%@OI+^9KEHX%) 5-V=I7/7T%6/CE\>?#
M>O:@/AOHOAZST_3-5DAOY7N[<R9:3YBT<AY ( &*^&[WQ-K6LV]W<7VA:HVH
MR$MN2V*K(6.6S@<4^W\=>*K74['4TTC6#J5F$2.=X2WRK]U<$8P.U 'VSKWP
M[^$/B)--T;P'XDATYFNA'J9N"T668 O"K'Y3AAP,5U&G_P#!.R[TO68I[76-
M(O=&DBS=P/,-N>J$KGDGU]Z^//#7Q,T^UEM'U;PQXBGNI+E;JYG@@VI&^[<V
M$_B)X&:Z+Q_^UMXP\6^)=2U"+P_K=O:RE8X;:"-H5,2@ !@!U.!0!9_:=\,/
MX7\0_P!GP(;72M-_=16CP;")L_.HQ]X=\]*]-^"G[;.L6UIHFC^*;6SDT.V:
M+3K6:%A$UD#QNV_Q#GDFG7?[5WP^^(WPTTS3_'W@;Q)<>)X%\R:_M+$$L^<;
M22>1M YKR?6_'OPR_P"$TU%K+P-XFE\)):#^S[1+,1SBX"Y4R,<Y&[KZB@#Z
MF^(EEI'QOO9[O3[U9O#FDV[_ &V6.W3;+*K8B2/ S@]#BOG;Q3\$IOAMHFF?
M%FR&GS64MX5M]-+;O)F0G)8$8(! ^N:ROV>_CK8_#;6;[4M:TGQ2GG[\6UG9
M[D+-P"03C"CVYKVWQY^V#\-/$OP[O?"%OX+\3SP7$XE:[N],&X97#F, _*<Y
M_.@#T+]D[Q1J,6K77C;7KZ.U.LZ:9I[EILQVQW@ D9VKE>@ZUV/QQU?P]=^*
M1IEQX>2_U*8I=6GBTQ,L00_=4?WG]#TKXTTC]I;1O#^DZ[X:T_P'K<?AJ_A6
M%(98&8*4^Z^.N3U/.*[#P;^W&@L;6S\7^#_$&KV%M"+2*Q6V^1$ ^5P>N5]*
M /9?BO>E[#QA>Z7:R>)]0N=+BBNVD<2):A<!=W9<$=C7D7A#X :G=>#=3^*?
MBYO[(O[>Z_T>.YC ,VS&%C0\OD<9I\7[8WA&RTF?1X? 7B/^R]2E:#5=EMLD
MN;9CGKV85@_&[]J;P_\ $GP;::!IWA3Q-:II8)L+B6!VDX.U0W./NT <O\34
M_MGXI2ZQ'HL=TT\</DP6=L55$( #[1P3U!]Z^PM.M_ ?P0T);R7089=9U.SB
MO((BIN!;2(H&74C"[CDX/0U\4_"WXZ:?\-_&VG:U'X7\27=O:VODRP7,'F><
M>I ST7/:K7CC]I&;XC^/[W5]6T3Q3!IE[()6MH(O]41_" ,97@#% 'M'Q4_:
M,TJW\=VE[8V!N7>UEMIK6Z4_O'<#YL]!@FO!=+T'XB2RG6$^UZ[I]M(8Y;:"
M4L( QSY?^SD<UV5W\8_AE\0-,T:'Q;X5\965[IRDI<Z?9J06)Y##@D<#G/%>
MKZ'^VI\+OAGX&GT_PO\ "_Q%?ZGJ$I%\;RW8)(N,;\YY.,<4 ?*T_P /M5\1
MZE?367AN9K)FV*%EVK&3R?F/4#UKUCX.ZO:^#_AEXXAU2Y$$"R6T%FT"A;JU
MF*R$/$PP?X0"?>K-U^TMX&\=VVB6OB/P#XIT2+3K"XBD.C1X6XE))C!7L!QS
M7SM_PE4D3:M!+X8UO5=/N3B!+F-EDBQ]UMP[KS]<T =#XO\ %.AV*7GV/2;^
M'4[VUBS-/<[R689ED;W;K7E9,,2A#(7VD@ ] *%.MB.X3^P-4P_*DPL2/09Q
MTJO;6>K(Q,WA[4Y!V'D-R?RH Z'X>?Z1\0_#(1MFW4K7!/IYJU_2$GW%^E?S
M?_#M-8C\?>&V;P_J"YU.V!<P-@#S5]J_I 3[B_2@!U%%% !1110 5XI^VM_R
M:/\ %[_L6;[_ -%-7M=>-_MDV5QJ7[*7Q8M;2WENKF;PW>I'!"A=W8Q-@*HY
M)]A0!_._&52!#"V6P,YZYQ5M[I[FSQ+\S1C XKJ_^$%UZ:TM[=/"'B&U\J/<
MSG2)SO?'3[M9EIX*\8VLV5\'^("K$AMVES$8_P"^: , 1H(&=\JXZ*1UJ&.-
MC&3T/?\ ^M747/@#Q/\ :"\'A+Q(8QRJR:5-U_[YHN_!GC&[6)#X,UQ @QN7
M2IP3[GY: .?B#6[JXWEL<[QD5?LI6A2--Q0M(&93]TCW%6&\ >,2RY\)^(64
M?]0N?_XFI&\!^+Y)BY\(^(E]-NES_P#Q- %22-;O7'$*Q(LC\"/A%_ ]JT=3
M\,:AI=G!J-R&2RF8K%+GY7(ZXK9N/!6H-X<TO[-X+\5Q:Y&SB]D?3)C'(I/R
M[/EXP.N:J3>$O%DML8V\+^)I8T/[J%],G*I[_=H KW7@^[7P\FLK>VTN]RCQ
M12!I%7'5@.@KF%D6%1,C!2#V/S ^M=5!X9\:06!M8_"&O)EBS2C2I]S#^Z?E
MZ4S3O 6NK%?_ &[P9XF>5H<6QATJ;"R9'WLKTQGI0!W=_P#M"?$_Q1X%6TU'
MXB:C+I-B8[=-*>[99)$(..!RRC'>O++O5I+YF\T;59MQ(')-6E\ >+A,K_\
M"(^(<K_U"Y__ (FKMIX2\60V=U!+X)UV4R_=D.E3[D/J/EH YZWO9;>\$L<A
M0C[I'6K,MU+J7EKY2B9,Y<#YI<G^(UIR^"/%<L*(?!OB ,A^5AI4W(]_EJVW
M@7Q/"EL\/AKQ%YHY8?V1.-O_ ([S0!O?#;XI^)O@S?:E?Z"8K:YU:QDL96FB
M#J8G^5@N>A]ZYV[:<V+QVDF4D8-<11XY:O9O#VN7_@GX+ZUX8D\ 7WB:]\21
M'=/+HEPMQI3*W&URG?KQ7EFC^&_$VFAIU\(>(/M<* Q,^DSD.WH1MH S-&UK
M6_ OBBPUO3I'L;^UE#I+%)M;GJ,CL1P:Z]O"+>*H=3UBZN+?3KV>[WMH<2,9
M&W98NHZ8_P :S,^-G2-9? 6J.5D\TL=&FR6]#\O3VJYIR^-3K<6IW?AWQ$+I
M7W"2/1YLKCH/N],4 =C\*GOM8M9O!VEW]WI2:A,OVB(2%8)-N?F9>A(KU >"
MM)LY_L\KQ1F%=A$8YE(ZL3ZFO-+!;BQ\7Z5J7]@>)9[4S":\5=&N(F..2HPO
M>O4/$'B;1M5C34K+0_$]E+)(?^)?)HMRS1KGNVW% &!X[\':9X:T:UOK.UCP
M]RD\A?'.#P,UP7C6YM-5N;S6M>6XFU&X9A%*^!%)G_# _*NN^(^N#7=!M=+M
M/#_BBX8L9)93HMP%7'\(^6O$KS0/%-\#$_A7Q0+2,_NHFTR=L?\ CM $5[?2
M'0GMK6\WC?YIMU/R _[OK[U4NM/DMIH[:[>)FE02;;=\J"1W]#6A'X9\0VRA
MH/!WB%9#][=I$YS_ ..UI1:3KTFFW$,W@[7_ #I&!$@T:;<,>AV\4 <%>;[B
MZ,RK'9LIX2/CIQT_6I=>O)+^9G-Y-?[P!OG^^2!6C=>!_$\TL[CPEXDW$?*3
MI<W/_CM4W\"^,_-25/"7B ,!T_LJ? _\=H QK*(K/YLL1*CY2I'\JM6=])I4
MSW4,[17,;D1]^#U_&KS^!O&<F&?PEXA+9YQI<^/_ $&IK3P;XRL[L3+X.UV4
M@$ 2:3,1R.XVT 4M'AW7Q^UW M(2IF\TC)R!D8^M:_BKQ-I>M:?IL%C8K8S)
M%B[N6)9KB3/WB>W%26G@/7IH;@77A/Q+%*(\QLFE3%2WH1MXJK;> ?%+S;)/
M"6OQHV 7.E3X _[YH R/["GFD@M8<37,YV+&",L2..>E?LM_P2)A>W_946*0
M;735[E6'H017Y'7OPVUZQND^RZ%XCN!MYD31YQMR/=:_7S_@DWHNHZ#^RVEM
MJ=A=Z=<_VI<-Y-Y"T3X)&#A@#0!]HT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %4[K1["^E\VYL;:XDQC?+"K''IDBKE% &;_P (
MWI'_ $"[+_P'3_"C_A&](_Z!=E_X#I_A6E10!F_\(WI'_0+LO_ =/\*/^$;T
MC_H%V7_@.G^%:5% &;_PC>D?] NR_P# =/\ "C_A&](_Z!=E_P" Z?X5I44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cgtx-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ': Q8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M =_X@^&$:6_C;Q$?$%]%X7\0G2[JSN9A-/:6_P ]C(KQ16SF(KM0(P.Q?F+
M _6NBOQW^+T&D'_@I!^S;J6CZ3'HUOJNF>&+^2$2>;(69V ,LQ :9PBHAD?Y
MF"#-=U^V_P#M/G]I?X*_&C0M(^&]B_A[X>ZS:V4GB;5-47[9'<F<Q%[>U$#
M9*2J6\X'8?\ :V4 ?J=17Y(ZY^T1\1_@5_P3E^ =EX%M!96_B22XL+O7XKM8
M[F!A=S,MO".J-*H?]\/N!3C#,&'T[\5?V\_'GP.\3?#O1O'OP;TOPR_C!_*%
MS/XS\Z'3G$H1A.\5BXX#*_R%L@^H- 'VC17QW\6OVY?&OPH\)_$;Q;-\*M$U
M3PIX-UR/0VO[;QFWF7\CF/F*,6!VE!+'O#L,$D*7VDUD?#__ (*-ZSK_ ,0/
MA5HGBOX/7/A+0_B2"-#UB/Q#%>NS;@GSVXA0JOF%02S [6# -TH ^VZ*^(_B
MQ_P4UTWP%XA\>)H?@ZT\2^&/!5Y:Z=JFK2^(X[2XGN99-CI:VHAD:41\[F+(
M,HP..-WV1X6\16GB_P ,Z1KVGES8:I9PWUN95VOY<B!UR.QPPXH U**_,#_@
MH1^TIXR\!_M$> _%&@?:[?P1X!UJ*QO9O,N((;W4)8C)- 0 OF*EN,,4+#$V
MT]<5[U_P4H^(,LW[!^O>(/#6H2PV>N)IX2=%VM-:7,B94@C(#(V".",T ?8M
M%?D/^R%H4?A']K?X,7T=H/A/I6J>#DBB2^$4:^*9_GWB(Q&2-V8NG^M9).!@
M;MH/WS^W;\;-4^ '[,?B[Q9H>]-9"1V-E<1E0;:69Q&LN&!!VDYQC\J /?Z*
M_/G]C_\ 9,\"?%']C^X\9>/M%L_B!XU\<6EUJ%UX@\01M/?Q,-\<:1W#LTB%
M=F=Z%2<C.=HKP'X*_&O5OBK^PY\?OAC\09(_$VI>!-)DGTB\OK<SO#'&2@_?
M/D;HW"^6<!@,\X P ?L)17Y%>.-2T.R_8<_9-3Q1X>U#6=(?5!]GFTC7DT^>
M&Z\Z7;O22RG62+;N)PR-D =\CZQ^+G_!06?P1\2/B-X4\*?#U/%:?#[26U77
M]0O]<_LU8P I\N%!;3&1CO7!^49/;K0!]B45\23_ /!2M-._9\\'_$74/AXE
MMJ_B[6/[*T?0(O$44R.N0#/-.D):(=?E,1;@<<@UZ/X#_; NO&/B#XL^#+CP
MG8V'Q%^'T#7,^E1ZS+-I][&$#!DO#:*R_> (,.<]B.: /I2BOSFT_P#X*U>(
MIO!WAOQC=_ 2XA\):YJ[:+;:A;>+()I)+E0"R)";=6) (^]L4_WJ]=^"_P#P
M4"'C_P"//BGX6>-?A]<?#C6=%LYKU3/JBZ@\B1+YCAUBB"QD1?,0'?GY1DT
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M=TGXA?"WX8Z-X$TX_$[QKIJZA<V.JZ^!8:*3&T@BEF@AD>1BL;](U&"A&02
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG73Y>H13@$.+=(F>-1C')+9_AQR?H_XQ_LN_%_Q%\:/@/\1O#=GX3EU'P1I
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M+3K'2Q%'I]G9PJS*R1Q0Q*LKO-(&;:25BB&<* /HBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S-_X*1?M;_&CX#_'_
M $70/ OBV7P[X8N]&MIGCBT>SO&>Y::X#%3-$Q)*H@V[@/3')KY:T/\ X*=_
MM&7][%9/X^A2ZV21R/>6&EQ1%^BL#]E4+C!R&8@Y[5VG_!8^69/VH=*5;42[
MO"EJR2[<E-MS<ESQUP,=>!DG&>1\'136]K<IDEF9@9)(V#'&Y2"A/1N#G/K0
M!]N^&/\ @H'^T?K>N6=G??%+^S8+C:QF;0],VI'U+\VW3 /)QSC/I63\0_\
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MS1A45!$ZR(2)&+9!.>.,<?G6IH=];Z'JL=R\,<WDKDPRR,1(?16CP5/OG\:
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M;WY8&0YPK-ECOX'#54\,O?\ A_7+.^L%L92XWQ7%W((UB)..&$@((/(&<^U
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M_P %0?VGXI2LOQ)="#@@^'],!'_DK7S-K7BC4O$>J_VAJEP;VYV+%\P"*$4
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M'=.^22^1C/H0<^AH ^HF_P""GW[3FP;?B=EL9(/A_3!_[;5"O_!43]IXD?\
M%S/_ "@Z7_\ (U?.5Y+HUS;Z6;07%G,(]EV9/G&\?Q)CL?SX-1:A;7=E#+ H
MM[VVW^;]KME#]L?? R!_LG'TH ^I;G_@I=^TW!IQN/\ A:2!P1F,Z%I>[\!]
MFK*_X>C?M._]%,_\H&E__(U?+#S-)C<2?K3=O&??&.] 'U3_ ,/1_P!IW_HI
MO_E TO\ ^1J/^'H_[3O_ $4W_P H&E__ "-7RN4/.01CKQ3>] 'U6W_!4?\
M:=/_ #4O'';0-,_^1J3_ (>C_M._]%,_\H&F?_(U?*V.,^M)F@#ZUE_X*D?M
M*2%V'Q*6/<A9%AT'3B$;=]T[K;H!]>W/6O</V%/V^/CO\9/VJ? O@_QAXZ_M
MCPYJ<EVMW9?V180>8$LYY%^>*!7&'13P1TYXK\V\XQBOJ3_@F7&8_P!N;X89
M4J#)?D ^ATZY- '] =%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?!NDP>);/4=+ALGEG:W^T"Z,;2-;LG)(VD *1P=P/7/4"@#DR8C(?*RBX/\
MK?F]?0>E%M=RVI/ER-&&QN*<'@YX/X5M:UX&UG0$B:ZLW1).DG\/Y]OQK%CD
ME@BD53M5U^;H"1GI0 EP(EG<0EVBS\I< -CW S7J'P!N]-M/&FE:AXCA_MCP
MUIDK7%_IQB\YXH  7EC5@5S\HX)&[ !XK@[&%-8MY(YY9HWMXQ]F2"V5T.7&
M1(^X,JX+$'#<X& #D>\^%K?6OV<O@MI_Q+TR\/AOQOJVM_9='Q=%;IK!8G\^
M7R\C=$7V)OPR-EE- '@/B2[M[GQ!JDMA-)-8S7,CQ/);K;,Z%B5)B5F5.WRA
MB!T!-9A!;)Y/J:V-6\6:IKEYJ%WJ$R74U_,T]P3$BAI&.2P"@;3GTP*DT;PG
MJ&LW\=NEC>2O)&)$CCA8O)DX4#C^)N >G- &&O!S@''8]Z^EKC3_  ]#\&I8
M]6U/1DU)= C-K%X@@E,RRF5V"6?V9FQ+MY!F 4ASN PI/F>B?#75=#@U'7=2
ML[?2!HMXEO-8:_$S,9"X4JT>T8"Y&XN .@ZD"H?CM\0O^%A_$"ZU&W:SCLQ'
M#'''IL<D-L&6-58I&[':,@X"X4# 4 8H X*/[/$TRS)),"A$9CD"8;L3PV1Z
M@8^M/LTDNE%H+I8(';>PE<B,$ @,0.^"1TSS5R/Q5J$=BEF3;36Z1S1()[.&
M4J),;R&9"0W PV<K_"162&(&.U '6Z])K.H>'M!T^>(/8V,<ILY8W=A(K$%\
M L0"#@?*!GOGBJ7A_P <:KX1:X.B7<U@+N'R+J(,'CG7.0&1@01D X.>1FL(
M>2[Q@[XTQ\[<.<^H''Y?K4W]GR&S^T(\<BEB#&C9< ?Q$#H/<T 27TMUJ9DN
M[JYDN;A54,TI);:/E&2>N, =^/I4-M.L&,;U8YR\;E6QZ=^/PH8I.B"/<)1A
M-G4$<\YS^F*G_M"&+2OL7]G6WVI9Q+]O)<R[=I'EE2VS;DY^[G(ZXH ZO4_&
MM[)X+A\,6T]C/86-RM^EZB,LPD*A=L3288*,\@ 9(SR #7$7$\MU/)--(\TT
MC%WDD8LS,3DDD]23WJ]9/;PV,DC.!<AAM4J3O4\%<@X]\$=NM0ZA8/8M"7>)
MQ-$)4\J5'(4Y&&"D[&X/RM@]#CD4 5*F@G:WWLFTLRE/G16P#W&0<'W'(J)5
MW,!T)XYKH])U&QTO3Q+) #JMM-N@9XXW3&.0\;(=_MD\>AH U/ 7Q)U'PE=9
M6:<J5P#&<M].HSFNVCUN#Q5<RWMV\4=RZNP5N.G;YC]ZO)=:UA-4$>+06[+C
M)!'/K@  #/':LY)'0':[*/8T ;.OSV5QJD<<:FV@WYF>,;R,GDA3CD#MG!]J
MZ/3M:TS1[C6-"TF]M+O2;QHW36-5TV-)_D(8#_EH\:DY#*C'<!SGI7 =372:
M7=Z7::<D0N;@7<C;I2ULNR!@?E*.')/UPN/>@#H=1&E>,O%-U!=ZI::'"()9
M5N8[63R9IE7Y4157<%?'&5&,]JY+P_9-)JUK#.PMX9VP'FB5@1[!R%_6M&?1
M;O7=:4Q7%O-<W$H2,.RJKDC/WL[>OO\ 7'2G^&-$U+5[W5H]ES)]BM)1.\5N
MMP(5'&#DX09XW+T[4 ;'Q(\8Z?XKU'3H(?#]GH-CIUNEENLII+@SE!]XN[MU
M.3M0JHSQ535?$5W/ID%A#92VMG;*HV+/*T4;]2Z#>5!(Z\5B0*]P-/M'\O38
MUEV-,YD.#GEF"AF'X+GT%;"63:GXNB$MPD"272B1Y_,FV*"!N97 9@V. >>>
M<4 >C3>'3X*^'T>I:_8ZC90W%R8K4, "PVY8X8;LY()Y P:\HM!<7EK/=Q(4
MV2;5EB5E;';D#'YFOI#]KO2_"VFR>'AHF@WUI&T,?EW5[Y-J+MQ&-[I;K\RQ
MAN >F>_KX7H%M'=6BK96T:WIW*[WDR[CN.W$(4!RWLI8^U 'Z _\$7+G4-0^
M(OQ N+V4S*FCP1))),7=OW^>023^/2OUFK\E_P#@C'#?Z/\ %SXGZ/>"6W^S
MZ7"SVDRLKQ/Y^/F# $'%?K10 4444 %%%% !7Q/_ ,%?6*_L=7>"1G7+$<?5
MZ^V*^*O^"O#K'^QY>EDW'^V[$+SC!R_- 'XFW\E[H&A6UAF!4O5^UM)'$GFE
M6& OF8WA2!G82!GG'>N?Y'0_E2$DG)ZU?T+0[_Q)J<6GZ9;-=WLH=DA0@%@J
MEFZ^BJ3^% %%20PQP>U.D8R$N[EI"><\D^^:(RJM\X)QVS5NSBLQ%(]X902I
M,2QXPY]">WY&@"B%+' I\D7E\%ANS@J.U'G-N8Y.6&#SU%$1 <-G;CH?0T -
MR-O0Y[FM"VGTQTMX[BUGCPI66>&0,S$MD-M(QPO&W(SZBJ+HPD9?OMGJ.<TL
M"%Y JQF5F^55 .23]* 'W4444K>1*98?X6=-C$>XR<'\3]:@K:CT.[M+9-0=
MX[6W8D*9F4.1TR$R6([<"M&_L_#-CIT5Q%J3ZK<7 YM([9H'@PW)+DE>1G&
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MR,S.!GDG+''<UU.N>"M0O/ ^CZW#!ILBK</8^18RC[0 I)WR1C^$DX\PD@G
M!XH ];U/]H33F\,)8H;6\VO)!;F2/<8E&/GY V9R2#@YP>!UKYU\0VOV;7KB
M..YM+L,^Y9;0[HF# $8X]^G8Y%6+G0+R'<JVCJ(9!!<,PPBR9;@MN([=>!Q^
M=?7/#E]HQ,ES%$L9E:+-O()$5Q@E=RDCOZT =9\);;Q--XY_L706C2]NH9K"
M>.2=(%:)E99,LV/X2WJ:U_C7\0=<\0:M<Z=+:0+H6D11:';L+=90HAS@B=D#
M;R0QSPQ7"G@8JO\ "K2],T5M0\37&KV[C3;%Y4M@ KR3ME5AQ(A#9]0.,Y[5
M'\-/"T?Q=^+]O8I87:+J$SR);0QF[<L!D@CY2_/7'//XT 2>!/@CX@\4:;%K
MMS:7.E^"A/##?ZB;B /AR<&.*1T,I^5B%7. I).!FG^*?BC'_:]QI&E7LVJ^
M&+:P?2;-M7EG;<ASMG"ALQE6.]4'R@@94Y.<'Q7XTU"*VN_#40AM],A/V=K:
M*V6 Y21F^?;]]@Q(W,6. !G@5Q:*2W";L<D>U '03ZS_ &W::G<ZSK>HW.JR
M10B%GW3^?M95V2NS@JJQC*\-]U1P.F,=/E8QB,"5G8*J(<N3C/W>OZ57ZMT_
M"KVGZ%?:K,L-I:R3SLVU8D7+,?0#UH JO;O$Y60;"!G!(HAC1_,W-C:I(YQD
MU-<RRVSM \)@91L>*1<[3W(!^Z:O6>J64%I,\VF6MW+(539)O4(!SN7:X.3C
M!XZ'J#0!C5M^&KF^T?Q%:S:>8Y+N,@@-*%C((Y#.'  QU^8>]9\]Q;75XT@M
M%M(G?/DVSL50>B[RQ_,FM15L+/2GO$N_M-R;I8Q9S)AS$%)+$C..0!@'O0 L
M>EW/B(7EU96;R7T!>>:*R0%(XE&2X1%^55 Y;./;O6.?-6Y5I)2)&;<7#@G)
M[YSU^IK;C\5W\,<)L;J73G64D26FV$IN!! *;>#^ K&U'_C]<O,L[$Y>2/H6
M[_7GOWH [?X>MX4LKW7!XGT\:K +.003&Z:+RIOX6'EDAS_LYY]1UK D;2;C
M3;AG%U;?.S6D4*@H_/.[+DKC(]?K6/)+"71;:)L _P#+3#%S^ Z>U)YLL,KX
M!BE?*E2H P>",&@">YOO,5TACMHEEV@QQ1DLN !P6R>>O7\N*AEB=HCE$5XP
M"S%P&(/ X)Y_"F21&U8A]C/Z!@P'Y'%+'+,S2CS)!*Z[2=QRP]#Z\4 5Z*"I
M'48IS.S!06)"] 3TH 10"1DD ^@R:N6\LBK'Y0=&7.]ES@^F<G'\JBBNI([2
M:!758Y""PV EL>^,U:T>Q2_E$#GRY)F58I))%BB!SR6=N@% '4VVE6@\1Z-L
MO1>F:V,\C G=))@DQE<DKZ9Z'TK$E\475G!?6>G-<:;87JA9XS)O>1>X9P%R
M#Z8 K?T5Y;?QY]NCO+0#1BDYN)C'/&WEXX7 *-D],\>]8'CNX&H>,M5N%O8+
M];BX:5;F!G\M]YW?Q@$8S@]@0<<4 '@G3H-6\26=M>-=BRD?;*UFJ-+M_P!E
M7(#'IQFN]T30]_CN99'GO-%SY,FH2AY)6V]!M:1#NR,$9Q5G]F/X83_$;XDP
M:,C:C;3S1.8;W2[?[0UN0/\ 6L0X*QJ<%G 8@<XK7U'Q';_#3QA=^$M8DTS5
MYK;4VDU'Q%X?NG<W3*<CRG9<, W)^0%CWH \]^(VN7^K^,;A9&NBEJHABADC
M\KRHEZ 1Y.U>>A/?WK5^'WB&RT.\LM;^VZI'J5M+);*J&)($1T(#!G1U7!)!
M78WKD&M3]HGPMKGA#QG+/KMM!!-K-K#=1/%(#)<1NNY977)VDCJ %QZ>O%:*
M^D6ND"./6M3T_59]PN?)A'DF$C'E@K)DD]]P ^M 'Z.?\$:;M;SXC^/]EE:V
M*P:/#"&A\YI+O%P<S.SLP)[?+M'^S7ZNU^3/_!&G69M5^+GQ$21D>.VT*V@B
M9>I19R!D9('T&!7ZS4 %%%% !1110 5\6_\ !7"PN-3_ &19[6T@DN;B37;$
M)%$I9F/SG@"OM*OB7_@K_P#\F=77_8=L?YO0!^'$]C<6JAIH)(U)*AF4@$CW
MJ#M[UOZ+XYUC0M*N=-MKD-8S_>M[A%FC4]RJ."H)]0,^]1PWL<D1^T:- ZA_
M-DFBWQOMZ$#G:!_P&@#,MX)IH9&CB=XX\;R/NJ3T)]*;/<O.L2-PD2[54'@>
MI_&M>/\ LM5+6=Y/:M(^TM/#DPKST=&R<YP?EK.O;";3)$8E7C<;HY4.5<>H
M_P #R* *OEL5+!3M'4XXJ]H8TP:C&VL?:C8*"72SVB5^#@ MP.<9.#@=JB6_
M?[(+<A2@.>F*J4 =.(['Q#%:Z?HVA7']I$L21=><\JA<XQM&,8)XI;KQK<6^
MBKI>GVT.E!F)N7MMZO,1D*K$L<[03C@8R?6N91GBD5D+*ZD%2."#V(J:0G>)
M-D@R/F+'))[G.* (FGD:(1&1C&#N"$G /KBF C!&.?6GF,G)'S#&21VJPFEW
M4END\5M-+$S&,.L;$;P,E<XP3@@X]#0!%:W)MG.1OC;AXST85H6)T87!:Z>\
M2#',<,:LQZ\9+#';G![\42>&]172WU*:!H;<-M$DSJN\X!P 2"3@@\ ]:M>3
MHMMX;8FY:\U7SE98XXBJ*A7Y@7(Y(...E &0]O$V6CG7:/X7!!]A[U;LC<6<
M5P+29I$GC,,PB) *DYVGV)4'GTJ/4=0M[J*W$%E%:[%PVQBVX^ISS^N/3%:E
MGXTNH--%DUK:R0#&?D*%\9V[RI&[;N."<XH R7TG4!;-.;.<6XD$)E$1V;^R
MYQC/M6_I>E:?X8O_ #?$UJMXL:@_V=#<;7DW*>K*?EQP>_/4$<5F/<S:FH,%
MI(EI!\S01.[(I/4C))![]:HWMM(LY7SUN]JC#(6/'IR >* -G4/'>HO%J-II
ML]QI6F7Z1PW%G!<R;9HDQY<<G.'52,@$8!Z 59^&T6E0^)8;G6M3&F:<D,Y:
MXCC:9U<1,43RU(;#MMCW9P-Y/.*Y7(BP5(9NY[?3ZUUVG3POX(D7461%BD9;
M0?8TW98$D[^&<9!'\6WCID4 6+'6+?6_#-UI]U92F>VMF%I<J2^?WA8C:5.
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MZU]8_P#!,C2UA_;.^%U[)=6X:6?45CME?=+\NGW&2RC[HY.,]<&@#]]J***
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M4 @T_P#8R\*Q^&/V_P#X8QQ!41I;_"]#_P @^YYQ0!^W%%%% !1110 4444
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M][IE[I<&NI>Z#!)]ICLHY6%NS$;3+'%)SNQU*@D=R!7(WUE-'';WJV4MG;W
M(C>13L=EP&V,1S@]N<>M 'Z/_P#!$V&-/BA\19(W)5]$M\J[ L#Y_/3M]<?2
MOUVK\A/^")))^*WQ)W* W]BVY)!Z_OZ_7N@ HHHH **** "OB7_@K]_R9W=?
M]AVQ_F]?;5?%?_!7:-)?V/;Q7#<ZW9;2#C!R_7VH _#!H&"*WRG<,@*V2/J*
MC4 L-Q(7/) R0*T=(O?L<=XJQL998BJ2+U3U.>U4;>)IY0BXR<]?SH :Y&2
M<J.AQ@T*K=L@']:5(GFD5$4N[' 51DFK^TSVMJCLNV'<A5QLVDL>I[^OM0!'
M;QV<$@>X\R:+9@H,(V_'89.0#],U4P23D%CC/!Z5IZK(=9U>;R+2WLSC"V]J
MS,@ '12S,3TSR363TXH E#B57\QV!QN&!G+>_(Q]:BH!P<X!^M% #L[GX 7/
M84@)0\<$4E.2)Y6"HI=CT51DT (S;L< ?2I9K*>W@@FDB=(9P6B=E(#@'!(]
M<$$?A4)&*DAYD4%Q&IX9B,@#UH D40QV\RR*YG)4Q.&PH'.<@CG/&.1WZYHN
MH&AEDC)C;9W1@1^![U$Z%691R!SD>GK4YADN+7<B-((ER[*"0H)X)/:@"KTH
MIVXJK*,8/4X!/YU)/=/<! XC 10H\N-4SCUP!D^YYH B'N>.]:6LVD%E>O;V
M4QNE@R&N0C1^9SPP1@"O;@\UG[R5"X&,^E7-/LQ,CR3L+:U(8"YDC9EWJN0@
MVCJ>![9H HX+MW)-=CH-L=-RCW43RS1F-XH5.4!^4D-C#':V?E).#7.0ZE]B
MF@FLU-O/"=R3*WSA\Y#9QP1VQBF6VIW4#3B.5F:Y7RY<\EP6!QZ]5!H U+QH
MM#;RQ:H]YN#I*S;P@QQQ@9/?TYZ5K^,C;RZ+H<7VF);PEWO '9@KN00^ ",8
MP/ES]WI6?X@OXS%#++;M'J89MP#JJ1$-GB,#*G/J359/$4EV?/U.#^URJ) 6
MN&8%$480 @CG QSZ4 9<3E9'@AD.Q\ ^C$=#S1=01VSHJ3B60C][M7"JV>@/
M?MS@<YQGJ>OU%=#O+>WM]!@_LFZN;ABGVN[6:1$*@;6F 50O4 ;<\DDX(%0-
MX+ATTV4^JW5H+>2U:Z\NVNE#3J'*E4D^9-^0>/1>F: .8NPLV94C2+)RRK("
M.>0 ,YQC%+8V?VT.QDBAC@3?(SN 2NX#@$C<?F'RCG&3C )JU,VC2*ZPI=Q'
M+,AD93@=E8@<]^0!]!4-W>-%;I:) ENHPS\9:0]B2?8]!Q[4 :FN^(-)O1#'
MI^AQ6B11^6\S2NSS'LY&=JGJ<*,?6J.MZW=:H;:":ZFFM;:)((@SLP"*.,!B
M<=2<=!DXQ6>0L91DD5R0<K@_+]<C'Y4W?C*D;0/7J/QH EDD6XCA1(0DB#82
MN3YF23DY)YYQQQQ3[*WCE$T;P3RW#)B%8F VOD<L""2, C P<D'/&#7;="SQ
M,<C/(5LJ2.^1P::KE6!!VD=&7@B@!0C!6)&-IP<]0:V_#OC75?"Y?[!<M$&&
M",\#\*R&DCEARY;S]^<XR&'J3GK^%1,I5CQ0!Z=HW[07BG0DGCCN5G61BR;L
M@)].GZU[=_P3O\7ZAXP_;S^&=WJ,@EF,M^ 0, ?\2^YKY"))KZA_X)C_ /)\
MOPQ_ZZW_ /Z;[F@#^@:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /QD_X*^6VH+^U=IEW9I</"GA.S6X,*D83[5==6
MP1CI7S&/$EW>:QKU_/%I]EXE,$0U+2]\T$&J1@IN3,# $NI#.NZ,_*2"7)%?
M7'_!7OQ#<V7[0FAV(%D]L- M;L,T ,\,B3W.#O9<%6Z;"3DCH.I^*?!WBE[&
M/7=0U!9&36H9HGU&S0;HYR-Z;8R5Z,!DJ1@,?I0!@:EJBWBV6G#2(;2"&V$=
MU+83M</<')?S"S.RJV"JX3 ^0?+G.='4-;2\TW_BE=/O=$L[6V>.Z5[L/+.I
M^61@,#)P?F*@87KQS7G\-W-;RK)%*\3J00R'!&#D=/0BM"37I]0U-KW4)I[B
MZD<O+=%R\TC$Y+,6)W$^] $MK::0]A)>SW3++'*J#34+"25"#EQ*4*@@[1@C
MN3VQ4FC>*KSPHGF:->36EY+$T<TR?*RANJHP.1D#DC!YQ2W&CI=!;RV5IC<^
M8_V>&/:(@,X)(R .N1Q@8[<TR#PW_:%L\EO<Q2748)>TB+22'!'*X7&,'CD_
M=/J,@'>?#/5=7\9RZA!J&H6SVVC:?=ZLLEV(TE>1(W8*)BA9F9FP 6^8XYR!
MCSVUNKXWAGM6DMRY(,R<%<_> ;L.OYUT>C:)/H?AB_N[@7=C=WD@L8D("EHR
M#YF5W!NV.1@\\Y%=)\/XM(@2XMM;,;!2KGS#LPO^]]/J/4=Z . ET^-&,KL9
MD;YG.<L>>>:R+FW$#\,KH2>5/3V__5FNW\::KH\5[(--D6>%NR%O?C!4 =OT
MQ7#R3@2JT0:-5.0K-NP: (>AY%=CI.C6Z^&Y[V\MS+%-#*L*65[&)0X&5:5,
MLVU2 <%5SS\U<I=7<U_<--<S/-,V 9)&)/ P/R  J)AM8C(;W% "[0&((*XX
MY[4F ">]=-X=\/IK&FWU_-JUCI-CIB*\J7%TIN9W8X @@R&D8\=!M7JS**YZ
M<+O5D0K$>F\YSZYQ0!&%R>2%^M6)M0FG>(RMYOE#:A88..W(YJO(<NV,$9XQ
MG'Z\TN%\C.T[]WWMPZ?3K^- "KL+ LS $\X7)'ZC-/N;V6[2)'(V1#:BA0,#
M\*GT*V6[UFS@=499)54AY1&IY[MV'O6UXCD;PQXBU&Q2"SN(E'E9DM4( /S?
M*2"<C. _4@ T +IOART-A;RW=^B0W,;22 HR/#MZ&,.564GD8!]LY-9FHZ/>
M:?ID$T]K/%:3RM]FGFAV>:!][!SVR,CG&>M=SK&H7GBSP?X=L]1EN'M-+6:2
MW2W(D2&)@NX!5R4RR#@@+DDYZT:MJMO>Z#;QVNA0Z+I:1+;RSWENEU(^X_ZP
M2>6IC/4\'/(&3@4 >?+=QC1GM3; SF<.LY;D+@@J!CN2#GVJ"VA%S<I'(XC!
M."QR:V9O#UC>>)#INDZM%-9YPM_J %M'TR2W+8YXZG-4KRTN;*$VDGV9HTE!
MWQ%&))7(^8<XQVZ?C0!-=QW'FSPWM[,O[LL8FE$ARHPJME@/RR0.@-06=RUE
M)Y<D4=U$5(,/F97D?>R#@$>O:HH--FNY=L4+O@C.TU<NTD$:Q+E40F(B1L[/
M0$X'/6@"&:"*Q2W9;E9"ZAG6!BV"#QNS@9]JI7+2/<.TK@NQRQ!#?J*GM(8[
MA9HY';>B?NEC .YL]/\ ]6:U/#WA/4O%<JVUE;Q_*')GED2)$P,MO=B .!P"
M?I0!!?W$<MUOLVNG@"HT<=WR6<#!(V\8ZX]JUM#OK&Z\/:C:71N(TVF9HDG<
MK)+V?;D+\H)X.2?:L&^AMXY8HK9UD<#:[ _)G.."3^O2N]\&^(M*-L]A>16A
MM+"PGE=)QY4ES<8.!')"A);.-I?/?D"@#D]#G^RW#16M]>:=9S)(ES=!&82Q
M#UC7\,C)&3U%:=_XJT>#2;*VTJ#5+B_67S;F\O[G$<A!&T)$G*\;@27).>-M
M4[+PI=:AX7N=;FOX8%#,L2SS;#+CE\9X8X[#))KFS!)&$<@$,,C:0?Y4 ===
M^*5OK*[AN9)].G ,EG!:PJ(E+'Y@SL=Y!'<D_C5%O%MQ?65K8ZDS3:; <0JI
M4O"<Y+!> WT;\Q5/0] N-7E#1@"%&&_GD>W_ -<\5T'Q%\$1^$+JQD@82V5S
M;I-AL%XV.<H2#STZ^] $=SJVF2:="T+F^N?+(,K6WV=[5@V5VNK;>1Z@@=JQ
MHO$MS)#=Q3_9IQ< [Y[J%7F!/!(8@G=_M=?3%-TG7K?2_M16T8-(N(R)<A#[
MJ00P]C6GXZ;2]6&G:IH]O';QR6ZQW42.2WGK]YRN/E!XX!(]Z /T$_X(G*/^
M%J_$DK(LBG1K<!E&"?W_ %QVK]=J_(C_ ((EK*OQ-^(9D4*IT2 QX11E?/ZD
MCD_C7Z[T %%%% !1110 5\7?\%<)6B_8_O=B%F.M60&#@CE^:^T:^)_^"O<C
M1_L=W95BO_$\L0<'&1EZ /Q)U&W>2Z>6*V6W66 2-'$VY5]>K$_F<U7MM.AO
M+-Y$E6-HL;UD89QW8?X5H:3J;WUK!IQ:.-HG9HF;AF+#&W/;GUJOIUFT=GK)
M^3SX8@I0L#\I;YB.><<?G0!:T!+>[@FVS)87-JPFMYW;#-SRIP.?7VZ<TFOW
MB7%A:PLI$T.9&*RH5??R3A5&#GL>0*K:% Q8EH\!E8*Q4Y) S@>IQ[&I[31H
M+F_OEENI-D=LTQ,8#L3QQP3D<]>* ,.)7DG A#,Y/"CDG\JMP:)?ZC)*;>QF
M=4(\S9&Q6/.<;CVZ'KZ'TJCL)#, 2HZG'2MZVN)=%T"26VU4Q-?J8Y;&)W5B
MH8X+_+M(ZD<]Z ,.>%K>5HV*%D."48,#]".#^%+$L;12[SM8#*MSU]/\^E,"
M@G!.!ZXI#CMTH #MQQDGWI6;*J-Q/J".!3:<A4'Y@2/:@!HI<]N:<C^6X90#
M@Y&X9I3.W&,*?55 /YT . 0$C(9<?>.014DJQFV+HP0;_EC9\M_*JN:EAF\H
M/P&W*0 1^M $5%.W$YSS0>6XQS0 F>N!_P#6JY-+)!81P%3&'^<JZY)]&!(X
M!!['G ]J-)\V+4;>2)8C+&XD4S(KQ_+\WS*P*L..000>F#TK8CN$UBXDU74K
M=I;*W?RVBB/EI@@[(T('&".G8#\* .;4X/I6]H&B)J!N&*&YEBC+I%'((]Q'
M\1)'0#.1P>13M#T:PUK69/M=]'H.F+F1YI5DE,:]@H526/0= .>2!4.J:AN/
MV2SE=M/C8^62FQI/]IAD\T +>+:_V)&BV^;U)=QE1_E"D8VD'J<C.1ZUE02^
M7N1EWH_5>^>QS5[3-0ETR\@N4^;R7#JI) SZ\=*3-N;.=Y(F-VSEE?/R[>_;
MKGOF@#/?<F1@JH.,5HVMS;/IT]K)9L\I&^&97 *-\N<_+RN >..2.?6I<2B[
MDC8!ED/WY'?.YO6DBF$. <LN<$ ]2#UZ>E $.WYR"=HS@MVI2RMM!7: ",KG
M+'L3G\*O:M'%!=2FVS):,^Z)I  ^W (!&3@X([D>AIDILIFGD59X4/\ J8F8
M28^K\?HM %#H:DCP6^<?+TSZ4/$5D"MA<XYYQSWI1-)#*2CE6 *Y!SQTH ==
MP26\S),I67 +!@003ST/-0D8-:TL_P!ITZW:6VE<1[T>X3'S]U!..Q89SV('
M'%4!=NEOY:L I)XQ\V#COZ<?S]: (/O8QRU6)KF61F=\#S&+_*@49/7 ' _"
MF3B']WY+NY*#?O0+ANX')R/?BF!MP"$[>>IZ4 "KZ#)KZA_X)D#'[<GPP_ZZ
MW_/_ '#[FOE]6X/=J^H/^"8^?^&Y?ACWS+?\_P#</N: /Z!**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(G_@J]I=
MU>_M/Z!/Y_V#2HM"L8[N^O;8W%C%ON+G8'0*Q+':2!C)"G'0X^)/'7Q$T3Q!
MX2T;1%\(06&L60E:ZU595B6X:0A@PB5!MP,  -C"IA5^;=]F?\%@K7Q#XG_:
M,\.:'I%E>WL">'H9C';O*R,[SSKDIG8I &,@ G=@DX&/SOO[6[T>\DL[^WQ)
M;2-&UO/E=K X8$ @]1C\* +=S#H=C]GBAN)=1WQ SW C9%C<]0BD@MM&!DX!
M.>,8-4XYK*QGCN$C6]^=O]'F#! .-N2"">IXXZ>]:EO8M%I-I>:6)&U*]FFM
MWMXHR1&GRA0K9YW;V7!R<+G/-4+SPIK&G3%+K3Y[=EY;>F-HR!R>W4?F/6@!
MOEWJF&X@M3#YJ.X\M20R@G<V#G@>O3BMCPYHVK/+>7=G-]@N;>$S )YGG2CA
MB4 !/W3D]!MSDUV=O\,WT2VTV[FNXM)WPK<2W5[Y:JJOQ\D9+&<8P<<'.1UX
MK,TB#2=",=K'J\%C>1W1;^T%ADEN0R9 &W"B-3N!QDG*GG'% '6_#[P'X@^-
M\USIUG=Q:C/:S+?7&LWB20P6,2JJM+=2>4P2%00,@CD<@_+7/?$#X9^(;C4V
MF$$8GD_U5HC;6FB55Q.BG#;6# C<JD@\#@X@U?4Y+;XB1Q7OC+[;IUP=T^H@
M$Q@$G(=4WEAT)&,G/(!R*T_B#'-I&H6]K!\1DO+;[+Y27=I<WC6SP,-PC17@
MC=1\QRK*!SQF@#AO#'PXU'7[J1KDG2M)MY EYJ4\3,EN.YV*-SG'.U02:=XL
M^&_B#PSIUAJ,^C7L6A7_ )SZ=J4ULT8O(XWV-( >0,CH>G(KJ+JUT^SL+33A
MXKTNZ>9I9I;VWFNVE Z+&4"A2SGGH3Q\Q KI_%\FG:5X0T<_\)/=7%U;SO<6
MNGZQ!,L:1#A\(Q=6+R#LI4A<DYXH \#SUJ[:0I&OG3;#E@BAI,%20<.5P20,
M5Z!'\3='/A?Q)I5OX#T07^I2*\.LDR//9D%2PA4_(JMM;@*I&[ .!BN$U"TM
MK6VL98[J.:YE5FE2-V)C.1M)R@ SSP"W3MQ0 W7KZ?4=8N9[JXCNY"VPS0H$
M1PHVJ54  # '85GMU.,[<\9JQ) 7G)DG!D=^<@[FS_%R /S-6VT"[DU..RAQ
M=W,DAC5(#O)(QTQP>O8F@#,4*2=Q(XXP,\U9M].ENQ(8FC;8NX@N 3SC !P2
M?858AMK"VN&6ZNFE5,9^S)D.#C(!;H1D]1V[U%:WGV&Z6XAE='5^-O!P>_L:
M (T6;3;E&>.2&1"#M8%3_B*[GXBMINOV&C:OI5B89&M@=0,9+(9LX/)0$= <
M$M][KS6#=ZU96>I0BWC%W;Q,CF5U4LV ,#!4#CD'(.?>I9M2U35K5[I[$7.G
MF8LQ@B$8!ZD,(\8'L?3CI0!2UC7(+BRT^VLX3!]F5OW@&UVW8R"0<GI_G)JW
M+JEM;:"FBM'+>DR)<@I<LD:-M((V?=9L$?-U[>M:/A#PW::GK'GB788)XPEI
M(N&=<Y=F&<E0,YVY/TZCI_$O@&QFUWQ/JND&]M=(L-S136L41Q*XS$BQ>9O$
M/_30;B%Y*YZ@'G6JZ#=Z9<M8A97DRI\B2/$H)0,<J"V.OKTQTZ"C97/EL5W
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MQY4F<KSUW9YX%:>O>.]4G\-V5H0(GFG>[N-34S&>^E)SND=V(;!)^Z!U.<T
M4?B1%)I_BF\TJ20R0Z9*]I&$F62-55CPC#@C_)J/1/$"V,49FC218Y49#L!7
M@?=;*UL6?AVX\=:>UY;V]DC0[8IKJXNDMPK $DD,P&".YYS^53G0/# ^RZ=%
MKNH!))%$Y$*M"CD8WXW@C'^Z2<]1TH W?"?C#29M0NII;7[.9F+;"4*^P'R@
M<UD_$[48M;",B1HL8 VQG[I[GC@UF7.DZ%8:FJ1:VI1':.YWP,K*0V 5!)W
MCG@U;C\$7OC3Q&VD>$;EM?2"W:X:6.!U"HHRY*@$\?2@#@&BVKTZGCMCZUU.
M@ZFO@G5H+B*:WN8IX7BDD1H[J)P1@[H'4$ 9Z.!R,BL>^TMTU$I-<QR'=MDF
MV.(UQQZ _I5*6QGCD;]T65<9902H!Z'- 'ZD?\$=/"PT'XD>.;R*6.6TO]$@
MDA)>,RD"?!)522JYZ @9K]5J_(/_ ((C.Q^*GQ*4]!HUOV_Z;U^OE !1110
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MW%)'(@3#+@X/S#J:1]\A\QB3D]30!'WI5;:0<9ISIM/!R,4J@@@NA)/3/\Z
M&[LG)X[<"OJ;_@F,R/\ MO\ PR&P^8LE_P#,#Q_R#[GJ*^7#E%V8&3URO(/U
MKZI_X)EV$\7[<?PU!0J8FOGD5AM*K]@N!R#[D?G0!^_5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?EI_P5G\)>(/'
MOQ&T;3-"BO[F:VT43M;Q']TZ;Y2X"#)9OW:GIQ@&OS'T_P #Z_K<1N+;2KJ:
MS@V^=<B$^7&&; 9WQ@ G@$^PK]F_VU=+M_%GQLT?0/[<L="O)]-M_*N+O_:E
MF&>!S@ ]_6OS+_:&TGQ%:_$W7_"D6O1:[';LEC%-IL85+X1*JQ1JP +A0L8"
MYQD#'8T 4-(\,:GX#U/3;;6;&XT32IY3-!J,%K#=12NJ_?3<=D@"R#()QA@2
M>:Y3Q?H]SX4LS=P"VU"WGN!)%J5OL5A\FXJK+R& =<YX&>%XK)\%Z?XCUG6_
ML-O9W-]+8N7D E9&M]O4;P?EZ8/X>U=-X=:Y^"/BSS_$NGC[0J"9=$U*W>:U
MN5;&^VF&Y64%",\YY - 'FUUJMSX@FSJ$MQ=W#D$7$LI=\8 Q\QYX ''I2ZU
M!I-DD5K8M<75VH(N)IH]BJX/W8P&Y7'4L,Y[5V^FZ;H'C/4Y],M$^RZG=W.^
MTNC(MK96B[LE0K%MPP.#N7U^:ET#X >)-5NT$\ND:3IL^H_V4-5U74(8+>*4
MJ7W$NP.S8,EL$#([D4 </<17[FV@NT:[$<?E0;3YGE@Y(4$'@@DG:>Y/'6O1
M_$GVVY\)>%KW5GLH=&L8"UG;W5D5:\8R 2!C&29,8^\3P..,UM^&_@AHGA3[
M1JNM^)],\336A91HWAJ=[B25P<+^]"",IG^)6[C!SD \2>*?$'Q*D\-^&=3T
M>6];37N(-,LKAVB2-9MC!'<R+%&5P&+(BEBS%B>, &7X \*Z7XP\1VNOZ6\.
MF&RF,]Q!=/$+>/RT,A8KP=C;2,;<9(&>E<W\9OB''\1?B+J>O06,%F+B)8A#
M9QLD"XC"DHC%MJDACCWXQ7O,VFZ_\"OA?+XJG@T6POY;QK'1X-,9M22=2A:>
M59TE:"1(U<(20X)8CGG'BUY=?#WQK>?:KJ_U3PQJ5Q(OG11:=%<VS,S?/(&$
ML93J3L"8XP&% 'F2^?#"[([+%)\K;&X8#'!_3K6Q/K_]NPZ58W\<,-M9*MM'
M+;P*LBQERQ)"@>8WS'ELG&!G %>G6'@7PUX-\5ZY=0:A/XFT;3T6+3=9%P-*
M#W;9",4(D8JI!8J""54G(J"=?#7B.^U<76B71\36UR9?[8TG5@;*7+\NT<T)
M.T9)W;U&!SZT <UXI^'=U:Z[KMQX<TS4;K1-,*L]S=V158XF5=CRY+!"VX'#
M'C<!S3-!TN]\.:5I&MV&JV<]S>7@3[!IZ!]1M]OS*ZDH=H."/D/LPP1GJ_C#
MXPUS4_'%]+J]W!=;[BV\PQ2V[,5C@2-?+\DF(H0,Y4>G/)SR-GXA-M/+/'=,
MU]=.^+^VD9+F*/HPVX &X' P<=: +6I^&-#LM,GD;6K2[UDG[9-;2P/';QQX
M)"(\?+2$D#:%51SSQQP+V^%5V>-0_(56W''OC./H>:[>5]&OIG\^WDM!$BJ&
M6X'F7#ES^\D/."<C(VL>*YG4=.6WF8YCED#9=()"XQZY]_ZT >G?"S]GCQ+\
M3(M-U#2;72H=)N7^RF\U>]$<8E.>JY#?B 1[U[+XW_9X\?\ PJ\ S2:WK%KX
MHT.""3R;70YO-MK%F(Y=&52P! Z@\CC/6HOACXET3QAX'TS3G\3PZ9_92I#:
M:9JNIPPB,,27:)G*#&X_=&3R:V?B5XO$'A9M&\,>)K?5-/N@T.H20R94JIYC
M!8 GW(./0F@#QO5? SV^A6FH2G45N6TOS+6:R90SA2V\M&R*W &,AN 1R>E>
M3QZCE]J6L4AV!95:4$L.A !X].@R.:ZW3]=BLMR:O<ZC#9QJ]G')"V/(!!9<
MQX^93@$XZ@?2L+5X]*G"WD6I7%Q:2>895BLMKPL0 NXY52K$] >/>@#/L=1L
M'OE^U:=-);,HC6))<LO3A<C R<]0>M>EZCX=@\#>'UU0I<:&VK[A#I4J(9VA
M/RY\YMN5/.<#\!UKR[0PD#_:+K,ULN6:*-@I)'09P<5UVM?$FQ\17T2[+RPM
MC#Y,AN;II04Q@J0J]\#&  .^>H .6FTZWU.YD @71BD):.)Y6=9F'&58YZD'
MOCCCWV/#*3Z=J-Q-;716[M% 0PW<<,:[B 2K2,"1ZD?H*N6NL:==Z!##9016
M.I7-SY;3I*TSI$",*Z,AXST*MZ@@U@QVOA^RURYAU*74B8G9/]%5(\2 D=6)
MXR.N,^PH Z?0K!-8UO4/$'B?3)-2T"U4Q7MU;N;DPL251R%GC).[I\P4^AKG
M[I_"NG0SSV9O;B\('V:&8!%4[N7?!^7*]$!;'=S4QU]+F0ZEJ*W<-]/(%:_T
M\Q)"T2KMV^0J*-V0I+;AGDD$G-.\1ZM=7<\-YXGTI+IKJ&,0W:#[/.T*\ C9
ME-V  2ZL>F>QH BB\0:U8![.>9I(Y1&\ME/'D2*OS)E64J<>XQ7//8->,9+=
M=Y=R-FY0P/7[OICN !_*NQU"+P3'X?N'L9Y4OY!^[MKD,SQ' P?.3Y&[Y^5<
M=.>M<G;R&SN([FX4R0<JP"*21Z<C'/K0!K?#^YU'^UY(;%HWGFA>-5NLF-QC
M[A'0Y]^!5&;36M;M_.6-V$0/EK,N[).!C&<D>E;6GV,VA>(]-O/#^KV^IR,J
MSM);QLJ6Q8'<CB15^[T+;2G/6J?BF :#XAC)CM9;N+/G(A26!CVP8V*MP>V!
MF@# D+"5I.>?ED08!/KVP*9!/-9R_:('DMV'W64X/Y\5JZ'HUU=V=]J*LL5K
M:+F9V0X4L<*,XX)[<YK1TWPRNK ):S[[;(=MXQCUZ4 06_B76+VWF<7L4&V/
M8Y^XTV>,''WC]:33]2O;70M0T\V2O;W13?*D*;LJ<CDC./H15F^DN+*]ACBM
MU>.V7$*RQ@ +ZD  ')[G)]ZT[.V^TVEQ/(AE)&YL8"CCG QG\J /NO\ X(F/
M$WQ6^)0BB,8&BV_WFSG]_7Z\U^17_!%10OQ;^)>#G_B36_/_ &WK]=: "BBB
M@ HHHH *^+/^"N5LUW^R!=1(I=SK=C@ 9[O7VG7QC_P5IO9;#]D:YEBE:$_V
MY8@X9@&&7^4XY(/I0!^&44BV[,C99<GY9$Y!]>M:T&HC2/MHM+B>-9U39)%<
M8(7J0X7K]#C%:(\56[Z?J)DT^U,CE4C5K<2+"C'Y@I[-WW'GWZURKE'G_= E
M,\!NOXT :\$=UX@3[):6D9V\E@O[R3GN?7Z8_&LW4-,N-+N6MKJ![>9.J2*0
MP^M>M?#9;>WT!ML*K=S-A65C\OH2*ZKQI\.81X7GO=5NS/<LAEC*1AG&/4^E
M 'B&AQPFW'VF +%@NKE"%EV]4W8X^HX]:=>7&H:M%%?ZI>7,MG''Y$)F82O&
MH^ZJ*[ A1ZKTJ7PQ8?\ "2:E]E^T"VE\MDMH5BW^:_:, $<GU]N]:0UO43H-
MUIL]U(7M6$1MKO+Q@="!D85AM SD9&!VH Y:\TY=.CBD-Y;3^=$)45#O.#_"
MP_A8>A_.HM1UN_UF:![Z^NKQH(4MX3<3-(8XE&%122<*!P .!VJW':V>I32R
M&X\DH-WE",D;1C.6' _E4,"6VGRI)=V,UQ XW1[9?+W#IUP: +5KXMU&UTXV
MBR(\7.-ZY9?7FLN[NI+YC-*P+\#'>M*2'2[]IFM(KVRR04BD99D"9^8L^%/'
M'\)K-^Q/*\BP_O0G<=Q[#K0!7DD,C%FQD^@Q3:5E*D@@@CL:2@ J6WB6655D
M?RD/\9&13K.U>\G6*,<GDD] .Y-2ZE(%D%K'<)<V]OE(Y40J&!))/(!ZGO0!
M9N]0;3ID73;B2",*&#Q,5;)7# D<]R,=.33-/#W]W']JN2(I)%2224NVU6/+
MD#D@8)-9V>GM6_I5U/H-E)<(P2ZOXFBBD67#QQ\ASC'&[&.N<9XP: #Q=XE_
MMVXMK:"..WTJP0P6D4<:J0F22S'&78DDDL2>W0 5D1X-E,=G\2@-^=0R)LD9
M=P;!QN7H:T+2.*^TQK5=BW:2[TR.9%(P1GVP#CW/I0!G(<9Q@Y]1F@M\W;\*
MF98EB_UF9 .5([^Q_P#U5"P 13SD^O2@!\2^;*L?0.P!(&<?UJ53)9RE%G<0
M,PW-"QPW49QQS@G@^M-)-K(6CE5R1C*#UZ]:C1FB((90&ZYP>_<4 ;'B/1WT
MW4DM%A>,M$L@63.\ C<-P..QZCCC-4H+V;2;P*T<4@B8AHF 96XP>1UX[@UU
M>L+_ ,)1X'76/[0ENK^RN!!/8QV"I';Q%1LD\Q3T)4@+C V\=<5Q4BJ0NW.[
M'S#' H [!?"<%WHEG?6Z1R0WTQ@B(NE:=)0IQ&(QC&6QD$'@I@\Y.+J!TJ.R
MM8(C=B\ARMT6";)#N8Y3'(P-HYSG!/'07[74[W_A#4@$SO;VTLICMXX^$+A0
M[L=OIM')[KCI6##-<7EQ;JNZ><%8XT*[RW0*H&#GTQ0!%;M HF\Z.212F$*.
M%VMG@GY3D8SQQ]>*?9I&DT37);[+O^8JN<XY(ZCGIW[TT6MQ<ROMB=R&PVQ,
M@'GT''0_D:DD@@MDECDF9IU*X6- RD\Y!;(QCCH"#SZ#( HNWA2XCA"K#,NW
M;(BNP4-D8)&0<CJ,'\*B25(V4A5<8QB09^OX=?>IM.M8;ZX,<LXMX@"0[],U
M7E002,JX<#^+UH GCM?MLS1VD3LH8[0V"WMD\=A^A-)9R>3)MDCCD#$ )*<
M^G/8>O(IT%Y<_9A:+(!&&9U3@?,0 3GZ 8_^O4,4)"^82%4'!+'K^'7_ !H
M62,)(0[!<'DKS^1KZA_X)GS*W[<GPP523^]OQD^G]GW7_P!:OEJ6-T?#(4.
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M0H+_ $#2 5L8K>8V[1!CEP"0ZH&_V5 &!C'.0#R_3X]:\+:3%JR%+:RU+?;
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M_9]NH-(\4^(O$]__ &C/-I-E-<A+***18V(PCO(QPIWE0-@W9/&"* /-M?\
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M'';Q2DMN#*,<#!R1S71^']/UOQ9XDFOM)EGMI-1G:TD6ZN6N))+CGAC( Q)
M//(_E4,7[7D5EK&G7UIX2L].BM("EJ;:..,POWE78JGS">K[MQQSQQ7(>.?C
M#IGCCPMI,1A31+M&:*>>U WR!6#*S1K@*>2,\DX]A@ ]'U#6?!'@S6=2\/\
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MO5?3]/?4+A;6"V>XN7&(TC;!SUY'?Z<4M]/JFE:G)%=O<VU_;D1.LA(DC*<
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M-^6 V\C@<\C!KQ_0_ ">-=*N!I%G-=:G?7362VTDRP7$AD'[MTA4G(4YS\[
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MCW4K1"[CM'DVL,9+JH+(#N&"P&>V:3XR_%SQMXQU>]L?$>J$:5;W<LUO8:3
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MT!4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ'I,6LW"(EG:RARQBC17WKNC0MND5B27PH)#  Y+X'^-?LNKQ:IXE,6I:3"
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M;NOZ5A^)=%^&'C6[\.KX9U-],U/45C_M"&ZMUM[:TF+$.%R1E NW'/)SSVH
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MP&?S(Y3YF1(P;+'\177Q^(]NI1ZK%#;7JNB"[M/+\J$%2 "45N1^7- 'WO\
M\$6[*ZL_BW\2EO;22SN#H\&Y)(V0C]_Z&OUOK\CO^"+E]]N^,?Q0D\I(2=(A
M;;&6*\W!/&XDXK]<: "BBB@ HHHH *^*?^"O*._['EYM!.W6[$G S@9>OM:O
MBS_@KG*L/[(5P[*' UVQ.UAD$Y?J.XH _"Z6-HP-RE01N&1U%.M;.>]F6*"&
M2:1LX6-2Q('7@5V,OB32SX4ETZYM[V36GE"J9C']GMXAR-OR[R3G&. !Z]*N
MZAH=WI.GFT4&Q=@H-M*81<2E@"K)CYPA![$YH X>\M7TN[>!G1I4.&V$,H_$
M<'\*C(5\LX*#!PRC.3[U=U72Q9*I$4J,HVS"8KNW>RCD#ZU698VM T;,SX^=
M2F #VP<T 5,@9XR/>I61X&VNK(_]TCFI[/2[G4"!:P27#CDI&A8@5H>)3<:A
MK,S[9M@ ""7DJH  !ZT 0>'K@V6JIN98_-5HBT@RH##'/M6I'>RW'AF:S-JC
M16TIS/#!TSTW2?7H*Q;:W+20%MT.TY:3T /4<BN@\2.TYMM82&"&PN&^:VC5
MH@6!PP 9B6!]02.>QXH H:+?W/AZ0SV]_;AG7$EK.OF1R]0 RD,C8SGYJWK/
MQ#HUQ)I5KJAN3IJ-MN3!%%E022WEJ-G&3W;ITVU3\;6MAYNG-IAMQ'-9Q2ND
M!W!'QR"2,@GT)-<M%*(YXVEC9T5P656VDC/(!P<?7% '7OI^I1G4IM&:46-N
M&0Q%!YHC8\;E!/MSD_6LP>));&WV)I]O;7@962Y56$B8],G .<'.,CMBFIY4
MNH0Q7R3^;.4$4J2;GC!/'&!D_6KWB#P]J$^OWZ1;=2^R9+RHBK\BC[Q"G Z<
M\T :?@_PJ/$%[9:IJNIOIF@O*8KC4YXC<B ]/G12"5R1G'(!R >E8%T@MYM1
MGMA!)8EFMDN1$0K=P0I)*DX_6H+WQ8^I6:VMS9P".,8B: &-D'IU((]R"?>J
M]S)<+H5M;^;FU:5[A8O/W;3@*24['Y1SCD4 1Z19W>IW,4%I*PNP=T"&41],
MD[2Q'/' ')-=/K=JVCZ986EUI\=Q?+"992)%8H&)(\S9D[QD\,01C!7BN-C0
M2W"!V*Q@C+*,X'K73ZU=2ZY>2WKZFVJ79C19);R1WFE./F+%L\# Y)';&><
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MYK$\1:_X:TC0=7M="TQ;ZRUF**.>]UAOM=S;2+)O\V%Q&@0D+L.,G!/->I_
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M*Z?%&H>-1;M*\SD@;01T '))/;@9->J>&?$2R[XU?[5*H\I8[B,H\:CU..U
M'3:C]G76!/I]Q]JNI87,4<ZD[GVD?+U^;T^E>+^)-/LM*U4A)Y;R*7YL*@A;
M)4CDG)&UCC&/F Z\@UZ=JVL6?A[Q +5KJ 3VV'<BXV;#U.UE!.>W /TKA[[P
M?C3=(\2275L]CJKW +7/F1K%)&Q!4MU?@@Y4=3ST- %:QTZY_P"$=N9[&"Q#
MN LEP[E9E4$'$>2 221D!21MZ]:N'1O#E_'%;/J=U;Q1NLKWCQA8Y$)1'V(J
MMA@0>790<C@$<^DV^AWGB+X00+H6A'4(%U>[CMO$CNZ+;1PPPR,?*3<R'!/S
M.6&" !D9KR3QG\-M:\%*+N\\G[/,%8-'=0N^657&Z-'9@"&!!8 '\"* *-W:
M6'AF>18G34Y)-KVE[#(R>2P.?89Z9ZX(K'NKZ\6_DNIYY1?^9O,I8^9NSUW>
MOO6M;^(X+WP^FBW%NZ.]RTPN!*!&K$ #$>,+T.2#R-O'R\W?BKICV7B^ZFBT
MV"PT^Z_>V@LU;[/)'TW1DDY&0>_'(H S],\9WT;00WES--;1MN1@%9XCW9=P
M// _ 8XJI=ZU>O.7FVMN&Y9&@17([-N !S[YK*#LAZD$#C!Z5OV>MQ6FE36&
MI:5;W?[AEM9G!BD@9F#;B4P7[@!\@9XH J:67UC5;:*\E,D;.%+2.?E&<D ]
ML\_G7V5\!OVM_#OP)MDT.XTYOL<; ^="F]E//?@]Z^(D=F88R,<<5+=3S32M
M+)G<_)/UZ4 ?J-\3/^"HWAVZ\&R6>@QW=]JTMN4B#HZ1AN@R3SQ]*_,SQ;XL
MU/QKKMYK6KW3W=_=R%WD=LGZ>P]JS/M<@@C V@*2 1][\?S-++,DCR.X<LPS
MUS\WJ?7O0!$WRINW ENH':F*<_+C.>GK000!D=>>E.A@DFWE$9EC7<Y49VC(
M&3^)'YT /"HL7.\2ACNXX X_7K2/*91'$J@! 0,$\\YKJ+K3;/[38Z:]O<RZ
MI/:J/.4G][<.VY..=PVD)QC)P?KSUTD*1I%&C^>.),]S[#'% "1:A<):&T$S
MQVDA'F1(V%<KG:S ?>(WM@GU(!K[!_X)CZK&?VM/ &DPZ5')-%>WD[:FKY*Q
M?V=<*$*Y902V#N4@\D'(QCXW,BAAY(:,;0#O8')QSV'!YX_G7VW_ ,$F]=\.
M0_M8Z?;Z@\^FZM>VDL>E6\$;2VT\BP2&4/ELH^P,ZN<J )%P"RX /W(HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\
MB_\ @K)H^D6'[2&C^(M0L[CQ'(OARVC.@VZLBF)+BX9Y)IE^9$(;'R<\'E>_
MR)H'[7/CSPIJGF^!8=)\$M]B;3+:#0M)B,L4#-N94N)A).&))^?>7]P *^G?
M^"R,5D/VB?#\QEE6]_X1V"/&\*B@SSE3P,YX;J>W'>OA*]U5]-TZ&SBECN?/
MC#-<- %8#.0 >IY'4^G% 'K?P[^(.N^//&']M?$+7M0\1:=ID9O;W^W;B\NX
M'\L-Y*2^6X92TC;%8NH!?)(R36TMS\3_ -L_XEW&J7EW/*3Y:3S2+':6%E:H
M"0I("JJ*H./7!/)-<GXQO[KPC\(M$\.:'9Z[8V?BA5U#59[R!8X]4,3?NU3"
M;RB.22N]E)5&P#@*[X/>$M>\46MVV@17<MW9VEQ<2):6GG"&%!DNR@.7 RPZ
M#Z^@!R7Q4\91>*=?CT?2+""UT33Y6AL8[.("29CA3*[[0\A<KN&[D X&*[KQ
M]X6TOP-\._#G@?4$-EXVEN)=2UUM0MKB&6PC,:B"&1&7LI=_E!SO7TKB]&T[
M3_%.L1P102:=9VJINFC#2#=T+ $\%VQQD $XXHF\81:)J^H6D%G8:E,281=P
MJLH48 ;8Q!63&-H)R",D=0: &>!;34O$ETFC:+%+):[F9EDE)A>0*0&*G"CC
MN1GFNH\!Z]J-IX4U6PMKV*ROM)O(M32VMX0KL(PR2?O$(QA9"<$-G!Z5DSV&
MI> /"%WJ,VFRO::W ;:QO9V.P\ S>65<9905!&#MW#(&157X2>%-2\5^*]&3
MP_%8W.HS7)5K&:Y6 %3@;2TK@,&Y&,T =S^TKXLBUV[T/4=#N!;^'=2MS)'I
MT4\S06]T%"RMMD0*'(*Y\M0,;<5Y9X"\3CPWKYU2>_U+2KBU9)HI=*VJ=ZD%
M1M)48Z>OTKTK5/!5]KFB:_:Z9"UK<>%[N]O+G3A')NMH00,L$!*D8 R<*.Y'
M?RFRM-%N(8Y+_4GLWD5W0Q1BX9Y!PJORIC4^OS>N#B@#W']HWQ)8?&C1-*\7
M76F'3/'YLXO[2@A"JEY$6;;<>4$!#GC<2QW<'BO*/ 5G!ID]P9[2.Z:10$9Q
MO,1&#N!SC/L0:[ZV^,E[9^.M-U33[[4+6'3[ 6B/;ZGMG$.P1LB2^661>7?8
M 3\W S6QX^^$<7@'P]I/C>U\1Z3-X2\22R?8+6)II+J'8,$2[HAC)!P3@MG)
M5>0 #,T"2PU2ZDMKN..>-,X++ANGITQG^E1Z7H>A^,+N^\(ZFK:?=2[Y=)NH
M)X83'<=DD\UE4HX&W[RX.#GC!Q9/$6FZ3H3W^FZA#<REQ$R'_6[CD_<X., _
M,.!P,@D"O-;?Q%>V>OBX9%@D$@WK+'N*\Y_CS@^] &A!OT9XMMF5:7,,B7 $
MC2$]1M/3H!P._P!*]=C^(WB+19=+\-VFF:C9)-;L+S38RS+>JYP@=  5"C
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M*%6;[.WNJN W/?(%6-4NHY_%%O::'&8X(G2V@-HDB/<-PAD*%V.]^I .,G
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MTSPC93O%8W,%UO1;HQ*9D! _=["2$ QN4@#AB>^*QO#OBI_"EM<10BVU.VO
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MI5@]Y-:3701_+P"P191M)(QA5(8D\5Y/XUEM_$_B^_U'3YS]ENV>6#SX?+;
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M]IO/*>1[VR@CAED8+QN"A0Q)Y+')/J:R_'OA<^''TYDCCCBN;.*;,=Q'(&+
MGHI.WZ'D=ZKZ9:VRZJ;:[,MO' D@?S8R_P P'3: #R?7I67J\JW1@G^U_:79
M &CVD>5C^'GK^% 'Z2?\$3)HO^%D?$6*/#8T>W;=SG_7]#7ZYU^17_!%*6%O
MBK\18X I1-#M_G";68F?G/K7ZZT %%%% !1110 5\3?\%?1G]CNZ_P"P[8_S
M>OMFOB;_ (*^@G]CRZ Z_P!NV/\ -Z /PT4A >"0?4U:L=2>QF$J1KP"#AF7
M=GW4@_EZ5%':222*F.6.,]:MW&C7$"%5.X8W,HR#Q[&@#/$DDS!?O,Q].2:N
MW^BWFE[1<1E&(!QG.,],UT'PY^&^M>/]<M;73+:0H9TCDN,86/)ZDU]K_M<_
MLG^$OA#\&='U%/$L5]XBEA1V@AMC@\#)W]OQYH _/Q(I"^1\A!ZYQBK%X7GE
MW23/(YY=Y#DD_7)S]:AW>2YR-^#T[&I;^ZDN'4R%6;:!\N, =AQ0!-<W"Q6E
MM#!<F554LRD$!6/;!'ZU1)/4'![XXJ65(]L81@S<AB <?F?\!2R0M&@9@ .V
M.] %G65LC/";!WDC\E#)NS@2X^<#/.,UI>';RSMD\N]MDNH[A3 S<LUN"?OJ
MN0"W'3.#FN>;Y6.>M7K R7,2VP\M8Q)OWL%4Y(P 6].._ H C*^3?21(=\>2
MH\U0I(]2,G!_&MJ$/<Q0%2;PQ ,RJI.U5' YQP.]2WFFSZU/9+%I?V.6WB6&
MY*.V'(_Y:<YZCDX)'?BI_$LMA!IPT^R&%23S'D:W!;.WH)<!BOH,8ZF@"CJW
MB.YOM,%G(XEVR[S*=QD(VA0,D_=  P.U=U\!_P!HKQ-\!]4>[T2;="YS):2,
M0C_EWKR,N3SFD#'/O0![)^T#^T]XJ_:&U"V?6BD%K;G,-M$<A3ZD]S]:X)?&
M=U;6IL#:6!4D[[G[,C3G(''F')P" >/<=.*R="BM&OE-^LC6Y5O]2V&!P<'H
M> <9HD%I;:B9/WLT ;*@X#'Z@C&#0!8T:^>TU:/47V3+:3+,VUUC9B#D;?Q'
M85'?ZT^M:M<7^HS3//*[2^8N#(7)R"6[_6JZ7*K9W,31 /*ZE6W?= SD8QSG
M(YXQCWJO#'M)>3;M''//Z"@#1 T)K"0R2:D=0.TJPCC\K/\ $"-V?H<_A3(]
M,MVLA*]Z8W9AY<#0-F0="5/3C'K5'S47(*JP(X)!!!_ UT7@G2HO$>JB&YNV
M@%K ]PCM*L:_(-P7<W"9/3WP,9- '5ZI=VNH>$_"6@W T^VM]\B0ZFAB^TJ6
MDPQG"X?8&R5\P9 Z$C KB/$7AV+0-8U"P?4(;HVDAC%Q;$20S8)Y1E)# ]B/
M6KNKMIVI7%W?R7[?:9#O"LI#,Q)!  7;QC).X#GC-6);V]\9M8^'M/!GM;=R
M;.WCMTC9Y'95)<@_>8[1DL0. ,#B@#-6[T&!3^[NK]PHVR7("!>>@16.?J6_
M"G2Z[:P1V\D+2WEPD>SR[J%%AC .0%4$[NIZ]S6Y>? _QQISR17WA'5M/>.=
MK:2XO(#!;Q.I 8/(X"IC<,EF &16!XH\'S>$K@6UWJ.EW5SM#>7IE]'>*,^L
MD1://'3=F@"*ZUR"[BDG;3[>*^>?S1*F2H']T(<C&?7/TK.FU*YGG\UYY'D_
MO,QS[5 Z[7*[@V.-PZ&I+>00[CY:R%AM^;/RT :U[X@GF-L9KR;44@11 ER=
MWDA< +SGC Q@>U0G5Y[N5O.;_16<L;= 0F3Z =_2J&T3,/I]T=!5J),E%P<
MY '8^M %6101O4#9G&W//Y5(UA)!#YDV$VL 8F<*_(SG;UQ[XI)-]N)8&D9!
MP2BG(8CUY^M,M[Z6VDW(^#M*990V >N,_4T $DNU#Y4A56)S&&)P..O'L/RJ
M)F:.7(RC Y]"*5,*^20O<8 85(D3%G9<2[/09!_"@#;\,6FEZ]/<VFK7SZ?/
M)&SVEWY1D5I@#B)P.@?H&P0&QG"EF7Z1_P"":>FSV7[:_P ,))8)(0;O48][
MY 8C3KC*@$=5SSS_ !+QW/RE<; Y5"=B]#GJ:^S_ /@G=<:/=_MM>"I+6WDM
MY(KZ6WMDDN0Q9%TJ]$DC+C+,S(ARIPNXC'*X /W2HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y:_:3_X)Z^ _VH/B
MG8^./%&M:Y:WEKIT6FBRL)(E@=$>1PQW(6SF4]&QP*Y35_\ @EC\,]=O[>YO
MM7U.86]FEA%;K:64<2Q#=G*I"NYSN/[P_..,,,#'VA10!\46/_!*KX<:(FKC
M1?$_B/1/[2ES,EF\/E^2593;['1E:,[LD.&^Z.:B\"?\$I_ ?P]U^QUG3/'7
MB_[?8S?:+5VEM@(7[E5$0 !."1CL*^W** /A _\ !(GX="265/&7B5)Y)#*9
MA#9&13G/RMY&5YYXJ_\ $O\ X)4^$?B_K%AJOBSXD^,M5U&RLHM/AN'^QJ_D
MQYV!B(!N(W'DY/O7W!10!\!6'_!&[X76,L3?\)?XHF5&W,DHM&\SG//[G/Y8
MI=7_ ."-WPLU40)_PE_BRVAA!5(HI+<J,G)^]$?\BOORB@#X?3_@DS\-+3P0
M_ABQ\6>*[&RG827<D4ML7NG!RI?,/0=@*YVS_P"",OPMLYX)%\9>*F\J43!6
M%I\Q'8GR,D>W2OT"HH ^)?$7_!*'X7^*(=4-]K.M->WTD;"\B6")K=%Z1Q1I
M&(T4]_DSR>>:HZ3_ ,$C/A=HVDWMI#XD\0O<749A:\ECLVD2,J00O[C /(.[
MKQWK[HHH ^(]4_X)2^ -:\%Z3X9O?&WB^XT_27>2Q#SP,("^-^%,17G:.U<M
M!_P1E^&=O*DB>//&0:,EH_GM/D)[C]SP>!7Z"T4 ?"5O_P $B/AM%Y+2^,O%
M=S-""$EE:U)Y.3N_<_,?<U8\9_\ !)3X;^-Y[>6[\5>(K0PC 2R2UB1NF21Y
M77@5]RT4 ? .E?\ !&_X9Z1J<%]#XV\6L\,HE1':UVAATZ0@_K45]_P1H^&F
MI7+SW'CWQG(SL6;,EKR3U)_<\U^@=% 'YZR_\$6?A3*J#_A-/%X91C<'M<GZ
M_N:=/_P1?^&%S$$E\=>,9,'(9GM2?3_GC]/RK]"** /@K0_^"/7PQ\/7"W-G
MXN\3K=+TF<6K?^.F';TXZ=_6I;?_ ()$?#RRT2;3+7QSXKMH9V8S2HMGYT@;
MJID\C<%]@0#WS7WA10!^>UG_ ,$6OA997"RIXW\8;@<_ZRU'\H:U]._X) ?#
M73+F]EC\:>+76\0QRQR26S J3DC/E9_6OO*B@#X+?_@CU\+GL-8M_P#A+O%:
MMJ;(7D#VN8U5LA5_<]. .:HC_@C1\,3H9TI_''B][42^>F3:;D?&"0?(].U?
MH%10!^=Q_P"")WPJ/7QSXQ/;[]I_\9JS'_P1<^%,=HT'_"8^+"2"!+NM0XS[
MB'G\:_0BB@#\]E_X(N?"T6RP'QOXO9%)()>UR,^G[FEMO^"+OPLM',D7C?Q@
MLIZ/YEKD?^0:_0BB@#\^M0_X(R_#+5+I[BY\=>+WF?&Y@;09XQV@JHO_  10
M^%:D%?'/C%2.00]I_P#&:_1"B@#\][W_ ((O_#'4!%YWCOQBQC& V^TR1[_N
M:J_\.3?A3_T/'C'_ +[M/_C-?HE10!\R_LG?L&>#_P!D3Q'KVL^&O$&MZQ/J
M]HEG-'JIA*HJON!7RXU.<^M?35%% !1110 4444 %>4?M,?L[:+^U#\,9/!&
MOZGJ&DZ>]Y#>&YTPH)@T><#YU88.[GBO5Z* /@W0_P#@C]\,-$+'_A+?%%X[
M+M+W36S''I_JNU7=2_X)*_#B_G$D?B[Q/9X4+MA-MCCZQ&ON6B@#XR^&?_!+
MOP%\,-:N]4L/%WB:[N;CK]I>WVK] L0KN_B_^PMX.^-/A[3])UO7-;BBLHO*
M2:WDB$C+UY+(1^E?25% 'YX2?\$4?A2^0/&_C%5)R!OM./\ R#3?^')_PJVX
M/CCQB?\ @=I_\9K]$:* /SM'_!$[X5#_ )GCQC_WW:__ !FI6_X(J?"IL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cgtx-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &U S(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDDMNCM;^8X43(2/D96.<J1Z5I.48IM1O8PIPG4E&+G:YP7_"6:Y_T&]3_P#
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ML!FE&A05*HG==CX/-<AKXO%2KT6K2MOZ6/RQHK]3O^'</PA_YYZ]_P"#0_\
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M +:POG]W_!)_U:QO=??_ , _+&BOU._X=P_"'_GGKW_@T/\ \31_P[A^$/\
MSSU[_P &A_\ B:/[:POG]W_!#_5K&]U]_P#P#\L:*_4[_AW#\(?^>>O?^#0_
M_$T?\.X?A#_SSU[_ ,&A_P#B:/[:POG]W_!#_5K&]U]__ /RQHK]3O\ AW#\
M(?\ GGKW_@T/_P 31_P[A^$/_//7O_!H?_B:/[:POG]W_!#_ %:QO=??_P
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M(W8P%^4#L..E31>.O$L$=A''XBU>./3U*6:)?R@6P(P1&-WR CC"XXK]8/\
MAUY\%?\ GGXB_P#!L?\ XBC_ (=>?!7_ )Y^(O\ P;'_ .(H_M7"]G]PO[<P
M7\K^X_)^Y\<^)+V*2.X\0ZM<1R##I+?2LKC:%P06Y^4!?H .E5M6\3ZQK\%K
M#JFKW^I0VB>7;QWEU),L*]-J!B0HX' K]:?^'7GP5_YY^(O_  ;'_P"(H_X=
M>?!7_GGXB_\ !L?_ (BC^U<*NC^X%GF"6T7]Q^2-QKFI75Q:W$^HW<T]HJ);
MRR3NSPJGW A)RH7L!C':M"?Q[XGNG=YO$FL2O)$\+L^H3,6C<Y="2W*L>2.A
M/6OU>_X=>?!7_GGXB_\ !L?_ (BC_AUY\%?^>?B+_P &Q_\ B*/[6PO9_</^
MW<$^C^X_)P^,_$!F,IU[5#*;@71?[;+N\[;M$N=WW\<;NN.,U7D\1:M,EVDF
MJ7LBW:+%<*]RY$R*<JK\_, >@.0.U?K7_P .O/@K_P \_$7_ (-C_P#$4?\
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MBDZ1_P!\S?\ QNOQ!W'U-6-/L;O5;V&SLH);JZF8)'#"I9W;T %']C4?YG^
MO]7<.OMO\/\ (_;;_AN?X$_]%)TC_OF;_P"-T?\ #<_P)_Z*3I'_ 'S-_P#&
MZ_'#2_A%XZUR\N+73O"6M7US;OY<L5O9N[(V-V, =<<\=N:Q]:\)Z[X<OY[+
M5-)OK"[@C6:6&>%E:.-L;7;CA3D8/3D5"RC#MV4W^!"R'"-V51W]5_D?M/\
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M?AT[J/XONGU\TM=]#99WC;<LI77HET:6R6RD]-M0HHHKTCP@HHHH \U^)?\
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MGW%^E?(9S_%CZ'P'$7\>'I^HZBBBOGCY,**** "BBB@ HHHH **** "BBB@
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M ,%[T>WI?SK[T'U7$?\ /M_<SS.BO3/^&9/BU_T3CQ+_ ."]Z/\ AF3XM?\
M1./$O_@O>CV]+^=?>@^JXC_GV_N9YS9W<UA=0W-M*T,\+AXY$."K Y!%6-4U
MFYU:\FN92(VE8NZ1$JFYOO$+G R>3CBN^_X9D^+7_1./$O\ X+WH_P"&9/BU
M_P!$X\2_^"]Z7MJ-[\R^]%?5\2E;D=O1GF@=E((8@CD$'D5-%?W$*21K/*(I
M#F2,2,%?_> /->B_\,R?%K_HG'B7_P %[T?\,R?%K_HG'B7_ ,%[T_;T?YE]
MZ$L+B%M!_<S@M9UNYURY2:Y*@11K#%%&-J1(O15'850KTS_AF3XM?]$X\2_^
M"]Z/^&9/BU_T3CQ+_P""]Z%6HI64E]Z!X;$2=W!_<SS.BO3/^&9/BU_T3CQ+
M_P""]Z/^&9/BU_T3CQ+_ ."]Z/;TOYU]Z%]5Q'_/M_<SU/\ X)U_\G%6_P#V
M#;C^0K]5*_-[]A;X+^/? OQU@U/Q%X/UG1-.%A/&;J^M&CCW$# R>YK](:^*
MSB49XF\7?1'Z=P["5/!<LU9\SW^1^2/_  5+_P"3A[3_ +!,/\S7QO7Z ?\
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M_%]Z/*,9JQ;7]Q90W$5O,T$=PH281G&]0<X/MGM["O3_ /AE#XR_]$P\4_\
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MG)8/,SV<<AF2%L$(Y&"1GIG SCKBJH '0 ?2O5_^&4/C+_T3#Q3_ ."UZ/\
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MY4M% ";%_NC\J-B_W1^5+10 ^W4"=, #FM.LV#_7)]:TJPJ;G;0V90O5!FY
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M1KGJ;G;0^$****R.@**** "BBB@ HHHH **** "BBB@ HHHH 0]*_+GXT_\
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M .OFU_\ 0):^I*^6_P!A+_D!^+_^OFU_] EKZDK\@SO_ )&%7Y?DC^E^%?\
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MQTOPU\=:IXQ\5>(TNK>6RTV*VL+BRMY_*+JLT<C,24)_NJ,$G!![&I;3X!>
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M 1R,T ?/#2_%N/[6%GU7?;7)^R,]M QN;#[/E3+@;1<;P>%'7 Z$BLG0M?\
MBY;>(+JUUFS\1W'AF:> +>6UG%]LA:2UR2H&/W:S<-E3MSR,5].X'I1M'H*
M/G+69/'O@\:RVB:9K)EOM2O'9[:RCF:1C;IY4AP,8+J>1@9XZ5PGB5?BYKWC
M/P[JK^&M2F\0Z+-?SV\S6^+1;:2U01 -POFEMX*G^+ .!S7V1M!["C:,YP*
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MUA)=Z?!?3NR2JK*A@#JJR0X8&3YF^9>2",'ZUI,4  Z>E+110 4444 %%%%
M!7SK\4/ASXTO?'%Y=:!I-W/;27S7Z7EOJJPJ%.G/ T01I%.XS!#C 7HV<YQ]
M%44 ?&&O?"KXN:[>:_:R>']2E\)ZC!&LVDW>KV_FSW#6 B,BL+D@*DR[F4D;
MMP89((JUI'P=^)WA[X?:EH_]BZG)KMOX>2STO4=(UZ*WB4_9T0VI1I0=RR!F
M\SY1U(;)VU]BT4 ?,NL_ 'Q38:I8:MX801_NK*YFM-4U.>29;I08IUW>:04,
M;E_O'YT&,<&CQ%\++W3M:UI=8,WA[P(^G7-C/JC:RQ5$VPBU?F3S 5??@<8(
M_BW9/TU10!P'P3TK4K3P/:WVM0QV^LZDJW-W'"S%5;:%4#< 1\H7K^9ZUW]%
M% !1110 4444 %(PR*6B@#YMT/X/>*?#WP_MOAT=+&LQ0^(UUIO$=[)$;=H%
MU'[;A8_-,OG\! "NT$D[\#!\E&C?$;X;^#C=^,+/7],%VEE;:C-<>(+1HKUQ
MJ,DCQ%WN&6,/;-L+GRP0H7>. ?NRB@#Y8\*^#/&GB;2O#KVLNOSQV?V%]-U[
M4]0A#V_EW6;OS%AG998YH/E1D:56!7=M(W&OJ/@GXGR:=!.OA[76U"VDTR6'
M?K-N0ABU:66XR/M6"3:OMYSD-MXQQ]7T4 ?.7[-?B*#7O%VNW%IJ&JW<3Q%9
M5EO+:X@ED$\I%S(J3-+%,\;1IMDCBXB^[V'T;110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 AZ5^7/QI_Y*]XT_["]S_P"C#7ZC'I7Y
M<?&DC_A;WC3D?\A>Y[_]-#7W?"?\>KZ?J?D?B-_N=#_$_P CC**,CU'YT9'J
M/SK]-/P.P449'J/SHR/4?G0%@HHR/4?G1D>H_.@+!11D>H_.C(]1^= 6/LK]
M@3_D#>,?^N]K_P"@R5]8U\G?L"$'1_&/.?W]K_Z#)7UC7XOG_P#R,JOR_P#2
M4?U-P?\ \B+#^DO_ $J04445\^?9!1110 4444 %%%% !1110 4444 %%%%
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MG@UT7AW0-/\ "NBV>D:7";>PLXQ%#"97DV*.@W.2Q_$FFD[ZB;5M#1HHHJB
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M)8K.*-HD(4Q0J& ZD# [GL*+/N#:[%FBLA?$MN^G172VUZS.4!M!;,;F+<<
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M:3I6J1ZC>7+7";8%;]TT !D5\@;6&Y>#@G<"..:TNC&S.PHHHIB/+_BSX?\
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M=%%%?II^!A1110 4444 %%%% 'V#^PE_R _%_P#U\VO_ *!+7U)7RW^PE_R
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MCE0N9GD&F_LW:;I4.LV]OXAU06FJV<=O<0M#;,1(L*PF97,>]2RHF4!V97(
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M\V]5=B0&Q&1GGL:^R**]+ YA7R^3G0=F_*YX>:Y-A,YIQIXM-J+NK.Q\,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cgtx-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '= LP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM.#MD0]&!(!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?X3?#CPYX,LM4U#6;#0;*/3[2[U3R3<&",;8D<PQQH=B!4!" D("Q9B6/5T
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M#PC+J=G'=36VK/:AK-F3=LD59C(#GC!C# D;E0Y [FBBO3C%QO=W^[[M$O\
M,\F<E*UHI>E]?/5O_+R/E+XU_M(>(H/@9X\U)-)CT"&^'C'PYHFI:7JLDE[;
MWFEVNI-'=./*C$8D_LR[8!'9HF6#!D\US!V?C[]IJZ\#_$<>'/\ A'!J5HOB
M+2=!DNK3[=,L8OFMD$LT\=FUK;2QO=1_Z--.KR1LD@9=\22WO#_[)7@>UM?$
MH\0VUQXIN]=N->,TM[>W7E6UKJMW/-<06T)F9+4F.<1/) (VDV;C@M@;^J_L
MV_#O7/&%SXFO]"FNM5GU2TUQEDU.[^RIJ-L8/(O([;S?)CN MM$AE1 [)O1B
MR2.K69G":O\ M1Z[I'POT3X@_P#"$V=SX<\0Z3::EI,4&KRR7YDO+ZTMK.&:
MUBM7D.Z.^BED:W$Q1@\2I*?+>6I#\8O&_CW7_!,FG>&KK08XO'%UI!75C?:3
M'J^GKHD\XNS!=6L4P D<#R=CCS+<XE*CS!Z!:?LP?#&RTS5M-C\+HVFZC$\'
MV&6\N)(+&-YEG9;&-I"M@#,D4N+41?/#"_WHHRMNX_9Y\#W/A^UTA[+5 MM?
MMJD>IIK^H)JANS$8#.VH"<73OY!\G<TI/E 1_< 4 'EMQ^UUKMQX?\=:OIW@
MBP:+P)X<EUO7(+S6W1Y)X+[4K.YM;9EMF#HITF[D2=MOF9A4Q1^8[Q>Q>)?&
M%];?%CP1X1L#'"NHVFI:S?2RQ[_,M+06\!A3D;7:?4+9]W(VPR+C+ BGKG[/
MO@#Q#%I<%SH @LM.LHM,2PT^\N+*TN+*+/E6EU;PR)'=6Z;G"P3K)&HEE 4"
M1PT_BOPEJ4WQ>\ ^+=.B2YAL;;4]$U&.1P@@M+I(+C[0O.6<3Z=:Q;1_#<.W
M\% '$^$/VHI?&5MH<]C\,?%C_P#"2>'F\4:!;+<:7Y^H62RVD;@AKQ4AE O8
M)=CN 8V'S>8&B76\0^,-6\3^!]>U36H_&OP*T_P_&=3NM9F.AW4D]M'%*TP"
MJU^H1 H=LHCY";21O%6++]FCP0FA>"M$U2P_X2;1?"OAEO"EMIVNPP7=O=VI
M:P</<1M'M>56TVW8$!5!+';G;M=J_P"S-\/9OA]XL\'^'?#FG?#_ $WQ3:BQ
MU>;PAIMI83W5OR&C8B$J0R/+'DJ6597V%6(8 ' ^ ?$WQ(\$_#OX:>*_&^O:
MKJBZ]KRVVLZ=K5G:17.G66I2>3I<;)!:V["ZAF;3XI>"H-S>DJP6$Q?2->??
M%3PIJGCK5?!.C00$>'H-:AUO6KII$4;+(BXM8$Y+^8UZMI)PNPQ6\X9U+(LG
MH- !1110 4444 %%%% !1110!\U?MVW_ ,+++X<>'X_BSK^C:#X<NM:A@D_M
M;0IM7>YAP7N(;:.([K::2)&C%Z%9H5D?85>16&5_P3HU+PWJ'P?\4IX5\7:?
MXXTJV\32PC6M+\%6WA6WE?[%9NRI:0!=VW>%,LBJ[$%<%$1FN?'C]F9_&OQ(
MMM?A^)?QPT^;7+V"#^R/!'BJ"PTS2D6%8GN!',%"( N]UC9Y7+R,D; -MWOV
M.K?3M,\.>/\ 1]*^(^O_ !1LM*\5RVB:WX@UE=7D3_0;)_)CNEP)%7S,L B>
M7(\L>&V>9( ?0%%9J>)M'DN[VT35;%KJRE$%U MRA>WD,:2!'7.58I)&^#@[
M74]"*@\/>,=&\5W>MVVD:A'?RZ+>C3K\1 XAN#!%/Y>[&&/EW$394D#=C.00
M #9J@^@:9)KL6MMIUHVLQ6SV<>HF!3<) [*[Q"3&X(S(C%<X)121D"K]% 'R
MO^T-_P GS_LD?7Q;_P"FN.OJBOE?]H;_ )/G_9(^OBW_ --<=?5% !1110 4
M444 %%<_XU\-:CXJTJ*TTSQ9K'@ZX282M?Z)%9R3.H5@8R+NWG3:20<A V5&
M& R#Y_\ LKOXEUWX+^#O%_BCQMK'B[4O$_A_3-5EBU*VL((;.66V6618!:VT
M)VEI,8D,A 1<$?,6 /8**** "BBB@#E_&WQ+\.?#I;1O$.H-8+=;_)*VTLP;
M9MW9\M6QC<.N.OL:M^#O'&B^/M,EU#0KMKVTBF,#R-!)"0X56(Q(JGHR\XQS
M5'XL?\DL\9?]@:\_]$/74Q_ZM?H* '4444 %%%% !1110 4444 0W=REE:S7
M$@D:.%&D80QM(Y &3M1068^@ )/0"O$_B%\0?$'C+Q-;^&/!VL:AX/M+>T%]
MJVKS:*\5^1([+;16:WD)AY,,QE=XY-JB-54-+OC]RKB?B3\*--^)']GW3ZCJ
M7A_7M-$B6&NZ/)&MU:I*4\Z,+*DD4D<@C3<DL;KE$< /'&ZZ4W&,DYJZ(FI.
M+479G#_#WQ_K_A#Q!=>&O&&K:CXPM9;7[;I>L0:*\M]A7"SQ7BV4 A&#)$8G
M5(]ZF12I,)DD]HM+E+VUAN(Q(L<R+(HFC:-P",C<C ,I]00".A%<A\-_A3IW
MPW%_<IJ&H^(->U(1K?Z]K#QM=W21%_)C(B2.*..,2/M2*-%R[N07DD=NUHJ.
M+DW!6004E%*3U/)_VA?%?C3P?IGA*\\+3:99Z;-XHT2QUFZNPTERUM<ZK9VI
M@MX]NP&1;B3=*S914PJ%I!)%Q7BSXB>,+3QQXMUNU\236ND>&?&_A[P?%X:2
MTMFLKV&__LKS[B>1HS<><HU9]GE2QH#;Q;D<&0/[OXF\+:7XPTZ&PU>U^UVD
M-[::@D?F,F)[:XCN8'RI!^66&-L=#MP002#S>N_!7PMXC\2_VU>6]X)7OK/5
M;FSM[Z:"TN[VT*&UN9H48+))'Y: %AAA%#O#^1!Y699Y5\*_BGXOU.7X3>+M
M9UK^T=$^*OG^3X>6. 1:%OLI]0L_)E2)9)-MO;213^:S[I75X_*53&=OQ'^T
M7KNC>,O$^G6W@-;O0/#_ (DTWPO<ZU+K*1&6ZU""Q-H8H!$S%5GU"))BQ79&
M5DC\]B\4?>>'?@UX8\+^*E\065O<F]A.H-:)/=/+%9M?7"W-Z8E8\&6958YS
MMP538I*F[>?"WPQJ']L?:-,\S^U]:LO$-[_I$H\V_M/LOV:;AOEV?8+7Y5PK
M>5\P.YMP!YGX>_:2UCQ6NG:9I'@F+4O%Z/J\FKZ/!K 6*V@T[47T^;[/<20J
M)II94)@CE6!'"R>9+#M^;TSX3^.O^%H?"SP;XR^P_P!F?\)%HMEJ_P!B\WS?
ML_VB!)?+W[5W;=^-VT9QG Z5Y?\ %;]GJXO6TR?P'I>FP7<0UM9)KWQ'J^E2
M02ZG<1W-Q.LEE)NG0SHSM:ML#$IY<T'EX;U?X:^"+;X9_#GPKX/L[B6[L_#^
ME6FDPW$X DE2"%8E9L<9(0$XXR: /(O!O[0NKW&B>%+Y_"WB'QOJ?CZVU#Q1
MHNF:"-.@73]%BDMDMO,-U<P8=H;NSD=2\K>=-.%*QJBKUEE\=+_Q!X5\*>)/
M#'PP\8>*M%\1:+::U;W.GSZ1#Y"7">8L,JW-_$PE52I;:&3YAAR<XH_"3X*:
MAX)D\ R7]]"$\#Z#JOA&PMXD\PW6GR75E]AGDDR,3+;:= )0$"M++(5VJJ@O
M\.?LK_#J'P!X(T#Q?X.\+^/=2\,>'['P_'K6MZ#;3S2Q6T008\Q7**6WOLW$
M N>3DD@'%>)/C=XCT#]HJWT%M6@33[CQ-:^'8M)NTCATLV4NEI=M<-?")BNJ
M?:&=([,R[I(?*/V=5E%V/5O@_P"*M3UJT\3:%KMQ]OU[PGK4NBW>H+&J+>(8
M8;NUF.T*/,:TN[7S=J1IYXF"((PF>:NOV>I7UK[':^)I++P!)XB3Q=/X=6S$
MER^IK=K>D+=NYV6K72+<F$1^9YA8"982(1T_PI\)ZEH-SXXUC6(!::GXE\27
M.HO;1R*\<<$4<-C:,I'_ #TM;*VF8'E7E<<8P #O:*** "BBB@#YX_;;T;59
MOASX:\2Z78KJ@\)>((]7NK#_ (2YO"TMQ"]I=66V/4@5\E@]XC$%T#HKIDE@
MK>9_LQ7OBKQI\:X?%FJ^ [/5;&TT/3/#%OXTT;QO9:ZMBEO#?W,T=U.LBW$T
MS&]LH9(S&R/+$+@MA8FKT_\ ;;\.R:W\+M%O$B^%KKI&N17SO\8)94T.,&WN
M(,D(0KRYG"JL@*_,S ;U0AW[%$JM\+]70'X/[EUJ7(^"H_XE',$&#+_T\_WC
M_<$7I0!Y]^T,W[2?@[QQXN\2^$/B+\.? WPQ,]J8I_B%>-&(Y#;P1N4?RG6*
M-I 5",RDOO.WYP6]-_8]\4^-?&'PZUG4/'?Q#\#_ !)U7^VI(X-1\ 7:7.GV
ML M[?%NSK&G[T.9)"&W'$J\XP!Q/_!1'Q%X=\,_#GX>W?BI_#-KHO_"90+-?
M^+M"GUNQM<6%\VYK*%@9BX4PX8$*)BXV.B2)TW[$'B[P9XS^%6L7O@:[\%7N
MCQZW+"\O@7PE<>&[/SA;V[,)+:=F9I<,F9 <%=@ZJ: /H:BBB@ HHHH ^(?@
MEX-\<^!_^"A^IV'Q ^(A^)FLR?"Q9X=6.B6^D^3 =6VK!Y4)*MAE=MYY/F8Z
M**^WJ^7X_P#E)Q<?]D?B_P#3U)7U!0 4444 %%%% !1110 4444 %%%% !11
M10!E:[K-WI'D?9="U#6_,W;OL,ENOE8QC=YTL?7)QMST.<<9^:[#P[=_%&*\
M\3:OXS\6VVKW%Y=)#;Z/XAN=/AT7RYGC%G]GMIOL\TMNR-'(\JR^9(DF<Q[8
MU^J:\Y\6_L]^!/''B.?6]7TJ[EN;K9]NM;;5KRVL=1VJ$_TRTBF6"ZS&J1-Y
MT;[XT2-MR*JC>C.--WG&YC4A*:M%V*OP,\?Z_P"+_ GAN76-)O\ 4)9+<Q/X
MI1K-;/5%C+(E_&D<Q98[E469%5"%$RC) W5ZA3(HDMXDBB18XT4*J(,!0.@
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MFE2,!8L@AIC<2JLH[7QEX2U&7XE>!_&.DQ)=2Z6M[HVHVTC@$Z=>>2\DL0.
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MWOM,LWO9-3>2VMXUNKD0Q$P[6!MR\I*JENC,ZJ5"\S\!9;H:K\4;+5;;3/\
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M-%,PCQR9&($7F9&>S\)>*=+\<^%=&\2:)<_;=%UBRAU"QN?+:/S8)4$D;[7
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M^ ?@SQ?X=\?Z#K^F'6M%\<7RZAK%E=R'8\JVUM;J8RN&3:MG P(.0Z[@0<8
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M&B>)-=U/P]INM^;;F(W-BMVTC2()-ZQ2BQG,+H'W!<N(LINUO&?B#4+CXP>
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M46U'I%7?R1UX3#2Q=>-",E%R=KR=DO5L_9NN>\5_$+PUX'DLH==UNRTV\O\
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M2UOY="6Q\/Z?J>F7_A^-[+4(VN(X[JYCFF:6430S3L))("OE,R+N5@J@9_P
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M7'XY\.W%[:!K3Q#>7<EM,D:0W<9BDN'5FC6\C20%3Y9G0-M8K5GXR>(/VHM
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MMY8U<[RX>;YXBZJ8<$D.K55_X2+Q(?#YN_\ A$G_ +3&L?8O[..HPY-E]O\
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MM6\8_;&T$WD=XBK_ &1ID?FI<1*L<P=HW8LHX<NI.Y6KK/BK\)?$?BE;W4/
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M/".G!3XI^P?\(MJ-U=[_ /B5CS/-\^"+;C]WMV[LY;.,#/W+0 4444 %%%%
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M7HM9>E_\A;6?^NT?_HI* -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M18E$11L[EV8Q@Y.1CG-6U4(H50%4#  Z"@#XA^"'_"T_^'A^I_\ "W?^$/\
M^$D_X58OV?\ X0K[5]C^R_VM\N_[3\_F[_-SCY=NSOFOM^OE^/\ Y2<7'_9'
MXO\ T]25]04 %%%% !1110 4444 %%%% !1110 4444 9/BT:X?"NL_\(S]@
M'B3[%-_9G]J[_LGVK8?)\_9\_E[]N[;\VW..:^4_AM^U#XZ^(/C3POI&DZ1I
ML.H>(+]&U&TOK*9)M,M;?'V_SU61C#)&J-;_ # JMU+#&^-U?85>5_#WX(>&
M_!7Q@^('C;3DG_M/7GA0VTOEFVL 462X^RJ$!B^T2E9I_F/FR(KMR,UW8>O2
MI4ZD:E-2<E9-]'W^Z_SL<E:C4J3IRA-Q2>J[KM]_X7/5****X3K"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \I_:7_ .2=Z-_V.GA/_P!2'3Z]
M6KRG]I?_ ))WHW_8Z>$__4AT^O5J /E7]IW7?VB?@S=>(_&/PL3P=XH\%S*F
MIZI:>,;F<7&C^7;K'.\!$T42VBQVZ3,NXR>9+,P#;L#UK]G[X>>*? OAK6[[
MQYJUEK'COQ/JTFMZW+I*%-/AE,,-M%!:JR*XBCM[6W0&3<[,K,S'=QY9^V/^
MT-9^"?AOK_@I-!TGQEXJ\9:H/ FA>%X];1&OI;RSA+M> /%);HOVH*RHV<2V
MS>9$+@-'ZA^S]XY\:^+=&\3:5\1;/0;;QIX7UC^R-1E\,23MIUR7L[6]CDA$
MX$BXBO(T8,3\T;$'#   YSXY:9\3O&NHZ3J'PCEM=$\5^#M>>&>/QG<W]KHF
ML6<VG9D_=6S8NE62Y@V.R_)+;2@$88/T'[/?B+XEZWH_BBS^*Z^$!XIT?6OL
M*GP5/))9F!K.UG3>LKM+')F=\K($.W8P4HRN^1\5OV+/@I\;O%TOBCQIX L=
M8\031)#-?K//;23*@PAD\F1 [!<*&8%MJJN<* .O^#/P(\#_ +/GAN^T#P!H
M@\/Z/>WS:C-:+<RSJ9VCCC9@978C*PIP#C@GN: .^K\\O@=KWB+2OVOOBC;:
M;:Z1JOQ'UN;Q=; ZC/J0NM+AM;FUDTB34TDN!&+*6.>)(3;6Y(CV%)&WS*GZ
M&T4 ? ^M-\:6_;H_9A_X6]'X#C&?$_\ 9?\ PA,EZV?^)7^^\_[2H_Z9;=O^
MWGM7WQ7RO^T-_P GS_LD?7Q;_P"FN.OJB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y3X9_\ (M7/_87U7_TX7%;VLZ+8>(=-
MFT_4[2&^L9L>9;SH&1\$,,@^A /X5F^'_ 'AOPG=R76C:)8Z9<2)Y;RVL*HS
M+D'!([9 _*N*<*KQ,*D4N5)IZN^K72WEWZ^6O?3G16%G3DWS-IK16T36KNGK
MS=GMYZ;]%%%=IP!1110 4444 %%%% !1110 4444 %%%% !1110!X%\7;G]I
ML_$6YM?A9;_#$^#4L;>9+SQG'?)<&Y9I5EA7[-*V\((XWW-'&,3JHWE'([WX
M*?\ "T_^$5NO^%N_\(?_ ,))]M?[/_PA7VK[']EV1[=_VGY_-W^;G'R[=G?-
M>+_'/]E[5OB-\3]>\2MX:TOQ@FJZ;%I"74_CG5/#-Q;:9A3/I3QV=O+'=6\D
M@EE9Y"&/VEDP!%&U6_V7?A?K/P(U/4?"OAOX>>$?#?@JYU,OJEOH7CN\U>;3
M+K[&KAWBNK)&+R#[,"OFJ CQ,$^\S@'I/[1RZW<> HK32?AK9?%FUNKHIJ/A
M>_6T,5S$MO-) 2;J5(D NTM-SE92J[BL9(#+SG['?@[4OA_\.-3\/ZUI_A;2
M]<MM2$VI67A/2;33;>UN9[2VN&MVBMII [0K,D(FD$<DD<<;%"-LTO,_\%#=
M.\-W_P ![&3Q?XGT70/#%KK]G/J&G^()[Z.TUN'$BM9L+%UN'==WVE%0/^\M
M$++L#,N3_P $V/#'AOPY\&/%<W@_6_"VM>&-4\5W5YIY\)F^6&"$6UK"$FAO
MG>X@G;R?-:)Y'QYRE6*%: /K.BBB@ HHHH ^/_ OQ"\*_$K_ (*1WVI^$/$V
MC^*M-B^$R6TEYHE_%>0I*-89C&7C9@&"NAVYSA@>XK[ KY?C_P"4G%Q_V1^+
M_P!/4E?4% !1110 4444 %%%% !1110 4444 %%%% ",P12S$*H&23T%8NE7
MULVL:N%N(B6FC  <<_NDK9=%D1E90RL,%2,@BO ?@E^U3X-^,WCWQ!X4LO#&
MO:#K^CW%NK66I^';V&:WCDLHKD/>,;<16C^8;B%4>0^8;?<C,KK0!] 4444
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M;"YN;(2&)+D11RM&K.J[\+-&=P&.<<$$  \A^-7[//QF^*7Q-MO$/A_XZ0^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cgtx-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *O G0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,F/+'.3N/2M;XK?LO^)?$/[2/A?XS^"/&EIX=U_3-+.C7NGZIIC7EI>VV]V
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M30_!^F>#D\(66A7NE"^>SC6-HQ/#*\@"R%"BEBI8A2,\\ %7QQ^WA#X2\"?
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M7A2_\%RZ5X]^&GC/3-]NLWA2WL2=?AMYY%:X:=(K8-%.GF.\I:8J'#;F;O\
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MZKKNEW=];6_VC3+RRCR26CC1&C?<I"LA.Y3S@XK+^%?C?XAW/A;]FWQ=KGQ
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M$0_9M)B$MNJ"+RUB9)<0@R QHJG)[ C#<UQ/AC]A?X?^%+3PM9VFK^+9=/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;"/3-0U:.9Y;.,DB(I/)&%Y[X09]\T >H4444 %%%% !1110 4444 %%%%
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MEW7U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%(6"]2!]:0.I/#
M_C0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/XJ_\D[U[_KV
M:NLKD_BK_P D[U[_ *]FKK*XH?[U/_#'\YGH3_W.G_BG^4 HHHKM//"BBB@
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MT+7[J&YU31=/U*Y@XBFN[6.5X^<_*6!(YYXK6H **** "BBB@ HHHH ****
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MS<^(=6NX+EI]4NY6EDN"+J8!BS<XP!@=@ .U 'O%%%% !1110 4444 %%%%
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MZ;'!;Z&MB!/'>"1B\[7&[)4H579MQQGCG<WPKHWBK3CXE.N^(K;5Q=ZA+-I
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M6EUJ;SZ/%:V'V9K&S**%@D.YO-96#'?P3G/ (5>IHHH **** "BBB@ HHHH
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MPKY2_;\^,SZ%^S;J,W@;Q+?KKUSJNGV<5SX4N"]Y$&G#R!3'G:6BCE SP>E
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M7QBU36-3UCP7X%\++XFU#3Y8H]4U*_U$6&GV<F%F$/F".5Y)=NPE4C(4.-S
M\&HQE-VBKDRDHJ[/3?BK_P D[U[_ *]FKS7]N/\ Y-=\:?6Q_P#2ZWI8_C1'
M\2/!7C/0]3T*\\)^+=)L8YKW2+R1)E:*7.R>WF0[9HBR.N["L"A#*IP#!^W#
M=P-^R_XT031E\V/RAQG_ (_K>N&*<<743_EC^<ST9M/!4VOYI_E ]\HJ*.ZA
MF;;'-&[>BL":EKL. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^+?BC\4M>TS6O'_B.UMM/>+1(#%9VMO",*JY +LW&20.@]\^W_$'_D0O$O\
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MPKK95"C3EROFG9^=H=CCOV$/AC$ESXE^(<?VF/3;J1M(TB*2YDD26.%RL]P
MS'K*K1@^D3'HPK[ K'\'^$]+\!^%-'\-Z);"STC2;2*QM( <[(HU"J">I. ,
MD\D\UL48BM]8JRJM)7=[+9>1E1I^QIQIWO9;L****YS8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *XGXT?%?2?@?\+_$'CC6XIY].TB%9&@MES),[NL<<:YX!:1T7)P!NR2
M#7;5Y#^USXHT[P9^S5\0]7U73].U>T@TMT&G:LCM;74KD1Q0N$^8;Y'1001@
MD'*@9 !RGP=_:FUWQQXSTOPMXP^'_P#PAFKWS7T)2#6(]02&>V$3-&Q5$^]'
M,K!@" 00>:^B:_*3P9HWQ4_8O\91^*[SX6>"9[JXT6YU.9V\5WEW="WA$;W=
MO"\TKJDP3:2<,K!,*S$ ']5[:<7-O%,HPLBAP#[C- $E%%<K\4+/Q=J'@35;
M?P'J&GZ5XL=8_L-WJL1EMHSYBE]ZCDY3>![D4 <I^T9^T9X6_9K\!3^(O$4I
MEN9%=-.TN$$S7TX0L(T !('&2V"%&37"^)_VSM,\'_LL^$/B_J/AZ=[WQ3#9
MKIOANUNE>2:[N5RD E95! &XEMO120IZ5;USP?XU'[-WCF7XKW.@>)O%]II6
MJ26=_I-EY<<$36C!0H89#YWY([$5\L_%;2]4MO\ @GI^S/XGMM+FU"P\(:AH
MFMZLD49=H+1+:6-Y"@^8A6E3. <#)Z T ?6_[-?[34OQSU#Q9X=U_P )77@3
MQUX5GCBU70KBY%TJ)("8I(Y@JAU;:P^Z,%3U&#7J?Q!_Y$+Q+_V#+G_T4U?*
M_P"R!XOM/C9^TE\>/B=X;@N'\#:K%I>DZ=JLT+P?;)+>.7S66.0*X \Q.64=
M<=0:XGQ7_P $M-$TGPOK%\OQG^)L[6UG-,(I=50H^U"<,-G0XP: /6O^"8O_
M "9!\.O^NFJ_^G6[KZDKY9_X)@IY?[#GPW3).U]4&3U/_$TNZ^IJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KE?AC_P DV\._]@^+_P!!%7?$-EXB
MNIHCHNJ6-A$%/F+=V;3ECV((D7%8?A#PKXI\,6.G:?<:[IUWIEG$(3''IS1R
M.H&!\WFD _A0-;ESX=_\D]L/^N4G_H;5Q'['O_)MG@?_ *]I?_1\E=O\._\
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MK8_^EUO7%#_>I_X8_G,]"?\ N=/_ !3_ "@>[4445VGGA1110 4444 %%%%
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M .G6[KZDKY;_ ."8O_)D'PZ_ZZ:K_P"G6[KZDH **** "BBB@ HHHH ****
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MRY_]%-0!\\_\$PF+?L.?#@LNUB^JDKG.#_:EWQ7U-7RW_P $Q?\ DR#X=?\
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MBZGXBUC1=9T6P\'7]R)D:&*[%U;+&_HV#("!]1FNJ\.:]J>L2SK?^';O1%0
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M -\3_P#R)1_PBG[>O_0Y?"G_ +XG_P#D2@#[:HKXE_X13]O7_H<OA3_WQ/\
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MPCU*^DU/3O%:_M8#XBK??V))8RO8&,SQD2QQHIMC#]F)PQ.\MG'[O83^R5%
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MDY*C ;.WC% 'VC\+/C)X1^-6G:SJ'@W5DUK3M*U)]*N+N%2(S<+%%*RH3]X
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M/Q&BL=0\801?\+'\8>*HUN]49KC9)#]@C)5D^\OF+C[ISW  /VHHK\S/B?\
M&S6OV,_BE^T9X1N+^\FMO%VAQ>)?!7G3(_E7D\@M6AAC)Y'F3$XSD):%L'-?
M;?[*WPWO/A1\ /!?A[4YYKK6(K!)[^>XW>8UQ(-[[MQ)R"VT\_PT >L4444
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MRZ\@DB,:"-"756\I2%<#:'E.<X!^YZ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***^<=2_X*!_!?2=1NK&YUV^6XMI7AD4:9.0&4D$9V\\BHE.,/B=CGJX
MBC0M[6:C?N['T=17S1_P\3^"/_0?O_\ P5S_ /Q-'_#Q/X(_]!^__P#!7/\
M_$U'MJ?\R.?^T,'_ ,_8_>CZ7HKYH_X>)_!'_H/W_P#X*Y__ (FC_AXG\$?^
M@_?_ /@KG_\ B:/;4_YD']H8/_G['[T?2]%?-'_#Q/X(_P#0?O\ _P %<_\
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M!_:&#_Y^Q^]'TO17S1_P\3^"/_0?O_\ P5S_ /Q-'_#Q/X(_]!^__P#!7/\
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MM3_F0?VA@_\ G['[T?2]%?-'_#Q/X(_]!^__ /!7/_\ $T?\/$_@C_T'[_\
M\%<__P 31[:G_,@_M#!_\_8_>CZ7HKYH_P"'B?P1_P"@_?\ _@KG_P#B:/\
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MHHHK0ZPHHHH **** "BBB@ HHHH *_!+Q]_R/7B/_L)7/_HUJ_>VOP2\??\
M(]>(_P#L)7/_ *-:O,QNT3XKB7X:7S_0P:***\H^$"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "IUL;EX?.6WE:'_ )Z!"5_.H*^^_P!A
M'XCVJ^!]'^&WB!UFT3Q7=:S:QI,P^61(K,A%STR))< ?Q-FM:<%4ERMV.[!X
M>.*J^SE+E\_/9?F? \4,D\@2)&D<]%09)_"GO97$<RQ-!*LK=$*$,?H*^N/@
ME\-KO]GS]J"(:D@%W#XGM_#>D"1<><)V!FG4'[RI:L%]0UW$W;%=1^TQ=SI_
MP48\!!9I%":EH:* Y& TZ!@/8@G/KFK5'W;M];'2LO:H^TG*SYE&UNY\2?V1
M?9Q]BN/^_3?X572)Y)!&J,TA. @&3GZ5^J'Q9\,_$>]_;,\-:[H-Y=6W@?2[
M&VDUB3^TE2U@7,Y9IH3(."HZE<<>QQ\L:QK_ (7US_@H/I.I>")+9O#\VO6'
MDR6*>7$[[(A,5&!P9 _L>O>JG0Y.O6QM7RSV#LY?:Y=5:_FM=4?+$]K-:L%F
MB>%B,@2*5)_.B"TGNB1##),1U\M"V/RKZ:_X*.7<\_[3FJ0R322106%HL4;,
M2L8,0)"CMDDGCN:](_X)4NW_  GGCI-QV?V; =N>,^:>:E4KU?9W.>&!4\=]
M3YNK5[=O*_ZGQ!-IUU;QEY;::)!_$\9 _.J]?H7\/AK'A7]DOXGZA\2+Y_B'
MI>H7+16>E6-XNK26$BJ06DF1G6(<Q/C=\H4'@MBOG[P/^R5;^*O@+!\5-1\:
M6GA[11=""[%W:R2"W7[2L!?*9)Y88 '4@$CD@=%Z6[7*J9=47+[/5N+DT]+)
M/KK8^=:DM[>6[N(X((WFFD8(D<:EF8GH !U->Y1_L_>'M2@^(_B;1O%8UGP-
MX/D@ EA 2]OTD*+N16 " ,_4C!P1UKK/$7[.%[\$OCC\+VT+Q,5T_P 3/%>Z
M-J5U:@SVS?(<31=#C>O0]STQ4>REN8+ UG[S6EUM;J[7^]'S/J>EWFBW\]CJ
M%I-8WL#%);>XC,<D;>C*>0:JU]D>-?V;_$WQT_:Z\<^%?$7BZT.OV.DPZK-J
MD5D4AD01VZK&(P<K@3*,Y/W3ZUY_X[_99T_1/@!_PLKP[XDFUJ.QU*33=2@G
MM1 JE9/+WQ?,25WX'/)W X%4Z,E>RT7Z%U,OK1<W%>[&_:_NO72_0^>X8);E
M]D,;ROUVHI)_2DEADMY#'*C1N.JN,$?A78_!KXDWOPC^)F@>*K*1T-A<JTR(
M3^]A)Q(A&1G*D\'C.*^I_P!O#X.?\)5\7/!GCK0)/M.C>.H;>![N-]\:3HBA
M6##Y0&@"%1GDQN:F-/F@Y+=&=+"^VH2JP>L6KKR?7[SXHFMY;<J)8GB+#(WJ
M1D>M1U](W/@=_C/X;\:_%3Q'KM^G@/P@8=*LH(/WMS,N4BBCCWG"+NDC8DY^
M^W<54UG]DBXT[XF_#WP_'K@;1/'5HE[IFI/ =\*.F]4E0'&X J#@]SZ4_92Z
M#>"JO6"NG:WS=D_1L^>:*^H[']B*6\^(OQ*\'_\ "6PI?>#+*&^:7[(Q6[CD
MMUF..?E(W!><YSFN:\!?LQZ;XJ^ FH_%75/%_P#8NCZ9<>1>6_V%II ?-1 $
MPPR6,B@9QR>>.:/93[?T@^H8B]N7OU7V79_<> T5]@M^Q1X0A^*7@KP]+X[O
MO[.\9Z=]NT=4L!]K_P!49,S<[%7 /3)SQCO7EMA^R_JEMXU^(VG:Y=M8Z%X#
M$LFJ:G'"29D#8B$2\@-*,, 3P#DYQ0Z,UT'/+\1#>/6VZ[7_ "U/$**]4^-?
MP2?X7:-X(\16EV]YX>\8:=_:&GF< 3PD!"\4F."5$D9W# .[VKRNLY1<79G'
M4IRI2Y)K7^F%%%%29!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->5>)O&'PI\/_M2^'/'7@O5;C_A$GU6/4KZS;3GA;3V#AG6-<89#R5 Z<C'
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M ?E(//2O3;KP-H6O?L._#E=2O[31[F3Q;-:?VG!9?:)Y\M=*D:D;=RY(/S.
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M *M3_P"?J^[_ ()^#%%?O/\ \*U\(_\ 0JZ)_P""Z'_XFC_A6OA'_H5=$_\
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MX5KX1_Z%71/_  70_P#Q-'U)_P P?ZM3_P"?J^[_ ()^#%%?O/\ \*U\(_\
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M6I_\_5]W_!/P8HK]Y_\ A6OA'_H5=$_\%T/_ ,31_P *U\(_]"KHG_@NA_\
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MZX/^[7-7Q-+#V=5VN1*2CN=_17GO_"UG_P"@8O\ W_\ _L:/^%K/_P! Q?\
MO_\ _8UR?VGA/Y_P?^1'M8=ST*BO/?\ A:S_ /0,7_O_ /\ V-'_  M9_P#H
M&+_W_P#_ +&C^T\)_/\ @_\ (/:P[GH5%>>_\+6?_H&+_P!__P#[&C_A:S_]
M Q?^_P#_ /8T?VGA/Y_P?^0>UAW/0J*\]_X6L_\ T#%_[_\ _P!C1_PM9_\
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MB&VCZK<68L!*(B!O\W&> >F/>J_M'#.+ES:>C_R\A^UA:]SM**\]_P"%K/\
M] Q?^_\ _P#8T?\ "UG_ .@8O_?_ /\ L:G^T\)_/^#_ ,A>UAW/0J*\]_X6
ML_\ T#%_[_\ _P!C1_PM9_\ H&+_ -__ /[&C^T\)_/^#_R#VL.YZ%17GO\
MPM9_^@8O_?\ _P#L:/\ A:S_ /0,7_O_ /\ V-']IX3^?\'_ )![6'<]"HKS
MW_A:S_\ 0,7_ +__ /V-'_"UG_Z!B_\ ?_\ ^QH_M/"?S_@_\@]K#N>A45Y[
M_P +6?\ Z!B_]_\ _P"QH_X6L_\ T#%_[_\ _P!C1_:>$_G_  ?^0>UAW/0J
M*\]_X6L__0,7_O\ _P#V-'_"UG_Z!B_]_P#_ .QH_M/"?S_@_P#(/:P[GH5%
M>>_\+6?_ *!B_P#?_P#^QH_X6L__ $#%_P"__P#]C1_:>$_G_!_Y![6'<]"H
MKSW_ (6L_P#T#%_[_P#_ -C1_P +6?\ Z!B_]_\ _P"QH_M/"?S_ (/_ "#V
ML.YZ%17GO_"UG_Z!B_\ ?_\ ^QJ_>?$)K32=.O?L(8W?F?)YN-NUL=<<YJUF
M.&DFU+;R?IV\Q^U@^IV=%>>_\+6?_H&+_P!__P#[&C_A:S_] Q?^_P#_ /8U
M']IX3^?\'_D+VL.YZ%17GO\ PM9_^@8O_?\ _P#L:/\ A:S_ /0,7_O_ /\
MV-']IX3^?\'_ )![6'<]"HKSW_A:S_\ 0,7_ +__ /V-'_"UG_Z!B_\ ?_\
M^QH_M/"?S_@_\@]K#N>A45Y[_P +6?\ Z!B_]_\ _P"QH_X6L_\ T#%_[_\
M_P!C1_:>$_G_  ?^0>UAW/0J*\]_X6L__0,7_O\ _P#V-'_"UG_Z!B_]_P#_
M .QH_M/"?S_@_P#(/:P[GH5%>>_\+6?_ *!B_P#?_P#^QH_X6L__ $#%_P"_
M_P#]C1_:>$_G_!_Y![6'<]"HKSW_ (6L_P#T#%_[_P#_ -C6AKGQ!;1KT6XL
M1+F-7W>;CJ,XZ5:S'#.+DI:+R?\ D/VL-[G945Y[_P +6?\ Z!B_]_\ _P"Q
MH_X6L_\ T#%_[_\ _P!C4?VGA/Y_P?\ D+VL.YZ%17GO_"UG_P"@8O\ W_\
M_L:/^%K/_P! Q?\ O_\ _8T?VGA/Y_P?^0>UAW/0J*\]_P"%K/\ ] Q?^_\
M_P#8T?\ "UG_ .@8O_?_ /\ L:/[3PG\_P"#_P @]K#N>A45Y[_PM9_^@8O_
M '__ /L:/^%K/_T#%_[_ /\ ]C1_:>$_G_!_Y![6'<]"HKSW_A:S_P#0,7_O
M_P#_ &-'_"UG_P"@8O\ W_\ _L:/[3PG\_X/_(/:P[GH5%>>_P#"UG_Z!B_]
M_P#_ .QH_P"%K/\ ] Q?^_\ _P#8T?VGA/Y_P?\ D'M8=ST*BO/?^%K/_P!
MQ?\ O_\ _8T?\+6?_H&+_P!__P#[&C^T\)_/^#_R#VL.YZ%17GO_  M9_P#H
M&+_W_P#_ +&C_A:S_P#0,7_O_P#_ &-']IX3^?\ !_Y![6'<]"HKSW_A:S_]
M Q?^_P#_ /8UUGAG7#XATS[68?(.\IL#;NGO@5O1QM"O+DIRN_1E1G&3LC6H
MHHKM- HHHH **** "BBB@ HHHH *\&O_ /C^N?\ KHW\S7O->#7_ /Q_7/\
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M)/$-IKMQ/KOB&YN&AA%B)Y%,;/(V9LC "QJ^,<XK]#-7LI-2TF]M(I_LLMQ
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M5'4JKHK=MQX.#76?MF:)J_B"/X56VBV=_<747C+3[EY[*QDNEM(TD4M-(%!
M5<@_,0#@^];NI_LLZ?K^B?$V'5->GN=:\?+#%J&JQVL<;1111I'&D:=!P@SS
MR?I6U+V-.$)SW_R:_2Y2Y4DV9/CW]H75OA;H*PQ^'FD@T[PK%KZ:MJ+E;74F
M0-YUC&X^[<;%\Q<[L@/E  &.EKG[2-S=:M8>'O"NAKJ?BJ?PFWBYK"23<K(!
M&5LU*X/FR>9A7(P, X;.!G^+_P!D-/&6L7VH77CK6(6O_"W_  BMS#'#'Y?D
M':6>,'[A9HT+ =?F&>>-=_V:#9^)O!_BC1_%EUI/B?0-(_L26^2SB>/4+8 !
M5EB/&1M4Y!ZJ/2E?#V5]_F+W3F?$W[9-MH-_=:>VA/;ZUH^AV>M:MHLS[KKS
M)]FZQ@'RDS1ARQ)7!VXP,DKY5!X_\6:/^W#\:K[P]$FJK8^$[:_CTK4KN2.$
M*+>P=@J@$!SDC/ &XGGH?HO4OV? OQ9E\?Z!XGOO#^JWVGIINJ1Q01RK?1KC
M:Y+#Y9 !]X>W'%9E_P#LMVEQ\6/'OCVV\37]GJ7B[1UT:>)849;>,1P1[T)Z
MM^X!YX^8U=.I0@G9;KSWNO\ )C3BBEHW[43^/M:\!:-X5T,PWOBCP_+XEDN-
M5?\ =65LA*A-J',CM("F<J%!#?-]ROIG]D7XNZ;\<_@=HWC'3+=[.&_>3S+.
M5P[V\JG#H6'!P1P>,@@X'0>"6G[->C>'];\(:KX;U"?1+KPWH5QX?AQ&)EFM
MI%^7>&/5)/W@QU/!XKZ%_97^%ND_!CX+Z-X0T4R266G%U\Z;'F3.3EG;'<DG
MZ# [5Z.6N@ZW[O>WZO\ X!K2Y>;0]<HHHKZ@ZPHHHH **** "BBB@ HHHH *
M\S\+?$KP5XT^(WB_P59:3*OB'PND$NIQ76F>6H6<,8F1R,/O",1CTKTROEGX
M31WTG[=/[1OV*YM[?&F>&-_GV[2Y_P!&N,8PZX[^M3*,9?$KBLF>C^#/C'X(
M^(7A;Q#KWA[PYJ.IVNAZC)I=S#'HQ$SW$<@CE2)",OM8\X]#7IP\/:40#_9E
MF/K;I_A7Q'\$=:U'PW^R]\2-0L=0FT^^A^+%TANK5S$=KZY;QR#@_=9'<$$G
M@UZ?\6=.U37/&_QA2'QWXE\/IHGA/3M8TZVTK5# D%T1?YE"X.5/V>-60Y1L
MY*EL$1[*G_*ON"R['T=_PCVE?] RS_\  =/\*/\ A'M*_P"@99_^ Z?X5\E>
M"KOQ=\8K'59O%?BSQ+X,U9_AQH6NR:=H]^]C]DU"5M222=5.67 @BS&28V)!
M=6(0K'^S?\3?''Q\U/3]"^(J:OX8>/P18:E#)IUW<::]_-/)(LTX*E6.%CB[
MD L2-N[%'LJ?\J^X++L?7/\ PCVE?] RS_\  =/\*/\ A'M*_P"@99_^ Z?X
M5\;? SXW^*_C78> ='^)&KW?@Z;6O!=UJ$&K:?>?V:=3NQ=- L\2@@[E@5)M
MIRA,P95   T/V@/'NL^'? ?B8:#\0KSQ'K?A_P "6.II=Q7O]EQ(S3S9OV>$
MG[3+<"#Y80GEH+60-)&+@!CV5/\ E7W!9=CZY_X1[2O^@99_^ Z?X4?\(]I7
M_0,L_P#P'3_"OB?X@>+O$WB&[^/FIQ>./$%G%H7PUL?$NF6NE:F]O!;7_P!A
MNW\Q?+(."T:DIG:Q^\#A<;7@+QIXKO?B7\)8[SQ;K-W%X^^&T^M:S#)=$1"\
M$$#++;QC"VY7S&QY07/4Y/-'LJ?\J^X++L?7W_"/:5_T#+/_ ,!T_P */^$>
MTK_H&6?_ (#I_A7Q]X)U'QGHNA?LU>(['Q9XF\6ZAXXBM[#Q)9W^H--;M;2V
M!E>Y6-0!%) 8E D3:3EC(7=BQZ_PAX]N;G2?V;W?Q7=3:EJ&M7MAJ,<FHLYO
M(1I.IR8N$W?O"LUO;D%LD,.#R<GLJ?\ *ON"R['TE_PCVE?] RS_ / =/\*/
M^$>TK_H&6?\ X#I_A7S_ /!CQ3XGT_XKGPSXVMM6BU.XBO[O3-9MM4DO]&UN
MT$X8,BEO]%FB$B*8F4G'W6(%?2%'LJ?\J^X++L9__"/:5_T#+/\ \!T_PH_X
M1[2O^@99_P#@.G^%:%%'LJ?\J^X++L9__"/:5_T#+/\ \!T_PH_X1[2O^@99
M_P#@.G^%:%%'LJ?\J^X++L9__"/:5_T#+/\ [\)_A3Y]%T^YE:6:PMI9&^\[
MPJQ/U)%7:*?LX;<J^X+(S_\ A'M*_P"@99_^ Z?X4?\ "/:5_P! RS_\!T_P
MK0HI>RI_RK[@LNQG_P#"/:5_T#+/_P !T_PH_P"$>TK_ *!EG_X#I_A6A7,>
M-]0\96%O;'P?H.A:[.S$3IKFMS:8L:XX*M%:7)8Y[$+]:/94_P"5?<%EV..\
M8_%'PAX1UK7=-70TU23PY8PZIKSV<$3?V;:RB<QNRGEV/V>3]VH+8P<8-=G<
MW/A.S\+2^)9TTR+08K(ZB^H-$GE+;!/,,I./N[/FSZ5X5#KMGX$\=?M)7/B*
MP:QNKFST[5EE1/,^VVS:9]G5(. 9=DUM<KC .6' W5:\6:'?WW[%.N_#JVN9
M;GQV/AN\1T=%!OF9K)HUC\G[WS.IB'OGO1[*G_*ON"R['8>'OC%X'U<6DFH:
M3%H%OJ&C/XCTZ74((U^U:<L:2--M&2A59 3&P##!R.*F\/?$_P -:KXWTOPM
MJ?A9_#NHZW:3:AH9O[>+;J5O%L,A7;G8ZB1&,;X8 YQ7G/CB#0_CU\2?AMI^
ME6LLOAK5/".JS7&HVJ!'LK2YMXXHU.1\C?O!A2."O(XJEX7\!^.M?_:/^&@U
M+Q/I_BS0OAKH]Z;W7;+1!8I/=7<"P0VQ;[5*'G\H&9PB(J*T9_Y;(%/94_Y5
M]P678]\\8ZGX>\'06"S:3;WFI:G<BRT[3K>WC\Z\G*L^Q<X  1'=F) 549CT
MKD/$GQB\$>&]5UV&728IM,\.W%O::YJJ01K!I\TY01*V[!;_ %B%BN0@(+8K
M.\3R:K+^V7X#ANHXSX>C\':O-9,X7/V[[59++COD0E1]&;U->0?$^*XL?@?^
MTMX3DLGUGQ/J>MN;*PN(S&UXEZEK%;-&6&'56R-PX!B.2*/94_Y5]P678^J?
M%%SX7\&^&K_7]6M;*WTNQA,\TPME;"CT &23P !US7%V_P 5_!]M:>(WU_0E
M\.7FA:5_;UU97=O$TIT\^9MN$"9W ^4X(ZJ1@X-<=^U+$WC[X)^(?#'AK6X#
MXC\-3Z3?ZSIMI(9+B&W66.<QR1IEAYD4;D9&" >U<7\6;FWU+]H#QMXYAT6T
M\7^#=)^#-Y;WT?GCRKUY[PS1VK8R</';3$D [0PS]X9/94_Y5]P678]V\.^+
MM-UG6;C1;WP:VD:TEJ-0AL9T@=IK0R>6)=R$A3D$["0PQTKI_#9\-^+=#L]7
MTRSLKBQNDWQO]G4$<X96!&592"K*>000>17SU^SEH.M_##XQW7A.[UR/XAZ#
M=^'8;G2?$L2%IM.@C?;]BE<RN3&68M$268@89F*Y/7?LF2PEOC/!97=Q=:;!
M\2=96W\]BPC9A!)<(F>BBYDN.!QG-'LJ?\J^X++L>U?\(]I7_0,L_P#P'3_"
MC_A'M*_Z!EG_ . Z?X5H44>RI_RK[@LNQG_\(]I7_0,L_P#P'3_"GOHVGR11
MQ/8VS11YV(T*E5SUP,<9J[13]G#^5?<%D9__  CVE?\ 0,L__ =/\*/^$>TK
M_H&6?_@.G^%:%<[XUOO%EA80OX1T31=<O2^)8=;UB;38U3'57CM;@L<]BH^M
M+V5/^5?<%EV.8\:>-_#?A+Q#!X?@T"/6M>>PEU:33[*&+S(;*-U22=MV.,N
M!U8@@9(-='X4G\,>-?#>FZ]H]K97>EZA MQ;S"V4;D89'!&0?:O&(;J;PO\
MM:W_ (F\6Z;;:0+WX:6R->P79GMHYK:^F>[MXY&2-I,?:82&*(6'.T<@7_@3
MJ>H^&/@!HWA^QN(+SX@3:'=ZQI>@:M*+29HS(?+#*062-6EB0OM.-PR.<4>R
MI_RK[@LNQU)^*/@E_C?!\+K?38+K7WTN759I(K>,PP(CJNQC_?.X' Z#KBJ7
MAOXS>!/%%]HYM-,@_L/7+^YTO1]:,,1M[^ZMY)HY44#Y@-T#[68 /QM)S7SQ
MX(E^(UI^VQX%T_Q'X)L="NG\':@ES>1^)AJ,TB-.K/=L1:Q OY@5?+   ;@@
M*%KHOAY?6\_P!_9L\(V>E7=CX@T_5+"POK 6F)K&XT]9([]Y5'W!YD,IWG[V
MX'^*CV5/^5?<%EV/I[Q;=>'/!>B2:GJ&G6WE"2."***U5I)II'6.*)!CEG=E
M4#U(KB_&'Q8\)>#[S6K67P^+VX\/:4-;U^.U@B9M,M#'(^\C_EHV(F^1,L>#
MC!JA\<Y+L_&#X"6\\<!\.2^);QKII6P?M::5>-:*!W^82-_O(G?%<[K/B73_
M (>^,_V@KO7;:24MHL.LPB:#B\M([%T:*(_\M"'C==HR<GIS1[*G_*ON"R['
MNNF6&@:SIMIJ%C::?=V-W$D\%Q#"C)+&P#*RG'((((/O7#_"+XD^$/C-!XNF
MT707MD\-:[-X>NTO[%8I&N8889)<(>0 9MG/4H3TP:B_9UU"T\/?"GX>> M1
MN[>U\9Z-X/TIM0T)Y5^UVJK;QQ%GCSD#>C+GID&O-OV'+F&:\_:)\N5'_P"+
MMZT_RL#\IAM<'Z'!Y]C1[*G_ "K[@LNQZ[X.\6>'O'NBZ[?:/X<9IM)N[BPD
MLKNS2"9[B'AD ;@9/ )XYS6SX2N_#'C?0;?5])L[2:TE9XR&ME5XI$8I)&ZD
M95T=65@>A4UP7[-]_;7EQ\3E@N(IV3QEJ)81N&(!<8SCUJG^SQ+K ^(GQQMI
MX8H_#L/BM?[,:+'+M9P-<#C_ &R#]2:/94_Y5]P678]B_P"$>TK_ *!EG_X#
MI_A4D^C:?=/OFL;:5\ ;GA5C@=!R*N44_9PVY4%D9_\ PCVE?] RS_\  =/\
M*/\ A'M*_P"@99_^ Z?X5H44O94_Y5]P678S_P#A'M*_Z!EG_P" Z?X4?\(]
MI7_0,L__  '3_"M"BCV5/^5?<%EV,_\ X1[2O^@99_\ @.G^%'_"/:5_T#+/
M_P !T_PK0HH]E3_E7W!9=CR/Q?\ %3POX2N/&Y?PR;NP\%Z?%J6M7T5O$(X8
MF4R2*N>7>. &8J.HP!EB!74ZOX@\&:+\/KKQO/'82>&K?36U8WL-NK*]L(_,
M#KQ\V5Y [Y%?/_B#2KGX?Z9^U/IDZ3:KJ?B*"35](M9HF"WOVNQ%K!;1GG>S
M7*>2%')++Q\PS+\6?!%UXL_8UU?X%V-VI^(NF> [ SZ?;(\OS0)&-BLHPQD:
M!D4 Y.0<8H]E3_E7W!9=CV'P]XZ\/:KXC\.Z#J7AM?#^L:]HG]M65G?10[V"
ME!/ 0I.)(O-B+#H0YP3M;&5IOQ@\'ZO^T/>?".UT 2:K:: ^ORZE]GB^RE%N
M4MVB4]2X9^>, J1U%>6?$C0_$OQ7^-?PD\6_#.XTV:?1/!>JWJW&K&>"%/MT
M=O%:;RL;,C/LE8 KD")SM.TBN;^&FC>.]"_X*"Z';ZUX6\.:/;0_"^>VF;1M
M7N+N(0?VDKB0.]G"&G:;:&C(4;&9]Y("$]E3_E7W!9=CZ:\(^(M&\5^+O&'A
M_P#X1E;"X\.7,$#S3PQ%+E98A(LD>W) QD?-@Y%<K9?%BPB\?^'_  WK_P .
M;SPS!XB\T:1J=]';M'<.B[_*=$8O#(R98(X!X8'!%7/AG=PGXT?&*42+Y<<^
MFJ[YX4K:G<,^V>:Q[?XN_#+Q]\4/#UXOC33-5O;*X>TT/2M/E$[M<2H4DG<)
MEL;=RC.%4;F.25*GLJ?\J^X++L>R_P#"/:5_T#+/_P !T_PH_P"$>TK_ *!E
MG_X#I_A6A11[*G_*ON"R[&?_ ,(]I7_0,L__  '3_"C_ (1[2O\ H&6?_@.G
M^%:%%'LJ?\J^X++L9_\ PCVE?] RS_\  =/\*M6UI!91>7;PQP1YSLB4*,_0
M5-15*$(NZ5@LD%%%%6,**** "BBB@ HHHH **** "O.E\:Z1IFM:A>P:!##J
M-T5CNKR)466X$>0@=PN6"@G&2<9.*]%K\QOBA\5_%'A?XM_':U3XBW-B?"FG
MVFJ^'M$N4LME[.\,LKVQ4Q"6569$0!&#C?U)Q7EXZI6AR^QE;^DNS[F-1R7P
MGW.OB;PVNF7.G+X4LAI]U,;B>T$,?E2RE@YD=-N&8L V2,Y /6N/?3=%U+XI
M^(?%VL:1!J4>HZ?I]A!;2#YHA;O<LV\]'5S<#Y",?NP2#QCRW1?CK9QVWAC3
MM;TS5(_$NIZ987UQ:VEA(Z0FX*H23_"J2-AL\J.O0XW_ /A;FA?VEIUIMN]F
MJ!_[-N_*'D7Y5/,VPOGYRRY*^N#BOGWC\:NOX(Y_:5#M)]-T34_BKK/BW5-'
MM[ZWN]'TW2K:T(PT MIKR1\L.&CD^U(#'C:?)&0>,=7J.O\ AO5;C3[BY\-1
M-<:?M%K,C!'A4$$(K* =G RGW3@9!Q7RYX?^*]WJD+^*M8NM?T.PTOQ)<:7+
MIYT^/[/>QRSO9VT1SEPR2")V8-PQ8'*L O<VOQGTJ^A_T?2-<FOE@>YDTT6!
M%U%&KE S(2,!F5MOKM-5+'8V/VOP7^0>TJ=SUKQ8G@;QUI6G:9X@\#:;J^GZ
M<R-9VUU#&T=OLP%"#;A0  ,#C QBIM;NO!?B74([[5O ^EZI>1VILDGO+:*5
ME@)SY660_)GG'09/J:\6N?V@?"/V_P .6>FSW6OS>(M/FU/2_P"R8//%S#%M
MWX.0 PW#@X/!!P17,ZK^TYI[^+_A;IFAZ1J.JV/C2*ZO%N8K<$I##"Q9 -W^
ML5S'N'\*Y[D4+&XY]?P7]=&'M*A]+V>L^$]/MKNWM?!NFVUO>6RV=S%%;1*L
M\ 4J(G 3YD 9AM.1@GCFG7?BC1OLR-9>'+*VOK6R>RL)_*3_ $6,K@1H0H*I
MPN54@8 KQG3/C1X;UCQ-I.A0R74=QK N_P"SKB6 K#=FW($PC;N0#GD<@&N>
M_9G\4ZWXI\)>)6UW59]9NM.\3ZGID5U<I&LA@@F*1AA&JKG Y( R:3Q^,47)
MRM;R7^0>TGW/7?@QIVA_"7P1X8TI='ANM9TG2;;39M2C^7S&CB5'=%.?+#E=
MS!?O'ELGFM;2+7P#H-S-<:?X#TNTGEO1J321P1@_:0' E'R\,/,DP1TWMCJ:
M\!^'WB_4_COJ?C2]LM>U'PSHN@:[=>'K2+3%MV>Z:%4\RXD:6.3@LQ"*H& I
M+;MV%Z[3]?N_ EK9:7XFU23Q#K>HWUP+!+.V'G2P!MP)1< "-"N]NF2.Y HE
MC\7%V<]>UE_D#J374]DT?7_#?A^\>ZT[PU%:3MGYXV'R9Y8(,80$\D+C)Y.3
M6W_PM6#_ *!\G_?T?X5\Z+\>O#$F@:?JT::E+'>:C)I"VT=DQGCO$5B8'3JK
M'80.W(YQS57PQ\>-/\1^(;^RDT75](TZVTNTU7^T-3MO(01SB4J'4G*']U@
MC);(P,4OKV.LW?\ !![2H?2O_"U8/^@?)_W]'^%'_"U8/^@?)_W]'^%?.]Q\
M<= L[K6K.>UU2'4]*TM-9DTYK0_:9K-F9?-B0'+@,I4]P<>M;7@KXCZ1\0%\
M[1?M%S9&U@NEO?*Q ZRKN55?."P'W@/NG@\TGF&-2NW^"_R%[2H>W?\ "U8/
M^@?)_P!_1_A1_P +5@_Z!\G_ ']'^%>=45G_ &GBOYOP7^0O:S[GHH^*D)('
M]GR?]_1_A5W6?B%%H^ISV;63RF(@;Q(!G@'T]Z\N7[P^M;?C?_D:=0_WE_\
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M3CCL9*WO[^2[V[ JDWU/LJ#Q]I5K?WE]#H,4-[>!%N;F,(LDX0$('8+EMH)
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MXVCD1(I2><XFC(QC-=!\)_'<GB2]\6>'+Z[%[K'A74AI]Q<!-K31M&LL,C
M .5;#;0!E20 #@.6/Q:3:G?Y+_(/:3[GT/\ \+5@_P"@?)_W]'^%7M9^($6C
MW@MVLWE)17W"0#J,^E>65O\ C?\ Y#2_]<(O_013CF.)=*4G+5-=%YA[6=KW
M.F_X6K!_T#Y/^_H_PH_X6K!_T#Y/^_H_PKSJBL/[3Q7\WX+_ ")]K/N>B_\
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M2$0,[$*, 9/%2\?BTK\_2^R[V%[2?<^D/^%JP?\ 0/D_[^C_  H_X6K!_P!
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M0=NW@G-5/!_[.GB[P=J7P2OA-H][)X)_MJ'4(A=2HLB7N-CQL8B25 Y4@<G
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cgtx-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +( L@# 2(  A$! Q$!_\0
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MB)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\
MXN@#MJ*XGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_ .+H [:BN)\OXB?\
M_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\
MOXB?\_'AC_P'N?\ XN@#MJ*XGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_
M .+H [:BN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G
M_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\ XN@#MJ*XGR_B)_S\>&/_  'N?_BZ
M/+^(G_/QX8_\![G_ .+H [:BN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y
M_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\ XN@#MJ*XGR_B
M)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_ .+H [:BN)\OXB?\_'AC_P ![G_X
MNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'
MN?\ XN@#MJ*XGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_ .+H [:BN)\O
MXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_
M^+H\OXB?\_'AC_P'N?\ XN@#MJ*XGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\
M![G_ .+H [:BN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?
M+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\ XN@#MJ*XGR_B)_S\>&/_  'N
M?_BZ/+^(G_/QX8_\![G_ .+H [:BN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/
M_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\ XN@#MJ*X
MGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_ .+H [:BN)\OXB?\_'AC_P !
M[G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'A
MC_P'N?\ XN@#MJ*XGR_B)_S\>&/_  'N?_BZ/+^(G_/QX8_\![G_ .+H [:B
MN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\
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MB@#BO&EK_87B#1?%%N!&ZSQ:9?DN%66UF<*N<]TE9&!ZX+C^(UV@Z5PGQO\
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M18M2;3-4NK&+4%'43QPR*LF1PV1\W?->XVUG!96<5K;1);VT2"*.*)=JHH&
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M4C4(K<DGOT )Z D 'F]C^P_\+;-O#)DM_$=\/#+EM&6\\4ZC*M@-NW9$#/\
M(H'&!C@ = !7N%_I:7^DSV FN+:.6$P^;;3-'*@(QE7'(8=CUJ[10!X7_P ,
M9?#7_A3T_P +3;:TW@.:Y^TOH[:Y=%"WF&8C?OWA3*?,*@X+<UM^(OV:/"WB
MOQ+X6\0ZGJ/B6XUSPPDBZ3?KK]U');>8-LK?*X#%UPK%@<J #Q6GK7[0WP^T
M+7[K19_$4=QJ=I*(+J#3[:>\^RR8SLF,*.(CCG#D5'>_M*?"W3_"\OB.;Q[H
M(T*.]CTUM02]5X1=/$)4AW+GYRA#;>M 'H6H:?;:K87-E>0K<6ES$T,T,@RK
MHP(92/0@D5X4/V(/A8GP_A\$I9ZZGAJ*XBN4LO\ A(KYMK1'="JL92RI&V65
M%(569CC)-= ?VM/A&MS<6Q\=:8+FVB$T\)\S?#&>CNNS*J>S' KLK#XK^#M3
M\ Q^-[?Q/I3>$)(C.NMO=(EH8PQ4MYC$#&X$?44 <EJ_[-?A7Q!XT\+>+-2O
MO$5[K_A@.-)NY==N?]%WIY<I"AMI,B#:Y8$L*YWQG^P]\'O'?Q U+QEJ/AJ>
M#6M4"KJ9TW5+JR@U #J)XH9%23=@;LCYN^3DU[#X0\8:+X]\-6'B#P]J,&K:
M+?Q^;:WML=T<R9(W*>XR#7,0_'WX?SZK%8)XHLO,FO3IL4YWBVDN@Q0P+<%?
M*:3>"NP-G<,8SQ0!W=K:PV-M%;V\206\2"..*)0JHH& H X     KS7Q]^SE
MX*^(/C*R\8W%I>Z-XQLXC;Q>(= OY=/O3'_SSD>)@)4&!A) R^V.*Z_QQ\0/
M#7PT\/SZYXJUW3_#VD0_?O-1N%ACSC. 6/).#@#)/85HKKVG-H8UDWL,>E?9
M_M9O)7"1+#MW^8S-@*NWDDXP.M '-^$/A1HGA'5WUA9+_6-=>#[+_:VM7DEY
M=)#D$Q(SG$:%@&*H%!(!.<#'+I^S-X5TXZBNA:CXE\+6VIW,M[?VNB:_<V\5
MS/*S-+(5W'8[EB2T>P\#G@5:^&_[4'PI^+WB*?0?!WCW1/$&L0HTC65G<YD9
M%QN900-ZC<.5R*]1H \D\2?LM_#_ ,2?"W3_ (;M87VF>!K.W-L-#TG4I[.&
M:,N'(E,;!I"7&XEB2Q9B<[CGO?!/@^S\!^'+31+"XOKFRM%$<)U"[>YD1  %
M3>Y+$   9-;U% %?4+,:C87%JTLT FC:,RV\ACD3(QE6'*D=B.E>.Z?^R/X!
MTSP-XM\(0?VZ- \5W4M[K-L^N73&[FESY[%R^X>;GYP" V!7M5% 'CVK_LL>
M"]<TWP78W<^OM#X.99-$*:Y<J]I(@94?<&RS*C% 6S\N!7KT4?E1(FYFV@#+
MG)/U/>GT4 %%%% !1110 4444 <'\;_^2=W/_7_IW_I=!7=CI7"?&_\ Y)W<
M_P#7_IW_ *705W8Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <'\'O\ D :S_P!C!JW_ *6RUWE<'\'O^0!K/_8P:M_Z6RUWE !1110 4444
M %%%% !1110 4444 %%%(> <<F@#PC]J*:S\=0Z!\(9]3.F0>,GE;6+B.;RG
MBTBW"M<@/D!3*[0P#/:9S@[37#?\$[_'%Y_PK?Q!\)]>OX]0\3_#'5)-#EG1
MU;S[$LS6<PP2-I0,@]HQG)R:[GP7\,KKXA?$KQYXE^)_@2RDCEF@L/#UOJRV
M>H1P:=$F<@!GV2R323._ X\H;FV\<!J?P5\5_"G]LC2/'?PS\!6:^!-3T(:1
MXFMM/N;2Q5W$A:*>*$LN73Y,Y R,@9.* -/0-VG?M]_$VXMH'N9S\/=+G$(;
MF1UNIPJCTSM JK\2/VD?BU\.!X%TJ3PCX2UCQWXPFC@L/"%EJ5RMS'\F^>26
M1HPJQ0C.^3&..!UQU&G^!_&6C_M?>-O'I\,M=>&KSPA::597,-_;AY[F"628
MH8V<,NXR; QX!7)P#FN(^$'@OXD>'_&/C'XI^.?AQ>Z]\5=;1[33U@U'338Z
M-IZ%C;V,$AG#[22&EDV@L>QP2P!G>([OQ;%_P42U2/PQ:Z9<>))OA);QQRZG
M(XL+9O[4<F1PO[QT## 1,$EADJ,L.F\$_MG7DGP!UGQ=XMT&RMO%^D^*I?!)
MTO3;IOLE_JBSI"GDNREUB)?<Q*LRJCD*V #MZ'\./&?_  VY/\1K[05@\-3^
M 8/#SWD=Y"P%ZMW]I;$>[?Y>"4#$?>'3'->0P_LJ?$C6_@#\2-$BM8?#7C4?
M$FY\?>&)+F[AGMYF^T+- DIC+;<A64@XPQ4Y(S0![)X)_: \62_'#2_!&N:7
M8Z_HFNV,MQ8^(?#=A=PQ:=<0IOEM[P3%@ PSY<JLNXC!0$\9'A/]J?Q5K?PG
M^/\ XJN_#6CPZG\,]9U33H=/AO93#=1V-O'*[-,4SN;,A&$ ^Z#W:NF^#'C_
M .-7Q#U?3U\;?#FV^&NG:8L@U2274HKYM5N-NQ4M40DQ0[F,AD<ECL5%!!9A
MYIX/^"'C[3?@[^U5H=UX;,.J^/\ 6]=U#0H/M]LPFCOK80Q!V#D1E2N6#= >
M-QXH ;KO[6WQ3\*?"_X6?%'4?!.@77@OQ-'I4.HV-I?2#4TDO8T*3Q;CY2QF
M1L"-F9L%"S+EMO=^$/CI\1-/_:0T_P"&GCW0?#EO;Z_H4VMZ7<:!=SR/9^2X
M26WN&E51*?F&)$5!Q]WGCA_B3\$_'^O?L:?";P!I_ADW'BC0F\/KJ%J=0MD2
M$6!C,K"0OM8-Y1V[23\PSCFN]\6?#CQ7J7[97@/QS;:&TOA73?#5_I=W??:X
M%:*:>0.O[LOO8 ( 2 >6&,X- '%Z_P#MD>(M1\"W'Q"\$:5I6O>&[:^<0>'3
M!=R:MJUA',T3W$$J#RHW8J9(XRL@:,*2ZLVQ=3QQ^TM\39OCC:_#GP'X)T2\
MN=4\%-XJTZXU^_EMF1C,D:K<HJYCVG>"B[RS-'\R .1Q/P3T+]H+]F;3;OX.
M:1X L/&?A>VNKC_A%?&LVKQV]O96LTCRXOHB/,<QM(3MC4%L%5XPU>F+\,/&
MD/[:V@>/+C36U+PW:^ CX9NM:6>WB,EXUT)VE\C?N"$+C@'#-@ @9H [KQC\
M*!\<OA_X7L?B!I6F6UTGV6^U:PAB%R8YT\N5X+>X."BF1 I<#+("!C.1PUM^
MT1XF\9?$'XB>'/" \,/JW@S4EL6\*:E.XU35(A#'(]U&RR 1(3-M0&-P3&=S
M)N&/HTYP<=:^*?VD/@-JOQOD\5K>_#:^L/B7:7<P\#_$#0+J"U*P@*8#=3I(
M'C5"75E=6)3F/YFV@ ^U)6=87:- \@!*J6P">PSVKY!B_:=^,OB3X<?%;Q#H
MWA+P;IUQ\/=:U.QOAJ.H7,\5S'8PJ\D<(158NWS,)&V*,JNPG+#ZP\/VE]I^
M@:=;:G>C4M2AMHX[F\6(1"XE" /($'"[F!..V<5\N>!_A'X_L/@_^TMHVH>%
MQ::IXUUO7=0T.W74;>3SX[VW\J(.P;;&01ELG@'C)H =J_[6'C_3_!?PW^*C
M^#M%M/A=XFGTNWO+*:_DEUBUCOBBI=*R@0E%>11Y>"Y&"2A8JGH.M_&_Q/I'
M[57A3X8R:%I<?A[6]'O]335!=R273&W*KL\O:JQC+ YR^0?X2.?+/&_P5^(&
MH_L1_#/X>6'A<W/BW1?[!CO+-M1MD2/[!+$\C>:7VL&\DA<9/S#('->@^+OA
MYXLUC]L7X<^-[;0F;PMHWA_4;"\OWO(%*37!5D CW;V \L D#'S#&<&@#*/[
M0GQ&^(?PVUSXC?"KPSHWB?P]8:G+::;HL\DGV[7H+>X,%Q-%*KA+<EDD,:LD
MA94!.TL%&[XQ_:)OG\50^$?#]O::#K\6B0:UJ=QXEMIIXM.-PKBVM6BMV#/*
MS12;B'"HJ$@N2%KR3X(>&OCO^S -6^$NC> +'QKX2;4KJY\,>,)M6BMK>Q@G
MD:4B_CQYCE'DR1&N6^8+QM(W_BAX,^,GP=^.=A\5? NDK\4=.U/0+30?%/A^
M*>/3[J62W=C%>0!CLSF63*<[0S#H<J >M?LT_&C6/C3X+U*\\0^%[GPOKND:
MG-I-W&\<BVMV\>"+FU:0!FAD5@06&0<C)QD^0?&OQ5\2H_VW/A+X>TRZT+_A
M'Y--U?4+*QN&N4\R1(%CDDN&4$%E61Q&%'&Y\GYACZ#^$S^-K_1[W5O'-O;Z
M1J.HW'G6^@6TJW TJ (JK"\Z@":0D,[LOR@OM7(7<WDGQU^'WCQOVFOA+\0_
M"7AJ'Q/I^CV.J:5?0MJ,=H;8W*ILF?>/FC&TYV MV Y% &;??'SXV>(?B/\
M$[P7X+\">%+S5/!M[IH\S4=7F2"YM;F)I>'"#$Q0I\N J;6R7RHJ/QO^UCXE
MF\/^*O$?@33=(U"R\.7MQ9QZ-J%O=O>ZXUK(\=T+=X1M@_>(T<>]9"Y4L0@*
M@]9\'/!GC/0?VE/C7XBUOPZMAX>\4?V4^FZBE]#+YC6EMY$@:)6+H&)W+D=
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MZEX1LM,\0:A?W\^FG^UXY5U!IKY9\H< 1Q[5(!D(9C@D** /?M=^-VK^ _\
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MX7_%S5_V*O!_P\?X>);>)-"ET*U%F^MVV9$T^XBEEG9\[%23R $4%F^;+8%
M'JN@_'3Q[H?[1^A?#OQ[H?A^ST[Q7I%WJ>B2Z'<SSSVLML4,UO<M(%5_D8D2
M(JC(QM/6KW[=/Q.U?X/_ +*7Q"\3Z!,UMK,%DEM:W"J28'GE2'S!CHRK(S G
M@,!FJ7Q#^&_BOQ#^UU\(O&]EH;2>&O#^DZK:ZC>-=P*T4ET@" 1E]S;2GS$
MCYAC/./3_C7\)])^.?PJ\3>!-<:2/3=<LVMGEA^_"V0T<B]BR.J, >"5P>*
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M7A/X&VC^'_"7]K>,[73(+>WT.ZOX84\\(J?O)@Y38I!8[220,#D\ 'D_Q_\
MAKIGCK]I;X$Q^';(6'BSPQ?/K=_K-C"%:TT6.-T^RRLN/EN)BL:*>R7!7@,#
M]1#@5\I?##5/CKX:CALI/A%'_;NLW\4VN>+]=\56=POS,JR2BV@ ;RXX\K%
MC *H W$EF;ZM&<<T +1110 4444 %%%% !1110 4444 %%%% '!_&_\ Y)W<
M_P#7_IW_ *705W8Z5PGQO_Y)W<_]?^G?^ET%=V.E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '!_![_D :S_V,&K?^ELM=Y7!_![_ ) &L_\
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M .#^#W_( UG_ +&#5O\ TMEKO*X/X/?\@#6?^Q@U;_TMEKO* "BBB@ HHHH
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MN=L_*IP:=X<^-OP_\8>*#X<T+QIH.M:X+8W9L-/U&*>7R@VTMA&.<'KW&1G
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MX 3G@RL#SF@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q/&WB[3?
M/A#6O$FL3BWTO2;.6^NI>/ECC0NV/4X& .Y(KX)_8S_:.\3R_$#7])\7Z[K=
MY>>.]#G\7:9#K6GW-O%IU^C2M-86K3QH)8UMFMG!CW)^[8C&3G[\\4>%M(\:
MZ!>Z)KVFVNL:/>IY=S8WL0EAF7(.UU/!&0.#67XQ^'FD>+K.U:2PL%U;38IA
MH^HW%HLS:;+)$T7F1#((^5L$ KD<9H ^*-=^,_Q"^&WPB\5:O9ZOJMSK5U\(
MM,\1:4MU(;X37*L$U#4B2/W$B?:X"8MOEL$#\X=5Z;P[IT?P0^*'P+E\*_$[
MQ#XONOB#<26NN:9K>NG4TU.W^Q27+:A&K$K"8W6/F+ *R!<>OU#\-_@YX9^&
MGA33M&L-,M)7MM(MM%GO9+=?-N[>%"JK(3G*Y>1MN<9D;U-4?A[^SC\+_A/X
M@N]<\'> M \-ZO=(8Y+S3K%(I-AVY12!\BG:I*K@$C.* /#/VF?CYK'P1^*_
MB_6-+M/M\VB?#(ZU#;7=].+220:HD6&MU(7=AC^\'S8^7.*],^!?Q8\;^*OB
M9\2? _CO3= M=2\+IIEY;W?AZ6=X9X+U)V5&$P#;T,!!88#9!VK7HOB?X6^#
M_&MS>7&O^&=*UF>\T_\ LJYEOK1)6FM/,$OD,6',>\!MIXR,UJV/A;1],UW4
M]:M-,M+;5]3CABO;Z*%5FN4A#"%9&'+! [[0>FXXZT >,_LR^-[G4-%^)DNN
MZV]TUAX^\16L)O[G<8+:*\81QKDY"*HP . *^>-1_;/^*7BOP1\2H+6V\/:;
M(/AYJ?C#P_XATRVOXXU2WG2)A&;E5,[>7+O2546/>%X92<?6EQ^S)\);KQ<_
MBF;X;>%IO$;WO]HMJLFDPM<M<[]_G&0KG?O^;=USS1H/[,WPJ\,1ZDFE^ -!
MLUU*RGTR[$=DO[VSF;=+;'/2%FY\L84=@* /F_5/VP?BKH'B^\\+Z?X/TOQ5
M=>$K#1)=?&G07DC:F]^0<64A;9%MB((-P<R.&5><9Z75_P!J7XA6EG\5=9%K
MX+TO0/"_B:7PEI3:D]\]S?WOFVXC/EP*[/A)G_=1J7D=0!L&37M4G[,GPIEN
M/#<\G@#09)?#MO'::6SV:M]FAC<O&@SU578NH;.&)88/-;NL?!WP1K^@:QHE
M_P"%M+N-+UB^.IW]L;956XNR5/VAL8/FY1#Y@.X%0<\4 ?'GA/\ :1\9_%[X
MC_!]-8C;P[?Z9\2=<\+ZM::89[:WOUM]-,J,\,C%P/WBG9)DAES74_M/_&;5
M?V5_C/?>+KC4KNY\-^+O!EW9Z=ILTSR11^(+/Y[58UR0GGI*$.%Y9 QX!KZ0
M\-_ GX=^#S8G1/!.A:4UC?2:G;-:6$<9ANWC$4DZD#B1HP%+]2.":W/%W@'P
MWX^@TZ#Q+H.G:]#IUY'J%I'J-LDZP7* A)4# X=0S8(YY- 'QG9_'/XI? >#
M1_ASINACQOJOA/PWI>J^)KG6/MDMYJMU>2R&:*WN%'EQ;2CA'G^5FPG!4UL:
M]^V7\0M'^)&MVZ:#X9D\':/\0[+P/<;GN1J$JW7E[)4.?+!3<<YZ]@,<_3/C
MOX&?#_XG:Q8ZKXL\'Z/X@U"S41Q7%_:+*WEAMXC;/WXP^'"-E0P#8R :LW/P
M<\#7CWCS^$=&F>\U2/6KAGLHR9;Z/'EW+<<RK@8?J,4 ?$?PN_:@^-NG:9:Z
M9>77A?Q)XB\3?$O5_"UK<ZA]J6WLA CG 5"&$*L@V*!G;G)W'-;_ ("_:*\:
MZ7K_ (G\*Z#;Z7+XO\0?%76?#T%YXHU6[FTRT%I917$I12WF*KYVQ0(0H)_/
MZPT[X!_#G2?$=QKUGX*T2WUF?4SK+WJ62>;]M*E3< X^60AFRPQG<QZDU%XC
M_9Z^&GB[1M2TK5_ VA7VGZEJ;:U=PR62 37[+M:Z) !\XC@R [L=Z /DOQS^
MU+XJ^'OQ+/C+49-*UJ:R^%4]Q-HWAS6VNM$FU/\ MVWLUE23 R 9!N^4NJ[D
MR2,GZ5_9X^)7CGQY!XGL?'?A^VTG4='O(H8+^PM[BVM[Z.2!9"5AN?WT;(Q9
M#O\ O8#+PPKJ1\#/AV+%;,>!_#XM%TAM!$ TV+8-/9Q(UKMVX\HN Q3IN&>M
M7_A_\+?"7PJTJ?3?"/A^Q\/V=Q-]HF2RB"F:3 &]VZNV !EB> !T% 'PCX8^
M(GB+XP:%\#;?5?$VO^'_  Y\7O$_B34_$&HV.JM;RPQVPE6PTJ.?_E@CQQ(I
M1"&8QOM.6-=E\3_#\FB_#"W\#> _C->>,9(?&CVKZ%K'B=K&]O8H[;S'T&+5
M(U+HP#(^7)8CY2PQ7T7H'[-/A*U^'FM^!/$-C9^+O"%[K-[JUKI6JV4;1V0N
M9FG:)#U.V629E?A@'Q_"*V)OV>OAI<?#4?#Y_ N@GP6K&1=$^PH+=9"2?,"X
MXDR2=X^;)SF@#X8UKQ-K^M?!?PGX2TJ3XE3:Q9_%/_A']1\.S>*[>/4X!_94
M\_V"WU6-E6:W7Y'625MQVD'^&O5]/MM8^!NH_ +4;FW\::->Z[XLN_#>I:'X
MA\1C7)FM[NWD9&DE1V1@DEK#*I!.Q7E'\1%?3GA?X(> /!6AZ/H^A>#M%TK3
M-'O?[1L+>VLD5;>ZV-']H7C/F[&93(?F()&:/%WPQC\9?$+P3XDO-3F2T\*R
M75W;:7'& DUY+#Y"3N_7]W$\ZA1P3,2<[0* .V!R!2T44 %%%% '!_&__DG=
MS_U_Z=_Z705W8Z5PGQO_ .2=W/\ U_Z=_P"ET%=V.E "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '!_![_ ) &L_\ 8P:M_P"ELM=Y7!_![_D
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M=U-/->>%;<S7]K96L>]Y(_F0#,[VD9RPRLCCD$XY+PI\4_'?Q%\8_LZ>(?\
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M4-V\ED64F)A/;P.I8N%\M0H"\5'%^QAX!BOM#O/M&N/<6,OG7[OJ&3KCB_\
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ML\QI @]T\/?!'P%X4BLX](\(Z1IZV5W'?VWDVB@PSQPM!&Z'JI2)WC7'"JQ
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M7\'_ !/I>OZAI^O7DMKH=D+^^9M+N%,<)ECB# %/F.^5!@<\YZ UIZ7^V?\
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MOQZ_:2T?X@?L06/BC5K.ZT:]UY--O3:06=Q=11M'JD"R*)DCV DQMM5BK-D
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M<V_Y9"6SNW;CT9LE?E(KJ*Y[P&YD\/[C-)/_ *7=C?)?B]/%S*,>8.PZ!/X
M G\- '14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ^);K4]/TJWL$#M/J:NT1).%3"$,69B ,9Y/0UXA\2?VLO#GASX8>"_%LOQ
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 <'\;_P#DG=S_ -?^G?\
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MF*QIA5+$@ FKNF?"7P9I'AC_ (1RV\+:2-",QN6T^2T22%I2>9&5P<MTY//
M]*A0Q;6LDM/QOZ=O^&9"IXYI)S2TZ=[^:[?=V9YW<?M7Z%!X;T/6(_#VM7T-
M]HA\0W:6:PL=/LUD$;R.6D7?AB>(]Q(4G'2O< <C-<IXD^$_@WQ@NDKK/AG2
M]132L?84GM5*VX&,*HQ@+P/EZ<#BNLKHI1K1;]K)-:6_4ZJ$:\7+VTDUI:WX
M_P!:A11172=9P?QO_P"2=W/_ %_Z=_Z705W8Z5PGQO\ ^2=W/_7_ *=_Z705
MW8Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\'O^0!K/\
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MI_\ X0=M_P#)- 'O]%?+?@[P7^T7XCO_ !3!J'Q@M=&BTG5FT^SFF\!P8U"
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M,<=W#+("Z L"4C< CG)'(Z@ ]+5QCH>OH:7>/?\ (UX)_P ,+?!G_H7=4_\
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MEVLXC_I"_,D!C0\'E3\S=2GQ4_8&\#:IX+GM_ ^GWFD^(S=V3QW5UXHU;RQ
MMU$UTG^O?E[<3(/EZL.5^\ #ZHWCW_(T;Q[_ )&O!!^PM\&N_AS5/_"HU;_Y
M*KF8/V"/ "_$J]O)-,O6\'-I,$5O8#Q1JWFI?":8RR'_ $C[K1-"H^8\H>!U
M(!]0[Q[_ )&C>/?\C7@G_#"WP9_Z%W5/_"HU;_Y*K#\"_L&?#:Q\&Z+;^)M(
MO[_Q#%:1I?W4'BC5O+EG"C>R_P"DKP3D]!]!0!]+A@3W_(TZOG27]C?POX.\
M9>!_$7P_M+G1[W2=;2ZU%[SQ!J,XFLO)F5XUCEFD1F+O&<$#[IY'?Z* P!0
MM%%% '!_&_\ Y)W<_P#7_IW_ *705W8Z5PGQO_Y)W<_]?^G?^ET%=V.E "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '!_![_D :S_V,&K?^ELM
M=Y7!_![_ ) &L_\ 8P:M_P"ELM=Y0 4444 %%%% !1110 5Y3^T'\=+7X+>"
MK[4;=+'4-8C-N!:W=YY,5I%-,L/VRZVAY$M8RVZ21$8@ \=2/53TKX[^,GPB
M\5>*?B=-J_PU\#+!X@@\6*^H^*/%WEFUN+:?19;2<0H3YTMI%NMF,'^KDEW
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M&P+'SKB"U/$SI\I93_RS\P@%@H.?^SQ\>#\2/A;K>OZY?:5J!\.WEQ976O:
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MX>D$46M-Y42O+'(=S26MQ#'$DD,@RA3;G=&'JQ\;?#_Q M?$D6M:%I&G^+O
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M526."2:[3X7? K0OA+J+7FD75_/(?#^D^',7<BL/L^GK,L#<*/G83ON/0X&
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M=\C2],&E0M]HCW-$-6@U3+'R^6\^W1<]-A(QGD %O7?VOO"US<Z_HWAFRO\
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M.>5XK_Y^-'_[\3?_ !='E>*_^?C1_P#OQ-_\70!T=%<YY7BO_GXT?_OQ-_\
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M_P#/QH__ 'XF_P#BZ .CHKG/*\5_\_&C_P#?B;_XNCRO%?\ S\:/_P!^)O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "OFO\ ;;_Y%CPU_P!?LO\
MZ*KZ4KYK_;;_ .18\-?]?LO_ **KZ3AS_D:T?5_DSXKC3_D08KT7_I2/D.BB
MBOZ!/X_"BBB@ HHHH **** "BBB@#L/@Y_R5;P?_ -A:V_\ 1@K]'QTK\X/@
MY_R5;P?_ -A:V_\ 1@K]'QTK\AXV_P!YH_X7^9_1GA?_ +CB/\:_(6BBBOS@
M_:0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***YSQOX@UCPUI8O-(\/2^(V0GS;:WN%BE"^JA@=_?@'/H#6E.G*K-0C
MN^[2_%V1C6K1H4W5G>R[)M_<DV_DCHZ*^9IOVV+.WE>*7PA>Q2(=K(]VJLI]
M""G!IG_#;VG_ /0IW?\ X&I_\37T7^K6:O\ Y<_C'_,^-?&W#ZT>)7_@,_\
MY$^G**^8_P#AM[3_ /H4[O\ \#4_^)H_X;>T_P#Z%.[_ / U/_B:/]6LV_Y\
M_C'_ #%_KOP__P!!*_\  9?_ ")].5\U_MM_\BQX:_Z_9?\ T55?_AM[3_\
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MMLO_ (U1_P (7XK_ .BA:C_X+;+_ .-4 =Q17#_\(7XK_P"BA:C_ ."VR_\
MC5'_  A?BO\ Z*%J/_@MLO\ XU0!W%%</_PA?BO_ **%J/\ X+;+_P"-4?\
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M_DU?J<]X*\ Z%\/M*73]"T^.RAX,C@9DE8#&YV/+'Z_ABNAKD/$'Q)M_#OQ
M\,>$Y-#UZ\GU]+AH]4LM.>;3[3R4W%;F<<1%NBYZD8XXST>HZI'IUC=W'ERW
M1MHC*T%JAEF8 $X5!R2<<#O7S-2I.K-SJ.[>[>Y]S1HT\/35*C%1BMDE9+Y%
MRBN(^"WQ>T'X\_#32/'7AD78T+53/]E-[$(I6$4\D)8J"< M&Q&3G!&0#D#M
MZS-@HKE_B/\ $KP[\)_#$GB'Q1J*:9I27%O:F9E+?O)I5BC 4<G+.,XZ $G@
M&NG#!ER#QZT +17GOPH^-^@?&*]\76FB6VIV\WA?5FT:_&I6OV<_:%C5V"*2
M6(&\#) R0<9&"?068*"3T% "T5YQ\*/CMH'QAUSQGI6CV6KV5WX3U%=+U!=6
MLC:DS&/?\BL=Q7!ZD#/49!!/H] !145S.+:WEF*/((T+[(UW,V!G '<^U<Y\
M,_'L/Q.\#:5XGM]'UG0(M01V&F^(+(V=]!M=D(EB))4DKD<G(((X- '44444
M %%%% !17G/B'X_^"O"OQ@T#X9ZIJ4UGXLUVW^TV$+V<OD3#]YA1/M\L.?)D
MPA;/ XY&?10<B@!:**\X^.WQW\/_ +/7@U/$WB6SU:[TUKJ&S_XE-D;AD>5P
MB%SD*BEB!N=@,X R2 0#T>BN4UKXA0Z)\0/#?A1]$UR[EUR&ZF35;2Q,FGVG
MD*&*W$P.(F?.$!'S$8XXKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#B?B4D>E'0_$HD$$VEW\,3R;22\%Q(D$D9QU!+HW^]&I[5VHZ5PGQO_ .2=
MW/\ U_Z=_P"ET%=V.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '!_![_ ) &L_\ 8P:M_P"ELM=Y7!_![_D :S_V,&K?^ELM=Y0 4444 %%%
M% !1110 444AZ<=: %HKSCP_<_%23Q9\1DU>T\,QZ!&(1X.>"6;SI3Y+&3[;
MUP/,V#Y!G&[K@$\]<7WQY/P4\,3V^G>"?^%I/=VXUJVFFN!I:6YE(E,3#Y]_
ME[#W ._&["Y ,#XS_$'QOHWC77+*37K/X<>$;/1TGT;66@M[ZZUK4FWE[=+=
MR69(U5<HB;V+@AP.*\UU+]JWXG:W^S#\%OB5H5EX<M=2\6ZUINEZK93Q3%29
M[MH#Y#EB(E8IR760J'.,E03V6O\ P>^*-C^TKXU\6:1%X;UWP_XJT.#2K34=
M;N95NO#HB4AHXHD7]Y#*SN[*K*6;:6<!<'@/!/[+'Q?M?V7OAM\/-2E\(VFJ
M>$O$NG:I&%NKAXVM;2Y>X.Z01G=+(Y4!0H55'+$G  /2?"GQ/^)'A#]JNR^'
M'C;5]&\1:1XF\.SZY8R:9IK6;:9/!(J2P<NQEB(8D,QWYQT'%<'KGQ)\?_M&
M_LN?$CXF>'-=TO1?"ES8:U;Z+H$VG&7[9I\"7%O)+=S,1(DTA1W18]JQX0-Y
MF6Q[!XC^#?B36OVL?!_Q+B?34\.:-X?O-'G@DN'%X\D[A]ZH(RFU=JCEP3D\
M<<^,> _V?_C7\'OA)X\^"FB6OAGQ%X'O+;4E\-^(+_4I(+FRANC(6MIX%B/F
MOF5B'#*H+$DD84 'NO[''_)J'P@QT_X133<9]/LZ5YK8?$/XT^/?V@?BQ\-K
M#Q#X7\/6>@Z=IMS8ZM#I,ES+;?:5E9<Q228E<E0&8L%"H,(2Q(]G_9T\!ZU\
M+O@;X'\(>('L9-6T+2;?39GTZ1Y(7\I @96=5)R%!/ P3CG&3RW@?X1>)_#'
M[2/Q3^(=R=+ET?Q/IVF6=A:Q7$GVE'M$<9ES&%4.9#]TMC H \J\'_ME>)-:
M_9I^&_B*;3],;X@>,?$Z^#+9I$==/6\^TRPM=.JG<(PD+R>6""3A<@'(Z_Q!
M\5?''P)^./P^\+>+-5A\7^#/'T\NFVNKC3EM;O2M26-6CB<1?))#*=VW(WK\
MV6(7)X'1OV)?&5O^R_X>\%/KVD:5\0?"/BF7Q7H&KVDLT]E]I-Q),BS HC[2
M)GC. <8##/2O4KGX;^,?C9\0_ASXC\=:'I_A31_!=S+JRZ/!J(OY;W4S%Y<,
M@D5$"0PAW8?Q.Q&54+\P!R.C_M"_$)?#/[06CZQ>>'+7X@_#B9KC3R--F6SO
M+%K?S[21X_/+,TVUT(1_E; P3P>A^%_[0NN_%GX0_!O5](N-/7Q3XOF']J1F
MPD,-HENCG4,1F0,FQT$2EF/S21D@AJO?$#]FZ]\4?M.^#_B)I^I+8:%%IK6?
MB33P1NU$VTZ7&G#&W@)-N=CG)$:+C#$T[X#?LV3?"'XL_$SQ#)?BZT/6-3DN
M_#VGDY_LV.Z$<U^J\ *)+A%PHZ+$O7)H ]QUD:@VDW0TM[:+4C&1;O>(SPK)
MV+JI!(SU ()]17P_??M<?%+_ (=W7_QKM[C0%\76][=1W'F:>[6ZQ?VFUH@A
MC$@PRAD(,A?.WY@Q.:^Z+II5MY&@C668*2B.^Q6;L"<' SWP?H:^,#^QKX]D
M_8%U?X#M?^'5\27M[)(FI"[G-F(GU$7NX_N=^X<IMVXZ'/:@#O+OXE?%/P-^
MT[\+_#GB+4M"U3PK\0;?5(_[-L;%HGT>:SM_M"%+@L6N-Z85BRH,AB%7(6O7
MOCMXMUGP!\&?&_BCP]]A.L:'H]UJ=NNI1/+ QAB:4JRHRL<A".&')!]JXCXB
M_"?Q;XP^-7P/\:V8T>"P\%'4I-5LY[J3S96N[06^+=A'A@F7;Y]F[Y>G..D_
M:>./V:OBSG_H4M6_](Y: /ESQ!^T/^T#X*^ ?@7X]W\OA;4?!ATS3+S6_"UM
M9/\ ;)K:X6,2W:W.X*LA9PRQ*NU P#%RI)]=\8?&_6_'7C[Q1X/\):Q?^#XO
M#UI9O/J]OX8FUJ:>ZNK?SXE$:*T:1)&R%MQWNS878%W-YO\ #KX>>.?C_P#L
M5?#'X9W^E:7HOA?5/#FCC4O$$5^9FDTY$@E6*"#8&6X=%56+D(AWE2_RBNP^
M(?P:^+?PP^.&I?$GX+2:#K=EXELK2P\0>%?$MP]N@:UB,=O<6\R#Y2$PK!LG
MKUR-@!F^%_VJ?B3K/@GX8^&]?\()X*^,'C77+O1A!JMC+%:PVMK'YUSJ,<#N
M'=1$4VQLXS(Q&=HY[.S^*GC/X9_M$:!\*_%&H0>*=.\9:7>WWASQ ]FEM<07
M5J"\]M<QQ$(Z",HRR*J')*D,3D8GQ;_9I\>^-=)\">-H-?TR_P#C!X/UQ_$%
MNMPTT.DR+*B)/IT>,O'#Y<42AR"69&9@/-;'6Z5\,O$GQ'^.'A'XF^--'L_#
M">#]-N[/1](M[_[9.]S>+&MS/-*H5 BHFR- &)W,[;3M4 'A7@OXR_M+_%KX
M&ZYX]\.:CX,L[[PYJFJ!M,;2Y93K:VDC#[.@W_Z.I"%1EG=F/WT&,VOC/\5X
M/CG\-_V0?'EM:/8)KOQ)T2Z>U<Y\F3R[E9$![@.K 'N,'C-9W['<WQ&U']G'
MQAH/A;0]&F?4_$FO6UAK5WJ!2*R+W$BO)<P%"SE6)95CR'& Q3DUZEXM_9,U
M*Q\ _L_>#/!MQI_]D_#3Q%IVMW=SJD\D<MXELCB0(JHX\R5I9'Y(53@#@\ %
MCQ;\;M>\>_$+Q]X1\(>(KGPHO@^6VLFU&S\*SZX;J]D@\YU?8"B1(&1"HQ(6
MW$,H W>E_LW_ !%\6?%'X1:-KOCGPE=>"?%K^9!J.D75O)"$D1ROF1K)\WEN
MNUADG&2,G&3X]XK^#OQE^$WQZ\4^//@\?#.N^'?&WV>36O#/B*XEM!;7L<>S
M[7%*BL?F4#<.I+'@X4CZ)^'>C:]HOAF%?%.J0ZMXBN)'N;Z>T1DMDD<Y\J!&
M)*Q1KM1<\L%W-\S&@#RRS^+GB_3?VI]9^&?B"72[;0]2\/'6O"U]'9.DLKI(
M$N8I',I5VBRK;5"DJV3@5PGP?_:L\2?$'X%^-]2N+K0Y_B/I.OOX=L+6TLY(
M[.>XF>-=.E$;S;WAF65)-^Y<KOQPN:[[]J#]GB]^-UWX!U+1-4.@ZSH&L9GO
MXCME;2[B-H+^!&ZAGC88[94<>F=I_P"RVFB_M41_$#2YHM/\'/HELMSHD#;1
M)JMJKV]K/MQC:EK+(F./F5#SV +OB_XD^/?"7[2GPA\%SWNC3^%_$]EJ;7CP
M63I=27%I:JY.6=E2-FD#!0"PVX+')K@_V5SXWU'XX_'K^WO&$&NV^G^)8K*=
M)=*$3R1"Q0Q1PLLV(8TWXV[7+8))W.QKU'XE?"KQ/XL_:&^$?C;39-*BT#P@
MFJI?Q74L@NI_MENL2^2H0K\I122S#@G K"^&WPG\>_#7X\_%;5;>/1+[P5XP
MOH-;ANI;F1;V&=;7R7MS&$VX+HC"3<<+GAF/R@'RW\$?&WQ4^#W_  3[\+?$
M#PIJGAZU\,>$WO+J70;NQ>>;5;8:K<K<*\^X>00&'EA%)^0EF.X*OZ/Z?>QZ
ME86]W#GRIXUE3<,':P!&1]#7R;HO[*GCG3_V"+[X&7%WH$GBB>VN[1=2CNIA
M8D3WCW&\DP[P5$A7;M.2HY&>/I_1+34=)\'V-M)%;W&JVUE'$T:R%(9)5C (
MW;20I8==I(!Z'I0!\A?ME:Q\-/C3XSUCX3^._'7A[PGINAZ!)?Q_VUJT=IOU
MFZ1TLGVLRLXMXA)*P^Z3<1?>P0/3/V"OCE_PO?\ 9G\.:G=7276NZ0AT3576
M4R%[BW 42%CRWF1^7)GU<\\&NV^!GPOU/PCX2OSXUMM(OO%^K:I=ZKJM[8$S
MPSRRR$H$:2-7"I$(HE4@X6)1D]:X+X7? 3QQ\+/VH_B3XOTR30$^&?C4P3S:
M0MW/]MM;N*$+]H1/*\OYVW[E##AE.?DVD XW]FQO$<>J_M3_ /"(K8_\)&?B
M+<K9'4E+6R,8H 6D564L%4LVT,"<8R,UO/\ &'XFZC^TGIWPN\+:_P"&_$\>
MEQ+J'C._DT.6W32+9BOE0(RW3!KF4$E5(PJX8@C(&I\//@S\3?AA;_'2^T23
MPRWB#QGXAFUW09+J\G,%J946/%R!#G*! ^$W!C\N5'S$^!OP:^(?P5\"0^'[
M"PT&?6M1U&/4O$7BR^U^>[N]1N'E0W<YC:R7+-&KHB%P%&WYL@D@'EOA9/B"
M_P 4/VK9? _B#2_"LMCKUO>G4;ZP-^\LD>F1.(!$6540A2&D)8\X51C-=SI?
M[6^K>+?A-\$+NSLX]+\5_$FUEN)9HM/GU"*PBMHM]W+';Q9>1BQC6-"<+YH9
MBPC8-U/@?X(^+_#7B'X^:I=-HTJ^/+S[7I$,-U+F("T-LHN&,7RYVHQV!\98
M<X&?+[S]COXB:-^S_P#!NV\,>(=(TKXN_"AII-*NA))+IM^DF4F@D)16598]
MH)V\8*Y ;< #N_A;\0?C%>^*?'OA&^MO[5L;*QCU#PWX[UOP[<:;!.SG$EK<
MVX\O?)&2<&(KN5<G!->4:M^UA\5_^'?7A?XSV-WH">)+Z8+J!N-/=EVRZFUJ
MBP('VH54K\S[\A3D$G-?1?PMM?C#J]OJFO?$5- TO4&LFM-,\+:%=R26B.22
MT]S<.A9G8JBJ$!$:;OO,Y"^*W'['/CH_L$Z%\"H]0\/OXDLKJ%IM1:YF6R\N
M/4#> J?*+EB-J8*@9).<  @'1>+?B3\:O W[2'A/P5_;'A75[+Q[IFHRV$%Q
MITL,6A3VBJY;>C^9=J4< JQC+,"08QQ47@S]H_Q9\-=<^/OA_P"(U[;>,1\-
M-+@\0PZKI=@MC+=VLUO),(&BWL@=?+VA@<'.37H?Q#^$/B;Q7^T9\(_B#9/I
M<>D>$K75(-0M;BXD%Q*;R)$'DX0J=A3)W%<YXKE+O]EW6/%?Q8^/6IZ_=65M
MX3^)?A^TT*(Z=<NU]:B&!X6=E:()\PD9AACC: <YR #G]1^,GQC\/>*/ 6L6
M5A?^-],UN_@L_$?AJR\(7=K'HT,HR;FVNY%1G$1PK&7.\98+&#A:>D_$K]H+
MXD_''XR> _#>O^"-(_X0F^T4Q7%WI5Q(DD%Q"]PT6/,+%F7"M(2!^[&Q5+EE
MU_@]X"_:1TNQTOX>^--7\+IX/T0PP#Q?I$TXU;4;.'9Y<(B/RQ2.%"O*22%+
M;06(>N[^$/P;\3>!?VB_C5X\U-M+?1?'<FEO90VMS(]Q;?8[9H/WJM&J_.&W
M?*QVXQSUH ]-UWP-:>(_%.AZQJ4TES'HLC7-C8,J>3%=,CQ_:#QN+K'(Z+R
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MR^.4$>E>(/#'A^/Q-IVO)>Z%\1K:]V3Z=8+>"9!Y:HLIG$(\DQ@F-FP^\'H
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MM+C*A+>.VV[$G"#RQ(Q*H.?WA4;OKP4 +1110 4444 %%%% !1110!P?QO\
M^2=W/_7_ *=_Z705W8Z5PGQO_P"2=W/_ %_Z=_Z705W8Z4 +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <'\'O^0!K/_8P:M_Z6RUWE<'\'O^0!
MK/\ V,&K?^ELM=Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6!X[\#Z5\2/">I>&]<6YDTC4H6MKN&UNI;9IHF!5XR\;
M*VUE)! /()%;]% ',?#GX=:-\*O"=EX:\/+>1:-8QI#:6UY?37?V>)$5$B1I
M69@BJH 7.!73T44 %5]0LDU&QGM7DFB29#&7@E:*101C*NI!4^A!R*L44 <%
M\*/@AX5^"EA>6/A*'4+*QNYGN9+6YU2YNX_-=R\DBK,[;69B22,9KO:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X/XW_\ ).[G_K_T
M[_TN@KNQTKA/C?\ \D[N?^O_ $[_ -+H*[L=* %HHHH **** "BBB@ HHHH
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MS9Y806R6E&851 3([J2"(LI]@6LZ7-O'-&28Y%#J64J<'D9!Y'7H: ):***
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MY\MD@5&WY:U9<$J6+_(&*,*X[1OVBM?BT_6]3>ST_5C=ZFK6-C_:2I'96O\
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MI?!F>;[3/I;P3Z%IVGRQZ=&Z;[NWENS).VX#=OCGA7)^;]WCH%KVV@ HHHH
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MH$;F+4-18,/+FO)%.88\ D6R')W#S6ZQ#U2BB@ HHHH **** "BBB@ HHHH
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M:^WH*KS0<5=M<LGM-6W:[/06DQ2U%=74-C;37-S,EO;PH9))96"JB@9))/
M'>MCS4FW9$M%>%?%_P#:X\,?##1O#6JZ?;/XPT_6KM[9+G2)U:./9C?\W(9_
MF&$X)]17N%M.+JWBF5659%#A74JP!&>0>A]JPIUZ564H0E=JU_GL>IBLJQN!
MH4L3B:3C"HY*+?5Q=I*VZL]-4B6BBBMSR@HHHH **** "BBB@ HHHH ^/OVR
M-,O--\7:=K%U-IFG:1>)#96]S??$;5= >>YR_P"Z2WM$97X8'=UYYP *]O\
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MUB$17! F< %0!\H'"''*!3SG-;U !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <'\;_ /DG=S_U_P"G?^ET%=V.E<)\;_\
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MEW4*+Y4DJ28EDC6-L'T8Y[9K[%'2O /VNQA?@QR>?B9HG?WEKW\=* %HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.#^-_P#R3NY_Z_\ 3O\ TN@KNQTKA/C?_P D[N?^O_3O_2Z"N['2@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_@]_R -9_[&#5O_2V6N\K@
M_@]_R -9_P"Q@U;_ -+9:[R@ HHHH *\5_:XATF;X40_V@-;;4$UBP?11X>M
M(KN[.I"8?9@L4W[EQN^\)2%QGD'%>U5\_P#[9?PU7XA_#W2UM_"%EXNUF#4H
M8+--3FNUM+/S756N)4MG5W"E4[_*2&R ": )/V0X+.'PYXO:;^WU\72:Z[^(
MT\16%O93K>&WAV[(K8F$1^3Y)4HS9ZL<DU[Y7R_^P%IFH:=\-?$AO_"2>$7F
MUHR?9H["\LUE<V\/FMMNY'E9EDWQE\[6,>5R.:^H* "OG_\ ;;_Y)#I'_8W^
M'?\ TZ6]?0%?/_[;?_)(=(_[&_P[_P"G2WH ]_7I^)I:1>GXFEH 9+D1/@L#
M@\J,G\*QO!,DLOA32WGGU&YF:!2TNKVX@NF/K+&%4*WL *V9>8WP&)P>%.#^
M%8_@N*6#PKID<T.HVTJP -%J]P)[I3Z2R!F#-[@GZT ;=%%% !1110 4444
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MNG_9S\&>(_ /PETG2/%ERUUKJR7$\[RZC+J,JB29W1)+F0!IG5&52^%!*Y
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M0Z9YS&AC*^(RZA&E"I%PY'^\45)).SDKW=KI[J]EH%%%%=I\R%%%% !1110
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MUI^BHCZA?VUBKDA&N9EC#$=<;B,U\H>+7^.'Q ^-'B;P<\=U;_"[5H;NR@U
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MC_A$X!.@AUVX)UK-OY^RQ_T']XW_ "SP<?/Q[U;O?BO\5[.X\'Q#X7Z7<?\
M"1R^6SQ:]<%=+_T=IMUW_H/R#Y?+XS\Y KO_ (L_$[2_@_X#U/Q5K$=Q/9V0
M4>3:INDD=F"JH[#)(Y/ I_PJ^)&F_%SP%I/BO28KB"ROT9EANEVR1LK%64XX
M."#R.#5>UI^T]E?WK7MY&?\ 9^*^I_VA[-^QYN3FZ<UKV];:GF>F_$[XGK;>
M.KV#X1Z1:2:#=31NG]M3I+K31VZ2^;;8L?WH;=Y:D\EE([5XQ\9/#'C[Q%^U
M3\&M4O-,TS3]1OX;F2VLK?Q'<>4OV-5G8,QLP8R_FA6 5MVW'%?;SN(T9CG
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M+]X]>/SK9\5^(?VC_P#A?NF0Z4;.X\,3+'.DEH"=&>)47S#)*09%&YQGG/\
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MN?\ K_T[_P!+H*[L=*X3XW_\D[N?^O\ T[_TN@KNQTH 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X/X/?\@#6?^Q@U;_TMEKO*X/X/?\ ( UG
M_L8-6_\ 2V6N\H **** "BBB@ HHHH *CF@CN%"RHLB@AL.H(R.0>:DHH **
M** .2^*GPZL?BMX&U#PU?SRVL5RT,T=S"%+P30RI-#( W!VR1H<'J 1WI/A=
M\/(?AIX7;2UOIM4N[B]NM2O;Z=0C7%U<3--,^T<("[G"CH !SUKKJ* "BBB@
M"MJ.FVFL6,]E?6L-[9SJ4EM[B,21R+Z,IX(^M&G:=:Z18P65C;0V=G @2*WM
MXPD<:CH%4< ?2K-%*RO<OGER\E]-[=+]Q",C%>':O^RU8W[:Y=VWB&[LM8O/
M%W_"8V-\+:.3[#=&U6U*!#Q(AC#CG!RV>U>Y4AX%,@Y[X=^!M-^&7@70/">C
M^;_9FBV,-A;&9MSE(U"@L>Y.,GW-=%7QW\4?VW]1^'7A[XS7'EZ!)KG@C7[;
M2M.TJX,JMJ$,@MBTC$-D,!<-TXS'[U[Q=_'_ ,)Z5XV3PC<7L]QJXO8](>:"
MT8V_]H/;/=):;\X$K0QM)MY !4$@L 0#TRBO!]-_;1^'&K^"M3\4VL^JRZ3I
M_A^+Q/,_]FN'^P/<36XD"GDD/;S97J A/(Q71:-^TEX5UOQ1HWAZ*WUFUU?5
M86NH;34=-DM)EMQ<&W69HI=LFQG'#!3\K*QPIS0!ZM7D7QW^ DGQNU/PA+/X
MA:QTOP_>G46T6>R6ZLM0N ,0O<1EUWB(Y95)QN()!Q7KM% 'C_@C]F_2_!GQ
M/NO&*ZK<W9:;4+NUT]XU2.VN+]X7O9 P^9@[0*54\(&8<Y&/8*** "BBB@ H
MHHH \(\1_LMCQAK]_P"(-;\7WU_KZM9MI%\;.&,6!M;W[9 SQJ L[!\)E@/W
M8V\$ECZ7\*_AU8?"?P%I7A;39IKFVLA(S7%P1OFEDD>65SC@;I)'.!P,X'2N
MLHH **** "BBB@ HHHH **** "BBB@!KQJ^-RAL'(R,X/K3J** "N8^)WP_T
M[XJ_#WQ%X/U9I4TW6[&6QG>$X=%=2-RGU'!'TKIZ* //_@]\*G^%^GZX][J[
M:_KFNZB=3U+4?LPMDEE\F*! D09@BB*&,8R<D$]\#T"BB@ HHHH **** /,/
M'_P*T_XB?$&T\1ZEJ$HM(_#NI>')]-2(8GAO#'O?S,Y4@1X P<[O:H_@5\#5
M^#5IJC7&NS>(=3U!+.WDO)+9;=1;VENMO;H$4D9"+EFS\S,3A1@#U.OGSQQ\
M8?&6G?M6Z+\--,NM)M=!O_"=UX@>>XTV2>Y66&;R@@83HNTY#?=SQC/.0 ?0
M=%?)_P"S]^V<OB+]G_PMXY^(TD*:SKFEZMX@DL_#VERB&ST_3YO*N)6W2.2%
MS&2<Y)DP%P":]4L_VHO >H>.Y?"=O>7<VJ1ZQ::&62T<PFYN;.2\A ?H5:&%
MVW#@8 [B@#URD(R,'I7A'AW]M/X:^)-$L-8@N-7M-*U&]&F6-_J&E36MM=79
M:X7R$FD CWYM7&"PY>,9RX%>ZPRB:%) K*'4-M88(R.XH H0>'['3H[@Z99V
MFFW$J%?.@MT4YYP2 !NP3G!KYL\'?L6:AX8\,26MSX[AU3Q-'XAB\5V_B>;0
M5%Y)J:^8IEN<SD3IY4SQK&-@0'BOJ6BDDEHA)):(Y3X5?#G3OA)\.] \'Z5)
M--8Z1:K;1S3G,DF,EG;'&2Q)P.!FNKHHIC"BBB@ K"\::/J^N>'Y[30M;'A[
M4V9&CO6LTNT # LCQ.0&5@"IP5.#P0>:W:* /F8_L0Z28=!B/B:[\N*V6TUO
M%H@.IQ+J?]IJJ88"V N"P 4,!&VP= U?3 &*6B@ HHHH X/XW_\ ).[G_K_T
M[_TN@KNQTKA/C?\ \D[N?^O_ $[_ -+H*[L=* %HHHH **** "BBB@ HHHH
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M_P (E<?]#'K/_?V+_P"-UT5% '._\(E<?]#'K/\ W]B_^-T?\(E<?]#'K/\
MW]B_^-UT5% '._\ ")7'_0QZS_W]B_\ C='_  B5Q_T,>L_]_8O_ (W7144
M<[_PB5Q_T,>L_P#?V+_XW1_PB5Q_T,>L_P#?V+_XW7144 <[_P (E<?]#'K/
M_?V+_P"-T?\ ")7'_0QZS_W]B_\ C==%10!SO_")7'_0QZS_ -_8O_C='_")
M7'_0QZS_ -_8O_C==%10!SO_  B5Q_T,>L_]_8O_ (W1_P (E<?]#'K/_?V+
M_P"-UT5% '._\(E<?]#'K/\ W]B_^-T?\(E<?]#'K/\ W]B_^-UT5% '._\
M")7'_0QZS_W]B_\ C='_  B5Q_T,>L_]_8O_ (W7144 <[_PB5Q_T,>L_P#?
MV+_XW1_PB5Q_T,>L_P#?V+_XW7144 <[_P (E<?]#'K/_?V+_P"-T?\ ")7'
M_0QZS_W]B_\ C==%10!SO_")7'_0QZS_ -_8O_C='_")7'_0QZS_ -_8O_C=
M=%10!SO_  B5Q_T,>L_]_8O_ (W1_P (E<?]#'K/_?V+_P"-UT5% '._\(E<
M?]#'K/\ W]B_^-T?\(E<?]#'K/\ W]B_^-UT5% '._\ ")7'_0QZS_W]B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cgtx-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &= FL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y#_A)-4\3ZA<VOAU((+"TE,-QJ]V"RLXR'2",8
MWE2 "S,%!R &P<:/CFYN+;PIJ'V24V]S,JV\<ZDAHFD81AQCNN[(^E:>E:7:
MZ)IEII]E%Y%G:1+!#'N+;44  9))/ ZDYH R?[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QJK?7/B3PTC7;^7XBTZ-"T\,$(BO%]XQG9)CJ5.T]<%CA3U=% %;3=1M]
M7L+>]M)!-;3H)(W (W*>G!JS7+^%X9-)\2^(])W!K/?%J5LH)_=+/O#Q\_\
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MKX*_\%$OCM\//#8U6^\'67AV'5K?0IK^YOI6N%M+28B-IG=R[O<2]23\P X
M% 'Z).P1&8Y( R< D_D.M?-7AK]M.V\6?M9'X(0>#=4TB]MM/:_N[_5Y(T<+
MY2RQA(HV? 9)(V^<JPW$,BL"*A^"G[8/B[XL?$73O#.J_L^_$+P)8W22L^N:
M]82Q6D&Q&8!V:)0"Q&T<]2*^?/#1Q_P6J\7?]@"/_P!-UK0!^D%%%% !1110
M 4444 %%%% '/6/_ "4'6O\ L%V'_HV[KH:YZQ_Y*#K7_8+L/_1MW70T <]X
M\_Y%J7_KXMO_ $HCKH:Y[QY_R+4O_7Q;?^E$==#0 4444 %%%% !1110 444
M4 %<!XI^$,?BCXK>$O'A\4Z_IEYX;M[FU@TNP>V6RN8[@QF99U>!I'#>3#T<
M;3&I7!R3W]% ' ?'/X)^'/V@?AQJ'@[Q-"S65PR3PW$6!+:W$9W1S1G^\I[=
M""0>":X7]I+]CKPA^TM8>&I=6U'5O#OB;PW()=*\1:%,L5U 0/N'<K!DW!7P
M,,"@VLH+!O>:* /)](_9TTF+X2^(? ?B'Q'XC\:P^(;.6QU/6-?OA-?31NA3
M:K!0J!0QVA5XZG<<D^%W7_!+[P1K_@WP=X>\2?$+Q[K5OX28C1S]MM8X[6+S
M&<1+']G92,L,LV7^4 ,J (/LRB@#Q;QS^ROH/CO]H'P7\8;GQ+XDT_Q1X4M1
M9V5M936OV*2(F7S1)');N29%G=&*LIV[=I5E#5O_ !U^ /AK]H#P]INGZ[+?
MZ9?Z3?PZII.MZ1*L-]IMU$P9)8796 /&""I&/< CTJB@#P[P1^SGI'PL^(/C
M#XO:E?ZSX\^(>JZ9';W-T\%O&3%!'@16EO&J*K2!(P=[,25&&4%L_ _PEU/X
MX>"_@S')H/[57A+PHL,=W=1^#_$MI9S:Y#*))"8)XY(I9_/9ACRP&;+84'@5
M^M-% 'R+9?LP:A^UEX%^"'CSXT:GXD\,_$+PM:I?KIFE+:6L<=V98Y#+-%);
MR,)'$$!:/<%4J0$0[A7L_P"TC^SEX6_:C^&K^"?%MQJ=IIINXKY+C2+A89XY
M8\@$%E=""&8$,K#G(P0"/4Z* /F33/V / NE?%'P=\0XO%GCN;Q7X;M%LA?W
M.N^=)J$:JR8G9HRR@H[(5A,2X/ !R:W-,_8V\.Z3\4OB;\0(/%_BPZ_X_P!.
MFTS4M\MD8;:)]@0VZ?9>&C2-40N7^7.X.QW5[_10!\LZ1_P3P\!Z%^SCKGP2
MM/%7B]/!NM:FFJ7CM<637;.IB81B0VN A>")CA=V4QN + VOB'^P%X)^)OPL
M^''@/6?%7BX:7X"&W2;NWGLDN7  6,2G[*4;8BJHPBY"@MN))/TY10!XE<_L
MIZ)J'[2&B_&N]\6>*+SQ3I.FC2;>R>:T2P-MY;JR-&ENKG<\LDI^?[[<84!!
M[;110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1XQ^
M :^(?BS'\2='\9^(?"OB>/28=&V:>;>6QN+>*::94G@FB?>"\YR59' 4;&0D
MD^KT4 >-6/PETKX7^(/%7QB\176K>.?'*:/)'+=16X+0V4*M+]BT^T3A5+!B
MJL7D9G.9#NKS#X)0>#?VI_C5X9_:#TG09M.N=)\-OI<[7,JLWVR63<D)4?\
M+2"$N6;&#]KB4',3A?K2B@#P_P"/'[)'A?\ :'^('@'Q9XDUWQ#:7'@FY%YI
M5AIDMM';&;S8Y6>3? \C;C#$I < !. "6)H>&OV,/"/AOX^>,_BV/$'B6_\
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M3QS:4/"/_"S-$$T+0R_;S=[IMC*^[RQ%LWY!7=N*X( (/UE7S3^VY][X _\
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M=?.G_!1#_DRWXJ_]@Q/_ $?%0!]%T444 %%%% !1110 4444 %%%% !1110
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MI\.KZKH#:/ -+MY)%C2UC+.LD8E,N7#$@D A3G/3_M_OH=_\/]#T34OA5?\
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M *^=/^"B'_)EOQ5_[!B?^CXJ^BZ^=/\ @HA_R9;\5?\ L&)_Z/BH ^BZ***
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M* "BBB@#GK'_ )*#K7_8+L/_ $;=UT-<]8_\E!UK_L%V'_HV[KH: .>\>?\
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M1S7TK7S]^R[^RU!\%HKSQ1XGGMO$/Q.UF-5U'5T4F*TB'(M+3<,I"IZG ,A
M+=%"_0-=>"6(6&IK%M.I9<UMK];'+BW0=>;PJ:IW=K[V\PHHHKM.0*:[K$C.
M[!$49+,< #U-.IDT,=Q"\4J++%(I5T<95@>""#U% '*?\+?\!_\ 0[>'?_!M
M!_\ %UNZ%XDTGQ1:/=:-JEEJUJCF)I[&X29%< $J64D X(./<>M?)/QN_9P^
M$ND_'S]GS3['X7>"[.PU36]4BO[6W\/VD<5VB:3<R(LJ"/#A756 8'!4$<BO
MJ?P5\/?"OPUTJ73/"'AG1_"NFRS&YDL]$L(K.%Y2JJ9"D:J"Q5$&[&<*!V%
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M0O\ @HJMOJ?AOX?Z!=77CN]MM6UB6*;PM\/H6-_K$:6[2$^8%8*("JR[2#O
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M&/P8\867A;Q?X@N=,UR]@CN8+:+1[ZZ5HW=D0^9#"Z#+(PP6!&,D $4 <O\
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M;8MN>]@MI)&CD:/&51%!! QBOKJ]M_M=G/!N"^;&R;BNX#(QT[_2OCKX=_\
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M>%6\/VMJNG[Y)FBQ=1_O)/+0%/F^]NR>17W%7S3^VY][X _]E:T'^5Q7TM0
M51US5HM T34-4FAN;B&RMY+EX;*!YYY%12Q6.- 6=R!@*H))P "35ZB@#\LO
M&WCO7OVQM1M_'K^)+WPOI>G2L_@ZRT:XVR:5,C$?:YRI^>X;&TH3A5RHY)-?
M8G[&7[1>L?'?PGKFG>)]/\OQ3X3NDTS4M6LH_P#B7:C)M)$D+CY0^ #)%U0L
MO #"O%?VJOV6=.M/CCX$N?!GB&_\#VWQ-UM]'\2V>FQHT4A6WEN&N[<,,0W#
M+"\;, 0=RMMRK;_L_P"'GP[\/?"KPAIWACPMID6DZ+8)LAMXLGW+,QY9B>2Q
M)))R37S>7X/,J&-Q%7%5U.E)^Y&VW^5MNM]]&>_CL5E];!T*6&HN%2*]YWW_
M ,^_2VVJ.DHHHKZ0\ **** "BBB@ HHHH **** "BBB@ HHHH **** .>L?^
M2@ZU_P!@NP_]&W==#7/6/_)0=:_[!=A_Z-NZZ&@#GO'G_(M2_P#7Q;?^E$==
M#7/>//\ D6I?^OBV_P#2B.NAH **** ///C)\9[/X/Z7:2MH6M>*=5O?,-KH
M^@VOG3R1Q@--*Q8JD<:!ER[L!EE R6 K3\+_ !0TGQ1XIO?#L>^UUBVTZTU<
M6TQ4M):7 81RC!/ >.5"#R"F>C GS#]KX6&I>&M#T.3P?XD\8:GJ4\ZQQ^#=
M0^PZO9VRQ9EGADW("GF&WCDC+J")02&VA3X5\%O'?@G]GWQY8>'_  ;X4U;6
MM8UOP\?$'C#Q)XTUT_VK86EC<K8SQO\ NI5EDMRDV8D=$_T<JI.5H ^WO$VJ
MZCH^FBXTS1)]?N=X7[);SQ0MM.<MNE95P..,YYKYH\)_$CQAJ_Q(^'MEJ6F:
MIH]E<^+?$D,TD]_#*DZQF[V6Y6-V.(]H R-OR<'I7U6[K$C.[!$49+,< #U-
M?/5E^T7^SE>>,M TNP\:>'+_ ,1#6G32X+*X:9S?WDA1RA7()D>9@3G'S'I0
M!]#T444 %%%% !1110 5\V?!WX@VOQ'_ &L?B%?VFDZYH\=KX6TNR:'7M,EL
M)9&2[O271) "T9W<..#@XZ5])UXIX?\ ^3QO&O\ V)6C_P#I9?T >UT444 %
M?*7[4'PB_:'^.GAWQGX%TK5/AC8> =;46\$MY!J(U2.$,CC<ZL8M^Y>R$8[5
M]6T4 >1?"&/X\IXBNC\4KCX=3:#]D;[.OA""_CNOM.]-N\W#LOE[/,S@9SM[
M9KUVBB@ HHHH *BN[6&^M9K:XC6:"9#')&PR&4C!!^H-2T4 ?#I7X\?LL^)O
M"/PG\%7/@GQ#X0\1:O?6GA.;Q&MT+K3K9+>2[^S3&$JI2,)(B$ G[HX  'T7
M^SC\&)/@[X)N1J\UOJ7C;7KR35_$FKP#(O+V0DMM)4-Y:#"(IZ*.<DDGE/C]
M_P G'?LT_P#8?U?_ -,UU7T%0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'R!\?/#W[2OA3XSMKGPBT/P;XK\/ZO>07K+XC>X:73YXK"2W*X>Y
M"1(PW-OMUC8LX5L@N7]!_9RU+]H'6/$FL7/QK\*^"-#MTM$CTZY\+M(\\C%R
M720O-(=F,$ 8YKK?VAOBCJWPJ\&V-YHD>AQZAJ5^-.CU/Q1>/::3II:":19[
MN5%)$>Z)8P/EW/+&NX9K-^&'[1WAWXH?%+5O!N@Z]HWB:72-%MK_ %"[T.4R
MP07#N0T:R@E9%8$$8Y7:0V2V% /4M4U73[6XL]/O9DCEU-GM[>.0$"9PC.R
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M4UR?A_\ Y/&\:_\ 8E:/_P"EE_7M=>*>'_\ D\;QK_V)6C_^EE_0![71110
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M** "BN2^)WC_ /X5QX8&I1:->^(M1N+F&QL-'TYXDGO+B5PJ(K2NB*.K,S,
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M444 %%%% !1110!SUC_R4'6O^P78?^C;NNAKGK'_ )*#K7_8+L/_ $;=UT-
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M6P?RU#,@&_.T_>SS7O=%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!SUC_ ,E!UK_L%V'_ *-NZZ&N>L?^2@ZU_P!@NP_]&W==
M#0!SWCS_ )%J7_KXMO\ THCKH:Y[QY_R+4O_ %\6W_I1'70T %%%% !1110
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M !H TJ*S?^$DTC_H*67_ ($)_C1_PDFD?]!2R_\  A/\: -*BLW_ (232/\
MH*67_@0G^-'_  DFD?\ 04LO_ A/\: -*BLW_A)-(_Z"EE_X$)_C1_PDFD?]
M!2R_\"$_QH TJ*S?^$DTC_H*67_@0G^-'_"2:1_T%++_ ,"$_P : -*BLW_A
M)-(_Z"EE_P"!"?XT?\))I'_04LO_  (3_&@#2HK-_P"$DTC_ *"EE_X$)_C1
M_P ))I'_ $%++_P(3_&@#2HK-_X232/^@I9?^!"?XT?\))I'_04LO_ A/\:
M-*BLW_A)-(_Z"EE_X$)_C1_PDFD?]!2R_P# A/\ &@#2HK-_X232/^@I9?\
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MB@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\
MWX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!
MMG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/
M_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_
M  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_W
MX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$
M?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_
MX1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"
MM"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_
M *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2
M_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@
M#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!M
MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H
M&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\
M^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX
M7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_
M 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?T
MO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C
M_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7
M_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&
MV?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']
M+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"
MB@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\
MWX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"K=M:PV<7E
MP0QP1YSLC4*/R%2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cgtx-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &; ?@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JOJ&H6NDV-Q>WMQ%:6EO&TLT\SA$C0#)9B>  .YJQ7C_
M .UQ\,-<^,G[.OCGPAX;N!!K6IZ>\=L&?8LK AO*)R,!\;23Q\W- '-_#O\
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M7]I&3L@NRORSX.0/ER3QR10!]O7%_;6L:R37$42,P56=PH)/0 GO4QD4'!8
M]<$U\"_&/24\,?M)IH'B/]UX'TWX=7W]AV]XP%HUTL1\UT#?*9@<$$_,.V*\
MLM_$/B'2_A)^R7XD\>7MWIRP^()4FU/6)C$5LRI\GSI&(X(QC>>: /U,\U,
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M-6.\6G]Q^7WPW\">*-9^(>F:=I>FWUOJEM=QLY:%T-KM899R0-H'O7Z?H"%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -=UC4LQ"J!DD] *K:=JUEJ\)EL;N"\B#%2]O*LB@CJ,J2,U\/?\%>_%
M/C/PW^SMI\7AF:ZM='OM0^SZU/:L5(AVY1&(.=K-G/8X%?#G_!)OQ/XSL/VH
M+#2M"FNI-!O+:4ZS;!V\@1 961EZ;@V,$^IH _<^BBB@ HHHH ***9-,EO$\
MLCK'&@+,[' 4#J2>PH ?16=X?\1Z7XKTJ'4]&U"WU/3YL^5=6D@DC?!P=K#@
M\^E:- !1110 4444 %%%% !1110 445C>,==N/#7AK4-2M+$ZE=01$PVGG+"
MLCGA0TC<(N2,N?NC)P<8H V"0* <U\:>*_V=O%GQ;N)M1\<?M0:MI-Q.P==&
M\"W,.FZ=9#J(TR[22[23^\<AF[@< =C\)/!OCWX1ZN\6F?%VX^-/A6%XH]1T
M;6A%+JNGA^%FANHV^?@!C#(!E0Q5@>& /INBD'(I: "BBB@ KR;]I*'XIS>!
M#_PJNY\,VVJ!W-Z?$\4KQ-;>6VX1^6<A\[>O&,UZS7GWQM^+7@[X2>#9[WQE
MXCT_PW:7RR6EO-J$NQ993&Q"+P<G )Q[4 >!_P#!*C_DS#PG_P!?5[_Z/:OK
MVOD+_@E1_P F8>$_^OJ]_P#1[5]>T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y\1O&UI\
M./ FO>)[Y6>UTFSENW10<OL7(48]3@?C71U3UG2+3Q!I-[IE_"MS8WD+V\\+
M]'1@0P/U!- 'XM6/_!8?XQI\4%U>ZAT9_"!G ;PZMDH"PY[3_P"L\S'<DC/\
M-?LSX0\2V_C+PMI.N6BLEMJ-K'=1JW50ZA@#],U\&V/_  1F^&UI\3%UY_%F
MLS>&$G$Z^'6@C!X;.PW&<E.V-@;'\5?H%IVGV^DV%O96D2P6MO&L442]$11@
M ?0"@"+6M$T_Q'I=SINJV-MJ6G7*&.>TNXEEBE7T9&!!'UKFOAU\'/ _PCM;
MBW\&>$](\,Q7+EYO[,M$A,ISGYB!D^P)P.U=E10 4444 %%%>%_M*?M<>$_V
M=K*WL)4F\2^.-1PFD^$]+'F7EW(>%R #L3/\1'T!H ]*^)?Q/\,?"#P??^)_
M%VKV^BZ-9)NDN+AL9/957JS'LHR37QHTGQ5_X*'WC+$=2^%/[/Q;#,1Y6K>(
MX\_^0XC^7^]VZ+X<?LI>,?V@/%]E\3?VDYH[R>W?SM%^'ELV=-TM>JF89Q+)
MTR#GW)Z#[/@@CMH4BAC6*) %5$&%4#H .PH P?A]X T/X7>#=*\+>&[(:?HF
MEP+;VUN&+;4'J222?>NBHHH **** "BBB@ HHHH **** "N/^+?POTCXS?#S
M6?!FO-<+H^KQ""Z^RN$D,>]6(#$'&=N,]LUV%% 'Y)?'[X'?L3_LZ^.SX.\0
M:1X^U?7H[=+FYM]!N6N!;*XR@D9F0 L.0!G@C.,BOJ3_ ()NR_"*3PKXW7X.
MZ5XGTG04U&W%U#XH=#,9_))RBJ6(7;MZGD],5R7[0VL_%RP_:A\30_#SQM\,
M/AE&VBZ>TTGB^YC6XUA<R8EPT;X\IBT>/E.&4G=E=OKO[&.H>.-1?QRWC_QI
MX.\<:XEW:)]N\%R1O:QQ^2Q6-]D:?O.<\@\%<<4 ?3-%%% !1110 5RGQ,\'
MZ#XQ\)7]OKVBZ=K<$,,DT46HVJ3JCA& 90X(!YZBNKKG_'6L6&C^%]1>_O;:
MQ22WD1'N9EB5FV'@%B!F@#YB_P""5'_)F'A/_KZO?_1[5]>U\A?\$J/^3,/"
M?_7U>_\ H]J^O: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R7]H[]I[P/^RYX-C\0^
M-+JX"7$GDVEA8QB2YNGQDA%) X'))( KCOV7/VZ_AO\ M7W-_I_AEM0TK7+)
M/-DTK5XDCE>/^^A1F5@._.1Z5Y?_ ,%.?V1O%W[2W@?0=0\$+'?ZWH,LC'2I
M)%C-S&XYV,Q"[ACH2,^M>,_\$SOV#_B5\'OB3?\ C_Q[8GPKY-E+8V6GO-'+
M/*TF 9&",P55P,9/)[4 ?9WQ"_;<^"?PL\>)X.\3>/M/T[7]P26 ))*ENQZ"
M61%*1GV8C'?%>UV%_;:I907EG/'<VLZ"2*:)@R.I&0P(Z@BOYU?VIOV?OB/\
M*OB[XJ'BC0-4>*6]GNX]6%N[V]S$SDB190-N,$9YXZ5]F?L6_P#!4OPK\-O!
MO@OX:>,M!O[+3K"%;-_$QO1,D9SPSQ;0P0=,AB1Z4 ?K-2,P4$DX [FN)U#X
MV^ ],^&[^/YO%FDGP:L7G?VU'=*]NR^BLI.X]MHYSQBOD*^\8_%/_@H1?2:9
MX+.H?#'X#^88[OQ),GEZGKJ _,EN/X(STST]2?NT =I\9_VQM:\8^,[GX3_L
M\Z?%XP\=Y\O4/$)PVE:$N<,\DGW7<<\#(R/XCQ7<?LT_L=Z)\$+N[\6>(+^3
MQS\4M5)DU/Q9J0+2EFZI"#GRT^G)[^E>F?!KX(>#O@)X-MO#/@S1XM+T^+EW
M'S37#]Y)9#R['U/X8KO* "BBB@ HHHH **** "BBB@ HHHH **** "L7QBWB
M!/#5\WA6+39]?" VD>L2R16K-D9$C1JS*,9Y /..*VJ* /A?XO\ PH^%WQ&\
M<7'BG]H+X)^)]+U9H4M3K^F7EQJVDK%'NV /9$21CD<RP)R^,D#->Z?LI_"[
MX.?#?PUJ\OP7O[.]\/:K<1W$XT_5?M\*2JA3ABS,I(Z@GJ.@KY[_ &GOBSXY
M\*?M!ZY'X8^._@[X56EE:6!ET/QD&9M094=_,B5HV A;S?+)C(8O$V?NK7*6
M?Q1F\<?M0^(_$NE:PWA]=%^'^G>(1IN@WWEVTFI220B5;N--HN'"RF';,"0-
MO"G& #](Z*0=.N:6@ HHHH *\O\ VA/@9X(^.O@:33O'&AQZ[9Z>7OK:-YI(
M_+F$;*'!1@>C$>G->H5E^*/^1:U7_KUE_P#0#0!\K?\ !*C_ ),P\)_]?5[_
M .CVKZ]KY"_X)4?\F8>$_P#KZO?_ $>U?7M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,EE6&-I
M'8*B@LS'H *^3?%/[=']E^,)[33/#D=[H=O*8GGEN"DTH!P64 ;1[9S7EX_,
M\+EL8RQ4^7FVW?Y'I8++L3F#E'#1O;?9?F?6M%><^(?COX8\-?#FQ\8W<TIL
M+Y%:V@B4&:5B/N 9QD=SG K)^$'[2WAGXP:E-IEE!=Z9J<:&1;:]5<R(.I5E
M)!QW%4\RP:JQH>U7-)72[WV^_H2LOQ3I2K>S?+'1OM;?[CURD  Z<4M%>D>>
M<5\:/AA9?&?X6>)O!.H7$EK:ZW9O:M/%]Z,G!5L=\, <=Z_GU_:A_91\8?LI
M>,8-$\4R6-U%>*TUC>V%P'2>(-C<5.&0^S#\Z_8SX[_MD:C)XS?X4? O2H_'
M7Q/E^2YN5^?3=$7H9+B0?*67^[T!Z\\5M?LZ?L7:;\--:G\>^/\ 4W^(OQ8U
M$;[S7]2'F1VQ/6.V1N(U'3.,X]!Q0!\6?\$WOV'+OXI^$K;Q3\51K$O@FSO/
MM.B>$KR1X[*[EP-UR\1/*YX P V.217ZRV-C;:99PVEI!':VL*".*&% B(HX
M  '  ]!4RJ%  & .PI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MK*\4>(H/"?A^^UBZ@N;BULHC-,EG$991&.694'+;1EMJY8@' )P" ?%W[6/C
MZ+6/C@NC:5^RJ?C=K'A>UMIY]=N2L(MC-N>*-"87\Q/E8\G ;=@9!-==^SCX
M2TGXVZ]XF\4_$/\ 9TT;X9>*;75+6]A2[M%EN[F0(S+<M-L0/\X.!MZKDY.,
M9_Q;_9?;]I[XAK\2/!O[0>J^&-/O-,@L[>+PK<"2*2%"S;BZ3KG+,>,<8]2:
MZ7X"^"K+]D^34-#\1?%*^^)WB'Q;J4 TV"]?S-4E9(]C($,K$QH/G9\A47);
M'4@'U%TI:0<TM "$X%4]+UK3];AEETZ^MK^.&5H)'M9ED"2*<,A*DX8=P>17
M+?&G0K+Q'\+/$]EJ$33VK:?.S1K*\>2(V(Y0@]0.]?"/['GB[4? O_!*KQGX
M@TF8V^J:?;:S<6\Z]4D"?*WU!Y_"@#]"=(\<>'/$&K7NEZ7K^EZEJ=B2+JRM
M+V.6:WP=I\Q%8E>>.0.:G\4?\BUJO_7K+_Z :_,GPQKEUX+N/V";[1P;6YU%
M;RSO&MT&ZXBN)(1,K_WMQ=F.>YW=>:^HOCK^V3J'PX\4>)/",7P1^)OBB&TA
M\L:YH>B-/83;X0Q9)!U"[L$]BI]* ,K_ ()4?\F8>$_^OJ]_]'M7U[7R%_P2
MH_Y,P\)_]?5[_P"CVKZ]H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!DT*7$3Q2+N1U*L/4'K7P'\7
M_@+X=\#_ !!-M=>/=+TO3[V4S>1/#-+<VR,<X*QJPQUPQ(K[^/2OSR_:2^&/
MBK3?BOJ][)I=[?6FIW/F6EU;PO*LF>B94'##TKX7BV$?JL*CH\[3\]/NMOL?
M:<+3DL3."J\B:\M?OOMN?0'Q:^ Z?$#X,>&--\#WL%_'I"B2T+2J$NT*X)#]
M 3U]*Y7]F#]F[Q9X+\<#Q)XEMDTJ*VB>.&V\Y9))6;C)V$@*/<\UZY^R[X,U
MKP-\)[&QUV-[:[DE>=;60_-"C'(4^A]NU3?M!_M+>"OV;?"RZMXIO6:[N28]
M/TBT7S+R_E[)%&.3S@%N@KKP^387%U*&95(.$TH^[?1-+33?3_ASDKYMB,+"
MME].:E!M^]U=WKY:_P##'H'BGQ7H_@G0;S6M?U.UTC2;.,RW%Y>2B..-1W)/
M\N]?$^M?%OXG?MX:I=>&_A"]YX ^$,<A@U/Q]=1-'=ZDO1H[)#T4CC=^9'2K
M'A3]GWXA_MFZ[9>-OC^)O#W@2*07.B_#.UD*J5ZK)>L,%F(_A//^Z.*^V=&T
M:P\.Z5::9IEG#I^GVL8A@M;:,)'$@& JJ. !7UY\L<#\"/V>?!/[.OA"+0/!
MVE):*0&N[^7Y[J]D[R32=6)_(=@*]+I"<#-? /[3?_!6?0/@;\4KOP7X>\'O
MXODTR7R=2OGU#[+&DG\21#RW+D=R<#- 'W_17G7P!^..@_M$_"[2/''AQ9XM
M/OPP:WN0!)!(IP\;8X)![C@UZ+0 4444 %%%% !1110 4444 %%%% !1110
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MWQ#\,?#V*?X=_#NQ^(VH2S-'=V5]=1P+;P>4Y,P+L 2" , YYH \O_X)4?\
M)F'A/_KZO?\ T>U?7M?(7_!*C_DS#PG_ -?5[_Z/:OKV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D.*I:WK>G^&])N]4U6\@T_3K2-IKBZN9 D<2 9+,QX KXF\4?M ?$7]M#6[
MWP9\ 3+X;\ 12&VUGXEWD13>.C1V*G!+$?Q=?]T<T >@_M _MF/X;\6K\,/A
M%HX^(?Q8N@4-G;MFSTD?\];J0<#;UVY^N.E+^S[^QA_PB_BMOB;\6M8_X6+\
M6;K#G4+D9M-+_P"F5K&> %Z;L?0"O3_V?/V:O!7[-OA4Z3X5L2UW<8?4-8NS
MYEY?R]WED/)YR0.@KU:@!#P.*_-[X[_$?Q;K'Q2UD7VHW]@UA<M#;6D,[QK
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M+:;KUP9!IVG^(?#%M9?VD4SGR) KHW^[G<!_#Q77_!#X?_L]?M&V'BB+P_\
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MV./"%MJ/A;1SXK77_"WP_P!5FU+2?#PAA\VRN),LJ7$RL2Z)N8JI5#R-Q;%
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MA[_P36U#XS_VU\1_B3\06T_QMJ6K#4FL-)ECO[;2W1]S0SEV(D=5PN,X0>M
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MU8)<112JSPL1D!P#E3CG!I--UBPUF.22PO;>^CBD:)VMI5D"N#AE)4G!'<4
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M0^'['5[72;J*]L8;J(,MO-']QU'8@<>F.#Q4NO\ PX\,^*?$V@>(=6T2TO\
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M$<<42A510,!0!P !V%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'/B/6M5U&.Z@@\0O9MKFFV\JI;ZLUL^Z#SLJ6!!P#L9=P #9%>Q+Y< CC&U
M?E11QT'0#Z"@#XL\*_!#Q#\ =>LTM/$%GJ?C_6_#=IX-T>.TMY!!:VEL2\VH
MSAR3\@(.T<9VJ"2XKL_@7^TQX!T[4/#?P_T/2M6M=%O=0OM%TO7KTQL-1OK8
M[KEY #O!D=F8.1\[;LA>,^\:7\/-*TWQYK7BJ2::^UK5+>.U!NF1A:VT?/DP
M@*"J,YWMDDLV,G"J!Y]X1_9(\ ^#OB!;>)K'^T)7T^]N]4T_2)[A6LM/NKH
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M]@0*@M/V^?%-K\,=&^,>IW%C;^$;WQI-H-QH;V8_T?3U4!91*I+^<,[CU4]
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M'(->B>,?V"OAWX[U#QM=7>M>*;=/%=_!J-_:V>JJL$=U#C9(BF,X88'WMP]
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M9O'J'BW4=6C>2UFWKCS58JQR 3F,8'0+7N_A_1K/POHFFZ/9(L-I96Z6T$?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XU^U)
M^SUH/[1'P^&E:_JVNZ3!ILC:A%)H5X+:1W6-U"N2C;EPQXQZ5[+67XH_Y%K5
M?^O67_T T ?*W_!*C_DS#PG_ -?5[_Z/:OKVOD+_ ()4?\F8>$_^OJ]_]'M7
MU[0 4444 %4]6U>QT'3;G4-2NX+"QMHVEGN;F01QQH!DLS'@ >IKB/C?\>_!
M7[/7@V;Q)XUUB/3;-<K! /GN+N3'$<,8Y=C[<#J2!S7RAI7PV^)W_!0'4;;7
M?B=#??#CX)1R+<:=X*A<QWVM*#E9+MQRJ'KM_P"^1T>@"]XI_:'^(W[8_B&\
M\$_L]F3P[X(MY#;ZU\3[R)E3&<-'8J>7;'1NO^Z,-7T/^SO^R]X'_9J\.26'
MABR>?5+S#ZGKM\WFWVH2=2TLAYQDDA1P/<\UZ/X5\)Z/X'\/6.A:!IMMI&CV
M,0AMK*SC$<<2CL /S)ZDDD\UK4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !115;4;L6%A<7+?=BC:0
M\=@,_P!* )?/C\[RMZ^;MW;,_-CUQZ5)7X['XUZ]J7[+^O\ QZ2[E_X3V'XJ
MJ]KJH8K,EF(D"6>[K]G".R^4<KR203S7ZZV5RVO^&X+@/)9M>6JR!H6&^+>@
M/RD@C(SP2.W2@#3W G&>?2LSQ1_R+6J_]>LO_H!KXB_8?NM2_P"&P_VD].U#
M7-6UY--N+6UMI]8O'NI4C#.0@9NBC/   '%>O_&K]N;X2_"[7O$?@KQ#JNJV
M^O64)BFB@T.[GC#/$'7$B1E3PZ\@\=.QH Y3_@E1_P F8>$_^OJ]_P#1[5]>
MU^8W[ '[</PG^"W[,GAWPKXHU75;;6;6>Z>6*VT2[N4 >4LN'CC*G@]C7T9_
MP\X^ W_0<US_ ,)N_P#_ (U0!]6U\W_M*?ME:1\'=6MO _A+3)?'_P 6=4_=
MZ?X6TP[FB8C(DN6'^K0=<'DCG@9(^7OVDO\ @IZ/%E_:^#?A-<7OAG3+\!-1
M\>:IH]TS6<;#YOL]LL9D+C^\R]>@_B&S^S?^T+^RG^S;I5P^EZUXCUWQ7J!\
MS5?%.K>&[^6^OI#]XES$2B$\[ ?J6/- 'K_P-_8VU;5O&D7Q8^/^IP^.?B4V
M)+'3?O:9H*]1'!']UF7^]C (R-Q^:OKBOE/_ (><? ;_ *#FN?\ A-W_ /\
M&JC7_@J%\ 'G>%?$.LM,@!:,>';XL!ZD>5F@#ZQHKY2_X><? ;_H.:Y_X3=_
M_P#&J/\ AYQ\!O\ H.:Y_P"$W?\ _P :H ^K:*^3?^'H?[/_ -I%O_PD.L^?
MMW>7_P ([?;L>N/*SBI?^'G'P&_Z#FN?^$W?_P#QJ@#ZMHKY,G_X*B?L_6SQ
MI-XBUB)Y#M17\.WRECZ#,7-3?\/./@-_T'-<_P#";O\ _P"-4 ?5M%?)J?\
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M_P""H7P N6D$7B'69#&=KA/#M\=I]#B+B@#ZRHKY2_X><? ;_H.:Y_X3=_\
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MUZI10 @&!CK]:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9;\*_%.#P0OB74=<OY_"-VM[8W"WJQ/(ZC $H1 K#&.BJ??K0!^?E[-=S>
MOVZGNR_VG[:@^9B3@*VWD\],5^A_[*DMU-^SC\.GO"[7!T2VW&0DG[G'7VQ6
M3XY_9'\%>//$6OZI<W&KZ?!XC,!U[3--NUAM=6\HY0SC86SC@E&7<.#FO9K&
MQ@TRR@M+6)(+:"-8HHHQA411@*!V   H GHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^&_V[T5?VB_V:2% )\129P.ORTWXV37I_X*9?!:.7(LAHER8<
M$X)W'=QTS7OWQ>_99\/_ !I\9^'_ !-KGB#Q';7_ (?G^TZ7'IUW##%:R]V
M,+%B?]HD5T'Q%^!.B?$B[\/:G>7^IZ;XCT$L;#7]-ECCO(PR[74[D9&5AU!3
M /(P: /G/_@F1+>/X:^+"3M*;5/&5Y]G#YV %CNV_CUK[4KD/A9\*_#WP<\(
M6_ASPU;/;V$<CS.\TADEGE=MSRR.?O,Q.2:Z^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/B9^T
MQX+^$GC'0O"_B(ZO#K.O2B#2H;72+BX6]E) \N-T4J6!9>"1UKI/ 7Q?\)?$
MJ]U2PT+5X[C5M*=8]1TJ='@O+)F&0)H) '3.>"1@]B:^4OVXUS^U5^RCQ_S-
M#9X_Z:05QGQ*U77M$_X*6ZWXC\%VTE]%H'@*:;7HK8;D=Q#.T,4FT$[B_D$
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M',?QA^)/B'XEZ_\ M,Z%K/B*\L--\(^%(UTS2K27R87\V%7EGE0\2DEMGS9
M!X /- 'V+'^T)X(EM_ LZ:E<-'XU8+HC+83GSR5W#=A/W?']_%>C[ACK7PKX
M2^(GB7P;X7_8_P!)T;6+C3],U_RK/4[2-4*7,0B+!6W*2.1U4BN7^+O[0?Q(
M\,:#^TA)I_C+4+:3PKXJTFST:0I 3:PS!3)$,Q_,&W'[V3Z&@#]$LU!%J%K/
M=3VL5S%)<P!3+$C@M&&SMW#J,X.,^E?"?C3XX?$#X<_'KP__ ,)C-K4OP\\1
MMIEOIOB/0;G?%I]QM5I;:ZMU&T^:S#)8;P"-AQD5QWAGQKXC^$'A7]K#QUH^
MM:QJ&MZ+K)AMCJ%S]HC&8L"60,OS>6#QS@ =* /TDR *\[T/X^^#O$'Q9U7X
M;6UW=IXOTVV%Y<6-Q8S1KY). ZR,NQ@?8U\:?$OXI?&?X5? :?QK:^*+27P_
MXDLM'CLIEU1M2OK.>:1%NKD2/$JHK!SA%)5&' %;'P4TV/2_^"DWBR"*^O-2
MB'@JT*W-]<M<2/G')D;DYZ\D]: /L'XF?&7PM\)8K#_A(+V5+G4':.TLK.VD
MN;F<JI9BL48+$*H))Q@5O>#_ !=I7CSPQIOB#1+DW>E:C"MQ;3-&T99#TRK
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MP,F%2_KQ0!]N?%SXX^$O@?IVF:AXNN[FQL=1O$L(;B"REN$$SD!%<QJ=N2<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.$\:_ [P/\1=>TW6O$GAZWUC5=,<26-U<O(7M'R#NBPP\ML@<K@\#TK=\+^
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M+O$$GBO7])T=-%T^ZF4@I'UEF<G[TLC=3C@ #GK7LM% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cgtx-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *1 I$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***0D#J<4 +144]S%:H&FE2)2<!G8*,^G-/1UD164AE
M89!!R"* '44V218D9W8(BC)9C@ >IIB74,FS9*C;P2N&!W =<>M $M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>=_&/X[^%?@3
M;:#=^+9;VTL=9U!-,@O(+-YH8[A_N+*Z\1AN<%L#Y3Z4 >B45@:EXRLM,\7:
M+X<>&[EO]5AN+B)H("\44<.S>TKCA 3(BC/4L!65\2_BYX=^$J>&7\13SVZ>
M(=;MO#]@T-N\NZ\N-WE*VT?*#M/S'@4 =I17*?$CXDZ3\+/#B:UK,5_-9M=P
M6873K.2YEWRR"-#L0$XR>3V%=5N!_E0 M%<)\(/C/X:^-_A^_P!8\,2W4EK8
M:C/I5RMY:O;R1W,.WS$*L,\%@,].OI7=T %%%% !1110 4444 %%%% !117C
M=W^TYX,M?B=;Z WBSP^NE-I4]W+<-=C>EPD\2+'G=@ J[G&,Y7K0![)16)XG
M\5V?ACPI?:]*?/M+:W-PHBY,W'R*GJ6)50.Y85\_?LT?M1:Y\4/@;XXU?Q1I
M<6F_$/P3>:G8ZWHQ 1(IX!))&HVD_*5 3.3DQOR>"0#Z<HKXJ_97_:1^('Q&
M^(7PWTS7]0^U:=XB\#RZ]?R7VG+9I+?^>A5;!\*)5CBD175-^WJQ#$U[_P#%
M7]I#PO\ "?Q ="O8=0U;68=&N/$=U8Z9$KR6VF0,%FNFWLH8*<X1"TC;3M4X
MH ]6HKY,\6_M.:C<_'*]T[0_$T-M\/+GX.7/CFTU*'3%NY89A<%4NE0X:4+%
MAO))&XC'4UL>$OVOO#GASP#X6CUK6]0\=ZX_A ^,M4U6PTE;)8])5F5[Z2)W
M4*-PVB*/=(Q'"4 ?3=%>#ZY^V7X$T:RL;E(=7OXYO#(\972P6@5[#1BP47<R
MNZGDD8C7=(1DA>#5?Q_^VU\/O UU?VD%OKWBB]L_#<?BY[?0M.,N[2WP?M(>
M1D0* 0Q#,#CH">* /H"BO#/"_P"V1\//$^N7]AYFIZ5:P>&/^$RMM4U*R,5K
M?Z2,^9=0D$MM3 W!U1N?E##.(F_;+\!6/ACQ%KNKQZOHEIHNCV7B&2.\LB99
M],NVVVUU&B%B59LJ4;:Z$$,HH ]XHKP!_P!M3P0M]HUFVE>)+:?7M4&FZ#_:
M6G#3TUH>2)C<6KW#QJ\(4JH8D%G=%4-O7/M?A7Q!#XM\,:1KEO;W-I;ZG9PW
ML=O>Q^7/$LB!PLB9.UP&P1G@@B@#4HHHH **** "N9\<ZWXCT6SM7\.>&T\2
M3R2[98GU%+,1+CAMS*V[GC KIJ3K0!XO^S1XP\:>)/ OAT>(?#)L;%M,61=7
MEUJ.\DGDR  R! PR"QR2<;<=Z\#_ &^_BSXD\,ZEH_B#PG>731_#'5;'7M0T
MR&PG>+4BX=9HGF5"BB.WD#$%AQ<$]57'VWINF6>CV$%C86L-E9P+LBM[= D:
M+Z!1P!6'/\-O#=UX8\0>'I],2?1O$#73:G:2R.ZW7VG/G[B6SA@Q& 0 .!@
M4 ?+'[0?B6+XB_'K]D;4] -GJNEZY_;NI64&H;C:7&[25>!I$P>@<\[25R<8
MYK?_ &%?%VB>#?V+;-HIM0OE\&#5+;5HY5$DJW%O-++/'#CAX_F_=@?PE >0
M<:7CO]CNVO/&WP-7P8\?ACP1X!?6?/M+74KF&\C6[MMD?V60;B"LF6(9U '
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M4 %%%% !1110 4444 %%)N'J/SI-Z_WA^= #J*;O7^\/SHWK_>'YT .KRO\
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M7]9^ _A7XK66B^-K>;6?&>N7FN66HR:5A-,EG7"@Q^<?.V'!ZJ#CD5H_LU?
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M>#_V[/%&K7.G7$EKHOCJ;43!I2[YY5@U&166-"RAG<2D=0#SDXS6]X-_:G\
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M*75R$EA:=!(A#GY@01D#^\!W%?.?BF(/+]LU*")TE8(E_IS*;=BJX5 % \O
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M&)A<V]O&)!YC2LR(K9P=I(^8^@7)XZ4W6_#]K<ZU>-I-W9O:NS%;=MT+H <
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MX8 @\#C/M7[G_P#!(LY_8^T\_P#4:U#_ -#6N1*VI<59L^U*_);_ (+1*/\
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M[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXTM(O3\32U1N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-]_!R/UK"I3HS<9UI:RU5U>_X]^Y=-MW4=C7EMI'T@0)$7DW1+N!XR0Y(Q^
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M/Z85Z?B:6D7I^)I:904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4EU(+<_1P_\ !%3Q \!C;XIZ5U# C0ILY_[_ %02?\$2_$#R;C\5=+^G]AS
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M )JMIO\ X(YO_CU?G-_PD>L8_P"0M?K_ -O<G_Q5-/B;5P?^0M?_ /@7)_\
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M\4M(*6OU4_H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MICSSEFR6%9Z_,XPPQV&>]?TC/^RU\&9 -_PE\#MCIN\.VA_]ITP?LJ_!8?\
M-(_ W_A.6?\ \;J^E@A1<8V;U/YP(8S)+MEF6,>IYJ_936%I+_I2R3J#A1&V
M!7]&0_97^"X_YI)X&_\ "<L__C=)_P ,K_!? '_"I/ W_A.6?_QNI<>;1L4Z
M#GHV?FC_ ,$AO$UG+^T#K&D:?9BUB/A^ZN)68*SN1-; #=UP-QXZ5^P%<5X.
M^"?P\^'FJOJ?A7P)X:\-:D\1@:\TC2;>UF:,D$H7C0$J2JG&<<#TKM:F%.-.
MZAUU'A\/'#1<8]7?YGCO[8H!_92^+P/3_A%-2_\ 2=Z_G/FM9(6W %E/?%?T
M^^*O"^E^-_#6J>']<LX]1T?4[:2SO+24D+-$ZE70X(.""1P:\)_X=Y_L[A-O
M_"K='V^GF3__ !RNR#HN$HU%KT:_K8UG%R:L?SYM$XYVGGVI-I"_=.[Z5_07
M_P .[_V=?^B5Z-_WW<?_ !VC_AW=^SK_ -$KT?\ [^7'_P =KBY!>S?<_GV\
MEL9.1QQQ30K+T4_E7]!?_#N[]G7_ *)7H_\ W\N/_CM'_#N[]G7_ *)7H_\
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MK6M7]JD]I?F8?Z#(=W.W/)!P?PKF=-^+GB31M;U2Z.M;I[^/RIYLH68<?EP
M*_HV;P;H+D%M%TYB.,FTC/\ [+33X(\/$Y_L/3<_]><7_P 37##*J7O.M[[D
MM6_+LNB\EI?4X*>0T/>EB/WDI))MJ^VUD[I+1:+2^NY_,E#J+P7BS13(SA]R
MEF!.:_1+X+Z[8^.?#>C:Q/ID ,0C7[6Z*-S*=N1Z]",U^K7_  @_A[_H!:9_
MX!1?_$U;A\.Z7;1B.+3K2)!T5+= !^ %<&=Y%'-Z<(QGRRB][7T>ZW1Y7$O"
MT<_HTX1J>SE![VOH]UHU_70T!2T45]4?>!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444USA&/M0 I8#N/S
MI-Z^H_.OQ/\ VLOVI?C7X:_:B^*GA_PQ\0O$UEI>EZC*UOI]A<,4MX41&;
M^5%!9B>@ S[UYU)^TE^T[IKR7=WXZ^(=OIL=Q):QRR^:/-D3=OB7='AG4*Q9
M>JA22!BLW-+0'I<_?7>O]X?G1O7^\/SK\!;K]IW]J33X$U&3Q;\0K3396B$4
MEX)_*<R+F("0Q@$N.5 ^]D8S4]U^TK^TY)=6^G)XH^)-OK$D<LL<"O<EIDC.
MV1EB,>[",K!B,@$$'&*?-MH/EDFE;\O\_P#,_?/>O]X?G2[E]1^=?A5HOQ8_
M:MUVR\7WEMXL^)*VOA6PAO\ 4_M<\L$L0D*JJ[#&26;?O"X^XC-G S5;P?\
MM!?M6:YK^EZ%IOBWQY?ZCK[QV=A;3K(K.S(DI*/(@ VQLCE^@1PY^7FESOHB
M&VE=(_=W>OJ/SHWKZC\Z_!JX_:$_:CLH=2NKWQOX_6.P\P.I\R+"Q%1*\GR#
M8J%X]S''WU'\0J@?VD/VJ)%^T'Q3\3/)EEAC#QQS["\H'E(I\KJ^]=H'WMRD
M9XJY>ZKL(OGOR]/Z_K[C]]-Z_P!X?G1O7^\/SK\#-2^/G[5^GPS32^*_B?:Q
MP0-<S&Z@N8Q%$N=\C,8P BXY8X YYK:UKXU_M,6EQI<&A_$[Q_XK-SHUGJD[
MZ59WW^C&YW;(W$D(S@C =<H^,*QP<).ZNC3ENKH_=G>O]X?G1O7U'YU_/K=_
MM=?M :3:WB7_ ,5?%]M?17!@^S2ZALE1EX</&0&7!('(ZY'8T:!^VO\ '%KE
MS>?%;Q2T%M%)*6^WD'<!\H;CG+ #!]36D4Y?(4DU%R6MC^@K>O\ >'YT;U_O
M#\Z_GBA_;6^/[J\W_"UO%<@1U0 7QPS$YVX YZ'I1;_MK?'6^G<'XP>)[5W8
M;$?46$8SDGYL' ' Y]>O%8.HHW+<&K^1_0[O7^\/SHWK_>'YU_.RO[:_Q^<$
MCXM>+&"Y+;=1)(Q[4L/[;7[0&UIU^*_BN2.)EW;M08CGH#]<4^= X-']$P8'
MH0:6OR<_X)9_M&_$WXM?M':IH_C#QUKGB+2XO#MU<K9:G>F6,2B>V"N%(Z@,
MXS_M5^L=6G<AJSL)TI-Z_P!X?G7EW[4_B'4O"7[-OQ/UK1KV;3=5T_PW?W5K
M>6S;9(94@9E=3V((!!K\)X?VV_CW<S[(_BWXO;$98XOFSD#)Z=O?TY-#=B&U
M'5G]%.]?[P_.C>O]X?G7\[>M?MJ_'C3+^6VB^-'B34!$Q0SVVH/Y;$<94D D
M'L<"JUI^W#\?Y9@B_%?Q7*Q!"H+]R23P,8[THR4DI(F,U*'.MC^BW>O]X?G1
MO7^\/SK^=VY_;7^.\"M&_P 8/%J7*[?W9OVY;^('IMQZ<]^E$W[;?QX@,<+?
M%7QEYA7=\VH%=V1\I''2MX4W-VB2JL7L?T1;U_O#\Z-Z^H_.OYWI/VW_ ([R
MR&.+XL^*5(0G/]I-@D#)[?6H?^&YOCTJ(L7Q4\5EP[8E;4&.[(& 0>..3_P+
MZ5OB<,\.[-W]/(:J7Z']$^]?[P_.C>O]X?G7\\!_;5_:#M[*[W?%/Q6YC*"2
M3[<S"//(^8< G!ZU6/[;/Q[^R>?_ ,+;\6 ,2J@ZFW+#&>WOWQ^-<W+I="56
M+V/Z*-Z_WA^=&]?[P_.OYU_^&WOCU]DBV_%_Q0\LCY*#46RH'&#D<=?7%;OB
M#]L;X[:+JFGQO\5O%T=L]K!+((]5$DK;ERY Y .=V%[ #/-9<RLV1+$0C)0>
M[O\ @?T&;E]1^=)O7^\/SK^>9_VZ_CDMLEJ/BOXKFMU9I%G6\"2GIE2Q7/IU
M) ZCK5"3]N+X_-;*S_%KQ00N%1DU':3G)YXRWU[41=RHU&]U8_HHWK_>'YT;
MU_O#\Z_G5_X;J^/4,H:+XK>*U^7:PFU OR1@XR.._P!/PKL;;]L3XYZCX,T^
M_/Q/\6(T4US'/<0:DPWX"%=P(.?O$?+Q@<\\T[J\4]+_ .3?Z&5;$QH<KFM&
M[?@W^GXG[\[U_O#\Z4$'H<U_/*W[9'Q]DFC2U^,/B>?SF(A)U+:6 8+D@],D
MX&<5^N/_  37\?\ BSXD_LSVNK^--:OM>UP:O?0/>:C)OE*(ZA1GT':M90<-
MV;0JQF[19]54A8#J0*6OS'_X*T_'[XC?!SX@> K7P3XRUCPU:WNE74MQ#IMR
M8EE=9@ S>I -9&KT/TVWK_>'YT;U_O#\Z_G/?]N/X^@)_P 7<\5'(SQJ+<4)
M^W)\>]X#_%OQ84SSMU%LT7"Y_1AO7^\/SHWK_>'YU_.C%^V[^T!,0(_BSXL<
MGC"Z@Q-33_MO_'LNK?\ "V/%B($&X_V@PSCC(X[X_G2<DB7))V/Z*-Z_WA^=
M&]?[P_.OYT(/VYOCVLR%OBSXJ8!@=IU%L'Z\4Z7]N'X]1N<?%WQ6X(R"-088
M/Y4[ZV'?6Q_1;O7^\/SHWK_>'YU_.>G[</Q^DSM^+7BPD<G_ (F+8 ]:1_VX
M_CZIQ_PMOQ6?^XBU%QWZ']&.]?[P_.C>O]X?G7\YJ_MR?'TG'_"V_%8_[B+4
MY?VX_C[CCXM>*SQS_P 3!J87/Z,-Z_WA^=&]?[P_.OYS/^&Y?C[_ -%;\5_^
M#%J</VY/CX1C_A;?BP>I_M%C0,_HQWK_ 'A^=&]?[P_.OYS/^&Y?CZ?^:M^*
M_P#P8M3G_;D^/8QM^+?BP\<YU!NM ']&.]?[P_.C>OJ/SK^<T?MQ_'TC_DK?
MBOC_ *B+5WOP)_;*^.'B'XS?#S3=2^*7B6\TZ]\2:?:W-O-J!99HGN8E=&'=
M2I(_$T";L?OO12#I^-+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "FO]QOI3J:_P!QOI0!^)?Q4^)EU\+/
M^"A/Q9U0;YB;J[M1:26T5U:W"310*T5S"[*)(&3<&4,"/E8?=JOXV^*J:G\+
M/B+;#1-/M_#WB?Q"-8\%VEOJT,]WI+GS+>[WQHQ>,-;@;=X3/R,I;(KU;XF6
M7@W3OVG_ (FZH+5M1\4#Q'.LT$K.=BE(< *%P5*%CC.221R.GS-^U%=>'/!G
MBBUTG1?#-FMO=6XO+B]=9HGNRSL<@[@!TP0,@-N Z5M4P=2-"GB791FY13\X
M[MKMV[_*Y\I#-YXC,7@J="2M=7T7P[NU]MK/K?RN>@ZM^V%I4W@JYTJYT'Q%
MI=GJ%GX/L8[K3M1ACFM/[&EWS-"<'8\B_P"K./E8 FO1/ 7[27A7XT_$S0[2
MPBUKP_!I6@>-(8KO5+J$O.+Z-YHOWN_)N,Y!+DEV 8DECCX;U+Q_#J$+&VTO
MRI2H5Q<7)GC"@\;$*C'OR01VJM_PGNN+J27J74EJFXDP\F!@<90Q_=VD=L5S
M025E4E]W_!/I4L4X:02?F_NVN?3OBW]L#PQK/@?Q-X1'A_58]%U'P!HG@VQU
MEEC\^XN-+=I%GD@+ *DC.5.'8H%4X;)4=1??MQ:3JOQ$TO5;'P]JU])/XUTW
MQKJD+749_L];:Q2U>RMG)"LN=WSML&PJA&037R5J6BVVKZ='K>BRYGM'WWFF
MR/@PY.X-%ZH<'J<@G&#63JNC7TVHO8V^G3.C@&VBCC9BP;# Y ^8_-U/3/;I
M4SG4BVD[;_\ #]!0G"H][25[WZ6[KYW[-:H^C_!O[1_@[P7\)_%?@Z2P\3:A
M?ZCI/B+3K>_NKJW=/+OO(:)A&)"(CFW_ 'JH6+G:2S!%4>W_ !!^*7AC3SX6
M\1Z5\3]/U'4]#\2>'-=\1^'6LQ;W.L36T,,,,=M=+*T#B.)9 WEJJ?-ER2!7
MY]Z9X;O(KS+J(IXB=L4D;,6(!ST!48XR&QU&*H-!=6[BYFBPTH\Q))" &P?O
M#UY_7Z5GSJ=T]S?DC.\8R7_!\CZFO_VNM.U+1EM9M&U=HTTOQE87+R7L1WMK
M3N8IB">6C#8?NQ'R]ZTKC]NO0SX<GT^#PSJJRR>%O"7AX.]S$55](O#/+)])
M%.U.X.2:^13=WE\C1L1,=V\@*&=B>_')K5T[P_)J>M,L2P()I9#%# VX$JA<
M(N2<CHO4G/'/>XSM+EN:/DHINH]OT.Q^.'Q T_XS?'KQCXSCMYM&TS5M1DO_
M "+B03-%D#*%D!!)*D#''([ FN N-1W6T6FVL6RW9Q(Y8_/._8,?0'( ''?K
MS5C7;0Z1:_V:J O%)_I4JAANEQRG(_@RRY'!Y//%9DMHQ<QA&+[PB0L").1Q
MQCUKHJ2M%16[*@HS2F]NGRZ_\/Y;,A8J,O&WS8P4*]  !GZY[?K4+B,Q;@VV
M3=C9MXQZYS^E661\2_N4B@9AD 9*G!P 3SZ\?G57S-B$%5;<._;FN7EDEJCJ
M1)*\?GEU7:C'<JH3\H_N@D=NE1I,R2^8K%6Z97@X/':B282I@1@'.=Q8D].G
MI3$<1\\$\]NG%2EIJ"CIJ?>'_!'-@W[5FI_=W?\ ")W@.T8Z7%H!QC_]=?M5
M7XG_ /!&TY_:NU;G/_%*7G_I1:5^V%=$=$<=16EH>._MBA3^RE\7@Y*I_P (
MKJ62!D@?9W[5_.7?+*EP]Y%;BSM[G<R)"Q";"<%%)).!G&"2<=:_HR_;)_Y-
M/^,'_8J:E_Z3O7\WN#(YR>2>]%M;LYY1N[EBVB,GF.H^2-/F(SQGC/YFGWEV
MAN$:T7[,L84 H2&) ^\3GJ3SQ^E)!<M'+P=OF(58XY(/!Q4]I:>>T]OYH=4'
MFKLCW;FXXSV&"<YXXJFK*Z,6[/FD1Q0S6UJ9WMMRS#]W)(IZ!AEE['GCOU-6
M]*NXXI+VYGLH;K]RRKYC%/*<XPXP>2/0Y')XJFMI=3$1Q@N%?*HA[MW _ <_
M2K5E.;)6,A0N-^T2J74':1@@=^<@]B!7=A&H.53^5-_.VGXV,ZEI1?5OL43<
MJQ>5@3.6#+M 5%YR>!^@&!2H5N5(6,;P,[0#SW)Z]>*@$@"D*H!(P2><C\>A
MJ['$;6VM;V!COWLK_O%R"/8'< 0>IX/.*Y8UK.T]F;2M']"?3;V:XM9-+5]D
M,S*=BR>6KN/N[N<'&3@GID]*N6.BI/H\LTY$>TGRY%G0LS'@1^66SR>2W8#W
MJK#(EC-)?001%$8 )*HF121D#D<]Q^!JA/*DUS))&B1!F! R %SUP/3V[5M.
M].RDM'K\OZ[G,XRFW[/1:/Y]>O:W<U;+7;VWAG$ A@BP7VPQJIR0J$;OO8('
M3..2<9-+!I-P\DVG7%N\=\H1HH0F7)('RA!URIS^ ]:JZ8ODS!EC-VUQ!)$L
M4$A5E<@KDC!SZX[^HJWHM['!J,"ZL;AK+(62.W*K($;^[G@'TS10A3=248:7
M3\[_ )&52/)S.FEW\W_7GO?<KQV4,KQ*'C0*K[A/(%/RXXQR03S@>M+J2VEN
MUM]F@4311 3$RB17<\[AQ\I (&.>0:KPN(Y4D:*)TB<;ED!(?GV'2MB;Q)%<
M6CQI96JXYVA  <YXQZ#. .V!6<\,]J;O;IM_P_H.?M%)63:];?\ #D'AWRDB
MO9[FV$T-J@E"@@9?.$4Y_AZDXY./>NUTKXDPWV@ZEHVHVUE:V,%L\^GR6D91
MK>X)&1U.]9 2&4\'@]L5R>EZF=&T'4]+N+6.Y&I^5( LFQK:2)FVLV%)QAF^
M4$9R#6+&6:-W3;M&25(W 'UQCU]:\]X9N<IUHV::Y?DEKY:W7FO)G%6PD,9*
M3JQV:Y7?R6J[.]UYKNF7-2M$M"3B*= H4;) Y)Z@J5XP,@'KW%?MY_P26AEM
M_P!C_2DEZ_VM?,.<_*74C]#7X?1VYF,<1A,]S*%=!"Q+;1N!Z'Y?<$< 9 YK
M]RO^"5.F'1OV4;2S:>"XDAUO4%=[=]Z;O,7(#=\'C(XK6-1R?+)GIT9)25-O
M4^Q*_)+_ (+4:/>:I\1OAP;*![ADTB[\Q8QD@?:%P?SK];:_)C_@LUJ]UI?Q
M0^'26TSQBXT6ZB=8QEF'VE.![_\ UQWJY.R.BLYJ#=.U_/8_,%T.20I HB1G
M)VC)QG%='=06EY#',MK'I90?OPQ8ACR-R+U )X*CH?2H-.CTV.UFN%Q/=K&$
MCM9&*EI&)&X8&&"C'RDC.?:LW.RT5S%8GW;\KO\ U\OQ*&F3+9:G!,)/*\O#
MJV,C(&1G\:FF+K"LAD@NAM\D 'D;@6SCV)(SZU>5\6;HR%+N4M-G>!L11@\>
MK8(Y[=!S3;UKC6[DW,=N(& "PA(AEEQA%XX)P.N,DUE)^\N8Q<[SYFK+O_7S
M,*2)[>1XY(V1QP0PP14T<!DD=4#B0?PE23C')_"FW7VF.3R[KS%91]U\Y [=
M:D+SQRM-)<2+,XP6W'<01W/TK9MM'8VVAKEC!B%6%N),!V'))['\JKEMV ['
M@8'M[5-*GELR';&XSP#^%(MN' 6-ED<OM Y!/O\ 2FK#325RN1SBE1B#QWJZ
MT-O!"8W827'F8^3HJC.>>AS_ $IC^0G"[X]V002&P,\?TJKCY[]"N=WS*N2O
M4XIN:G<+;NZI*L@9<;@"#Z]ZB$9(!) STSWH1:=QASUH-2*/O*1N(Z$'I39%
M*-\PQGGFG<=PC=HW#+U'J,UZ1^S>%'[0/PSS@M_PE6E8ZYQ]LBKS8*."3P?3
MK7I/[.,BG]H/X8("<?\ "4Z5U'7_ $R*DQ/?0_I=7I^)I:1>GXTM44%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !37^XWTIU-?[C?2@#\*_VW_B#J?AC]I[XF6NF:C=64EMKRW<3V;>6BR;$
M(9P "S XP3G]:\4\<:Y-\2[W38-021+U;9)+::.(!#$5R^1G)Y#-QWW8 /%=
MW^WM*K?M?_%2WB,C0#5O-<.-N76)"<>PR1G/.:\3>Y%KHEO-OBD42NL"2;C*
MJX^9O8=!CH23Z&N"=.'/S):W[=_Z?ROYG&L)23C6A%*>MG;77^MNUQ]KX<E0
MM)8"UU98YO+62.0,9&4GE$.UMI!4_,O^%4?[$O+Z^\J6/R9YG9R\A6-.A8D]
M@."<#L*L:O#9SV5O=Z;;21VD28N%=BZI(<8!)'4]B.HQP,&J>G73Z?;2W$6Q
M9B#"-HP^U@ QQV&.,_[1K./-K+^OS.Z$JCBY)Z[:K5>NOST-W3_$6F^&KV06
M,4VK*R^7///*T4<ZG&1Y8YV[N06.>A(!KJ_$NCQ^/-)&O>%YIV^RVT<5YHB.
M6>U$42JT@&?]60!C ]1VQ7E,,HV.N,;ARV.<=Q].G/M6OX?\2ZGX3UFTU32+
MZ:POX)=\<L+=.O;H1@X(/'-=46UZK:YS5\%-25?#R_>+N])>373U2TZ::&?;
MV<MQED:,2EL)"1S)SR!V/T)Y[5#=%XKB19E974A@DJE3@]!CL,&O5]6\*6OQ
M9@O=5\.M;VOB1=T]YX<C?Y;@#)::V).&POS-&>5R2,BO-VL)3&HGW"121LG)
M&>GZ_P"?2DHRG+O_ %^1T83%QQ3=])+>+W7^:?1K1]'T4-KFWO[9M/66:1P%
MC4Q_,S'@K@$DCDCW':O3K9'TO1X[2\TT#5-:M7O8;*S)CBMDPRK(8LE=[C=U
M'"!<8)KC?!^F?VSKEGILBW*"XN4""%_W8/\ $YSTPH)W \ 'K3_%NOK?7U]%
M!,3:EPQ:8$-,$^1$SR=JC@+D#Y<\$X"BG"2FUJOZZ''BH/$UHT%TU;_+;I?6
MW6UMFS;EL+V73(LVXMHV1P4M]PEF!QNC6,9R  .<  >N,5S$FM >3<P6BVSQ
MR[_,,8D[\9=L[NASN[]!Z8L%W-$V^*1X]I^5U)7!^M6I]6NKS38K0ROL4_,2
MQ ?'*@]CM^;&>FXUZM>O&M+VE."CY+33^NAW0PS@_>LU]UOSN-O=1FU(D-*K
M)%'Y:E(55F49(S@#/NQYK- &T.R!AT(SCGUJU+ 0K/&3(CD [E4,#@$\ G R
M2 >X_$4N#9R[Y),[5*!"=S>FT\\#K^'->;'31Z(ZH<L5:)5"+-* SJB  ;@N
M./7 JO5GRP7?#*I49P#P2.PQ4<B?(K9R3G@?Y^M.R3LF:Z'W1_P1L/\ QE9J
MPX_Y%2]Y_P"WBTK]L*_$_P#X(W#'[5^K?]BI>_\ I1:5^V%:QV.*I\1XW^V3
M_P FG_&#_L5-2_\ 2=Z_G$C,TL,D2H&1?G8A1D 'UZ@<_P J_H\_;(./V4/B
M_P#]BIJ7_I.]?SEQ7,J126RRCR1EF5<*7SC(SC/8<'TI2OI8YIMVT17#K$R$
M1(^W.=PSG.<9YK>@O?LEDCBUM!/*L?[P@'<A+*5(SSG&3WZ?CU'PZ^'NE>-=
M2TRS:_\ L]U,ZPS"0J%!.>0.N ,<C.:['Q?\,+"'1YK?PS+/J,5M? WBF!<Q
MNJ')1LYV  @9'."3VKZ/#9'C,3@ZF,C3;IQW?1?K^!\KB\XPD,1'"SOS=;IV
M2OU>VO3N>,21S2V]R8(P4AZLI^94SMR3Z$D#U_.H-QFT^(+L66%B-J+\S#N6
M]>N/I]*OZU;P;$FM7D:63(D"MN! Z9P!AN,D$>XJI');K?(ZQ;(7&?+=B2.,
M<G&3Z_C7E8.2]IR3V>C\NG_!/<A+FC=+^NWYE-9)()FD9%CWAE.4&,$$'CMU
M[=.U%D+=KF$7#-%$6 >11N(7/)Q]*?(R6]X7<B=@=W/0G/>G1L]_<"+:DI"L
M$WX0  $]<CW(]_6N6K#V,FI;K?Y'4WI?RW_K]2?3],N-4UB'2[.'[3<SR"**
M-1]]B<#%5-25(Y]BPB)T&U]K[@S#J1Z9]*?;)';7D(E8O"ZY;R\Y 9>WJ1G]
M,59T:[L;43+J5F+RWD!7".R2Q-M.UU/3J02"#D#''6HJSDXQGO;2R_X>W];F
M3<H/G6J26BW;Z];?+\2'2;VYT^1I[:X^S.@/SY'=2N,'U!(_&E5I[ZY!Y,S
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MSJ:PM(+Q+L_:8K0K$S^7(&P&# !5ZDDYK3O#9Z0D21MYT4A0&6)3D?+ABK$
MDAN.@XX]ZX7+DE97;?3^OZT/+YO9U&HW=^G_  ?ZO:Y%J=O!8W$406.$RVT3
M2/=KAE.P%@H&<<]">O'2LI(HFNHKD3>;%YJ[T<CS.1DX4'D<=?6MB^T57TVT
MN6N/-'E2B!0A5Y%$NP-@\#YFQ@]@?2H(;&'3II;?YX]0B3F51N$<F<%.N/\
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M51S&QX ) /F9!' '.0?CRWT6W^S37LYD-E!EEDV?O9'881<AMN-ZGGJ!DC/
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MR>:TFR2VC,LZ *-O7:,9(&X'UXX%:FL>-M8>TU)[+5+B"VN2HG19@IF'.!(
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MV4FVM;R*N<@N 6\ODM]!ZC/!%=!,;^'4'%CI@BNIY(6:*S4RG>S'9Y+@'"G
M^Z3DXY/ "WEEK@O]1>ST_6(4N#F4+$^[AN<N$!8\GIM Z8[5"A5J65K?IM_7
M6_S.5XJ;2BFE?75^G]+=/YF5INFW=N)H//CA>X<I)%*HWG ) *'G'/IC< 0<
MBK$",UXEU->/(;J7R0T>-T[9&X;F(VCIST///6NPTRW?^Q;F'Q*W]G6ME_I8
ML[B,3W-^T9V,JY&Y2 >=S  !L D5S'VG2M8G>[@U*+2[Q4*EKN!D!SN/[ORL
MA>H4?+P#QC%>Q'$<E"5*$$I=7U_KIIK^G-'%.JY^[MU2O^*7I>U[>NW/ZYJ,
MTD4-O#(#;QDJ9$<XD; S@==HS@<=*Z2_N(5^%^C/<$I>'5KL*KC(\EHX02JX
MP/F#9QC!Q6:V@Z#IL\+WVK'4<HI-OI4#*,X& 9)0H&>.5#<]JT_B!J$5WI^C
M6,5B(KBS@DEGAB<[+59'RD0!&<JFS)R221DYS7#"JZ<&K[[_ )Z^MK&\I0G.
MC"FG9-MNUOLOO;=OTU1Q,'S2SYG/DJ"XVMC)'"XS[D>^*T#<2KJLY7$MO-*&
MFM86(5HPP<#TP.WIBJ6G"%U^<Q(VU\B1&Y!7@ C/\N*M:@(8MTZJX>2"-HR$
MPH4IM;Z\@C\^M53<&]M#U)V<[?UT_P"'+^O6.E:>D217D=XCR;F>WC=9.1DC
M+#;P>,C_ /5SPBAN%<QL8V0' 92V[GN1T/X8XJ]'>+?6,%O<3-'#;!O+81AB
MI8YP>AQGZX]*9'I[+"'MV65@Q&Z,$GIR"IY''KQ^1K6I15_=>XZ:]G'EE)W_
M *\K&>]NA>,1LS%@,@C:0W<5(DK)(R @!3NR<'I_.M6VL91;P7*PRB(.V&V\
M&09P%(';C/I6%.K)*ZL"D@."",$>U<]2DX*S-D^=M=B6=4EMS("J!9-NW=S@
MCJ%_#D^XJIG .*M00RO$Z;"%;G+# R.>OTJ#8,@$CK@XYK)Q>A4;*Z/NG_@C
M=S^U=JQ X_X12\_]*+2OVOK\4O\ @C@1_P -7:NH! 'A6]X/_7S:U^UM7'8X
MZOQ'C?[9/_)I_P 8/^Q4U+_TG>OYO&R2<U_2)^V3_P FG_%__L5-2_\ 2=Z_
MG"NMDMP[1+Y498[59LD#W/\ 7O5JQBW9D.5"C;N#=SFA,9SC/IS3HD0S*)&*
MQDC<R#) [X'>I+>1;>X238LJJ=VR5?E;'8C-0V2W;82TM6O;F.%7CC,C8#3.
M$0'W8\#\:GMT"6K%PZ(^5W 9!."0/SQFF6]TUMND*13"3<-D@! .",[?;=Q_
M]:FQR,T;1LQ9<%@,\!O7]*[,&Y*J_1K[TT9RYF_(C,;Q.N5SGYAQD$5))AH8
M6SM<@@X&!@=/QZ_I3 2Z$ <KSD=AWI  T/"<KR6&2<9[_G7/4BE)-%[V;&$$
M $X.:LV]RR+)B9H0R%"$'#C(^4^W>H&@>)59T(5NA]:F1Q''&?*WKN)P_P!T
M_E^%$)6O;^NHI6:[EM+DVKW*Q2I,N2%GP5+]LC/(%+;8OR?WKBX/!^7<"H!)
MSCGL*A:W^S[H)W"HN>,_Q<<CUQG\LXK0LM02PDN84"7,)#1O(@*B5=V=P)7*
MC(0^N,CN:Z'B'&/LUJOU..>D;P5W_7R*Z6T7VUHG,1+GEQ)MC48)(SW_ #]N
M:L[6T98S<1)<0M"TD&PH02P !)&3Q@<9!&.W-9,EHR7 4RJ5S@2C[OU]:NP:
M@+2-]\4=T5C:)%D4X4$D[N,'(R<9]:VI^]%WTL$XMI6=_P"NG8@N"=I>$,(W
MX(.,JW<?3K6CI,$L>BZA-]BEN]VU X3?%$.0S-Z-R I]SBJEK(U[-!:6L"K)
M+)Y:L#M+9/&<G Y[_P!*8;J6VLY[,,T:[LRB,\,P) R0<$#M^..IK:M&G*/M
M*>[WOMI;7SO_ , )IR7(NZ^Z_P#P"U8:P-*:TO;7R!/:R!EBE!<;L??P>#SS
MCH,=#7[>?\$F+MK[]DBTN'55>77-1=@@P,F1<\5^&EPLGV2)A9&&!SM23:<2
M,"<_,>IYQQBOW*_X)*S"X_9$L9!''$#K6H?)$,*/G4<<FO(D^:?,T;4J<5)S
M2UVO^GWW/L^OR-_X+5VOVGXF_#8%@@.CW8#MPH/VA.IK]<J_)G_@L[//:?$W
MX;&.4K%<:/>02H@#$J9T/*GMG'-*5VM#6JW&#<=S\[ EA!800VL<J73O*5O)
MF5HV12-I _A.0V>N015>[E7R+E);N2Z17(0I(=LB' /7IS@X('!-7+QWL?#E
MI<VT861F:TG= 'C!4[P"<=6!SZ86JTFN3WB-& (YE14$CA0SJ.2AP.F<8]*Z
M%1A5ERU)M2\E?MYK7^MSQ8*4O>2NKOKKO_7Z#_"EZNFZHUI>_N[6[BDM)(U(
M# .N%.3P!N"Y]A6'=P)&S[T,%Q&^UH"I"X&.^<YS6MH]NVHR2V<L<*S8X,C?
M,PXPHQUR2,&MW4KR>2SM_P"UM&M[N2U9HFE=WCE;;QF1P=K8QM!]@.<4E1C)
M>X]%N_\ /?\ KJ5*K[*O=*[=KV:\[-7TUV?R..6'[,\D;2^5&3APH^\/0$9R
M/_K4CBV,<[1"1G60>6& 8&/GEO?I6]I=YX?GN+?S=+U*0;P)(8;M 68G@J2I
M.?PKI+?P3HVOV>H76AP:B)D66;^S[M TT,:<M*CC"RH#PRX! YKGY'>R_K^E
M^ 5L='#N]:+2[Z6^=F_O>ENMR+POI%EXJT*6>[:U$^C![F2P12LMU&?FVIQR
M05Y]%;-<VVIMXGU*\NM58R[@\S/$A+(>-OK\H^50"0, #BNZ^$4%M-XIMY+^
M"1;"Q#76J7D:@QI;%"LF<<Y(.!@]^E<]+X4LSIFH:AH]S_:MG$^)4PT1ARYV
M;CQD;<?C776PTZ=*+2_+^O(\FGB(4\55IS;^S9](\S=U?97:OK9ZI=CAMLEQ
M,FU Q8$!0O6IK8VL*_OHDE8PM@J^<,1P<>HKI]#\/7'B.8M<6*P6,2%Y[Q@T
M4,$?0$G/8]/4\4_^SM"\.O-]NAD<>5N@64^;YC'HP"E01P><D?6N949N-YKE
M7W7/:EC:=W22;DNB_P"'_K<XZ1H9MH2-_,*@<8Y;_#]:??.?,6W\S<(?E!WY
M7/?'XUU5GXAT,6,UN=-FBD=A,;VTB19(L*1M7).%.>>:PKVY-IY9M?LVQ8U*
MR6PZ^[9&0WK71&E!*[E]VK_3\S>G6G.=G!JVU_Z_ Z;PEHC3V<%IJ6E0/9W<
MH;[=+)L9%'49'3(_I52Z^&NHV\=Y+ ),!_\ 1HW S<1<G(8'&X#'R]\\5F:E
MY#^&]/O/M$DMY)+(DD0C(5,8.2QZE@0<#WSVKL/AA\9)?"LMOIVKV46M:"#C
M[)*@9DR?O(?4?6OJ,"LDQK]EBN>$OY[IZ^<;?*Z=_P!/(Q'UZE">(PBYG?6.
MJO9]+NUWMT36J:/-EMB)=KD+M!+%CP..!]:[W]F\9_:&^%^ ?^1HTO\ ]+(J
MZGXD^$]%U/5O[9\&YU+1;M5N# (S'Y4HY9)%)..AXSR.>E9_P(M]W[1/PUN1
M$EN)/%FF%8DF!VK]LBZ*.WI7E9EE5?+JG++6+5T];-/9K3JCT,!F4,;",TFF
MUJGHT^S6Z>_W'])"]/QI:0=/QI:\4]H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FO]QOI3J:_W&^E 'X(?
MM>V%E??MC?&)]0_X\+;5I9G#-@,^R)54\C@DXSD8SG->+>(;&;79K-HX(PP8
MQ']\Q$:\;8L= %&>1[DGD5ZW^WA,;']J/XO[9P9;S7-CQJ_(C6.-AD#W"]>F
M/>O!+&_O;'3"L4K+$T@)*';C@$Y;'I@8IXGF48\CV.94JDI^VA+6]DNFVOX_
M?9&KJFO76GHMIIVJ2"&W145$E,?0]1SUW-G /&3Z&L?3M9O;>]EN6N;B4?-O
MD%TT98]<A\YSGGWJHTAM(HYH2 _S(6R2>00<@C X.*J2,Q10=Q'3)X'3ICVK
ME<II<C>AZ%/#PC%QLM>O5G56&MV%FCW/F727B(8\)$H6X5B1(CMNY&TD9QGY
MCG&*S-0M)M*OF"H\D3J)5Q\V5ZC/7IT].#S6="RR%PZ,[E" NW)W<>X[ _Y-
M;27#>(K>WT])1'/&Y^RQ[5C4;C\R9& ,G!';.?6BG&4KQ7]>AFZ?LI<RVZW[
M=/DG^O:Q)X:N(K6&34[Z%9X[60-#&T D6>?JD;$D?)U9NN< 8YK,O9Q=-=7,
MMQ))=SL7D5XN?O9)W#I^7?%6/$)32Y(M(0$K9,?.D5C^\F.-YY[+@*,=0N>]
M9 D$LZ&3DECO+ G.?H>:JHFG9%TH*;]MWV].GW[]]NQ8L$22[3;<?8SSME+'
M*M@X/'/)P,^];VE)!-I5X\\RD00R"1C"Y5@V"B@X.#YG3@#D\\U5L_#@2Q:[
MGGC2S?Y7F,<CM#R,'  &3D8&2>><#FDDOD=7LH8\1E/+EF=AOE*D[23T"CY>
M!Z#J<5K!<ZNC.K)5G:#V_"V_]>C\RE%;0K&8@DCSNVU&'"C@'G\?Y_2M;0X"
MVK#SXA96[';(2<(4W<CGAB<' [D>U<Y*/G* [57)"D8Y[TD5S(H" G:#D+DX
MS752J*G-.70ZI49332>YZIJVE1^%;B)[^WC*S@BWFGW2+Q@%D*D*<?*,@D#-
M>=>(;U;_ %BZEB !>0DD ?.V>HQTR><5K1Z_?W5O'ITS@V"MYRVL[$@<<A3U
M&<=,C/Y5@3H\!9@25;(1_P#/MBO8S7$K,JWUJG34%9*RVTM^9A0I3IO]X[R6
MGR_KU!KI[9)(LE9I%V/(3D;>/E&/YU24L>WRCDXI2A^5G("^@//Y423%R< 1
MJ>JID"OG-5JSLBK;'W3_ ,$<,?\ #6&KX.1_PBEY_P"E%I7[75^*'_!&]=O[
M5VJ\@Y\)WAX_Z^;6OVOIQV..K\1XY^V0"?V3_B^ ,G_A%-2_])WK^<%"@23/
M4]/ER0>U?T??MD_\FG_&#_L5-2_])WK^<0QQK&0&$LK DXSA/IZT-V.>3&H9
MI(RD:$JN68*,X]S[5=C@^V:9NDFRT;A(V>X 2)3N)&PC)R><CCKW-6)Q;/ID
M$@O)!>L!')N^5#'@87CTQWZ\52TV)8[GS68"% =Q9>H(Q@>_I^=2DZJO!:HY
M>;FBVM&B*:#[%,_F;9TP522,Y1CCJ#CW^O2DL'7[0J21ET;@[?O >U6M2U.Z
MUHP->7*R/$@BCW#!" ?*.!CMCU_"H[:S#('5SG'4H0JGW/\ A77A83=2+DM5
MO\B[OD_>;D1*^0&V8DR &'0CGMZTHNO(G6X@)BEC<%"JC'!R,C\/?-:.([*"
MTFANGCEZR%4\L@#IM)/S'Y3SQSCO6.KF/!7&X<Y(R:BM&\N5KH$&JE]">\N9
MKJ>-KUYF? #/)RV,]1G&>/4U:L7D8R0)"\]D9DDD0X!P"0,MC*\,1QQDCKQ5
M&<?O&+\2D\@<CGWJU8NBW/G><MLP961,,02.><9[@?G4PA:%TNPII<EDOZ^1
M"Y4R7*D;"#PA7<W!Z9[8'7Z4^ZN&G96W8+]6"!1C &.G.,4V2?9++(=_GON)
M(.,9Z_S-,COYD@$6]BJDLGS$;"<9(^N!^56XI2U>I2B]&D2@LT@'FJB!2V9&
MW+D\>AYY_6DM9[9(R)HB^""NUL!N>0WX=Q4ODJUHGG*H60%HY0<8/4@GOZ?R
MZTELT NT:X3S+-)E+PPR!69#UVY[X'7MD57/RMM/^OZ[D733_0MV7EK;ATDC
M@E(>)@R].00=V[(ZD9P  ._-4KTV2W$D<*S!0V WF*X]\8 SSG'3C%3311+$
MR6Z("THX=_WFT@D+VR..3CKBLT*1-A<9!]>.*523C:#>JW^?^7^8J<4VY7.D
MT[58;>YM6E:*]L%0I-'-*8F(D 63'4C&>" >F<'D5^U__!)$I_PR%8>7]W^V
M]1Q_W\6OPS\B2^GF>"WV+M:7RXLD*HY/7)P!ZU^Y/_!(Q=O['VG@]1K6H9'I
M\ZU@HV?,][%TJ<82;3U_KY=6?:E?DU_P6=,G_"S/AJEM)%'=/I%VJ^;W'VA#
MA2> 3C%?K+7Y3_\ !8B"TO?BM\-(+LL4.CWF!LRN3.@!)!!&#CU^E$I<D6V&
M*DH4G)]/F?F?I;S17UWI<S-;0W@\N42 81P<JQ.. &')]":=-X?O]$1A>VR0
MJS??R&; '5<'D<]170AI89U2[LH-0MK9XG%FTH$>TC#<CYR#U !X(/&>*FL-
M-TN30GNEU5K#39+GR?L=]#YF]LG)B(.X8&W+$#KBEAZD)RLM'H>)+%N+YK:.
MU[*]WY6UO;NFO.RN<OIT L[RW<2';&X"/#*$D+'[N">5]>E2SW-ZDY6&[E>-
MW\MXS)O#'.?F7/(YS[\ULW6H6$.OK:Z?I%M;QVB!%34E$[R'&2'.=O7/([8K
M2LI/#&IZK&+S0XK>;#S7$=A-(D<2JF<\@Y+'L..>M>Y3H*G'V]&JDGUL_6U]
M7^!,\2U^\G3;5K]&^_?\O3L<P]S)>7+R0V=EIP4$K+'PN1R<$]^]>O\ P!T#
M4OB1XZA>ZENC)8*&ANHT!5]H \N0\ J5)&">F:Y"P^+6EZ-KULVE>$]#T:WC
M90[RP->Y('WOWI(!)QG ]<5U7PK^*_BOPM=:YXBNM7<06(++9HZ)%+<2-A2%
M48 7D^PZ5WY97PRQ*CB)\T;;)6BEU^:WT1\]G/UZK@:L:%%0DXVCS/6\G:VB
MDM=$_>MKJ>A_';P:WP_TVQU7PZMU_8YO66^;3HOW;2D#:KD8Q&%!&#U]:\&T
M.ZGETS4M'T[3&U"&5FDDD7EGFSB$J #P!D%<\YYQBNO\>?'CQ9XL_L:73[D6
MD*I(9([.-55Y?,)+LH_BQM'([5RNI_%KQE<6,MA)J<\,D>6=8H4ADD4D#JJ@
MGWR>0*,YPF']NYQ4HPTLG_*MK-/;JO4X,ER_,L/@H4<2H2G?5N33TD[7M'5K
MIJNG8R?&PU/PE9W'AB]!ANY)ENM1 CV[Y /D3..50$GC@EO:L:X-M/&++S)+
MQHL^2,%,+C. 2>G?'K70O\2#="W_ +?MCXKBBB,;+JLC,T;]O+<$,  .A)JO
M97W@S5[V66XM=2TB=CO0Q2"Y0-UQ@@$#\^*^82C-\U[+[ORN?7476HTU[:D[
MK5N-FF]KV^+;RT6EV<6V(T8('PQVYW8^H(_*GB9+)P(L/*KAO.R<$8^[M^M=
M[J^B^'KM]EW>2V4TX66WU-'%U#*O1@0N"O..HR.<]JY'6?#MUI\PB*Q3>660
MO!R>#P6'\.1R,]15.C*-I1=UY'IT,92KV4KI^?7Y[/LU]Z%,D%QI%V%N$A(D
MCD2&4%CG!!"'L.G4>GI4>GZ997<J*;XJY&<% @W9' 8G%5HO*.ENI3$HF!,R
MC.%QC!_&JJQ[F &68M@( <FLG)O1:,Z5!VDHR:U\NQZ58>(O^$2UJ?3?/>&V
MM@ZSQPX*2?+D%CP2P; QC'7%=-\#[JTU#]H7X9RZ1:J]LWB;2Y)]Z;9$<W<6
M[@'[N>F*\IT>"35_[2DP)FBM99C'@D@#&6&/0>M==^S;<S0?M$?#(QDPA_$^
MEC"\ J;N+CW%?5TLW:PL<-BO>6MG97C?M?H[.ZV[6>IYU'!PC5<XOWTE?L_-
M^9_2T.E+2+T_&EKY4]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FO]QOI3J;)]QOH: /Y\?VZYS;_M@_%8
MD*DBZW(0Q)R08X\#'IS^M>#W=V))Y2$C1& (CA8E!TXZ_P"2*]\_;L6"Z_:R
M^+",SBYBU^3 )&&C*1C _P!H''4]#[5\_"",R%07!)P-RX+\XQCIZ5S\_-*S
MZ'33L]6M4-DA5=FV3>7')R!@U/&TB26\T\P9,F-5+GA1C/8_+S^/-,$EO!)E
M4,F5.8Y%PJ_W3UYXP?K3!YQF#2A@&);:PP&]0/Y5$EU9M+WO0=<V4T)C:13L
M=<I)T5P#C*]R*Z'P_H5W:6.I:PL+/]DA)CWQY&YI%CR0>N-S=.AQ7,RL9V=B
MF2<X"\;1]/2ND\'ZI-!'/IT;A(;UD42F/YHY5R8F#?PX<@'G'/?%=6&:VEN<
M]?G]C9-=+^E]?PN95W!/>Z6+V20R.CK;LC E\8.P],8P".3G@4[P]I,6ISS-
M<7$=M;V\+SR/*&*8 X7Y><LV%&.Y],FM:\@>RM(K>6&:WF>5Q=Q2.5:)P>'Q
MCC@D<Y[]*U/#?A0_V5J>I0:MIYBA$:1AVW2+O^;?M_A* '.3ZXR16SC&;<T_
MZ_X<YJF)5.E+WK7=E]]O/Y?><]K?B*_U66"V65HK:(@P6L("QH<!0P4?Q8 &
MXY8XY-9Z?Z"2A"2/(/F!&2O/0>C5T$MU::0GE)(T5P[?O[FV(W("IVJN0#@[
MADJ1D9SVK'F^S)*1;%FB#D>:>)&!Z$]0!^M8P:3LEH:T7&W)"%H_G_7WO<CF
M87N^6X9X;G& S)@2#ISQP?4\Y^M9S#8,C.<\'L:FD=R 7E)8'')S_GO4\K6[
M %I?.+?>!3;M.>Q]".>GM[UT2HII6.U?NTD;'AYK6]U*$WR[DD0B1I'(YP>A
M]2,=>F14.H64,T<DD9C@1)#A)#R1P"H/1L9R?SK.CMEEMV>WD 92,Q,<-SW'
MJ.!^8I;=6FC$6Y%D<MC<VWH.<Y_#OZ^M>NJL(8=4K>K,'=OF4C.?][N8MEO>
MHU;!Z CT(IRMY;AE)4@Y%22/&ZQD+M./G;'4Y//ZX[=*^;E+4ZGIH?<O_!&[
M'_#5FK?]BI>]_P#IXM*_:^OQ3_X(Z1K%^UEK"*X<#PK>C< 1G_2+3L>:_:RK
MCJCAJZR/&_VR?^33_C!_V*FI?^D[U_. 7!R.%Y)Y&?UK^C_]LG_DT_XP?]BI
MJ7_I.]?S>.,.W(//4=*IJYBU<N7$L8ME39(78AAO?A1TX ]>.OI^--AN]L;1
MK$H8MN5QG>.#\N<].?TJ&0*SY4@#TS20%5D#.-RCD@'!(] <&DER;&7*N4DV
MFXWMM /7"G&/PJ0VY2RCFW*H9BO+<G ';\>M5UDPQ*\59GNI&B@A.?*1"%7/
M<G)/\OR%>C!.4'46^PI<R:2)70&U@9PY5\G(XQ@XXSU[]*J7+B:<LL?E*<80
ML3CCWJ[<AOL<$+*0ZIGY\\ DG !Z>OXU5$: Q%FWN3S&!T'89_/]*O%Q?-%V
MW2_)?Y$4WU]1T2K#.VTJP7^/&1]13KN2 [7A1LXPS] Q[D#MUZ>U79+:.SO[
MCR@EY:PLQW3*5R.@W=,'\N15%)?+M+K)R\C!?F"GC.2>>0<@=/4UE4J^SBH1
M7]?\!$QESM27E^)3R6SWS3E<A2HX7OBI9;K=%'&B"-$'./XSG.3_ )[4TQDM
M%DI'Y@&#G@#.,G\JXEKJSIOW1)/J$]S;0VS2N]M S&%'.=FX\X],X!ID$0(+
M.Q5!W%1HN7QU'L*L7P\H)$C.8P-P#KMZ]_RQ711A&*=1K1?F^_XLBRC[L=!)
M/*?SS([+,,; JAE?GG)SQQ]:<@EC@8L)#"F"/EP-S#@G\C]<4RQM/MMU!!YD
M4/F.$\R9]J)GC+'L/>K=U<SQ1&S >,0N&+, &XZ9XS@=N<<USMMRYI/4B3UY
M%_2)K#4);5ENEL $6(VRO%N4&0CY6)Y!;H<=#CI7[A?\$F9;B7]D/3_M+%I!
MK.H#YAR/WB_US7X:!KO4$C@&^20MO158DR,3C.,\GC' S7[B?\$CPP_9 L V
M[<-:U '=U_UBUG!*[TU%3@E)RZGVG7YG?\%6OA#XI^*WQ*\!Q>'X(6@M-&NY
MIY;B5(E!$Z$ ,>2<9P*_3&O@K_@HK=Z/?>.?"FCW4CQZK_9-S>VL+RB**[1)
ME$D>[LX!#@9P0".N*^FX?R[#9KF-/"8N7+"5]?.VF_F>)Q'BZ^!RVIB,,ES*
MVZYDM4F[76WJK;O1'Y@>/_AEKW@'PYI]WK.GRQO.03)&A;SE)RF'Y"@$\GU[
M5YIJ]I??VG%#?+'#<1Q)&L3G_5ICY0>^1^>>M?4?[0=^NE?"SP_H>K7EE)J6
MGO<,]F+[S9K=7(9"-O!8+GY<D#CWKYDOKNQDO$^S6]PEP08X[BYDQYBX&"ZY
MX[]\8(KR\YP,,JS"MA*$U*$6[275='O_ %T/F^&L=B,=A/;UHJ]YJZ6C2>C6
MNS6O7I;1%"ZU&)KMH9X8Y(E; $2F..-N-Q'<\#O]:Z+1HCJNLW%FEP8MUO-;
MQ7$05_E&"-Q&,KQU&3UKD1>0FZ ,*3[CEO,)4/\ CG(JU#?IIVRX@(MI),LK
MQ;@T1!R5&3R>@S7/AIN+<92T:L[[?UUZ'UM:@Y0Y8:.VG77O_2U]3.O9@^HM
M(D:P\\*,D?7GKD\_C74^"K&YUW1O$.A6T#S7KP+?0I&A;/DDLZ\=,J2<_P"S
MCO6=J[:=JD$-U:3RPREL7,,A&T,>=R'K@\D@]#4^D26.CSI*VJZA8SB,K(;5
MQO8YX"D=L8ZGJ*]&E@*M*HI0E%QVO?2VV[ZV[]0KR=7#\L4U)6MHW9Q=U?NM
M/GW.Z\"ZGI^E>'@)M1AT^2>1_-.3&03C"G'/09_&L?X@^(QXEAL=2DU--8U%
MW6U6&/(FBCCP$W?*,Y!P#FI/'2R:U9V?B"2UE;2+C]RUTKAY8Y@H^9N "& R
M >X89R*X6&UCEE013P_/N"$R&(H_8DD>W'/>ON,YXJK3R>&2JG!J"2YK>];?
M1^?ETL>-@\)2JU/KLG:5W=:.W>-[7[7VV70K3V\<\@C@),TCG]UL.0Q. M12
M13V>%>,QY)4LR\9'WAGU'>I+BTN9$-VML880XC+*QVJX'.23P3UY]:6Y!G@@
M5969LG$&[(4GKCZXK\LLW9]#ZI2V5[HV/#>I6UG#):W4<<EC<J5N&N%/RGLT
M9ZJPX.>_3I6C.J- T1\Z_OX49=ZL1B,'$;!1RYVXSGHI%<XEO _E>9(3$JCS
MMH&]/4@<9]L^M:*:@=/M;.X9)FN!GRWWD%(0<;,@=\]>PXK>A.*NJC?D_/\
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M/I7B-E;>=%=,L\4;PPLYCE(7*Y (7/5N<X] ?2O;_P!O#"_MA_%=CR/[<<$
M@''EI7@2,"'7;G..2,D>]<TD[Z,[4FXZ#IV\Q]P&%[4V2:24Y=RQ]"<T](_,
M=?F)3<$WD8 ]*:R?9WW'8Q5BH&0PX_I1UL;)K8? Q+B.0_NRV6( )'T]_P :
MZ&YMKG7[LWL<B);RR")4FND+C '\.0< #KC'I7-*A)RH(&,Y-=+X#O[?3?%6
ME7-[-%'9K.!+EB %/&3CD#GG';-:TDX34['+B6Z<'5@KR2?^=EYNQ1N-9GGU
M.:6YE\]W9B2AP&.,#IV&!@=,#WKK-%U1(_"^M7PN8X;@206<4<J;=BR;RS;5
M&UP$3&3R-PP,X-5(O"MB]IJ0U6Y30)+6$S6@\B6<W\NX 11E1@#:=VYCC ]^
M-?PQX3N]?\*WJVHD-N+B"=%AB:5I9%!0H%QDXW@]A@GG( K>BI5IU(J+ND^G
ME=^3TO>QYF*E0E2B]DG'TM=>J=UO;IN< X6V68*B/O3;M<9*<YS_ /7JK;S[
M)59FX!')&<8Z<5I:DS6S,LL1@OXYBC#)"@ <J5//WL]?<=JI16:WA55=(;AV
MVA'.U>OKT Y[],5RIM-OJ>O!Z<TBM.X:1R. 3P!TJ+/.:Z#1_"EY=7J"6VE>
MV!^:18V9>1D=.O;IVYI;CPI?RZNUI:V5PZ,Q\LB,X< #D$\8Y')[$5JJ=235
MD]2W6IK=^9CQ1M)M"\E@ H"G))XQ6P)T@:^$L1D$=O\ 9T5VP5?@;OIU./I5
MQ?#T7AORIM9G1)F&]+6 B1UP<?/V'TSGZ5SNI7T<ZQ0PPK##&.H))D/]YLGK
M].!79**I4[3>K_K^NNQRJ2KOW=5WZ??_ )$,\7EN5+*K ?,0X8$_A216PD;'
MG1CD#DD=?P[5 232A@/K7GJQV6=MS[P_X(ZA1^UCK!#EC_PBUZ#D8_Y>;2OV
MKK\6?^"/"I)^U1J,Z +N\)WB.H/1A<6O/XXS7[35I'8X)N[/&_VR?^33_C!_
MV*FI?^D[U_-XP&>,G\*_I#_;)_Y-/^,'_8J:E_Z3O7\WX#^6Y7(0$9YXR>G]
M:;,WH,SUI[NAD++'L0]%SG%$2"255W!=QQUZ?G2B L%VMS@[@>,5<(2J2Y8J
M[$VNI(UO/9MMEC>)F4-MD7&0>0>>Q'.:6.4O(BW+.$.#NQD@>PIT\TTW$H9W
M&/G8DDC&!D]^ ,>F*B554Y9@2!P.N:ZX*K326W?LS)7:][<Z+3K1+O2KF5ED
MGEAPH?:2H0]#OY"D'''HU2>'?",OB77;+3X/)CDNI4A5[B3RXT9FP-['H,]_
M>M7PWXE^RQ/I=I8LFC3O$]W#<7(\QR JOAMHQDEBO!(W=ZW]+\/R:AXE:/P@
M;F^C2XWV\4B*EPT:9(8J"1N !)"D\C-?=Y1@YYK2J*=/E4%=2[.W57Z;[V:7
MW?,U\74H>T3]W2Z;>BT6]M%KK:^W4X-=0O/!>LZA!:7T<L,T<EI.]J^Y)XFZ
MCG\.O((%8)F= NTE&&,!2>H[_6NCU3PM/YC7EHJK9.6=7W!1%S]TY.<C(K+?
M36L4AGE('/R"-L[B.3SVQD5\YB^'\7AJTE7A9O=O2_GYZ=K^1[-"I1:YDTY.
MU^[:[F=M.X9&]CR>YJQ=I))(4591"I)C$H^8*>1GM3I+Z1D;"B('C<HQV/'Y
M&J[2NLIWLS<8Z]>,5Y52%"#ZM?=_G]YVKF;O8>DHMTR$1WP06]/3\:C:9QR6
MRS@ _3W_ "%.V1FW\SSAG)'E8Y'H?3'7\O>H&8N<L2Q]37+*LY:1T2Z?UU\R
MDD]2]:S26S0W1\J55<95E#XP0>5/8^G0X-)J#VTQ22'S&D95W[CWP=V?J<=.
ME58=S$1B0('(!W'"^V:FMXT-[&D\G[K> [*-W'MCK7,US2YGN0XJ,N8:9HTC
MA>$R17"?>(/4Y/S ]N,#'MG/-?NE_P $E"#^Q[I73=_:U_G"D'.]3SGJ?>OP
MZU*PM(;Q8;=ITCB^2>:=?XMQ^8*.0,8XY.<U^X'_  2.<R?L@6#$Y)UK4#G_
M (&M*.NHZ;4[21]IU^3_ /P6/U:[T7XN_"Z]M79);72[F=2B[CD7,?4=Q]>*
M_6"OR@_X++ZE/IOQ,^&OV9U@DN-'OH&D"@LP,R84^V>?K6T9SIOGI[KY$8E<
MU)QM>_1_TS\]?B%XAMO%OBS6-7DG18GNS+#'"A5-K?PJ.P4\?2N:FL88N8[P
MRR*_[R,QL2%QD,/4=:EN+"&&.X6\=(9UE51'AO-7'WN.F.^?6H+.6.26U$4@
ML9%1U^T$D;CV!/3H<?CS7'.I*HW-R;//P]*-"C&G2;Y8I+RLEZ?EU*CRI X\
ML),AS@./7OCL143-ADRP7(.3C/?KBM>QT\:B8$AEMUNI93$(&(3Y\'#$]/;T
MZ55N(;"QNQ S27@1L2M"=JDYY"9&?Q/Y5K'WCMC4CS<JW_K^O,LZ1;3:A9BW
M"VZ">5;>&:7"[6!W'YNV0<<\<UFR,MM=B/RU*QG:RL=REAP3D=JUKBUTRU?;
M/YZJT"21F)AME)Y/./PZ<$&F6E]I-M!/$UC<2R,/EE\X!DXZ ;3Q[]:KE6Z?
MYF,9O648MI]-OQN:6@^)KBR1["6-]0TVY41W-F[,RL#@JX_NE3DKCO5C5O T
MUG?2V%G-:W>YBT0>9$N-H7/*D]"#^)'%<TNLO% 8H(U@B/#%/]8PYX+]<>W2
MEL+UD@G\U!+ JX!?ED.?EVGUZGWKUJ=6C4HK#U=UM+]/3KY/IK<PEAZD)NI2
M]V^ZWN^CW6J_%:7T1J3Z+JT\S0VEA<7(,821DC+LN%&X<9X&>I]*Q9]/>SD<
M,#&Z@%4?[W7KBK,D,D[^=82$S2'F& ,"!CK_ (U=>74K?3X1?6]Q<V"'</-!
M(4],*^,J>O?'M7++#SBF^1KSM=?>M/FC6,IPLKKTV?XO7\"G8V\NK/%:VZ37
M%W<2HC+LW%G)(50>W^?2FR-]GG\K:T@A!C<DX"L#DXP>1G/%:%_:_8$@N+.1
MFMKM5>"2+*M'M.&)4'[V<C]1UK*CM;J\D6+RW\M,L-X '/.237)"E5<G",;^
M6Y4)*=Y7]W^K_=M8M6=Y<130/:;[7;(TL4JKPQS\N?3TYKLO#_BV2U46<\SQ
MQ26\D<OER*?,/)^;VS_C7*V/AV22;]_=V]OD,\IDF"KL"YVY&>6Q@#UK5TG3
M;?5K69;)90\,&;K4'4M&IW;455Z\Y"__ %J^SX?SG%\.XCZPI679V=^RMOK_
M ,,>=C(X>K&TE==^U[VU_+?79&?J>G76L7=Q%:HMQY<9D7;* =JC).#C)QVZ
MUT7[.MO)!^T+\+_,4K_Q5.EC!'/_ !^15R4UNXL\23*L\+X-LQ._?R"WKP *
M[?\ 9XM5B^/GPR<WEO))_P )9I0,:%BS?Z7$=V<8KY?'8JMB\74Q-9ZS=WIU
M9ZE"3@N6^FVS/Z4EZ?B:6D7I^-+7,>@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !37^XWTIU(1D$'OQ0!_/
M;^WO9N/VO_BNRE1G6F(7<-W^JC.<>E?/\<,N3'L(D(/#<$C_ "*_4+XY>)/V
M&M?^,7C2]\9W?B__ (2Q]4GAU;[)]N6(W$3^6X4+\NT-'QCC@5Q4E_\ \$\Y
M2 \WC,Q@ >5G4-O Q_2LW!LVC5<4HV/STM$/F' 1QM)8.<KC'\_US2RE6<B)
M!$@8A=XRYYXS7Z!M)_P3P( \_P :!1T -_C^5-_XUW?\]O&G_D__ (4<DEL7
M[57N?GO)-)(55W9PG !.0![49VNGE[F.!U'?_P#77Z$?\:[O^>WC3_R?_P *
M56_X)WHP83>-,@Y!S?\ ^%'+):E>VBMD?"%EXAN+73X[">-;VR27S/L\I.$8
M_P!T@Y&1Z?EQ7V3^S?XY\/Z)H4XMI)= EBMI?LKZQ$@5GP79%D0[CMQ@OLSL
M&,C.*ZEA_P $\5A1C/XTV,3@;K_J.O\ .I+*^_X)Z:?=)<PW/C195Z-F_P#Q
MKUL!F.)P%95J35U=:J^CT:/G<URZ&9T/9PER.]]-5?TV]=#YY\93^$9K/4KO
MQ \$^LZHY18[! B!(FSYJX(!D(DP W!V9(.:\@2^T2[N@1ILZ.H&2)HUC8#U
M^0 8 ZCKUZU]Q&Y_X)YL%S=>-CM  RVH< =!]*/M'_!/$KM2?QI&N!D(=0^;
MW-<%:<JN)J8G9R=[+1+T71'1A<(L-%IS<F_.R72R2V5K:>5SYDT?QMX?B$-Z
MM[;1W:X7:VY>B ("".@P.1Z<UQ_CKXF'446RTAYH(0[-/*VP-(V> I7H@&<
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M^#I__B:7.'*C\+P>1WJ281+,0C,\61@D8-?N:/\ @D9^S\#D:?X@S_V&G_\
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MDTQV9^%M2;]B *2&(^8Y[5^YY_X)'_  HJFP\0E5Z#^VI./_ !VF_P##HO\
M9^_Z!_B#_P '3_\ Q-9\X6ON?AS#<Q10'B03=F!X_&I[74-BR%K>.8LI7D9Q
M[U^W_P#PZ*_9^_Z!_B#_ ,'3_P#Q-3Q_\$F/@+#&$CM/$<8&?N:Y(.O7M7H4
M,RQ&'BX0=UV>J^YW,I4DS\-'NK9T -OAO[P-,Q;NP #)]:_<?_AT7^S]_P!
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M]6Q4X3C\<KGH=?D9_P %JY&B^*/PT*\_\2>[R#Z?:%K]<Z\(_:)_8O\ AO\
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MN/C3%<7,XNM-@FM)D\OR\9VCOM)[U^LY_P""1O[/Y.38>(2?^PU)_P#$T?\
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MW?YGZ(44@.0#2UUG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME8M<FNUL[9(+L9N TK,N(HK<B$X(+"-MHR_/>?&6SO-'^/EU\0-1UO0]0M_
MNC:8UBV@ZO#J\L<D.+>P65Y'C^T3 1"XE9<A<KDY(4_$9/S<#!]*&<MV ^@Q
M2MK<ZK*]SZ8_;U\*:.OQ?3Q_X8^RIH/CNTCUUK&*ZAEGTZ^D4-=VTZ([%'$A
M+\_*1)\I.#CYH((1>E21LRQR8<(< $ XW#/3W[?E70^$-&@\0^)-*T74+L:?
M;W5PH>_=2XAB/)8)QGCGUI<R6KV_KH8UJT:$)5);1NWZ):Z=?S*6E:0L<0U'
M4(F_LZ-@#V\YCR$7D'D=2.GY4^;Q =1N=LJ);6A4#[/;92+< <,5R1GGM6EX
MKO)/$&H6VF:9<07&F6<DD%C#$&C6.,OP[&3&-V02S'ZXKFHO-LKMXP 903'\
MF'YZ<8X/X5V>W4/<ATW\SCI+VZ]I5TET79=/GW^Y;7-26UAM_LC3[[EYOWDB
MVA V1 D8Z'#<9Y' QQ4=Q8R7D4]Q=ZBBM" 1#/(6F<$]%'3WY(%=G97$5UX!
MN4M+EAJK2);W,,,&T?9NBHTFX9.X$D8.2!S7-ZK&UAIS6%S]K5Q)OB6:$1X;
M &6W<@;>P/O6<FE%R[[=[?=_PZU.6CB)3FX[-.WG;375;=/-:W,Q9S-IDT0F
MBAMTVL(Y &E=N<A3C.">2.G ]!46DZO=Z'>F>RD-M<A2@E7&]/4J?X3QC([$
MCO4%](;B3SL11ECM\N%-JK@ ?3G_ /75O2(+:ZU2$7CRQP.!O,(W.<\< ]3S
MFLZ45-I25UVW[7]3TI1@J<G-73W5K_\ #F_X[N9KJ\BO+B&WG_M.S@NA)".8
MVQM(W #)RK;@<\D]ZP-/M;1+22XENXUN5E2..VDB9E=6#;G+#@;<+QU.[CI7
M8?$;7]*?Q;J4GAUGTO38=L,5BP+B0C<"2,LG )YR>3D=2:X412W2@1KN$8Y5
M!S[G _G5M<]W:VW_  W;[G^)PX&\L+"Z<%9>J\K:K:R=GWV9I:?;R0:Y!EH[
ML0S!6VN=C+G'W@/ND>G:O4?#WA'2/!=C9^*M<_LZ]OC.ZVWA^:X):YC 8"?)
MZKD@*!U*_44WX1:1::)X5U+QS>V+7AL[DPPV\R%+25O+)VEAU.3PH'&,UYIJ
MFC:HTR7UY%,L-P&E6Y"[D(!&<-G'#$*>>"<5ZM2*P]",I?&_NMKI:Z=WOZ:]
MF>15G_:->IAHU.2,;1D^LG9MQ6MU;JUKKIW/U._X(J7=Y?K\;+G4"[7DMYI3
M2F08;=MN^U?IS7YP_P#!&B^EUSPI\2=7O))Y]4N)M.AN9YE)\W8MSL;>3\QV
MM@^FT>M?H]7C.;FW*6_]?U?J?3X:7/26EK:66VCMIY::>1XY^V/Q^RA\7_\
ML5-2_P#2=Z_G"N5/F-Z5_1[^V."W[*'Q?"@DGPIJ0 '?_1WK^<&Y<;E&,.HP
MU=M*25&<9;77ZF[W1%&V&'&:60A2-N1[YZTJ+N.3E<@X..*D\O*D9! SANU$
M(.<&H^J!M7(E"O\ >;:?7'6E4.N.< CC!I$!0JQR%SP<58@LY#&\CPRI$@RT
MJH<#L,_B1^=<\:G+*[%)I;L2.22%@03GK3YKN29]SN68\TV2X:1UW2M,0H7<
MV>GI]*L75LJK&T3I("@W;,_*?0Y_I7T-"I6J4[4Y/3H8NR:NM1MO<,C [O\
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M3MY)''08%=3+KE[I&J:1?RQ:AK%_I9GDU74X9?+-P9 $,*2J-WEJ!][/.YL
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MYE=6;[N/?YM-(_>M?NCZ4M(OW1]*6O6/HPHHHH **** "BBB@ HHHH ****
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M^Y @63/(4#L/PYSVJ:Y:^UW44,<0FN+CA!;Q*A8#C[J\#@?UH3?,I7TU\O\
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MQ/3RV7<P.2<#D#&/?W_]@_P"OA;]J_X.ZM%J]IJD-]J5RB&R))C MI,>8#C
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M3O7\W@;:^< X/0C-,HL7MA+ITBQS[ [(L@"2*_##(SM)P<=CS4,K!WW*BHN
M,+G'3KR:8",\C-*G6G!-V4MR4FEKN61&8X5! ^?YLYSQ2W'ER2NP"A0V/W?R
M@CV!YICQ/$^T]0*L65N)9X@8PQ+!2CMM4Y]^U>W.A4G)0Y;..EOS_$Q;27-<
MK3*2D;!0%Q@$=3SW_.A%..6"@\>E6[<^3.%P0O()"AF]\9JY8Z&VH0RR1K*"
M@!W%1MZXY.>/ZUTTLOG5G[BN^VI$JL8+WMC/,+0X9<%0VUCU7/IGO4##<XR2
M<]2>:W9M)T^#=LU-;F/Y1A(RK9/48;GC'49[5/INF:+,S&76GL61@<2VI<,N
MX#@*3EN^#@<=:[)975M>4X^G-&_W7,/K,(QYK-_]NO\ *US#>*:% V#''+RA
M"D*^#V^AK>M--:Q@;56E6WFB198HD!4G(!#JW X)' )/!., D>D_";X'-\0]
M>MI;BYAO-("R22".\C@8A%!8!B3M^\@Y'<CC;6?X^^&$5I;:;)8:G&UNS302
M*2WE1R( Q ;&T[0VUBI(R!_>JJ<%@U*I?WHVM;5+?7Y6^_YH^?GG>#J8KZDI
M^]UTTZZ/L_=>_P CRR"<K/"Z%=V0"HS^9]S[5))=-<7,L,CK$DDI)+Y^4Y/4
MXS3M'N#97I(G1$7YMS X)4Y&,#.<\CI[U7N[IK^_N+J[D>:6=VD>7^(NQR6/
MXG-<ZKU(8=\O?7_ACZ/EO-Z:6W)YXA:J?*N/](@D/,9&WCH58=<U2O-0EO+R
M6>1F,DK%G+,6)8]22?4\_C3O*D@@=V4A2=H)'!(ZU6"!\-NXS\QQ]VO.QM3E
M<*L=)-=/N_1&M.*W>OF3+?N+8P>7$5+!MQC&X'ZU^YO_  2296_9 TXH<K_;
M%_\ P[>=Z9[^N>>_M7X6<)O'#[A@-Z=#7[H_\$C6!_8[TP!0I76-0!(_B_>+
MR?\ /:O)=2<U9O0V44G=(^TZ_(3_ (*Y^-U\*?M V%EHMJT/B/4_"EO!-JBL
M#)';?:;@B*(8)1F(;+#!(.,X)K]>Z_%;_@L?:N_[5FC7()\J'PI8F38X5P#=
M78XS_,9QQFH525+WHNS_ ,SGQ5"EB*:A6U5T[=&UM?NKVT?4^%#*EI<Q7MEO
MADMS'N69LGS0.3P!P2#QU'O4_B6P_L^:"3SDN1>1+<K-&-@(;.Y2A ((?<.>
MN,C@BF)<3ZI]J9+=6BAMP)&6$,R1!E&\G^]DJ"W4Y]ZO^)8;.32=(NX;V&\N
MI;??=Q"/8]N^]E5-V?W@*@-G&020>V?/YG&I&_IWZ75WT^?INT<_,X58)^G?
MI=7?3YNVMM6T<^DJ_9GC<NW(*@/@ ]^.]2:>]TL[&U4ES&X;:F[Y-IWD\'C;
MG)[#-+:(QF)B=86.</*P50N#GKUX/3K6S;Z)#;:-_:<6IOM9OL\D$:;97R/F
MV@GE>0I/KGC'7:I4C#1]3HJU805GU]7JPT[Q5)I]I<:=!%!_95S+!)<Q7"B3
MS&CR =V 0I+L<#';TK.O;&YT^)(GMD$=T!)#<8W;UZ?*V<$>HZ@\<=*:;NW<
M7 42H@#-$5"!MQ8<,?[NT=!WKL?"GC"QTPV5GJFE3?88"[3O;2A;GRCM*^09
M,^6P8$[EY.\GH*/=@G[NKZ^BZ]^BV[=#AJ\V&3J4:=V]U?5V6C\WLNM]$/TG
MX:10V"WVO^(;'0=)>-6R"+FXD8MAD2!#G<, \X&,'/7'J$/BW2OBE\+Y/#NE
M:0\-YHERMS8*]^1+-#&N'4*6Z[0&R<\\#M7EGCGX>WOA>SM=1T]SJ.BZA$#;
MW*RI+P_S%,*205)VDX W9 )K!\&:A=Z/JSZI;7IT^[M8':!RO$K!<>61CD%<
MY]>G>IPMKN=67/!Z66UN]ENUO=MVMT39\_7PBS2@L6JW-*#O"VBBUT:6MWM*
M[=E>R6IM7GBG1!HULB://'X@MQ(MS+=2%UE8MC:!E61=I(VDMWZ9KM-4L=0\
M3>'!J]GJ4#O%:P17&GYD+V]M(0I4NPSM4A#GDYQUQ5R]TJTLEU#Q)I$$=W?:
MQI,ES;-+;F=;:3<IE6(8!$@!;!(.T<\BN9^#_C'5=*\2HT5];Z39:C;/97TD
MD2)#-%G.79B!NW$$L.0.QZ5RU*;PU2I2V2ZN[33M)-*S?+U77IH<<Y>WH2Q.
M%5G3=[2;=[ZRCLVEHTK==%9%S5+W7M+T*V\^*QNM+U">5%2ZM$,KW$0V$%F5
M6!"D;0<<,1C&*A^&%SIEYXFT^UN);Z.&VCOHITA9?D1K=U$F=KC=DD9 /&.F
M,UA?%>.WT'QE?Z=IU_)JFGI]QV+;=S_,P(Z9(V\KUP#6EX.TK3M*\,:EJ_B5
M-362_E^SP1V*%9BBC,DJN>.&*(00?O'IBL*E!T(R<_BUV5G?;;OTOIKV.B5*
MG_9W/M[5:<JLWS72T[J+UVVOY'$W=[;G5;D:4US!II1HD2X=3*(N@#LH53DG
MG''Y5H?\(QJ4<C:AF.YM4MQ=37D-RA(C+JI?[V2P9UXZYZC -9TFNW=G9O8E
MFC3RV41Q,%*EN#N(&7&W(()[UG7DKB15>.1%V)L\WEE&!T]NN!7=",]$K)??
M=?A_7<^I5.H[*-DO/6Z_#7SU^9V^LZ587'AB*[2^!O\ 3;D6/F(KSK<QEB4?
M</E1 O ZECN' %>W_P#!./4)H?VP_ 5NYM\+>R0C>F9,>3)PK8[8YSS@UXL;
M&UF^"TE[9QB7R-:,$QG.UU5HE,;8#8/1Q[;CD<YKU_\ X)[6MN?VSOAFT8>V
MC6^D=1.GSR.;=PZ@@8 !R0#T'KFNK$.=%MQ;U2WMUBK_ 'N^_KHCRJ34Z-6$
MFW:4EK;2UGZZWNNR?9(_?]?NCZ4M(OW1]*6M#ZH**** "BBB@ HHHH ****
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MQ P<<G-8$:7?AO3;0+=26NIRG[9#]D8+)$A!4[V&'4D $+GH<]Z_2KQ?X)\
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MQ,,/&.+FI5-;M*RW=K)WZ'C?[9/_ ":?\8/^Q4U+_P!)WK^;L]37](G[9/\
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M(Y[X2VLF2#$BK\^WLQ(3OV/ YKVC_@FUIL]Q^UQX"N+I)"EO?R%7D9LAS;R
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D-
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M;=>!_P!]4A_8+_:!\L ?";Q'N]1;+_\ %5Y2@KZ[(W/!UN]CIB.-T7&5(X<
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MMNLG==[[WT^7S1]'W/\ P4:_:0MYYXT^+-S,8I"@/]F68WC.-P_<?C5_3O\
M@IY^T%8D+=>/Y+Q5< C^S;3+ =3N$0X/I7(^ _V5=?U70(-7UG7+7PS%>DQQ
MVDH,ES,#U&!]S/3D^GK4WB3X(?#+P1J"K?\ C@ZM#Y165+<I$\4I7*[A\QP"
M#D?A7=2I4L0_9I_>N5.W:3LON9\U4XGRRI5>%A4E4DK_  1D]5OJER[^>YT<
MO_!2#]H^_AN)+3XESQPP<L6T^R#;2< \P_H*CT[_ (*'_M,:Q)Y5M\4+KS5Y
MPUA8C<,XX_<<US>HZ+\"?"?A*0/>:UK^O7('E^6?+CB ;E^@!#*> >1]:O\
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M_&*GL_\ @H]^T[J$HBM?B1J-S*>B0Z59.?R$%?.K36$7A]&0!]3DG;?N'"(
M,$?7)'X54T?6K[0+^*]T^YDM;F,[EDC/3_&N=N<HRY%JMK_UL8\\YPDX+57M
M?9_\ ^DI/^"DO[3$4[0O\3;Y)58J4;3;($$=L>139/\ @I1^TM$Y5_B=>HP.
M"K:;9 C_ ,@5\\:7H^I^*+Z[DM(6OKF-'O)E# ,47YG?GTZFJ%U=R7=RTTG+
M,V[!R0/SJE*\N7JMRHU+RY+JZW\NWWGTI_P\L_:4_P"BH7G_ (+;'_XQ0/\
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M/EBX8.BI8V:CK:[:2?9Z]^W<];_X>6?M*?\ 14+S_P %UC_\8H_X>6?M*?\
M14+S_P %UC_\8KE/AO\ LN>)/%=S:RWTMKH]C(IE>XN+B-?+0-M)VD\G/\/7
MBN:O_@S+#XON/#UCXATV\*W/D17Q<I;2GU#\X]*]F&!QE2;A&A/17^&5M[;V
ML<,.(,LJ5IT(5DY05W:[26VK2M\KW/41_P %*_VE"0/^%HW@^NG6/_QBK"?\
M%)?VC4,!E^*UX48_.L>FV.Y1_P!^*\PTSX ^(-3U>X@OI[/3[.&Y6VFU&24&
M-&8[0>.H^E9FM_ SQ1IDVH-9VJZO962-++=V; J$#%<X//:E/ XN$)3E3DHQ
MW=G9>KV1HLZR^I/V:KQ3]=-=M=KZ[;['KDW_  4K_:0$K^5\4;TQY^7=IUCG
M'_?BF?\ #RS]I3_HJ%Y_X+K'_P",5\XVEI,DF9+*6:(.HD 0Y'/(![$]*FUQ
M;"6\$FEQ3Q6[*-T$OS-$_=<]_K7G\UI<EOF>NJBYE#\?\SZ*?_@I9^TCN^3X
MH7P7_:TZQ_\ C%-_X>6?M*?]%0O/_!=8_P#QBOFMX]NT)#(&5?GWC.#GJ/;I
MUJ,YFD/ #$Y]!5IFB9],?\/+/VE/^BH7G_@NL?\ XQ7LO['G[>?QS^)7[2OP
M_P##/BCXAWNI:)J>J1V]Q9_8+-5F4@DJS+$& XZ@YKX*U+2KC29(DN @:2-9
M5".'^4],X/'TKWO_ ()^7:6G[8GPN+VT5SYFKI&/-S^[)5L.N"/F';.14\RE
M'FCJ3S*4.:&OH?T0(<JI]J=34^XOTIU6:!1110 4444 %%%% !1110 4444
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M<L(M)UVZMK.Y-S:+(5BG49$BYX./Z5;\-Z&GB,16,6K0:;=238<:C+Y-OMX
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MZYM;@94$?NF]*['Q^9I_V@[O6?#%M#XUAO->T":_\*ZUI<L=RA2*!XM2TB^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cgtx-20221231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "8 K@# 2(  A$! Q$!_\0
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MC=+0KT44&KM;4R"E7[P^M,R34D?WU^M0O>8S^@S_ ()Q_P#)GGP[_P"O-O\
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M9DE<)V.:^BC3SW*>(Z%&K4E4I-:OH?TKDG#V,RG"J6.K>TF]4^R/S*\HK,4
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M>"Q>%S2O*%#XH_%<_C[+LTPF=8F=.AK4C\5QUKXDMTD8/@_6N?UZ]BO+G=&
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M<@J:^<PV'J8ZA6C?EYUH^QT/'4DYT:*M;JC[=_:7\;Z%X(\,P_\ "*31I.R
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MS8O]T?E4RJ<ZT-Z4Y86=Y1U[,_GCN_V&/CN<[/A1XG/TL3_C6<?V%?C]D_\
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MC8O]T?E2YV%CP3]A7P7KGP^_9>\#Z#XCTJYT76+.U*7%E>)LEC.X\$=J]]I
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M]K;^C5MS\>I/^"8?[1NT[?AV,_\ 89L/_C]5/^'87[2NX_\ %NAC_L-:?_\
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M12"1KDML$(B*^9YF[C9MS7FG[,GQX\2?%#XS_%WPSJM_!?Z-X:O8HM.<:?\
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M:9]O#W2S1VS>7&[(LKKN1"X& Q7G!-'M%M<KZUAKV]I&_JNNQ^&R_P#!,/\
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ML5Z'X[_:"\;^$OVL?A;\+Y-(T:#P[XHM[JYFU!9GFNW,$!9E"858AO*\Y<D
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cgtx-20221231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'P N@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS#@>5+/C)8 _H#10!^?/Q'\$7WA#_@H]^SU)I^AZ_J'ACPUX:?3KW7UTV::
M3RQWR S3*FWS&>1&<GO+D]37E_[9^E>(OB%J'[2.A>&?A=XKT:XN;K0YS/:Z
M3=W2^)FMF*27)?YX8DC0Q[%AV/)D,^2&0?JM10!^:_Q_/B;XL^#?@/\  J+0
MO$.A^&KO1='O?'?B232;Q8XX((%861>.-B\N5=O+9<"1H<D?,4T_BC-?P?'_
M . ?Q)\/>'/'?ACX7Z3I&I>&H)=#\/>;>Z6(GGMHW-D\,ICBD1(V4M%GRV7
M## _16B@#RO]F+X<>'/A1\%]#\.>$H==@\.VYEELU\1C%X4DD9\LN%* [B0K
M*K 8! ->J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI\1]5T:VTBQU/[+JEU:V4=W<1*BI-<Z4NJ0JR[MW,#X)Q@,"#V)]KH ****
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MAAXN^-G_  COAN;73XS$>L^'=0A>+R8]3-HEH]M=!G4Q(GV>&;S,%60R*"9
MD;>J_!GX:0_"7X0^$O PN#J$6AZ7!IS3N/\ 6[$"L<8Z$Y_"NWHH _/K_@IU
M\!OASX#_ &5-9UCP[X(T+1=6&HVBB]L;&.*4!I/F 8#//>ON#X9?\DX\*_\
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M ,0K[2OM-A;>%]7\-S6NB7'FQ1YN;6ZMK@1.$*-,MO*C(N_8WDKO<9<<%/\
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MR?!_AWQ#\1_A3X5T+XJ:']IU6XTV[TCQ&A"F&X;RS"\V1C"S!=ZX QO'"XH
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MUHREV339T%%%%=YZ84UD5QAE##T(S3J* /D[]L^-4\0>"]B*/]*7H,=Z^G]
M@C&B:<WEH&^S1\@#^Z*^8OVTO^0_X+R<#[4O/XU]0:!_R M.[_Z-'_Z"*^3R
MY?\ "MC?^W/R/A\I2_MO,/\ MS\B_1117UA]P%%%% !1110 4444 %%%% !1
M110!\:_\%9_^3.=:_P"PE9?^C*^I?AE_R3CPK_V"K7_T4M?+7_!6?_DSG6O^
MPE9?^C*^I?AE_P DX\*_]@JU_P#12T :VKZ%8:]':IJ%K'=+:W,=W")!_JYH
MVW(X]P:O$A023@#J32U@^/;QM.\#>(KM#AX--N95([%8F/\ 2@#S^[_:_P#@
M=874UM<?%OP9#<0NT<D3ZW;AD8'!!&_@@BHO^&RO@1_T6#P5_P"#RW_^+KQ3
M_@G]\!OASXH_9%\ :SK_ ( \+ZYJVH175S/?ZEHUM<3REKN8C=(Z%C@8 R>
M .U?0W_#-/PA_P"B5>"?_"=L_P#XW0!B?\-E? C_ *+!X*_\'EO_ /%U&_[8
M7P$DFCE;XN>!VECR$<ZW;%ESUP=W&<"M_P#X9I^$/_1*O!/_ (3MG_\ &Z/^
M&:?A#_T2KP3_ .$[9_\ QN@#$_X;*^!'_18/!7_@\M__ (NC_ALKX$?]%@\%
M?^#RW_\ BZV_^&:?A#_T2KP3_P"$[9__ !NC_AFGX0_]$J\$_P#A.V?_ ,;H
M Q/^&RO@1_T6#P5_X/+?_P"+KT#P)\2/"OQ0T9]7\(>(],\3Z6DI@:\TFZ2X
MB60 $H60D9 (./<5S7_#-/PA_P"B5>"?_"=L_P#XW7@_[%EM9>%?VB?VHO!N
MDV5MI>BZ7KVFWMK8V4*PP0_:+:0,$10%4?N%X H ^P**** "BBB@ HHHH **
M** "BBB@ HHHH *X[XP*6^&?B !2Q-MT6V%P?O#_ )9GAOH:[&BHG'G@X]S*
MK3]K3E3O:Z:^\^+?A5!(OQ'\.DPRJ!>1\GPQ# !S_P ]!ROU%=CJ/PL\3+\=
M?%/Q(\&)+;WLOB"TT[6M+U2TEAM]:TM;2QC\V)G !D@ECG9'7(.&&<-\WU#1
M79D>(J9'[7V5I>T7*T]FFTVFM;[*VJ:>JU29Y6 RU8*FZ?/S7=^O:W=GRSXI
M\4_%_3H/&EQ:VFHB[MHM7#K:Z==7 W?:85T4V:;660F'S3-Y60.3+M^6G_$R
M\^(GAC5A9>'=9\;:JB)I5Y%,ND-,DAGU?=>[G6VV@Q6SE%A)&V/JKL@9?J.B
MOI89]3A*#>%A:+O:RUV=G=/16:2_E=MU<])TG_,?'2^)_C/<>(O!0TFV\6'P
M_::XJW+WNF/&9-..LM 7G,H\YW^Q.C%7087]X"65BG0^"6\7>"?V./$4&D:9
MKNF>,K&_U<VEM'I4S77F2ZG-+"\<31GS%,<R-N"LF"<_=8#ZDHK6MQ%"M"-/
MZK!14XST^URN3M+35>\UM^H*C9WYNECXTU;7_CQ'XBU>W\,?V]=7WVCQ9%&N
MLZ<Z644"W4!TSRI&B",WE?:#$Q9MQ(5V*  3^(/%_P ;[#PCXEET^RUXPO;>
M((O"QBTR::\D6*2V?3GNE="Z2%!=*OG!2X"A@S,"WV)16JXEI7A?!4WRN^V^
MK>NG2]EIHKK5NZ7L7K[S/F'QEXM^*^G^+_$^FQZ1K5_X474].NCK6C6\J7$-
MA,ZQ7%LD3(6D>,(TA>U!;8Y^Y(0:]&\::)\0M?\ @S:6>AZS;KXE>RC6ZGU#
M3#'-=/\ +\RJES&L#'!)!+=<8%>L45X.-S&&+HPI1HQARVU6[M%+7ULV[66V
MFES6,.5WN><?$30/$FH^#]%6:6#6;FQU.VO-4@TZS,*7MM')N=(X7E<YP!\I
M<[BN.^*?\1+"UUSX=^*[S2]&N'U&_P!->W1Q8/'<3MAD5/+*B3@XZJ!@@YP.
M/1**^=G14G)WW5OZ^\YJF%C4<VW\2MZ:-77W_P!:W\\\6VS7.H?#Z6UL+I]N
MJI=3M'9R?ND-M*FZ3Y?DY= =V"._0XX_2?#VLVB^,%O+"YFTV6TOTALY+:62
M2WDEG8B.,@$3I(,29&=G3CFO<Z*SEAE*7-?^K6_0QG@8U)\[E_5DOT_IV:\B
MO)8+N^^']I)X5U>YN;86TLFIQZ<Z_92J[!&TC;2HR2S=>!C!W<>NT45M3I^S
MOKN=-&C[%R;=[VZ6V5@HHHK8Z@HHHH **** "BBB@ HHHH ***Y/PE\4?#OC
MCQ+XHT#1[N6?5/#4\-OJD$MM)"8))4\Q!\ZC=E,-D9&"#T(H ZRBN D^.?A*
M+Q+)HSWEQ&R:FFBM?O;.ME]O<#;:B<C89"65=H)^8[?O<4_QQ\:O#'P^U.ZL
M-4DO9+FRL!JEZMC92W'V.T+.HGEV [4)CDY_V&]* .\KBOC;_P D<\<?]@2\
M_P#1+UV4,R7$*2QL'C=0RLO0@\@UQOQM_P"2.>./^P)>?^B7H ^>?^"57_)F
M'A7_ *_+[_TH:OKNOD3_ ()5?\F8>%?^OR^_]*&KZ[H ^-?CW_P3DTKXY?$K
M4?%T_BZ\TN2\^];Q1%@#SWWBO@[]DO\ 9)MOVBOB9XU\-7?BB[TZ'P^,QS1H
M6\[]X4Y&X8Z5^W3=#7YE?\$O6W_M%_&([2N5Z$<_\?#5^QY!Q#F?]BXY^U_@
MQAR:+W=;=M=.YY]6E#VD=-[GVA^R[^SA:_LS^";OP]::O-K*7%S]H,TRE2#C
M&,$FO9J**_)\7BJV.KRQ.(ES3EJWW.Z,5%604445R%!1110 4444 %%%% !7
MFWBWX#>"O$M[>ZMJ.D)<7LJ,SR'')P?:O2:KZA_QX7/_ %R;^1KFQ&'HXB'+
M6@I)=U<X\5A:&*ARUX*27=7/B;]E3X4>&?'FL^+8M:L!>)921K &/"@[L_R%
M?8OA#P9I/@72O[.T:V%I:;M_ECU_R*^9_P!B'']O>.L#:/-BX_[ZKZTKY;A?
M#T5E].LH+G][6VOQ/J?&<&X3#QRNEB%32F^97MK\3ZA1117V1]^>0_$;]ISP
MK\,?%,V@ZK;ZA)>1(CLUO&I3##(QEA7,?\-N>!/^?/5O^_*?_%UYI\7;"QU/
M]L72+74H8;BQE>T66*X ,;+L&0P/&*^C?^%7_"__ *%_P[_WZBKX6EBLVQM?
M$1H581C3FXJZUT^9^:T,;G>88G%0PU:G"%*;BE*+;T^9\F?M$?';P_\ %+5?
M#MQI,%[&EA,))O/C"DC/;!/->T:9^VGX%LM-M+=K35BT4*(3Y*=0H']^O2O^
M%7_"_P#Z%_PY_P!^HJ/^%7_"_P#Z%_PY_P!^HJFEE^;4:]3$0Q%/FG:^CZ$T
M,JSS#XFKBH8FESU+7]UVTT5M3S[_ (;=\"?\^>K?]^4_^+KW/PWKMOXHT#3]
M7M%=;:^@2XC$@PP5AD9'KS7RU^UWX-\'>'_A_IT_A_2])LKIK\*TEBB!RNQN
M#M[=*^AO@Y_R2CPC_P!@NW_]%BN_+,7CI8^K@\9.,N6*=XJVYZF3X[,99G6P
M&/G&?)%23BK;L[&BBBOK3[@**** "BBB@ HHHH **** /C7_ (*S_P#)G.M?
M]A*R_P#1E?4OPR_Y)QX5_P"P5:_^BEKY:_X*S_\ )G.M?]A*R_\ 1E?4OPR_
MY)QX5_[!5K_Z*6@#I:H:]H\/B'0]1TJX9TM[ZVDMI&C(#!74J2,]\&K]% '%
M?!?X3Z3\#?A?X?\  FA3W=UI.BPM!;S7SJTS*79R6*JH)RQZ 5VM%% !1110
M 4444 %>>> O@;X=^'/Q)^('CC2I+YM9\;R6DNJ+<3*T*FV218_*4*"O$K9R
M3GCI7H=% !1110 4AS@XZTM% 'R3XQ\9?'GP])JE\+0)I-N[NLF8CB/)P<8S
MTKG?!GQ=^./Q"TV6^T&(7EM&VQI/W2\_B*^J/B]_R37Q#_UZ/7D7[#X(^&EZ
M220;G@>G6OSRO@:T<SIX18JIRSBW\78_*L1EN(AF]+ K&5>6<92?O:IKMY'M
M_@635YO">FOKR[-7,*FY7(.'QSTXK>HHK[^G#V<%"][+=[GZA2A[.$87;LK7
M>[]0HHHK0U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HKPWXI_ML?!KX+>,KKPIXQ\90Z/KUJD<DMH]M,Y5
M74.ARJ$<J0>M<3J7_!3O]G+3K"XN1X^6[,2%Q!;6%PTDA'\*@H!D^Y ]Q0!]
M44444 %?.WP%_P"3JOVG_P#L*>'_ /TS05]$UP?@SX267@OXC>.?&-OJ%S<7
MWC"6UFU"WE5?*1[>W2WB,>!D?NT ().3SQ0!\'07=Q>?\$D_&FJW=Y/=>)+_
M %*>^UB6XR)EU!]:C,V\<%7W8)'&":].^$UWK=[XS_;:D\30+;:F'@1HT&!Y
M*Z2ZP$>QA$9SWS7T-J'[.>B:EJLR27US'X7N->7Q/<^'88TC@N-15UDWNZ@,
M8S*JS-&?OR EB5)4V_&7P'TOQ1K^O:I:7]SH+>)K&/3?$26'R'4X$#*A)!&R
M4(S1^</GV%5SA%V@'(?L&7.N7/['/PFDU]'2^&B1)&)$"G[(I9;4X'8VXA(/
M4@@GDUX-\9/^"F?@2X\,^-O"@\&>-1=FUO--^T'2QY._:\>[=N^[GG/I7W5I
M&D6.@:39:7IMI#8:;90);6UI;H$BAB10J(BC@*J@  = *Y#XV6=NOP?\<,((
M@W]BWASL&?\ 4O0!\Z_\$O=1CTK]ASP_?RAC%;3:A.X4<E5F<G'O@5SS?\%>
M/A$K$'1/$V0<?\>T7_QRM'_@F_\ \H_K/_<U7_T9)7XTS?ZZ3_>-?K? G#67
M\00Q#QR;Y'&UG;?FO^1P8JM.E;EZG["_\/>?A">/[%\3#_MVB_\ CE?'G[&?
M[7OA#]GWXK>/O$OB.TU2[L]>&+9;*%&=?WK/\P+ #@CH:^.J*_:<+P5E&$P]
M?"THRY:R2E[W9W5M-#S98FI)J3Z'[$?\/>?A#_T!/$W_ (#1?_'*ZWX3?\%+
MOAI\8OB-H7@S1M)UZ#4]8G^SP274$8C5MI;YB')QA3VK\2J]]_8+_P"3O?AE
M_P!A(_\ HJ2OFLR\/\CPN!KUZ<9<T(2:][JHMKH;PQ=24DF?OC1117\P'M!1
M110 4444 %%%8?CF>6U\%:_-#(T4T=A.Z2(<,K"-B"#ZU$Y<D7+L9U)^SA*;
MZ*YN57O_ /CQN?\ KFW\C7Y>M\8/&RL0/%>L8'_3]+_\52-\8/&S*0?%6L$$
M8(^VR?\ Q5?FSXXP[7\&7WH_(WXC85K_ '>7WH^F/V(@?[>\=9.?WL63_P!]
M5]9U^3NA>,M=\,23OI.KWNFM/@RFUG:/S,=,X(SUK7_X7#XW_P"AKUC_ ,#I
M?_BJ\G*>*J.782.&E2;:OJFNK;/$R3C7#Y5@882=&4G&^J:ZMO\ 4_4NBO@;
M]F;XC^*=?^,^@66H^(=2O;20R[X)[IW1L1.1D$X/(!_"OOFOT;*,UAF]!UX1
M<4G;7T3_ %/U?(<[IY[AI8FG!Q2ERV?HGT]3X;_:$\*#QQ^U/;:$UR;-;X6L
M)G"[BF4'.,C-=I_PP?#_ -#C-_X!_P#V=<5^T-=:W9?M2VT_AR(3ZV@M3:1E
M0VZ38,#!X-=?_P )O^TI_P! ./\ \ XO\:_/84\OGC,6\9AYU'[25G%-I+MH
MT?ED*65SQ^->/PE2K+VLK."DTEV=FM2;_A@^'_H<9O\ P#_^SH_X8/A_Z'&;
M_P  _P#[.H?^$W_:4_Z <?\ X!Q?XT?\)O\ M*?] ./_ , XO\:ZO8Y)_P!
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M>7DL06/;  !^HE%%% !1110 4444 %<5\;?^2.>./^P)>?\ HEZ[6N*^-O\
MR1SQQ_V!+S_T2] 'R_\ \$W_ /E']9_[FJ_^C)*_&F;_ %TG^\:_9;_@F_\
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MOON>9_\ #<O@O_H%ZM_WPG_Q5'_#<O@O_H%ZM_WPG_Q5>F?\(Y\+O^?'PO\
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MCGZ5Z]^W,,_\$]9O^O'2?_0X:]/*\)',,=0PDG95)1C?M=I$3ER1<NQ]"?\
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M-?@7$V3PR+,IX&G-R45%W>FZ3/5HU'5@I,****^6-PHHHH **** /"/VT?\
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M,D5S$LR+<0M#(%8 @,C@,C<\JP!!X(!KD_C;_P D<\<?]@2\_P#1+T ?+_\
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M6U85_P"%/T?Y'-B?X$_1_D?E*_WV^M-IS_?;ZTVOY;/XR6P4444#/7_V3O\
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M_FG^%>6_M$QZ[+^U';IX:8IKI6U%HP*C$FP8^]Q^==-_97[3O_/[-_W\L_\
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MZ]S_ /26:TOCCZH_?&OS&_X*,?\ )?H/^P/;_P#H4E?IS7YC?\%&/^2_0?\
M8'M__0I*_P \^(?]R^:/Z5\'O^2F7_7N?Z'RU1117YB?W(%%%% '[#_LJ?\
M)NW@/_L&K_Z$U=Q\0/\ D1/$?_8.N/\ T6U</^RI_P F[> _^P:O_H35W'Q
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MA7G2C!6BVNO^9_7&0>$>4YME6&Q]7$5%*K",FERV3:OI>)]B?M*?%SP?XO\
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M$\//^174_P"OC_\ 28GQ%\>/"UKXU_:PL=$O9)(K6]^RPR/$0& *#IFO4?\
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M %SM_P";U\C5]<_L"_\ 'SXO_P"N=O\ S>OJN%_^1O1^?_I+/L^#?^1[A_\
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MH(D"1IN8ECA5 R22<<DUJ5G>&[+4-,\.Z79ZMJ7]M:K;VL45WJ0MUM_M<RH
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M_P 17MO_  LWX8?]![PY_P!_8J/^%F_##_H/>'/^_L5>MR9A_P!#*'_@$/\
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M5L>H? /X:S_#'X"^"? ^I2>?<Z3HEOI]RPP,N(P' P2.#D9![5Z-10!^6/\
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M//\ R0OP%_V!K7_T6*^RX:_C5/3]3^;?&[_D68/_ *^/_P!).+_;1_Y(G/\
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MB>(_^P=<?^BVKA_V5/\ DW;P'_V#5_\ 0FKN/B!_R(GB/_L'7'_HMJ_8J?\
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MH^&_^1U@_P#KY#_TI&-;^'+T/Q;HHHK^W3YH**** /T-_P""-?\ R5'X@_\
M8&A_]'BOUAK\GO\ @C7_ ,E1^(/_ &!H?_1XK]8:_DCQ#_Y*&MZ0_P#24>_A
M/X*/RR_X*!?\G(:G_P!>-K_Z+%?-U?2/_!0+_DY#4_\ KQM?_18KYNK^5<R_
MWRK_ (G^9_I9P7_R3>7_ /7J'_I*"BBBO-/LPK]F_P!GG_DA?@+_ + UK_Z+
M%?C)7[-_L\_\D+\!?]@:U_\ 18K[+AK^-4]/U/YM\;O^19@_^OC_ /23B_VT
M?^2)S_\ 7]!_,U^?=?H)^VC_ ,D3G_Z_H/YFOS[KX_C+_D9K_"OS9_ECQ_\
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M3O\ DNWASZS?^B7K]'*_./\ 9._Y+MX<^LW_ *)>OT<K]KX*_P"1?/\ QO\
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MD ]"KBOC;_R1SQQ_V!+S_P!$O786MS%>VT-Q!(LT$R"2.1#D,I&00?0BN/\
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M$\^(5=\D??5EUV]W30[&BBBOOS]0"BBB@ HHHH **** "BBB@#XU_P""L_\
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MR_\ Q-'_  BGBC_H4-?_ /!?+_\ $U_2WY,?_/-?RH\F/_GFOY5]-_Q$;/\
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MDQ_\\U_*C^P,#V?WA_Q%SBG_ )^0_P# $?G5\%_^"DGA_P"&_P *_#7AF_\
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cgtx-20221231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '= LL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*V7\H(HZ /)%_:I^*JY)U'PO(<< Z#,HS[G[8:WM+_;,\;V3K_:GA+0M5CV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR@'R\\E5:,_-&-WU[UH X+P\Q^'VO1^&YW*Z'>LQT:1B2(7P6>T)/0 9:/\
MV0R_P#/>UF^(M!MO$NCW&G71D6*8#$D+;9(V!RKHW\+*P# ]B!6+X0\1W+7M
MQX=UI\Z[8QA_.V;$OH<X%Q&/KPZC[C<="I(!UE%%% !1110 4444 %%%% !1
M110 4444 %%%<9\6_BQX?^"_@J\\3>([EXK2$K%#;P(9+B\G8XC@@C'+RNV
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ME\P.-/TA3V/G69Q^=]5<I?*?LG_PVK\"?^BK^%?_  8I1_PVK\"?^BK^%?\
MP8I7XS_9M4Q_QZZ1^>G_ /R=4Z:3K3L =.T\@_W8[$D_^3M'*'*?LC_PVK\"
M?^BK^%?_  8I1_PVK\"?^BK^%?\ P8I7XZ)X1UB0970K5P>ZVEB1_P"EM31^
M!M:?.=#M(\=GL;/^EX:.5ARG["_\-J_ G_HJ_A7_ ,&*4?\ #:OP)_Z*OX5_
M\&*5^/P\&:K&O.D::?<V5H?_ &[K)F@CCN7@#^&DFCP'BDM[8.A/0$?:<C\:
M'%H+'[+_ /#:OP)_Z*OX5_\ !BE2I^V5\$9%#)\3_#CJ>C+>@@U^,+)' "TC
M>'D ZDZ4&Q^ D/Z5[5\&/@GX9^*6A)-??$'0?"VK[W7^S[WPPB)(@)VO%+)=
MH'!'48!!!&,8)YZ]:&&A[2KMZ-_E<N%-S=D?I>W[:?P-1BK?%'PV&!P0;T?X
M4G_#:OP+_P"BI>&O_ T?X5\:P?\ !/MKF!)H?'FFRPN,I)'X05D8>H(O<'\*
M<?\ @GRX.#X\TW/_ &*"_P#R;7D?VW@/^?GX/_(W^J5>WY'V1_PVM\"_^BI>
M&O\ P-'^%/C_ &S_ ('S-MC^*'AN1NN$O Q_05\6G_@G>Y.?^%AV@]AX23_Y
M,J!_^">-\FXQ?$6P4]B?"JK^>+JFL[R__GY^$O\ (/JE7M^1]O#]L7X*DX_X
M63H'XW/_ -:IH_VN?@Y,NZ/XAZ'(N<92<D?H*^&8_P#@GIK*GGQY9W7LNB&$
M'\I'KRWXP_ ?3_A=IZ*_C_1;C4G?$6E:7<BXU&?'W]EOL1?E&6)=U QUKIHY
MI@J\E"G4NWY/_(B6&J05Y+\C]/8_VKOA),V(_'NCR-UPDK$_HM6H_P!IGX82
MH&3QGIA4]]S?_$U^*>J^$O%]KK-Y;Z9KMI?6,,NR&_CM95,Z%597"$'&5=?E
MSD'/-(/#7CJS_>3:M"T61N$FG;@?S'\J];E,.4_;#_AI7X7[<GQQHZ^S7&#^
M1%2#]I#X6GK\0/#JCU;48P/U-?C=KS7K_P!C76F+!I!%G(M[#)8)<I),D[QF
M1=ZET#*%^4L<8Z\UA7-CJ)C9[K6K;RNN!X4M^3^(%'*'*?MM#^T'\,)V54^(
M?A;<W 4ZQ;@_J]7H_C-X!F&8_&_AR1?5-7MR/_0Z_#6;0]$;2A>'2])2[AO5
M@-PNBM")5EBG?#0_: I8&$8<,#AF&#1;74]JV+"2RM0.T>E(N?H&O<T<H<I^
MYO\ PM_P-Q_Q6/A_G_J*V_\ \75RP^(_A35)!'9^)='NY"=H6#4(7)/I@-7X
M=V&H7NJ)K$6KR6FH6\FBWRQP36]M@2E (W_X^)=I5B""=N#WK*U&'489%>ZN
M+&%E=6VVL=L#][H"EP^/UHY1<I^_=+572B6TRT).284.3_NBK502%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1
MS3QVT+RRNL<2*6=W. H'4D]A0 _I7":QJUUXZUB?P_HLSPZ7:R>7J^JPM@@C
MK:P-_P ]#_&X_P!6#@?.?E;<:O??$KS;/0;BXTW0-VR?7HOD>Y7^)+0GG!Z&
M?H/X,GYE['1M&LO#VEVVG:=;1V=E;H$BAB&%4?YR2>I))/- $UE90:;9P6MK
M#';VT"".**)0JHH& H Z "IZ*\B^-/[2&@_"1O[+AC/B#Q;(@DBT.UE"M&A.
M!-<28(ABX/)!9L$(K'H =E\4/B3HWPF\$:GXFUV?RK&S3B-.9)Y6.(X8Q_%(
M[$*H[DU\(>%?#7B#X^?%:2TU"=[?6_$#_P!H:[?6K8.FV"?*(86P0"H*P1'N
MS22]0<YWBSQ5XF^*OC&PEUV2;Q9XH=C)IFAZ;&5M[('*L\,3'$2@,5:YE.<<
M;A]RO>?@K\/_ !W\*[35KF&]\+1ZOK3QRW4D]G<W1ME1-L5NK++$'1"7;=A<
MM(YQC%<=?%T,.TJLK/\ KL:1ISG\*/J+0-!T_P +:)8Z1I=K%8Z=8PI;VUM"
MN$BC4850/0 5S'C7XQ>&_!-Y_9LUQ+JOB!UW0Z#I,?VF^DZ8/EK_ *M>1\\A
M1!GE@*\'^*WQ*@\#6/VOXF?%6YL(9E+QZ)X<B&G-< 8!V"-GN63W\U0,\N*\
ML\(_$CXD>/;&2R^!'PBC\.>'IVR?$6OQK$DY&<R'<0LC9!Y+3')PP4G-<;Q[
MJZ86#EYO1?YFRH6UJ.Q]*77B3XD>+_NW6G>!K1C\L%G -4O\#NTCX@0^JJDG
M^_7F?Q<_:"U7X#Z3+K$WQ'LO$VK6HROA+4+2U274 &7S$5K<"2!PI)\QP47J
MP(KS#7_V=_&7B;6I=$\;_%+7O''B=U1[GPSX5G^S6%BART;WEQ(/*A0@94>3
MYK?PAP,CJ/!7_!.OP!87GV_Q3)?:TQ82#2+>_FBL4(Z*[ K+<8/(+E>>0JYQ
M40HXV4U.I5MY)%.5!*R5SZNC^+WA2#PSI>MZIK=CH=OJ%A'J,<6IW4<$HB=
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MX?\ ["GP6^+.D/>:/XD\3/) RI>Z;?RK'=64I&?+FB*Y1L=.S#E2PYKB[O\
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M\379;P2Y6&RO9S\VCL3A8Y&/_+L2<!CS$< _)]S[55@Z@@@@^E?2G".HHHH
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M4+,F7)) Z#-?8]% 'F7AKX8ZAHGQ:?Q,TMH--/A>TT188BWF"6*9W)QC&S#
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MC29O"5EK>BZRNB:A>6,5]+:?9A:,;B,1M(AC>-U8;=S*PZ!A7(>'KOQ?\/\
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M'B&.^U7Q5IMGJ]QXDLH+2RD;5K+7[W5-+DFPZO@7J"6VN6P&DA#NH&S[ISD
M^LZ*** "BBB@ HHHH **** "BBB@ HHHH *S_$&H_P!D:'J%^%#FUMY)]I.
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M.RPW<2](BDDI\P+A661F(W*,_0/BGQ/IW@WP[?ZWJ]PMIIUC"TT\I!.U0.<
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M=4;D @^2?"WPS!\=9@]K''8^ ;5K6YNE0;)]2F:..X6W('"1*'C\PY)<Y08
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M9!+HFENEQJ.?NRR?>AMC]2 [?[*@'[]8T-IJ&MZI:Z1I$(N=5O"=F_\ U<*
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M6XWV6*G7E"\7?9:J[O\ H>K6R^HZ48*4;JWVX^G\Q+\#O GQ':T^-5OIMWX
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MPM%%% !1110 445A^+_&^@> -';5?$FL66B:<#M%Q>S",.W]U!U=O]E03[4
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M:UFSGC+(1NZ#A@PXY!KZ#^%'[=4EN_\ 8_C?3+S7!;GRSXDT&SW*2"!BXA&
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M\1ZC /F8@'!EB/<DL30!/)^S3\0/"8!\ _'GQ781*6*Z?XPMX?$%N%('RAY
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M5'7YD!(_A[5V?@?]JSX1?$>?[+H/Q!T.?4,-G3KJY^R7BXQG=;SA)%ZCJHH
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M:H==O7\.P$_8D57U1QGYE892W!!_B'S/_L8'\==/XIUY?#>B3WOE^?/E8K>
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MJ$OKBR@FG51@"1HU+ #ZDUL4V-%C154!57@ = *=7KGA!1110 4444 %%%%
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M"AMS1D<X)!XJ_P#M&>.= _:0_9<\3P_"_6K?QM=SRV($'A^07-U$1>P,VZ(
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MSP'*@KG->T?L1FS;PG\0SIVMW/B73SXWU/[/J]VP>2[C"0!7,@ $O3 D'WP
MW.<U]#7>GVVH6TUO=6\5Q;S(8Y8ID#K(I&"&!X(]C4L420($C140  *HP ,8
M% #Z*** "BBB@ HHHH *0]#2TAZ&@#COAU_Q\>*O^PW/_P"@15V5<;\.O^/C
MQ5_V&Y__ $"*NRK*E\)Z&/\ ]XE\OR05!>6-OJ-I-:W4$5Q;3*4DAE0.CJ>"
M&4\$'T-3T5J>>>(M^Q[\.M,\96GBCPI:ZC\/]7BNTNK@^$K^2PM[X!MS1W%N
MO[IU?)#'8&QP&%>UR1)+&T;J'1@0RL,@CTI]% ' M\ _AR[$GP5HA).3_H2?
MX4'X!_#DG)\%:)G_ *\D_P *[ZBL/J]'^1?<CD^J8;_GW'[D>6:E^S!\,=5N
M!-+X4MH6"A=MG++;I]=L;@9YZXS20_LN_#""SGME\*P,DQ!9Y)YGD7']QR^Y
M/?:1GO7JE%1]5P][^S7W(S_L_"7O[&/_ ("O\CQ5?V/_ (9KJC71TJ[: IL%
MD;Z7R5/]X<[\_P# L<]*N_\ #)WPM_Z%D_\ @?<__'*]=HJ5@\,O^7:^Y$++
M<$O^7,?_  %?Y'DUO^RK\+K:>.5?"ZNR,&"RWEPZ''JK2$$>Q&*WU^!?P^6T
MFME\&Z*L,Q4NHLT&2N<<XSQDUW5%6L-0CM!?<C6.!PL/AI17R7^1P)^ GPZ*
M;?\ A"M$V^UFE0)^SO\ #6/IX,TH_P"]#N_F:]%HI_5Z/\B^Y#^IX9_\NH_<
MCRJ\_9<^%][<"9_"L,38 VP7$T2<?[*N!^E;VG?!'P#I-W'<VG@_189X_N2"
MR0D<8[BNWHH6&HQ=U!?<A1P6%@[QI13]$</>_ _P!J-S)<7/@[199I#N=VLD
MR3^55V^ 'PX=2I\%:( ?2S4'\Z] HI^PHO["^Y%/"8=ZNG'[D<"/@'\.@@3_
M (0K1-H];-#5W2O@YX&T2222Q\):-;O(NQREE'\R^G(KL:*%0I+507W(:PN'
MB[JFON1YZ/V??ANK;O\ A"]')Z\VH(_*DE_9Z^&TY&[P7I Q_P \[<)_+%>A
MT4OJ]'^1?<B?J>&_Y]1^Y'GJ_L^?#=4*CP7HY![FV!/Y]:U-$^$G@OPY.\VF
M>%M(LI7 !>*S0'CWQ7744U0I1=U!?<BHX7#Q=XTTGZ(Y^X^'_AF[MY()O#VE
MR0R*49#91X(/!'W:PX?@1\/()5DC\%Z(KJ=P(LDX/Y5WE%4Z-.6KBON*EAZ,
MW>4$_DC$_P"$(\._] +3/_ .+_XFI;7PEHEC<1SV^CV$$\9RDD5K&K*?4$#(
MK6HJN2/8T5*"U44-**>H!_"D,2,""BD$8((ZT^BK-#F](^&WA/P_?K?:9X8T
M;3KQ591<6FGPQ2 $8(W*H.".#5F\\$^']0T>VTFZT/3;G2[8AH+*:SB>&(C.
M"J%=JXR>@[UMT4 8%_\ #_PSJMI#:WOAW2;NVAE>>.&>QB=$D<DLX!4@,222
M1R<G-7+CPQH]V]RTVE64S73Q23M);(QE:,YC+9'S%2!M)Z=L5IT4 9'B#PCH
M?BR*&+6]'T_5XX7WQI?VL<X1L8R X.#CN*MZAH]AJMHMK>V5O=VRLKK#/$KH
M&4@J0"",@@$'MBKE% &0GA'0XK@3IH^GI,+DWHD6UC#"<C!ESMSO(XW=<=ZK
M1_#[PQ$;\IX=TE#?N)+LK81#[0P;<#)\OSG=SDYYYKH** ,R3PSI$TLDLFEV
M3R27"7;NULA+3( $D)QRZA5PW48&#Q56U\">'+'4/M]MH&EV][Y;0_:8K*)9
M-C$EEW!<X)8DC.#D^M;M% &'J'@?P[JNGV5A>Z#IEW8V6/LUM/91/'!@8&Q2
MI"X'' %/_P"$,T 6DEK_ &)IWV:2!+5X?LD>QHDR4C(VX*KDX7H,G%;-% &/
M)X.T*;6K?6)-%T]]6MT$<-\UI&9XU&<*LFW<!R> >YK/^*/_ "3CQ-_V#KC_
M -%M745R_P 4?^2<>)O^P=<?^BVK.I\#]#LP7^]4O\2_-'16?_'I#_N+_*IJ
MAL_^/2'_ '%_E4U6MCEENPHHHIDA1110 4444 %%%% !1110 4444 %%%% "
M%03G'/K7!>.?@+\/?B1<-<>(_!^DZG>,06O'M@EP<# _>IA^![UWU%)J^XTV
MG='S)KW[ W@B[5FT37_$N@N%PD7VU;V'=C@D7".^/977I7$V?[!?B+PQ)<2:
M3XXT[4Y+R7S;E]5TAXGR%"JJF*; 4 <#'<^M?:-%91HTX2YHQ29U5,7B*T/9
MU*C<>S;9X/\  +]FZ?X8^(+_ ,2>(M1L]7UV2#['9BQA>."S@)#2;0[,2\C!
M=S=E15'\6?>***V.0S?$E@FJ>']2LY9)XH[BVEB:2VF:&50R$$HZD,K<\,.0
M>17YX?#35-(\+?#3P1I'C7X@>*?!'AB'X=VNL:#):ZS<VS76J.\HN=CC)E>%
M4M?*M#N3$SGRVSQ^D-,:)'V[D4[3E<CH?44 ?$6D^*_BS/X@\'^!O$5_K-MK
M7Q&L]"UN>>W8Q+I"6\6=:@1QCR=XA@P VX/>/@?+7*_#3XL>-W\?V&KWGB>2
M[\30ZEK+>)/"L&K7U]?-90+<L(1I?D""T,8^S^3+O59"R LYEK]"<"FB- Y8
M* S8RP')H ^$OV1?BQJ>J_'C0--_X2Q]4\/>(?"-QJ#V]SXFN=;FDU!)+5E\
MYY8HXH+D1/,7@MP%4 Y'RJ:^\*8L2+T11SG@=_6GT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !2'FEHH Y%? $]K?ZC<:?XHUC3([ZX:ZDMX([1XU<
MJH.TR0,V#M'!8U+_ ,(?JW_0\:[_ -^-/_\ D6NIHK/V<?Z;.YXRJ][/UC%O
M[VCEO^$/U;_H>-=_[\:?_P#(M'_"'ZM_T/&N_P#?C3__ )%KJ:*/9KS^]B^M
MU.T?_ (?_(G+?\(?JW_0\:[_ -^-/_\ D6C_ (0_5O\ H>-=_P"_&G__ "+7
M4T4>S7G][#ZW4[1_\ A_\B<M_P (?JW_ $/&N_\ ?C3_ /Y%H_X0_5O^AXUW
M_OQI_P#\BUU-%'LUY_>P^MU.T?\ P"'_ ,B<M_PA^K?]#QKO_?C3_P#Y%H_X
M0_5O^AXUW_OQI_\ \BUU-%'LUY_>P^MU.T?_  "'_P B<M_PA^K?]#QKO_?C
M3_\ Y%H_X0_5O^AXUW_OQI__ ,BUU-%'LUY_>P^MU.T?_ (?_(G+?\(?JW_0
M\:[_ -^-/_\ D6C_ (0_5O\ H>-=_P"_&G__ "+74T4>S7G][#ZW4[1_\ A_
M\B<M_P (?JW_ $/&N_\ ?C3_ /Y%H_X0_5O^AXUW_OQI_P#\BUU-%'LUY_>P
M^MU.T?\ P"'_ ,B<M_PA^K?]#QKO_?C3_P#Y%H_X0_5O^AXUW_OQI_\ \BUU
M-%'LUY_>P^MU.T?_  "'_P B<M_PA^K?]#QKO_?C3_\ Y%H_X0_5O^AXUW_O
MQI__ ,BUU-%'LUY_>P^MU.T?_ (?_(G+?\(?JW_0\:[_ -^-/_\ D6C_ (0_
M5O\ H>-=_P"_&G__ "+74T4>S7G][#ZW4[1_\ A_\B<M_P (?JW_ $/&N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cgtx-20221231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *3 Q<# 2(  A$! Q$!_\0
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MF. !5>SU.SU!YTM;J&X>W?RYEBD5S&V =K8/!P0<'L:5T.SW+5%%%,04444
M%%%07M];Z;:RW5W/%:VT2EY)IG"(@[DD\ ?6C8:5]$3T5%;7,-[;QSV\J3P2
MJ'22-@RNIY!!'!!]:+JZALK>2>XE2""-2[R2,%55'4DG@"E?J%G>Q+14%E?6
M^I6D5U:3Q75M*H:.:%PZ.#T((X(I5NX6?8)4+9QM##-%T%GL344U'6095@PR
M1D'/(.#^M.IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^,OQ?U_2O"LNH3ZGI?V72=865 L$(1<+"K<LYP/E&!N4DY& ?8_V6O!M_P"
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M23_&X4445WGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/WH]>HKR'_AK7X2?]#OIWY2?_$4?\-:_"3_H=]._*3_XBCVU/^9?>'US#?\
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MA)_T.^G?E)_\11_PUK\)/^AWT[\I/_B*/;4_YE]X?7,-_P _(_>CUZBO(?\
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M=]._*3_XBCVU/^9?>'US#?\ /R/WH]>HKR'_ (:U^$G_ $.^G?E)_P#$4?\
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MOPD_Z'?3ORD_^(H]M3_F7WA]<PW_ #\C]Z/7J*\A_P"&M?A)_P!#OIWY2?\
MQ%'_  UK\)/^AWT[\I/_ (BCVU/^9?>'US#?\_(_>CUZBO(?^&M?A)_T.^G?
ME)_\11_PUK\)/^AWT[\I/_B*/;4_YE]X?7,-_P _(_>CUZBO(?\ AK7X2?\
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M-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH
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M5'U"OV_$/[!QW\J^]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\ 0W:M_P"
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M_0W:M_X#Q4?4*_;\0_L''?RK[T?GY17Z!_\ #MOPO_T-VK?^ \5'_#MOPO\
M]#=JW_@/%1]0K]OQ#^P<=_*OO1^?E%?H'_P[;\+_ /0W:M_X#Q4?\.V_"_\
MT-VK?^ \5'U"OV_$/[!QW\J^]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\
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M'(4'JHK*33_VK],\,)J>J3:*_P .)U:SFU*=U9DOX(UEY?(E*,09!\QSR>*
M/H'-!8"OE#X+7>N2ZS>?!;6M4UF]U7P9XBFO[O6+G4)WNK[26(N+!GFW9)=I
MTB9<X*VTHQUQPZ>,)X?%GPS\4Z5XEU26TU3XBWVE7.J:KJS+<:E;#[8)X39A
MC%':PO"BIN^;Y58*F_+ 'U9\-?BHOQ$UWQMI9T>YTB?POJJZ5,MU+&YE8V\4
MX<>6S #;,O&<^N#P)_C'\6=#^"'PZUCQGXA>0:7IJ*SI NZ20LP555>Y)/Y
MGH*X#]GUA_PMCX_KD;AXN@.,\_\ (*LO\#2?%&UO?BM\25\+V.DZ=XAT/P[8
MR3:O9ZA?M:Q/=7<3Q0QDK#+N*6[3N5(&//A;/ H ]A;7HI_#G]L:=#)K$$EL
M+JWCLF0M<J5W+Y99@I+ C&2!SUKQ[0?VN?#NJ:7X$UG4/#NO^'_#GC66.WTC
M6K^.W:V::3'E13&*9VA9^=N]0"5(R*Q/V*?$VHZ3\/\ 6OAEXIF1?$_PWO6T
M:Y+3>8'LMOF6<P8@'882%!('^K[=!P_[.'P-N/BY^SK\#9_$?B>27PQH4%GK
M5MH=A9)#YUQ#DPB><NS.J-N.%"9)YH ]<NOVH+4>*/B'H.G>!O%&MWG@3R3J
MXT];-B5EB,T9A5K@-*3&"=H&[MC/%:'B']IOPEHOP"7XPV<=_KO@\VJ7A;3X
MT$XC+B,G9*Z<JYVE<YR#UQ7R]K=I\09/C7^UI<?#Z^$=S;W.@27VGV]L'OKV
MU^P'SH[24DK%/Y8<(3&^6(X!Q76?&X^"!_P3/UZ/X=DKX1CT&);*.1]TL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKD888(R#FO [QO%UA^UEH/PU/Q%\2S:!=>#)]9F<FS$[W4=TL0?<+?@%2?E
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M;::S\5Z;I$FK:5;.MC)+]OABN8'GVG@+YB$@A=_R;B?E/K^J?'GPIHW_  L
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M*)U(!['\,/VHM&\;_"30_&^JZ=?Z$NM70M+&QDMG>6ZE>1UBBAP/WK%4Y*\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSD\^AP ;NF:9::+I]M86%M%9V5M&L4-O @1(T P%51P !VJU17'>.?B_X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"B(D=>.^T/\ 9?T'PUXOU/5--U[Q!:Z%J6I'6+GPG'=1_P!EO>,P9I=OE^8
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M(^ 7@CPUJ/B>?2/"T6LQMKS:8)_L27,*+!')((?*(9MXY&0!R1@&@#F_B?\
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MBSUS5;,^$K*73[*PS%-%-#,%$_GO(C22,^Q26+9SD]2: //OAK\6OBO\15\
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M%VK'2'DOA+OMV$;2>8-A 887&#CGO0![2!BEKR3]I;XZ-\ OAJ_B.WTHZ]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(RQ+I]W$FXG)QDHI9NY&3S7C?B'X6Z]\!OBWX=L/"EI%/\)/%_BFRNI=,B#
M^'M15O,9XE&0+>?RR"O 5R,8R WU\5!Z@'M1B@#R/Q#I/Q#T$^)]=OM?LO%?
MA>&SOIX/".FZ"T-_<)Y3F*W2Y^TL"_W5W>6-Q[+GCYA^ GC"PN?CK\#]5L<V
M^CW7@6[TJ.QTW3YEM=,D0VI^PM,VYIGA\O$CNW!3<0N:^^Z3 - 'P=K*Z+>_
M [P-=ZI!;RV2?&::X=[J'E+:;6;M]V"-RJ\3*>V5//%9WQ;\(V5OH_[2FL>
M[:TL_ FI>%-/TN&WT:V"VVH:N&?<;=8QM9DC9$8QC!9\'+(V/L+XM?"J3XH_
M\(L%U@Z2FA:W:ZZH2V$IGEMV+1HQ+#"9/..3ZBN^CC6- JJ% Z!1@"@#X]^(
M%MHWA;X]>//[*\.#5=#N/@]<JVE:2&@74Y$N)F^SB6(9$K1-@$$N ^1FN!\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYY4A0LJ!G8*"S$!1SW)( ^M<-\:/BYIWP5\'1>(-40?9)+^VL6GF8QV]N9I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN&BFB$T375Q.(B &P[?:6R1PNT !NM?3U% '@'BGX#>)]?U;XX3QWNDQV_Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]U_X+;C_ .(K\NJ*/[1K=E_7S#_6/&=H_<_\S]1?^&ZOA!_T'[K_ ,%MQ_\
M$4?\-U?"#_H/W7_@MN/_ (BORZHH_M&MV7]?,/\ 6/&=H_<_\S]1?^&ZOA!_
MT'[K_P %MQ_\11_PW5\(/^@_=?\ @MN/_B*_+JBC^T:W9?U\P_UCQG:/W/\
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M7]?,/]8\9VC]S_S/U%_X;J^$'_0?NO\ P6W'_P 11_PW5\(/^@_=?^"VX_\
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MU?"#_H/W7_@MN/\ XBORZHH_M&MV7]?,/]8\9VC]S_S/U%_X;J^$'_0?NO\
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M\-U?"#_H/W7_ (+;C_XBORZHH_M&MV7]?,/]8\9VC]S_ ,S]1?\ ANKX0?\
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M# V7C_?#"QD$CY<9*XR2U>5^&OCKKTG@E?A[<W6F:7HFI:JEU=:T]GF>UWL
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M?I\E^!TU<QPTU*T;74K:+K9+\%=^9] OX$\%?LSZUX2M/%)TNZD6R.JZ\UU
MEW=WTCJZPV5M P.R(,I+2$#)4#<,XK-\%#PMH'[.'C;X@Z[X2TJ>/6O$;QZ3
M83P*)3%Y@/V=9-N53.]2R8PJMCD 5Y=XY_:;\1?$"&SGU/1O#YU^WMA:?\)
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M#^N?G#_\31_P[E\#_P#0?US\X?\ XFOK6BCZI0_E#^R<#_SZ1\E?\.Y? _\
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M .@_KGYP_P#Q-'_#N7P/_P!!_7/SA_\ B:^KY;N&":&*25$EG)6)&8 N0"2
M._ )_"H-3UFPT6)9+^\@LXV.U7GD5 3Z9)H^J4/Y0_LG _\ /I'RO_P[E\#_
M /0?US\X?_B:/^'<O@?_ *#^N?G#_P#$U].V?B_1-0\W[-JUE<&*,RR>5<(V
MU!U8X/ Y'-11^._#LLBQIKFGL[' 4749)/IUH^J4/Y0_LG _\^D?,_\ P[E\
M#_\ 0?US\X?_ (FC_AW+X'_Z#^N?G#_\37UK69X;\3:1XQT:WU?0M3M-8TNX
MW>3>V,RS0R;6*MM=20<,I!]P:/JE#^4/[)P/_/I'R[_P[E\#_P#0?US\X?\
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M^M:*/JE#^4/[)P/_ #Z1\E?\.Y? _P#T']<_.'_XFC_AW+X'_P"@_KGYP_\
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MKKFGL[$ *+J,DD].];%U=0V5O)<7$J0P1J6>21@JJ!U))Z4?5*'\H?V3@?\
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M _\ T']<_.'_ .)KZUHH^J4/Y0_LG _\^D?)7_#N7P/_ -!_7/SA_P#B:/\
MAW+X'_Z#^N?G#_\ $U]:T4?5*'\H?V3@?^?2/DK_ (=R^!_^@_KGYP__ !-'
M_#N7P/\ ]!_7/SA_^)KZUHH^J4/Y0_LG _\ /I'R5_P[E\#_ /0?US\X?_B:
M/^'<O@?_ *#^N?G#_P#$U]:T4?5*'\H?V3@?^?2/DK_AW+X'_P"@_KGYP_\
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M^N?G#_\ $T?\.Y? _P#T']<_.'_XFOK6BCZI0_E#^R<#_P ^D?)7_#N7P/\
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M[)%!(##H0":K>,_$TWA+1&U"#1-2\02":*+[%I,2R3D.X4OAF4;5SN;G@ T
M;M%)G\*"0*  C- &*XSX8?%/3OBI::_-I]G?6+:+K-SHES#?Q"-_/@*[B "?
ME.X$$\^PKL\T +129KA)/C#I4?QBG^&_V'4#K<6@?\)$)Q"#!);^>("JMG)?
M<1QC&.] '>45PWP5^+NC_'7X<Z;XST*"[MM+OWGCBCOD"2@Q3/$V0"0/FC..
M>F*[C(]:  C- &*,T9H 6BDR*,T +129'K2T %%)FEH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JVI?\ (/N?^N3?R-6:JZGIL&L:=<V-TKM;W$;12!)&C8J1@X92
M"/J"#0!\&_ Z?5;#_@GU\%;K1]=U'0;K_A(]/M'DT^15,D<^O^3(K@J<C:YX
MXSWR,@]:?#6M7GQ6^./P^;Q]XNCT+2-&L?$-E+'JA%W#=RQ3%]LV-PCW1JWE
M#"=L8X/T-9_L[?#[3O!MEX4M?#ZVWAZRNTO[;3XKNX6.&=7WJZ8DRI#_ #@
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M'B?6_'WA#X_>)7\3:EH?B+P5JNH6>C0V=P8X;"*RMTFA9X =LWG$L6,@8%6
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M^S?H7BFT_9M\6?\ "5-?_P!F:C/J5[X?M-5O#<7MKI,D>ZVBFE#$EP-Q^]D
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MX0^&V@Z=J]NUEX3\72^(TM[N6:98+8K<1QV4+D;BL:7) 9L?<'&#Q]'T4 ?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4>:2GSR1[@A;@-M!(SF@#[IU+5+31].N=0OKF*ULK:-IIIY6"I&BC+,Q/0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#T)YFU/7_#F@_MC>.K[7-/:YCG\"Z4J#^SFGDDS<7>Z+:%)W. JA.K%0.<4
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M!FN0_:6T/46\>>(]:\)W>KZ)XQCT"&UBLY+%[W1_%469F%A)&%_UJEG7*L&
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M,IO!;=@@#U(%<ZWQ[C\-_'7Q+:Z_XGL(_ D7A.PURRE:$1A&FN;J-OGW$O\
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M "UR&G?"_2=,^)VL>.XI;MM:U33[?3)T>4&$0PLS)M7;D'+N2<G.XUUV:,T
M! (KC?B'\*=&^)EWX5N-7DNT?PWK$.N60MI0@-S&&";P0=RX=N..M=EFC-
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MC)( QW6:,T &.<TM)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC
M- "T4F:,T +129HH _-O]H+]I3XE^$OC/XNTC2?%EW9:;9W[Q06Z11$1J ,
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MO_?F'_XBO(**/;5/YG]X?7,3_P _9?>SU_\ X:W^+G_0[7O_ 'YA_P#B*/\
MAK?XN?\ 0[7O_?F'_P"(KR"BCVU3^9_>'US$_P#/V7WL]?\ ^&M_BY_T.U[_
M -^8?_B*/^&M_BY_T.U[_P!^8?\ XBO(**/;5/YG]X?7,3_S]E][/7_^&M_B
MY_T.U[_WYA_^(H_X:W^+G_0[7O\ WYA_^(KR"BCVU3^9_>'US$_\_9?>SU__
M (:W^+G_ $.U[_WYA_\ B*/^&M_BY_T.U[_WYA_^(KR"BCVU3^9_>'US$_\
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MG_0[7O\ WYA_^(KR"BCVU3^9_>'US$_\_9?>SU__ (:W^+G_ $.U[_WYA_\
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M $*&M_\ @!)_A1_PICQW_P!"AK?_ ( 2?X4<DNP>PJ_R/[CBZ*[3_A3'CO\
MZ%#6_P#P D_PH_X4QX[_ .A0UO\ \ )/\*.278/85?Y']QQ=%=I_PICQW_T*
M&M_^ $G^%'_"F/'?_0H:W_X 2?X4<DNP>PJ_R/[CBZ*[3_A3'CO_ *%#6_\
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M . $G^%')+L'L*O\C^XXNBNT_P"%,>._^A0UO_P D_PH_P"%,>._^A0UO_P
MD_PHY)=@]A5_D?W'%T5VG_"F/'?_ $*&M_\ @!)_A1_PICQW_P!"AK?_ ( 2
M?X4<DNP>PJ_R/[CBZ*[3_A3'CO\ Z%#6_P#P D_PH_X4QX[_ .A0UO\ \ )/
M\*.278/85?Y']QQ=%=I_PICQW_T*&M_^ $G^%'_"F/'?_0H:W_X 2?X4<DNP
M>PJ_R/[CBZ*[3_A3'CO_ *%#6_\ P D_PH_X4QX[_P"A0UO_ , )/\*.278/
M85?Y']QQ=%=I_P *8\=_]"AK?_@!)_A1_P *8\=_]"AK?_@!)_A1R2[!["K_
M "/[CBZ*[3_A3'CO_H4-;_\  "3_  H_X4QX[_Z%#6__   D_P *.278/85?
MY']QQ=%=I_PICQW_ -"AK?\ X 2?X4?\*8\=_P#0H:W_ . $G^%')+L'L*O\
MC^XXNBNT_P"%,>._^A0UO_P D_PH_P"%,>._^A0UO_P D_PHY)=@]A5_D?W'
M%T5VG_"F/'?_ $*&M_\ @!)_A1_PICQW_P!"AK?_ ( 2?X4<DNP>PJ_R/[CB
MZ*[3_A3'CO\ Z%#6_P#P D_PH_X4QX[_ .A0UO\ \ )/\*.278/85?Y']QQ=
M%=I_PICQW_T*&M_^ $G^%'_"F/'?_0H:W_X 2?X4<DNP>PJ_R/[CBZ*[3_A3
M'CO_ *%#6_\ P D_PH_X4QX[_P"A0UO_ , )/\*.278/85?Y']QQ=%=I_P *
M8\=_]"AK?_@!)_A1_P *8\=_]"AK?_@!)_A1R2[!["K_ "/[CBZ*[3_A3'CO
M_H4-;_\  "3_  H_X4QX[_Z%#6__   D_P *.278/85?Y']QQ=%=I_PICQW_
M -"AK?\ X 2?X4?\*8\=_P#0H:W_ . $G^%')+L'L*O\C^XXNBNT_P"%,>._
M^A0UO_P D_PH_P"%,>._^A0UO_P D_PHY)=@]A5_D?W'%T5VG_"F/'?_ $*&
MM_\ @!)_A1_PICQW_P!"AK?_ ( 2?X4<DNP>PJ_R/[CBZ*[3_A3'CO\ Z%#6
M_P#P D_PH_X4QX[_ .A0UO\ \ )/\*.278/85?Y']QQ=%=I_PICQW_T*&M_^
M $G^%%')+L'L*O\ (_N/V1V@T;12UB>-?%^F> /".L>)-9G%MI6E6DM[<RGG
M;&BEC@=SQ@#N2!7VI^V&UM%&T5XU\-M?^)/Q.\%:;XR-WI?AN'5H?MUAH%S8
M/-(ENX#0K/.)1AV7#-M0[-V/FV\]+X%^*-I>+H'AKQ/J6F:?\2+C38KN^T"&
M8>;&Y4>840G<8PV0&H ] VBC:*\H\5_M-^ _"^J^&[ ZW;7CZUJDVEK+!(&C
MMY(8W>;S&Z+MV;<'G+8[&NIUKXN>#/#NIG3M3\2Z987JF-6AGN54H9,>6&R>
M"V1C/7- '7;11M%<YK/Q&\,>'M533=2URQLK]O+(MYIE5_WC;(\CMN;@>IKR
MSPI\9KW2?C)\:],\::YIMEX5\*?V.]C=21BW2".ZBE<B5RQR=P1<\ X' S0!
M[MM%&T5R6N?%OP;X:TJUU+5?$>G6%A=1&>*XN)U5&C'5\G^$=STK@_%/Q)UZ
MS_:,^&.@Z?J%G/X.\3:-JEZR10[G>2W6%D<2[L%")@0 .W4YX /:=HHVBN13
MXN^"Y==?14\3:8VJJLK?9!<KYA$0S+@9YV#[V.E8OPZ_:!\&_$KP;J'B?3M5
MA@TFQNI[>>6Z81[!'/)"KL#T#F,E<\D$4 >D;11M%<=!\8_!%SH6L:RGBG2O
M[+T<@:C=&Z4):$@$>:2?DR"#SZBKN@_$KPKXHUZ[T32?$&GZCJ]I"MQ/96]P
MKRQQDX#E0<[<D#/K0!TFT4;17.^*_B+X7\"S6</B'7]/T66\65[=+ZX6(RB)
M#)(5R>=J L?0"LFY^.7P_L[2PNIO%^CQVM]#'<VTYNTV21.2J.#G&UB" >YH
M [C:*-HKC==^,W@;PS>:A::KXKTFPNM/A2XNX9[M%>"-R0KN,Y )!P3Z4[3O
MC'X&U;Q#8Z%9>+-(NM8OHA/:V4-XC2SH4$@9%!^8;"&X[$&@#L-HHVBN5NOB
MKX0LO$2:%/XCTZ'5VG%LMH]PH<S$9$>,_>(YV]:Y/]H+XP6?PY^'OBLZ?XBT
MO3/%UGH\^H6-O?8DRRH[)NCW X<H5!SU]<8H ]6VBC:*\N\(?&C1--^%/@G6
MO&?B"PTS4=5T*TU&=KF18MQ>!'DDV]E#,>>@K.\0_$C6;;]HKX<^';#4;2?P
MIXAT35-1=(X079[?[/Y;++N(*D3DX [#DYH ]BVBC:*\S\&_$S1K#0I[_7/'
M^AZO;7_B"YL=/O('2&,,TQ6*S!W$-*GW#W)%=+X9^*'A'QE:ZG<Z'XCTW5;?
M3#B]DM;E76W^7=\Y!^7Y>>>W- '3[11M%<GHWQ9\&^(-:BTC3O$NFW>J31I-
M'9Q7*F5XV4LKA<Y*E02"..#7%?M!^//%G@.]^'X\.7VFVT&O^)+70+M;^R:<
MHLZRGS4(D3E?+ VGKGJ,4 >P[11M%>&?##XS>(=1^/WC/X7>(5L=2?1M-MM6
MMM9TV%H4,<K;?(FC+-MD'488Y'88KTF'XK>#Y_%">'(_$>FMKDDCQ)8BX7S7
M=1ET49Y8 $D#D4 =5M%&T5R&I_%_P5HMV;:_\4:79S"X>SVSW2+^_0;GBR3]
M\ Y*]:6\^+W@K3K#6KZY\4:7!::),+?4YI+E0MG(1N"RG/R$@@\]N: .NVBC
M:*\4U'XFZ\O[4GA/PK;7]I-X/U;PK>ZPJQP_O'ECE@56\S<<KMDR, =3UXKN
M=,^,O@C6;J>VL/$^F7EQ#;2WC10W"LQ@B($D@ ZJI(R1TR* .RVBC:*\(/[1
M?A[XF_"*/Q-X7\;:7X16?4$@CO=;C! 5;LQ[#&64AI50[0>1O'&:]/\ %/Q1
M\)^"+C[/K_B'3]*F$7GLEU.J%8\D;VST7(/)XX- '4;11M%<EK/Q<\%>'KV*
MSU+Q3I5E=RVAOHX)KM%=X!C]XHSDK\R\CU%;?AOQ+I7C#0[36=$U&VU72KM/
M,M[RTD$D4JY(RK#@\@C\* -+:*-HKE-4^*_@[1-:;2+_ ,2:;::BLB0M;S7"
MJRR/C8AR>&;(P#UR*\S^)_QA-Y\6[#X7:-XHMO#&HWFCW=\VJ&);B2*Z26WB
MMX!&Q .XW!<]R$P,9R #W?:*-HKDXO%0\#^#M'F\=ZQI=IJKQQ6]S<PL8K>:
MZV_,(@WS8)#$#K@>U6K3XB^&+[PM_P ));Z[83:#N9/[02=3#N5RC+NSC(<%
M<=<C% '1;11M%>1>/_VH_ /@?PK9ZVFN6>JQ7>L0:'$EI,&_TEY41U8C[NQ6
M+MG& /<5KVWC_3IO'^IW0\;Z0^@6F@6]W-H^5$UMNE=A>/)NXC=-J@$8RI.:
M /1MHHVBN,T+XT>!/%&M6.D:1XNT?4=3OH/M5K:6UXCR3Q;0^] #\PVD-QV(
MKIM:US3_  YILVH:G>0V-E$ 7GG<*JY.!R?4T 7=HHVBN"E^/7P[M[*&[E\9
MZ-%;S79T])'O$ -R,9AZ_?\ F7Y>O(IGQ1^.G@_X2:-KM[KFKP1W.D:<=3FL
M$;=<&')"D(.?F8;0?7Z4 >@;11M%<'I'QK\)WW@O1?$5WK-E86NJ1*T:RSC_
M %FP,\8]2N3G'I6RWQ'\+C0M-UH:[8/I6I$"RNTG5H[G*EAL(/S?*I/'8&@#
MH]HHVBO#_$'QBO+GXY?!S3/#NL6&I>"_%UIJ\\LEO&)#*;6%&1DE#8VEI.0!
MU3KS7H=O\6_!MUH$VMP^)=-ETF&?[,]XMPIC$N<;,_WL@C% '6[11M%>,?%O
MXP/'\/\ 1?$G@77M.O;27Q-I6D74L2"X5DGU""VFC#!AL=1(W4'![=Z[WQ-\
M5/"/@N^6SUWQ%IVE7+;3Y=U<*A 8X4G)XR>!GK0!U6T4;17F]A\>?#.H_&/5
M?AU%=*-7TZR@NI6<[59Y3)B-<_>(6,L2.!D#K6[HWQ8\'>(=3;3M-\2:;>7J
MQR3>1%<*69(SB1@,\A20"1TS0!U>T4;17!VWQY^'5YJ%G8P>-M#FN[RZ:QMX
MDOHRTEP&*F(<\ON!&WKD5T_BCQ9HW@G19]8U_5+71]+@&9;R]E$42#W8\"@#
M5VBC:*XNR^-7@/4IM4BM/%ND7,FEVXN[U(KM&,$)./,8 \+GC/3-78_BAX2F
MU'P]8)XCTUKSQ#;BZTB$7*[K^(IOWPC/SC8-V1VYH Z?:*-HKE)_BMX0M_$T
M7AV3Q'IR:Y-,;:*Q:X42O-MW^6!GEMHSMZXK@?@3\5M4\1VGQ2N/%VHV8@\,
M^+KW1HKE(OL\:6\,4)4L"QY)=B>>IH ]IVBC:*X^Q^,/@G4M'U+5;;Q/IDNG
MZ;(D-[.MRNVW=\;%?GY2V1@'KD8K"\:?M'>!/!GPYUKQI)KMM?Z5I<WV6864
M@D?[20"L&.SG<IP<<'/2@#TW:*-HKSN7QK;ZW\0_"$6E>--)CL;RQO+AM#VJ
M]QJ(&T+-$V[(6-@V>.<UL0_%GP=<>((]#C\2::^JR3M;1VHN5WO*N=T:C/+#
M!R!SP: .LVBC:*XC4/C?X TJ:XBO/&&C6TEM??V;,LEX@,5S\O[IN>&^=.#_
M 'AZUV5Y>0:?:375S,D%M C22RR,%5%49+$GH  3F@"7:*-HKC-+^,W@;68-
M1FL_%6E3Q:=:K?7;K=+B"W)(69N>$.UL-TX-2:%\8?!'B?7+;1M)\5:3J.JW
M-L+R&SMKM'DDA*JXD50>5VNC9]&'K0!U^T4;17SO^TY^T*? 6GZ'9^$O$>E?
MVY)XHTS2=0LW FE6&:=%D51N&UPK#.0>&Z#K7N/BCQ?HO@C19=7\0:I::-ID
M3*CW=[*(HU+-M4%CQDD@#W- &OM%&T5R_AGXI>$/&>LZII.A>)-,U;4]+8K?
M6EI=)));$,5.]0<CD$?4&FZ-\5/"/B36_P"QM+\1Z=>:LT;RI:0W"M(R*0&9
M5S\P!(R1ZB@#JMHHVBOG+X$_M%_:=!\?WOQ+\2:3IO\ 9?CS4O#5A<2!;2)X
MX!$L: %CEB68]2<MBO9]>^)_A/PO?7=EJ_B+3M-NK2P.J3PW-PJ-%:!MIG8$
M\(#QNZ9H Z;:*-HKA3\=?AZ+VYM#XRT875M:K>RP_;$WK =F),9^Z?,3G_:'
MK6G9_$_PGJ/A-?$]KXAT^Y\/LQ1=1BN%:$L&*E0P.,A@1CKD4 =/M%&T5Q:?
M&KP&^CVFJCQ=HXT^[OCID%P;Q DET.L .?\ 6#!^7KQ6-I_Q+T?QKXW\)S>&
MO'^B7FCW=E?2G2[=DEEU#8RH)8G#<+$RN&P.K>U 'INT4;17!VWQZ^'EW>Z=
M9Q>,=(>YU*58;*(72YN7;[JQ\_,3V J_IGQ<\&:UKQT2P\3:9=ZL/.Q:0W*M
M(WDG$V #SL/#8Z=Z .MVBC:*\#?]H[0?B;\-?%5_X9\9:=X.N+#5#ID.KZN@
M:-&2X6/>T;%>)"'102#R#7K'BOXD>&/ K1)X@UVQTIY(VE5;J8(3&OWGP?X1
MD9/2@#I-HHVBN2UKXN^"O#DMC%JGBG2;&2^MVN[59[M%,\*@%I$Y^90"#D>H
MK5\*>,=$\=Z%#K/AW5;36M*F9UCO+*42QL58JP##C(((/H10!L;11M%>#>$/
MV@+#PYXT^(VC_$3QAHFF_P!F^)(]+T@W!6S\R)K"TGV@,Y+,&N""<\^W2O5;
M/XE>%M0\677ABVU^PG\0VL0GGTR.=3/%&0"&9,Y ((YH Z3:*-HK'\/^*])\
M9:0^H:#J=MJ5IN>(7-LXD0.O##@]0>"*^7Y/C]\2XO#?QPUG^UO#>/AOJLUK
M';W.G21+J$44,<S!I///ENP8J#AAG% 'UQM%&T5\\>,?CKKT_A#X'>,-+V>'
M])\7:UI]OJFG:C;[ID@N())<!]P";?+P3@Y!!X[^O:/\4_".O>&;WQ#8>)-,
MN]$L7:.[OXKE3# RXW*[9PI&1P?44 =3M%&T5S_A;X@>'/&TEW'H6LV>J2VA
M47$=M*&>+<,KN'49'2NAH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:**6B@ KA
M?CG\.7^+GP@\7^#HKE;.;6M,FLHYV&51V7Y2?;<!GVS7=44 >"_!CXSQZ+X#
MTCPMXNTC4]$\;Z)906%YI7V&5S<21KY8>V901,C^7N!4G@C.*R_VC[77O#]G
MX,^+NA:2R^,/#EVMG<:.LH+WUA>2+"]JQ7AF$C02 9(#(V,YS7T;M&<UY_K?
MP<M/$?Q+L?%FH:[K-Q;V*Q/!X?-PHTX3QEBDYCVY9P2",G 90>H% 'E/Q)\/
MR_"G1_@3-/;ZCJL.B>*C<ZQ=6%K)=2O/<6%]').R("WSW-QUQQY@KA%TV[T+
MP%^T/\/_ !;I.H:KXB\5:OJ5]I""T9AJT5Y!&EH(F QF)D5&R?W?EY. ,U]H
MXXQ05!- 'Q1X]T7Q5\/KJTN_#&JW5[\1['0=%LM7\+:I:&[TWQ.8DV@Q28RL
MRMYOS@\$*6 &#7/_ !(CUK3_ -ICXE>/;/3;K7O#>BW^A3W?AIK5L:TD=L\+
MR6YQB66VDD1U0_*3G.&"D?>Y4$YHVC_)H ^+_'GB*VL/C?K.N^)['Q?J7P_\
M;:#8Q:3>Z%;SN(GB$J36,\*J74N92X!&,LP//34UCPI+I/Q.^!.@Z!I]_P"%
MXM-\):W90"Y+S_V2US%;I9QR2\C>#&1MR<>60,@#/UYM%&!F@#XA_9VTO3-;
M7X=>%_$/A#QA#\0_!5Q']ICOFFAT^P>)"DEVDH 1DE7.$!.XRX(QEA7TF'7X
M_@=HUI!X>UFYN/ 7Q,N=9\0Z5)9RH;BR.I7DX:(%<7&U9X)]JYY0'J!7W,%
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MEQ%I(MW4_+RN_'S#*X(.:^\=H_R:  * /CW]G[4HK3P]X>^%7CKP'JFH^/\
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MW2G'*87.-PIT%I<?%S3?V>;3P]I5QX8\1>"M:M9]<MY;)HFTBUM[.6&ZM2Q
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MB_XC\->&/C?KOA[P/H[Z[X0UO_3+6&Y8'5(%L+><S,ZQY,HBD4;<'_5XSTH
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MH ^@--UJPUAKI;&\@NS:R^1.(9 _E2;0VUL=#M93CT(J[7Q_\,_B=-\']/\
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M0>/_  )X,NK?1M/M?%^KZU=:5J.BRW$F-.-L9?M(=MF=R>6@Y !,B\\C(!]
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M)X&T#5?!?AS1M<O]=L+WQ=JK65OJ&I%='2;[&\DL$D@!+PPEB$C&?WAQT7@
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M/Q'H_COXT?'/2?'EY +*QT*S/AFWGO&A1K%[61Y[F':PRS2NH+CD;5&0*Q/
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M%LUQ(99C#&$,CGJS8')/J>:M44 59M*LKB^@O);2"2\@#+%</&IDC!ZA6QD
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M17+M"I:9 ,!7./F&"1@YJS:6<&GVT5M:PQV]O$H2.*) J(!T  X J:D) [T
M+124M !1110 444F<T +1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8WC#2M2UOPY?6.D:H^BZA.@2._C0.T/S#+*"""=N0,CJ:V:* /E?P
M_+XMUK]J'QU\/6^(7B&+1-)\.V.I6;@6IE6>9W5BQ\GYE&!@8'UKO=,_:<\+
MP>*[SP9*VKZEK>B7EOI6K7::9(L,$KP/)YTC8PL9$9.[I\PQQS69X1^'WBC3
MOVOO'/C.YT9X?#.JZ!8Z9:WYGB.Z6!V9LH&W '<,$CL:SO!'P[\>>&OB)^T7
MKEMHMO!)XH>"Y\.27TT;V]Q+#9&$"558LJF0 G('RF@#O/!7[1/AKQOK<&F6
MMOJ5O/?:,?$&E^?:,/[2L P7SH0.3]]#L.&PZG&#61X7_:T\$>+;_P '1V0U
M)=/\5RR6VF:K/9/':27*[R+<R$8$C+&Q"GGH.IQ7D/P?^%'Q'\/?%GX:^+-7
M\'3Q'3O"MUH^MW$VIV[L;MWBD+11(^U(=T;*B( %! P ,U!H7P"\?VGP;_9N
MT"?PZ(]3\%>+(=3UF/[7"1#;QM/EU.[#Y\U3A<G@T ?0V@_'?0?$GB"RT^P@
MOKBSO[^ZTVSU5("UI-/;+*;A=X^[L,$BY;&XJ=N:JZ;^T9X5U37=#LH5OVL=
M?>>+1]6%JYM;^2'.]8W YR 2I. ^/E)KR;P9\$O$VB_%#2]8T33=0\&6M_>Z
MDWBS2?MBS:5<QR)*L-S;*2Q29W9'.S&!N# < [/[.UO\5_ _AGPO\.=>\$6E
MM:>%H$L9/$RWT<EM>VL*E8C!'GS!(ZJ@(8 +R3C@$ N77[67@3Q[X$\27%E-
MXFM-$BTS5)+C7;#2YE-HML?+E97*$+(H)=<C@+DBMZX_:&\,>!!X7\+./$&N
MZW>^'1JMC"E@]Q=7T,<<8SE5 :5MPR!WR3@5YM\/_@QXWTC]C/XD> K[0#:^
M)]737XK&R%U"R/\ ;6E:$[PVU0/-&<D8P:S;N\U?PC^T[\%TN-"NKC4K7X<7
M=M>Z?:.DDL++);*V#NP^&&.">.: /29_VM="U=/AG-X9LKS5K3QAK$NE23>0
MRM820Q22312I]X2CRR-F.Q/3&>@T;XE>%]*^(?Q6FN_$>IQGP_9Z?=:Q;:JO
ME66F1F*8JT!*C(=8V=CE@2%QZ5XXOP&\;Z!)X8\5V&@17>I+\1]0\97V@PW4
M4;VUO<VTMNJ*Y8(S@>6[8/5V SC-:_Q&^!7B_P")6J_'^R-A'I5OXO\ #>D:
M?I6H/<(T4MS:BX9PP!W*I:9%R0,@,: /8-%^.FAZGX@AT:ZM-3TG4+VQDU+3
M(+ZT:-]1MT +M"O5F 928^'&X96N>\)_M8>"O&>I>$X=.CU8V/B>XGLM.U2;
M3I8[62YBWGR#(1@.5BD8*>RGOQ7/77A7Q?\ %SXA_"GQ+K?AJ[\+/X+:\U#4
M8Y)XB;B[DM?)$$!1CN0LS,7.%*@#.3QQ?A3X,^/=*^%'P#T6?PXZZGX4\:/J
M^K1?;(2(;4F]&\-OPYQ=(=JY/RM0![9^T]XBU3PC^S]X^\0:'J$NEZQI.C7-
M_:74(4E)(T+KD,""#C!!'0FN[\+1S1>&=+6XNI+RX^RQ>9<RXWRML&YC@ 9)
MR>.*X7]IKPQK7C;X">./#?A[3FU36=9TFXTZVMUE2(;Y4*!BSD  9R>:AM_%
M7CNXTG0],L_ U[I=W));07EY=W5JT-G$,>=)A929" "  .210!E>%OC'X,\-
MV?Q4UR[\2:Q)IV@ZZT&IG68BHLYVCBQ;VZ; Q3+KM&"27X)S6OIW[1OAB75?
M$FE:I!J6AZGX<LCJ>K0WUFX2TM?+:19FD4%-I5'P<]5(Z\5X9\7? 6JQ>"/C
MQ!K?A_9_PF7BK3I/#T7]H11274@CLX(WC;=\LH>W:55?&<#.!G$.FW'BRXUW
MXB0MX,U6W^*GB;PU)9Z5?^(7M)].N4MT;;;8A=D&3*S'?\K%L$@<4 >\:#^T
M;X:U>]UJQN;;5-*U'3-)CU][*ZLW\Z73I,A;B-%R67*L"/O*1@@5!X-_:;\)
M>-O%/A?1;*/4H6\3Z6=4T>\NK)XK>]58UDDCCD(PSHCJ6 Z9]C7A?A3X,_$.
MR^*>H>*7\&W=O8ZC\-I/#=PU]J\$]V^H"1I-S8?;ALA1MPHP.%%=+H?P=\;6
MNL_LHSRZ#LB\!:1<6.OL;J+-L[:=':KMPWS@NA/RYXQ0!7_:8^/-S>:-X)N_
M!6H:M9V#^.=.TF75K6'%I>C[68;B .020"K#(PI*L 217U=)/'#&[R.J(@+,
MS'  '4FOA^3X0_%&W^!?@3X52^#'O+_P;XITVZ&M6MU"MG>V%O=/*LJ;G#!R
MF RD [N>XKW[QA^SA'XC_P"$MNX?&'B>*]UVPU"T6RN-2WV%NUS!)%E80HX3
MS,J-W!44 <3X^^.?_"3_ !"^"<GAF[UJRTC6O$Q@2?R-ECJ]E]CN'=PQ&2 Z
M1%>1N#%AN'(]&D_:4\'P>(=%T^2:Y%AK&I-HECK/D$V4^H*Q7[.LG]XE7 ;[
MI*L 2017C?A;P?\ $J]\'? 7PUJO@.;3KKX?:]9#4[M;RW:"6""PN+830X;+
M*1,C$8XP5Y(J]\"_ /C[X=0:?\.-5^'>E7^FZ+JLL]GXUGE@>%[(W+S(_E\R
M"XPS* !P=I) H ["?]M;X>0?VA<.-932=,UA]#U357TN9;;3K@%5 G8K\@+M
MLR>X.>.:ZWQ[^T-X7^'MSJ(U 7DUCI$T,.L7]K 9(--,JJR&4CMM=2<9VAE+
M8!%?,W@_0M;^)'PU_:.\ :/H$M]+XC\?ZU8KJ4K1BTM1(;=9)7).<Q#YP ,L
M0 O.<=_!X$\>_#'XD>.=*LO -I\0O"/B[4/[4L=2O+B '3Y9(8TFAN5EY,0,
M88;<Y' !/% 'H_C']J;PAX0N/%-L8-7U2Z\-V=OJ%_%I^GR2E;:42-YX(&#&
MJ1LY<<8QSDXK<UGXS:!<V^D6>BS7NM7^O:6=6L8M&B\V;[%\G^DC(PJ_O$QN
M^\3@ GBO++WX3^,$UOX]>7HJ74'B;P;8:-I,\;PPQ75S!:743KY>[]TI:X3&
M[@ 'TYP_A1\-?B#\&-?^'>M3>%Y-:M&\ :7X0U>QL[F(W&G7EF[,L@)8*T+^
M8X)4D@@$X% &O^R?\;)IOV<?"&H>)M4O/$/B76+_ %2WLXG :[O?)NY\ #
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M(QQ78_%/X&^._%?C'XVZGHVDVR2:M_PC%_H,E[-&8;ZXTN9IWB<!LH'.U 6
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MDX"@#@"NCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XKHLGPO\
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MAMX&\&6OC._%AX0UA-9L9GM(FD>1'+Q(_."JL[GC!.0.W(!Q'C?]HCQ_X7^
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MQS<?#S6%U.Y\/VGB#0/&\GA?4]78&.V>U0)(;B&!FW-*4E11%N)+9YQ73?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 0@'K2T44 %%%% !1110 4AYI:* "BBB@!.M  '2EHH **** "DVC.?Z
MTM% !1110 4444 %%%% !1110 4444 %%%% !2;03FEHH **** "BBB@ I H
M!S2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cgtx-20221231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *, DL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+<D&1U1<;FQQD]: .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)^B*Y91<':2/F<1AJV$J.E7CRR04445)S!1110 4444 %%%% !1110 4444
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MFNZC0GS1GT/N<FR/%JO0QFCA=/?H?/-%%%>N?K9^IO\ P28_Y(MXO_[& _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYT!]68NDGVV]-T"JX(!C1 #ZGY*VJ*3DWN;4\-3I.\0HHHJ#J"BBB@ HHHH
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M/5GA\8U#FU6WFV?0X3 9[PU!XN%/W6O>ZVC%NUXJ[2L]-7:VMCW_ ,9?M/\
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M 4444 %%%% 'S5^U#\5[M+'5?"FD0,;H0':YP3+/M)4*N>0IVMSU*MP=H#?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;[=U99(O.=5WQ<DA58 @D J",+UK;\0WMKXLO=>\4:O/(\ VVEOY ._S0-J
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MNAPO*$MQ]M@BD'F*ODK(BK@,Z^N0.#SDG/)IFJ:9-<^!DLUTIM6O[Q&MTC2
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MZ]@U%M4$ED&B2$8\IDY4C[QYY!ZU^C6O^!L:#:2SS^4Q7;!.X!3DC:K YR<
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M,H8>A%9^M^'[#Q!IDMA>VT<UM)U1E!Y['ZBOD,NXIQN7TX8>"7LX^6K7K?\
M0PI8ETXJ'0_.#6=*\27K0P6L<>EH6/G6\;!D 8_,HZ\=/7I[53^),<MQXBL]
M4N_.T?3PD&G+<1$A2IPK!2.H+9)_^M7V)>?LPQQ:I)<Z;K$T"'+*LHW\^AZ$
MCUYR<\G/->#?%>34K.YO+74=(-LUE"R6]JZL\)*)G=ENH)#'/6OTK+.(\-F5
M>,(12LNMD];;7;N[GIT<3#:*_IE2?PE9Z.=,%CJRZJMFQEMX;9"0'<)E22#N
M/R<IQ@YSC!KO++X2^(O$WA=K1?#=O&EPF#<7,F]\=20K*=K>XZ G'J.L_9$\
M(:9?^#5U*[LTDO[=Q"'89QM4#]>OXU]**H0 *  .PKX+.>(,;3Q<\-3E94Y-
M7TNVF]>WG:WS9RUL2X2<(WT/#/A9\%]2L]4M]7\02[9;7 @MDQA<=R0!D\GD
M^M;OQC^#1\>,E_ITD4.H!%CD69-R2JK;UX[,".O(P2"#7J]%?'QQ^)CB/K2F
M^?O_ ,#:WD>>ZLN;F1\FO^S_ .)M!2.]BT^TN[PE=\L3L)0JD$ 9R#WY/K@8
MQ7FWCN#6-(L'U'4].EU&ZBF$3/K6]P&(X5=C+G 4_D*^^Z\'_;#B2/X7V;)&
MH9M5C!('/^IFKZ_)<\QM?'4:%:2DI22;:UMV35MSKI8F;DHON?,NOZ'_ ,)K
MX8AE6SMX$:!9)[ASQ:N@W;<D_*G.\9['J>37.:/\*94BM=)-Q<FT1Q(ZZ= <
M/,I8@EAP6&X8YPO(Q7O_ ( ^!]I\2O VGZO"8X[^,JA2==\9 4#...?Y\9Z"
MOHKP+\/[#P?X>M-/\B*62$<R%!DGUKW\?Q?4P*EAL&O>4I)W6BMHFG?4ZJF+
M45:/0\A^%G[/4@\.6\VHZAJ&GW+#:4BG97,?4 D'/OCI7MG@[P;8>"=,-EIZ
ML$9B[,YRS,>22?4UN@8&!TI:_*\1B:V*FZE:3DV[_P!(\F=24]PHHHKF,@HH
MHH **** "BBB@ HHHH ***HW>MV-BP6>YC1BVW .3GTXJ)3C!7D[(J,93=HJ
MY>K)USQ%;Z'&ID(9V( 7=BKL>H6\\,LD,R2B,9;8V2O&>1VKY,_:#\:ZKHNF
MO<6<QN)Y82%\QMO[QG^9O90IP ,'\J\;-,>\'14J>KEL>KE^"^M57&>B6Y['
M-\7C/J316]W;GRN)((YH=WN=I8M^'6NE_P"$X\S1;N5VB?$#LL]L3\IVDC<I
MR5/OR,^E?F5<?$6;0G2-[6.,SCS))8$)8#LI8D'Z#I[5]5? GQG9S>"[>:]E
MNHHY7VR23_, 2VW&>XYX^N.U?(4<WQ,9^]+?NSZ:KEE!QTCL<U^TE+=6J"WT
MVZDLP;=!B,'Y8AN.0<]3\I)ZU\R:EXKUJWNXH[>YEN[=%&[>[$[CG/?H,FOO
MKQ#X#DUK0T2Z2*XDMR\<;2#(E"D!26Z@\*>#W->40?L^PZ[>S7%OHRZ3+'.#
M.EQ,S"93DML7H/P ZUY-6C44[..YZ5.K!QNGL;7P:\436G@W15NM/29+EEC:
M. 8)!;!D^G(X]1[UZGK7@=/^$=@GN)V0H&ACO6(!'[S: W8YPO7^M<QHVB6/
MPUGAOM?O5AM;NX@L;="H$5J[OMB 'N=OY?C7J?Q;U+0] \"G3=4O9+'[4!':
M-!'OD:9,.NU> QR <$\\U]'EN7?6*$W75ET\F>'C\=[&M!4GKU/([/X2IJ#1
MW6L7">=#-YL!LX0J,!_>P/7!K9TVUTCX<^*=$TD@O_;]]]BG9<F02,C.A8_P
M@A2*Y;X&_%B.V_M_2KIUD2[DF>RDEC99;2[*LS6K[N0K$%H\^I7L*\J/BE](
M^+]Y>:I?,MEIOB#P]=LTK\);/$R&<D_P[F^8UT4,NH4JE-MW[]+:K1_?]QA6
MQU:I":2MV\]]ON/KCX\76DVG@5HKR_@L98)([JWAD4L)?+8$KM4$X(R,@<9!
M[5Y3\(/B5;CX8ZUI1G%[JNGV4]SI5_(?,^TVX)('IYD.0K#K@*>AKW+XC_#G
M1_B-H\:7V8+JV/G6>HPG$ENWJ#W4]U/!%?*_P[T6]U?XE&TTNTV::=6M;Z\E
MB3$$2-:'[2 /23>!M]QZ5]#B+QK1TT:M_7:U[W^78\2A:5)Z[:_UZVM_3.:^
M'GBR_N_VAM(N-4NW=;;QO=V"M*V3&&L-J G_ &B!CZU]B?%WX;GXD^&?LD-Z
MUC?6[&6W<_-$YQRDJ=&1AP>XZBODGXM?"VYTCQ1/=J)%TB]O;:UO-1A#1LKY
M_P!$OE./EDC;Y'/<?6OLA;C4/#W@"'^V[^&ZUF*S6*:[C78DUP5QE5[9;M1A
M)Q]A+GV5[_FPQ$)>VCR;NW_ /D;P%HTUK\5M-\.Z/#/+')=6]VT:DNEC;O;R
M)=1[^R'@ 'OMQTKD?B9X-UKP=\27N;2?R-3FU*QDC:1?W::G:C,&?1+F,E1Z
M-Q7M:^*]'^$MMJ<\,]S>7MX(5E-N@E,LB1A-JJ< *-IY8]36%=?$;PUXL@%O
MK-NT)G>)WBN[=(WCD1]T;ADY#!CQG&,U\U/-:,%",4[QW?S3?XH]Z&759.<I
M6L]E\K+\&?6.@7\^JZ'IU[=6KV-S<6\<LMK)]Z)F4$H?<$X_"K]<_P"%_$]O
MK%I$IE'FE1@,?F;(_G705]I2JPKP52F[IGRM2G*E)PFK-!1116QD%%%% !11
M10!S7Q&\+/XS\(7FDQQVTLDCPRHMV\J)NCE20'?$RNC IE74_*V#@XP?'?\
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M<%&QSP?O#CU_*O$CG6%E/D39Z[RK$QASZ&O\1/B%#X>AF@C8B16$1;D#>5W
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M92ENCP]?V@]0?5)K^;6)@EP?W5L;:-8N?;D\ _F.2:^@_@U\1-0\7Z \MQ/
MRN#%&L;].Q^AY'&?TKY%\7_!CQ!;SJ^H6I^Q1_<NQC'S<DC)SGKZU[3\'O#
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M]UO"R20HQ27&?E8C<HP3P#S@UWGQ@U"Y^'_AB26&X5KJ[@NMEP  8MENSAL
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MJEM:7\>?EN6FE"B%AW81DOGJ,"O3_P!FS2=4\(>%]4\+ZG:K#;:7J$BZ5.K
MBXLFPT9R.ZDLISS@"N>^._PEM[R>&[T'3[>UU2=[J]DU.>0[8;DQ[8V*YZEF
MSP,_)@5U5Y.K@^;FZ7;_ *Z]&<U%*GBN7EZZ+^OO1PGB2VNQ\%_#TES<2ZA:
MVBW20R.2SO:I>1@C/<B!6_ &N^_9%E1-,\>6LQ5M47Q'<3SN#DR12*KP-]-F
M /I5QIM(_P"$-T7PK]A,MAIMM'$2$)DRJ;2RG<.H+9R#D,:QO@GX2U3P1\59
MI8S%-X:O]"BMWNU?DW,,N(0PZY\MV&>GR_2N3#XJA];M3G=-6^>G^7WG37P]
M;ZM><;-._P"?]>A@_'3Q!'X#^,FG:KX=FBM=0C51>SDAHX99P8U61.ZN%0D
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MORL!D8-2?$3XG6&D_!JX\0Z C#[1I]S+,EP,RVS1QX:(C^%@[*#6?^U#\,=
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M%1E3C>4E=WVU5CR<+EU23<:CLHO3Y.YT6D_#V\^$7]EZY92-J%AHNNPWUO\
M93YK6]M-(R7$+$?PA&SGI@#TKZ*_:1U?ROA]%IZ6LES#J=U#&]Q&,I"BNK[V
M/N0JC_>KYQ^%GQIO/%GB2&T:[@>U8;W,N%<JAX/'!XYY Z\5[=\5M?FD^%.L
MV9P$D^SO"RG@,MU#D#\&''L:]?A;,G4Q]&C/K.-GYW7Y_F3F& Y6JL.G]?A^
M1XO\+_#;^-_$EIX=ME7S_P"R[J_:9P=L.4D@3)']YI/R0UR=_9ZCX2\;:OJD
MMNX&EZW;^+[7_= 6&ZA/NHW\>@KL?AGXZL?AU;:EK,\QBOKBVBLT$66=T1Y'
M4!<@<%VR21G(&:ZJ;QYX8\>6$]AK$[A-0@DA9986@G7S% )!+$Y(QP?;K73Q
M/C:>%SG$TU?FYVW]Z:+I8.I6CS/;I^*?YGT;XUU31/\ A -2U#6)(SHC69FD
M<G@H5RI'OTQCOBOC+PSJ&JZ7XMNGT?4KB"?2WL[VT19,*'N&C$]I(HX92921
MD<9]J^L-!\,Z'XH^'NE^%;\OJ%C8V]O$OF/AY!$J[&;'?Y03V)_(>+2^"H-,
M^->G6&GZ3)8^&K#6#/>ONR9/+MO-221F/.^9T_")>.*5:K"HZ>(4DH]_75_@
MK>K/&I4Y0YZ+3;[?E^+O\CP;QL+^U\0>-$_>?VH?"$1M@>&8F9S>8_V@2X-?
M4_QCM-/D^"G@F/3U1M/62W%L1R!']CFVX_ "JGQ&\$>'O%VOQ:MIJ"35XKG*
MQB=-LD4C 7 P.2&7)VGOGUKD=%N=0O?V:/#MCJ5E<VEUHVO2Z>(KA2CK$AG2
M)B",D%&4#\Z]3AFM3_M.G",D[-6?I?\ X?YFN)ISCR3:MK^=O^&^16^ _CSP
MMI&F7.EZ[?\ ]DS"^CB24H2K>8B,A9U^X"Q*_-QQ6K\9O&$^A_$'P_HMC<L+
M>TUFVN7??@O'% 9YB[=U *<5X5H=Q#<7EWYMF6A&EW-K<RE,+.\FU+:,'^)A
M(01CIO\ >O3_ (W>"KO1?%ND?:2S6KV\NFS3DY95NK9(DF_X#)&5)[ CUKGS
MR*AF&*GRI3526OS;7WM'0Y.<U!RO%K;[K_@SZ,\(^(Y/C!\*++Q'%8_8+R]M
MY9;-'/3E@A)_NL I(]#[5Y/X>\;Z!>ZQ>3:Y'::7J%E/!%!/<L%^9UPP);A=
MKAE()ZBO2?V8M8_M+X'^&H)%\NZTJ Z7=(1C;+ 3&WY[0?QKYX^+OB/PGKWQ
M#O\ 5(HX_L<DUU:W0 PEW:QV[&:4CT$JC:WJ3ZUY>88>C-0KR5VOE=6W]488
M&O5BY48NR_+_ (#/4?C)XAN?!5J;&UA@N]:NQ;-;E>%R\ZH,XZ\;CZ86O5?A
M-\0;/XG>$#JUE:M;VB74]FN3E9?*<H74]U)!Q7S/\2;"^\,67@2\U,2ND%KI
MZW$TG)2-H)H0Q]TEE7/U%>Q?L?W2I\$=-T1U"7^@W%QIEVH&,R)*QW?\"5E;
M\:WP5*%&M4A#1+^O^#\S'%5)5:4)3U?]?U\CD-8\82?##XHW&E>)9GDT%H)9
M3=K%O>)&D#13%>I0#?$V.A0'H:Z?XOZI!X:\,:8^@W)NGUI9(X)(WW!U:(JA
M1N@R\D?->??M ^+8[_XGVTEWI\\-GHH:VAG9"%G&WS+IFX_U8C7:,]6Z5MZO
MX6O?"OP3^'5\]L[MI-HCSP."6BWF.7;[8V%1[E17)4H0M65.GMJM-?/\;V.F
M%6=Z3G/?1ZZ>7X'>_LP>)W\1_#&.V\IVM-&N9-(M[V1MQO5A"J9N?5MP_"O'
M?VI_ .A_#NQNM9LSY*7<BWT-J!_Q[7*SPJ6B]!()""O3/U->C?L>ZF(/A[J?
MA:3/VGP_JEQ#N(_UL,KF>*3\5DQ^%1_''PMIGBGQ5'<:W<K/IELEKY%DCXS-
M%,TLAD/0)_J<^NW%=N+K0I8:-63O:VOY_>M#EPU*=2O*G%6W_KY,\:U'PW<?
M$+X<>)]+0L-!L+B*Q60DYLS($F0*>ZPSDC'99,?PUU/[*&L^*(/'&IM)9&33
M-:D==;@08_L[5($"O(#T*2JJ\#H2*EC^-&@-'>Z+8J++2!NWA-/Q;R;CR6.[
MDD^HS]:]"^$&I>&],D\2:GH<LF[6I1=W4>\M$)PFW<@/0D  CV'2O%P>88;V
MJ7,UIY:O_+1?=ZGJXK!5_9MV3U_KY_YEGXV2>'_$3P1:G,MU:6T<T3VK,?*8
MDKN+XYP-A7 Z[B*\U@^/^GW%S+"(;VQL8P8XY'LHUC<=P!G)!_/VKGOVBEFF
MT>V6T,UL9K;:I@&-J$[V ]&;:<]^E?)NI:EJMO<0II\TS*JYD5RQ+-]>/;@U
M\YC,?6KUG.]O0]W"X.E1I*-KGWQX"A\/W=]XA\2^'Y98[S5-,339H%?,#-&#
MY9 /(89*_0_2O./CQX/O?&+V\EG'%<1-$'A! +[N.3[?.W/4"HO@5XFU/3?
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M!SZU>8Y-4C)2PZNNQ&!S2$DXUW9GQ5\'O ?_  B.LMK-\"+: A!" 6=I?[H
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M<R2*3YGFLVXXQ@=>#_A66,S*O6K2E%\J?1-FF%P%*E22DKOS/T&^#?B#P_\
MV]J^L:8$C>\@@@N1$QV$Q@A3M/W3@]NV*\Q_:!O+J;P[9M:3S6MU=0/AD7)^
M<AG;_>.''MVKE_V>/$VIV7@V>ZFMXI7\XA8PFUI#MSMS[<\^A/I7NVK>%/\
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M."G'5<_A^5=]17SV(PU+%0Y*JNB:->IAY<]-V9X[I7PG@TJ%;2+3/M8C=O\
M2;DGS!NQD!B#Q@=JD^*GA:'1O!UC]GC59!J5JNU.!C>!^@KUZN!^-;^5X,BF
M&=T>H6A&/>95_K6N39=A\+CJ4Z:UYE:YUU,=7Q%H2>A\F>&OA]:^*/#4EY=V
MK74"JJR"$_.!@=B<'UZ@Y%8^E_L^6E]=P7>G0W=_I)D*S37"+&PV\X'UX&>>
M]?0?[,WAZWUCP+,7+PS+*I$L>,_='4'@BO7H_ \:2DB<QQYR%BRN?7/.*\3B
M3):M;.<54ALYR_-GOT\UITH*$MT>3?"[X?WZXDU*"*.9<+:Q1YVQQ 8 .>_+
M?D*SOB;\,Y->LS;WEHSRV1:'<F 7C .UE['(.<'U([5]&6UI%:H%C4#W[U6U
M?1H-8@,<NY'Q\LJ?>6N9Y'#ZK[%/WM[GFK-I_6/:->[M8_.F_P#V>;#6KZY;
MP^;S49(7 GLY(0OD*>,;BQ)P:]S^$WPENM,F6PNK1;;PW:)B!F.9))<\LW;G
MM]?>OH5?!+1.OES1QEA^\FC!1F/;(Z&MZPTI+2WC1SYK+W;G)]:\W#Y!/G3J
MO0[ZV<PY7[-:GDWB/P)<26LD6H;%MKB3S8,#.TD$F-AT/?\  ^U>-W_P-&OZ
ME,DNE6=C<)&#'JC,Q20CH,%C]*^Q[FVBO(&AF19(V&"K#(-90\(Z: H$3*BG
M=L$C;?RS77B,A4Y\U*6GF<]#.>6%JBU\CQ+P-\'GTK4K:<N)H+>/RH[./'E]
MLL1ZG!_.O=+318(-*^QSHEPC9+AU&"?I_GI5JRTZVTZ(1V\2QH/2K->M@,MI
MX*+ZM[GF8S'SQ4ET2V.?C\(V+X4>:L"](B^X?FV3^M:]EI]OIT*Q6\8C4#'%
M6 ,4M>E"A2IOFA%)G#.M4FK2DVA",T 8I:*W,0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O<6,5Q#<( 86G0HTL)
MV2#(QD,.01V/:LWPKX1T[P=H%MI%@DKVL+/*9+N9IY997<R22R2.2S.SLS%B
M>I-;5% &3XA\+:;XGTN73[^ /;2S13NJ':6>.19$)(_VD6M(6\2J%$2!0"
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ME[*6ZV/T#(,Q]I'ZI5>JV].WR_+T/;J***]D^R"BBB@ HHHH **** "BBB@
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MS4G=[GV/#V*G7=5597>C_3_(Z&BBBO9/LPHHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,@HHHKL/9"O._B]\!?!_P :]*-MXBTU3>(N+?4[?Y+F \XPXZCD_*V5/ID
MCT2BIE&,URR5T9U*<*L7"HKI]S\MOCM^QWXP^#TMQJ%E$_B3PPH+C4+2,^9
MO/$T8Y7 _B&5QW'0>!5^XU?,WQV_8<\*_$H3:IX8\KPIXA8[F$4?^AW![[XQ
M]T_[2^^0<\>)7R^WO4?N/B,?P\U>IA/_  %_H_\ /[S\TJ^C_P!@7Q)_87[0
M%O:LR+'JNG7%D=Y[_+*N/?,0'T)KR'XF?"3Q5\(M<;2_$^E36,F?W5P!N@G&
M <QR#AAR,XY'0@'BK'P,\5IX(^,7@W6I9DM[:UU2#[1+(,JD+.$E;CT1FKS*
M3=*K%RTLSY?"REA<7!S5G%J]_P 3]C:***^P/V,**** "BBB@ HHHH ****
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M>2*^RJY<!2]G3YGNSS,@PGU?#>UDO>G^73_,****],^F"BBB@ HHHH ****
M"BBB@ HJD-:T]IO)%];&7=M\L3+NSZ8SUJ[0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?$O[3/BK1+?\ :[LM$\:?$?QOX)\(IX&BOXX/"FKZ
MA:(]U]NG4O(MJ#D[%QN8=%'/ K[:KS/_ (5)<_\ #23?$[^T8OLA\*IX>_L_
MRSYF];N2?S=V<8PX&,=J /G;X/\ QDM?AC'\1_'5EXE\9^,/V?M)T**_AU[Q
M;/<7=S<:B)&5H]/DN 'FB9<*Q8A%D"A3RY'JOAS]J#5K+QAI6B?$CP-'X"CU
MRVN[G2+J#7(M4\P6T+3S1W"1QJ89!"C/@&13M8;L@9SO&?['\7B6#XL>&;#6
MHM$^'WQ#L1+<Z5:VQ\VPU<,"UW =VS9+M4R1X&YD!!4EBT>A_L\Z[;:K:WVN
M:/X'TC2]/TZ]@O+?P3H44=]K32VS0_ZR5 ;8#?(0D;9)*@OMW*0"M9?M>>+;
MF#P1K\WPBN+7P%XUU?3=-T777UZ%I_)O)56*YN+58R8E*,'50[DY524SD=G8
M_M(_;?@#J'Q,_P"$=V?9-3NM._LO[=G?Y.IO8;_-\OC=L\S&WC.W)^]7R_X7
M\37OC30_@-\,_#GCK0]?M_"_B+299=$@TJ:#6XK"QD5HQ?QNY6U,,41#MC$D
MGEA2 V']HN_V:?B&GP\UCX9Z;XF\/VO@J[UZ;6(=1FM)I-22"2^:^:U90PCR
M9B1YW_/-BH0, ] &OX8^*'B'PWK/QTO(=*USQS=6'BZUT_2=$M)B_E^;866U
M0SDK! ))&>1\;4!=R#SG@_C1^UA\0]$^$/QBLSX0L_!?Q'\+Z##K%J;#Q!!J
ML*V\LIC,V\PKMDCVNWE/'A@%PW/'<_$3]EO5O%ND^/K>UUNS*^)/%NG^(WT^
MZ21;:ZMK>"VBEL+DJ<F.80,&(!&U_NFN:O/V,=3\16'Q%M;B7PIX1T_Q7X37
MPW!I7A736CBL75_,69I#@S$L[@G:ORJ@ R"2 =GJ_P"T?XRM]5L?">E_#6TU
M+XC1Z8FKZYHTOB:."QTJ&221(4-Z8#YLLAB8J@C' )) P3Z;\)/BEIWQ>\')
MKFGP36,T5S/I]_IUR5,UE>02&.:!RI()5E."#A@5(X(KQCQ)^S=XFU_XD6_Q
M(N]*\!ZWXBU'0X-)US0=:M9+BP,T,KM'=6L[(TB$)(RE"F& 7G(W5[!\%OAY
M=_#+P';Z/J-YI]]J+3S75Q+I6EPZ=:JTCDA(H8E "HNU S9=MN6))X .[HHH
MH **** "BBB@ HHHH **** "BBB@""TLK?3XFBM;>*VB:1Y2D*!%+NQ=VP.[
M,S,3W))/)J>BB@-@HHHH **** "BBB@ HHHH **** /S/T#Q/\.?"7PDU[4O
M''[.FI^+TN?%.MV$GC6/3].$$LDNKW4<.^\>=9X%4E(?-95"$  GY<^IW_Q^
MUK]D/X3?!3X<^._%6C:5XMU33[EM0\2ZU'/J-MIMM 08X]D)5[B7$L42G<JG
MRG8L>-WTMX#^"&C^$?A7J?@+49/^$AT;4KK5)[M+F/RQ+'?7<]Q)$0#T'GE,
M@Y.,\&N'L_V7-4TCP[X!73OB+J,7B[P1]HM-+\2W5DEP\^G3%=UG=Q,^V8;8
MX1Y@*.#$I!!+;@#Q[2OV_=0\1_#/4M3THZ/>OHWBN+0]8\96&F7USI%GILL#
MSQZFUL,3*/D$)C9]JR<F3#**D^)GQ<\7_$WX.> -5TSQ1X5NQ-\5-!L+76_#
MCRS6>I6IO(6A:: 3AX6#E?-MG<D&,C(R&'LR_LW^)(O#D3Q_%WQ*?'":\=>;
MQ%+'&\#DQ^4UF;+B/[+Y? C!#!\/O['$O?V.6O\ P-K=@_CJ[@\6ZGXPMO&_
M_"0VNE6T<<&H0-$8MEIC84 A7(9F9F)9F.2" ,C^,GQ2\?7WQ*O/ D'A@Z/X
M"O7T;R-3MIVGUW4+>%)+M%990+1 9 B$K,21D\' S-"_:E\6?%/XD^'--\$V
M.AZ?X6N_!FE^.;Z\UM9I+J.UGGFCGMD2-@IE"HNUB0H9&!W!@5Z77/V7-;>\
M\7?\(Q\3=1\)Z;XS59/$5E:Z7;2B6Z,:17%U:LP_T:69$PW#C)W  C-=/X._
M9PT#P)\28_$FD2M!I4'@ZS\%VVA,A>.*UMI9'1O-9BS$B3:=V2<9)))H ^8O
M!W_!2JP\07WAK4IO%'A">'6M9AL6\%V=E?#4[.TGE\N*8WC?N9)DW1M)'L5=
MH?:Y8 '[XKP+PG^S+X@\(1Z+X>M/BKK1^'.CWZ7=GX=^Q0)<K#&0\5FUZN'-
MND@&%"AB@$98KQ7OM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_$+XK:;\.-<\%Z7?VEU
M<S>*M7&CVKVX4K%*8WDW29(^7$9'&3DCBNVKYX_:F_Y*-^SW_P!CS'_Z27%
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M^*D^IPQ1V3_:"/\ A*5(N% 7<1Y'.\?P=]M 'W/1110 4444 %%%% !1110
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M%V[\0^%_#8;[#I=II":?<71"F.$7MPDK"=(XV8;%CC#,$9ONX/N%% !1110
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M#FJRWMG>1PL%EB=988I(F4LG)!#;C@Y4T 7OA7^S0GPR\6> =;'B)M1/A3P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M()!#(5!9-PX;!R,CKBKE% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cgtx-20221231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (" SX# 2(  A$! Q$!_\0
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M !1110 445Q/QB^,7A?X%^ M2\6^+=1BT_3+.,L%9AYD[X^6.->K,3P /Y4
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MD$]Z /%[*\_X4[_P4'_::TSPE#%H^FO\/;C5?LELNR(72VUK,LH48&0\LO\
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MX:U"2PU7Q'IVGWD8!:"XN%1QGID&IE.,%>3L1.<::O-V]3J:*X?_ (7A\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^_- 'WW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Y;?%Y?BZW_!4CQN/@LVBIXM_X12V\TZ[_J/LOEVN_'^UN\O'MFOU)K\M
M?C!^TEX;_9:_X*C^-O&'BG3M8U339_"EMIRPZ'!'-.)'CM7#%9)(QMQ&V3G.
M2.* /TK^'X\0CP'X<'BXVQ\5_P!FVW]KFR_U'VSRE\_R_P#8\S=CVQ6_7/\
MP^\:67Q(\!>&_%NFPW-MIVO:;;:I;0WB*DT<4T2R(LBJ6 8!@" 2,YY-=!0
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MH **** /CKP+\&T^+GQ \8/XDU.:TO;.[;?;Q@>8^YCAN>@&!7HG_#&GA?\
MZ"VH_P#CO^%>2WEEXU^,GQ.U[6/"\+6C6LQB,\4@@"A20H8C[Q./>M__ (5/
M\;O^@M+_ .#"OP_!PP;A*^73K^]+W]?>U>OZ']!8Z>.4X<N:0P_NQO3;7NOE
M6GZGU'X.\+V_@OPQI^B6LCS6]E'Y:/)]XC)//YULUS7PWT[5M(\#:/9ZY(9M
M6AAVW#E]Y+9/?OQBNEK]FPMO84^6/*K+3MIM\MC\(Q?-]9J<T^=\S][OKO\
M/<****ZCD"BBB@ HHHH **** "O@S_@C]_R1;XE_]CW>_P#I-;5]#_M/Z=\=
M-1T30U^!NJ>']+U1;B0ZD_B!=R/#M&P)^[?G=G/2OG#_ ((W"X7X#?$$7A5K
ML>-KH3%/NE_LMKNQ[9S0!]]T444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS_@C]_R1;XE_]CW>_P#I-;5]YU\&?\$?O^2+?$O_ +'N]_\ 2:VH ^\Z***
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MLKX:H0JTL15G5D[)2DFK=6THK\]V=O1117ZZ?FX4444 %%%% !1110 4444
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MSO=;W7+H[Z^C1]R45XA^S=\0?&7Q+CU34]>GA?28"+>$1P*A>;@DY']U<?\
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M_P ,Z-?:_P"/[C3GO+:."V9[>RB&0;B9L8PO7;WQSQ7:_LN6_P ?K>W\1?\
M"];KPY<S%H/[)_X1X8 7$GG>9\H[^7C\:M_M?:59+^SC\4-0%I +]M N(VNO
M+'FE O"[NN/:@#CO@#^TCJ=Y^PW9?&+QU.-1U&UTB\U*]:")8O.,3R;555P
M2%4?6OE2W_;-_:<\(^!?#7QV\4VWAN;X3:YJ2P/HD4.V>UMFD*!P_P![/!P2
M3G'W0#7>?#;1[O7O^".U[9V433W)\,7\BQH,LP2:1R .YPIXKQ3XM_%#PMXH
M_P""4?@'PGI>MV=YXGGN[2S71XYT-T)4N7W QYW#@@@D=Q0!]0_M-?M0_$C5
M/BWX#^$/P-&G6_B?Q%IPUBYUG5(Q)%:VY4LHP<@?*,DD'[R@#-+^S;^V+XN2
M+XO^$?C/;V$?C7X:0O>75WIHV17ML%)WA>@/W#D8!$B\#%>16DUK\(/^"BOP
MKN_%M[!HEG?^!8+.&ZO7$47G" +M9VX!W1L.3UP.]<:NG?\ "Y?VA?VV?$/@
M^>+7-)G\(2Z3!=6K!XIIS'  %89!&;:7!'!QD4 ;0_;0_:<TCX>67Q_U"Q\/
MW'PFNM2$'_".PP 7*6I<J'#_ '@>,;BV,]@#7Z:^&=>MO%/AW3-9LVW6E_;1
MW,1_V74,/YU^3NN?%SPA<?\ !)/2?#$.OV,WB-I([#^R8YE-UYPF+8\K.[&.
M^,<U^G/P&T2Z\-?!3P+I5ZI6[L]%M()5/4,L2@T =Y1110 5\(?&/Q+9_!?]
MM_3O&'BNUDET"ZLU$%T(]_E';MW >JGTYYK[OKYB_:9^*_P2U&\N/!/Q%CNI
MKVU =9+>W)>$L."C@\5Y&9Q3HJ7.HN+35]KKH>%G$%*A&7.H2C)-.6UUT9I_
M$[]L3X20?#_5_+UZU\027=G)"FF6ZF1IBR$;&!&%!SSFL'_@G5X?O](^"5W>
M7<;PV^H:B\ULK\;D"A2P]B01^%?.>A:3^ROI6L)>76L^)-3@1PZVDT&U#@YP
MQ!R17WE\$_BCX/\ B?X5,W@I6CT?3F%HL1@\D1X&0 OIBO.P56>+Q2JUIQO%
M-)1=]]V>3E]:>.QL:^(J0O%-*,7=Z[MGH5%%%?4'V84444 %%%% !1110!\U
M_"[PQ-X:\;>./ NKZ1<!-=CFDM]1* QO$00>?3YQT[^E>67'Q;OM ^&%[\--
M5\/B6_MI)+=+F63YH?G)QLV\L&S@@],>G/J'CS]K&\TSQ3=Z5X=T6._BM9&C
M,\C$F0C@E54=*XN\_:%UC4=234;KP!I=S?IC;<RV9:08Z?,5SQ7X?C<3E]&/
MU;"8IIQYXM^SNN233<;];/9G]!8#"YE6G]:QN#4E-4YI>TY6IP32E:^ET]5Y
M?(^G?A+'J$7PU\.IJ@87XLT\P/U]L_ABNNKF_AUXCNO%O@C2-8O;<6MU=P^9
M)"H("')&.>>U=)7[)@N7ZK2Y&VN56;W:LM7YGX7C^?ZW6]HDI<TKI;)W=TO(
M****[#A/'_B-^S#X8^)OQK\"_$_4]0U:WUWP>&%C;6DL2VLN6W'S5:-F//\
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MLJ!D8.IZ,IR#7>FGL>:TUN.HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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MKA=1LU18T1AL.W.,C_@1KO*\>^/?P4U'XG?V?>:%?0Z?J=OF.0W,KI')&?\
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MO_@CI:Q67P,^(MO GEPP^.+N-$!SM46MJ /RK[XKX,_X(_?\D6^)?_8]WO\
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M581J "&SD'FO"O$/_!3.SU#1+ZULO <B74T+QHUW?+)$"01\RA 2/;->E?\
M!.S1M4TSX(7-Q?Q20VE[J,DUFL@(W)M4%A[$@C\#7B8"=-XR,:->516=[MZ?
M>?.Y74I/,(PP^(G5CRN]V[+:V^_Z'U-1117V)]\%%%% !1110 445Y5\2OB_
MK7P[\2B >$[O5]$,*/\ ;;0$L').Y3P1Q@?G7%B\91P-/VU=M1O;9O\ *YWX
M+ U\PJ^QPZ3E:]FTOS:U\CP+P#\8['X-?$#Q6I$VOZ5?3G$T)*.K*S'[KX_O
M$'Z#K7J?_#9WA#_H$:W_ -^H?_CE8.C>)O@/XAN7-_H<>E7;L6D%ZLH&XGGD
M-ZUZ-H_PD^$GB",/INDZ5? \X@N&8_EOR*_,\KIYM&G['+L91<+MI:MJ[O;5
M7^\_6,WJ9-*JJ^9X&NIV2;T2=DE?1VV70[[P=XHMO&OAG3]<LXI8;:]C\V..
M< .HR1S@D=O6MFJ6BZ+9>'M+MM-TZW6UL;==D4*$D(.N!FKM?J=%5%2BJKO*
MRO;:_6WS/Q^NZ;JS=%-0N[7WM?2_G8****V, HHHH **** "BBB@#Q']J+]D
MGPE^UIH>AZ5XMU77M*M](N)+F!]!N8H7=G4*0YDBD!&!V KYR_X(VV2:9\!O
MB#9Q,S1V_C:ZB5G.6(6UM0,^_%??=?!G_!'[_DBWQ+_['N]_])K:@#[SHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!G_!'[_DBWQ+_P"Q[O?_ $FMJ /O.BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^FYX.<K"O#KZW&4HW^SO?4\C\5?\$]/B?H&B76H6/B+2]:DMXVE-G!<31RR
M#.$W)M+>Q(^M?1?_  3^L-+A^"LEYIVJW.H375XWVR&Z0*UM,J@% <G<I&"#
MQUKYZU/]HS]I?7["?3ET&XM3<J8O-M=)9)%R,?*22 ?>OIW]B7X1:W\)/A+)
M;^(H3::IJ-VUVUHQ^:%-H"AO]K@DCZ5XF74Z'UQ2PL))6=^;IVL?.932PO\
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M""<[=PSC@X.,5[5_P22_X0.'QCXSTS7=$O;/XYZ<TL=]?:U=F>6>+?MD$2L
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MJB@8"@#@ #C%2US_ ,/O!5C\-O 7AOPEI<EQ-IN@Z;;:7:R7;!IGBAB6-"Y
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M +#>6]YY$AAE\B57\MQU5L'@CT-%GJ]CJ%S=VUK>6]S<6C!+B**56:%B,@.
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MF_#?X/\ A'X2#7!X4TA-)&M7[ZE?A)'?SKA@ 7^8G' ' P*[.B@#C/!7P?\
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M#;PGXQ\;P>/-*^(G@E?%7_'M'$=,N"&?;$R ;HB%VC.,]<#'/W1JG_(,N_\
MKB__ *":\/\ @'^SC\%?A'XV\07GP^M('\2V4:Z=>&34)+R;3H2=ZVZAV;RE
M.,X'I[5[';>*-$U76[_08-2M+G5;2-7NK!)0TL2-T++U - 'Y0?L(_LA?#W]
MJ#X<_&:+Q7I8;6DU^XM+#68F*SV1*!E9<'!PQS@\'H:[W_@F?\1IO@3\7/%_
M[.7CS2=-T?Q19W#G3]1AMEBDO"OS&-Y  9 Z%9(V;D@XYRH'WQ\//"GPV^&&
MO:IX8\'6.C:!J]W_ ,3.]TNPVI-)G"^<Z9SSP,_2J/BGX<_"?Q%\6M&U/7='
MT*Z^(L,(GT^XG"B_6.)B0Z'.["DGGMS0!^?^A^/(/V$_^"A/CV]^(UM<6/@W
MQV/,L]?2)GBC4MN5FVCD!BRMC)7CC&2-O_@HI^U[X'^/7PST[X-?">_/Q!\4
M>)]0MBYTB-I(K=$D#JN['S.SA0%7. &+%?E!^_/B3HOP\\;OIWA/QU8Z#K4E
M^S266E:S%%,TK*/F:)7!.0.Z\U@^%_A5\&_@)K5@VA^&O"_@[6-7E-I:30VT
M4-S<N1S$CD;CG^Z#B@#:^ _@.X^%_P &?!?A2\=9+W2-*M[6X93E?-5!OP>X
MW9Q7R1X*_P"4P_C_ /[$6+^5C7V[X@\5Z-X4CM7UG5+73$NIEMH&NI1&)96^
MZBYZD^E?$7@K_E,/X^_[$6+^5C0!]YT444 %%%% !1110 4444 %%%% 'SK^
MUY^TCJWP/L=!TKPQ81W_ (EUMW$/FQF01HNT$A!]YB6  ]C7F?QY_:N^(&BW
MWAWP%X,TV2;QK=Z?;SZA/%:>9*LTB F..+D CG)(X]NM7OV[--UWPKXV^''Q
M,TK36U2V\/SGSXPI(1@ZNF['0'##/; KYJ\0_M933?'JS^*.AZ"EA?K;BWNK
M&YF\R.88P<, "N1W]J^*S#&U*5:I3E4<;N*5E]FVK7G<_/,US&K0Q%6E.JX7
M<4K+:-M6O.YW]YXG_:V^'UI+XCU*WUJ73[<>=,LR0W2*@Y):-2Q5<=3@8&3Q
MBOL']FWXU6_[0GPQBUF[L8K?4()3:WUKC='Y@ .Y0?X6!S@].17RKXE_X*8Z
MKJ/AZ>UTOP;;V.I3Q-']HGNS+'$Q&,A=HW?0XKV3_@GH=#7X,7,>D-<RW8O2
MU_)<(%'G%1\J8_A QR>^:VR^O3^MJEAZSG%IWYN_2QOE6(I?751PN(E4@XMM
M2[]+72^9]010I!&L<:+'&HP%48 'TI]%%?7GW@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%>9^-/VC? /@'XH>%?A[J^M"/Q;XED\O3]/AB>5B>Q<
MJ"(P>Q;&: /3**\^^-?QZ\#?L]>$O^$C\>:Y'HNFM((8LQM++-(?X8XT!9C]
M!QU.!6;\"?VF_AQ^TEI=]>^ ?$,>K_8&"7=K)$\%Q;DYVEXI & .#AL8.#@\
M4 >IU\%_\$?44?!GXF-@;CXZO 3[?9[;_$U]Z5\&?\$?O^2+?$O_ +'N]_\
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M_B:@O_\ @K#'I5E/>7OP$^(EG:0(9)KB>U"1QH!DLS%<  =S7WR.@KF/BAX
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M;^!/%O[=WP6\'_ ?1K?3[_P+<_:O%FJZ.A6WA@CDB98Y''!<*DRGU,P4YYP
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M< "/:OTK^"OP[E^$_P +] \)S:W?^(I=-@,;:GJ;;KB8EF;+GU&['T KMZ*
M"BBB@ HHHH **** "BBB@ ILBED958HQ! 8=O>G44 ?G7\2!^VCX=;Q_\/X/
M#-C\3M!\1R2P:7XHFG@A-G;297:R!D (4X.Y>H)!-6?B!_P3Z\8VG[$/@;P3
MX8U"VNOB3X,U'^W[?<P$<UPS,\L$;OA1\Q4J6^4[ #@'(_0NB@#\_OAC\+?C
MK^TC^T_X)^)?QF\$V'@#1/ EJPL[&"<2->79Y+J [$#<%;G@!0 2237Z T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cgtx-20221231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 KT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M))_"O#-*_;3^'FKZKX+L(AK,<GC*_-EH3RZ<RI?*&*F=3NXBW+C<V#R.,'-
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MH **** "BBB@ HHHH **** "BBB@ HKYE_X* ?M$^)_V9O@O8^*?"?\ 9_\
M:<^L06!&I6S3QE'25C\JNI!R@YS^%?G?_P />/CKMS]G\(GU_P")5+Q_Y'J'
M))V&U97/VJHK\M?V9/\ @I3\4OC%XOU#PWK9\-6E]<6$SZ7)!I\BJ;E5+*K@
MRG(./:O)M2_X*W?'C3;^>UDMO"(DAD:-O^)5+U!P?^6WM7!3S"C5Q53"*_/!
M1;TZ2O9KOLU\ARBXJ,GL]OE_7XH_:.BOQ0?_ (*^_'=<XMO")^FE2_\ Q^E/
M_!7SX[A<FV\(_P#@JE_^/UZ',C/F1^UU%?B?_P /?_COS_H_A ?]PJ7_ ./T
MG_#W_P"._P#S[>$?K_94O_Q^CF071^V-%?BC_P /??CJQ.+;PBHQWTJ7_P"/
M4S_A[_\ 'C&?LWA#_P %4O\ \?HYD-M7/VQHK\3_ /A\!\=MW_'KX1'M_94O
M_P ?J6V_X+ ?')9@9++PE*G=!IDJD_CYU)RL5&TFE>Q^U=%?CYX9_P""K7QG
MN-!UK5=6M?#*6]O'LMS#ICC]\WW0P,V2OKBN3;_@K[\=P0/LWA'_ ,%4O_Q^
ML:=>%24HQ^S_ ,.:U*4J<(U);2O;OH[?G^3['[7T5^*;?\%>OCOU%MX1"Y R
M=+E_^/4P_P#!7WX[!B/L_A#CTTJ7G_R/6W,C$_:^BOQ3B_X*]?'9]V;?PB,#
MOI4O/_D:GP?\%>/CK(ZA[;PEM[E=*E_^/4.:01]YV1^U-%?C1>_\%<_C)!#*
M(;;PW*S*ABF?29%4'^($>=SZ BL@_P#!7KX\]1;>$2!U_P")3+_\?J(58S5T
M=->@Z$N5M-^3O_7?2ZLS]KJ*_%%?^"O7QX)_X]_"&/\ L%2__'ZV8/\ @JQ\
M?1:07<UMX.-O*"V4TV0E><<CSN*)UH0^)F,8.:;6RW\NA^RM%?B_K'_!7'XV
M62V_V8^$+AW4F1/[)E'EG/3_ %_-9S?\%@/COD8M?"(_[A4O_P ?JHU%-70Z
MM-T9<DM]-G?=7Z?TMGJ?MC17XG'_ (*__'< $VWA#'_8*E_^/4#_ (*__'<\
M?9_"(/\ V"I?_C]5S(RN?MC17XF_\/@/CQG'V7PC^.E2_P#Q^E7_ (*__'?/
MS6WA''MI4O/_ )'HYD-:G[8T5^)R_P#!7[X\L<?9?"//_4*E_P#C]>H?LQ_\
M%./C%\6_C[X*\':[;^&5TC6-12TN6L].DCEV'KM8RD _@:.9;!YGZPT4@Y H
M/ -4 M%?E!^W/^WS\:/@C^T;X@\)>$O$5E8:':10/#!-I-O.P+)D_.ZDGFO
M/^'J?[1O_0W:;_X(K3_XBE<5S]WJ*_"+_AZG^T;_ -#;IO\ X(K3_P"(K0N_
M^"J'[0DJ6S6_BC3H_DVR9T2U.6]?N\5+E9I$N5FE8_<VBOPD'_!4[]H\]/%N
MFG_N!6G_ ,12P_\ !4W]H^9PH\7:;D_]0*T_^(I\R-$F]$?NU17X;6W_  4V
M_:5DBE8^*-/(4<-_8-K_ /$TC?\ !3?]I.)"\OB[28UZ8;1+3/Y;:R]M"]KF
M;G&,N63LS]RJ*_"^+_@J+^T1+R?&VDH,]#H-KS_XY6E;?\%-/VA;IRJ>.M&
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M\%0?VB8Y/+_X2JR5P?F#Z!:@C\-M$<13EHF7":J*\=3]R**_%>[_ ."CW[1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7;V49CWS.88NF?XOP%6(K^UL6(LH 6Q_KYN3^ [5>U]].5+:XC<W$LR;G4C
M0YY%8=K=P0REC"2IZKNK&-ZL>9I^AM']\XNKMV_K46;6+F1F5YF8$^M23K!J
M$2NF^&54P^[Y@Y]1Z57>Z#[ML*;,Y(QSCZTU&>5&\MBD8YV@\UORI:I6,JL)
M2:45:VQ:M=,59DRPN,C.Q#T^IJPUM<BX:)82$!R8TYJC;S-*AB0[ .134O98
M> YR#]X'FI<9R9K!5*:C)V9//;RAEVAM[=JZ7P[+<B!%:3< >%(!Q6!8W"W4
M@6[EQ".3_> ]JU].;^SV=HV\R(G*R9XQ7M9-B<+A<;">-C>*\KD8INK3?G^A
MW.C3&;5K*.8JBAQEM@S7'>.8[&ZUB[N0TN3*ZE5.02#UKH/#5^LNI(V/-<9.
MT#CIUKEVCD@MY+BZBE8"X8A OW^:ZN)<UR_,L7&>!AR\JMVO>^W_  3QJ<>3
M$)57966SUUOIVZ&18H+AD2"S:9V&TAS\HKH[?3='BB$;1-+JA.TQ(_R+_B:P
M;N^O=1N5BR+2VSD*HVJ@/KZTLL\.F3.MK<^?+T\T X_"OD:D)3LKV?E?\6=E
M2FYZ<S372[_%FU->16"7<#D2.5VKA/E0>P'!/O5OPQ=)-=V[FX=XT!#9(!48
M]JXN"Z?[43OP",$G]:VM-N;>-+M;8.'$6-Q/4_2L:N'M!KJ_^&-Z-'#T;UJL
M;JZNN_E;MW%O];_LW5Y'MD('F;DD9R6Q]:=K'BN[N[YTB5(Y),?,!D\^YK!O
MI)%NQD[U('6DO$#3[X"P88!'H?K73'#T_=;5W8J4:<I:QLGT-[Q1<75C#IL4
MMT\CF+<2'R.:S;C41!IL=LC?>;S"Q'-2^(XS'+IULY+X@7/XUD7,#2.SQD,H
M.  >?RIT81<(W]?Q##S4(<L8[-M>6I8\T*L,QF\Q\_=SR*BF@EO+QRBD[CG/
M:ECMX[3#W)RPY$2]3]?2DFU!IR^XE 1A40<8KI2=[Q.N>)E77+'1?K8Z/PK%
M86@N79?M-P$P-WW ?ZUJW%PQB&]@P ^Z>@K&\*7]G:V<D-X!'!+,OFSJN9$4
M?W:KZIJL1E=8V9X2Q"OW*]L^]?1Y/F=#"0K4:T&V]G\OP(>6N=*.)C43ULUU
M6W3MY[=#&NE9KEG'1FXJWIEO)>ZI!&N%9G49_&H8'!NAE2P[ UJ:6LMC=+>;
M,A6W!B>F#7S=>HW=K=GM8/#QJRCS7<;Z^G4^BOC+\/+OPI%I]V9HY89M/CD!
M3J,KTK]HOV=VW? [P,?72+;K_N"OPS\>_%+4-3T[PW<W81K861&U_P"/;Q7[
MG?L^7 N_@EX(F4!5DTFW8 =LH*^=X=IXFEA^7$ZONO)M'T_$]?*JV'H1RN3Y
M8>[RM=M+^G3\3T*BBBOKS\\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /A'_@L9_R;!HW_8S6G_HJ>OQF0<DD<^]?
MM#_P5]A6?]FO0ED5GB'BBS+A!D[?*GR:_&74;@279\M_-@C_ '<3E=I*@\9%
M<\Y>]RHU=)>R]JWUM;^NG]::$,-JT\=Q*"@6)=S;C@D9QQZUVOPC^*&H?"SQ
M(FIV<%O>0GY+BRNTWPW"=T<=P:X0C<2%']:GA:0Q-"ARKG.,8YKGQ-"GBJ4J
M-97C+1KR.:5.G5CR2COOUN_3\.I[MJOPV\)?%N#^TO -X;+6GC,UUX?NR%_>
M9)86[?Q+Z \UXSJOAO4=&-Q!?VSVDMN^'CF&UP3QT/6J.GZI<Z7=QSVLSP31
MD,KHV"#]:]N\-?'_ $WQ*JV/Q-T$>*;'84^W6Q6*^C&."'QSC X->$X8[+%^
MZO6IKHVN=>2;LI?-I^;/ C'&X*H^1>UIO97M*/3=Z22WL]=]=CQ2QE@@$YF@
M$^4*H#T5NQ_"G:;ICZK<);VH'VAC\B$_>_&O;++X%Z/\4+.\O/AQJQNKV)MS
M:!?X2X,9[HV</SV'->,Z[H-_X5U2XT[4K:2ROK=RLD3Y#*:[\-F%#&2G3I2M
M46\7HUZQ?3S6C[GI8/,L/BW&#T<=7'X9*^]]'\GJBU;^$+ZY\\#RS+'$93%Y
M@W$>@'<^U99T^XABEF,918G"-NX*MZ8_"DM;^:QNDGAE9)4.58<X-7Y+AM2@
M+29DND^;CK(.ISZD5VWJP?O--'HN=&"O9WUZKY=/O_JS-:U.ZU@6T]W.TTH0
M(-YSP.G%=3\(-3OM-U;4WL[<7<36$PN+=B KQ[?FS7%[/.N"0 0>57^E=YHF
MFZIX(FU*^CCB:X73S*\;)D1)(, X^AKBQG)]7="RUV73<]#"5*\)_7W.7N25
MY+5IO;??T>ZO?0X6_LGT^YVSPM$Q 94(Q@'D?I70>&;"RLK*36=1*.(&7R;*
M12!=<_,N1TP*HV5K?>,+Z)9IWD*@)YSC(51TR?05LZTMO:F[T94^UQ1*/L-R
M0R;FR,L%[YY%76J.25%OWNMNW]?.U[&:G3C6E4I6E!7^+=73M=1;=[K3[-]]
M#.UKQ;_;5X+?R3::']H$RZ="V5C. #M.,YQ5779;"35Y$LK>2TL<@1Q2N2RC
MU_&L1E8,P/!!P1Z&I"A!W%]S<>^/QKJA0A3MR:)+^GZ^9O+'U:U.<)I.[3O9
M:)7]U::1U^%66VFB.A%H=,LQJ"VZ36TV8 TV#AL<X7Z=ZPY4#7#>3&T:$X49
MW8]LTX0W#Q1C:[(Q^4X."?:M?0?"VIZQJ0L(XS 8SOD$IV!,=23V-1>-%.<Y
M+_@"Q>*A[--Q<*<;=MVM=;)V>Z6OSL0ZS;V4,=E#8SR7$I0&>-TP4?\ NUKZ
M3JB:%9PW)@ADFEE*AY$^90!Z_C6OX2'ABSU&ZDEEOKG4X$>6WD3:$:11D9SV
M]ZYWQ+KUOKR6)A5(F"OYD2KM"DG.=W?-<*DZTO8N+Y5NWYW?W&&+E5Q:6)HP
MY(3NK:)624=$VY-NZ;5MFWL8BNS77G%0L<DAX!YZYQ5^_AMGG\ZWMGM(7D(1
M9'W8P.5_/^=8\D.V53M9(G.5W'/%6Q=QVD<T!2.YWJ-LC9#1G/5?>O2E&[3B
M=5"I&$)4JB26]WW2TMI>S\M-F]B"ZM?*B699%.\D-&#\RX]15=?+21"<R+W7
MIGVI9@ZOL?AL\]SFI;JT2.Z2++1?*N_>,;2:V3LK-G%*+DW*$;6LM>_S]" 2
M -E5XSD*>:4QL0Y*[<'D'C%"1 LV"=H_B%2B!U1)'B9D<$(Y) )JFT1&$I7N
MM/Z7YE<+A]IX/2GNBP@@DB0'&.,?G3I+=<NV=FT@;&;))J-@7."0,#'TIWN0
MX\EU;4LZ<\'FE;J5X;8CYFB4,V>U>X_L,>7_ ,-??"TQYV?VS#UZUX'@#J0!
MV]Z]Y_827'[7?PMX_P"8U%32]ZXW4;@H-+3KU]/3Y']"HZ"@]#0.@H/0UL0?
MA1_P4R<']K[QB JEUMK7J.H\LU\G6T(A83S+F/LO0FOKO_@I-:M_PU]XRNEY
M:.WM H/<F,U\KPZ)<W3KO&"YPI8XKAE4C&4DV5:<HV;M%#M/C,8-_*-P)Q&C
M'J:ECU>5W<./.)4J2Q/'T]*-=MKFV>.%(@T4 V%D.X9[]*JV,P@1LK]<USV5
M2//O<Z,KDIMU(NSU^[H:MM96>JZ1=)-,+>XA4O ,<.>ZFN3!\L$%>?>K\EP]
MNX9#\I.<5;\03)J4,%W!:K;KL"2;3D,X_B]LUI3O3E9ZI_A_PYT8F2E-.$=>
MIB-)\H'\J$F:,[D.TXQ3"#CTQ3H(C+)C('N:[6DEJ>?%RE)6W'PS[7+$D-CM
M2/EB&ZYILIP=H ],BE0;4'J:+=1N3MR=AZ+O/#5J0:A+96:QGYXF/*'O67;Q
MAGR6VXYJS(Y>R?YON-^E9S49*S.>HE))-'4^ =6F?7HU#F")CRL:_IS2^)]=
MEN=2U.W#R%TDS&0=NW'7(KG_  U=36=]'.G.UU//UKI]0TB.;Q?=.9/+A=?,
M<XZ9%>15A"GB7.2Z?DSGE16(Q$*-.%Y-/YV:9Q,ES([,6.XL,<U9L% C>0KE
M@/E]S4-Y&;:ZDCZJC?F*=;S*)R43!<<#/2O4>L=#><;0N,DC4!C(6WD<8'!-
M;GA&$SW,J,H&V(L3CJ,?SK!59'G\O).#@+FMS1F$&H0P(^7+;9#GJ3V%8XB_
MLVB*J]K'DAO8S8H96>:X:,G8V &'<]*;M\@[R"6!^;/J:U;U)-&:>,@L\DQV
M@\YQ49B "2SQ+ESQ'W+?2I52^O1G32HRK<W*M%N_S^XU_%,37>HV,D*#,5G&
M/<G'4US<\9TIRORO=$Y)'(6NK\9A]*M[)6RD\]LCML ''8"N+_>7756\TG[Y
MZ5CA/>I)_9/-P$%4HJ[TZ>>OZD4CBY/S*?/)Z]C47E,R$]T[=Z>ZRRR#<<$<
M GBK#HZR(T@\MF'!;HU>E>VB/1]G:[BKQ1+HT+3O-;EL!T)Y/4CI3(FCBA=)
M%W-UQZ&CYK54F#;03]T'D&I]6CC<17D/W)1AU]&K%N\M=G^9<*L*$TTOB((H
MGG1ID^1E_459%PWD^3DJ%Z@C&14<=UY>FO&KA=W4'J:I1SF1BLA.3P&HY7*]
M^AZ3K?54N5WYEJ=KXLN_M_@SP]-"I\J 20,=V?FZ].U?T&_LV#'P%\!<8_XD
MUMQ_VS%?SQ312CP!AI0JQW1/E]SD=:_H;_9I_P"2!^ ?^P-;?^BQ48**A"45
MT;_._P"IX="I*49*7\S^YN_ZGIE%%%>B= 4444 %%%% !1110 4444 %%%%
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M $1Z71117H'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;;>B6_\ 6W00-ALC]:]W_82Y_:\^%WK_ &S%7@YS@# ^M>\?L)?\G=_"T?\
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M4IJ+;NG*-I>ZVK)O;>[5G>UO,\J+ R9V\$YP*5Y0TVY1QCA6YHE4!V9.(R>
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MJ*=1)LUJP?M)2;YH]_\ @?\ !*<.J.MO-O2-V?KN7D?3TK^C;]G%M_P(\!L
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MBF7AD=N=OT^M3:-IJ:A]JB>Z2W\N)I%\S/SL/X1CN>U9\GS'/8]!WXJ?=DW
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MS_V$K[_X_0H.X<CO<_ [Y@&(&0?EI&4*JY.<]O2OWR_X=I_LUYS_ ,*OM/\
MP97W_P ?H_X=I_LU_P#1,+3_ ,&=]_\ 'Z?*7RGX&H-QP<;??BFE3C(R0:_?
M3_AVG^S7_P!$OM/_  97W_Q^C_AVG^S7_P!$PM/_  9WW_Q^GRA;0_ O9[4%
M3QC]*_?3_AVG^S7_ -$OM/\ P97W_P ?I/\ AVG^S7_T2^T_\&5]_P#'Z.47
M*?@;M)///OZ5=D1I[(MEG,;=2>@^E?O+_P .TOV:O^B7VG_@SOO_ (_4D?\
MP3:_9NB1T7X8V@5Q@_\ $RO3_P"UZB4&]A\O0_ ;'./Y4%3GG.?I7[[?\.T_
MV:_^B7VG_@ROO_C]'_#M/]FO_HE]I_X,K[_X_5V"Q^!GE8CR1@YQBF8(Z CZ
M"OWU/_!-/]FL_P#-+[3_ ,&=]_\ 'Z/^':7[-?\ T2^T_P#!G??_ !^CE#E/
MP*.2< '-*2QXQP/UK]]/^':7[-?_ $2^T_\ !G??_'Z/^':7[-?_ $2^T_\
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M]$8M+4)6=K'X'K=RH 1G\J=A;MOE39)C\#7[WG_@FI^S60 ?A?:8'_42OO\
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MPK*]S2HHHK< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cgtx-20221231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20221231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '; WH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YN
MZ^(WARVU)M/&JPW%ZN=]O:!KATQP0PC#;2,C@XK(U@7/CWQ+=Z%%<2VF@:9L
M74W@?:]Y*ZAEM@PY5 A5G(()WJHP-U=AIFDV6BV4=GI]I#8VL8PD%O&(T7Z
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M+L;YF/HN?]6OHJX KIL4 <]_PGND?WKO_P %]Q_\;H_X3W2/[UW_ ."^X_\
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M_0I>-O\ PF;O_P")H_X7G9?]"EXV_P#"9N__ (F@#TNBO-/^%YV7_0I>-O\
MPF;O_P")H_X7G9?]"EXV_P#"9N__ (F@#TNN<\=?\@JW_P"ON#_T8*Y9_CQI
ML*-)/X8\96T*#<\TWANZ1(U'5F8KP .2:TKWQ;H_COP/I.O>']1@U;1KZX@D
MMKVV;='*OFXRI[C(/Y4 =R*X7PY_R5CQ=_UYV7_M2NZ%<+X<_P"2L>+O^O.R
M_P#:E '=T444 %%%% !1110 44V218D9W8*JC)9C@ 5D?\)CH/\ T&M._P#
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M<%>$?M=_\B_\._\ L=M,_E+7NZ?<% #JCN/]1)_NG^525'<?ZB3_ '3_ "H
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M+(^,7_1'+#_PL8?_ )'KV2B@#QK_ (6/\8L_\D<L/_"QA_\ D>E_X61\8O\
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M_P"1?^'?_8[:9_*6O=T^X* '5'<?ZB3_ '3_ "J2H[C_ %$G^Z?Y4 8W@?\
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M\_Y$K7O^O&?_ -%M7F?[%O\ R:C\*O\ L7[7_P!!H ]JHHHH **** "BBB@
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MS?\  LL%/YBO2KOX7^#[_47U"Y\+:-<7SOYC7,MA$TA;UW%<YKIE4*    .
M!7E4\$XRG)SEJ[KWGIY=C[_&\3TZ]##T:>&IOV<%&5Z44Y-?:NG>[5D]5M?=
MF?H]QJ4FAVTVIVL,.J&$--;VTF^,28Y56/49[UY)=?';QOH<D_\ ;/P4\3K
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M,D]A6F/C+K_C@;/AWX.N=3M7'RZ]KY;3[#GHR*RF64=<[5'UK\F_^"?GQ/\
M'GQ%_;4\.2^+]6U'Q$+_ .T&\;54,ZLRVY*-AAA6&Q,-P1@<U^X '% &#X*L
M_$=GHV/%.HV6HZM)(TC'3K8PP1*>D:[B68#^\>3Z5OT44 %%%% "'I7CWP0_
MY*3\;O\ L:H?_379U[">E>/?!#_DI/QN_P"QJA_]-=G0![%7!VW_ "7+4O\
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M>?V4?A7_ -B_:_\ H->F>//^1*U[_KQG_P#1;5YG^Q;_ ,FH_"K_ +%^U_\
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MBE0Y5T895A[$$&K% !1110!D>+?#-EXR\-:EHFH1":SOH&@D4^A&*\J_9?\
M@(?@CX=U-;XQS:O?73;YE.?W"DB(9]Q\Q]S[5U_B?4?B3;ZQ<#0M(\-W.E*
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ML&B7NH^.O$&L0S1FZ\.^%K^^N-)@889'U" ((XAD Y63!(&Y>] 'V0OW:6D
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M=#TP>(CJ$GAS7_#SZ=KMQ/'J#7BQQ7,NU)U,QPLR%F,1"#BOOZX\=V'A_P
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MI7PX\9>!M.TVU46X\0:)]@M0BD*(XSO/(';T%>KTBC %+0 444E #)_]2_\
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M]VORD_X)Y_%WX@_$?]M/PXGBSQ#JNMP7;W=S=1W[%XWF6UVK(P(QO CC ;J
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M +36F>+/A;\,?#U_XGB%M)J<NJ:*(=8MKAI=D_VQ9IXI+/;#@I<+#-YAR Q
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M/Q+56W3/H<AQZR_'PG52=*7NSC*_+*#W3LF_-.SLTGT.'_9E^)WB'XO^ O\
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M4FTCN,*J\5UGSYZX\BQJ68A5 R2W %<QK7Q3\'>'5D.I>*='LB@RR2WT8?\
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MR:ZBL3P1X4MO G@O0/#5E)+-9Z-I]OIT$DQ!=HX8UC4M@ 9(49Q6W0 4444
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M6_"G_KA#_P"E+T ?3XKA?#G_ "5CQ=_UYV7_ +4KNA7"^'/^2L>+O^O.R_\
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MK_Z4ST =Y1110 4AZ&EI#T- ' ?![_CU\5_]C)J/_HVO0*\_^#W_ !Z^*_\
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ME<L>N3[\"J=K\(]%M65A-?R,L@D5I;HN00CH!DCG"R,.<GG)R>:7[^RV*?\
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MRX&T$ ,<Q2?]\D]*CT_X2:!I<UW+:I<0O>7"W5R5E_UTJR^:K-QR0W?T '0
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M1D<-D5UU:0Y[>^<.)6'37U=MKK?^O^&[L*2EHK0XPI,4M% "8HQ2T4 %%%%
M!1110 4444 (>E>/?!#_ )*3\;O^QJA_]-=G7L)Z5X]\$/\ DI/QN_[&J'_T
MUV= 'L5<';?\ERU+_L7;7_TIGKO*X.V_Y+EJ7_8NVO\ Z4ST =Y1110 4AZ&
MEI#T- ' ?![_ (]?%?\ V,FH_P#HVO0*\_\ @]_QZ^*_^QDU'_T;7H% !111
M0 4444 %)BEHH **** .?UCX@>'/#VL?V5J>M65AJ'V&74OL]Q*$;[-$0))>
M?X5W#)[9%8%C\?/AYJFOZ?H5EXQT>[UO4+)=0L].BNU,]Q R;T=5ZG<OS =2
M.>E<1^U-^SC>?'W3_#PTC6D\/ZE87,D%U=LI)FTVX0Q7EN,#JZ$8/JHZ=:X2
M/]C/4+#XZW7B2WN](N_"$^KVVN16MY/?+<V-Q!;""-(8HY5@8 (N'=20"RX(
M- '2V/[37PB^,'@$>*RUCJVH^&(G\1+H-U<P"_L'A9XQ*07V(PP>2V!N&<9K
MT>;]H#P#;:Y!X?E\3Z6GBB:R%]'H/VR,W;(8_,"A >6*Y(&>1R..:^=A^PWX
MCC^'VD:!'K6AQW=KX.USP[-,D4BI)<7UPLJ2_=SM4 [L\YZ5UGAW]F+QOX5\
M::F;'6_#$OA75;^+5[M[W37GU..X6R6V:&&1OE2,E PD&'4$J <T >D^$OVH
M?AYXFT#P5J%WXALO#UYXNMUN=+TK5KF.*ZD4MM VAB,D\#G!/ YKUFOAVP_8
M$\1V3>%([C5]"U>RCT+3]%UJTO)M0BBQ:W#RK) D$D8ESO\ NR\*P##TK[=D
MC;[.R1ML;;A6/.* *VMZU:>'='OM4OG,5G9PO<3.%+%44$DX')X%>*?#S]L#
MPIXZL&U/4-'UKPAX>FM%OK'7-=AB6PO(&D$:D312.L;EF7]W(5?!Z<'&/X?^
M%OQ,M=:T07MY(OV:+4H[W5EU(3"YN9W80736SC:ZQ1D@1G&"0 "!FO*X_P!C
MW6?"&F^+M9\2VNBBQNO#USIE[I7PUTB=)=?GDQMNYK0L(EE4C<!$/O,3NQ@4
M ?1H^)WP>^"D&J::?$7A[PI##J3_ &V![A8E6]F4SL&S_P M'7+XZFJ/BO\
M:C\-Z;=>'['PGINI_$K5-<LWU*SM/"HBF!M$(5IWDD=$5-Q"C+9+< 9KQ_X2
M_LK>+;[X>_"G5/%5U;+XNM->?Q3XD34HLRRS/;-!&@VY =$\H<\ JU:'@?\
M93^(/PA'AC7?!NO^&I/%.GV5_I-_:ZM!.;"YM9[Q[F,HT>'22-F'8AN1QUH
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MHVGAQIMF!N,;,O(&X88\$9K '[:>CIXL^*]C=^%=4T_1/ >A+K;7E]#Y$NI
MO(I\F)A]PM'A7;[QYP!S5+3_ -JM]"L_$-M>^!K;3/',NJ:+;16=I<J;>_DU
M1 +262;:#\@1ED)!(\KY<@B@#ZEK@[;_ )+EJ7_8NVO_ *4SU%\$?BM_PMSP
MC=ZC/IKZ/JNF:G=Z+J5BS^8L5U;2&.38_P#$AX8'@X89YJ6V_P"2Y:E_V+MK
M_P"E,] '>4444 %(>AI:0]#0!P'P>_X]?%?_ &,FH_\ HVO0*\_^#W_'KXK_
M .QDU'_T;7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5\_?M%?'#QU\,?''P_P!)\,^![S7=.UC5X[6YNXI[8+."DA,""212
MC_*&WL-N!C.:]I\5>,="\#:1)JOB+6;#0M-C(5KS4KE((@3T&YR!D^E6=(U?
M3/$VF6NIZ9>6NJ:?.HEM[NUD6:*0?WE=<@_44 6;*:2XLX)9H&MI9(U9X'(+
M1L1DJ2."1TXXJ:DR /05S.B?%#P=XE\0WF@Z3XJT74];L\_:-.L[^*6XAQUW
M1JQ88[\<4 =/1129 H H:_=ZA8:+>W&E:>NJZC%$S063W @69P.%,A!"Y]<'
M%>*_LH_$KXE?$;1?$,WQ \,IHQMM6NX+6Y%XCLRK*5$7EK&G"#@2<[^M=WI'
MQ]^'6O>/)_!>G^,=(N_%$+-&VF17 ,A=1ET'9F7NH)([BN^H 6BN.^(WQA\%
M_".TM;GQAXDL- CNG,=N+N3#S,!DA$&6; Y.!QWK>\-^)M)\8:'9ZSH>HVNK
M:5>1B6WO+.4212J>ZL.#0!IUSGCK_D%6_P#U]P?^C!71USGCK_D%6_\ U]P?
M^C!0!T0KA?#G_)6/%W_7G9?^U*[H5POAS_DK'B[_ *\[+_VI0!W=%%% !111
M0 5\T?$?]I;QK\)OB9K&GZ[X4TN]\)1:!>ZY;W&EW<CWMNMO@#[2& 3$C$ !
M#QW)Z5]+UX[J/[,^F:WXM\2ZQJ_C#Q9J]AXAMI+2^\.WEY =-,;(4"K&( XV
MY)7Y^#R<T >4W?[65EXA^$?CN+QA#'I%TFF6Z6SZ=;7-R)WO;1I(X]D:.RE?
MNECP>O%6_@_^V=\(_"WPJ\(:/J?B*_MM1L=)M;:XA/A[4R8Y$B567(ML'!!'
M%>U_";X)Z'\((M1.E7%[=SWZ6T4\]Y*"QC@C\N%0%  VKQG&3U-=!X[\;:5\
M.O"&J^)-7DE73-,C\VX,"F1P,@<*#R>1Q0!XZW[?'P-2Y2W;QC<+<N"R0-H.
MIB1@.I"_9LD#U%22?MW_  6CC9O^$GOCM!./^$=U09_\EJ]"\6S^%])N]&\=
M7FC7>I:G$$L+2ZL;62XN(8[@C(*I]U>A8D<5T?B[Q/IW@WPQJNMZFTGV#3K9
M[FX$8+N(U&3A<\\4 <KX&^->E>/?@O'\2;"TN4TF6RGOH[>7 E9(B_Y$[,C/
M3/->4>%?^"B_P3\0>&](U*^\0W>B76HQAUT^ZT>^DD5NZ!HX"CD?[!(KV_P#
M>^&/%?P]TJXT*PMX/#>JVGGV]D;98D:*0%F!BZ<[CD>YK3M/!7A^PMM*M[?1
M-/@@TG_D'QQVJ!;/C'[D8_=\<?+B@#PP_P#!0W]G\$ _$! 6#,,Z3?\ (4X8
MC_1^@/!]#UJ6V_X*!? >^F>&V\;O=3)R\4&B:C(Z_4"W)'XUV=WJ7PAMO&EO
MX.N+'P\NND-#'9MIB%%,A\PQ>9Y>Q7<C?Y98,V,X-%SK/PH^''Q0\MCI>A^,
M=6MUCD>"!HS)&\GR>:RC8N]Q@%R"Q&.: .6_X;L^"W_0T7W_ (3FJ?\ R+44
M7[>_P.GEECB\87,LL1 DCCT#4V:,GH& MLK^->Q:%XZ\/^)M=UK1M+U2*]U/
M19$BU"WB+%K9V&55CC&2.<9K4M-$T^PO+R[MK*WMKN\*M<SPQA))RHPI=ARQ
M X&<XH \(3]OGX&R7+VR>,;A[F,!G@70=2,B ]"5^S9 /8D5%_P\$^ OE)+_
M ,)RWE2/Y:2?V+J.UW_NJ?L^"WL.:][AT/3K;4[G4H;&WBU&Y18Y[Q(E6:55
M^ZK.!E@.P)XJD/!'AU;*ULQH.F"SM9_M5O;_ &./RX9LD^8BXPKY).X<Y)YH
M \0_X>#_  #_ .A\[LO_ "!]0ZK]X?\ 'OU'<=N]-M/^"AGP U"7RK3Q^MY+
MT\NVTC4)&Z9/"VY/3FO4O&5O\/\ P)H_]IZ_IFD65G]H<*QT]9'DGG&UPB*A
M9Y)!P0H+,.#FLWP_HGPMM]+L_B%HNFZ)IUC:V\L\>KV5L+58XRNR0MM"] FT
M[AD;<<8H XW_ (;L^"W_ $-%]_X3FJ?_ "+4"?M]_ R2[DM4\9SO=QJ'>W70
MM2,J*>A9/LV0#V)'->T^#?%^B?$+PQI_B+P[J":KHNH1^=:WD)8),F2-RYP<
M<&KD'A[2[;5[G5H=.M8M5NHUBGOHX56>5%^ZKR ;F [ G H \+_X;Z^!@NOL
MO_"93_:MN_[/_8.I>9M_O;/LV<>^,5&?^"@7P'"S,?'#A87\N5CHFHXB?^ZQ
M^S_*?8X->\G0-,.L#5CI]J=5$7V<7WDKYXCSG9YF-VW/.,XJL_@_09(;V%M%
MT]H;Z87-W&;5"MQ*""))!CYV! .XY/ H \/?_@H#\!XV97\;NC(P1@VB:B"K
M$9"G-OP2.0.IJ*/_ (*&?L_RS)#'X_22:3&R--(U!F?/3 %ODY[8KW6X\'Z#
M=7$MQ/HNGS3RS)<R2R6J,SRHI5)"2,EE4D!CR <"N&\->%_A1X_U"'5- TC1
M+N[\-7YACN;"U$)M+F,%2N5"Y*AB,<@9- ')?\-V?!;_ *&B^_\ "<U3_P"1
M:A;]OKX&)=+:MXRG6Z92ZVYT'4A(RCJP3[-DCWQBO4?#/Q<\'>,?$EYH.C:[
M!?:K:*S/ F\!U5BC-&Q 64*P*DH6 (P<5TKZ%ITNK1ZH]C;OJ<41@CO6B4S)
M&3DH'QN"D\XSB@#Y"^-G[3?PZ^,EY\.O#/A'6[G5-</BVPO!9MI%[;L88Q)O
M<&6%!A=PSSWK[)3[HJK-I%C<W]M?36<$M[;*ZP7,D8:2(-C>$8\J&P,XZX&:
MN4 %1W'^HD_W3_*I*CN/]1)_NG^5 &-X'_Y%/3/^N(JM>_\ (_:=_P!>4O\
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M!7IS]*@N_P!DKX:76DW6F+HDEM8W/A\^&9(8+EU!LC+YI7.<[RY+%SR23DT
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M ?+/_!-_0-7\*?LX0:3KVBZGH&J0ZK>R/9ZK836DH5Y2R,%D5201W%?4]%%
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M_P"/7Q7_ -C)J/\ Z-KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/'7_(*M_P#K[@_]
M&"NCKG/'7_(*M_\ K[@_]&"@#HA7"^'/^2L>+O\ KSLO_:E=T*X7PY_R5CQ=
M_P!>=E_[4H [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "H[C_42?[I_E4E1W'^HD_P!T_P J
M ,;P/_R*>F?]<15:]_Y'[3O^O*7_ -"%6? __(IZ9_UQ%5KW_D?M._Z\I?\
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M^Z?Y5)4=Q_J)/]T_RH QO __ "*>F?\ 7$56O?\ D?M._P"O*7_T(59\#_\
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MWS6[K(EPJR0R1I;R>8'3"2$)DCYC[P#D4 +1110 5P=M_P ERU+_ +%VU_\
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M3RFFSN$@&/E93RI7&W^'%=+=>#]$O?#JZ!/I5I)HJHL:V'D@0HJD%=JC@;2
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MD"4OL0-+TW@8Z4 >YZ5X,\/Z%-;S:;H6FZ?-;PO;PR6MG'$T43OO=%*@85G
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MPPKY:NBYD)8+DXSNQ\HH ^N/$>@Z#=E=4UBWM!]D7<;JZ(5$53N&\D@%0WS
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M-1_]&UV6N:U9>'-'O=4U&<6UA9PO//,P)$<:C+,< G@ GBN-^#W_ !Z^*_\
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M//+K]AK>C1ZZMG>ZC#/!<[$>9[>2)Y69W4(4VON/0<\< 'T&L$2JJB- %.0
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MO5/PO-XC?P_INKZS=>.IM-O]3OK;5A'+>QW%JB/+]E9(L"5$.4^:(8(VYX%
M'U+Y:8'RKC&.E97B?Q#H_@W1;O6]:N(;#3K6/=/=2J2L:9[X!.*^7;36_&=E
M8A-?U'Q?'K=C%:&%+.&^>*3%PX4R;(BDC&'9Y@.0>I&>:R?'VM>,M>MO&<$>
ME>-)-*OM OXVM+ZPNY@+E+A1$!@% S)DJ(4 *D9+'. #['LY;6_MK>[MS'+#
M+&LD4JC[RD9!'X&I9(XW*LZJQ0Y4D9*GVKQ;QMK&HZ'\._ SFP\32:(T,46K
M#PW;S&_@4P (WEQCS@!)C<$&1W&,UR'B"[\6:7J<MC8'QQ<AY='N;621;F1F
MCW,MQO9/D7@KYB''J0>30!]">']>T?Q/9/=Z7/!=VXEDA9T7'SJ<.I! .0:T
M_L\(Q^[08Z?*.*^6],T&XU?6;2Z6S\30W$%_K,2/:B_LU5VC)B8A=@()& YR
MIZ9K)\4^(/&5[I,!M9?'=E'<QZ/'+-#;7R2*X<I<X^4E3@'>0 #P23P: /KP
M11K(9 BB0C!8#D_C1Y2%BVQ=QZG'-?.D<NN+XLU;19KOQ_IE]IXG^QW\5O/>
M6%U8&+$;L[$QM(K$G Q/D"NH_9]\0ZI!H%MI6O0:W<7T\\HAU"ZCOIH9T11^
M\+7*^9!N_P"><A/.0I(H ]C$,8).Q<GJ<=:78O\ ='3'2G44 ,,,;.'**6 P
M&(Y ]*/*3^XO3'2GT4 4=8TBWUS2[NPN/,6&YC:)VA<QN PP2K#D'W%87@OX
M>6G@X;_MUYJ]TL0MX[O4?*,L<(Z1AHXTR,\_-DY[UU=% $8MXED+B- Y.2P4
M9/XT)!'& %C50#D #&#4E% $;P1R !HU8 Y (S@^M*T2-U13SGD4^B@!J1)&
M"$15!Z[1BD\I,8V+CITI]% "=*6BB@ HHHH **** "H[C_42?[I_E4E1W'^H
MD_W3_*@#&\#_ /(IZ9_UQ%5KW_D?M._Z\I?_ $(59\#_ /(IZ9_UQ%5KW_D?
MM._Z\I?_ $(4 =-47V>'S?-\M/-_O[1N_.I#TKYE@OO$^L0^,TOE\>V?BW3E
MNPT-LES'IES$)0\#VK@;&;:,!8F#,"0X)XH ]_UCQ-H?AK4=(T_4+F&SNM7N
M&@LHF0_OY@I<J"!C. 3SCH:UO+@N$/RQR(3D\ @D5\U:O<:GJWBOPW+/;^))
MM-F\4VUQ&UQ:WI\F)M.82,,J3"@D?'\(5CQ@CCG_  /HFN^$/ =CI\4'C.UE
MGTG5;9XUEU&39?(V^(C+'RR>=KC ;D GH0#ZY**005&">>*$1$SM4+GDX&,U
M\N7U_P"*S<^,-763QI>-I&H6T+:?:B\42V#PQ?:&MX_E$SJP8[HR7'S[>3@Q
MR:[XLT_QEX)DT5?&?B30KAXR--UB.]T^YAA>5_WSS8VR>6IPT-V Y55(;=P0
M#Z?FN[.VNH+:22)+BXW&*(XW.!C<0.X&1D^X]:L;5P!@8'0>E>$^.9]<L/B_
MXQN ]PMH/ Q.C_9U+RBZ$D_F^2J@N7Y@S@9^[[5QFC77B"PTKPF-4N/B/)%K
MFGP7,=_90WEQ+::IN_>)/&>8HRH3Y9D,0^<G!H ^EKKQ%I=AKMCH\]RD6I7L
M<DMO 5.9%3&\@XQQN'&<\U!XC\4Z%X(L[2?5[N#3;:YNX[.%W4A6GE;:B<#@
ML>.>]>"_#9O$^J?$C1+CQ1:^)#XBL[W5H;TSPS_V<D)9/LK)@>0-T8&&CY/S
M!OFS6)\;+'Q9XF\;:KI]YIWB"ZEM?$.BW.@1:<MTVGO8K)$9I)1'^Z+K)YI;
MS,LJA2!C% 'U<T<;*0RJ5(P00,8J""]M)KJ:UBEB:XM\>9$I&Y,C(R.V17RO
M?:9XP\4>%[R.Y/C'^T1HM\OB73YY;I4:Z#(T!M-A YQ)M$#8*X##.*[./4-0
M\.?&_1KRUBU2X\-V_@^-+^&*&6YN3,UR%M_,0AIF8*9"2<D ,3TH ]OU74-,
M\/:;<:AJ5Q:Z=86ZF2:YN76..-<\LS'  ]S4EY<V=OITM[,4-I$AN&D"[AM
MW;A@'/'/'->>?%*"U^(.IV'@*YL[FYL+^&6YU!9+6=;:2$+M$3S*FT$L^[;N
M#?N_P/D/A'QAXGB\'>%/"VN:?XH6VT:]N]#UC4=(L+V$S^4I2SN0X193!( 2
M6CR Q4,=N30!]#Q_$+PU>>$]-\2IJEO-H.H& VM\%8QR>:P6(CC(W,R@$@=1
M6Q9WMEJ'FI",^1*T+!XBF''7&X#/U&0:^-O#VF^+8/!6@Z'KVC^*X;6QT?0)
M=$M;*&\'FS)<1F]%RD7REU(R4F'"@%1U->A207OB+XA:!J5_'XFGM-)\5:@@
M*K?Q)%$86:/*KM#1?*0&PR?PYYP0#Z'TG4[37-/BO;,E[>495GB:,G''W6 (
MZ=Q5IX8Y597175OO!@"#]:^,O &L_$K4? .E)X@G\:6^IOX=SHUTD%X)_P"V
M1/.'6\4@*5VBWVB<>65W'U-=GX9U?7X_BE;W,^I>,G23Q=<6LEO<07IL?L;6
M1)&PQ>6(A.%VOV)(5L$B@#Z;,:$<JO;M^5<\?'_AO_A(X="_M2V;5I)I($MU
MRQ,J1K(Z9 P&".I()S@UXI\9[CX@W/B[Q'8Z*^LVE_Y&G3>$IK(S"QEE$O\
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M\,_$;Q+\#/'>@ZW<:C8>(-1T^>TTZZU"6%[B*=[,+)(IA. GV@R% 3D+CH,
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MX9#Y5TFZ6TNQ'@>81+)."/27I@<>6Z=\)/B.=6BUN3P,()K3PII>E:A:OJD
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M%7?!WP$\40V.EZAJ>CPV_B:V_L#_ (F$E\)I4DMH]EW+N#'.X#GNXX- 'O\
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M\T$-O&K7!.WE8]Q #-TY8 \9-)IOB73]5O[FPBF"ZC:I&]S9M_K(-Z[E#XR
M2.V37S]J7PS\5^(]-\>Z-JW@M)]7F@U1=*\4'5D\JXBN0?*B*;MX90$4AUV+
MMRA-=+\(OA3JG@OXM^.-;OM$M8K;6K?3O(U**2-G+16D44L;#[^2Z,<]#UH
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MF\\)+;^-8K*#2O[>N=51H=:5+Q;@S(%8E0V9'/F*KAV*\@;B ?6$,HFB1U!
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MM<G;?\ERU+_L7;7_ -*9Z .\HHHH *0]#2TAZ&@#@/@]_P >OBO_ +&34?\
MT;7::SK-CX>TJ[U/4[R#3].M(FGN+JYD$<<4:C+,S'@ #O7%_![_ (]?%?\
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M58/^Y"A<<%G)[4 ?0EA\3?"NIO9+::_83B]M?MEJZ3 I-%MW;D;H?E^; .<
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M-R."23DNIY(P!5CQY^SIXI^*-CX6GU?5M&T'6],OC>W5WX?@DB\UQ:20(P)
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M8QNQSBG44 %<';?\ERU+_L7;7_TIGKO*X.V_Y+EJ7_8NVO\ Z4ST =Y1110
M4AZ&EI#T- ' ?![_ (]?%?\ V,FH_P#HVMCXG^/+?X7_  \\1^+;NSNK^UT6
MQFOY;>S3?*Z1J6(49'8=>PR:Q_@]_P >OBO_ +&34?\ T;6[\1_!5M\2?A_X
MD\*7EQ+:6FMZ=<:=+/  9(UEC9"RY!&1NR,\4 <];?'+P]]ITRVO8]0L)[N2
MVM9&GL91#:W5PJF&WEDQM21MZ84G^-,XW#-[Q'X\/A;QW;6>HW5E:^'GT2[U
M&::5&66*2&:W0?/NP587!^7;G*C!.<5S%G\ G2\N$O?$DVH:1J5W8ZGJNG26
M4:K<7MJL(22-@?W2,;: M'AL[.&&3G5^)?P?_P"%F:OONM:EL-+?1KO29;>T
M@ GS.\4@F28M\K(T$9 *,.N<YX #3_CYX6U'7-*T=/[134K^^FTTP26$@^RW
M,5O]I,<[8VQ$P_O%W'##.,D8IZ_'7PQ))I4+375G+J3Q01M=VCH()ICBWCF!
MP8VE)&Q6QNW+TW"LVZ^!<WB'P#:Z%XD\47>IZM;WT.H1:U9VD-C)!+&^084B
M&(BR;D8@DD2/R 0!:F^#5Q;?$J3Q-I'B6XTK3;J.(7NB)9021R20ILB:.5EW
MPC:%5U7A@HQMY) ,?X<_M V^L>&_#8\0KO\ $6IRRQRQ:/92M%$JWSVB2LNY
MC&C,$!)) ).2 ,UW.N?$S1]!\5V7AV;[7/J=RL<C+;6SRK DDGE1O*1]U6?*
MYZ<'.!7GNA?LV?V=;^#8KW78+^3PW>37L-ZFE)!=AY+HW#+%,LFZ-&W&-T^9
M73@@'FNM\:_":+QIXX\.^()[N"W;19%FMWCLP+R-@VYECN0X98Y  DD9#*Z]
M@<$ &?;_ !Y\/6/A?^U;V^N-3C$=_=F73])G7$%K=_9YF,9+$>6Q )S\P4L
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M]H)0KNK'9,KB>0,C*!@C&,5Z#_PJK3+O2$74A#J6OBQ>Q;7I+2)+C:X(;:%
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M/^2L>+O^O.R_]J4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY^;CO8T$:*@)(48RQR?Q- #J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N<\=?\ (*M_^ON#_P!&"NCKG/'7_(*M_P#K[@_]&"@#
MHA7"^'/^2L>+O^O.R_\ :E=T*X7PY_R5CQ=_UYV7_M2@#NZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *CN/\ 42?[I_E4E1W'^HD_W3_*@#&\#_\ (IZ9_P!<15:]_P"1^T[_
M *\I?_0A5GP/_P BGIG_ %Q%5KW_ )'[3O\ KRE_]"% '34444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]K_\
M'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H**Y_
M_A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4_P#H
M5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\ VO\
M\>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^$CU/
M_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]
MK_\ 'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H
M**Y__A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4
M_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\
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M1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]K_\
M'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H**Y_
M_A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4_P#H
M5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\ VO\
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M_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\
MVO\ \>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^
M$CU/_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4
M?^_]K_\ 'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#Q
MZ@#H**Y__A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\
MX2/4_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'
M_O\ VO\ \>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\
M'J/^$CU/_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>cgtx-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 5:54:24 PM-->
<!--Modified on: 3/22/2023 5:54:24 PM-->
<xsd:schema targetNamespace="http://www.cogrx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:cgtx="http://www.cogrx.com/20221231" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2) (Imported)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40401 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" id="DisclosureCommitmentsAndContingenciesLeasesDetailss">
        <link:definition>40601 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40702 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" id="DisclosureIncomeTaxesNetLossDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Net loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" id="DisclosureDescriptionOfBusinessAndFinancialConditionDetails">
        <link:definition>40101 - Disclosure - Description of Business and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails">
        <link:definition>40302 - Disclosure - Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails">
        <link:definition>40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" id="DisclosureOtherCurrentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>40801 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>40802 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" id="DisclosureEquityBasedCompensationDetails">
        <link:definition>40901 - Disclosure - Equity-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" id="DisclosureEquityBasedCompensationFairValueOfOptionsDetails">
        <link:definition>40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" id="DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>40904 - Disclosure - Equity-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" id="DisclosureEquityBasedCompensationCompensationExpenseDetails">
        <link:definition>40905 - Disclosure - Equity-based Compensation - Compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" id="DisclosureNetLossPerShareAntidilutiveEffectDetails">
        <link:definition>41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41204 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41301 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" id="DisclosureDescriptionOfBusinessAndFinancialCondition">
        <link:definition>10101 - Disclosure - Description of Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" id="DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>10301 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10401 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" id="DisclosureOtherCurrentLiabilities">
        <link:definition>10601 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>10801 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" id="DisclosureEquityBasedCompensation">
        <link:definition>10901 - Disclosure - Equity-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>11101 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30403 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30703 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>30803 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" id="DisclosureEquityBasedCompensationTables">
        <link:definition>30903 - Disclosure - Equity-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31003 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" id="DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails">
        <link:definition>40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails">
        <link:definition>40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" id="DisclosureEquityBasedCompensationActivityForOptionsDetails">
        <link:definition>40903 - Disclosure - Equity-based Compensation - Activity for options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>41002 - Disclosure - Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>41101 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:element name="SeriesaConvertiblePreferredStockMember" id="cgtx_SeriesaConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBConvertiblePreferredStockMember" id="cgtx_SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesA1ConvertiblePreferredStockMember" id="cgtx_SeriesA1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesA2ConvertiblePreferredStockMember" id="cgtx_SeriesA2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesB1ConvertiblePreferredStockMember" id="cgtx_SeriesB1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantIncome" id="cgtx_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAdjustmentOfDerivativeLiability" id="cgtx_FairValueAdjustmentOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAdjustmentOfSimpleAgreementsForFutureEquity" id="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgtx_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" id="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" id="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInGrantReceivables" id="cgtx_IncreaseDecreaseInGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredOfferingCostsIncludedInAccountsPayable" id="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromSimpleAgreementsForFutureEquity" id="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" id="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConvertibleInstrumentsPolicyTextBlock" id="cgtx_ConvertibleInstrumentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantIncomePolicyPolicyTextBlock" id="cgtx_GrantIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmergingGrowthCompanyPolicyTextBlock" id="cgtx_EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReverseStockSplitPolicyTextBlock" id="cgtx_ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceInitialPublicOfferingGross" id="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConversionOfPreferredStockMember" id="cgtx_ConversionOfPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConversionOfSimpleAgreementsForFutureEquityMember" id="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AllowanceForCreditLossGrantsReceivableCurrent" id="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SimpleAgreementsForFutureEquityMember" id="cgtx_SimpleAgreementsForFutureEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputDiscountUponConversionMember" id="cgtx_MeasurementInputDiscountUponConversionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputDiscountUponImpliedReturnMember" id="cgtx_MeasurementInputDiscountUponImpliedReturnMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" id="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" id="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" id="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SimpleAgreementsForFutureEquityMeasurementInput" id="cgtx_SimpleAgreementsForFutureEquityMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="cgtx_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaycheckProtectionProgramLoanMember" id="cgtx_PaycheckProtectionProgramLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" id="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOverWhichUnforgivenPppLoanPayable" id="cgtx_PeriodOverWhichUnforgivenPppLoanPayable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LoanDeferralPaymentsPeriod" id="cgtx_LoanDeferralPaymentsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmendedAndRestatedEquityIncentivePlan2017Member" id="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" id="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationInterestExpensePercent" id="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingLossCarryForwardsSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryForwardsNotSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentTaxCreditCarryForwards" id="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityConversionOfStockAmountConverted" id="cgtx_TemporaryEquityConversionOfStockAmountConverted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityConversionOfStockSharesConverted" id="cgtx_TemporaryEquityConversionOfStockSharesConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PrepaymentOfInsuranceThroughThirdPartyFinancing" id="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherCurrentLiabilitiesTextBlock" id="cgtx_OtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InsurancePremiumFinancingAgreementMember" id="cgtx_InsurancePremiumFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityIncentivePlan2021Member" id="cgtx_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cgtx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesAvailableForFutureIssuanceUnder2021PlanMember" id="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesAvailableForFutureIssuanceUnderEsppMember" id="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceNewYorkMember" id="cgtx_OfficeSpaceNewYorkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LaboratoryAndOfficeSpacePittsburghPaMember" id="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" id="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" id="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" id="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" id="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredGrantIncomeCurrent" id="cgtx_DeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInDeferredGrantIncomeCurrent" id="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseAssets" id="cgtx_OperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OfficeSpaceLocatedInPittsburghPaMember" id="cgtx_OfficeSpaceLocatedInPittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cgtx_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" id="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LegalReservesProfessionalFeesAndOtherAccrualsCurrent" id="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumAggregateOfferingPrice" id="cgtx_MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingMember" id="cgtx_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" id="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityLineFinancingMember" id="cgtx_EquityLineFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LincolnParkCapitalFundLlcMember" id="cgtx_LincolnParkCapitalFundLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseAgreementTerm" id="cgtx_PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumValueOfStockToBeIssuedUnderAgreement" id="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>cgtx-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 5:54:24 PM-->
<!--Modified on: 3/22/2023 5:54:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetailss" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638151044630612087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638151044630612087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044630612087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151044630612087" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044630612087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638151044630612087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151044630612087" xlink:to="us-gaap_GrantsReceivableCurrent_638151044630612087" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151044630612087" xlink:to="us-gaap_PrepaidExpenseCurrent_638151044630622101" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151044630612087" xlink:to="us-gaap_OtherReceivablesNetCurrent_638151044630622101" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151044630622101" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151044630622101" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets_638151044630622101" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638151044630622101" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151044630622101" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044630622101" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638151044630622101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151044630622101" xlink:to="us-gaap_LiabilitiesCurrent_638151044630622101" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151044630622101" xlink:to="us-gaap_AccountsPayableCurrent_638151044630632083" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151044630622101" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151044630632083" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151044630622101" xlink:to="cgtx_DeferredGrantIncomeCurrent_638151044630632083" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151044630622101" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044630632083" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151044630622101" xlink:to="us-gaap_OtherLiabilitiesCurrent_638151044630632083" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151044630622101" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638151044630632083" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638151044630632083" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044630632083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044630632083" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638151044630642078" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151044630642078" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151044630642078" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151044630642078" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638151044630642078" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151044630642078" xlink:to="us-gaap_AdditionalPaidInCapital_638151044630642078" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151044630642078" xlink:to="us-gaap_CommonStockValue_638151044630642078" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638151044630642078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151044630642078" xlink:to="us-gaap_PreferredStockValue_638151044630642078" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044630652080" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638151044630652080" order="2" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2) (Imported)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637659674142902505" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637659674142902505" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044630652080" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637659674142902505" xlink:to="us-gaap_NetIncomeLoss_638151044630652080" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638151044630652080" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="cgtx_GrantIncome_638151044630652080" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044630652080" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="us-gaap_OtherNoncashIncomeExpense_638151044630652080" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044630652080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044630652080" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="us-gaap_InterestIncomeExpenseNet_638151044630662081" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638151044630652080" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044630662081" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638151044630652080" xlink:to="us-gaap_OperatingIncomeLoss_638151044630662081" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638151044630662081" xlink:to="us-gaap_OperatingExpenses_638151044630662081" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638151044630662081" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638151044630662081" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638151044630662081" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638151044630662081" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044630662081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044630662081" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044630672080" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044630672080" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638151044630672080" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" xlink:to="us-gaap_ProceedsFromWarrantExercises_638151044630672080" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044630672080" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638151044630672080" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151044630672080" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151044630672080" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151044630672080" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638151044630672080" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638151044630672080" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638151044630682079" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638151044630682079" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638151044630682079" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638151044630682079" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638151044630682079" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151044630682079" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638151044630682079" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638151044630682079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_ShareBasedCompensation_638151044630682079" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044630692078" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044630692078" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044630692078" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638151044630692078" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638151044630692078" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_AmortizationOfFinancingCosts_638151044630692078" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638151044630692078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638151044630692078" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044630702077" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044630672080" xlink:to="us-gaap_NetIncomeLoss_638151044630702077" order="17" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151044630702077" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151044630702077" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151044630702077" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151044630702077" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638151044630702077" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638151044630702077" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151044630712082" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638151044630712082" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638151044630712082" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xlink:type="extended" xlink:title="40601 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044630712082" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044630712082" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset_1" xlink:to="cgtx_OperatingLeaseAssets_638151044630712082" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151044630712082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151044630712082" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151044630722082" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151044630722082" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151044630722082" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151044630722082" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151044630722082" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638151044630722082" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638151044630722082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638151044630722082" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151044630732081" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638151044630732081" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_638151044630732081" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638151044630732081" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151044630732081" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151044630732081" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151044630732081" order="7" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044630732081" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638151044630732081" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044630732081" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638151044630732081" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044630732081" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638151044630742084" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638151044630742084" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638151044630742084" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsGross_638151044630742084" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638151044630742084" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsOther_638151044630742084" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638151044630742084" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638151044630742084" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151044630742084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151044630742084" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638151044630752079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638151044630752079" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151044630752079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151044630742084" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151044630752079" order="7" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>cgtx-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 5:54:24 PM-->
<!--Modified on: 3/22/2023 5:54:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStockAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStockDetails" roleURI="http://www.cogrx.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureNetLossPerShareAntidilutiveEffectDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cgtx-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesaConvertiblePreferredStockMember" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesBConvertiblePreferredStockMember" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="cgtx_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xlink:to="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockAmountConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockAmountConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cgtx_TemporaryEquityConversionOfStockAmountConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockSharesConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cgtx_TemporaryEquityConversionOfStockAmountConverted" xlink:to="cgtx_TemporaryEquityConversionOfStockSharesConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfPreferredStockMember" xlink:label="cgtx_ConversionOfPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cgtx_ConversionOfPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_GrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_DeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMember" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="cgtx_SimpleAgreementsForFutureEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponConversionMember" xlink:label="cgtx_MeasurementInputDiscountUponConversionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="cgtx_MeasurementInputDiscountUponConversionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponImpliedReturnMember" xlink:label="cgtx_MeasurementInputDiscountUponImpliedReturnMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="cgtx_MeasurementInputDiscountUponImpliedReturnMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputControlPremiumMember" xlink:label="us-gaap_MeasurementInputControlPremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputControlPremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMember" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="cgtx_SimpleAgreementsForFutureEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramLoanMember" xlink:label="cgtx_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMeasurementInput" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_SimpleAgreementsForFutureEquityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PeriodOverWhichUnforgivenPppLoanPayable" xlink:label="cgtx_PeriodOverWhichUnforgivenPppLoanPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_PeriodOverWhichUnforgivenPppLoanPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LoanDeferralPaymentsPeriod" xlink:label="cgtx_LoanDeferralPaymentsPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cgtx_LoanDeferralPaymentsPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AdjustmentForAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_OfficeSpaceNewYorkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesaConvertiblePreferredStockMember" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesBConvertiblePreferredStockMember" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfPreferredStockMember" xlink:label="cgtx_ConversionOfPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cgtx_ConversionOfPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cgtx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cgtx_PurchaseAgreementTerm" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>cgtx-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 5:54:24 PM-->
<!--Modified on: 3/22/2023 5:54:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredGrantIncomeCurrent" xlink:to="cgtx_DeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current portion of deferred grant income as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income and other liabilities, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 250,000,000 shares authorized at December 31, 2022 and December 31, 2021; 28,991,548 and 22,230,032 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncome" xlink:to="cgtx_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income related to grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in the fair value of derivative liability during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of the derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of the derivative liability</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value adjustment of simple agreements for future equity during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment Of Simple Agreements For Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of the Simple Agreements for Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of the Simple Agreements for Future Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends and Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock (as converted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesaConvertiblePreferredStockMember" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SeriesaConvertiblePreferredStockMember" xlink:to="cgtx_SeriesaConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:to="cgtx_SeriesA1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A-1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:to="cgtx_SeriesA2ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A-2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesBConvertiblePreferredStockMember" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SeriesBConvertiblePreferredStockMember" xlink:to="cgtx_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:to="cgtx_SeriesB1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series B-1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-1 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_FollowOnPublicOfferingMember" xlink:to="cgtx_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to follow on pubic offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B-1 convertible preferred stock upon conversion of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock upon conversion of debt (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xlink:to="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross value of stock issued during the period upon the conversion of simple agreements for future equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion Of Simple Agreements For Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of SAFE into common stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" xlink:to="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of the conversion of simple agreements for future equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion Of Simple Agreements For Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of SAFE into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross value of temporary stock issued during the period upon the conversion of convertible Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Values Conversion Of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of temporary shares issued during the period as a result of the conversion of convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt (in shares)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockAmountConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockAmountConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_TemporaryEquityConversionOfStockAmountConverted" xlink:to="cgtx_TemporaryEquityConversionOfStockAmountConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_TemporaryEquityConversionOfStockAmountConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_TemporaryEquityConversionOfStockAmountConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockSharesConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_TemporaryEquityConversionOfStockSharesConverted" xlink:to="cgtx_TemporaryEquityConversionOfStockSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, discounts and offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInGrantReceivables" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase and decrease in grant receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Grant Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in current deferred grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, current and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on loan payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from simple agreements for future equity ("SAFEs) entered into by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Simple Agreements for Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from simple agreements for future equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Simple Agreements for Future Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prepayment of insurance through third-party financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of Insurance Through Third Party Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of insurance through third-party financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remeasurement of right-of-use asset and operating lease liability</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Included In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock in initial public offering</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of the financial instrument issued [noncash or part noncash] in the conversion of Simple Agreements For Future Equity into common stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Simple Agreements For Future Equity Into Common Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Simple Agreements for Future Equity into common stock in initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OtherCurrentLiabilitiesTextBlock" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entire disclosure of other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" xlink:label="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" xlink:to="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Excludes preferred stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure Excluding Preferred Stock And Warrants [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConvertibleInstrumentsPolicyTextBlock" xlink:label="cgtx_ConvertibleInstrumentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ConvertibleInstrumentsPolicyTextBlock" xlink:to="cgtx_ConvertibleInstrumentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ConvertibleInstrumentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for Convertible Instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ConvertibleInstrumentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Instruments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ConvertibleInstrumentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Instruments</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncomePolicyPolicyTextBlock" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ReverseStockSplitPolicyTextBlock" xlink:label="cgtx_ReverseStockSplitPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ReverseStockSplitPolicyTextBlock" xlink:to="cgtx_ReverseStockSplitPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split policy disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Impact of Adoption of ASC 842</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of financial assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of changes in fair value of Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant unobservable inputs for SAFE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of options granted using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity for options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total equity-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding potentially dilutive common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the expected income tax (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AtMarketOfferingMember" xlink:to="cgtx_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Conversion Description [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfPreferredStockMember" xlink:label="cgtx_ConversionOfPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ConversionOfPreferredStockMember" xlink:to="cgtx_ConversionOfPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ConversionOfPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ConversionOfPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to conversion of simple agreements for future equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Simple Agreements For Future Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald And Co and B Riley Securities Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into SAFE</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumAggregateOfferingPrice" xlink:to="cgtx_MaximumAggregateOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity impact of the value of new stock to be issued under an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value of stock to be issued under agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for credit loss on grants receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Credit Loss, Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts on grants receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Priced in Active Markets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMember" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SimpleAgreementsForFutureEquityMember" xlink:to="cgtx_SimpleAgreementsForFutureEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to simple agreements for future equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SAFE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of the Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value recognized upon the issuance of SAFE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value recognized upon conversion into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponConversionMember" xlink:label="cgtx_MeasurementInputDiscountUponConversionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MeasurementInputDiscountUponConversionMember" xlink:to="cgtx_MeasurementInputDiscountUponConversionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MeasurementInputDiscountUponConversionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input representing discount upon conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MeasurementInputDiscountUponConversionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount upon conversion</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponImpliedReturnMember" xlink:label="cgtx_MeasurementInputDiscountUponImpliedReturnMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MeasurementInputDiscountUponImpliedReturnMember" xlink:to="cgtx_MeasurementInputDiscountUponImpliedReturnMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MeasurementInputDiscountUponImpliedReturnMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input representing discount upon implied return.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MeasurementInputDiscountUponImpliedReturnMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount upon implied return</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" xlink:to="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input representing probability of initial public offering occurrence.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of initial public offering occurrence</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" xlink:to="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input representing probability of dissolution event occurrence.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of dissolution event occurrence</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" xlink:to="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input representing probability of equity financing occurrence.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of equity financing occurrence</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputControlPremiumMember" xlink:label="us-gaap_MeasurementInputControlPremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputControlPremiumMember" xlink:to="us-gaap_MeasurementInputControlPremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputControlPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of change of control occurrence</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramLoanMember" xlink:label="cgtx_PaycheckProtectionProgramLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PaycheckProtectionProgramLoanMember" xlink:to="cgtx_PaycheckProtectionProgramLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to loan from Paycheck Protection Program (the "PPP"), a program implemented by the U.S. Small Business Administration (the "SBA") under the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") (the "PPP Loan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PPP Loan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMeasurementInput" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SimpleAgreementsForFutureEquityMeasurementInput" xlink:to="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure simple agreements for future equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Simple Agreements for Future Equity, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" xlink:to="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier applied on average monthly payroll expenses in PPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paycheck Protection Program Average Monthly Payroll Expenses Multiplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier applied on average monthly payroll expenses</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PeriodOverWhichUnforgivenPppLoanPayable" xlink:label="cgtx_PeriodOverWhichUnforgivenPppLoanPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PeriodOverWhichUnforgivenPppLoanPayable" xlink:to="cgtx_PeriodOverWhichUnforgivenPppLoanPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PeriodOverWhichUnforgivenPppLoanPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which unforgiven portion of PPP loan payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PeriodOverWhichUnforgivenPppLoanPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which unforgiven portion of PPP loan payable</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LoanDeferralPaymentsPeriod" xlink:label="cgtx_LoanDeferralPaymentsPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LoanDeferralPaymentsPeriod" xlink:to="cgtx_LoanDeferralPaymentsPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LoanDeferralPaymentsPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which deferral of payments done.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LoanDeferralPaymentsPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Deferral Payments Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LoanDeferralPaymentsPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferral payments period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation, benefits, and related accruals</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AccruedResearchAndDevelopmentExpenses" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Reserves, Professional Fees and Other Accruals, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal reserves, professional fees, and other accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_InsurancePremiumFinancingAgreementMember" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to insurance premium financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Periodic payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLeaseAssets" xlink:to="cgtx_OperatingLeaseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating lease assets as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceNewYorkMember" xlink:to="cgtx_OfficeSpaceNewYorkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to New York office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space, New York</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to laboratory and office space in Pittsburgh, PA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory And Office Space, Pittsburgh, PA</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to office space located in Pittsburgh, Pennsylvania.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space located In Pittsburgh, PA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of buyout options in dollars in an operating lease under the lessee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number of Buyout Options in Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of option at conclusion of the lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows used for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityIncentivePlan2021Member" xlink:to="cgtx_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">.Represents information relating to 2021 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmployeeStockPurchasePlanMember" xlink:to="cgtx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and Restated 2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of common shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that may be recycled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value - Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life -Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options granted during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options exercised during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which the unrecognized compensation cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Shares available for future issuance under 2021 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available For Future Issuance Under 2021 Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Shares available for future issuance under ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available For Future Issuance Under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive common stock equivalents outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of employees' compensation per person per year matched by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contributions to the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax computed at federal statutory rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D Credit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:to="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Interest Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible stock compensation (as percentage)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" xlink:to="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Fair Value Adjustment, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets after valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Operating Lease, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that expire</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are not subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that do not expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of federal research and development tax credit carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Tax Credit Carry Forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityLineFinancingMember" xlink:to="cgtx_EquityLineFinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LincolnParkCapitalFundLlcMember" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Lincoln Park Capital Fund, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park Capital Fund LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PurchaseAgreementTerm" xlink:to="cgtx_PurchaseAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>cgtx-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 5:54:24 PM-->
<!--Modified on: 3/22/2023 5:54:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureDescriptionOfBusinessAndFinancialCondition" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurements" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureAccruedExpenses" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureOtherCurrentLiabilities" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStock" roleURI="http://www.cogrx.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensation" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureNetLossPerShare" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureRetirementPlan" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStockTables" roleURI="http://www.cogrx.com/role/DisclosureCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationTables" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStockAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureCommonStockDetails" roleURI="http://www.cogrx.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationActivityForOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureNetLossPerShareAntidilutiveEffectDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638151044631382093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638151044631382093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638151044631382093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638151044631382093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638151044631382093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638151044631382093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638151044631382093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638151044631382093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638151044631382093" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638151044631392088" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638151044631392088" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638151044631392088" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638151044631392088" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638151044631392088" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638151044631392088" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638151044631392088" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638151044631392088" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638151044631392088" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638151044631392088" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638151044631392088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638151044631392088" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638151044631402078" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638151044631402078" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638151044631402078" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638151044631402078" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638151044631402078" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638151044631402078" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638151044631402078" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638151044631402078" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638151044631402078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638151044631402078" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638151044631412079" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638151044631412079" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638151044631412079" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638151044631412079" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638151044631412079" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638151044631412079" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638151044631412079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638151044631412079" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638151044631422076" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638151044631422076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631422076" xlink:to="us-gaap_AssetsCurrentAbstract_638151044631422076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151044631422076" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044631422076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151044631422076" xlink:to="us-gaap_GrantsReceivableCurrent_638151044631422076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151044631422076" xlink:to="us-gaap_PrepaidExpenseCurrent_638151044631422076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151044631422076" xlink:to="us-gaap_OtherReceivablesNetCurrent_638151044631422076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151044631422076" xlink:to="us-gaap_AssetsCurrent_638151044631422076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151044631422076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631422076" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151044631422076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631422076" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151044631432079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631422076" xlink:to="us-gaap_OtherAssets_638151044631432079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631422076" xlink:to="us-gaap_Assets_638151044631432079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="us-gaap_AccountsPayableCurrent_638151044631432079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151044631432079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="cgtx_DeferredGrantIncomeCurrent_638151044631432079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044631432079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="us-gaap_OtherLiabilitiesCurrent_638151044631432079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638151044631432079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631432079" xlink:to="us-gaap_LiabilitiesCurrent_638151044631432079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631442077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638151044631442077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_Liabilities_638151044631442077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_CommitmentsAndContingencies_638151044631442077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_TemporaryEquityAbstract_638151044631442077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_638151044631442077" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631442077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_StockholdersEquityAbstract_638151044631442077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_PreferredStockValue_638151044631442077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638151044631442077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_CommonStockValue_638151044631442077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_AdditionalPaidInCapital_638151044631452075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638151044631452075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151044631452075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151044631442077" xlink:to="us-gaap_StockholdersEquity_638151044631452075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151044631432079" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638151044631452075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638151044631452075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638151044631452075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638151044631462080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesAuthorized_638151044631462080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesIssued_638151044631462080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesOutstanding_638151044631462080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638151044631462080" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_638151044631462080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_638151044631462080" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_638151044631462080" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_638151044631462080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638151044631462080" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638151044631462080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638151044631462080" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638151044631462080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638151044631462080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638151044631462080" xlink:to="us-gaap_OperatingExpenses_638151044631462080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638151044631462080" xlink:to="us-gaap_OperatingIncomeLoss_638151044631472080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="cgtx_GrantIncome_638151044631472080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631472080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631472080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="us-gaap_OtherNoncashIncomeExpense_638151044631472080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631472080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="us-gaap_InterestIncomeExpenseNet_638151044631472080" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638151044631472080" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638151044631472080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638151044631472080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044631472080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044631472080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638151044631482078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044631482078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638151044631482078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638151044631482078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638151044631482078" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151044631482078" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151044631482078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151044631482078" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638151044631492080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631492080" xlink:to="us-gaap_StatementClassOfStockAxis_638151044631492080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="us-gaap_ConvertiblePreferredStockMember_638151044631492080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesaConvertiblePreferredStockMember" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="cgtx_SeriesaConvertiblePreferredStockMember_638151044631492080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="cgtx_SeriesA1ConvertiblePreferredStockMember_638151044631492080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="cgtx_SeriesA2ConvertiblePreferredStockMember_638151044631492080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesBConvertiblePreferredStockMember" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="cgtx_SeriesBConvertiblePreferredStockMember_638151044631492080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="cgtx_SeriesB1ConvertiblePreferredStockMember_638151044631492080" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631492080" xlink:to="us-gaap_ClassOfStockDomain_638151044631492080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631492080" xlink:to="us-gaap_StatementEquityComponentsAxis_638151044631492080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151044631492080" xlink:to="us-gaap_CommonStockMember_638151044631492080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638151044631492080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151044631492080" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638151044631492080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151044631492080" xlink:to="us-gaap_RetainedEarningsMember_638151044631502080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151044631492080" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638151044631502080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151044631492080" xlink:to="us-gaap_EquityComponentDomain_638151044631502080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631492080" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044631502080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631502080" xlink:to="us-gaap_IPOMember_638151044631502080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631502080" xlink:to="cgtx_FollowOnPublicOfferingMember_638151044631502080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631502080" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631502080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631492080" xlink:to="us-gaap_StatementLineItems_638151044631502080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631502080" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151044631502080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockholdersEquity_638151044631502080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_SharesOutstanding_638151044631512079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="cgtx_StockIssuedDuringPeriodValueWarrantsExercised_638151044631512079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="cgtx_StockIssuedDuringPeriodSharesWarrantsExercised_638151044631512079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638151044631512079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044631512079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638151044631512079" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_638151044631512079" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638151044631512079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638151044631512079" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638151044631612087" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_638151044631612087" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity_638151044631612087" xlink:to="cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity_638151044631612087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638151044631612087" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044631612087" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638151044631612087" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044631612087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_NetIncomeLoss_638151044631612087" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_StockholdersEquity_638151044631622085" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638151044631502080" xlink:to="us-gaap_SharesOutstanding_638151044631622085" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631502080" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631622085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638151044631622085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_638151044631622085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt_638151044631622085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:label="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_638151044631632079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt_638151044631632079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockAmountConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockAmountConverted_638151044631632079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="cgtx_TemporaryEquityConversionOfStockAmountConverted_638151044631632079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_TemporaryEquityConversionOfStockSharesConverted" xlink:label="cgtx_TemporaryEquityConversionOfStockSharesConverted_638151044631632079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_TemporaryEquityConversionOfStockAmountConverted_638151044631632079" xlink:to="cgtx_TemporaryEquityConversionOfStockSharesConverted_638151044631632079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631632079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638151044631632079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638151044631632079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638151044631622085" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638151044631632079" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StatementTable_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631642081" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" xlink:to="us-gaap_IPOMember_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" xlink:to="cgtx_FollowOnPublicOfferingMember_638151044631642081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631642081" xlink:to="us-gaap_StatementLineItems_638151044631642081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631642081" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631642081" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631642081" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638151044631642081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" xlink:to="us-gaap_IPOMember_638151044631642081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631642081" xlink:to="cgtx_FollowOnPublicOfferingMember_638151044631652081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044631642081" xlink:to="us-gaap_StatementLineItems_638151044631652081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_NetIncomeLoss_638151044631652081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638151044631652081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_ShareBasedCompensation_638151044631652081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638151044631652081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_AmortizationOfFinancingCosts_638151044631652081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638151044631652081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631652081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631652081" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631662126" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631662126" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151044631652081" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638151044631662126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151044631662126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638151044631662126" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638151044631662126" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638151044631662126" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638151044631662126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638151044631662126" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638151044631672094" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638151044631672094" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151044631662126" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151044631672094" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151044631672094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151044631672094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151044631672094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638151044631672094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638151044631672094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638151044631682092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044631682092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044631682092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_ProceedsFromWarrantExercises_638151044631682092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151044631672094" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151044631682092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044631682092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638151044631682092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638151044631682092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_638151044631692091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638151044631692091" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151044631692091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381510446316920911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638151044631692091" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381510446316920911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044631652081" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638151044631692091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638151044631692091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_638151044631692091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_638151044631692091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_638151044631702088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" xlink:to="us-gaap_ConversionOfStockAmountIssued1_638151044631702088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_638151044631702088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638151044631692091" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued_638151044631702088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business and Financial Condition" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638151044631702088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638151044631702088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638151044631712088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638151044631712088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Financial Instruments and Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638151044631712088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638151044631712088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638151044631712088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638151044631712088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638151044631712088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638151044631712088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_638151044631712088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_638151044631712088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638151044631722090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638151044631722090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="10801 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock" xlink:label="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_638151044631722090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock_638151044631722090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Equity-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638151044631722090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638151044631722090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638151044631722090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638151044631722090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlan" xlink:type="extended" xlink:title="11101 - Disclosure - Retirement Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638151044631732104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638151044631732104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638151044631732104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638151044631732104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638151044631732104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_3" xlink:to="us-gaap_SubsequentEventsTextBlock_638151044631732104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638151044631732104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638151044631732104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638151044631742091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638151044631742091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638151044631742091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638151044631742091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638151044631742091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConvertibleInstrumentsPolicyTextBlock" xlink:label="cgtx_ConvertibleInstrumentsPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_ConvertibleInstrumentsPolicyTextBlock_638151044631742091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_638151044631742091" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638151044631742091" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638151044631742091" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638151044631742091" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638151044631742091" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638151044631742091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638151044631742091" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638151044631752091" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638151044631752091" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638151044631752091" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638151044631752091" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_638151044631752091" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638151044631752091" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ReverseStockSplitPolicyTextBlock" xlink:label="cgtx_ReverseStockSplitPolicyTextBlock_638151044631752091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_ReverseStockSplitPolicyTextBlock_638151044631752091" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638151044631762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638151044631762091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638151044631762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638151044631762091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638151044631762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638151044631762091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638151044631762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638151044631762091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638151044631762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638151044631762091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638151044631772096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LeaseCostTableTextBlock_638151044631772096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638151044631772096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStockTables" xlink:type="extended" xlink:title="30803 - Disclosure - Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_638151044631772096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Equity-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638151044631772096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638151044631772096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638151044631772096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638151044631782093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638151044631782093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638151044631782093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638151044631782093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638151044631782093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638151044631782093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638151044631782093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" xlink:to="us-gaap_SubsequentEventTypeAxis_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638151044631792090" xlink:to="us-gaap_SubsequentEventTypeDomain_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638151044631792090" xlink:to="us-gaap_SubsequentEventMember_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044631792090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631792090" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" xlink:to="cgtx_FollowOnPublicOfferingMember_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" xlink:to="us-gaap_IPOMember_638151044631792090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" xlink:to="us-gaap_OverAllotmentOptionMember_638151044631792090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631792090" xlink:to="cgtx_AtMarketOfferingMember_638151044631792090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631792090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631792090" xlink:to="us-gaap_ConversionOfStockNameDomain_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfPreferredStockMember" xlink:label="cgtx_ConversionOfPreferredStockMember_638151044631792090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_638151044631792090" xlink:to="cgtx_ConversionOfPreferredStockMember_638151044631792090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_638151044631792090" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_638151044631802090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" xlink:to="srt_CounterpartyNameAxis_638151044631802090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638151044631802090" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638151044631802090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151044631802090" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638151044631802090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638151044631792090" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044631802090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_SharesIssuedPricePerShare_638151044631802090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638151044631802090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638151044631802090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638151044631802090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638151044631802090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_ConversionOfStockAmountConverted1_638151044631812090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="cgtx_MaximumAggregateOfferingPrice_638151044631812090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638151044631812090" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638151044631802090" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151044631812090" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631812090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631812090" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631812090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631812090" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631812090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638151044631812090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631812090" xlink:to="us-gaap_EquipmentMember_638151044631812090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631812090" xlink:to="us-gaap_FurnitureAndFixturesMember_638151044631822092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631812090" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638151044631822092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638151044631822092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="cgtx_GrantIncome_638151044631822092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="cgtx_DeferredGrantIncomeCurrent_638151044631822092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638151044631822092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_UnrecognizedTaxBenefits_638151044631822092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151044631822092" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638151044631822092" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_NumberOfOperatingSegments_638151044631822092" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638151044631822092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638151044631822092" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151044631832091" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044631832091" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631822092" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631832091" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631832091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631832091" xlink:to="srt_RestatementAxis_638151044631832091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638151044631832091" xlink:to="srt_RestatementDomain_638151044631832091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638151044631832091" xlink:to="srt_ScenarioPreviouslyReportedMember_638151044631832091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638151044631832091" xlink:to="srt_RestatementAdjustmentMember_638151044631832091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151044631832091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631832091" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151044631832091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151044631832091" xlink:to="us-gaap_TypeOfAdoptionMember_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638151044631842127" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631832091" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" xlink:to="us-gaap_DeferredRentCredit_638151044631842127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044631842127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631842127" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631842127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638151044631842127" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638151044631842127" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638151044631842127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638151044631842127" xlink:to="us-gaap_MoneyMarketFundsMember_638151044631842127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638151044631842127" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151044631852094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151044631852094" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151044631852094" xlink:to="us-gaap_FairValueInputsLevel1Member_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638151044631842127" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638151044631852094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638151044631852094" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638151044631852094" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638151044631852094" xlink:to="us-gaap_AssetsFairValueDisclosure_638151044631852094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631852094" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631852094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638151044631852094" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631852094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMember" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631852094" xlink:to="cgtx_SimpleAgreementsForFutureEquityMember_638151044631862090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631852094" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638151044631862090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631852094" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631862090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631862090" xlink:to="us-gaap_ConversionOfStockNameDomain_638151044631862090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfSimpleAgreementsForFutureEquityMember" xlink:label="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_638151044631862090" xlink:to="cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_638151044631862090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631852094" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631862090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631862090" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638151044631862090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638151044631862090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfDerivativeLiability" xlink:label="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="cgtx_FairValueAdjustmentOfDerivativeLiability_638151044631862090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631862090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638151044631862090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638151044631862090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638151044631862090" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638151044631872089" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631862090" xlink:to="cgtx_ProceedsFromSimpleAgreementsForFutureEquity_638151044631872089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631862090" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638151044631872089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" xlink:to="us-gaap_MeasurementInputTypeAxis_638151044631872089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638151044631872089" xlink:to="us-gaap_MeasurementInputTypeDomain_638151044631872089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638151044631872089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponConversionMember" xlink:label="cgtx_MeasurementInputDiscountUponConversionMember_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="cgtx_MeasurementInputDiscountUponConversionMember_638151044631872089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputDiscountUponImpliedReturnMember" xlink:label="cgtx_MeasurementInputDiscountUponImpliedReturnMember_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="cgtx_MeasurementInputDiscountUponImpliedReturnMember_638151044631872089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_638151044631872089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_638151044631872089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_638151044631882090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember" xlink:label="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_638151044631882090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputControlPremiumMember" xlink:label="us-gaap_MeasurementInputControlPremiumMember_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638151044631872089" xlink:to="us-gaap_MeasurementInputControlPremiumMember_638151044631882090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638151044631882090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638151044631882090" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631882090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMember" xlink:label="cgtx_SimpleAgreementsForFutureEquityMember_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638151044631882090" xlink:to="cgtx_SimpleAgreementsForFutureEquityMember_638151044631882090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" xlink:to="us-gaap_DebtInstrumentAxis_638151044631882090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638151044631882090" xlink:to="us-gaap_DebtInstrumentNameDomain_638151044631882090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramLoanMember" xlink:label="cgtx_PaycheckProtectionProgramLoanMember_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638151044631882090" xlink:to="cgtx_PaycheckProtectionProgramLoanMember_638151044631882090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638151044631872089" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SimpleAgreementsForFutureEquityMeasurementInput" xlink:label="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_638151044631882090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="cgtx_SimpleAgreementsForFutureEquityMeasurementInput_638151044631882090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity" xlink:label="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity_638151044631892092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="us-gaap_LongTermDebt_638151044631892092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151044631892092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier" xlink:label="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier_638151044631892092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PeriodOverWhichUnforgivenPppLoanPayable" xlink:label="cgtx_PeriodOverWhichUnforgivenPppLoanPayable_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="cgtx_PeriodOverWhichUnforgivenPppLoanPayable_638151044631892092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LoanDeferralPaymentsPeriod" xlink:label="cgtx_LoanDeferralPaymentsPeriod_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="cgtx_LoanDeferralPaymentsPeriod_638151044631892092" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638151044631882090" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151044631892092" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631892092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631892092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631892092" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631902091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631902091" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631902091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631902091" xlink:to="us-gaap_EquipmentMember_638151044631902091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631902091" xlink:to="us-gaap_FurnitureAndFixturesMember_638151044631902091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151044631892092" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638151044631902091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151044631902091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151044631902091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" xlink:to="us-gaap_Depreciation_638151044631902091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151044631902091" xlink:to="us-gaap_AdjustmentForAmortization_638151044631902091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151044631902091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151044631902091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638151044631912090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638151044631912090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151044631912090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151044631912090" xlink:to="us-gaap_DebtInstrumentAxis_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638151044631912090" xlink:to="us-gaap_DebtInstrumentNameDomain_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638151044631912090" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151044631912090" xlink:to="us-gaap_BalanceSheetLocationAxis_638151044631912090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638151044631912090" xlink:to="us-gaap_BalanceSheetLocationDomain_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638151044631912090" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151044631912090" xlink:to="us-gaap_DebtInstrumentLineItems_638151044631912090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638151044631912090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151044631912090" xlink:to="us-gaap_DebtInstrumentFaceAmount_638151044631912090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151044631912090" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151044631922095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151044631912090" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638151044631922095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151044631912090" xlink:to="us-gaap_ShortTermBorrowings_638151044631922095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_AssetsAbstract_638151044631922095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631922095" xlink:to="cgtx_OperatingLeaseAssets_638151044631922095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151044631922095" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151044631922095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LiabilitiesAbstract_638151044631922095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638151044631922095" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638151044631922095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151044631922095" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151044631922095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638151044631922095" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638151044631922095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631922095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638151044631922095" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151044631922095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638151044631922095" xlink:to="us-gaap_OperatingLeaseLiability_638151044631932090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LossContingenciesTable_638151044631932090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638151044631932090" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631932090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151044631932090" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631932090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631932090" xlink:to="cgtx_OfficeSpaceNewYorkMember_638151044631932090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631932090" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638151044631932090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151044631932090" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638151044631932090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638151044631932090" xlink:to="us-gaap_LossContingenciesLineItems_638151044631932090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638151044631932090" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638151044631932090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638151044631932090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638151044631932090" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151044631942102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151044631942102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151044631942102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151044631942102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151044631942102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151044631942102" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638151044631942102" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151044631942102" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638151044631932090" xlink:to="us-gaap_OperatingLeaseLiability_638151044631942102" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638151044631942102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638151044631932090" xlink:to="us-gaap_OperatingLeaseExpense_638151044631942102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638151044631952101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638151044631932090" xlink:to="us-gaap_AreaOfRealEstateProperty_638151044631952101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638151044631952101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638151044631952101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638151044631952101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638151044631952101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638151044631952101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" xlink:to="us-gaap_OperatingLeasePayments_638151044631952101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631962097" xlink:to="us-gaap_StatementClassOfStockAxis_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631962097" xlink:to="us-gaap_ClassOfStockDomain_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesaConvertiblePreferredStockMember" xlink:label="cgtx_SeriesaConvertiblePreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631962097" xlink:to="cgtx_SeriesaConvertiblePreferredStockMember_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA1ConvertiblePreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631962097" xlink:to="cgtx_SeriesA1ConvertiblePreferredStockMember_638151044631962097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesA2ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesA2ConvertiblePreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631962097" xlink:to="cgtx_SeriesA2ConvertiblePreferredStockMember_638151044631962097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesBConvertiblePreferredStockMember" xlink:label="cgtx_SeriesBConvertiblePreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631962097" xlink:to="cgtx_SeriesBConvertiblePreferredStockMember_638151044631962097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SeriesB1ConvertiblePreferredStockMember" xlink:label="cgtx_SeriesB1ConvertiblePreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631962097" xlink:to="cgtx_SeriesB1ConvertiblePreferredStockMember_638151044631962097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631962097" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631962097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_638151044631962097" xlink:to="us-gaap_ConversionOfStockNameDomain_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ConversionOfPreferredStockMember" xlink:label="cgtx_ConversionOfPreferredStockMember_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_638151044631962097" xlink:to="cgtx_ConversionOfPreferredStockMember_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631962097" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044631962097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631962097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044631962097" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631962097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044631962097" xlink:to="us-gaap_IPOMember_638151044631972095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631962097" xlink:to="us-gaap_ClassOfStockLineItems_638151044631972095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_CommonStockSharesAuthorized_638151044631972095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638151044631972095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_PreferredStockSharesAuthorized_638151044631972095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638151044631972095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_CommonStockSharesIssued_638151044631972095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_CommonStockSharesOutstanding_638151044631972095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638151044631972095" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638151044631972095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638151044631972095" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631972095" xlink:to="us-gaap_DividendsCommonStock_638151044631982094" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_ScheduleOfStockByClassTable_638151044631982094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631982094" xlink:to="us-gaap_StatementClassOfStockAxis_638151044631982094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638151044631982094" xlink:to="us-gaap_ClassOfStockDomain_638151044631982094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631982094" xlink:to="us-gaap_StockOptionMember_638151044631982094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631982094" xlink:to="cgtx_EquityIncentivePlan2021Member_638151044631982094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638151044631982094" xlink:to="cgtx_EmployeeStockPurchasePlanMember_638151044631982094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638151044631982094" xlink:to="us-gaap_ClassOfStockLineItems_638151044631982094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151044631982094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638151044631982094" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151044631982094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638151044631992097" xlink:to="us-gaap_PlanNameAxis_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638151044631992097" xlink:to="us-gaap_PlanNameDomain_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638151044631992097" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638151044631992097" xlink:to="cgtx_EquityIncentivePlan2021Member_638151044631992097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638151044631992097" xlink:to="cgtx_EmployeeStockPurchasePlanMember_638151044631992097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638151044631992097" xlink:to="us-gaap_AwardTypeAxis_638151044631992097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638151044631992097" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638151044631992097" xlink:to="us-gaap_EmployeeStockOptionMember_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638151044631992097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638151044631992097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151044631992097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151044631992097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638151044632002094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638151044632002094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638151044631992097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638151044632002094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_StatementTable_638151044632002094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044632002094" xlink:to="srt_RangeAxis_638151044632002094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638151044632002094" xlink:to="srt_RangeMember_638151044632002094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638151044632002094" xlink:to="srt_MinimumMember_638151044632002094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638151044632002094" xlink:to="srt_MaximumMember_638151044632002094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151044632002094" xlink:to="us-gaap_StatementLineItems_638151044632002094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638151044632002094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_SharePrice_638151044632002094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638151044632012100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638151044632012100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638151044632012100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638151044632012100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151044632012100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151044632002094" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638151044632012100" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Equity-based Compensation - Activity for options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151044632012100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151044632012100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151044632022094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044632022094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638151044632022094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638151044632022094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151044632022094" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151044632012100" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638151044632022094" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151044632022094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638151044632022094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638151044632022094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638151044632022094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638151044632022094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638151044632022094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151044632032096" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151044632022094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638151044632032096" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638151044632032096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638151044632032096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638151044632032096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151044632032096" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638151044632032096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Equity-based Compensation - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151044632032096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151044632032096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151044632042104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638151044632042104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151044632042104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638151044632042104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638151044632042104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151044632042104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151044632042104" xlink:to="us-gaap_IncomeStatementLocationAxis_638151044632042104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638151044632042104" xlink:to="us-gaap_IncomeStatementLocationDomain_638151044632042104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638151044632042104" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638151044632042104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638151044632042104" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638151044632042104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151044632042104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151044632042104" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151044632042104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151044632042104" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151044632042104" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638151044632052091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151044632042104" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638151044632052091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151044632052091" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151044632052091" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638151044632052091" xlink:to="us-gaap_StockOptionMember_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638151044632052091" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_638151044632052091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_SharesAvailableForFutureIssuanceUnderEsppMember" xlink:label="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638151044632052091" xlink:to="cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_638151044632052091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151044632052091" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151044632052091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638151044632052091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151044632052091" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638151044632052091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_NetIncomeLoss_638151044632062093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638151044632062093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638151044632062093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151044632062093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151044632062093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_EarningsPerShareBasic_638151044632062093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638151044632062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_EarningsPerShareDiluted_638151044632062093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Retirement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638151044632072095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638151044632072095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638151044632072095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638151044632072095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638151044632072095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638151044632072095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638151044632132096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638151044632132096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151044632132096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_NetIncomeLoss_638151044632132096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151044632132096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151044632132096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151044632132096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151044632132096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151044632142093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638151044632142093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_638151044632142093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638151044632142093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent" xlink:label="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent_638151044632142093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151044632142093" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638151044632142093" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151044632142093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638151044632142093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638151044632142093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638151044632142093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638151044632152093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151044632152093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638151044632152093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsOther_638151044632152093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsGross_638151044632152093" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638151044632152093" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638151044632142093" xlink:to="us-gaap_DeferredTaxAssetsNet_638151044632152093" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638151044632152093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638151044632152093" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638151044632152093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638151044632152093" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638151044632152093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638151044632152093" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638151044632152093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638151044632152093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638151044632152093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638151044632162093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638151044632162093" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638151044632162093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638151044632162093" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638151044632162093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638151044632162093" xlink:to="us-gaap_DomesticCountryMember_638151044632162093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638151044632162093" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638151044632162093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638151044632162093" xlink:to="us-gaap_ForeignCountryMember_638151044632162093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638151044632162093" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638151044632162093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638151044632162093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638151044632162093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638151044632162093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638151044632172102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="us-gaap_OperatingLossCarryforwards_638151044632172102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_638151044632172102" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151044632162093" xlink:to="us-gaap_UnrecognizedTaxBenefits_638151044632172102" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638151044632172102" xlink:to="us-gaap_SubsequentEventTypeAxis_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638151044632172102" xlink:to="us-gaap_SubsequentEventTypeDomain_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638151044632172102" xlink:to="us-gaap_SubsequentEventMember_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638151044632172102" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151044632172102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151044632172102" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638151044632172102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044632172102" xlink:to="cgtx_EquityLineFinancingMember_638151044632172102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151044632172102" xlink:to="cgtx_AtMarketOfferingMember_638151044632182098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638151044632172102" xlink:to="srt_CounterpartyNameAxis_638151044632182098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638151044632182098" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638151044632182098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151044632182098" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638151044632182098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151044632182098" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638151044632182098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638151044632172102" xlink:to="us-gaap_SubsequentEventLineItems_638151044632182098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638151044632182098" xlink:to="cgtx_MaximumAggregateOfferingPrice_638151044632182098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638151044632182098" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151044632182098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638151044632182098" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638151044632182098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20221231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm_638151044632182098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638151044632182098" xlink:to="cgtx_PurchaseAgreementTerm_638151044632182098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415662084464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COGNITION THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4365359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2500 Westchester Ave.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Purchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-2210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,225,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,262,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415666727664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,562<span></span>
</td>
<td class="nump">$ 54,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivables</a></td>
<td class="nump">3,672<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,647<span></span>
</td>
<td class="nump">58,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">1,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">50,425<span></span>
</td>
<td class="nump">59,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="nump">4,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,795<span></span>
</td>
<td class="nump">7,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred grant income and other liabilities, noncurrent</a></td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,176<span></span>
</td>
<td class="nump">7,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 250,000,000 shares authorized at December 31, 2022 and December 31, 2021; 28,991,548 and 22,230,032 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">155,820<span></span>
</td>
<td class="nump">145,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(115,401)<span></span>
</td>
<td class="num">(94,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">40,249<span></span>
</td>
<td class="nump">51,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 50,425<span></span>
</td>
<td class="nump">$ 59,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661950336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,991,548<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,991,548<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661987664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 30,324<span></span>
</td>
<td class="nump">$ 18,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,227<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">43,551<span></span>
</td>
<td class="nump">28,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,551)<span></span>
</td>
<td class="num">(28,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="nump">22,217<span></span>
</td>
<td class="nump">17,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfDerivativeLiability', window );">Change in the fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">22,154<span></span>
</td>
<td class="nump">16,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(21,397)<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Cumulative preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,532)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(21,397)<span></span>
</td>
<td class="num">(16,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Unrealized loss on foreign currency translation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (21,398)<span></span>
</td>
<td class="num">$ (11,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">23,640,199<span></span>
</td>
<td class="nump">5,190,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">23,640,199<span></span>
</td>
<td class="nump">5,190,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in the fair value of derivative liability during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value adjustment of simple agreements for future equity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660674624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Follow-on Public Offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="num">$ (68,220)<span></span>
</td>
<td class="num">$ (187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (68,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Issuance of Series B-1 convertible preferred stock upon conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="num">(14,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,906,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity', window );">Conversion of SAFE into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity', window );">Conversion of SAFE into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,453<span></span>
</td>
<td class="num">(94,004)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 55,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">40,524,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt', window );">Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt</a></td>
<td class="nump">$ 29,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt', window );">Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt (in shares)</a></td>
<td class="nump">10,926,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_TemporaryEquityConversionOfStockAmountConverted', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="num">$ (84,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_TemporaryEquityConversionOfStockSharesConverted', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="num">(51,450,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,761,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,761,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,397)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,820<span></span>
</td>
<td class="num">$ (115,401)<span></span>
</td>
<td class="num">$ (199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of simple agreements for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of simple agreements for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_TemporaryEquityConversionOfStockAmountConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_TemporaryEquityConversionOfStockAmountConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_TemporaryEquityConversionOfStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_TemporaryEquityConversionOfStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of temporary shares issued during the period as a result of the conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of temporary stock issued during the period upon the conversion of convertible Debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415665198912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, discounts and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, discounts and offering costs</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661823920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,397)<span></span>
</td>
<td class="num">$ (11,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3,572<span></span>
</td>
<td class="nump">5,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfDerivativeLiability', window );">Change in the fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInGrantReceivables', window );">Grant receivables</a></td>
<td class="num">(1,873)<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,092)<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent', window );">Deferred grant income, current and other liabilities</a></td>
<td class="nump">2,635<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,533)<span></span>
</td>
<td class="num">(3,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments for property and equipment</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on loan payable</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromSimpleAgreementsForFutureEquity', window );">Proceeds from issuance of Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,546<span></span>
</td>
<td class="nump">53,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(13,159)<span></span>
</td>
<td class="nump">49,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-beginning of period</a></td>
<td class="nump">54,721<span></span>
</td>
<td class="nump">5,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-end of period</a></td>
<td class="nump">41,562<span></span>
</td>
<td class="nump">54,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing', window );">Prepayment of insurance through third-party financing</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Remeasurement of right-of-use asset and operating lease liability</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in Accounts payable</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred stock into common stock in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued', window );">Conversion of Simple Agreements for Future Equity into common stock in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of Simple Agreements For Future Equity into common stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in the fair value of derivative liability during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value adjustment of simple agreements for future equity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current deferred grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInGrantReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase and decrease in grant receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInGrantReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of insurance through third-party financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from simple agreements for future equity ("SAFEs) entered into by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664634704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Financial Condition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August&#160;21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies for central nervous system (&#8220;CNS&#8221;) disorders. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July&#160;14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#8220;Subsidiary&#8221;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at&#160;year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the&#160;month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholders&#8217; deficit. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) of 3,768,116 shares of the Company&#8217;s common stock at a public offering price of $12.00 per share. The gross proceeds from the IPO, excluding the overallotment exercise, were $45,217 and the net proceeds were approximately $37,909, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Upon completion of the IPO, all of the Company&#8217;s then outstanding preferred stock was automatically converted into an aggregate of 15,906,537 shares of common stock and an aggregate amount of $8,942 of simple agreements for future equity (&#8220;SAFE&#8221;) was automatically converted into an aggregate of 931,485 shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 10, 2021, the representative of the underwriters for the IPO provided notice to the Company that it had elected to exercise its over-allotment option in full to purchase 565,217 shares of the Company&#8217;s common stock. The representative&#8217;s exercise of the over-allotment option closed on November 12, 2021, resulting in gross proceeds of $6,783 and net proceeds to the Company of approximately $6,308, after deducting underwriting discounts and commissions and other offering related expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, the Company closed its follow-on public offering of 5,000,000 shares of the Company&#8217;s common stock at a public offering price of $1.20 per share (&#8220;November 2022 Offering&#8221;). The gross proceeds from the November 2022 Offering were $6,000 and the net proceeds were approximately $5,184, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Additionally, the Company granted the underwriters in the November 2022 Offering an option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company held cash and cash equivalents of $41,562 at December 31, 2022. The Company expects that its cash and cash equivalents, including the net proceeds from its IPO and its follow-on public offering, will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663324992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be 5 and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">ASC 815,&#160;<i style="font-style:italic;">Derivatives and Hedging Activities</i>&#160;(&#8220;ASC 815&#8221;) requires companies to bifurcate certain conversion options and redemption features from their host instruments and account for them as free-standing derivative financial instruments should certain criteria be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company also follows ASC 480-10,&#160;<i style="font-style:italic;">Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a)&#160;a fixed monetary amount known at inception; (b)&#160;variations in something other than the fair value of the issuer&#8217;s equity shares; or (c)&#160;variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2022 and 2021, the Company generated grant income of $22,217 and $17,447, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2022 was $1,702 and $1,686, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2021 of $753 and $0, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company is involved in research and development aimed at the development of treatments for a variety of diseases related to the central nervous system, with a primary focus on Alzheimer&#8217;s Disease. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$616</span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$130</span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$486</span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. The Company will continue to report financial information for fiscal years ended before December 31, 2021 under ASC 840.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2022 and 2021 that met the recognition threshold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. In addition, the Company records its warrant liability, derivative liability, and SAFE at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $1 and $11 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The Company presents comprehensive loss in a single statement within its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Basic net loss attributable to common shares is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss attributable to common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the impact is anti-dilutive. The Company&#8217;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (ASU) No.&#160;2016-02,&#160;<i style="font-style:italic;">Leases</i>&#160;(Topic 842). ASU No.&#160;2016-02 requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company adopted ASU No.&#160;2016-02 on January 1, 2022. For additional information on the adoption of the new leasing standards, please refer to the section titled &#8220;Leases&#8221; above, and Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, <i style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for all entities. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material impact on the Company&#8217;s consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In November 2021, the FASB issued ASU 2021-10, <i style="font-style:italic;">Government Assistance (Topic 832)</i>: Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The Company adopted ASU 2021-10 on January 1, 2022. The adoption of ASU 2021-10 did not have a material impact on the Company&#8217;s consolidated financial statements. For additional information on the Company&#8217;s governmental assistance transactions, please refer to the sections titled &#8220;Grant Receivables&#8221; and &#8220;Grant Income&#8221; above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In July 2021, the Company's board of directors approved an amendment to the Company's second amended and restated certificate of incorporation to effect a <span style="-sec-ix-hidden:Hidden_nQx1SsH8n0-iTW-hmt6Uqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-3.2345 reverse stock split of the Company's common stock, which was effected on October 1, 2021 with a filing made with the Secretary of State of the State of Delaware. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shares. The par value of the common stock was not adjusted as a result of the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of our convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. All common share and per share data have been retrospectively revised to reflect the reverse stock split.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664194384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2022. The following table sets forth a summary of the changes in fair value of the Level&#160;3 liabilities for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SAFE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,209</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon the issuance of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,942</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,209)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,236</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon conversion of SAFE into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,178)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Derivative Liability&#160;&#8212;</span>&#160;The Company recognizes derivative liabilities as a result of the issuance of the convertible notes that contain conversion and redemption features that are required to be bifurcated. The fair value measurement of the derivative liability is classified as Level 3 under the fair value hierarchy as it has been valued using certain unobservable inputs. These inputs include: (1) probability of occurrence of future events (such as a qualified financing or a sale), and (2) discount rate for implied return required by investor. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of the derivative liability was determined by calculating the fair value of the notes with the conversion and redemption features as compared to the fair value of the notes without such features, with the difference representing the value of the conversion and redemption features, or the derivative liability. The conversion and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">redemption features are measured at fair value as of each reporting date and the change in the fair value for the period is recorded in the consolidated statements of operations as a change in the fair value of the derivative liability. The fair value of the derivative liability is based on Level 3 unobservable inputs. Changes in fair value are recognized as a gain or loss within other income (expense) on the consolidated statements of operations and comprehensive loss. The derivative liability expired unexercised upon the conversion of the convertible notes into Series B-1 convertible preferred stock in May of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Simple Agreement for Future Equity&#160;&#8212;</span>&#160;On March 25, 2021, the Company entered into SAFE with existing investors, pursuant to which the Company received gross proceeds in an aggregate amount equal to $8,942. The fair value of the SAFE liability is estimated using a fair value model that includes inputs such as: (1) probability of occurrence of future events (such as a change of control or public offering), and (2) discount rate for implied return required by investor. The Company recorded a change in fair value adjustment of $2,236 in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2021. Upon the occurrence of the Company&#8217;s IPO on October 7, 2021, the SAFE converted into 931,485 shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of the SAFE was determined using a probability weighted expected return method (PWERM), in which the probability and timing of potential future events is considered in order to estimate the fair value of the SAFE as of each valuation date. Management determined the fair value of the SAFE using the following significant unobservable inputs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">October 7,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 25,</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Conversion)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Issuance)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.35</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon conversion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">20.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">20.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon implied return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">18.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">18.9%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of IPO occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">100.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">45.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of dissolution event occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">15.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of equity financing occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">37.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of change of control occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In addition, the Company recorded the Series B-1 convertible preferred stock within mezzanine equity at fair value on the date of issuance, May 1, 2021. This non-recurring fair value measure was based on level 3 unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In April 2020, the Company received a $443&#160;unsecured loan, bearing interest at&#160;1.0%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). The PPP provided for loans to qualifying businesses for amounts up to&#160;2.5&#160;times of the average monthly payroll expenses of the qualifying business. The loan and accrued interest are forgivable after eight weeks if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The amount of loan forgiveness may be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over&#160;two years&#160;at an interest rate of&#160;1.0%, with a deferral of payments for the first&#160;six months. The Company used the proceeds for purposes consistent with the PPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On January 21, 2021, the Company received confirmation from the SBA that the PPP Loan had been forgiven in full, including all interest incurred. Accordingly, the Company recognized $443&#160;of income for the debt extinguishment pursuant to ASC 470-50-15-4 for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663383072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,014</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,015</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (870)</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 145</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2022 and 2021 was $83 and $93, respectively, which includes amortization expense of $2 and $38 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663392656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,285</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal reserves, professional fees, and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 216</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,751</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663470512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OtherCurrentLiabilitiesTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $838 of certain premiums at a 6.85% annual interest rate. Payments of approximately $72 are due monthly from November 2022 through December 2023. As of December 31, 2022, the outstanding principal of the loan was $634 included in other current liabilities on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In October 2021, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $1,453 of certain premiums at a 3.25% annual interest rate. Payments of approximately $134 are due monthly from October 2021 through September 2022. The loan paid in full as of September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663360928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2022 were as follows, in thousands:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2022 was $203. Rent expense was $163 for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 209</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,020</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (176)</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.0</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2022 was $172.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2022 and 2021, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663428912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2022 and 2021, there were 28,991,548 and 22,230,032 shares of common stock <span style="-sec-ix-hidden:Hidden_zrVKOEsWWUen0jAD0vBoIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Y0sKS617cUG-4b1iHZkpJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, in connection with the completion of the Company&#8217;s IPO, 2,819,027 shares of Series A convertible preferred stock, 3,730,366 shares of Series A-1 convertible preferred stock, 3,565,063 shares of Series A-2 convertible preferred stock, 30,409,890 shares of Series B convertible preferred stock, and 10,926,089 shares of Series B-1 convertible preferred stock automatically converted into 15,906,537 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2022, no dividends on common stock had been declared by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">As of December 31, 2022 and 2021, the Company has reserved the following shares of common stock for issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,640,438</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,561,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,242,271</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,450,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,092,241</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Excludes preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663485872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,561,085. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2022 pursuant to an evergreen provision therein by 1,111,502 shares, representing 5% of total common shares outstanding at December 31, 2021. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s Board of Directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2022, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.72 &#8211; $3.05</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.75 &#8211; $6.15</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.09%&#8201;&#8211;&#8201;92.73%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100.82%&#8201;&#8211;&#8201;101.83%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.87%&#8201;&#8211;&#8201;4.22%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.67%&#8201;&#8211;&#8201;1.06%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.50&#8201;&#8211;&#8201;6.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00&#8201;&#8211;&#8201;6.22</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Common Stock</i>&#8201;&#8212;&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,640,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.0</p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 524,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,761,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (646,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,752)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"> 6.7</p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,253,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"> 5.5</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock options granted was $1.83 and $9.09 during the years ended December 31, 2022 and 2021, respectively. There were 524,370 stock options granted at an aggregate fair value of $943 for the year ended December 31, 2022 and 1,697,076 stock options granted at an aggregate fair value of $15,424 for the year ended December 31, 2021. During the year ended December 31, 2022 and 2021, there were 1,761,516 and 321,686 stock options exercised, respectively, with an aggregate grant date fair value of $1,325 and $188, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2022 and 2021 was $2,738 and $1,610, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to incentive stock options and nonstatutory stock options as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 877</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,306</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,183</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, total future compensation expense related to unvested awards yet to be recognized by the Company was $6,501. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately 2.0&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660657824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented due to their antidilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,640,438</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,561,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,242,271</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,450,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,092,241</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The basic and diluted net loss per share attributable to common stockholders has been prepared as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,716)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cumulative preferred stock dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,532)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,248)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,640,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,190,883</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,640,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,190,883</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.13)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;font-style:normal;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663436112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $156 and $113 for the&#160;year ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663421616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,384)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,910)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (806)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,716)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2022 and 2021, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) is the excess of a U.S. shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. This results in a material increase to the Company&#8217;s net deferred tax assets. Furthermore, since the Company provides for a full valuation allowance against U.S deferred tax assets, this has an adverse effect on the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-deductible stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,238</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,959</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 545</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,058</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,045)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2022 and 2021. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2022 and 2021, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2022 and 2021. The valuation allowance decreased by $2,610 and increased by $3,866 for the years ended December 31, 2022 and 2021, respectively. The decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures, while the increase in 2021 was primarily a result of operating losses generated with no corresponding financial statement benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company is in a taxable position as of December 31, 2022 and has utilized NOL generated in prior years to fully offset their current income tax expense. As of December 31, 2022, the Company had federal net operating loss carryforwards of $36,272. Included in federal net operating loss carryforwards of $36,272 is $17,930 that begin to expire in 2033 and $18,342 that can be carried forward indefinitely. As of December 31, 2022, the Company had state net operating loss carryforwards of $12,248, available to reduce future state taxable income, which will begin to expire in 2027. As of December 31, 2022, the Company had foreign net operating loss carryforwards of $314 that can be carried forward indefinitely. As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $1,728 available to reduce future federal tax liabilities, which will begin to expire in 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue from 2018 to present; however, carryforward attributes that were generated prior to December 31, 2018 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663485872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Subsequent Events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, the Company filed the Shelf (File No. 333-268992) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock at our sole discretion, over a <span style="-sec-ix-hidden:Hidden_EOZZ9ib9PU6NThp6PBR4OA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">36-month</span></span> period commencing on March 10, 2023. The Company filed a supplemental registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415666697568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be 5 and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2022 or 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ConvertibleInstrumentsPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">ASC 815,&#160;<i style="font-style:italic;">Derivatives and Hedging Activities</i>&#160;(&#8220;ASC 815&#8221;) requires companies to bifurcate certain conversion options and redemption features from their host instruments and account for them as free-standing derivative financial instruments should certain criteria be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company also follows ASC 480-10,&#160;<i style="font-style:italic;">Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a)&#160;a fixed monetary amount known at inception; (b)&#160;variations in something other than the fair value of the issuer&#8217;s equity shares; or (c)&#160;variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncomePolicyPolicyTextBlock', window );">Grant income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2022 and 2021, the Company generated grant income of $22,217 and $17,447, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2022 was $1,702 and $1,686, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2021 of $753 and $0, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">The Company is involved in research and development aimed at the development of treatments for a variety of diseases related to the central nervous system, with a primary focus on Alzheimer&#8217;s Disease. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$616</span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$130</span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$486</span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. The Company will continue to report financial information for fiscal years ended before December 31, 2021 under ASC 840.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2022 and 2021 that met the recognition threshold.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. In addition, the Company records its warrant liability, derivative liability, and SAFE at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $1 and $11 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The Company presents comprehensive loss in a single statement within its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Basic net loss attributable to common shares is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss attributable to common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the impact is anti-dilutive. The Company&#8217;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (ASU) No.&#160;2016-02,&#160;<i style="font-style:italic;">Leases</i>&#160;(Topic 842). ASU No.&#160;2016-02 requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company adopted ASU No.&#160;2016-02 on January 1, 2022. For additional information on the adoption of the new leasing standards, please refer to the section titled &#8220;Leases&#8221; above, and Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, <i style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for all entities. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material impact on the Company&#8217;s consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In November 2021, the FASB issued ASU 2021-10, <i style="font-style:italic;">Government Assistance (Topic 832)</i>: Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The Company adopted ASU 2021-10 on January 1, 2022. The adoption of ASU 2021-10 did not have a material impact on the Company&#8217;s consolidated financial statements. For additional information on the Company&#8217;s governmental assistance transactions, please refer to the sections titled &#8220;Grant Receivables&#8221; and &#8220;Grant Income&#8221; above. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">In July 2021, the Company's board of directors approved an amendment to the Company's second amended and restated certificate of incorporation to effect a <span style="-sec-ix-hidden:Hidden_nQx1SsH8n0-iTW-hmt6Uqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-3.2345 reverse stock split of the Company's common stock, which was effected on October 1, 2021 with a filing made with the Secretary of State of the State of Delaware. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shares. The par value of the common stock was not adjusted as a result of the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of our convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. All common share and per share data have been retrospectively revised to reflect the reverse stock split.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ConvertibleInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Convertible Instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ConvertibleInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split policy disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663359344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Impact of Adoption of ASC 842</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664370064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of financial assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,687</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in fair value of Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SAFE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,209</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon the issuance of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,942</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of the derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,209)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in the fair value of SAFE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,236</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value recognized upon conversion of SAFE into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,178)</p></td></tr><tr><td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant unobservable inputs for SAFE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">October 7,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 25,</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Conversion)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Issuance)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.35</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon conversion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">20.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">20.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount upon implied return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">18.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">18.9%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of IPO occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">100.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">45.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of dissolution event occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">15.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of equity financing occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">37.0%</p></td></tr><tr><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of change of control occurrence</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660657824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,014</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,015</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (870)</p></td></tr><tr><td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 145</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663389232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,285</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal reserves, professional fees, and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 216</p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,751</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663300384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.0</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum lease commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 209</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,020</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (176)</p></td></tr><tr><td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663411024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of common stock reserved for issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,640,438</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,561,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,242,271</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,450,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,092,241</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415663358800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.72 &#8211; $3.05</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.75 &#8211; $6.15</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.09%&#8201;&#8211;&#8201;92.73%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100.82%&#8201;&#8211;&#8201;101.83%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.87%&#8201;&#8211;&#8201;4.22%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.67%&#8201;&#8211;&#8201;1.06%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.50&#8201;&#8211;&#8201;6.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00&#8201;&#8211;&#8201;6.22</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of activity for options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,640,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.0</p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 524,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,761,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (646,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,752)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"> 6.7</p></td></tr><tr><td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,253,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"> 5.5</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total equity-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 877</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,306</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,183</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415665426080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,640,438</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,561,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,242,271</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shares available for future issuance under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 209,532</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,450,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,092,241</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,716)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cumulative preferred stock dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,532)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,248)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,640,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,190,883</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,640,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,190,883</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.13)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.13)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661999760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of net loss components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,384)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,910)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (806)</p></td></tr><tr><td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,716)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the expected income tax (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-deductible stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,238</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,959</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 545</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,058</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,045)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660195536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Nov. 15, 2022</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
<th class="th"><div>Oct. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,562<span></span>
</td>
<td class="nump">$ 54,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,768,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Conversion Of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,906,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Conversion Of Simple Agreements For Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock into SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">565,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering | Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfSimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfSimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415665462976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent', window );">Allowance for doubtful accounts on grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,217<span></span>
</td>
<td class="nump">$ 17,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred grant income, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Unrealized loss on foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.3092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on grants receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AllowanceForCreditLossGrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415662691200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impact of Adoption (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660186816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 37,479<span></span>
</td>
<td class="nump">$ 46,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">37,479<span></span>
</td>
<td class="nump">46,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">37,479<span></span>
</td>
<td class="nump">46,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 37,479<span></span>
</td>
<td class="nump">$ 46,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660011712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of the Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value recognized upon the issuance of SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfDerivativeLiability', window );">Change in the fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair value recognized upon conversion into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromSimpleAgreementsForFutureEquity', window );">Proceeds from simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfSimpleAgreementsForFutureEquityMember', window );">Conversion Of Simple Agreements For Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of the Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of stock upon conversion of debt (in shares)</a></td>
<td class="nump">931,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember', window );">SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of the Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value recognized upon the issuance of SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair value recognized upon conversion into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromSimpleAgreementsForFutureEquity', window );">Proceeds from simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Liability.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of the Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfDerivativeLiability', window );">Change in the fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in the fair value of derivative liability during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value adjustment of simple agreements for future equity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from simple agreements for future equity ("SAFEs) entered into by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfSimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfSimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415666203520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 07, 2021</div></th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>Y</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_PaycheckProtectionProgramLoanMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier', window );">Multiplier applied on average monthly payroll expenses</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PeriodOverWhichUnforgivenPppLoanPayable', window );">Period over which unforgiven portion of PPP loan payable</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_LoanDeferralPaymentsPeriod', window );">Deferral payments period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember', window );">SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity', window );">Change in the fair value of the Simple Agreements for Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponConversionMember', window );">Discount upon conversion | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponImpliedReturnMember', window );">Discount upon implied return | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember', window );">Probability of initial public offering occurrence | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember', window );">Probability of dissolution event occurrence | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember', window );">Probability of equity financing occurrence | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputControlPremiumMember', window );">Probability of change of control occurrence | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value adjustment of simple agreements for future equity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LoanDeferralPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which deferral of payments done.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LoanDeferralPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiplier applied on average monthly payroll expenses in PPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PeriodOverWhichUnforgivenPppLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which unforgiven portion of PPP loan payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PeriodOverWhichUnforgivenPppLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_SimpleAgreementsForFutureEquityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure simple agreements for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_SimpleAgreementsForFutureEquityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cgtx_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponImpliedReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputDiscountUponImpliedReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputControlPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputControlPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415666347952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(953)<span></span>
</td>
<td class="num">(870)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415666272832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">$ 1,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_AccruedResearchAndDevelopmentExpenses', window );">Research and development costs</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent', window );">Legal reserves, professional fees, and other accruals</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,094<span></span>
</td>
<td class="nump">$ 1,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661909840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember', window );">Insurance Premium Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 1,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">6.85%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664573472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease assets</a></td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease assets as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660048304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember', window );">Office Space, New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember', window );">Laboratory And Office Space, Pittsburgh, PA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars', window );">Number of option at conclusion of the lease term | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember', window );">Office Space located In Pittsburgh, PA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of buyout options in dollars in an operating lease under the lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664590592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Term And Discount (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415751504848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415659912992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividend declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfPreferredStockMember', window );">Conversion Of Preferred Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock</a></td>
<td class="nump">15,906,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesaConvertiblePreferredStockMember', window );">Series A convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock</a></td>
<td class="nump">2,819,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock</a></td>
<td class="nump">3,730,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock</a></td>
<td class="nump">3,565,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesBConvertiblePreferredStockMember', window );">Series B convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock</a></td>
<td class="nump">30,409,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock</a></td>
<td class="nump">10,926,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cgtx_ConversionOfPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415662699968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">6,450,085<span></span>
</td>
<td class="nump">7,092,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">3,679,468<span></span>
</td>
<td class="nump">5,640,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">2,561,085<span></span>
</td>
<td class="nump">1,242,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cgtx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">209,532<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cgtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cgtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415662035648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 15, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,450,085<span></span>
</td>
<td class="nump">7,092,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,543,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member', window );">Amended and Restated 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,561,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">1,111,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber', window );">Number of shares that may be recycled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661718336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Fair value of options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">91.09%<span></span>
</td>
<td class="nump">100.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.73%<span></span>
</td>
<td class="nump">101.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 6.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661006944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Activity for options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">5,640,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">524,370<span></span>
</td>
<td class="nump">1,697,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(1,761,516)<span></span>
</td>
<td class="num">(321,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(646,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="num">(77,752)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">3,679,468<span></span>
</td>
<td class="nump">5,640,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,253,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">5.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired (in dollars per share)</a></td>
<td class="nump">12.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">5.13<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,085<span></span>
</td>
<td class="nump">$ 12,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value - Exercisable</a></td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life -Exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415664572928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 9.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">524,370<span></span>
</td>
<td class="nump">1,697,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue', window );">Fair value of options granted</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 15,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">1,761,516<span></span>
</td>
<td class="nump">321,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue', window );">Fair value of options exercised</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660599888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="nump">$ 5,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to options</a></td>
<td class="nump">$ 6,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which the unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 3,044<span></span>
</td>
<td class="nump">$ 4,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660597424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">6,450,085<span></span>
</td>
<td class="nump">7,092,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">3,679,468<span></span>
</td>
<td class="nump">5,640,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember', window );">Shares Available For Future Issuance Under 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">2,561,085<span></span>
</td>
<td class="nump">1,242,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnderEsppMember', window );">Shares Available For Future Issuance Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">209,532<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnderEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cgtx_SharesAvailableForFutureIssuanceUnderEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661831040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,397)<span></span>
</td>
<td class="num">$ (11,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Cumulative preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (21,397)<span></span>
</td>
<td class="num">$ (16,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">23,640,199<span></span>
</td>
<td class="nump">5,190,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">23,640,199<span></span>
</td>
<td class="nump">5,190,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661946352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employees' compensation per person per year matched by the Company</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Matching contributions to the plan</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415665195600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (21,384)<span></span>
</td>
<td class="num">$ (10,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (21,397)<span></span>
</td>
<td class="num">$ (11,716)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415656329856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax benefit (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate (as percentage)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as percentage)</a></td>
<td class="num">(15.30%)<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as percentage)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="num">(32.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">R&amp;D Credit (as percentage)</a></td>
<td class="num">(15.10%)<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent', window );">Interest expense (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Non-deductible stock compensation (as percentage)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent', window );">Fair value adjustments (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other (as percentage)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415660036928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,194<span></span>
</td>
<td class="nump">$ 13,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">4,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenditures</a></td>
<td class="nump">5,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">16,613<span></span>
</td>
<td class="nump">19,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(16,435)<span></span>
</td>
<td class="num">(19,045)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets after valuation allowance</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">$ (178)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415665594720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">(Decrease) increase in valuation allowance</a></td>
<td class="num">(2,610)<span></span>
</td>
<td class="nump">3,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentTaxCreditCarryForwards', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration', window );">Operating loss carryforwards that expire</a></td>
<td class="nump">17,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration', window );">Operating loss carryforwards that do not expire</a></td>
<td class="nump">18,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">36,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">12,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentTaxCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of federal research and development tax credit carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentTaxCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140415661780800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering | Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Equity Line Financing | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PurchaseAgreementTerm', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>cgtx-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgtx="http://www.cogrx.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgtx-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k0Fx52yg8EmU-X-cmYFt2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_enLCj8Q1xEml8KVpBZ04bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesaConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TaoGs-evLUaQbSnfNKRUJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_uKNBRS7LKkeAraJh_fQoTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YhglPqSICEOHSV_IdZw7eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_1ng_kk66vUmNmQ2gIQxa1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0haQ0rDcjEC7Lpsh3ZXY1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_66gOUrgOGkmMATI_UYMUcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-15</startDate>
            <endDate>2022-11-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_7_2021_To_10_7_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_J1qjrKQ97UC4V1Qbkn0BVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfSimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-07</startDate>
            <endDate>2021-10-07</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_NSbC4L6Dt0mqcQAgorA4fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wzhq5N306Uqh98sS1Rmuwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ALOa0B34YEu4wK2K83rlug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ob1HFOSlEUyTfi6gKd0HIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmHMF32sz0KA3893X1KYUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EjDdvR-xQEuO4zQmEOjdDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DVOWTmYar0GNsT5vClx9zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p9uGeWcXbEizrgTa2nWZiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OJPY2v-8HEm6XwyhP4ZZqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_G6KN4NQzqUuxhlJs_8voKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SFKIrluacUKxgPM0Dk_COA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-15</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFWuF54H3UCI_hJ6ZrtvQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_XYAfduBLiEyYZK5YwTJYpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_Mm4HIB07WkaEjnsTACDzAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Osz1MgsDcEWWlW4jGAr1bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DVoBTPqoMkip6hYlwzicaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_1pumPUEKZU2T8noHh3EBSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_NPy6437bOUm5rmu1Uvq-zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_LRRxx2Dlh0uhljHR9SnyHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_yahv0OkpPEaYE1i-7KtT_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_7A9Z0eNU2kGCYq5FHtJgjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6lpHwpsw-EWJo0Zgq6rNcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_oXjUmgTrE0eWw47O5kihsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_kLTU2zUbVEic1iFZs3Jr4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MFx5PzsB3EiVmUbOAvS2KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_J2XBpl_S60WJ_31CJUKMPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-GYnhwP-wE6fE3kPKJhleg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_zSXdcVC8VE-7xnTJfzdRMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_NdALTKUy0kmXAWKzuRjFpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_aO4rFi4jSEyn8DSa70-4Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rCOlfsot3EiDxI_jxFLXiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rdiZqGOI80qH1SRFtNcStA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_0h3qCBEleU-V3fVtO2hK3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_OuQa9AV1Z0aOm013SYiWPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4BX_LYCjYEOG2mey0sSEjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_Z7obri4_Hk2MEqxX8hrVuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_cFNoQhYPU0-zSAcDylTH8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_FHzzyuPXwUKyBLXHpnwHPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_AE0FpwKs-EOageu6dOfl8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f9FhQl3y6EiSdHDswe6MEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_YEX4tFts9UqlH27hYh2GNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_5Llp0meHlE2FcF9C5kq5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_uHgL9nAXWUGXP88TL0_l4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_XP8oKPKT_Ei7TjXFOpwjtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cgtx:ConversionOfSimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_-IP8DBZpCUSLq5j3zp66OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkBqUzrULkqvOk4_Dzd2oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_N1dAezJ1BEmEY5K2pYrnWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_sct--jfhGkOI2iY08mN67g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_n6-tqTA3EkmAO2tyD5S7NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_Sm3lzM60aUOPdd-qCWli3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_2SLhlXLD40WSZNvO2Kvf4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_XL_cLPnem0WdnDFZvFsDSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oSyBIfvMNk2jXeReNnXygw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hNnv6GZ7IUi4mGR9CBNWEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_t-1Qw68sI0aC5oM3AVvG-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_Ht59q_5JiEiVhpo-kC0tEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_RcqZUt4qD0CDmwKu-H5W3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_JWuAV66_FkKYy9ml74D0OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_nwX8yS5_AE26RPa_9Fo2wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_b88oSDVpj0-qGHOfTzZbKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_96iu6bqRR02okgqdFfwfwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_x9O6RRV7-EqAHJFc8zyb0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_BBPnWdc1jEC6JJ6WU38FKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_aYLK7DBMgEenBoD_1pqp7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnder2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_JbPg3qBfrkinytQJRc8rBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_Vt-R9TT6a0-mHF1vBUv27Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_GOEFjr5HT0K3IfUrhIxbaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cgtx:SharesAvailableForFutureIssuanceUnder2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aM0FMO2TMEaf1Fu_f9Yn8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2QI15J_3YUCTGyt7KkvUew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_At8s-OhSw0yRFbaWfIbeww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sWlYGe9ixUe9X9WZ9DcihQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_Kc3nx2ZzNkm9H6jyKJJoMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2023_V_7yKkzdtEiNANBLG-zv0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_T1dodM-JUE2PyHPTE4fWQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_raLm_xXRuUiTAX_TParm5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_Ew7Kbm3OAEy6EtEDlHqmug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfEquityFinancingOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_vyxTfLKJxUW9zuhqZTsSFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfDissolutionEventOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_1ncZ0wDVjUaMv3n8bW5Qww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponImpliedReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_MxmsAkGlGk6Tkcg1-sC0nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-07</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TIObl80f7UWIvJjeNn-tkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_HuWBldoXiEChJl-DHcYigA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_iqb3nfvhzUGG9vyRKPjbLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_O1QXNgSInE2t6P_Ih0REuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfEquityFinancingOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_QoK-U_gP1Ua8QKYjkoygBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputProbabilityOfDissolutionEventOccurrenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_h4s2HAgDWEyJ3_wpwJxxJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponImpliedReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_ngpHUyNFakCau2ySwCxAGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">cgtx:MeasurementInputDiscountUponConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_25_2021_To_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember__NxCd_fmOkGpRip87LsWsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-15</startDate>
            <endDate>2022-11-15</endDate>
        </period>
    </context>
    <context id="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-10</startDate>
            <endDate>2021-11-10</endDate>
        </period>
    </context>
    <context id="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cgtx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_QGjdHn6BlEOiqD30uxaG1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_lease_aWodb89n40ua9F3TL8eTqQ">
        <measure>cgtx:lease</measure>
    </unit>
    <unit id="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Y_KVexRmvX6US-liK6aNll8Q">
        <measure>cgtx:Y</measure>
    </unit>
    <unit id="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_0QdZH6dU9kC3NWhic3Tuew">
        <measure>cgtx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      id="Hidden_JrDevPImqEyKBMb6BdEzvg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      id="Hidden_7BjTKF9n-EG_gf6RvGM8aA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_0d2CGQKJrkiYj5T9E74Uxw_2_1">0001455365</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_TiEClwaiqECyC-pFc-FDtw_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_PcxGfAKvf0SNUwtCpOCDEw_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_0KWXnOMw10CM2diY9L7m9Q_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Hidden_Oi4h6fGa2US3JbBF6tZnLQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Hidden_Q5OFgkJEGUOCsvg-cFO3Fg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Hidden_MxgYh04ftUq-sNwdNmvJAg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Hidden_O5E8uWbUck6gpmHBRiqGIQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      id="Hidden_ovgd2fX3ZEaWm0wcmsqVsg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      id="Hidden_5TBw3xjUxk-WxRkuRpVO-Q"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Hidden__HQWsjBkFkmBXhs8jgM5nA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">22230032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Hidden_4NRuDtMjt0WCqOwgWiie7w"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">28991548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_7_1_2021_To_7_31_2021_NSbC4L6Dt0mqcQAgorA4fg"
      decimals="4"
      id="Hidden_nQx1SsH8n0-iTW-hmt6Uqw"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.3092</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Hidden_zrVKOEsWWUen0jAD0vBoIA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">22230032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Hidden_Y0sKS617cUG-4b1iHZkpJw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">28991548</us-gaap:CommonStockSharesOutstanding>
    <cgtx:PurchaseAgreementTerm
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg"
      id="Hidden_EOZZ9ib9PU6NThp6PBR4OA">P36M</cgtx:PurchaseAgreementTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_kZH7V6z-AUiVFin3qas7hw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_kXcCUEdUZE-gUyAMJN9-ew">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_i0OgEx1LKU6ohATcVBzkMw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_8voNyipXc02b7m6TiiYaWw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_Hhm4EBAmHUKyIU3vkwYGWQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_t79Mcio5gUO73pEIa1XfwQ">001-40886</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_nbZIah3rqES1T1KVeYBRqw">COGNITION THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_vvBw0A8aXUeZZiPc_okyNg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_fDt4tWkcS0i1Estzb70MUQ_1_1">13-4365359</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_jbY8gwHwtk-DEf8Ujr6n8w_4_0">2500 Westchester Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_C-NQYGx5VUiSPyGEuipQ9A">Purchase</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_z7FsRDtq5E6MgDclOPjoUw">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_zW6s0TS1QkqB7ixjDB6XZg_5_1">10577</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_5gfjXDxi70eGJNaslLbg5Q">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_uc1Pva8_DECgOmjPme7jjg">481-2210</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_XYhic_2JLkymqjvtgHHvRw_3_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_kAej8D8wHU-EyBp3WtFMVw_3_2">CGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_ISLYiNnZekKbMo0t60g3Dw_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_7R7n9awTXkSdXV9P-ONPGw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_NK-Owouxkku7EFJFIeqkuw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_fpN1snkbYkm65f6GxAjPpw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_YNHad5w3XUe-_uxAlM17Nw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_4R7-XV40UEqXNO-5mNbKpQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_dGHPzo6jc02hipfcOwPfiw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_ojUJb2s33kCiHtg5Z-cTEg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_NhHTyZOieE2U_rx6jr1_KA">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_T1-52oTVhUixWO-oSwg4HQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_Kc3nx2ZzNkm9H6jyKJJoMg"
      decimals="0"
      id="Narr_HEo4hbyPzUGVDoBkdBCSyw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">38225874</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_20_2023_V_7yKkzdtEiNANBLG-zv0g"
      decimals="INF"
      id="Narr_d5zj_4PfW0ah7HWFZWZH-g"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">29262587</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_nsphUVVh_kiha_LdH0FrQA_1_1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_DK0NNcjHs0m3yXHfzCJsjA_1_3">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_3aK-jaG-bUq32lkWwrNdCg_1_5">Philadelphia, PA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_32v469jtJkuRjf5fYnKK0Q_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">41562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_LzE3yk4CdUeE72o_gJBbJg_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">54721000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_lLz2VSzWGEOgbGk6qjyN4Q_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3672000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_iZE9tW5QHkSHqjQv38SieA_7_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1799000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_3utFbwpJP02yZ65QEt0e6A_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2413000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_I7XgPbDQ-EaLVDwRdWo5fg_8_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2005000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_p14wcYhyKUyfhpH19imK7A_9_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">467000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_2bQV-AsNtEqoLpc04aza9w_10_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">47647000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_XSddKiZCCUmTWIuJPlXKNg_10_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">58992000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_cBm3r6Nk10ykhqcOOmt5Gg_11_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_oN921YJjakeNpwxTDbihGQ_11_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">145000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_f55yyE5ntUiPloVKQldX0g_12_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">813000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_csgwQv0pN0mSJRXRoldZ8g_13_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1732000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_gOHuWVfIfU-ZyarGAGBlJA_14_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">50425000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_FIGUnetbMkiNdMzUSTdkwQ_14_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">59137000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_bpd53LzG3Ue5twneizeMtQ_17_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3216000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_kOb7Amj7P0a-GGdgAAt7Ww_17_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4168000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_Iu8EZ3M23UevkAvIV7KJNA_18_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2094000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_zPCBO5HaEUSoTuNZ7GaKWg_18_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1751000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_TkgjTZ54aUuGNdOyLidajQ_19_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1702000</cgtx:DeferredGrantIncomeCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_Cpg-ilyPCkSpRAiHf-dFbg_19_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">753000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_NIs7nXWZhU-krqU27sB6TQ_20_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_6wg6uLhgIku9dmdPQbPXtw_21_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">634000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_bLJ-u7LuPUeHwU-oV9DLcQ_21_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1192000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_-tmHBYdJ7kaa7c5i6EbF5Q_22_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">7795000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_J5pP0sxvIUmjQu3q2SF89Q_22_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">7864000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_fTt5zLYmMEWkD7BUJiPmIw_23_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_nd_JXzy7aEOJSToML9erBw_24_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1686000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_gzlmfDS7rEal6fTV2Ww0qg_25_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">10176000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_4qof0lbfQEmOb_X2gqFLNw_25_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">7864000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_FFwd-ub1zUGGLAqJyg_bBw"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr__-WGWkiX1UCoMOjOHG6PNg"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_yzRnZV3R-ke8zRMgZc_HFw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_GfWmOHPjWk6iN2KT-qna2g"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_mIaB4bEur0-saeV8Z1L5pw"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_Jgp6rULfGUWYS1AIU-vQEg"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_lEiAjkMZ70CxPbwuWQECXg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_cYrSL3bPUU610j2HEy2gyw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_j4RY_z3Z80mAynSS-DURZA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">28991548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_wGt9_-HLwEmBS1Z9F3wEig"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">22230032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_lwkuSp18nUOZhLHWDLQhNQ_29_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">29000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_D1gvcFyAwkyuD6JnB1uHtA_29_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">22000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_IDDDW2GSxUaotsa8D62tPg_30_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">155820000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_KJ_haXVKJ0-YivOUvd0OGg_30_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">145453000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_hsBuddxQqUizHTuEyc6vzg_31_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-115401000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_1IiMRKeV00uTiF1hRrEiCA_31_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-94004000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_PlKSjRSah0ernFGrtJoSNg_32_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-199000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_rhlE9exrb0apuNXsRjRcyA_32_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_GFlAV4SsxkqDc96K1WDNqw_33_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">40249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_ROlrrJznJ0uUTEawB9H4Cw_33_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">51273000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_SHL59Pf0w0CA1LecrslTpw_34_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">50425000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_yRy-mDm5qUiJi-spylOUvA_34_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">59137000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_FmSuBEtWMUKTLmvUOtQ_tQ_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">30324000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_zwh0C1ptz0Scpos7W54Ltg_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">18572000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_Dvd69gZhKkib3Q3HufvTbA_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">13227000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_cja9nAEzCE6qX9jMiwNWbw_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">10026000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc__4xSsaSmD0ml51MQS_cI9g_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">43551000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc__z-XOwQbUUmzJSK3JV0V6g_7_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">28598000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_6QsqJomi_U-R_-JhqcWeuw_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-43551000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_5ecDsCuf-USWolKPB8kvWA_8_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-28598000</us-gaap:OperatingIncomeLoss>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_OVAdpdTkskGvs3voKhAe8w_10_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">22217000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_oa2PJjuJjUua1jTn4ipULA_10_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">17447000</cgtx:GrantIncome>
    <cgtx:FairValueAdjustmentOfDerivativeLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_fVwttrnYr0qRD8nipxNHfg_11_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</cgtx:FairValueAdjustmentOfDerivativeLiability>
    <cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_9Lkc0OLRM02Lo14SvxPPNg_12_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2236000</cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_Xw-QV1qiuUaIjdWb_j_nCg_13_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-35000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_bjUPxMbvgkK5_GqO0U2DXw_13_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-88000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_8sbYEdde8keidDizIafhIQ_14_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">443000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_KbSJXIuNPUmpIUaP5f0_mw_15_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-28000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_AJo6ly55UkiuDKMl5XYl1A_15_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-893000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_mSEB7cm4ukSfbUm9Z4Fxug_16_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">22154000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_nJk2ga04ak6ugGytm0JpMA_16_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">16882000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_sGO23BrOUUaHNt-YI_EU_A_17_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_EYDju9ycv0-cGfP36XnKjQ_17_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_rhl96dYxcEuI20wF1EDKxw_18_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4532000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_a88mctrUrUCP3JSCrehzDg_19_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_cYyRztOD1Uuyx1VAOf0WMw_19_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-16248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_CCfft4Bn4Uynl1mHRGKQgA_20_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_j9DJa48X_E6PE82MN-BHCw_20_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_L-sTA45_JkKYMHfnMme3WA_21_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21398000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_LOPIp_NmR0yLVb5uCrSWGQ_21_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11727000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_cnyJCAyEJki4YdPiviBCGA_23_3"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="2"
      id="Tc_VeMpxHXXA0OKeRlGKISBjw_23_6"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-3.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_JTjEjUFgs0uW0mxu6-edUQ_24_3"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="2"
      id="Tc_PuJw6urKH0uVT9B6tOtwWA_24_6"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-3.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_zGAT0Bsu1k6njs8Shz8r_Q_26_3"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">23640199</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Tc_UC_EqmlO60GuhVccD1XzTQ_26_6"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5190883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_UUAu-d4SEE2a3W61Qk3wmg_27_3"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">23640199</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Tc_kHkZRVfbYUe1mQMGAfXEsQ_27_6"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5190883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA"
      decimals="INF"
      id="Tc_CizV4-yCUUSuOAnIGXoxzg_5_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">40524346</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_cpnJIOtbnUi6TfOJUzYYFA"
      decimals="-3"
      id="Tc_UHcg7FBjDEe8KlP5LU_J0Q_5_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">55370000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ"
      decimals="INF"
      id="Tc_zrbNgxCwDEKeP2fYOPqfjw_5_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">538793</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ"
      decimals="-3"
      id="Tc_BLa-H0zETUKETzDYZDjyoA_5_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OJPY2v-8HEm6XwyhP4ZZqg"
      decimals="-3"
      id="Tc_LwGSdNQdbk6BheH2-_cGqA_5_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p9uGeWcXbEizrgTa2nWZiQ"
      decimals="-3"
      id="Tc_mwtgZ9Rbnk28kTXfYROlYw_5_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-68220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_G6KN4NQzqUuxhlJs_8voKQ"
      decimals="-3"
      id="Tc_DWD-uroyGkyA5eVWtQLN3Q_5_20"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw"
      decimals="-3"
      id="Tc__1lY-xV9XEabX_cFhLYRIg_5_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-68184000</us-gaap:StockholdersEquity>
    <cgtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw"
      decimals="INF"
      id="Tc_D9Y0_cClu022jUUFGsZuSg_6_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">10926089</cgtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt>
    <cgtx:TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw"
      decimals="-3"
      id="Tc_0jGwuvvnHU-Hr7HgmBG7_w_6_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">29391000</cgtx:TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_9oPWeIGpMkCHH7XdakpgBg_6_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA"
      decimals="-3"
      id="Tc_LKnTsfy68kiEZuD3Qh5Wow_6_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-14068000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_EvdiASS_e0y8QpSeDYf-xQ_6_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-14465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <cgtx:TemporaryEquityConversionOfStockSharesConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw"
      decimals="INF"
      id="Tc_euUMp_RUFU-cx2OqhL2Bkg_7_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">-51450435</cgtx:TemporaryEquityConversionOfStockSharesConverted>
    <cgtx:TemporaryEquityConversionOfStockAmountConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_swYhwTh0GkCM2NDTZi34kw"
      decimals="-3"
      id="Tc_rzymLBrGkkOForQy_vgcRw_7_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-84761000</cgtx:TemporaryEquityConversionOfStockAmountConverted>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="INF"
      id="Tc_JQgiEJ6RfkORb29Y4T1-Gw_7_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">15906537</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="-3"
      id="Tc_PvJU5M5dxU64unIFCn718A_7_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">16000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_7OeUn9Xm-02u6Cnu-akeMQ_7_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">84745000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_ANqDpdbhA02W8ascxbJtNA_7_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">84761000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw"
      decimals="-3"
      id="Narr_R7grV6xRSU6sJnYuuYh8VQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">7783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ"
      decimals="INF"
      id="Tc_fEJAxn0610ylgoycDocr_A_8_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">4333333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UqbB3l27E020608Kzk_nhQ"
      decimals="-3"
      id="Tc_Do0mwrypnkewLTiuX9M7vw_8_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0haQ0rDcjEC7Lpsh3ZXY1A"
      decimals="-3"
      id="Tc_INSMIpdTz0mGa7T4rJ2Gyw_8_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">44213000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw"
      decimals="-3"
      id="Tc_7W7yfqT9I02k5VJjUTHGBQ_8_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">44217000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgtx:StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="INF"
      id="Tc_w-R-bp6EJ0mMEpMO-X5ZbA_9_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">931485</cgtx:StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity>
    <cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="-3"
      id="Tc_8x9PYGTiGkKRlwE0EATSXw_9_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1000</cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity>
    <cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_GrQmDkVjMkabQbJkFx3P6Q_9_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">11177000</cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity>
    <cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_TWA6G5B6M022cVFyIfwCMg_9_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">11178000</cgtx:StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="INF"
      id="Tc_-ztqhlP9sUmyT4qHoPIo3g_10_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">321686</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_tjMuSVKl4UKnVi5z11QDLQ_10_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">276000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_Fi0YN4XVz0e25h4vJl2k3A_10_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">276000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgtx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cM2pdGwzMkaLRuUW5gu1Bw"
      decimals="-3"
      id="Tc_1e3x2Nnd0U6TvDi_Ydbw6Q_11_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">198198000</cgtx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <cgtx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_xx8LjVm0u0avlL8xVL1q4g_11_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">34000</cgtx:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgtx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_2qZ1uiTcpEqvQCvjJcouyQ_11_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">34000</cgtx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TQoxOnUH1kGlyL-UThZDhg"
      decimals="-3"
      id="Tc_XJo02Yv4EU23ou2Gam4JfQ_12_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_i-wg1Ypm4EC4FtOIrT7p2Q_12_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rdiZqGOI80qH1SRFtNcStA"
      decimals="-3"
      id="Tc_ZApi04cgpk-5uNAFGiTKDw_13_20"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_zjnwgfQJ0EWJAHhreVhjIg_13_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YfdyE_4dwkODEGllU_uSiA"
      decimals="-3"
      id="Tc_wwOw8t8ExE6RdaKosX35mA_14_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_-_KDV6BgIUC_lavfFNEJ5g_14_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q"
      decimals="INF"
      id="Tc_0EsQ_iCF5U2yZq50BBevbQ_15_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">22230032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2UuxXbmCVEmIQRIUMirY5Q"
      decimals="-3"
      id="Tc_YlunXD8jNEuX-TQaNetmlg_15_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EjDdvR-xQEuO4zQmEOjdDg"
      decimals="-3"
      id="Tc_s9CfJKhLiE2TSccqDy27pg_15_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">145453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmHMF32sz0KA3893X1KYUg"
      decimals="-3"
      id="Tc_fhuDfbOFAEKQssH8HUaI-g_15_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-94004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DVOWTmYar0GNsT5vClx9zw"
      decimals="-3"
      id="Tc_tol-sGKiKUKNvhdM9kRPaw_15_20"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_BnS6JQH4N0SYCBCGVc3Xcw_15_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">51273000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w"
      decimals="INF"
      id="Tc_PQSx3rJG4k-9hn2iC9k99w_16_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1761516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eJ4DugH-5EC_qZuHA1f82w"
      decimals="-3"
      id="Tc_ms9rZF0pBUWs8MiD0wO40g_16_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g"
      decimals="-3"
      id="Tc_oQfZhRWUjkqgUPFoQPUFzg_16_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1616000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_5e786fqRD0u5gxaN7ZsO6Q_16_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1618000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A"
      decimals="-3"
      id="Narr_P8O29jTjK0S7X3BCcqBvAA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">816000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA"
      decimals="INF"
      id="Tc_c63kdjAqakOTWYXg9zjidA_17_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_EdfDWwkKRkOUmnk6fa8vAA"
      decimals="-3"
      id="Tc_ScMJIS4X1EKDxvG6Li-Y8Q_17_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_1ng_kk66vUmNmQ2gIQxa1w"
      decimals="-3"
      id="Tc_93IzBTWBQ0SoYQb2y2lvRA_17_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A"
      decimals="-3"
      id="Tc__T4rW9ML1kWDDh2s8KIDYg_17_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5184000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LuhjPMGbqkW9QFaBcafK0g"
      decimals="-3"
      id="Tc_xXSL3T4j30WsqXSNjN_a3g_18_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_UaMwymgJ3EulwEoOyEjzbw_18_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rCOlfsot3EiDxI_jxFLXiw"
      decimals="-3"
      id="Tc_XfUp-pNAnUmcyxvG_x0Y8A_19_20"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_PBa-j11DI02USj-SFlJrEw_19_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4BX_LYCjYEOG2mey0sSEjw"
      decimals="-3"
      id="Tc_7zpQE2zSik6cZ-dXPzxhvQ_20_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_HlSwkpq4RUye7CFQSuxqTw_20_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA"
      decimals="INF"
      id="Tc_MAMsQpzsWUe948NJareNKQ_21_8"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">28991548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JvqgnV8stEGbKG-NGFpCKA"
      decimals="-3"
      id="Tc_7I9eZt33h0KF9x7bWuWVoA_21_11"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ALOa0B34YEu4wK2K83rlug"
      decimals="-3"
      id="Tc_iCo6ofTm6EyaEGUOgldBmQ_21_14"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">155820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wzhq5N306Uqh98sS1Rmuwg"
      decimals="-3"
      id="Tc_3baNiw1PCEaicFEeBZuhDw_21_17"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-115401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ob1HFOSlEUyTfi6gKd0HIg"
      decimals="-3"
      id="Tc_FDi_vMGNW0S5UCbO5CcrWQ_21_20"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_BdoYLrQUukKZ3tWx5uYzeA_21_23"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">40249000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_jEMFZZi6Kk2ydLicgDroPQ_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_VvlO1i04akKam8cNGyLqJQ_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_XzWKZtu31026hS8LLpjQMQ_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">83000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_dN7n7puBwkqbWw9B_cW59A_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">93000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_WlJ1d3ROnkevfBvPPTm6WQ_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3572000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_D1vvusQl20ekNe8dmsW82w_7_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5183000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_fxL9TZMXDUqpXWOrf2ltiw_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">152000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_ZOj0t7aKX0yTGuVLhNh4UA_9_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">31000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_7_WO8XdSF0mOuBqHGISUzA_10_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">352000</us-gaap:AmortizationOfDebtDiscountPremium>
    <cgtx:FairValueAdjustmentOfDerivativeLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_LfQlVizKrE6k8nSslfzoXw_11_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</cgtx:FairValueAdjustmentOfDerivativeLiability>
    <cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_QJcxV3vtck65Nc0X94NWiw_12_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2236000</cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_2NA17UCKeU-Kj5x2GMD0zQ_13_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">443000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_94a0zuHgVE2MC_b47u1ckg_15_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1873000</cgtx:IncreaseDecreaseInGrantReceivables>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_6E8-Rb5OZUeM9Jp8dK0I1g_15_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1235000</cgtx:IncreaseDecreaseInGrantReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_UQuVUpKgcESmomuVsLsYdA_16_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-430000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_-BZaj-ot_0yOKb4oZP6aew_16_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_VyZLlR4jMUa9Gwn9Xvx3xg_17_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-467000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_mO7scI9CSEyVz-G98OwFdA_17_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-121000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_YF8E0rugNU-Zn7rKy4ko6A_18_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1732000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_G9rgKhv1gkC2qv3IBsNkDw_19_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1092000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_25QYdMUQE0SBYvqdpA4wug_19_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2165000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_YuDFPtcJP0SP3K3KqE11Rw_20_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">343000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_cZPG1ALaqESjke23nbEAKQ_20_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1269000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_E0GTjZyX1kiYVQftm3ejIA_21_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2635000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_73gtV6edGEi73t7637-CHQ_21_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">501000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_OxWLr20RqEWI8s2qdPPclg_22_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-121000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_BTIJc22Iy06yeHfPPtO6ZA_23_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-18533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_bV-zhlUlmUi8vrTq9tvx1Q_23_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-3631000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_IiglOzzMXUKFUJs33NShVg_25_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">171000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_ZNxRaxWil0Kj3BFQZf7B3A_25_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">27000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_DSQheS-e9k23NaRV5kh1UA_26_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-171000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_qaRA797ul0yqipBT2G0xVw_26_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-27000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_H0qoA9S1qEaPPPxh-wKh-A"
      decimals="-3"
      id="Tc_beCTDa6HvkGhjgoPOTA8yg_28_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5324000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_oIEifU5PO0a25ErLNUg2vA_29_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1618000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_wFtErnWcAEy27Hba6BgrMw_29_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">276000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_YClK_cSWekiaMrFN8vtKzQ_30_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1396000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_ZeuYCMpNiUWS08_8v2lWgg_30_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">268000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw"
      decimals="-3"
      id="Tc_sGjuosKl1k-AfOcE7uIzPw_31_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">44217000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cgtx:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_n9JYl74T40qeaZD9-WtslQ_32_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8942000</cgtx:ProceedsFromSimpleAgreementsForFutureEquity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_8RlyEGW1fk6M43Jed3zpKQ_33_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">34000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_ntpPQieB5Uu6bqddHA2lXw_34_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5546000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_kTMbhP0Wc0ScXClD49MZiA_34_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">53201000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_OBYHXbc_wkKRQUyYxtke4A_35_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_oS7DqBkTD0WXBIakxy8YTg_35_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_ltnS3qGWxE6g0iQntIImVw_36_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-13159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_cz91tyNVlEmxp1vVWWiyFA_36_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">49532000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_ZlZUkKxG-0SxGDFOffcxlQ_38_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">54721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw"
      decimals="-3"
      id="Tc_HGLSGsl_iUSAJ__L_xo7Hw_38_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5189000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_hfr65AlDpE2EvnAYcTQytw_39_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">41562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_xSgwz8-igki7rnn3Uf86yg_39_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">54721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_Ei1V46xA60GAQGi8BVbDNw_41_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">838000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_eekv-6ZUpkqS-N_wj_ZlBQ_41_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1191000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_FaCSuZ5l3kG0WQbdC3CQxg_42_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">349000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cgtx:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_TTXoDA3DxUa7lzIXtUisGg_43_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">140000</cgtx:DeferredOfferingCostsIncludedInAccountsPayable>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_euizZmPjsUWFk3dcAItIiw_44_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">84761000</us-gaap:ConversionOfStockAmountIssued1>
    <cgtx:ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_OFIWtfkREEufNcAlcuq7Yg_45_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">11178000</cgtx:ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_3sfv-SJfwEqDXNVT2ibWqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Description of Business and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cognition Therapeutics,&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated as a Delaware corporation on August&#160;21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies for central nervous system (&#x201c;CNS&#x201d;) disorders. The Company&#x2019;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at&#160;year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the&#160;month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) within stockholders&#x2019; deficit. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 13, 2021, the Company closed its initial public offering (&#x201c;IPO&#x201d;) of 3,768,116 shares of the Company&#x2019;s common stock at a public offering price of $12.00 per share. The gross proceeds from the IPO, excluding the overallotment exercise, were $45,217 and the net proceeds were approximately $37,909, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Upon completion of the IPO, all of the Company&#x2019;s then outstanding preferred stock was automatically converted into an aggregate of 15,906,537 shares of common stock and an aggregate amount of $8,942 of simple agreements for future equity (&#x201c;SAFE&#x201d;) was automatically converted into an aggregate of 931,485 shares of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 10, 2021, the representative of the underwriters for the IPO provided notice to the Company that it had elected to exercise its over-allotment option in full to purchase 565,217 shares of the Company&#x2019;s common stock. The representative&#x2019;s exercise of the over-allotment option closed on November 12, 2021, resulting in gross proceeds of $6,783 and net proceeds to the Company of approximately $6,308, after deducting underwriting discounts and commissions and other offering related expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 15, 2022, the Company closed its follow-on public offering of 5,000,000 shares of the Company&#x2019;s common stock at a public offering price of $1.20 per share (&#x201c;November 2022 Offering&#x201d;). The gross proceeds from the November 2022 Offering were $6,000 and the net proceeds were approximately $5,184, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Additionally, the Company granted the underwriters in the November 2022 Offering an option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf (the &#x201c;ATM&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The Company held cash and cash equivalents of $41,562 at December 31, 2022. The Company expects that its cash and cash equivalents, including the net proceeds from its IPO and its follow-on public offering, will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw"
      decimals="INF"
      id="Narr_V21sIwIxfE6V-AX0_mQ3Ww"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3768116</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFWuF54H3UCI_hJ6ZrtvQw"
      decimals="INF"
      id="Narr_csjCJVsVo0OwsOBUdiYz6A"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">12.00</us-gaap:SharesIssuedPricePerShare>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw"
      decimals="-3"
      id="Narr_y_Q04RUzx0OMQuN1VgAHhg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">45217000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SFVESG_dgEe_doAqciAxDw"
      decimals="-3"
      id="Narr_s-Em8XcAPESz9rT_Jt1BoQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">37909000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w"
      decimals="INF"
      id="Narr_hBZQ-Oe1c0uyfod2aeXMVw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">15906537</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA"
      decimals="-3"
      id="Narr_zGUnXyPiiEeNNGPO7aacbA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8942000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zzPuTo2LS0u4UzEd7fmXhA"
      decimals="INF"
      id="Narr_ukDg0yFlKkeKpB2ljTnetQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">931485</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A"
      decimals="INF"
      id="Narr_T0oUh1yBbUi5zUIZcP5g8Q"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">565217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A"
      decimals="-3"
      id="Narr_8i0DZu0YjkGId-G8Lh6-Xg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">6783000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_11_10_2021_To_11_10_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mXPOhkYER0KX3tn7sLjD5A"
      decimals="-3"
      id="Narr_T_5-aIcKqkigdhXqbSnP_g"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">6308000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg"
      decimals="INF"
      id="Narr_teIkya7aNk2bMYq6Zu3mRw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SFKIrluacUKxgPM0Dk_COA"
      decimals="2"
      id="Narr_ukXy4RGGIEmaFnuU26_FMA"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">1.20</us-gaap:SharesIssuedPricePerShare>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg"
      decimals="-3"
      id="Narr_av3R367pV0iTl-iwyaWnqA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">6000000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg"
      decimals="-3"
      id="Narr_uexMUjpwtEG43se5R321XQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5184000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_66gOUrgOGkmMATI_UYMUcA"
      decimals="INF"
      id="Narr_JoJio7LjO0yOmIvqGogosA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA"
      decimals="-3"
      id="Narr_LWiPboIUzEeAsuLKTowSkw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ"
      decimals="-3"
      id="Narr_xSLyHPLaJ02AVZPaFJ_vvg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_tmsK5gJjDEiJqCCIyIfuSw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">41562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_BMASJtCJpkCJY7KgNRNEJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; deficit as a reduction of proceeds generated as a result of the offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be 5 and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2022 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Convertible Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 815,&#160;&lt;i style="font-style:italic;"&gt;Derivatives and Hedging Activities&lt;/i&gt;&#160;(&#x201c;ASC 815&#x201d;) requires companies to bifurcate certain conversion options and redemption features from their host instruments and account for them as free-standing derivative financial instruments should certain criteria be met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also follows ASC 480-10,&#160;&lt;i style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a)&#160;a fixed monetary amount known at inception; (b)&#160;variations in something other than the fair value of the issuer&#x2019;s equity shares; or (c)&#160;variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2022 and 2021, the Company generated grant income of $22,217 and $17,447, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2022 was $1,702 and $1,686, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2021 of $753 and $0, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The Company is involved in research and development aimed at the development of treatments for a variety of diseases related to the central nervous system, with a primary focus on Alzheimer&#x2019;s Disease. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$616&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and corresponding current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$130&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$486&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. The Company will continue to report financial information for fiscal years ended before December 31, 2021 under ASC 840.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impact of Adoption of ASC 842 on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2022 and 2021 that met the recognition threshold.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/i&gt;, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. In addition, the Company records its warrant liability, derivative liability, and SAFE at fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $1 and $11 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The Company presents comprehensive loss in a single statement within its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;Basic net loss attributable to common shares is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss attributable to common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the impact is anti-dilutive. The Company&#x2019;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (ASU) No.&#160;2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(Topic 842). ASU No.&#160;2016-02 requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company adopted ASU No.&#160;2016-02 on January 1, 2022. For additional information on the adoption of the new leasing standards, please refer to the section titled &#x201c;Leases&#x201d; above, and Note 7.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;i style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for all entities. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i style="font-style:italic;"&gt;Government Assistance (Topic 832)&lt;/i&gt;: Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on an entity&#x2019;s financial statements. The Company adopted ASU 2021-10 on January 1, 2022. The adoption of ASU 2021-10 did not have a material impact on the Company&#x2019;s consolidated financial statements. For additional information on the Company&#x2019;s governmental assistance transactions, please refer to the sections titled &#x201c;Grant Receivables&#x201d; and &#x201c;Grant Income&#x201d; above. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In July 2021, the Company's board of directors approved an amendment to the Company's second amended and restated certificate of incorporation to effect a &lt;span style="-sec-ix-hidden:Hidden_nQx1SsH8n0-iTW-hmt6Uqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;-for-3.2345 reverse stock split of the Company's common stock, which was effected on October 1, 2021 with a filing made with the Secretary of State of the State of Delaware. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;shares. The par value of the common stock was not adjusted as a result of the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of our convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. All common share and per share data have been retrospectively revised to reflect the reverse stock split.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_ZEy4tDRVPUiKXi3KHIpwFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_uRy5-avr0UmNNTvMIVgPvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_ycqCCCBC7ESSvE7R-mLwsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_hmH_YpikbU2cNBS4ShBq6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:20.15pt;margin:0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <cgtx:AllowanceForCreditLossGrantsReceivableCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_yk07746wTkeS2bZijnFCjw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</cgtx:AllowanceForCreditLossGrantsReceivableCurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_VKh_bkzKz022NBKIk0_9mg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; deficit as a reduction of proceeds generated as a result of the offering.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_IZwaffecFkOCkeGesRQAWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be 5 and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2022 or 2021.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_J2XBpl_S60WJ_31CJUKMPQ"
      id="Narr_nI6KLxb_SkGnigACNAO8uQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MFx5PzsB3EiVmUbOAvS2KA"
      id="Narr_ogizgEhlREKzarxJM9l2sw">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <cgtx:ConvertibleInstrumentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_Th91FmEBC0y5T1TcNa8YOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Convertible Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 815,&#160;&lt;i style="font-style:italic;"&gt;Derivatives and Hedging Activities&lt;/i&gt;&#160;(&#x201c;ASC 815&#x201d;) requires companies to bifurcate certain conversion options and redemption features from their host instruments and account for them as free-standing derivative financial instruments should certain criteria be met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also follows ASC 480-10,&#160;&lt;i style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a)&#160;a fixed monetary amount known at inception; (b)&#160;variations in something other than the fair value of the issuer&#x2019;s equity shares; or (c)&#160;variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date.&lt;/p&gt;</cgtx:ConvertibleInstrumentsPolicyTextBlock>
    <cgtx:GrantIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_gd4A6geI_0COkyTu-PrykA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2022 and 2021, the Company generated grant income of $22,217 and $17,447, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2022 was $1,702 and $1,686, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2021 of $753 and $0, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2022, the Company has been awarded grants with project periods that extend through May 31, 2026, subject to extension.&lt;/p&gt;</cgtx:GrantIncomePolicyPolicyTextBlock>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr__DZS2aZMmUqwwmYbLMst4A"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">22217000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_OHnm-hYN3U2rzjCFde5UNw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">17447000</cgtx:GrantIncome>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_pQWi8HP5gUKdCMU0ONxszw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1702000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_tUjGLjd65kGOpUKhyqAbZg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1686000</us-gaap:OtherLiabilitiesNoncurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Narr_Ui-VGuCNhkKdld0VuywG7Q"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">753000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Narr_E5sVNV0f4k-zUB6q3tbSFA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_xKJFxVyp40ScjBY_juKVyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The Company is involved in research and development aimed at the development of treatments for a variety of diseases related to the central nervous system, with a primary focus on Alzheimer&#x2019;s Disease. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_wdigME0q-kG4oJBani_4vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$616&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and corresponding current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$130&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$486&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. The Company will continue to report financial information for fiscal years ended before December 31, 2021 under ASC 840.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impact of Adoption of ASC 842 on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg"
      decimals="-3"
      id="Narr_-Bl0PBAgPEKzeF9n1jaJqw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg"
      decimals="-3"
      id="Narr_GJbIaGNLO0WBQBz9vLu4kQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_0bbAreOlQ0-rUL4UBPsXkg"
      decimals="-3"
      id="Narr_MhK73cZzLEWz0AtC-iRK2A"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_rrAupAMvVE-QMlW0lrYRMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg"
      decimals="-3"
      id="Tc_2kEua8umX0eRzaul5dzOIA_4_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g"
      decimals="-3"
      id="Tc_avK-ybi7lkecfJdDqR1Stw_4_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentCredit
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_5Llp0meHlE2FcF9C5kq5gQ"
      decimals="-3"
      id="Tc_XzuZjR28NUautDMZnemn3A_5_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">6000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg"
      decimals="-3"
      id="Tc_nw-qnrQJYkql8VDw1v5ISg_5_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-6000</us-gaap:DeferredRentCredit>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg"
      decimals="-3"
      id="Tc_U-nDG4aiykSRgSx2TJxZUA_6_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g"
      decimals="-3"
      id="Tc_zd01b8Ah5kW1cDbaIJO0Fg_6_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_6hlBJbvQcUKJHdeaTNpEYg"
      decimals="-3"
      id="Tc_GHSn6klXkEGRhfeux2dIiQ_7_5"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g"
      decimals="-3"
      id="Tc_Z9TT7RU89ECsDxL3RL_i-A_7_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_MSqUJbwlSU2z-7lOQrrIIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2022 and 2021 that met the recognition threshold.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Narr__W1ntDxmykitutUHgApvBA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_B2NgQKYgQkiecFOZafMjDQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_vuUNc9qB4UWUJ8GExE85wA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/i&gt;, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Narr_xM56a7lpQkmP2n51JMV4UQ"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_MGGVewFWn0qSW4H2c0EH0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_grE2YiiueEiimwmcOoCS2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. In addition, the Company records its warrant liability, derivative liability, and SAFE at fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_sXdrYoeek0i3ukWLx2pX8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $1 and $11 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The Company presents comprehensive loss in a single statement within its consolidated financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_SqnraH5sMUmIs1qJpG0KPg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_7BGFFHBTX0OpSMyIMj2b3Q"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_sKlVElPsLUWU9Di_DZLAfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;Basic net loss attributable to common shares is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss attributable to common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the impact is anti-dilutive. The Company&#x2019;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_FqR_EpOMmkimZX224pLnrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Narr_KI0RUBIR5UKPoYyc8a3ftw"
      unitRef="Unit_Standard_segment_0QdZH6dU9kC3NWhic3Tuew">1</us-gaap:NumberOfOperatingSegments>
    <cgtx:EmergingGrowthCompanyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_46voZ798N0mAGjFmSK-mdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</cgtx:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_wVmY2Kwaw06ri7QWS68q4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (ASU) No.&#160;2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(Topic 842). ASU No.&#160;2016-02 requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company adopted ASU No.&#160;2016-02 on January 1, 2022. For additional information on the adoption of the new leasing standards, please refer to the section titled &#x201c;Leases&#x201d; above, and Note 7.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;i style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for all entities. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i style="font-style:italic;"&gt;Government Assistance (Topic 832)&lt;/i&gt;: Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on an entity&#x2019;s financial statements. The Company adopted ASU 2021-10 on January 1, 2022. The adoption of ASU 2021-10 did not have a material impact on the Company&#x2019;s consolidated financial statements. For additional information on the Company&#x2019;s governmental assistance transactions, please refer to the sections titled &#x201c;Grant Receivables&#x201d; and &#x201c;Grant Income&#x201d; above. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgtx:ReverseStockSplitPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_X5HqJQdFZkuNg096qRr4YQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In July 2021, the Company's board of directors approved an amendment to the Company's second amended and restated certificate of incorporation to effect a &lt;span style="-sec-ix-hidden:Hidden_nQx1SsH8n0-iTW-hmt6Uqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;-for-3.2345 reverse stock split of the Company's common stock, which was effected on October 1, 2021 with a filing made with the Secretary of State of the State of Delaware. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;shares. The par value of the common stock was not adjusted as a result of the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of our convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. All common share and per share data have been retrospectively revised to reflect the reverse stock split.&lt;/p&gt;</cgtx:ReverseStockSplitPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_JUCF3w8DHEysL0CI-VZwLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Financial Instruments and Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Financial assets and liabilities measured at fair value are summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;There were no Level 3 financial instruments during the year ended December 31, 2022. The following table sets forth a summary of the changes in fair value of the Level&#160;3 liabilities for the&#160;year ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SAFE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value recognized upon the issuance of SAFE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in the fair value of the derivative liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,209)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,209)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in the fair value of SAFE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value recognized upon conversion of SAFE into common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,178)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Derivative Liability&#160;&#x2014;&lt;/span&gt;&#160;The Company recognizes derivative liabilities as a result of the issuance of the convertible notes that contain conversion and redemption features that are required to be bifurcated. The fair value measurement of the derivative liability is classified as Level 3 under the fair value hierarchy as it has been valued using certain unobservable inputs. These inputs include: (1) probability of occurrence of future events (such as a qualified financing or a sale), and (2) discount rate for implied return required by investor. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The fair value of the derivative liability was determined by calculating the fair value of the notes with the conversion and redemption features as compared to the fair value of the notes without such features, with the difference representing the value of the conversion and redemption features, or the derivative liability. The conversion and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;redemption features are measured at fair value as of each reporting date and the change in the fair value for the period is recorded in the consolidated statements of operations as a change in the fair value of the derivative liability. The fair value of the derivative liability is based on Level 3 unobservable inputs. Changes in fair value are recognized as a gain or loss within other income (expense) on the consolidated statements of operations and comprehensive loss. The derivative liability expired unexercised upon the conversion of the convertible notes into Series B-1 convertible preferred stock in May of 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Simple Agreement for Future Equity&#160;&#x2014;&lt;/span&gt;&#160;On March 25, 2021, the Company entered into SAFE with existing investors, pursuant to which the Company received gross proceeds in an aggregate amount equal to $8,942. The fair value of the SAFE liability is estimated using a fair value model that includes inputs such as: (1) probability of occurrence of future events (such as a change of control or public offering), and (2) discount rate for implied return required by investor. The Company recorded a change in fair value adjustment of $2,236 in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2021. Upon the occurrence of the Company&#x2019;s IPO on October 7, 2021, the SAFE converted into 931,485 shares of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The fair value of the SAFE was determined using a probability weighted expected return method (PWERM), in which the probability and timing of potential future events is considered in order to estimate the fair value of the SAFE as of each valuation date. Management determined the fair value of the SAFE using the following significant unobservable inputs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;October 7,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 25,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Conversion)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Issuance)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount upon conversion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;20.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;20.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount upon implied return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;18.9%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;18.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of IPO occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;100.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;45.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of dissolution event occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;15.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of equity financing occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;37.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of change of control occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In addition, the Company recorded the Series B-1 convertible preferred stock within mezzanine equity at fair value on the date of issuance, May 1, 2021. This non-recurring fair value measure was based on level 3 unobservable inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In April 2020, the Company received a $443&#160;unsecured loan, bearing interest at&#160;1.0%, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;), a program implemented by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) (the &#x201c;PPP Loan&#x201d;). The PPP provided for loans to qualifying businesses for amounts up to&#160;2.5&#160;times of the average monthly payroll expenses of the qualifying business. The loan and accrued interest are forgivable after eight weeks if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The amount of loan forgiveness may be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over&#160;two years&#160;at an interest rate of&#160;1.0%, with a deferral of payments for the first&#160;six months. The Company used the proceeds for purposes consistent with the PPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;On January 21, 2021, the Company received confirmation from the SBA that the PPP Loan had been forgiven in full, including all interest incurred. Accordingly, the Company recognized $443&#160;of income for the debt extinguishment pursuant to ASC 470-50-15-4 for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_JLMKkWvsMESTL0H8UVt4wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oSyBIfvMNk2jXeReNnXygw"
      decimals="-3"
      id="Tc_Gv0CyJ5jxU-kUY5gCU3P-w_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">37479000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hNnv6GZ7IUi4mGR9CBNWEQ"
      decimals="-3"
      id="Tc_vLZBIAW9DUCnh9Ge1HtaGQ_7_12"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">37479000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_RcqZUt4qD0CDmwKu-H5W3Q"
      decimals="-3"
      id="Tc_4993jqkGQ0qELNKI2TODaQ_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">37479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_T2UqkgAY5ESys8dB3tOsdg_8_12"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">37479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_t-1Qw68sI0aC5oM3AVvG-Q"
      decimals="-3"
      id="Tc_Hj91V5J52UeV7XcGiMqXsw_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">46687000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_Ht59q_5JiEiVhpo-kC0tEg"
      decimals="-3"
      id="Tc_EikLu5WySUuS7dGaYKR5_w_7_12"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">46687000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_JWuAV66_FkKYy9ml74D0OQ"
      decimals="-3"
      id="Tc_BhNUgpB2J0yKP708bBKFiA_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">46687000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_1aKfUI7VvUCMHFU3jUdSGA_8_12"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">46687000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_5d2bKe0p1Ea-mQno3JQOJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SAFE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value recognized upon the issuance of SAFE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in the fair value of the derivative liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,209)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,209)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in the fair value of SAFE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value recognized upon conversion of SAFE into common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,178)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_YEX4tFts9UqlH27hYh2GNg"
      decimals="-3"
      id="Tc_b4wFk7bKyEKEjEHdtJ-b0w_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f9FhQl3y6EiSdHDswe6MEQ"
      decimals="-3"
      id="Tc_NMnXP7C6aU-4Hn11VFSxvQ_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw"
      decimals="-3"
      id="Tc_j4pvfSykykSSUFnoURQ5sA_4_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g"
      decimals="-3"
      id="Tc_tueCY50SO0eqlailL8rt7Q_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8942000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_AoY1YKKaKEGg7pzxmISf-w_5_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8942000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <cgtx:FairValueAdjustmentOfDerivativeLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_QGjdHn6BlEOiqD30uxaG1Q"
      decimals="-3"
      id="Tc_bsqSl_Bl1Um6o8LrdPhCOw_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</cgtx:FairValueAdjustmentOfDerivativeLiability>
    <cgtx:FairValueAdjustmentOfDerivativeLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_P5R_mOavjUmPsdRUGN9rxQ_6_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2209000</cgtx:FairValueAdjustmentOfDerivativeLiability>
    <cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g"
      decimals="-3"
      id="Tc_MhiZD1SNFUO3fRSu0VqKRg_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2236000</cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity>
    <cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_nA0ojTCshUu2tqhBGiDNJw_7_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2236000</cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g"
      decimals="-3"
      id="Tc_uiFqp3bXo0iA_WcRix8mFw_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">11178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_BocQ-3FLqEuyl1iv2uRAmw_8_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">11178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_AE0FpwKs-EOageu6dOfl8A"
      decimals="-3"
      id="Tc_iJj0zIiPCES5iFxI1Mb3UA_9_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_FHzzyuPXwUKyBLXHpnwHPw"
      decimals="-3"
      id="Tc_GoqltU9TIEKsmFb7klWl4A_9_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_QSoMt9G_HUS8I4_gcMCT9g_9_9"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <cgtx:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="Duration_3_25_2021_To_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember__NxCd_fmOkGpRip87LsWsA"
      decimals="-3"
      id="Narr_PnLdHaHUx0SvD5I0cd2mvA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8942000</cgtx:ProceedsFromSimpleAgreementsForFutureEquity>
    <cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_D-TX2Xc6y0CNaTHj6k6c2g"
      decimals="-3"
      id="Narr_RQA2vsMtwUi1DodLU5io-A"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2236000</cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_10_7_2021_To_10_7_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfSimpleAgreementsForFutureEquityMember_J1qjrKQ97UC4V1Qbkn0BVw"
      decimals="INF"
      id="Narr_-Q5DwhgnXkO13eDjSFRH4A"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">931485</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_fgLiHxsGP0uXE9jzjas5Uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;October 7,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 25,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Conversion)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Issuance)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount upon conversion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;20.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;20.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount upon implied return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;18.9%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;18.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of IPO occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;100.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;45.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of dissolution event occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;15.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of equity financing occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;37.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Probability of change of control occurrence&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TIObl80f7UWIvJjeNn-tkA"
      decimals="INF"
      id="Tc_uT4RsB85EU6D7J6Ihiq7AQ_4_4"
      unitRef="Unit_Standard_Y_KVexRmvX6US-liK6aNll8Q">0.35</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_MxmsAkGlGk6Tkcg1-sC0nQ"
      decimals="1"
      id="Tc_bztRM48Bdkep9KdH0EfXwQ_5_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">20.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponConversionMember_ngpHUyNFakCau2ySwCxAGQ"
      decimals="1"
      id="Tc_woXIhuJk7UKLhS_moiK8vA_5_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">20.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_1ncZ0wDVjUaMv3n8bW5Qww"
      decimals="1"
      id="Tc_XPD278HWL0mhVBV6oH-gXQ_6_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">18.9</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputDiscountUponImpliedReturnMember_h4s2HAgDWEyJ3_wpwJxxJg"
      decimals="1"
      id="Tc_THgzKtzz50moGjLX7ki4cA_6_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">18.9</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_raLm_xXRuUiTAX_TParm5g"
      decimals="1"
      id="Tc_lg0-n3MmUkC9DQdqZZLojA_7_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">100.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember_iqb3nfvhzUGG9vyRKPjbLQ"
      decimals="1"
      id="Tc_Eg23mIYqpkS0x8H1i_9E1Q_7_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">45.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_vyxTfLKJxUW9zuhqZTsSFg"
      decimals="1"
      id="Tc_hTjQAtCFrkaa-R9N0nyhgw_8_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember_QoK-U_gP1Ua8QKYjkoygBw"
      decimals="1"
      id="Tc_qua8UH1qg0uJKv8GOXXVOA_8_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">15.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_Ew7Kbm3OAEy6EtEDlHqmug"
      decimals="1"
      id="Tc_btl8ggaF5E6UYDPoi5GXFw_9_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember_O1QXNgSInE2t6P_Ih0REuA"
      decimals="1"
      id="Tc_ju2feHBvMEOClcta9tLQbg_9_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">37.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_10_7_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_T1dodM-JUE2PyHPTE4fWQg"
      decimals="1"
      id="Tc_fDE_6FHB60OXx2PHUcKO9A_10_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <cgtx:SimpleAgreementsForFutureEquityMeasurementInput
      contextRef="As_Of_3_25_2021_us-gaap_FairValueByLiabilityClassAxis_cgtx_SimpleAgreementsForFutureEquityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputControlPremiumMember_HuWBldoXiEChJl-DHcYigA"
      decimals="1"
      id="Tc_SH1togVTsEWtKqhMIFd_LA_10_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">3.0</cgtx:SimpleAgreementsForFutureEquityMeasurementInput>
    <us-gaap:LongTermDebt
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw"
      decimals="-3"
      id="Narr_rob-4UnbmUukLcAQbm-q_w"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">443000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw"
      decimals="3"
      id="Narr_T5T795wE9kGTs0g6v6hUBw"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cgtx:PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw"
      decimals="1"
      id="Narr_F6_MQMdB2k2P6YSFGhW9ZA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">2.5</cgtx:PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier>
    <cgtx:PeriodOverWhichUnforgivenPppLoanPayable
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw"
      id="Narr_VFQkMFDYtU-xifq2R5SeBA">P2Y</cgtx:PeriodOverWhichUnforgivenPppLoanPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw"
      decimals="3"
      id="Narr_f0FeNir8A0WhKppxAs82pA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cgtx:LoanDeferralPaymentsPeriod
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_-GCCPXEk-0at2PjSaX0Zjw"
      id="Narr_XeMTPrcMzkCpO7KdQdpDsw">P6M</cgtx:LoanDeferralPaymentsPeriod>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_cFNoQhYPU0-zSAcDylTH8Q"
      decimals="-3"
      id="Narr_BPJIngi5w06sL2WUOn9XAw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">443000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_Gv_uMtgvIkuaopriRsHKwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Property and equipment, net, consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (870)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;Depreciation expense for the&#160;years ended December&#160;31, 2022 and 2021 was $83 and $93, respectively, which includes amortization expense of $2 and $38 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_-8XC0xGvf0qxnc7E7EYv7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (870)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_zSXdcVC8VE-7xnTJfzdRMQ"
      decimals="-3"
      id="Tc_kOV7Bo1VyUGoazXyHPm3ag_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1057000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_aO4rFi4jSEyn8DSa70-4Pg"
      decimals="-3"
      id="Tc_89CX-O-SnEertb7Qd8-Lyg_3_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1014000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-GYnhwP-wE6fE3kPKJhleg"
      decimals="-3"
      id="Tc_o1JqiN7jnUWBMoHvnXey8g_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_NdALTKUy0kmXAWKzuRjFpQ"
      decimals="-3"
      id="Tc_tczQgHup_k25b9nnFi6YTQ_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_qWvN1g_NnUC1FsLJCflOyw_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_MSOlyJK7WkafoEAuYwp3OQ_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1015000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_MQBfTaJ0yEaLhVhAuERuEQ_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">953000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_Cpc29J_v7UaWccW3DuzCNg_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">870000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_MLPLU1LWc0q-k63IGKVhWQ_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_QKeMGtkFbE-Dy4Yzt-_AZQ_7_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">145000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_udPTuXyqPkKaXa9dioG1sA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">83000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_reIOU8NDMUSTJddHXZAuoA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">93000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_oVyLWCdtYkeIcRMNOujSEA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_R9aO5HZXykmtBUkaqS_Jbw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">38000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_j_j6hjecqUWKtcYcpg9j7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Accrued expense consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal reserves, professional fees, and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_pameAXwS8E6zgxF2e_dq8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal reserves, professional fees, and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_RQSdMuXRnkO4yNMOFd1dWQ_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">870000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_n9yNu-KAYU2fk5VvAUQ5Zg_3_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1285000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_zrkGgkokP0-yub9HBhCYhA_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">900000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_tuDJMgxXGUKmuYTFRKyecw_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">250000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_lem7sFGNdUS4MdFA5Dcqag_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">324000</cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent>
    <cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_s5S5MRJA70CLPUyheRVbvQ_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">216000</cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_EJi_TguLAEGtBMq7MVjsnQ_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2094000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_f-OSJfKCZ06se6lYwK4skA_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1751000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:OtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_4_PkVu-K3kyf0KmFPkHCBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $838 of certain premiums at a 6.85% annual interest rate. Payments of approximately $72 are due monthly from November 2022 through December 2023. As of December 31, 2022, the outstanding principal of the loan was $634 included in other current liabilities on the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;In October 2021, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $1,453 of certain premiums at a 3.25% annual interest rate. Payments of approximately $134 are due monthly from October 2021 through September 2022. The loan paid in full as of September 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cgtx:OtherCurrentLiabilitiesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw"
      decimals="-3"
      id="Narr_o9pqSCH9S0quhv-OqZaHrQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">838000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_M8FtIIdlG0iZw_A42RCWzw"
      decimals="4"
      id="Narr_EWVlgr5r8EC_L4Ho7--lRQ"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0685</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_uHgL9nAXWUGXP88TL0_l4Q"
      decimals="-3"
      id="Narr_sadx5Y-jWEiiUEJEyselnA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">72000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA"
      decimals="-3"
      id="Narr_bkIhYmZevU6wvLmfVAOTcA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">634000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA"
      decimals="-3"
      id="Narr_JvssCYPdjkyIHws7kOP5kA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1453000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_S0XiO18knkyXqAPDbz2DIA"
      decimals="4"
      id="Narr_0zcQS88ZpEKn9dv4z9bArg"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_XP8oKPKT_Ei7TjXFOpwjtA"
      decimals="-3"
      id="Narr_MUIUetZns0-uOi5KDeIYxQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">134000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_rgbDy3ss10qBgjKOlipX-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2022 were as follows, in thousands:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease costs for the year ended December 31, 2022 was $203. Rent expense was $163 for the year ended December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2022 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating cash flows used for operating leases for the year ended December 31, 2022 was $172.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Litigation and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;As of December&#160;31, 2022 and 2021, there was no litigation or contingency with at least a reasonable possibility of a material loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_nwX8yS5_AE26RPa_9Fo2wg"
      decimals="INF"
      id="Narr_lpBVVLiO3U-4zI0xR3ygiA"
      unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g">2864</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_b88oSDVpj0-qGHOfTzZbKA"
      decimals="INF"
      id="Narr_ecn7_F-bE0SI_JhIAM69HQ"
      unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g">6068</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_96iu6bqRR02okgqdFfwfwQ"
      decimals="INF"
      id="Narr_ma2rToQhAUmjjWqxR5u96A"
      unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g">2980</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_Z7obri4_Hk2MEqxX8hrVuw"
      id="Narr_XDbUWts0vU2crjlR5bTvcA">P45M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA"
      decimals="INF"
      id="Narr_Ai5d90cXQUqbI7Qj2BjYcw"
      unitRef="Unit_Standard_lease_aWodb89n40ua9F3TL8eTqQ">1</cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_Rpf7b_dG7EWGkAdIe-25RA"
      decimals="INF"
      id="Narr_LQ20bH7lykG3YbuhQGEovA"
      unitRef="Unit_Standard_sqft_QSmZUu_lG0yTgVSftTw84g">3706</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Group_6-XPdodKVUqolN4a2JQTBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <cgtx:OperatingLeaseAssets
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_Kn1Ei9x5vkqyVhVrcBBybA_4_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">813000</cgtx:OperatingLeaseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_EwW2UN8cckqkYRv7DUjWgQ_5_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">813000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_jNNqlkOoF0ikAJbaK7PZQQ_8_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_iYDvOM-W5k-RI7XtAutzsw_10_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_M6G_bq7ZBUePK5k5dwVzFg_11_2"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">844000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_auSOfrk73UGf8prOT74NTg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">203000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_83bFHNW5nUy3ew9VgP2MoA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">163000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_tz1zbV39IkKrHKdou5Sgtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2022 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_9ktvMSqJGEyKijLJVsd6vw_2_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_kPx9WhSJY0S8btTdIFoXjA_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">221000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_nP2ztAHZFUu8RABLQ2F0Tg_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">222000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_efwNkoF7IU626Tjx_31VKw_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">155000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_JTnvlWBtwEqTVYy1MbTgxQ_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">87000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_adJVq1UZTE2VFNZMYyZ-ww_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_XCUF6qpLVkq7fbu03hmnww_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1020000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_7o_VzPl4FUOnmmk75XFaww_9_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">176000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_8vbx8iZHOkK5U75SgZ6MEg_10_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">844000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      id="Tc_js0GYZStjEao7o3FRMU_7Q_4_1">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="3"
      id="Tc_RA2XhUlsRUm_MLhIR0JaIw_6_1"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_VSgJWU6UpEmEIRHmZZHDqQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">172000</us-gaap:OperatingLeasePayments>
    <cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_NJNMVwxkBESjLd0COC-ieA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2022 and 2021, there were 28,991,548 and 22,230,032 shares of common stock &lt;span style="-sec-ix-hidden:Hidden_zrVKOEsWWUen0jAD0vBoIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_Y0sKS617cUG-4b1iHZkpJw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 13, 2021, in connection with the completion of the Company&#x2019;s IPO, 2,819,027 shares of Series A convertible preferred stock, 3,730,366 shares of Series A-1 convertible preferred stock, 3,565,063 shares of Series A-2 convertible preferred stock, 30,409,890 shares of Series B convertible preferred stock, and 10,926,089 shares of Series B-1 convertible preferred stock automatically converted into 15,906,537 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Common stockholders are entitled to dividends if and when declared by the Company&#x2019;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2022, no dividends on common stock had been declared by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;As of December 31, 2022 and 2021, the Company has reserved the following shares of common stock for issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,561,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,242,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,450,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,092,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_astV6RG0N02PQZjh4hkZ3A"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_877D-dW31EO1hsoW00zheg"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_ehcgtF-SMU6uSAARc68shQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_ADrj0ktxNUW9bP0ZDZ0q3w"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Narr_G09Qmz_rEEuHNoNOIRH5Bg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">28991548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Narr_tn17Xy4CSUyYEvmUuMAgeA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">22230032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesaConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TaoGs-evLUaQbSnfNKRUJg"
      decimals="INF"
      id="Narr_LOtYLqly0kiSeFbfWPa7NQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">2819027</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YhglPqSICEOHSV_IdZw7eA"
      decimals="INF"
      id="Narr_A-Di9OP4i0iE0C6BKAPA8g"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3730366</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_uKNBRS7LKkeAraJh_fQoTw"
      decimals="INF"
      id="Narr_IQHmnl1SVE2pVIda9aZQ4Q"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3565063</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k0Fx52yg8EmU-X-cmYFt2Q"
      decimals="INF"
      id="Narr_zjmRhKEms0mWVxAnmWixug"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">30409890</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_10_13_2021_us-gaap_StatementClassOfStockAxis_cgtx_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_enLCj8Q1xEml8KVpBZ04bA"
      decimals="INF"
      id="Narr_ViiCLS-r-EGSGgk2bfoH4A"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">10926089</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cgtx_ConversionOfPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vY7MsB0UvE6nAnb_o3Wa-w"
      decimals="INF"
      id="Narr_bLCSVmRZekeyhHdm7au9-A"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">15906537</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_gbDH_7aUoUexdPtbkFkU5w"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_UCUl7csCDEC4QZT6_aIA-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,561,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,242,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,450,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,092,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_-IP8DBZpCUSLq5j3zp66OQ"
      decimals="INF"
      id="Tc_b-EA8DzqX0yWYxilJF6Bhw_3_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3679468</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_Sm3lzM60aUOPdd-qCWli3w"
      decimals="INF"
      id="Tc_DmRJkWBRQka3KRpB7l41FA_3_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5640438</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_N1dAezJ1BEmEY5K2pYrnWw"
      decimals="INF"
      id="Tc_vJl71nafWkm_GNWfdcFbJA_4_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">2561085</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EquityIncentivePlan2021Member_2SLhlXLD40WSZNvO2Kvf4Q"
      decimals="INF"
      id="Tc_BiBL3JHq80Ou6cXSge_nIg_4_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1242271</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_sct--jfhGkOI2iY08mN67g"
      decimals="INF"
      id="Tc_eCgoxHVBtkSQXmf7WjivDQ_5_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">209532</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cgtx_EmployeeStockPurchasePlanMember_XL_cLPnem0WdnDFZvFsDSA"
      decimals="INF"
      id="Tc_g-riIXWMT0Kh2ve9W3PLlA_5_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">209532</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Tc_ukGpJxePwE2csPRGpV6fFQ_6_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">6450085</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Tc_jQxzhupxJkmZfydKsnKRmA_6_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">7092241</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_k04wlCQ0-EmNIO6tHSOtIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 7, 2021, the date upon which the Company&#x2019;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,561,085. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2022 pursuant to an evergreen provision therein by 1,111,502 shares, representing 5% of total common shares outstanding at December 31, 2021. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#x2019;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#x2019;s Board of Directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2017 Plan or the 2007 Equity Incentive Plan (the &#x201c;2007 Plan&#x201d; and collectively with the 2017 Plan, the &#x201c;Prior Plans&#x201d;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 15, 2017, the Company&#x2019;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#x2019;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#x2019;s common stock at a discounted purchase price. As of December 31, 2022, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.72 &#x2013; $3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.75 &#x2013; $6.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.09%&#x2009;&#x2013;&#x2009;92.73%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100.82%&#x2009;&#x2013;&#x2009;101.83%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.87%&#x2009;&#x2013;&#x2009;4.22%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.67%&#x2009;&#x2013;&#x2009;1.06%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.50&#x2009;&#x2013;&#x2009;6.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00&#x2009;&#x2013;&#x2009;6.22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2009;&#x2014;&#x2009;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#x2019; expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#x2009;&#x2014;&#x2009;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividend Yield&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value of Common Stock&lt;/i&gt;&#x2009;&#x2014;&#x2009;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Activity for options was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 524,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,761,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (646,072)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,752)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,253,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of stock options granted was $1.83 and $9.09 during the years ended December 31, 2022 and 2021, respectively. There were 524,370 stock options granted at an aggregate fair value of $943 for the year ended December 31, 2022 and 1,697,076 stock options granted at an aggregate fair value of $15,424 for the year ended December 31, 2021. During the year ended December 31, 2022 and 2021, there were 1,761,516 and 321,686 stock options exercised, respectively, with an aggregate grant date fair value of $1,325 and $188, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2022 and 2021 was $2,738 and $1,610, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to incentive stock options and nonstatutory stock options as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,044&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, total future compensation expense related to unvested awards yet to be recognized by the Company was $6,501. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately 2.0&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw"
      decimals="INF"
      id="Narr_iEOmeOWnWUeEVW0qwLtJJg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">2561085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_n6-tqTA3EkmAO2tyD5S7NQ"
      decimals="INF"
      id="Narr_F3NSiDSoTU-VP_etUBF1CA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1111502</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_NPy6437bOUm5rmu1Uvq-zQ"
      decimals="2"
      id="Narr_rFNBnZqrukmiWGqw2AobeQ"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_1pumPUEKZU2T8noHh3EBSw"
      decimals="2"
      id="Narr_C-8NqfSLakGv5d-R5uO8ow"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkBqUzrULkqvOk4_Dzd2oQ"
      decimals="INF"
      id="Narr_8aR4WWYeO0Cdd9Cl6xmcvg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">7543185</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_o7_NCY7X206Pt4cn0mc_Bw"
      decimals="INF"
      id="Narr_SNLI1-vwTUeD3xkiMMjQLg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">4334131</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_yahv0OkpPEaYE1i-7KtT_A"
      decimals="INF"
      id="Narr_uQb93s24yU6wb-7V4mrlvA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">4334131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_LRRxx2Dlh0uhljHR9SnyHQ"
      decimals="INF"
      id="Narr_pyhNX1A_lEWC9uRokyTaJQ"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">209532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w"
      decimals="INF"
      id="Narr_hxVnFPmIVUOw6ds7o7K_dg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_lY_FvlOAkk6u6bSvZznW5w"
      decimals="2"
      id="Narr_JLSmhOtMMEyvsABqAAR4zA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_-K212FCHr0qteLAy0uDpyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.72 &#x2013; $3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.75 &#x2013; $6.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.09%&#x2009;&#x2013;&#x2009;92.73%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100.82%&#x2009;&#x2013;&#x2009;101.83%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.87%&#x2009;&#x2013;&#x2009;4.22%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.67%&#x2009;&#x2013;&#x2009;1.06%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.50&#x2009;&#x2013;&#x2009;6.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00&#x2009;&#x2013;&#x2009;6.22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_XYAfduBLiEyYZK5YwTJYpw"
      decimals="2"
      id="Narr_lJS9WZo82EKuX_pjNjHvjQ"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">1.72</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_Mm4HIB07WkaEjnsTACDzAA"
      decimals="2"
      id="Narr_i4jVeHL0CEmS0lufhmlcRg"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">3.05</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Osz1MgsDcEWWlW4jGAr1bw"
      decimals="2"
      id="Narr_Cf1h5ESEQUmHZw4NBaLplA"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">1.75</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DVoBTPqoMkip6hYlwzicaA"
      decimals="2"
      id="Narr_BLIKJJvv00mkkBka0p4HJw"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">6.15</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="4"
      id="Narr_NWSVc2ApeEyeocBS5ljQeQ"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.9109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="4"
      id="Narr_ECnC1Xy4WUidcX9WSWA53Q"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.9273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="4"
      id="Narr_kfUO_Zt4Qk2_dM2uZ47z9A"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">1.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="4"
      id="Narr_doXD5O25l0WQz1gMOLFMlA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">1.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="4"
      id="Narr_oIZ4GUCuM0-dE9ABTRvn0Q"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="4"
      id="Narr_lA3rllV8YkWQAa6ZRxyMUA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="4"
      id="Narr_yc0dcU_QwUKHfpsEqVEhfQ"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="4"
      id="Narr_8_6iQW_3GkWfOsXs9ZGpkA"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="4"
      id="Tc_2YtABIE9nkmRtllMyc55ZA_6_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="4"
      id="Tc_CNi8szm7nUiWZcJySleFvg_6_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_7A9Z0eNU2kGCYq5FHtJgjw"
      id="Narr_GrEkMuHglkawbUgJd8Q9mg">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6lpHwpsw-EWJo0Zgq6rNcA"
      id="Narr_YAOfTegJsEqFyFGEr6etBw">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_oXjUmgTrE0eWw47O5kihsg"
      id="Narr_VpI5Ibn6nU2v4d7Dy8P-BA">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_kLTU2zUbVEic1iFZs3Jr4A"
      id="Narr_lmMbSMs4OUihHshdiBNYiQ">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Narr_DZ6deQUzl0epB5ABUzs-bw"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_5WaUJ5A6rkqBgfCU7iKUdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 524,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,761,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (646,072)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,752)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,253,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.5pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="INF"
      id="Tc_NrfJ4c-ICUGfZBlFljDGLA_7_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5640438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="2"
      id="Tc_Q8At0JJ5_E-CSXrBFay7yA_7_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc__odr_-rRHU-zyH8JtY5CgA_7_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">12002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      id="Tc__m7d0m8IZES0PdW_QpNnUg_7_10">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_IJbUu_nrf0q1ja7Bra0_RQ_8_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">524370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_2t2u2Ie9r0Wujzu7uKrTgA_8_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">2.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_sj8FAvZw8ke04qr6e4BYKg_9_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1761516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_vjEQRjNx80WNqwypjJOcew_9_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">0.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_jzGf0vrEOEWq9R8KnbTW_A_10_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">646072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_NfQWDD4iBUmF9v33HqGJyw_10_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">5.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_Qme3aOuaAkWJlYIbJfagRA_11_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">77752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_OSoCtOA840mUKLMU3Feqrw_11_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">12.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Tc_aiDctbNDP0eW4fsuoxXkfw_12_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3679468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="2"
      id="Tc_pXSqCUgFlk2802CrdPzPIg_12_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_DSZbefkaZECw0hxg2JuvDQ_12_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2085000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_qJIdMUC7BUK5kv8yxGG0kg_12_10">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="INF"
      id="Tc_n04EZCxXSUqZF1_j91_8Gg_13_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">2253389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="2"
      id="Tc_rCHH46avxkKADt4uoyf7Og_13_5"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_pk6mw7k28E6xiM0sbhPhKQ_13_8"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1632000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tc_O1DfG3KaHkioDh5zX07KLw_13_10">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Narr_RMTtHouqw0CO-vY3AEibBA"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="2"
      id="Narr_fin4Dac24kOVa2L-J-5gvA"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">9.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Narr_Beytv4R0qkq8uGJ1KNoEDA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">524370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_8BOfBJuXq0-SU4bCCK3sEQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">943000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Narr_KfqvI5ERA0OkTzH8VWBVmA"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1697076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_rJyc4ARFE0eI1gNngSWwGQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">15424000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Narr_PteIQZh4DUKHQ6HCkshc5w"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1761516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Narr_yrLm3pCZkUy7zf3cJcoqzg"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">321686</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_TRcwDco8HUC4EUWdTWH7pw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1325000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_U7pkZOiQuU-FRuwdK2pOeA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">188000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_WCrqMwLOvkCyiHyYazkS1Q"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">2738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_ocuHpEqxLkyf1pRUjt7hhQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1610000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_GNK_OHQfNE2aprQBh10VMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,044&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aM0FMO2TMEaf1Fu_f9Yn8w"
      decimals="-3"
      id="Tc_oCcAh_lLSkasH-tItRXU1g_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_At8s-OhSw0yRFbaWfIbeww"
      decimals="-3"
      id="Tc_dcAb1isjBUaGJMU8xp1Zow_3_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2QI15J_3YUCTGyt7KkvUew"
      decimals="-3"
      id="Tc_HbeXGZpD50iNjtg7uMlMkg_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sWlYGe9ixUe9X9WZ9DcihQ"
      decimals="-3"
      id="Tc_Yk2_EPovmkuPJN4STJWUzA_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_dKw-vJsxCkC_JGo6hgQ2pg_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_0Qsh-kA0bkSSeBQslMxFqw_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_31Jt8SoqtkmthGVFwSHF-Q"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">6501000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Narr_jfBxq-REkEeb3AT5s6aDYQ">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_JicjruPBDEyRXmMxMtA27g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented due to their antidilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,561,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,242,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,450,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,092,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The basic and diluted net loss per share attributable to common stockholders has been prepared as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,716)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cumulative preferred stock dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,532)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,248)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,640,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,190,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,640,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,190,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-style:normal;font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_C8nIoJ2ZCkGo_4gl4EBBuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,640,438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,561,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,242,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Shares available for future issuance under ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 209,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,450,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,092,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_x9O6RRV7-EqAHJFc8zyb0A"
      decimals="INF"
      id="Tc_mnWQJNlnEUmUeGzbhdqrQA_3_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">3679468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_JbPg3qBfrkinytQJRc8rBw"
      decimals="INF"
      id="Tc_hRFfFbYr_kiEAH_OSFkI3g_3_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5640438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_aYLK7DBMgEenBoD_1pqp7g"
      decimals="INF"
      id="Tc_ILtzk6wRV0iXnjkepteUbA_4_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">2561085</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember_GOEFjr5HT0K3IfUrhIxbaw"
      decimals="INF"
      id="Tc_09_86tSqHECLvApCHiB1mw_4_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">1242271</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_BBPnWdc1jEC6JJ6WU38FKg"
      decimals="INF"
      id="Tc_X1gXKcrM4UGPinShytNgrQ_5_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">209532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cgtx_SharesAvailableForFutureIssuanceUnderEsppMember_Vt-R9TT6a0-mHF1vBUv27Q"
      decimals="INF"
      id="Tc_eEC4F6JCxEygliiMlrq-fw_5_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">209532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_ysqLYlD1ckukD7QmnmRHJA_6_2"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">6450085</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Tc__3NA7JH7I0OquFUICHR88g_6_4"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">7092241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_fHtA4hW6rUataDF5pwuU1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,716)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cumulative preferred stock dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,532)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,248)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,640,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,190,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,640,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,190,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_mhUzJnuQZ0i_uAEDmhaUTg_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_4b3-5U0yDUeH-xRQDhf5ZQ_3_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_KEUq0zUgXkqiD9IRaqpmkg_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4532000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_vNtgiYC9pkGpWedLHTfU4A_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_wxv08s32-Uaet3B9JE07Fg_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-16248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_QDUhCdmQJUGn4SlP35kHsg_8_3"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">23640199</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Tc_m5qF8NDSjES-SDq-U_V2Sg_8_6"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5190883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="INF"
      id="Tc_9Mj5mvUmakmKzqsIMc8eRw_9_3"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">23640199</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="INF"
      id="Tc_t24xAUhCZkS3oYzik6tn4w_9_6"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">5190883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_D6MpqlHtSkGuoJT0jaDlNg_11_3"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="2"
      id="Tc_EIdSDc0K9kuR887QTEvWkw_11_6"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-3.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Tc_1UmAfGfLNkiUbbsQy2STHQ_12_3"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="2"
      id="Tc_ePFce-0W10-guU8csQVu1g_12_6"
      unitRef="Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ">-3.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_0zWOqmJjNU-wGsFg-Cj5Ig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Retirement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#x2019; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $156 and $113 for the&#160;year ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="2"
      id="Narr_vFikY3UU6k6UkfuWLvpq2g"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_Fwae4JVppEuyA4-lkF5bqg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">156000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_DUj44FNAIkCDZBTB1K8Muw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">113000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_3uiTDQ8QQ0yIQPNT-awbAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The net loss consists of the following components:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,384)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,910)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (806)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,716)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2022 and 2021, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) is the excess of a U.S. shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;amp;D expense over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. This results in a material increase to the Company&#x2019;s net deferred tax assets. Furthermore, since the Company provides for a full valuation allowance against U.S deferred tax assets, this has an adverse effect on the effective tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-deductible stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2022 and 2021. Management has considered the Company&#x2019;s history of cumulative net losses and has concluded as of December 31, 2022 and 2021, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2022 and 2021. The valuation allowance decreased by $2,610 and increased by $3,866 for the years ended December 31, 2022 and 2021, respectively. The decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures, while the increase in 2021 was primarily a result of operating losses generated with no corresponding financial statement benefit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred net operating losses (&#x201c;NOL&#x201d;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;amp;D expenses, the Company is in a taxable position as of December 31, 2022 and has utilized NOL generated in prior years to fully offset their current income tax expense. As of December 31, 2022, the Company had federal net operating loss carryforwards of $36,272. Included in federal net operating loss carryforwards of $36,272 is $17,930 that begin to expire in 2033 and $18,342 that can be carried forward indefinitely. As of December 31, 2022, the Company had state net operating loss carryforwards of $12,248, available to reduce future state taxable income, which will begin to expire in 2027. As of December 31, 2022, the Company had foreign net operating loss carryforwards of $314 that can be carried forward indefinitely. As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $1,728 available to reduce future federal tax liabilities, which will begin to expire in 2027.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;Utilization of the Company&#x2019;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue from 2018 to present; however, carryforward attributes that were generated prior to December 31, 2018 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_RcwALMhT50-v6h7CRkTQgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,384)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,910)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (806)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,716)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_FZ0l5EV4vEyoswf5Lc-szw_3_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21384000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_QWQicsnTD0iCv-JopSnawQ_3_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-10910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_sOy-vsml4Ey8VPaxw5SBZg_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-13000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_iE3oulWy3kKCciy0mglycw_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-806000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Tc_dWKH365LhEGrJoDsH0X1Ag_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Tc_VDUJTgGrMkaeqCUjgig2bA_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-11716000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr__aeli2oE_UWDTwozDMLqTw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_KVRxpjDxjUWDcZ4L_NjH0g"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_dF4liTa_mkKlcHl05EaeLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-deductible stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_tjvO2NE5k0KnwwCubB_nww_3_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_YuBJhPBee0eEocgNWmOGTQ_3_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_D69IU39rzkGb8GKbrhea8w_4_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.153</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_DZafbukqkkq_IRo0HEVXsA_4_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_W8CV5hnp9U-ImlPHYBCXWA_5_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.120</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_xBoqpxjr0U2gp8ffc7lA5w_5_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.329</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_cBFoXVEwMECzVjpZaWgx8w_6_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.151</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_B7bVZ6Gcaka9BKOR4ZVz0w_6_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.112</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <cgtx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_a84S1QlghEGl9KN3Oxo5Lw_7_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.046</cgtx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_Fn76wdl-kkOQQxx6tH7j7A_8_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_omaZ36BEAkKUStzaXJLEIQ_8_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <cgtx:EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_vE6dNkm_zkGePnZPSf1lHQ_9_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.035</cgtx:EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="3"
      id="Tc_Fuoh_AAO8k-R9zOGXAKi6g_10_2"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="3"
      id="Tc_s1w_Fu4YdkicXSNjUL4HDg_10_4"
      unitRef="Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_JgBZMQRDU0-m9YwGeV6a5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_wc0pLrWIh0qmLTZTkPF1lw_4_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">8194000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_eqgKcvwAsU6h-I7KmsKsMw_4_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">13238000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_OLUyxj2fAkWMgTA3FXNtjQ_5_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1728000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_KG8kUIgcM0WuwWewMJCeyw_5_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">4959000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_jW9nN-Lmj0G8-zHTBi7FBA_6_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">307000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_k5uZo62bxUKbhtFtSbMLew_6_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">545000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cgtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_fL0QcLzK60OiqF7E8LKKcQ_7_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">178000</cgtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_fjAxzYpI6UWouRcIeDotuQ_8_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">5687000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_gtpm-MIBMkquej_v83WGGQ_9_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">354000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_vguSSmkoBUSPyDt1Sqdz9g_10_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">165000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_U3WfLqYhy0iFZ8ELYEY_pA_10_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">316000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_M3pDP-AFokq1kgPKg3nzZQ_11_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">16613000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_TkJCMUZ7WEuYfl7i-zfT5A_11_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">19058000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_rbJ8SlFrgUu4QlWwsmcRXA_12_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">16435000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_7Q-UDftodkWgqIAjacG7GA_12_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">19045000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_Zo7gmu9ebESchfpOSOXTMw_13_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">178000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_fGrQ_en3VEm5rEsWkllGlw_13_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">13000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_wJY37lx46E2LMRlnf_e79w_16_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">7000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_u5Qd3CQWQkOTOFHDEjpgIA_16_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">13000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_FRCj4_FdCk2KMwK2RyKZxg_17_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">171000</cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Tc_RVFzaLLO80GVZJV66QEKWg_18_3"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">178000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w"
      decimals="-3"
      id="Tc_TpY3Vts2XkWeXgc7yyvTbg_18_6"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">13000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      decimals="-3"
      id="Narr_Urnkx8DE20Cj6iJXRt1DOg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">-2610000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow"
      decimals="-3"
      id="Narr_PtbZ8wB-S0-0VzBEudPvbg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">3866000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw"
      decimals="-3"
      id="Narr_fdTtC9XpB0-ScJOa4IRFVg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">36272000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw"
      decimals="-3"
      id="Narr_v6fG8Yhu5kCuxgRpUFoeqA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">36272000</us-gaap:OperatingLossCarryforwards>
    <cgtx:OperatingLossCarryForwardsSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw"
      decimals="-3"
      id="Narr_qyBpIcvXJEiDVPdAsLGSYA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">17930000</cgtx:OperatingLossCarryForwardsSubjectToExpiration>
    <cgtx:OperatingLossCarryForwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6jrOssAnWEmMpubtgMpqJw"
      decimals="-3"
      id="Narr_YtquUIKE8E-NgqYoS8eMkA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">18342000</cgtx:OperatingLossCarryForwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_0h3qCBEleU-V3fVtO2hK3Q"
      decimals="-3"
      id="Narr_BtwFS2HVwE6liH8vhJk2LA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">12248000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_OuQa9AV1Z0aOm013SYiWPQ"
      decimals="-3"
      id="Narr_Cz3PAQChDki1T1PbmPfgYg"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">314000</us-gaap:OperatingLossCarryforwards>
    <cgtx:ResearchAndDevelopmentTaxCreditCarryForwards
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_99kNpWEflUSUhexkkPnV-A"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">1728000</cgtx:ResearchAndDevelopmentTaxCreditCarryForwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g"
      decimals="-3"
      id="Narr_r86VYS_0W0WTzM_aM7xtOA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA"
      id="Tb_jdQGUHl_nEC2766aCY4YzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 23, 2022, the Company filed the Shelf (File No. 333-268992) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) for an equity line financing (the &#x201c;Purchase Agreement&#x201d;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock at our sole discretion, over a &lt;span style="-sec-ix-hidden:Hidden_EOZZ9ib9PU6NThp6PBR4OA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;36-month&lt;/span&gt;&lt;/span&gt; period commencing on March 10, 2023. The Company filed a supplemental registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Park&#x2019;s commitment to purchase shares of common stock under the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA"
      decimals="-3"
      id="Narr_0kLhgTvdj0qjXHF1f1YyBA"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_s-LVOhnIOU2pq3ePoviZBQ"
      decimals="-3"
      id="Narr_JnhWm1ntOkCHK3VEhr29nw"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg"
      decimals="-3"
      id="Narr_1zxg5AToSUenAu3Kh89EPQ"
      unitRef="Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w">35000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg"
      decimals="INF"
      id="Narr_rVfHQbNc80GA_eeXLO2dFw"
      unitRef="Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MM2*U/ / 2AD@Z8Y@*&+3BE"E[3B@,R%1$[DN%C)"Q$L%E?2,)@%3:D5Z>1*
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M4)]S _B^%4(?7_(!ZBO,V7]02P,$%     @  3YW5OU%@U=G"P  LXP  !@
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MNNY&C]3=WGGU0#$_.)W0ZAM4,VE'=:QX]:&UKH,"G=:&:@Y4<Z&:!]5\J!9
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M7*#X^7V2Y*_?C O_.4F_[^8X_QM02P,$%     @  3YW5N2G0*/2 @  _P<
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MB'C#PD0,("19?EZ;!NH$\9@]?0Z*R(?#L!6*7J[Z,LS/F]-5<&=LH.0E&)A
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MV?"?:ZU(=/$"/5\:BA7]!RP0?U#RQ7\ 4$L#!!0    (  $^=U:!T#[+YP@
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M\,(VT]#BA?^<:8TS/(YC;LE$%B3"F:.O@43QBL[\_,R_\*Y/L!RV+(>GT#_
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M,5J\>36:I&^/,!T/3,?'T%\FRW&H20P'T>"3@IO"Z35M^QJ? EG"E98-4X]
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M3Y1L(0)9X^':VC>=<D5Z;@AW8-L0L\. ()O0['S@'3$'Z/B?CA<.^RN)SH+
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ML,K*-'I#0F8_TTF?L%A?BAV5]4IMZ<&ZSI84.="2=444P8S<T*)RLBS'BE3
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M$G\X0+L#N)\K96O!&6A^84;_ %!+ P04    "  !/G=608$:6X $  !F$0
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MH&$X#AI6"R^;.=U293/9&5X+6"JBNZ9AZL<"N-S.O<C;*Q[J366L(LAF+=O
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MM30X1-RVPJD-RAK@>2FEV0LVP/ ?R'X"4$L#!!0    (  $^=U8%M*!\D00
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M#2O(I:S0V9J[^SK^PN]+T"?]CL%S+'<G7V..5IAL#V;(R"=9FZDF5W4!Q7.
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M;'_/>-T>KT_F[27E'95;AGL:APTN]8<C;";9'OSM0(O:'K9KH?'HMI\%WI5
M&@/\OQ&XCW<#XZ"_?<W_!U!+ P04    "  !/G=6Y\KP$9@$  "!#0  &0
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MG%RM:8*3@.((/"9"\E3=4BD 3D*PQI2#;SA*"7@B6*2<Y-<^@OL]3G9$ )J
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M515MF@MUT0&N#=3S&6-RT]$3E%>GR1]02P,$%     @  3YW5F M1X2: @
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M+@UV0C<L\:T"90-POY#2O$YL.^Q?O_0?4$L#!!0    (  $^=U:M7;"W-P,
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MXN)PRX(52_,"^O>U$.IPDE=0;QF<_P=02P,$%     @  3YW5K_1%/8B @
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M(5P\^C3ES';#U!EHFM# :X,T#F&YH_<'K'>@\XTQ>#3\3 PO6O$*4$L#!!0
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M-95FHPOJ;+O!Z@QOFGB95\;3:,1E36\1VI! \;4Q?F^$!L/K5OP%4$L#!!0
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M>,EB*:[50W7]QY*M!<DB,7*E&F+>D3NKAC,MAX/?&0["X"O+Y%* 7[.(1KJ
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M*EV<J77?/NUFC:Y>5VK^_DH^\-=6ASJ4O;00G5@8V8;R(KM_G(-FPR@3Q?_
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ML= URW==?U;50EMJ.MJF\L#HHM#%5DL,JVJA+34=75-B8&,>WC5T*S4M=/W
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M9@=B:YM]K%G<WDKAM'RLN5L)Z8P##S_)Q__'5>KM@^)25_8_"5]3=5AGL%)
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M;[1OV@9S"\65D"QO@]4(\K1H?LE;FXB# .Q?"'#; /<X8'HAP&L#O&M[\-L
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MM5Q6:QI$B@0]4B&)5#OZQHZ:28*^J;07>AF,UADY.T&,'8P5 !(60L(B(-A
MI7FGTARN8,TA]8"$A9"P" @VT ,[O>%PC//FSRI_IARQS4>](I7<,9[^=^P/
M&DW,M+&B@-)"4%K4T@Y+J.]Y/O;ZQ=@PY0<>#QM3KMW*]57)#!N=<4A:"$J+
MH&A#6=Q>%A>N-K4L*%4@:2$H+8*B#57I/34V6L31]0G45[>TPQK@!E-\:MQ
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M:W-H965T<R]S:&5E=#4P+GAM;*U7;4_;,!#^*U:&IDT:Y*UOL#;2*'O[@(2
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M:?!^X![W>(4#90UP?2NQ@NW !N@NA>G_4$L#!!0    (  $^=U8PG=W34P,
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MX V]+*; ,6FT'?#[0DKS5+$#-,\R\_\ 4$L#!!0    (  $^=U8Y6.X/10,
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M*CN!KF^D-(\#V[QV+RO1?U!+ P04    "  !/G=6KLH2MD<#  "P%   #0
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MV5V33=,8JIM.QG5 OZWFM-NREV_2#4K^6.C/2S,=:?OP8+!;Q3*^LOU5UAC
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MYBZL[Z ^)J:=F%@[!YCW(E7@[UPV+Y#R,=&U?F+_'&!.Q$9 29PQRU\9-_Z
M(L;\$Q/[Y_"F<ZVY^^;H_:[[F)A_8F+_'*U$G'Y],/?$M7MZ^V^C,K&1I<CF
MT+V!]I3GZ5(SMVF6;:/8+;ULJCP?0]NBO%,\VW]JM?],[,>_4$L#!!0    (
M  $^=U83)^RZ[P$  *4B   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-VKM.ZT 4A>%7B?P 3/8MP!&AHJ%%O( 5)A>1Q)8]"'A[HE"$95&<!LVJ
MK+'E[;_Z9(U]]Y3W;=EUQW&[Z\?9QV%_')?-MI3^7TKC:IL/[7C5]?EXNK+N
MAD-;3LMAD_IV]=IN<M+Y?)&&GS.:^[N?,V?/GWW^GXG=>KU;Y8=N]7;(Q_++
MX/3>#:_C-N?2S)[;89/+LDD?^\OI,9T/<G6:W,P>7Y;-\/@B3:H=I!"D]8,,
M@JQ^D$.0UP\*"(KZ00L(6M0/NH:@Z_I!-Q!T4S_H%H)NZP?)'&6<$R1-L";0
M6I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R70
M6U%O)=!;)R_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$
M>AOJ;01Z&^IM!'H;ZFT$>MMDLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-
M0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!OGVQV$^CMJ+<3Z.VHMQ/H[:BW
M$^CMJ+<3Z.VHMQ/H':AW$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!V3CY4$>@?J
M'01Z!^H=!'H'ZAU_J?=8/O=YO/1\K_'Y?TEU.=V;+X\_+[]/HH2+,\X)_DJY
M_P)02P,$%     @  3YW5F(CYQC8 0  2"(  !,   !;0V]N=&5N=%]4>7!E
M<UTN>&ULS=I=3X,P% ;@O[)P:T;7K_D1YXUZJU[X!RJ<#3*@3=O-^>\M3$TT
M2EQFXGL#@;;G/;3)<\7EXXNC,-FU31<6616CNV L%!6U)N3649=&EM:W)J9'
MOV+.%&NS(B9FLSDK;!>IB]/8U\BN+F]H:39-G-SNTNM0VVZ1>6I"-KG>3^RS
M%IEQKJD+$],XVW;EEY3I6T*>5@YS0E6[<)(F9.S;A'[DYX"W=?=;\KXN:?)@
M?+PS;9K%=@T+\:6AD(^7^*9'NUS6!96VV+1I21Z<)U.&BBBV3;XO>C*>'-,.
MT_[*C\X?RHP%IID/WKJ03LS3X7'O1]*OGKI4B'RLQS_Q(S&5/OK[J#_MDLI?
M9J?M?;9^/9Q'8,/M^#W^?,8?]0_L0X#T(4'Z4"!]:) ^YB!]G(+T<0;2QSE(
M'WR&T@B*J!R%5(YB*D=!E:.HRE%8Y2BN<A18.8JL D56@2*K0)%5H,@J4&05
M*+(*%%D%BJP"15:!(JM$D56BR"I19)4HLDH4626*K!)%5HDBJT215:+(JE!D
M52BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+)J%%DUBJP:15:-(JM&D56CR*I1
M9-4HLNK_E/7)VO5?_]O0W_/6U-U[/AM^(+EZ!5!+ 0(4 Q0    (  $^=U8'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @  3YW5B0 "%_O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  3YW5IE<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  !/G=650*JRV\'  #6,   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  3YW5A.B;='7!0  31H
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M965T-BYX;6Q02P$"% ,4    "  !/G=6\UY=D&0(  #$*P  &
M    @($?+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M 3YW5L7/I)C%"0  U!@  !@              ("!N34  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    (  $^=U:0PH;LEAL  %Q2   8
M          " @;0_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  !/G=6@= ^R^<(   ='0  &0              @(& 6P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  $^=U:!/2#=TP(  #L'
M   9              " @9YD  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @  3YW5E"J,+^9 @  008  !D              ("!J&<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  !/G=6^ B<
MYAT#  #'!P  &0              @(%X:@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    (  $^=U;I(9S)708   ,1   9
M  " @<QM  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M 3YW5L*E>]W] P  90H  !D              ("!8'0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  !/G=6=3 A/N\,  ! )P  &0
M            @(&4>   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    (  $^=U91(S'<K@,  !$*   9              " @;J%  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @  3YW5O^M(PT) P
M$P<  !D              ("!GXD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  !/G=6._$2(B ,  "J(P  &0              @('?
MC   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  $^=U;D
M$VZW'@0   ()   9              " @3:9  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @  3YW5G/WF371'   D%P  !D
M     ("!BYT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  $^=U:\FG6U?@,  ,D)   9              "
M@?/'  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @  3YW
M5MH;+B^7 @  $P8  !D              ("!J,L  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  !/G=6!;2@?)$$  !N#0  &0
M        @(%VS@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   (  $^=U;;'>-Y:0,  (D)   9              " @3[3  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  3YW5N?*\!&8!   @0T
M !D              ("!WM8  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  !/G=66W1STE('  #Y1   &0              @(&MVP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  $^=U;6=*$#
MZ00  ($:   9              " @3;C  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @  3YW5O.*7LG! P  1!,  !D
M ("!5N@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  !
M/G=6P+XD ^P"  "F#   &0              @(%.[   >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  $^=U96%3KU(P4  !@B   9
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M970S.2YX;6Q02P$"% ,4    "  !/G=6,H>D H@"  "$!P  &0
M    @(&_!0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M  $^=U;KU@PECP4  #XH   9              " @7X( 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @  3YW5K_1%/8B @  W00  !D
M             ("!1 X! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  !/G=6/F/KHC\"  #I!   &0              @(&=$ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  $^=U9D;@]U& 4
M #\C   9              " @1,3 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @  3YW5FGV5Y/K @  O@P  !D              ("!
M8A@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  !/G=6
M1:GNOK<$  "((0  &0              @(&$&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    (  $^=U9)4I9*> ,  (<,   9
M      " @7(@ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @  3YW5O)G.WBU!    18  !D              ("!(20! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  !/G=6A>& ?"X#  !D"0
M&0              @($-*0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    (  $^=U: ;S1W4@,  !D-   9              " @7(L 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @  3YW5D5PKIU7
M P  ( X  !D              ("!^R\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  !/G=6,)W=TU,#  "O"@  &0
M@(&),P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  $^
M=U;E(,S+E0(  *H&   9              " @1,W 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @  3YW5C#U;K!_ @  N@8  !D
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M=#4X+GAM;%!+ 0(4 Q0    (  $^=U:NRA*V1P,  + 4   -
M  "  <-+ 0!X;"]S='EL97,N>&UL4$L! A0#%     @  3YW5I>*NQS
M$P(   L              ( !-4\! %]R96QS+RYR96QS4$L! A0#%     @
M 3YW5O, UW"P!   JB8   \              ( !'E ! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  $^=U83)^RZ[P$  *4B   :              "
M ?M4 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  $^
M=U9B(^<8V $  $@B   3              "  2)7 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !" $( !1(  "M9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</Role>
      <ShortName>Description of Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Equity-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Equity-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails</Role>
      <ShortName>Description of Business and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impact of Adoption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Term And Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommonStockTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Equity-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails</Role>
      <ShortName>Equity-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Fair value of options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Equity-based Compensation - Activity for options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Activity for options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Equity-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Equity-based Compensation - Compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Equity-based Compensation - Compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureRetirementPlan</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Net loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails</Role>
      <ShortName>Income Taxes - Net loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cgtx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: cgtx:PurchaseAgreementTerm, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  cgtx-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  cgtx-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="cgtx-20221231x10k.htm">cgtx-20221231x10k.htm</File>
    <File>cgtx-20221231.xsd</File>
    <File>cgtx-20221231_cal.xml</File>
    <File>cgtx-20221231_def.xml</File>
    <File>cgtx-20221231_lab.xml</File>
    <File>cgtx-20221231_pre.xml</File>
    <File>cgtx-20221231xex21d1.htm</File>
    <File>cgtx-20221231xex23d1.htm</File>
    <File>cgtx-20221231xex31d1.htm</File>
    <File>cgtx-20221231xex31d2.htm</File>
    <File>cgtx-20221231xex32d1.htm</File>
    <File>cgtx-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cgtx-20221231x10k001.jpg</File>
    <File>cgtx-20221231x10k002.jpg</File>
    <File>cgtx-20221231x10k003.jpg</File>
    <File>cgtx-20221231x10k004.jpg</File>
    <File>cgtx-20221231x10k005.jpg</File>
    <File>cgtx-20221231x10k006.jpg</File>
    <File>cgtx-20221231x10k007.jpg</File>
    <File>cgtx-20221231x10k008.jpg</File>
    <File>cgtx-20221231x10k009.jpg</File>
    <File>cgtx-20221231x10k010.jpg</File>
    <File>cgtx-20221231x10k011.jpg</File>
    <File>cgtx-20221231x10k012.jpg</File>
    <File>cgtx-20221231x10k013.jpg</File>
    <File>cgtx-20221231x10k014.jpg</File>
    <File>cgtx-20221231x10k015.jpg</File>
    <File>cgtx-20221231x10k016.jpg</File>
    <File>cgtx-20221231x10k017.jpg</File>
    <File>cgtx-20221231x10k018.jpg</File>
    <File>cgtx-20221231x10k019.jpg</File>
    <File>cgtx-20221231x10k020.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="502">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cgtx-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 502,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "cgtx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgtx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cgtx-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cgtx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgtx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cgtx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 480,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 13,
    "http://www.cogrx.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 18
   },
   "keyCustom": 47,
   "keyStandard": 262,
   "memberCustom": 28,
   "memberStandard": 28,
   "nsprefix": "cgtx",
   "nsuri": "http://www.cogrx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Financial Instruments and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Other Current Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities",
     "shortName": "Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cogrx.com/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Equity-based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensation",
     "shortName": "Equity-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Retirement Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GrantsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cogrx.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cogrx.com/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Equity-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables",
     "shortName": "Equity-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Description of Business and Financial Condition (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
     "shortName": "Description of Business and Financial Condition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_AzAbot57-k6v6o9gN4OhOg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
     "shortName": "Summary of Significant Accounting Policies - Impact of Adoption (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yo_gK8X2W0iZ-0gKHEhB8g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails",
     "shortName": "Financial Instruments and Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Changes in fair value of the Level 3 liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_Z5bYZA5mX0q2meCGmlQHAw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_0FzXOWK5S02NVj4SBVP9ow",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:FairValueAdjustmentOfSimpleAgreementsForFutureEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_cgtx_PaycheckProtectionProgramLoanMember_kNTZQi2ALk-WqeHJzcIxSw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails",
     "shortName": "Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_PNbBwns1IEOv2OCje5gauA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:OperatingLeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:OperatingLeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails",
     "shortName": "Commitments and Contingencies - Lease Term And Discount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cogrx.com/role/DisclosureCommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_StockOptionMember_-IP8DBZpCUSLq5j3zp66OQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "cgtx:StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Equity-based Compensation (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
     "shortName": "Equity-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkBqUzrULkqvOk4_Dzd2oQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
     "shortName": "Equity-based Compensation - Fair value of options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_8W_M9ufwWUWbb3rt_DpY9w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Equity-based Compensation - Activity for options (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
     "shortName": "Equity-based Compensation - Activity for options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Equity-based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
     "shortName": "Equity-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_BzCNvBjr4kOm1EuK3vFZXQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qKyplp-xpkKPNNRSX4-qPQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Equity-based Compensation - Compensation expense (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
     "shortName": "Equity-based Compensation - Compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails",
     "shortName": "Net Loss per Share - Antidilutive effect (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Basic and diluted net loss per share attributable to common stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Retirement Plan (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlanDetails",
     "shortName": "Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income Taxes - Net loss (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
     "shortName": "Income Taxes - Net loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of income tax benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4X3APqSthku1Sy2qw6uJuw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lnFGDf0dJ0aqt8fiZR4v6g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "As_Of_12_23_2022_ExuhmW8ucE2YVNRg_-RquA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgtx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_rxpPBmhX-Uu0XGusGtY-zg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_8dTmgqpshkeBCCZp3C_xxA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3pg57-czyEqnclzwVE_6Jw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_eLYoRZuRGUOG38edJauV6w",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of Business and Financial Condition",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition",
     "shortName": "Description of Business and Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cgtx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AKVM4O8mBkmG9wO8d2E1EA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "cgtx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_AllowanceForCreditLossGrantsReceivableCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on grants receivable, classified as current.",
        "label": "Allowance for Credit Loss, Grants Receivable, Current",
        "terseLabel": "Allowance for doubtful accounts on grants receivable"
       }
      }
     },
     "localname": "AllowanceForCreditLossGrantsReceivableCurrent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_AmendedAndRestatedEquityIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.",
        "label": "Amended and Restated 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedEquityIncentivePlan2017Member",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to at the market offering.",
        "label": "At The Market Offering"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.",
        "label": "Cantor Fitzgerald And Co and B Riley Securities Inc [Member]",
        "terseLabel": "Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc."
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoAndBRileySecuritiesIncMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_ConversionOfPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to conversion of preferred stock.",
        "label": "Conversion Of Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfPreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of Simple Agreements For Future Equity into common stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Simple Agreements For Future Equity Into Common Stock, Amount Issued",
        "terseLabel": "Conversion of Simple Agreements for Future Equity into common stock in initial public offering"
       }
      }
     },
     "localname": "ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ConversionOfSimpleAgreementsForFutureEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to conversion of simple agreements for future equity.",
        "label": "Conversion Of Simple Agreements For Future Equity"
       }
      }
     },
     "localname": "ConversionOfSimpleAgreementsForFutureEquityMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_ConvertibleInstrumentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Convertible Instruments.",
        "label": "Convertible Instruments [Policy Text Block]",
        "terseLabel": "Convertible Instruments"
       }
      }
     },
     "localname": "ConvertibleInstrumentsPolicyTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_DeferredGrantIncomeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of deferred grant income as at the end of the reporting period.",
        "label": "Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income, current"
       }
      }
     },
     "localname": "DeferredGrantIncomeCurrent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_DeferredOfferingCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred offering costs included in accounts payable.",
        "label": "Deferred Offering Costs Included In Accounts Payable",
        "terseLabel": "Deferred offering costs included in Accounts payable"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities",
        "label": "Deferred tax assets operating lease liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.",
        "label": "Deferred Tax Liabilities, Operating Lease, Right Of Use Asset",
        "negatedLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Fair Value Adjustment, Percent",
        "terseLabel": "Fair value adjustments (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgtx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest expense.",
        "label": "Effective Income Tax Rate Reconciliation, Interest Expense, Percent",
        "terseLabel": "Interest expense (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestExpensePercent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgtx_EmergingGrowthCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for emerging growth company status.",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Employee Stock Purchase Plan.",
        "label": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".Represents information relating to 2021 Equity Incentive Plan.",
        "label": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_EquityLineFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to equity line financing.",
        "label": "Equity Line Financing"
       }
      }
     },
     "localname": "EquityLineFinancingMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_FairValueAdjustmentOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in the fair value of derivative liability during the reporting period.",
        "label": "Fair Value Adjustment of Derivative Liability",
        "negatedLabel": "Change in the fair value of the derivative liability",
        "terseLabel": "Change in the fair value of the derivative liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfDerivativeLiability",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_FairValueAdjustmentOfSimpleAgreementsForFutureEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value adjustment of simple agreements for future equity during the reporting period.",
        "label": "Fair Value Adjustment Of Simple Agreements For Future Equity",
        "negatedLabel": "Change in the fair value of the Simple Agreements for Future Equity",
        "terseLabel": "Change in the fair value of the Simple Agreements for Future Equity"
       }
      }
     },
     "localname": "FairValueAdjustmentOfSimpleAgreementsForFutureEquity",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to follow on pubic offering.",
        "label": "Follow-on Public Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to grants.",
        "label": "Grant Income",
        "terseLabel": "Grant income",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_GrantIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income, Policy [Policy Text Block]",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current deferred grant income.",
        "label": "Increase (Decrease) In Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income, current and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncomeCurrent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_IncreaseDecreaseInGrantReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase and decrease in grant receivables.",
        "label": "Increase (Decrease) In Grant Receivables",
        "negatedLabel": "Grant receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInGrantReceivables",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_InsurancePremiumFinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to insurance premium financing agreement.",
        "label": "Insurance Premium Financing Agreement"
       }
      }
     },
     "localname": "InsurancePremiumFinancingAgreementMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_LaboratoryAndOfficeSpacePittsburghPaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to laboratory and office space in Pittsburgh, PA.",
        "label": "Laboratory And Office Space, Pittsburgh, PA"
       }
      }
     },
     "localname": "LaboratoryAndOfficeSpacePittsburghPaMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Legal Reserves, Professional Fees and Other Accruals, Current",
        "terseLabel": "Legal reserves, professional fees, and other accruals"
       }
      }
     },
     "localname": "LegalReservesProfessionalFeesAndOtherAccrualsCurrent",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of buyout options in dollars in an operating lease under the lessee.",
        "label": "Lessee, Operating Lease, Number of Buyout Options in Dollars",
        "terseLabel": "Number of option at conclusion of the lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cgtx_LincolnParkCapitalFundLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Lincoln Park Capital Fund, LLC.",
        "label": "Lincoln Park Capital Fund LLC [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLlcMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_LoanDeferralPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which deferral of payments done.",
        "label": "Loan Deferral Payments Period",
        "terseLabel": "Deferral payments period"
       }
      }
     },
     "localname": "LoanDeferralPaymentsPeriod",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgtx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_MaximumValueOfStockToBeIssuedUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity impact of the value of new stock to be issued under an agreement.",
        "label": "Maximum Value Of Stock To Be Issued Under Agreement",
        "terseLabel": "Maximum value of stock to be issued under agreement"
       }
      }
     },
     "localname": "MaximumValueOfStockToBeIssuedUnderAgreement",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_MeasurementInputDiscountUponConversionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input representing discount upon conversion.",
        "label": "Discount upon conversion"
       }
      }
     },
     "localname": "MeasurementInputDiscountUponConversionMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_MeasurementInputDiscountUponImpliedReturnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input representing discount upon implied return.",
        "label": "Discount upon implied return"
       }
      }
     },
     "localname": "MeasurementInputDiscountUponImpliedReturnMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_MeasurementInputProbabilityOfDissolutionEventOccurrenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input representing probability of dissolution event occurrence.",
        "label": "Probability of dissolution event occurrence"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfDissolutionEventOccurrenceMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_MeasurementInputProbabilityOfEquityFinancingOccurrenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input representing probability of equity financing occurrence.",
        "label": "Probability of equity financing occurrence"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfEquityFinancingOccurrenceMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input representing probability of initial public offering occurrence.",
        "label": "Probability of initial public offering occurrence"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfInitialPublicOfferingOccurrenceMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_OfficeSpaceLocatedInPittsburghPaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to office space located in Pittsburgh, Pennsylvania.",
        "label": "Office Space located In Pittsburgh, PA"
       }
      }
     },
     "localname": "OfficeSpaceLocatedInPittsburghPaMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_OfficeSpaceNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to New York office space.",
        "label": "Office Space, New York"
       }
      }
     },
     "localname": "OfficeSpaceNewYorkMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_OperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease assets as at the end of the reporting period.",
        "label": "Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseAssets",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_OperatingLossCarryForwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that do not expire"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsNotSubjectToExpiration",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_OperatingLossCarryForwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that expire"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsSubjectToExpiration",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_OtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiplier applied on average monthly payroll expenses in PPP.",
        "label": "Paycheck Protection Program Average Monthly Payroll Expenses Multiplier",
        "terseLabel": "Multiplier applied on average monthly payroll expenses"
       }
      }
     },
     "localname": "PaycheckProtectionProgramAverageMonthlyPayrollExpensesMultiplier",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cgtx_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to loan from Paycheck Protection Program (the \"PPP\"), a program implemented by the U.S. Small Business Administration (the \"SBA\") under the Coronavirus Aid, Relief, and Economic Security Act (the \"CARES Act\") (the \"PPP Loan\").",
        "label": "PPP Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_PeriodOverWhichUnforgivenPppLoanPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which unforgiven portion of PPP loan payable.",
        "label": "Period over which unforgiven portion of PPP loan payable"
       }
      }
     },
     "localname": "PeriodOverWhichUnforgivenPppLoanPayable",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment of insurance through third-party financing.",
        "label": "Prepayment of Insurance Through Third Party Financing",
        "terseLabel": "Prepayment of insurance through third-party financing"
       }
      }
     },
     "localname": "PrepaymentOfInsuranceThroughThirdPartyFinancing",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ProceedsFromSimpleAgreementsForFutureEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from simple agreements for future equity (\"SAFEs) entered into by the company during the period.",
        "label": "Proceeds From Simple Agreements for Future Equity",
        "terseLabel": "Proceeds from simple agreements for future equity",
        "verboseLabel": "Proceeds from issuance of Simple Agreements for Future Equity"
       }
      }
     },
     "localname": "ProceedsFromSimpleAgreementsForFutureEquity",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_PurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Purchase Agreement, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "PurchaseAgreementTerm",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgtx_ResearchAndDevelopmentTaxCreditCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of federal research and development tax credit carry forwards.",
        "label": "Research and Development Tax Credit Carry Forwards",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwards",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split policy disclosure.",
        "label": "Reverse Stock Split [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_SeriesA1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A-1 convertible preferred stock.",
        "label": "Series A-1 convertible preferred stock"
       }
      }
     },
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SeriesA2ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A-2 convertible preferred stock.",
        "label": "Series A-2 convertible preferred stock"
       }
      }
     },
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SeriesB1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series B-1 convertible preferred stock.",
        "label": "Series B-1 convertible preferred stock"
       }
      }
     },
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series B convertible preferred stock.",
        "label": "Series B convertible preferred stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SeriesaConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A convertible preferred stock.",
        "label": "Series A convertible preferred stock"
       }
      }
     },
     "localname": "SeriesaConvertiblePreferredStockMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options exercised during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options granted during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number",
        "terseLabel": "Number of shares that may be recycled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgtx_SharesAvailableForFutureIssuanceUnder2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Shares available for future issuance under 2021 Plan.",
        "label": "Shares Available For Future Issuance Under 2021 Plan"
       }
      }
     },
     "localname": "SharesAvailableForFutureIssuanceUnder2021PlanMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SharesAvailableForFutureIssuanceUnderEsppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Shares available for future issuance under ESPP.",
        "label": "Shares Available For Future Issuance Under ESPP"
       }
      }
     },
     "localname": "SharesAvailableForFutureIssuanceUnderEsppMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_SimpleAgreementsForFutureEquityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure simple agreements for future equity.",
        "label": "Simple Agreements for Future Equity, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "SimpleAgreementsForFutureEquityMeasurementInput",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cgtx_SimpleAgreementsForFutureEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to simple agreements for future equity.",
        "label": "SAFE"
       }
      }
     },
     "localname": "SimpleAgreementsForFutureEquityMember",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgtx_StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of simple agreements for future equity.",
        "label": "Stock Issued During Period, Shares, Conversion Of Simple Agreements For Future Equity",
        "terseLabel": "Conversion of SAFE into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfSimpleAgreementsForFutureEquity",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgtx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgtx_StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of simple agreements for future equity.",
        "label": "Stock Issued During Period, Value, Conversion Of Simple Agreements For Future Equity",
        "terseLabel": "Conversion of SAFE into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Excludes preferred stock and warrants.",
        "label": "Stockholders' Equity Note Disclosure Excluding Preferred Stock And Warrants [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureExcludingPreferredStockAndWarrantsTextBlock",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgtx_TemporaryEquityConversionOfStockAmountConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfStockAmountConverted",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgtx_TemporaryEquityConversionOfStockSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Temporary Equity, Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfStockSharesConverted",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of temporary shares issued during the period as a result of the conversion of convertible debt.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Debt",
        "terseLabel": "Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleDebt",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgtx_TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of temporary stock issued during the period upon the conversion of convertible Debt.",
        "label": "Temporary Equity Stock Issued During Period Values Conversion Of Convertible Debt",
        "terseLabel": "Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValuesConversionOfConvertibleDebt",
     "nsuri": "http://www.cogrx.com/20221231",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r279",
      "r296",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r319",
      "r465",
      "r479",
      "r496",
      "r497",
      "r512",
      "r516",
      "r521",
      "r573",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r319",
      "r465",
      "r479",
      "r496",
      "r497",
      "r512",
      "r516",
      "r521",
      "r573",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r302",
      "r319",
      "r350",
      "r351",
      "r352",
      "r464",
      "r465",
      "r479",
      "r496",
      "r497",
      "r512",
      "r516",
      "r521",
      "r567",
      "r573",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r302",
      "r319",
      "r350",
      "r351",
      "r352",
      "r464",
      "r465",
      "r479",
      "r496",
      "r497",
      "r512",
      "r516",
      "r521",
      "r567",
      "r573",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r279",
      "r296",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r203",
      "r204",
      "r222",
      "r409",
      "r410",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r154",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r222",
      "r254",
      "r255",
      "r384",
      "r405",
      "r409",
      "r410",
      "r411",
      "r442",
      "r456",
      "r457",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r154",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r222",
      "r254",
      "r255",
      "r384",
      "r405",
      "r409",
      "r410",
      "r411",
      "r442",
      "r456",
      "r457",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r154",
      "r191",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r207",
      "r222",
      "r384",
      "r405",
      "r409",
      "r410",
      "r442",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565",
      "r566",
      "r608",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69",
      "r161"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r167",
      "r474",
      "r487",
      "r491"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r27",
      "r30",
      "r110",
      "r457",
      "r482",
      "r483",
      "r534",
      "r535",
      "r536",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r543",
      "r544",
      "r545",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r45",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r208",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r359",
      "r360",
      "r361",
      "r381",
      "r382",
      "r383",
      "r384",
      "r394",
      "r395",
      "r396",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r434",
      "r435",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r467",
      "r468",
      "r469",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Issuance of Series B-1 convertible preferred stock upon conversion of debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r100",
      "r101",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r82",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of common stock, discounts and offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r37",
      "r45",
      "r124",
      "r291"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r35",
      "r291",
      "r436",
      "r539"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive common stock equivalents outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r141",
      "r163",
      "r184",
      "r234",
      "r242",
      "r244",
      "r249",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r397",
      "r399",
      "r416",
      "r520",
      "r571",
      "r572",
      "r619"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r157",
      "r169",
      "r184",
      "r249",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r397",
      "r399",
      "r416",
      "r520",
      "r571",
      "r572",
      "r619"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r53",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Financial Condition"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r159",
      "r499"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r47",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents-end of period",
        "periodStartLabel": "Cash and cash equivalents-beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r123"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r184",
      "r212",
      "r213",
      "r216",
      "r218",
      "r225",
      "r226",
      "r249",
      "r267",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r416",
      "r498",
      "r532",
      "r540",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r132",
      "r147"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r260",
      "r261",
      "r492",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r543",
      "r544",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 250,000,000 shares authorized at December 31, 2022 and December 31, 2021; 28,991,548 and 22,230,032 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r172",
      "r174",
      "r180",
      "r471",
      "r476"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r138",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock into SAFE"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of convertible preferred stock into common stock in initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred stock (as converted)",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r129",
      "r130",
      "r139",
      "r190",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r437",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r125",
      "r126",
      "r276",
      "r437",
      "r508",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r190",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r437",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r20",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r83",
      "r86",
      "r87",
      "r88",
      "r124",
      "r125",
      "r126",
      "r137",
      "r190",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r437",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r150",
      "r616"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets after valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r106",
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r108",
      "r605"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Matching contributions to the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage of employees' compensation per person per year matched by the Company"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r45",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r45",
      "r232"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Liability."
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r324",
      "r355",
      "r356",
      "r358",
      "r363",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r89",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividend declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r181",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r209",
      "r212",
      "r216",
      "r217",
      "r218",
      "r222",
      "r410",
      "r411",
      "r472",
      "r477",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r181",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r212",
      "r216",
      "r217",
      "r218",
      "r222",
      "r410",
      "r411",
      "r472",
      "r477",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r186",
      "r370",
      "r388"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory rate (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r603",
      "r606"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Non-deductible stock compensation (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r603",
      "r606"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r603",
      "r606"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "R&amp;D Credit (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which the unrecognized compensation cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r153",
      "r176",
      "r177",
      "r178",
      "r191",
      "r192",
      "r193",
      "r195",
      "r204",
      "r207",
      "r224",
      "r253",
      "r301",
      "r359",
      "r360",
      "r361",
      "r383",
      "r384",
      "r409",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r457",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of significant unobservable inputs for SAFE"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r113",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r284",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r413",
      "r461",
      "r462",
      "r463",
      "r508",
      "r509",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r284",
      "r304",
      "r309",
      "r413",
      "r461",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Priced in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Changes in fair value of the Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of changes in fair value of Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair value recognized upon the issuance of SAFE"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Fair value recognized upon conversion into common stock"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at beginning"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r284",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r461",
      "r462",
      "r463",
      "r508",
      "r509",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r45",
      "r76",
      "r77"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on debt extinguishment",
        "terseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivables"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r185",
      "r387"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r185",
      "r387"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r371",
      "r373",
      "r379",
      "r385",
      "r389",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r187",
      "r206",
      "r207",
      "r233",
      "r369",
      "r386",
      "r390",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r365",
      "r366",
      "r373",
      "r374",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r538",
      "r613"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Temporary equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum lease commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r184",
      "r249",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r398",
      "r399",
      "r400",
      "r416",
      "r505",
      "r571",
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r131",
      "r145",
      "r520",
      "r542",
      "r564",
      "r610"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r158",
      "r184",
      "r249",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r398",
      "r399",
      "r400",
      "r416",
      "r520",
      "r571",
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r130",
      "r143",
      "r283",
      "r293",
      "r508",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r262",
      "r263",
      "r264",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputControlPremiumMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount above fair value that investor seeking to acquire control of entity will pay.",
        "label": "Probability of change of control occurrence"
       }
      }
     },
     "localname": "MeasurementInputControlPremiumMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r33",
      "r46",
      "r133",
      "r148",
      "r156",
      "r170",
      "r173",
      "r178",
      "r184",
      "r194",
      "r198",
      "r199",
      "r201",
      "r202",
      "r206",
      "r207",
      "r214",
      "r234",
      "r241",
      "r243",
      "r245",
      "r249",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r411",
      "r416",
      "r506",
      "r571"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r198",
      "r199",
      "r201",
      "r202",
      "r209",
      "r210",
      "r215",
      "r218",
      "r234",
      "r241",
      "r243",
      "r245",
      "r506"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r234",
      "r241",
      "r243",
      "r245",
      "r506"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Minimum lease commitments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r445",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "totalLabel": "Total operating lease assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r450",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r449",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Financial Condition"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r127",
      "r140",
      "r162"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Unrealized loss on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r82",
      "r171",
      "r174",
      "r179",
      "r426",
      "r431",
      "r432",
      "r470",
      "r475",
      "r534",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities."
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Deferred grant income and other liabilities, noncurrent",
        "verboseLabel": "Deferred grant income, noncurrent"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Payments for property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r302",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r56",
      "r558"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Cumulative preferred stock dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r168",
      "r256",
      "r257",
      "r500"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r98"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r68",
      "r160"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r70",
      "r146",
      "r473",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Payments on loan payable"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r102",
      "r149",
      "r627"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r89",
      "r144",
      "r486",
      "r491",
      "r520"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r153",
      "r191",
      "r192",
      "r193",
      "r195",
      "r204",
      "r207",
      "r253",
      "r359",
      "r360",
      "r361",
      "r383",
      "r384",
      "r409",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r448",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Remeasurement of right-of-use asset and operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding potentially dilutive common stock"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of net loss components"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the expected income tax (benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of total equity-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r54",
      "r55",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Summary of Impact of Adoption of ASC 842"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r321",
      "r323",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of activity for options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of options granted using the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r78",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r164",
      "r165",
      "r166",
      "r225",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r512",
      "r532",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of common stock reserved for issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of common shares issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value - Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life -Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r1",
      "r129",
      "r142",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r53",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r184",
      "r212",
      "r213",
      "r216",
      "r218",
      "r225",
      "r226",
      "r249",
      "r267",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r416",
      "r498",
      "r532",
      "r540",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r82",
      "r153",
      "r176",
      "r177",
      "r178",
      "r191",
      "r192",
      "r193",
      "r195",
      "r204",
      "r207",
      "r224",
      "r253",
      "r301",
      "r359",
      "r360",
      "r361",
      "r383",
      "r384",
      "r409",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r457",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r224",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r82",
      "r83",
      "r89",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt (in shares)",
        "terseLabel": "Issuance of stock upon conversion of debt (in shares)",
        "verboseLabel": "Conversion of convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r89",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r25",
      "r82",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r82",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Options issued and outstanding"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockDetails",
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r65",
      "r520",
      "r542",
      "r564",
      "r610"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r433",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r433",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r433",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r433",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Description of Business and Financial Condition"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r267",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "terseLabel": "Total convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "verboseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r208",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r359",
      "r360",
      "r361",
      "r381",
      "r382",
      "r383",
      "r384",
      "r394",
      "r395",
      "r396",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r434",
      "r435",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r467",
      "r468",
      "r469",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r364",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized income tax"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r227",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "(Decrease) increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r211",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r209",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r529": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r531": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001558370-23-004401-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-004401-xbrl.zip
M4$L#!!0    (  $^=U;?R55'+1(   [*   1    8V=T>"TR,#(R,3(S,2YX
M<V3M7=USXC@2?[^J^Q]T>;G9AX1 ,KLWJ9V](D!NJ2.! V8_GK:$+4"WQF8E
M.0GWUU]+LHV-/V039L;<^24!W-U2]Z_5DEJ2]?W?7S<.>B:,4\_]>-&^NKY
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MU(RJ/$L=IU*9L[]..Z6E@:Z.JAT]7] !ZA/,DYFS4UMZJ,>DQC HW%D.L?5
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MAW0@+<=5F\E"O!_1;_33;R+[X;]02P,$%     @  3YW5MU.E84Y$   HO,
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M$$4M?HQCCU[FQF\&G10R [Z$NIN")/+<_;S,[;RO#9^-8"?KI_\!4$L#!!0
M   (  $^=U:P^:\(^RX  #8  P 5    8V=T>"TR,#(R,3(S,5]D968N>&UL
M[7U;=^,XDN;[GK/_@9O[L#T/3J>=5=V=>:IFCN1+M6:=EL=63DT_U:%)2,(4
M1:I TK;JUP] 2A0IXLH;0IEZJ"Q9PB4BOD  " 0"/_W;VRIP7A")<13^_.[B
M_8=W#@J]R,?AXN=W:7SFQA[&[_[M7__W__KI_YR=_=?X\<[Q(R]=H3!Q/(+<
M!/G.*TZ6SBQ:K]W0^8((P4'@C GV%\AQ+CZ\OWS_X?T/SMG9MHVQ&],Z4>AD
MC5V^ORA^N=JV%X6?G8_GEY?GEQ\N/SH_?O[QA\^7/S@/7XJ"7RA]<ZPL&>#P
M]\_LGV?:I4,9#>//;S'^^=TR2=:?S\]?7U_?OWY\'Y$%K?_AXOR_OMP]>4NT
M<L]P&"=NZ*%W#BW_.<Z^O(L\-\FD5*K^]DR"70,?SXN^A"787V>[8F?LJ[.+
MR[./%^_?8O_=ED3VLT8GN^+L5S\I*I0+_WB>_U@NBB5-E]C.R]=(V8KKXM.G
M3^?9K^^HH!WG)Q(%Z!'-G>R[S\EFC7Y^%^/5.F!M9=\M"9K__,Y;)&^4[<O+
MB\N<Z?_[E%#,F3I=16$<!=AG*E!\&4_G]'NJGPE^#M #;8/J%_L]\GX?A?G_
MEU'@4P6^1G/LX>3FCQ0GFW<.H^CKXZ1"O1<MR!O]=W7.?CWOJ^M,>%H(GL.4
MWH-+:.TE2K#G!A9%>4 '*+FZ\?(VB%[CCL2S;VY +J]Q[ 51G!)TC6*/X#6S
M;]/Y.(UQB.*80G.+0VH0L!M0PGW,?KY&B8L#/;9;M6]%#D_I:N62S73^A!<A
MG6,\-TQ&GA>E84)GQ <*G8=1W$P&AFT#YG^R6KM>,IV/_&C=7"=:]F5%/H6^
M3NA42;)E4*;&+B;_Z08I^H)<5BS[OIE4&O4 7A972S=<4###XM?I_ Z]H.#C
M'7:?<4"'?M-AU1\9X*7Z-8R>8T1>7#JK3L)URKZAD^B3.T?]RU*G<RL2?"#1
MFBXU-I1PMHQ8,VJ;B4/:DA7>IG0U1*Y2PM9%K4>.JC$K'%Y%JQ5.=II'EP5L
M,J!;TL9<ZC1HC=,HS!?!?K[X80-O'I&5VWQ6U6[5-L^MV;/+2;Y#R9P9E*8U
M"N,6H*D:@\1A:>J<9BNRAN/2O'E(4BA_OGEC'QM.N0W:MR*'>Y3<17'\0&?X
M)=V6CZ@9]7&0)O@%W<SGR&LXQ>HW:X7K24AI1C/W#<7W+B$NHZL9H]*6+.WU
MZ/KMCY1.C#<OS?<KPE:,><K(WC%F1D/BAKY+?#:_IW$2K49O.+Z.5BZF)G3N
MID$2&XA%O[&JW,MLN,3;<;+]6&:F$ 0.DW,?K\ZW9<[=(."W729>(-&=LY=Y
ME7_,>,I:ZX J^IG:'VJ(SOQ,#!V26&^Z"WJSILY6:/6,2)?$5MOM@-(E)8IX
MZ3,Z*P31(;W<UKO5AWQ ]*,0N[;U*6;-HWCEOD<IW;FQ_V7MGZ,8S0OJ7S'=
MI9Z%U 9'KTW5(R"D:(]U>+;]@_)Q\?>SBXNSR]RJ'/959H7RA\-L?7Y'_]QV
MR1KIW.;EO*&W!-$-NE]\BQ/6UZ=/GSY\<,Z<?<OTCUWC#FW=R9MW6/M.WH%3
M])#QL^,HB+Q*CP$[,8M(79SQ3KOF;OR<"32-SQ:NNV;G>)?GB+:\^R:STIDL
MMU_\MO>E!VX<3^?Y5H<2M^LG<)]1D!U>RLO_=G$@"JT:YQ98+M-Q73'!![S6
M"PJ9Y!>M<K=7T1&I\DGU?=?NG$0K,VE'*BK2F':1NWO=8D+<#K$VYBF7P)ZK
MSQI4.[/(D5,;$3K(?WYG23<*TO.-!-LW1&'F[- 8$KPZZF$AJF6#_0-:I*.#
M6U;(KK!T=V-$(?Y(@QA[0X5/?'FX"(FV/&+HCH5N,EVR>7(#I#&!B,J+1XJL
MAA66]V3<NROZ<4;<,':]S,DD&S+JBF(A:%5M/Y@TT(E,J1I^5(FY*(\H/>KM
M#J\\TB/.3OHS2L>;KR'^(RW' $A&FVYU\<+&H $0\F%(RE=UXAKZ4JC6:3WL
M&L 4:5,W^/#3YZ:R')1S87^6*_GE9K0KQ1S'*2V=X03E@3 KG]9$Y4T8[G@2
MDXL_TB3%RLS%);TR;\E([F&<Q"0IJ0W]:Z\R](_?'ED4"&<T5'ZKJ4+MUT')
M_5+Q9AX2G/\J)GG_>V-=%0DGXG8SF!X>D,6TCD..Y261&R^9GX[^C^V)7N@J
M3KY!%U<03_C2*C:X?D1Q0K"7()]/&_];KIYWT:10<FT;;;^6TD$[ZH[@X9=7
M$@;+TT1;QNR.\B)R8;PI/OX#(T(%M]QD48:2$:]76:C#^M6M2J8</UBG4[ID
M,VI#+2?=5EH/;F-@HQ;4#CZR=;DKCW)CKL ,ZUV0Y"8["- ;S?4Z.H.87\LJ
M^Z4(T2UP_C1\1%Y*" X78S?&]9!@^G,4>K16%L=TR);>>.^K7S4,??;<I5V1
MJAC/G/3)F$T3Q!,$U_+T*0#+6XW\B/)7%F(6)E/RB!?+1+;3$)57'1SS:X!A
M6>>8G%?#C.TN':H:0-0/SD7D#+_$%Y//.4$7D6UW[)36(]F(5_A,1<6%*B2K
M (5?Z;@15S#BN<-1HX%!I$O,X&-&3'QYR,B)MCMBKM%SLK\J)ADK]8)"C>$7
MM<^=\IA.5%R3TXX/Z*02C_2(&'Q$\(@NCP49L79'PD/@AHP>R1@H%Q'JQ&$A
MF[Q(M;U:2,E/AYHMD&,DZW1P3:X26=;A.G%V-3>_F%*$=>W2W$@465)#J >*
M.H 8EVJ]M(XI\QV."3U((@.2!A\Q4A;* TA)NMWQ-'IUB:_8.E3*"-6F5LI*
M: 6[EE>[GCAB^[=%[KH=;_9E'MQ--G,SRO?DA[[6E-)'5^* CIXZ:SV41;H1
M]4_[X&/^@-=*R$A//-HU#K\PMP?*C%<J.T"HE1/J,;>D==:DXYQ34H^]#D>9
M3,"1LOO!!PJ'W/)@$9!I>2(LW>5^8K[US-]^\^8%J8_\6PH'&]EIXN99P6Y<
M$N)P45P%'V_X#<BFU?YZ%$_2_?8)!SCE]*VJ9BC"KJ?5070C,N-J^ FW3RF4
M+9(.]\,'?LZ88*;S2>CC%^RG+B\B1UB.&UTI+&F-I5]QLGQ$089@O,3K671#
ML4CXT34-6M 3@[J-5H&H*H"BQF0-&K@J8&,7Q-J ?,M>T&W"-+;L3LI9T\8;
MQ8Y8HZ;8QZA7%Y1 E&=M&C7-!=+QZ9L9:)$Q@<-[;748JCAS]1B!X.&=N6^C
M-%E&=";>*)V[AX45KDU><1B<:GASZ\4-N.W<ARN1?,U]RR?$DN>V3GC=:<LG
MV.[H&+L!RWG_M$1(Y_!#5%RH,[(*4/B5CA)Q!2.>.QPI&AA$NL0,/EK$Q)?'
MBYQH"U?F4+P[<!%=G*N6X-]%JY>QP(!P)U0KHV*BH]V,6'21I,MAK]@=DEA<
MM..19MGQZ/]W&N<9?V\C<H]>2UGE2132CUY^@B!S)9JT(?9LF;9B0UQLJ;K/
MKR^]?\<K*F1>5+B]*Z\A-I&:MN$=<F:\E*<($0_#3P[%6?R3AT*7X$@P17#+
M<6VLL.1@+&W[_1K&:^1EKTT)IPUA63YKLM*MIA&5>",- @:=5 0$[Z86*:'#
M:_D5&Y>(K%VZWQ>$^HF*<15!5'"X%=$Z)=[2C=%H0=#V>:(J29*5DF9=P0K*
MH':K(:$ (VI SZ CA$__?NUE0/?A@/GI_$"@=_3/_)=&J4E[>TVMA+$@A^F'
M#Q^S'*9%;_3SU?3^:7HWN1[-;JZ=IQG]WY>;^]F3,[UE/_WGS>-L,KZ[<1X>
M;VYO'A^S,M.K_^^,[K>?_C&]N[YY?/I_SE^N;VXG5Y/9OS@W__%U,OOG._W,
MUH7F#IL)<L;NK(EBK X*G5NBL:MLE24.M$R#]D#E)D_>CR'>NI0/0"5P2\[*
M@6D9&)O6J31[PZ*>)5P3")F6*=-KVL:C]-2)=%/&*=<7#M4$Z'(0I.I43097
MH]^NX/?OYCRXV)^$5^X:)VX@!4%19U! +EL"HN#%+CB/['V)$/F[T!1%OB!^
MX4'A^-@2#A$3E@>)YZ6K-&"+O/P=,<H(04MFIU^VCYW(!XQ^_4'1^J'MX-'G
MRRZ G>71M[($$]@X@R58G0W+TWWS)/_P%EXBG9+G_K<.@6B'JEA_*6I!6(V)
MM:N>EU?"2BM\ZJ\NL6]^>T($H]@U$[Y130BK+SD 1NST!\+HHC$*&E4AK+JT
M8=#@IT<<+IOCH*X*83VECX.:G_YP&#>&05US4!1^;(F"FIT>06ANE#2J#@K#
M7]O"T+-1@O.VBI5-A6#.T-A4B-FPC$=_#[_ V72H=,[L_1?;D$T>IM+M1NEW
M"!L+?0VKQ"_OF>ACXKB-@B!ZG88/Z7. O>F<VDD<+L2SA;P\A.V#F9@UF +B
M?+K#(9K0CTJO4ZE@3WADS^5J^C=J9'-=3-OYXC!B('OR]+,7A0EZ2VZ"K.C/
M[V*T8!_VOP=1C/R?WR4D'?Z<=A)Z!+GLS?'\_Y.P?$*?.T,?J7[=1H1E6Q"9
M*M-60(PT+8R-65L3G%U[R'3+]N [I%0X^.H%(<PY#;6S.D;KK$&"B-VVCJ=I
M$K.7>*G9%B%4+P=A#'4!4)VS[O 1[3<9D9,X3I%_G;+)\H%.F9&?I8S>IJR-
M;][H]@''Z-#F-6D @D.L!51-6+:%8:Y.;4 4M@#!G=83BD*>(9E*B0)FOTTS
MRH28MV@'@@NOJ[G0C'/X^.>JVX$"2!N"X#WL3P.DK -2@=(EFEDDB%[*>'D^
MS"?WB*AX8IR@)T1>L(=ROME3#XL<S6P0"&.^^NYV4/7Z6V_JU;^@CDP9#Z*)
M*K'Q+,=U"X53-SVH4OW=JE*IA0%(<633</FIX1(/^\Q:#18U&FT.JBJ?K"QP
M-*0 7T?RB;IC)=%N=%B7T <[JZ!!]:2!?Z+R&#E>K8/]G3!VL_@V35*"N-Z^
M;IL>5AFZ=Q!V*PV[[HY^=*)!VS:=QGV,'#V_B25-Z74A<H]>LU^:+#A*=8=5
MB!Z]U'KLP@<WU]B&Z-8J#PMO]YYM4WX!X2NZ='(7Q91BN@6:N6\"=/6J#HMM
M]_YN,VX!(4N)VE,H@/"@S+!8]>>A/F +$"AUYF9HM8Z(2S;-HR1D34 X,VP:
M(B'C"Q"F!V1>N81LJ.T?K5ANC5&2$/R<)BRT9Q8]T(D@%+GK&K0#,[I"K=*5
MW%KF;,,%7S<00UT-9EQ&*VAMQ&@<DB!9@(M\-AP/>[=-0[#13:'N5A) U$'J
MPFNG#AI-PPP0Z5P=-"0QM#I4/##9M8!L$MK2Q0__,6X"9A1(<WC5'%N'L:QJ
M#6&L-6'=1]E0=[5AK'&LAO&G<^#IX?(%Y!(EV-LGXU/FBOMQJ%QQSE\J!/[+
MNU/NN._U;F'SG'&GNX6GNX6GNX6GNX6]>05.=PM/=PN!!4B6MICL7_84RE44
M)QJO-31H$L08U$*_'9_ UOMNO+RE1F3/J'S9_H-1BN?1TS^<V[OIKT^G)?=I
MR7U:<I^6W*<E]VG)?5IRGY;<W^62^QXE;+GU0*(73-=6X\U72LLDG-*YTV5/
M38VHXKWD+[D_QPFA>BB.+S)N",1XTT*Z"7> 0A? !XCQL6FNG,<1(E;:M-U'
MH4=9S11P%K%KC*&' U2A?19U,U3[[Q;"P.Y&>?J7%2!]O$9K@CR</RF+U@'*
M@ O]T2HB"?XS^UZ@4WI5(1B5H09=68OTI -($[(3X?'AG6O1TDU0&((5L(&V
M2!Z \"TXNF,Q(8]XL4RF<\KL*(Y14M;*FS?&@,@)9=X,A  X&SIA+BE VE*F
M;SJ_Q:%+I10NI'YW:14(<6\VM$ N%;"(LQ"]:QQGSP\_$+3"Z4H+=FX]"$%Q
M]K'GBJ;WZ+E;%Y,L-G<O $8*P2^4K!=TA]UG' CN_.K7A9#Z:$B$#<5C!^4&
MM[R;M0,A,Q$,](_I9O<O5+@QDP6*IW0-PMA.<;S<J;$P\9!&/0A9A6P8? W1
M %* >IQXP>XV?$#A53)I $+V(!LJ82*CWJ>).C&_L&2>E'U$)ZWGH';77[L6
M!#>/N3X7QER'1= CERXHUR[VK[>Q\MLMY2C,WYW,MIRB?5O3QB#X>II!WI9S
MT)J042H>T285(7ANND:XSB5\-/=3CMDXYE>&X(GI!=4:IZ"1'7F9)R!^<#>2
MF#^->A"\*UWC66,2.I0D1?YNPR].KJA7%8(SI0= :WQ:6.[N)O9L=9>O]*]2
MPDG;T: ^!"](ITM@&;.@QV/UY$7DXFQ0'X)?H_.I4\0L((CU SM:AZK!\%2T
M ]F$6_@H3\(7%'<1F"AM",)>IU5@HI0[0"C3)=WNSI+W1XH)HHQ0Q4PV#P&=
M9NA6F[G*URMQ)BV3!B"XI9JK=1EU$ZX!H:W/?.NQ#,,CU0W:)ES#1[N(>FAK
MP:4-0?!KM++@4NX H4SI]A#RXUO*NLF;2AKU -MK#26NV&LULX @?43K[?PR
MG3\M(Y+,$%E)SH EY0$;84,()4P"@JZL:+L[WA,F=S>HW@[3&)6*^A#6R-V/
M3@73O7NI*I;"/&3'J#J$.;(=@N8\ QVKVX<T=_.!:/TKKP+!]]_]B*SS"0A#
M?79;KVUA' 5T@Z\)UX#0OJ'S@)=,YS=OWM(-%^B1KN^G(>.$_<=,S(L;,+/S
M2#=F!'L)\MD/=#]>_:)44J 6O?0$P3[H[8EZ81^0(K7B),^I6W<*>T'*,FV7
M99;+4:!C0Q,!P7SIJ=_0D@&FF92[ YX4#AI5)0B'H?K(RS@!AE37T\XQ33 "
MAXV> G<VVL&I!$N<MHMG+AS$H<]96K'K1T$4T\V1QO!NURR$HW)] ]".UP%<
M!#M7U'0^"6GGS%\Q6Y(H72QG2TS\!Y<DFX):OIO L DH([L+[2XY#@RE &BH
M']P@GCXG5)!L#[5;7]Q&Q"SRI56+$/R\7>I')T+IW1+L8K)V_LGL'G&^TF0T
MRH-*&[4 P>G;N1TP%0(@,R!X"B)/\GHAFL\5E2#XA?L8S"J^>Q^O!L_^3L(D
MNHI6JRBL4<H;QUVU#,%%U/GX[DHX@V9)WO-UC6*/X'6>-V"<QG0"BN.],-R
M\I?G>[Y&='H*]-(F__#AXL.%<^;L^V%_[+MRHKFSZ\QQ0]\ING.*_IR_;'L$
M_'Q)D3-V2G*(OZ!DR?PS3*L0*J7;'&_JA7?%I)F8.^WBE,>Y@SS./8!^R@)]
MR@+]7>0E[B3],_B\Q%.Z(AA1\O)4'1D5TF3<DO(0]K[-DG-+F#JE1C<)U8>8
M&GV4?'')[^RY>I7Q$96$L ]L8'9$[%B>FNFTA?Y(Z4"[>6$9PVE7BF46M[2%
M19;(Y RPR.** !R.\I65N#R@!95$,Q68P'A+XX PZ>0A* MBD:52+@D8,,Q<
MS<<VWGP-,:6RY%J0V#W]ZA8,H6CV[]D0ZLL$&/1LPI;:1FD-(-;15*&ER)7Y
MZ]O!7'TJ6;SZ4]>!8!DUE(OK[^5S9-FYKP>&9B,0MI]-T=%DL0>[%I.D9-/H
M7WM[1O^@1*9A@LB:!0 P7CA3EKB8A:E)M'OJ:6H2\SX\5(]HG1)OZ<9[/3HD
MC3L)&=:U/!VIE'*'B@%'O1A!-Z1%;W'RYP(1-_!9)%Y$_QD_X@!MGI"7DNS4
M;A)Z$B-HWHC-*:J1$N[-H3FS]K=:-?_[G>IU-T4EBR^]:;'#/_WIPJ@>X9MQ
MI7>$KU/F8<M#WK-G3^)[])K])'[G3Z\RA&5- ]W0Y Y0"%%.6T[S \$>HB1G
MWXD %)<'X8LWQTS,T*#7?:57CW\A]9?[&K4 PJFOC5$C%@$-KF_U/K[H=I_Q
MX+-R][Y[5U?9AFB'71Y4 G$_SAA %5>04<O#^_*O$^-XV7(]$#?<VF-79ZSW
M&?"+^X97Z6JTH/NF!;OFNQWOV4S,F_ 4%4!<-3*;WQ0<#05!]G[-EMA9-$;Y
M$/X:4DZ+3:T$$+WJ$/)I-H-'CS](YHY_$S*Y<@G94/7*&!*9/+VZP[I=/G1F
M]_2XLQ3O_92N5LQ?,'_"BQ#/L<=2.N9W4)A1B.BBB,6]&\5Z7]9CO;?=L#CO
M4D?.OB=GU]4QA'E[2^2G#'UA)DQI"+=V]>'W#WQRQAM%!)%634 AVX8 'NPA
MU*Q:WP<*F%+%#VG5!')6;J"M6OC!B2\J2))&%M5*03@Y-U"]2@J>0U[L G";
M$BH_=LN+77QZ8Y]B*1:R"A!\RPUAD;$%U,2ISH9T*MH['])GJ^)3UI[.AC__
M$<6+L\L:S/UV&Y$K@GR<L&</L^<^XOT369('4@P; #T(Q;M!0RX![0>%S'Z-
MT3P-[O!<M#S6J@GA\*?98-5BKW<O3.EA'=[HJOP,X1"GP=BI\#!8=@R]YYW
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M184A[/B[4.4RJ")>+5\0W)N@XN,_,%T8$&^YN4,O*)!86=W*<'RF32VN+J=
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MKW4&&&_\RQ+4;%]1ZXV3BD[QQII9?0AWD)N,,S,N 8VQKR$I(N4HN=L%EVB
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M'/RS66!3""JH$T9^JE418/8RIH[$'0\^1NR 38H4*6*5SY Z6:.(?=V*#\1
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MEPU2O+I21(0\9)F'=E/H3UQP:2(3Z6AN/.B7'WI'O4Y7_&&O;8"#N&_M-X_
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M*%%3O6J]VF47KIE\4 ?RE<*V;:*<1O>CA#R8!YBGEF??G0QB"!BBS6@%H;!
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MW.HE/U8QV"[8+OFXP&:P:DNR!G=1&-<,"_TS$[J;T/_[GLUTP<C:Z#LR[[G
M\11?02,^C\EX#H ]B?X&LI0SF7@"!T<P,8\K9""E$/@0&K61\^4]0'/BOX3^
MVG>AY,J^.A+ZPN1PVOZXO+["50BS=PG,&2&EOO):92_G@%$=A!^EU"4:')G
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MO>+!C.9FV)_):)&Z_V,).[BT""=T?KB.XJW8RX621FP,Y_=P(BCU"SN[6RX
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M%%N 9MN"@L?/B [-"HR_]!,WB !).QW2-/='#CR=3=%^PM;0&3&4=-?!^*E
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MK&WT3%_\$/9J9S7>2*QSDR1[VKH=8YC7B8XW6B8V,=XH&9W@>*.G+\+Q9D%
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MY_1.:I)+B<X3A?W-=A?X\)I"NH][1GXSB;D&O\(@6O'?T'_.$*!29Q(4\(4
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MR"X($+8P@QC)?S+?*5RFJMF_?5]*P<#Q-_;'_$\9@?_^_P-02P,$%     @
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M';^<)$/  C'K'PZCVHE$T<RF[,HXQ7M>,K?R,<<2U>TGCA*)*+J%HT^J@:)
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M![V"\:20A*97RH/V)WQ9IZ^6#ER(LH%=R7A&-(!G61IZZCT',7Z(5C>>*:V
MZI5KEID\)?:0>2Q<PF330+RBL01H"=&(+(:%]\]%=I="=<Q6>"-TEKWC_8A4
MA,2+U]'7X!7X(;%WV3VN5![4-22WIK'T:(M1U8O<FI#D'D01 "2UH>"2DE'#
M>%+(8LN]3R>6L&%[9B9&!5IQXWD@!2PG@2T^R%VX8C&(8I(G3T*R0=+V7@%>
M2D?,>:1!2\931Q7FG%76^#Q#@ARFT;%>]/L50N#%^"=JV!6UAO$LD<66L\$6
MM^8V*4LAHUME9T;AA5#=LA0_F<>0YBASKMCB^,1V%((ECLA[!>*[7-GJQC.F
M%="<-+;X1?=#NL6XPJEE/$6:X,N9H8GWL_WR%BRP!7T$ZQ#*QF,(U36>)<U1
MYES1VUUZLP)P@7#] L,?\1*;32<0<9F*U#-6^>T0YHJWQ7?Z 'X4! ?# /WH
M@L+*2\Q>R#9C+'N4 L[)I(F/E6)%'@%.BP_(9?.GM>]Q3ER%ZABK_^;H\M"N
MCEVH \?T/I.H%:&(WO.3LY/S-A&]Z;<.(Y[W8__+1W<)9HF/MN4,6X=#U\C[
M4='VJ1]2QD/;^+4OD)1;Z4?*X^ZSUE;E8^V"M'MQ&'ZS0";-MY0M.J_:(NED
MW_J;),59OP>X9K#MSN7FTO'Q\XI/2P!BM)!/UF@8"*< YU37SI3PU,!PK#:!
M:MEU@ZTL"ND6LY$[FP2/P$T@?KR.W,_X'H0O$8 D_O8N6"<Q^G.([(#O";U2
MT\6G;&)CUV*Q[ K%5F[DX4X\U[$%B H\A $LR1/7SR3G+@/OCR1;IPM3N<MO
MV\3MWN74SR607E]PD%JU?:RNVNK?<=!_:=;Q@PX#+-6HW6H<K*^OT1!50=5X
M- 1K^#YN[]D&J4'_J3KH]Q]O,&"XJWS%88#!O7-55)\>$%I<B#=0YO\7Q/_/
MVK[60#EH;(?5\+'.2&0M->Z_5,<],P&\_D:@]TSP Q@*$F2.TX,*605*:>U,
M@+34JT9!!FJG%N!LH,L8$[3N<;#<B"1RD[CYYL0)[I@@7Z1;LI-+:L30C_.D
MCP<#I&:6K_4S2_YL@/X320?O!PRZIB1=N]Q<^4XD<8986TN[X<X7.VL!*8[1
M\%4C)=^_U+B^J(YK:M9__0>YANG_AS42^^GFQS\<F#Z*D5Y#VCE5QU&4K-+?
M26Y.57Q$.Q/47NE,$]65R"P[E*R36%$;18F-W=A[%5T4MV_X8!FK0$R6'4#N
MI'2S6OOA!H G %\]'$U0)[2Q3[J!KX+.\;'M(O#^1 H!"$&J)7'R*OY>65E?
MD;+.;>9T'](S_/AQ[P$7F:7EZ4EU:5E]QD7_-:6B]UR&/8 (8F_F^0F^;?Z$
M#]6)7SU]+@W,;M&8PY1/XHSGLD_!J/^0=I:(I5;F:4:7 K%VM;<O!AS_X>+T
M/%B28":YQ)-JS1KFM4=MN*NS\%B)U+Q5<^>B^&2)_C.6TK=+!IVWL&T, [RF
MF\RW?<PB&+*G=R1M@72+VMD#CJY8)D$->'MGG?D<X$WLSG(\HEW&7F2MY-0C
MW:1-?%.$WEIW09ZS& FF+BY6DFM2K=E$L_; #=^E7X/(A=XZW4)<)I$7@(C<
M^<JO9UV%P<S#?[X&L>/Y8BNACR<U3ST6/H5OH.8?2^]\;6^#;;\W^DOV17U7
M2Q.X< +O3R)]U.\H]+U9_E;@M*"90O*E)_0;(')TI*3M(59@R4N$MJWX,C-,
MCP._@7@9SNZ"5Q#% #PYA8/6:N&\&!EY-+NE\!/E,7TQ_(NSRO1>8_:ZEINB
MY9V?FL%AWU)[1I\:OWFTUW,HI;6C4^<ZKZ>9J&AL8\QUN'*\0)PS:7DM62.J
M0B$",'#:1(%O8/4"H)CZT[(FJ)ZA/*[R&2B-5WQJ*@L6E#-?U);7D@ #S!CB
MPE&TIQ^(-SN #\X*_?@,G2!"2S:\PV).'MR*&C-)1*TUM&@&>4B[0LGR=1OZ
M?OAC$DR3%]]S)W/4#2]8U,X6W/+ZJ;F9FG;Z;@;9Z.GC;CIAKA6V?[=/VV(0
MC3;RDU< <? /N7:2QK@QM4TM;Z_VY2 K<K*J-.GC^)L#?P<QWYC7E[1/M;)@
M%;VL.<P03]^"BX@C+EL+?R>)10I>;L9V0+2Z?BSI?W?02E9#6@[U),,#D[E+
M8-30CDJM]"I $PYT#;<)10C3O!<$"WUVX=717^T</>U-,(WP:J[K)V^U]L%X
M 4%ZC',;PMLDWE[3$U.^4",EZ7P]L8H-S06@WV8C@G%A@D#_VDT.Z!\(=A+$
M "+QQALLL)J5!JV8=@SH<44A)1/]EJ<<4CR"=0+=I1/MQL ^V-JU@U1=;>@C
MI<LR!=J!U7$N<0)4]-:+_UP Z/@SDN@"_<_EH^>#S>[NP%W@,N82V4:THD([
MG>[/*DI$T4&PJPZ'7/=> .YBL)(ZZ=I6TH8TNAUWL264<4GENVI]<PF#O(NB
M!,RN$^P92N]!DOLET0/X0?Y$Y91098VY):SH&K8TQVY;N#V!G(IB"CT7Y/>3
M:*RAE;>4*%)P]8J,IRQLIC!T 9A%^+(C!H;S[-\%:.YU_/(YX2\PC/:-1X,6
M["*&*@'T$^+>9^9D,8E0S(IP?;O8I :^HEVU+ERJN*^*1OB40B!V)3M9TP!S
M!VM>K:@R7N$-:OKK6((M^_7*PCNUE3!"L#/.:/+*,&55\\UY\U;):KQ80+!P
M8I ;3+)HJUO$,"O8I?Z&>#.]Z_UB< :+/&:2B>4YO 2I#?P>( 1;WQ6#!2+5
M[>5$8_090VQY6OC*B9;8+8G^@QU1KTBJ^/Y7?.5 N$%#A<B)-J.(U+6+0NVA
M9_QI^YHPFKQ>0HV?F)6[Y7M6O>4K\\:L]A=\53XRVW\B^-TU=_HS.*QKMH+5
MM;,4;"74.,[: #4Z#)V*]W+#N?\J4%,[7K32<ZTCI)$([&0,]_:K0$WM&--4
MQ1)DX: WFBQ;D,S;#WNES"$!1W55$H@@-5KAMPD,/!QR1S+(O.&?(J;NZ17*
MPCE#PCFSA0:2H/6+3E0Q7_#"2/@5M6-(7^L+M@0Z.-A5<V$*W^_$AT6W(;Q"
MO?!(>NA?( (7/0(7>.1%ZJL$0HK_2ZH![<C14)M[7K#V,K L)H0JUN\1F"?^
MO3>G;6\%:MI'HK;@C8@:(<,A30I89T<*?[9/P4((]0KHH&@Q3\U8 ,.8'.BE
M+=6Q)&#+XBXF\1+ 0J+.AS!P:\G!KV ?/QIB5A1OP3WAZ(TDWP.X?77EV7G+
MTE33-AR4TO;20P:P7G$5:B*)J^_U0&1+%R#U[]6_LW;K>)"<$1;>5L-9T-T8
MS*Z]5V\&@AE.5,V*2.[RN_:R=1C1*8HKT<<FDCD!2Q"")1+B-L$ZWD:B/27P
M%D&ZC' WA?P?2''D7WXJ]-F_DX@D;GG B3Z0[6!-NLH_9B_'>Y27HG 8?8C]
MD& 'ZF2^?:;["2S(-7 *-ZGE[:67'&1% 2_:3/FU#T.GH<AKM#[>Q9L^8N72
MHG%EF[&734HDD7LC3RQAV79HW0.T#GGT%DMD@[]'@#PN09LE677*4CM'4CNU
MA#_RL'.RM/5=ZS-IE660;]4W]7XNL4J'0A@AW#EC-/%7=\47OO>+5^_@6,.!
MGA/'U&=]Q()][U9KM(68S,>S%)]L\.]9B^#?]Z/TZ[AL_OT#BP@^[W\1/$1$
ML ;6A*V$FK5M&Z#Z17!Q$T=%^0M"E$1B>R6TTV\K?>W4+PK59 TS4H#ME=%&
MRZ)JH2J2@<<X53ZY('#02F(*P:L7)I&_>03K$-^(K0VT%*FBJZ(9:BNKNA%
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M8)8'6\@=TGRJ'M)D[8WR!DTXGDDC G!*6=)[Q^<E.&74&. PYF:U]L,- (^
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M$67C><^)=Z.4UHX%JC8!;(2*/'B#!K&5\=XZ+ABO\,,50@38%=>< 6P]\EC
M@:G7:8^QR34NSI X/]G#&FG@>IT<*>91>BG:<[-+TD+4V:MC-5M$L%IV8O2T
M#&&,TQ9=AA"&/] 6G/HV=+6D96001=A/#IW.#HNNPM7*(T%1^#0-/Q"!D(+
M10OL>^!(AP]]J1X;%;Y KGF7OH'^GG[&@#,DAJ@*P5?L$R6I-GX[[__,.(I
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M<;(/_*B!BXHR$Z(T:NO@"2<EF+9/F6OWM%('T<EV<D@&>L:2"TML5!EZ]N*
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MPD!KHW/^]B'53!;2\A__'U!+ P04    "  !/G=6*5K%(J4I! "H_"0 %0
M &-G='@M,C R,C$R,S%X,3!K+FAT;>R]]W/JR+8P^ONM^OX'O7WN.6>FRGA+
M(GO/S%>89(P-F.#TZA752 W(*( "P7_]Z]4M"1&=P 9OG;IWCP&IP^J5>X6_
M_N]44[DQ-BW%T/_^KW#*_Y?#NF3(BM[[^[^M9B&2^N___>=_./(_^@_'_?7_
M1"*<<G]>O^)D0W(TK-N<9&)D8YF;*';_C&L:PR'2N6MLFHJJ<N>F(O>P^XK
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M!WNWL27UFVK!V[;Z6PJAM]0IB Y[\61$>I[E1[JD/D]N\^W$Y<$*F@.I G#
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MBN1GY\/HG5VXO@4$%]^&X,7F?8B\.U?4CQAYEP-:,='=]Q/+ZC%OSSJ89WE
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M8\^XAJ>2<NQJ#=1"@[X-2,&Q1GO<-<;T)S)P8\Z(F%JK!'=.R!43!8@ P/0
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M%T__]RNP*Q>6(B6W'HYT3(P&$=0E$Y\A=8)FEKO+9/HT^N]?'<.4R2^\MR@
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M$)$7$3G !P%-?<0EV_%O\."&RX ;1 DNZ=$8*2J<4VCRA=BTA$U$1;,5UV5
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M=U4'0TRC5S1#,LRA >6(02^S0ZH.J3JDZF"^&82J^,8-)>D^,L$8D@W)F3<
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M/W)]'GG?I+GP,9YO3CL;/(..[<OI O2$+/F?O#AY21\]F]^4%5E"%],LFS,
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MU<HB8_PDJR"H%0Q8N^1;YV6;)9-QD^L%36%9(ED]$4O+*#DN<<456C33E%Q
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M:21FWX]H)9)_[N_NDN[2CH%BMOL$IX(.>6__.8 LE0^Z&9P,:^-9:T$09QG
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MLJUHZ":S( ]+LBJC?>"8_"V$)L9"%*%8<=E+G(&0L)SG;3L,N8';Z?$/RGS
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M5?5NR6<.CN^2SUS-B456H2L.@U_F[/R(UT+K+H[A"O3(![%DF3@'O97$V%$
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M' PKJI%1\J,J!X3?E*+Y#RD_Z;872D('!.'^@'@9RM95O:BN\^MTNI+S>)S
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MLU!\ELAS'V^V;%JHJSX$+'*</O+Q+N.+(7>*$E./W1 UWHI!.=UL3LI<"U.
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M[0U')<#R>!!YH@+67?)UX$DYYGZ6!BKR:[E)59:1F[2#AE;<1$!U!1VM+\
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ML])3L+(T1Z1LW(C56$5="LX#1J'' [7#0IR%OP(M5]29M7,B P'%.BYQ/5D
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M[3C!:S)^R<7YBUXPN+/79R<:7.*QTE$IJ_RO5*S6WY%*6AG_Z4G09Z9SP+W
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M;;#&V4AR@'8!]6'('E_J :.Q52(2Y"[ ]50)!U]W![XN'.EUET1&^[2_:8#
M*W\C.;5CRQ8D#WSNV&=';:X_I\WH:N>/]/T,EVG4('W-ZG?IM[E;Q-.F#DGJ
MD?<H9U4OSHI Q*[?947)E5IPM$:R\9P&+LK@8NM-YQM/=X5ULTE.'H$&ZFL>
M;9W2]],18P-F99XA6B=_<1&MC",F-CT=/ST=6>>L\ ^G#XAUTHLFR793>Z:#
M78F28'TYC<.7?S5[(Y,DJ2I1#_?]6,#RDO&&Z",B!2WXA(+SNS-(*XA2X!)<
M=%$6M'&^&D=F_0 Y+W?+(.6,?SU']*Z87T0\L/CD=VFHU7Q.&$=W#+?>/3(J
M_%VG71'2#O=C1NI; Q:1M4$BL9QIK**D(\/_F"(#6#OSHOTL?AO^M"9\$ ZB
M;;*X[UZGM(N+6BP<!*M&+GP1F.3GI]UAB'B>0:3'.PIKLE=Q<-M&XV2W7VA:
MVGBM+<1W(E@'"2_$(2?2$A)=[LEE9"A ISM BW\#U$ $2GQDZ;&#;7ILFQY[
MJ.FQNXAL\L6/6+[L[1[L]^[5*^_VNF$DW&K 1**L6,H;IN29-JHKR.FA#[/R
MM0P42Q6O6^HO8/P%AX9&0@+O8Q 7)]YR4"\2D19-9SS0_$08*OM AN*C$A&?
ME72(5%>85EI)$H6!VA=O]P;/Y)C3C[O/#WI ?B))RC6RL3/NY\JJRRNLNBOG
M>?0-79E-8)%>I\5BDB)]C;%< #2<76X4BX?<= TL,IO>!:GD 'BV9%^FH@$S
M&->/O*PNTT+-?TZM6D:S#27S7V/=TI'=-'#S"O";H\KBM=,ER-B!\A%"/2#L
M_['E95 X/E3!:ZM:K.RL"9"!-$[ZR#C*WB(V6.N.:,*Z$,RS/$$!@4DJ3DXV
MF0!4R_FX294Z6 (-_+J4F-4XP^WG.!FN!$T2GD*\DHHF%QP=4*ES"4G<,."X
MSF>+:9,6&8D(  4P('Q+AC0I1_2#07"K!IA9C<FXU6QOR&3!>^&7PIPXC2OI
M#I&4>"&9:08N9FYY\0PQ<@'SGWEC.4W@/$SU^.RL/3Y99>>%'LB>'X)N,,,;
M!H &P2].='W\L\,S%Y\J>:TZ:&'8]B9,XK,9##A>&9X8'7%[VAW'S06L()SF
M)>1-+BZ)BST&X %,(R\6'"'4S:+Y!B\&;CU:EI/S5X99X&.=\NEG0//,06AX
M+Z=I ;Q@ZVKQ:_$W<8C2HIYH7 9/#E</<TBF)#[X[W[INW83MU^A,#;R:;HH
M?-F(GBR^TQ;38%WD,!"MUU>,--%@MBW_=&HGM<@R=9OYZ>VY:DW)YM+7NEM\
MO$WNY74XP3%G3>@ **P9FCV.WW(Q1%VK=RMU$20:L]E\6BXU>>'!SEZSDH&3
MSW./?"#'+&6FIQF)-ST$;V5/M-@B$C_Z JVV"$\$5[S00)>(Q O:FA1^W;A(
MA)47J(H8P9.'XYQS:'1U>E@6%YUF^TP/I&U\FDAXF8/<'9(SS\0-QW'(1**S
M?))8"B!*72<XVI7HS(G0T>#A^VRT$,R'@Z'[&X/0VIK'1#<G?'P+Q^V42A-<
M@Y9 U**8CI'6K*3M/N@-&5UQ6$,5V>8PURWU\A!LG9%I-"OD\ 8%^8+I5.+[
M8Q1SY4,N$2-#99X.]9CUDU>D)JNQR+Q0@V8BZBUCYNNF+'0[X2HSKTOH7:Q5
M9PN.AH95 5!V/!0?#,4!C(T,KI0CBSD=EEA6 R(&!0,R"+D)'8]C@R&':;)1
MP!A<@L;*&8+K:0J%"R&R&O67>8WBFI8 P:2&>1G<SA&C_?/,-$-99ZV-N2D7
M4\1"BVR2-U9JP1^:E2J% WR>WN+.1:0WT/KA5$AH<"10+.PK![B#.A=Z=!;9
M5PQ3<#N(H\9[Z!^.A2A@3G"]FY5Y:$W753Y7^R.,N_NY\Y]DX.'JR21XV#*7
MZ*S72Y+CL\TB"'$@6'"S(69#=[9S, &Q]"0;@8 Q.X1.4&+S73EE.609&^1[
MO'\Y"6V_*TW"768@N9G3]^T5G!-Q3[]Q=42A84\JCKW0;"QI0GW8G%3VJ,KG
MXBLY>\4>I:KFILH;TJ(P'@N@6:'/ATMH/PVAT;_K&<R?8C$;BO:97Y$:)H%2
MU)R'YE&-\G'WTH0"JD1MV_1:#ZL6,08&L%MWK2V597>R<)DLR%Z92L:48<2<
MI ZF57]0_&VP&(CN%_;B:Z:3Z&23VLY,J[,_,/)#$2D$5R^?P^NC_1G%,1VY
MR[R;J-I-I\!'1()O#?:4Y0%95Z-TC'3C^D+H-;6P_%C&BJ@ADE]#X70^1E'W
M.J^RJO5GU4^+VKQ33C>97Q"BEYWAR3GY]J=#7_91YD\.M_F3;?[DH>9/.L-S
M;-U8Y!GUGX6IH75F%YN<J$^ ,QX:.*%5THO,$O]E4CY/\J>FL)T5*#HSKYS8
MZ:W$M3H#6E[A5?1<>C!]:HCB20OE^S0ZZRH4<-=A(&9:%O#@IF1Y2]@SB/V1
M^XG O7M$[:/<+N@S7:H*G2YC65@&Y4D IDA4KFO]_X@J7,2"51<R#!VQ>B%]
M0:.I#=5HVD4+1QK&\)E0EZ6P""XP3:C5"H6QUCUS$3"M[>4&7846NBCTEGW
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M7>Q8\FN\T!IZXP7;!1BM&DG+7K03G+AR5A>XC384"3@33U,O^<\+ (]?T [
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MD8A:&FRJ$K[P[1(-9*5M27*D_A7!O>H!H*EW];):4.\DE=7SO&WZ)5BZI3S
MVJIJ_4MZ]PI5EYAI]*_J87I-<)C"\20'Z^^YKMJ.7LK5@DE+#K*>5=<?Y='T
M',B3J?.!NM(Z>U\[+,&G+.Q1=DZM5(+VQE8JF(>]KZ#4#EU-3'^M=IOI]C6*
MFM..(YJED35*"I"P8"D[5#+WQ?)]X^B=(591YB<08K_>G"W>YOD!W^8V??'4
MK*_>B#<)C 19! F[?'1I3D-#_K*V['HLDW2M;S!PK]%/F,_9]_X6#-U]D(6N
MQW.A:RYTG6JA*QK4?=6T'M4G!2V.C:WV9 AJB$ /,N-&2!@4<+W+"K*5?7V&
M7,+$J& _4B*JNJ70BSAO5*P4E71&,N*(TCPG3J/IJ +=L,CZ()G/ZC;R+%2"
MK,QU5)"%</MTMH#"SQ4_@>DEQOTL2FZ@R5E==F5XGW#N>="!#C%O^LCV\4OS
M@,217AX;G+0G3&9D,Y/LB'C*FVK=T:M(OZVW!DBK"KD*F?]@,H)!('SR,5W,
M\\6S5%K&29#P^H"S(B\!:R7\/\O%QK/?P=VSZ,=E$P6EYS'^47[,XY%2)L,I
M$L!7CT4QQ62F/+QL74%PZYIG@E]9Z,1I"D.L:4I6.1K)R:4$]?'44K)W=Z-A
M)3M\%>..+\#T$:Z]2UB)Z5O*1PM$LX85TIA ![K,A1) JC!2>0H[DCGR#WUM
MY:"29"B7F1@3.]TU5@DF]<#A9X*+CU^Z?_J'!#Y\&V1X@CE%Z:HD%OF(F.'S
MQ5\Y="B:-64+CKPU0>*JKB&6NY)!\7;I='IL4MI-:(_H.J1CA$,9;)F<O0=H
MC*$,ZZ/U=TQ!-9<+27+*C%&LV/'6U=*SJF/QZ&W0X3DP+&8G&+8%@R+0Y60,
M*@Z:U0+&,-/5<&"L@.Q)"[GKHB7A&VQ8<M$$:J\0_-2J);^5?#%W-HA-.E_\
MR(DJJS"#'A8KC0(9TBQC/CE/]9D'T_\OG<V=REOI](/T4Z2',PV/EA&[HSHN
MTDNJYC'*$SDWCOPG6+MLAYDH)S,R?I;+TY#++2&M@D^9\1 W;@E$6:DM6JJ7
MVF]>4"'RLZ^>SF(TB]% C)(Y%5!PAV32##%0Q<E'GPTL.:"'$5XYB]@L8D,+
MNNV::/:$:%K;637,3"!EU%+OFFKBQY.6)W: F6V_D:1\<&BKM15)U8Z&;^34
MHFU9W%E.9SGMRZFEQO/B7QU/4R0(6\E9<<@6"W)D4R-Y9D;7!4->*B:QU%37
M+&:SF TLKHPEV>1K0M93B% ?*IDSTN:7R ,8 7]#J;A55G/E%$(6(E5H.\0-
MVWQ#\#J9H44T3E8&_892(R<D@(]F^3L%^9,Y>=2DOG'U[$E<6=GC]X7.<V/0
M-"E[G<RJ.)\6O/':$]23U;WN(R/)$,=7K[\#-7JDK*2TJ\U>B8DK1JGX7GX>
MK9E2]T2&+N:C=269HG2.\X+ $AEE&MP4T ;D%G%4@SY);Z*1SJ^@D<,V9[2.
M30*CEW8T:!LNQP"RUK4%C6B0W+SV92@^F$8]U@#B6%H#',E@ON#!=_8+F$_"
MSY$4C15%:*7/\=\TH2M/@@MM%%P2?4./-E&HWJU8]^4BF&HJ(^1+;>&PS@X&
MH)&U-]![3)X[  C* (*!X0PRE6[&M^S/AGC&NQEM#KT%8V/[C\R%(="@&+$T
MYA8RP[/'] Q0HU:X<>4I&E[4'!A[0[TK31YVAPP,'LCM R68>;\8:]@* 8X5
MW("MS1Q?C9_)>1$L#@!#Q)LTLKD,=8D < &]:%.<7#Y-C'ENK\* E.XKO@@G
MA[ *QX>;YO"X=#C6#/(3I)O61HORGUVY5OR.^GD8MUB>N3>(O%6&\N8S4C2K
M(/Y!N#[I5% ME:QW%;"ZNN5-FHST_ X.O[$< CCP,K$<>R%C9(X Y($G&:,I
MF=Z#Z\0)%F5,[1DKM45JO7+IQ 0R='DUOJ$P+4$X<IQ8U=):*X_C('($WG1\
M?Y?=- +7BY7%<,FK8E78?)5D/:KM]@PW P$$-9N/UE08BY7H*EHPJZ:,(WJT
M]G/H5D1P0JT9@Z2=LZ'#G8L5B^*Z$.;_&A#9'47/P>\#@<LKI3CBLZQT=41Z
M6$JQW'.CA@78YNBH)',OG?C_[#:7[&GN\DL>_\SM(3M+5_,A$Z(,V7(ZV-HY
MX8=0)+PW/2>"]&D!EB/)?Y.LM39&2XNS0V$:O*G.<HK]$@\2C?1D1B/-:*13
M12.E&A*'O@73')#H"G:7:5['9+PWC9,>CL10I6[>D1HUN6YPA@KFV3C$TVZ*
M;'U5%0)#<:UI_IK+Q55U0U7UI=6&$XR&J:6$#ZYQ@PL "Q+CL+!W%R-5U,Y^
MTGTU#G>L6>0\[PA#19:L)LJCH?Y&%2?8LXSF?+II;G!R=T$)YQON6CAPD\6$
MS<)%Z7YY^<\*[J.[%*G7O+QD\KRB=-^T"XX964^K=>EG37N0CFCR>#>H.6Y/
M["4Z%MSH%S:!>ZW5%6N,_QKDB-RLEF^2<%0;N(I&,$<;\=N)?)&"E;_H9L<G
M@4.+$8IMW;57-,&')VRUY,>%X[7I,[EJ,V=TKAW/<@KN,/$):W:6.BQQML I
M8*\S//Q/8=V)J+35*6NT$M];%?L[SBE=!^?DI-NC^8DU!4:/Z]U'8_35CD%V
M&)Y=P$OC2>]M2H#AL8W(90@H+Q;X!Z&GN4$2C!NQ,S6L9)H'N:0606OHP4,X
M3HYM^-#9XA@TO/8+4%][B$$.O%WQ]OY5W121OY7HK'S39FU$^3$C1LP[A%]S
M-)FV6I9NFLL/S[XSSH:"Z9:??:?M86X6O8<].>KZHZB*R$$PO2;[JLCA^S((
M4F(7[N/G1C,&]U#KF[67(QQ(&#YP&VFUBHR.SX0ZD]/R-$P*ZTC]YU#_-EQP
MN^@.X#R@1Z(-:)1W("\;3ZO@K[ C .XT3XR1X268JX32[8-W2#9D9->#&XQ'
M/.N_I+-\:\*QML(<)]VO>]T?^AKW$?*KKO)C1<<A/%7+#_+X,UDB0ZCTM9\]
M-L_?<@. Z;&3<PHY3SMS/+$^!>[4^B,D,X[R(:S!A9 *9LH/J*PJ?,[?"";T
M\T>?_V[U^]\]^3T/SU[\SGY!7_O]TGT1DZ4UR\.Q+Z\W_TY(9SV1YI@L,S40
M)V2VR=0'/5&6C#+V';J,;W+F@V#4A(5TJ%[GUA+M'RQ^<^D2>%&BS)T2MEXV
MV!S-+>"(,Q0TQ%W:_4Z-A=('GJ6)GXCZ-O/:HR"1](P;SP-<Y9;@R2PZS.\B
M>@$MRA3=)FEG%K^B#'<R+@12AL$TDSAQ)H>.2FG 8_Y.TQM[^&.-YK1OJ^KM
M,D6"2_0HBROTE(1X('+XOQVJL0.XY,37K7?LT['XK6]ID :"?F7N[#VC3;".
M74F<["I$0CU6,2BHM@ @GA#GDO"MMOWGUI.22#X1:Q[=-8+DD ;<,<$^OD)=
MQLFL/6@&I.YH*$H0"A!)M M05Q@!#KWJY![P(4R>Q"3/\1U-?Q^);Z2C1$82
MV3&M"D !N6Z_>_Q[:N0S@7(<F&7<&HI10-<,:]#DYO;U_/[^_MK4^S%2IV\6
M](914-@9__E 9RG\[>GO]8A1:DULX/BG4Y\D:1:D7&L+@-?. YCY$OBZ8'+#
M*_[NL^1QH(IPP!A4'*^JIVS#H'@Y*2Y46C(%-B5,LSB9P*<0'7%B?]'2R6F6
M&6<[,"JL:K3\$ -YY=U.A45/(]2;+-R2[ W9CJ@7QV\0M66()4*,A4Z)++WT
MPO7W\[!=HM-2%]%D<,EN!^/ ,YY#5&>7P5N]6KS\[_2S-N]D1%O;@_#]TI>L
M!N,BF)X25/RCYY:_224^+^BW+?H[YTC$+1 !Z#TDLL1J_,V^>#;,N%.V$N_:
MGRMPC\%MWMRZMKUUA>)H<H[VBK4S&],7X*.L9'9Z+F$B*"NPSJ<5 OLL8C2%
MTLKG*W^:OO">8Q(JZ14MAG1G3G]%\T<Y[:X0R+[,FY!'ONLKVJK?L@H<7[,H
MBI/D3*6R=LL#!IG/Z]\UOT=!M.8YB**GHSA7[[CET"-<N$D'69NL. LA?4&9
MFL);/WTTF!T)KHV#:?&[KA _2U2DJ>U?\F@L]B/<UJR9 BY(""?UX37PC =>
MC9N,6&2N@WN^VFD34=^#**-/C8]R?:HE(*^ W.BBZ!;'WZ197<E\XES:VJID
MQ ;3U:T,WK3Z!^^R9V5*.$[HF9X^.L.*4EO-$<SPE)U"XDZ4ZY2GX<Z@^!?O
M7.Y4O/JBQ2%5+8-"-19$9;>XO!0+F#SO$IW2EZ6.7;?I.EPDE1OL"FLLPQ&D
MBR-SJ?QTZK^BX["I=M>(-3NJY]S!XQ)ZG57.:0?UIQ,*D1CY@SA@T' WYO/T
M]1R&IV86VZE7ST$RD\B87-F,T[:*VF:P'*8E< U2<?U(3F]W,1C,ZMQ^=D]2
M-K!DFT ,J8SFC?*TBQL37NK+Q>/PY%\^^?R;)Z.7U+,977J>2>WG(#O'B-./
M+82724QT-8JI(ZUNH1Y=4V87J:!'HM:P>)^:#,FJP\B &&/;[AC33<2ZH[F.
ML&CCN25--E#8DX!O91JC$>5@TYF$T:#@2:,F(3]:&Q*[*JJ$8,Y0X])767MV
M-KHQ"ZTCP;)U?I!%O:=S46\NZIUJ48]J(QN"F298C98)A9LF,O%&5$94O,D,
M#4?!UV<>6!(L+<BM@/5E,KI.+#6]0MI;7!4HK#-DQ[V*0@]NH\B4/(4OIA$H
M;)<0KOD$/ZMZA@JI;SBMR*0?/]<,.#M0MD[P-N.XS M0T/8=@<;P7H."@>02
MJ;;66O+(Y0$M19A0I'$H=[YX024$K!';X]$ELTANM/C1P]%E"QH R_FBD7Q?
MV:JEY]R-?GAQHZZ.9VG0@AUYLI+AGDH_EL>QN7OIY-,Q/M ^YV>94ZJ=:.,P
M(=TQP$T,7+J_WO=7!ASTNX4"3.3NGC;6$9,S41@8O;PY!&+K'>]T2LP\<=.V
MI09YCA/D,:,+F[S'%J2C3&$H@M ,MHNX"ZZ*W:9&\)M$M=GBIB:/LK1AJQ;9
M63SM$<C#SSM4 7-)0/3ED8B_@>H&</JA+@RZU'M(N97#[-+'GTG!H&@<KR?X
MHC #JZIEXF:/G;%)$BLI*?KHAJWR=<;Y29G10M9?XYA-SB$<5PH\=G5#(Z W
MQEW1!ZW",QX!KO8F@"GVE#2I>RCP"\;URE9!*2_=Q+H,5 ;E6:^V.2I2EK C
M4= Q-PE*Y%2JZ$P=\)?88O'7[.;3D9<-GH;X*TB+Q3''CL6&X#9$NJF %*''
M:&E&1M9)>GE%<D4YI82/C$HF5=>Z898<N.FE+H)#</9?Q?HMN:W0-EV;IQ]A
MB,N+<';".6'@Z 6UP7,7P1@NDS=>@*6],9K\84=SEG:Y7&.TQB$[,A;S=W'(
M8].5S17-AZ-[_EX++:,/H,./ZD,-EB*8"4:3PBWJK>=2Z7[HA2I2%4I[7!B-
M!#WLL^_?\,K\2 !9J*F73"44SKODP<WJ_^W\#4&V"4*O(QE9V'";OW1!AA9O
M\OJZ6.=";CCRC?_L&DIS+:&OPM(0(1,^=A'BH;K,<40+Y' BD&#B$E%HXGM&
M9%.3+*A09_P/HLEX^M5I=!4]_NI!M!1-@'5,3-^A/MAM5_>Z&0=1!S712&,P
M)C[086.O@&HOX&!B)S&86/),C]050&AKGG9(MDE($RDH$.:.H#D8CTQ9T'W'
MYI24'D_FV!VU],+_6H(S6'Z]EI^!KEYGS95P);\MB#T+*;9@_G-N&[VA 4)Y
M8>B 6OIB) AR!S9H!!N.&5R*-;7>$Q@[XQ+<1J8^9S652=7=P#W TQWGS/>^
M#$>\1I)UN\0;7Q)E-K+,T"M+%T*)1HVSB3<,(K^YJG;*"4UJ8RGXBUMZ$*WU
MXGL@S&M6*/R/@B8^RL[:QAZC[T9CX6P\,-4BPRUHMX/S?VG9_(;%B'-'-M*M
ME<S5=5$!4\J5$UZ .'!XKZ %^1S53D^H7W)6;?>NVIP6&_=L%K^+3-;DU:OC
MH.5C(6,/0<BBS?9+)6#GH]:TNWRU"Z%VK;-%EX!]U,4UAC$'[?6OG#TA D3O
MMD8 /@ ;_WX9-2B.MQPK4I'C&C7J3>H4H;,G<V$IZ!!W;)7K'RF[CU<'05GP
M(SN@0:0WB.>D']6-<!CH;= 0T-KQ=GM,,"%4@:CA](:D;1;<84)<A');9K_E
M#%)8&U%/W*,J*>IJM=.2#C7H9T?FV=/\E7NHY'&$+! (:_2[5 5[PX M9_:0
M5.#+I'_E7?=*S%Z\\:Q<9N62*)=$3L3C#U%"5R.S\8KF 4G=A*3T@L?]Z*]D
MM,SCK[_^ N?V+R]?75RD)*--;#38%?Y2&;D*3=)[I^/"C2DZ288N?5NE]*51
MZQE760D6 _48[P)'YG:]D_IK^<_YNC,E)&/21"WPWR@NP43!?<XI/@UHC][S
MD$DLZH$LAZ<]WI-T2[$]XJ;N@*M[1S]WAW!3TS3;C'.:K,.$WI;_)I?+HX)B
MU[ J2X&G&B)QD^\*X9-<+ISJ)#4Z?!.*T5LP5YJSUG!]_[:W%C'0Z1$8S^!4
MH QE(#M##][Q8&FYH6.02"9IC_GSBZ%#G\T^W:QV3UGM<F9C+!OD.5LU_Q&$
M_*W*.'V<3[EX/IQ#LYD_W.)/6.6N7JS(K2$PP@$35Y"[B9>G,1ET(I#RPJ%
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MYF-.TPXRM'J[9DTD>"C@;\@79-<EX>59T[BII"]+8G)K"!.R(WUB(>$T*D8
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M=+7X3F;V'W\&.?F*.-E^RG\.%V-@3R%ERV=H,OE/LB"+NF.O0&HK$X%?5R*
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MM,/\I=D2 DA<*H_T#R\O"!5"!<W&@12&7VLB^0N !S\&&P54QE/%'MSDPF
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MFDTB-J@W+H?D4&!'/&E8!K;)@.F'H 6^%:HPJ0F773C%5 R>ZMG(FJ9:\^A
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M/(LIA/WE#\^7/%T*5/4.MI)X'B$,IUD-X=,&4LF$CMC1HLYG9CXS)WYFJ/#
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MAG7)6Z8U\V-9*OR77:P)W9$5"G]A^=!5V$*"HG CX)OZU R.$,H6/B[WG1C
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M'JM.&+2NCT<BDR#3,SL1W'ND):1UV]!-%F]?[3-L6KW5L*#\V\ECOII>Q_=
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M"7VP?]KT:R,8&.94=1+263]#LPL8T=F6[L]F?*X=4F>. ')VBA/LK?X)^$=
M8^?4)4HFJ)QI$+-HIZA!Q^6Q0[  TT&M3TN(3%O##6&96I%^2Q94&N!&M'E,
ML=,1" K4:OIM92[GA6=A("^+$5L9F]8R) Y5)MN82/[J@;A[P"5'Q>9&^-T[
M:C*<!?Y(<I+U3A.>\T4Z+&:H=5\<@T83?O.%(^B(G?@7IH#.]*EE+8=DEL9]
MJHZ;2@/(:3H_%_A5DS@)VY%.-.F:_".3-9K=75R Q_E;6+/58>AZG="N()AI
M/\=ZJ&+*!Z*^ V*@'H+Y)7(^^H>P?4XC(OL4$#S==$3H=M^V*^O;IKH=70</
M$I@GS$F8=3@,>'^"#T7:-%J! T-KY3>S>04=V+7]$#Y+E56>K741B2UV(*8L
M#^LA6#?FH.(?+7OCLO*?[?)*K J+E(<?/V$T'>G@HEU3]3:E#_/8E@)L3<P!
M ?9!S^'4D>WM3#25D25SE\>RP2.4B8QLV3HE!DT^G8'WCT^I:0;<IW,P_D5:
M=J$U4!HT1V? EG;Z$#5C:@#-(3ECK@R.XG?UZ ?\)IX:%SXFC.B.PI-@#\77
MMG,'202^B7C$KE+A'W;,CI/:O#JTK.^VG;N71XC>MF!?BIO9*QVN>[:R;NIO
M//"B?FJ8Q-]=,(D73.+GQ22^1X#P0]F]ZU8_"/@ZG./OPP'\JX?D?U-OB5KA
M]%A"FA\Y[ML7^6U)*HW%L8#_K09;E3^-?((#./ ]3VX@1S#&H$&F19_C7Q42
M%J.TL,OJ7-!$S$/=J+-B''Z+J+#U022ZP)^0-662JWDH_::;\52E.*(C1Y<%
MB\X5B1XXS:X@8$#M51!-RI@6NH3+6H9AQK4?+3P5C9)EFUN7>7RGVS+21$&R
M5!2&D!ZH;HIG+,8UH]'WMEG)IC)58&HSINQA(A]"D:S\7NS^X-,V(\>GDS!2
M/3TOJ7F%@RR.B(GA)C(EX\,S6J-Y <599F*(7HM#,C?;W%BZ/9>"TGF/'5N<
M. "%%RA=5#ELSP(SKI?FS'32EXC !+QBT'SA/K2?PJ##N6$"1'5VPBLU8@73
MX0A'^R1U-V\FPE$,^T.7PCXC@9/$I7#2'.O7@J]JW2BC."LZN>DCB5.:I#76
M0UDI7V.>)*\2!;I$'0=[U=#/?K]&OU+G5L(.IO>.QY:QT3BZ$ME*0Z'^/ 4D
M9]6 [TNFVD9,4Z,VDY]>%>9\YOUQ$3O^,L/_U5\DXB,M#XWZRGH?WLF4E440
MN@E.<P@UVRYR&VK#MTA3]4YP6Q6?.6BA")C24BG1.=VVQQX&)9CAAB2JG0J3
MGEO*/?. ^&HXU?F1?F%=,DV5[O P%CXD75,-M-^F R^AA5J&W7K+\>'\B-E2
M!'O34)_5T'D2I9:<K&GKEPC1  (4'(\=.!G##%&=J3\I72SL>]Y/W([P0QT9
M=?T1ZH8O6#C1 D*Y'&RX5KAB:DO-#N\H')G )"14[D]'K(,U?IA7)9W%7==L
M2G8?9V?&5=/2AR>M:6/J61HDS/G\0YF^GJO6TQ0-KO=1C@;YP2@,5H:IC=TK
M;%9^TCO#K2&OW5,XED_>JKQU70;A"!?09LO2&RY;53EI+-!_Z469X5K)?/J#
MVT7#RJ\'-4D0UK!&U1$M0!A[47?.BQ^Q7HSH$!^<$&?A4VFN/I*Z5"\>1BK_
M/)OY#\\H*S(4D^H)W>HU)$>9$4 YWUB^SY,IQ"SGY&EI'2$Z:\;;F+Z%2=6"
M'[1G?5J,06@5I$+AILE1K>$LG>=2#=]UG:_.:J"+5L/E5(>\(R<Q#!J.' J*
M]!?S]4&GZQW9@6>3Z'$H3D17\ #RL#GO=26-?(L-?+$_S]&8_!*]S\(R3AZ_
MQ0\V8>I/*6\K)=M&:3?F4-8[:?2JYMTE55Z.SSREY2<D?WUOB_.DR%\3T>9$
M4XI^0\.<U)-WRT<Q3SBU%%]O2UHQBB&DN9U"$ZA8M,U=O_^<W+S7W8-R"^%E
MF7K[14;LV[^5V'J[>OD2:>9GQ Z"M_\M,MK\Y^) ,BR%6*YD/CT#JV.AX*"-
MCD=&M)^M)-TS2U7$?ITD,'>%M1H2W;0R^OU91R1+3\P".?X4I/"09%9:?Y@#
M3GQO[QJ9)*(F37?J^N(@F8A(7AZ3(>1G$GEY8B>VX1(!@U-C<K90@I)A\%[3
M'2IA/-9$-=ADC[/.5M?+,$VV7)U&I]7=0 H;SS6*!_%Z#=7PD9MP/Q8!]06U
M>$$MSII"9V'&L8T[(A>,^F4C/_*-'+%Y(11IA[)7!354#.C?;AF5N$4%_(93
MBS'M:K>[KS!$51X0*+&\QK(,#30G%]G<E_4X.=:\=%U=3MEC/V7NNA <236A
M.'&>KJ7VO;O%J=U-WC+>BMA"N617]]1^-5 J8ET1C:Z&^$D3XZ4=Y')2GL!)
M\2%A>6"E@"2.BW%@&0MY&D+A,#05:GA'G" ?13DUV4M#R'TG]*E!O7Y_@7I=
MH%Z/AW[NEY+M<\@1ETYF'OV8"TO1(G/0^\4DECW@WB8CI(D8I3*EW_1\LLYI
M$<?')<(X4Q23Y,YZF_ @RAOT(B7=?B-S/TK\\9/ [$E55X:?($@Q5E<J+^9]
MS\KBJ_R.&/BHL++-3^&D/-OFIT0*TR42&86R6J*+I?QF9@E'89[K8I;M4R$A
M?IG-]N0E+E/Z9"V9I"E+2S+[E#U5%X.O3 M(NI86TVH).J\-.$=WR!&5'[!@
M5[0I-$/,CC@TJN>K-VE7'%6Y#]J-TN>$_8RU, +F,;#C3*^<IJ&38[I\GCG2
MSC>;L+])..P4\0">ZSF6?>]G8;QIPH&]J M^:(&)=ZQV(P0;11O(:QQW15TV
MDRH!\49W*/X1*BP1LI\!K_I:XPS,_^/A6A^R<'2_O0^NE>^?3N\?O7XB-[>[
MB&0^-:/%P4(33 %=#_LPQC '_PIQ<YC$8CN>XP0K.#?9!B>0)T7\YG ,HSH4
MA[74B$%^/5[(S#5]"++U=3AYR,?A-U^%$[E;?84B"^6_OJ?R(77V_'?9Y:L?
MRDTXA^$<9UZOS_V2#+D3ZR3T=NF@W"OW17[@7JVJ8?@P2<"55%D#P,$!_ BV
M=5MN!Q8^H"84[O>!QF7LKYN' (]E&X_ED1 D12;JBJHK(MA"!R4E)8%Z3@>R
M%7;V&03QDD#D?:6YIW#?/?GK^I60TRF;;SR*,7\L&)%UV1P)@Y]O@#TC9 R(
MA$ON%B5QXNU@$FK2_TU]BFN"+>^2+7NW;PROAWWZ+OBU$:$LU7J#[:U/DK;C
MSHMI$7L_YA"(DO2=%%GU2IX%;$LG@^F+]GXO>Q^2?GG&J9BY-3"3P0;&H30)
M4TQ8C4/GJ&+XX&.@G3LYKG:.3F"I$'LT,DK$AA$2?[V9UK7M3O)O;C[\U>JZ
MIGJVL]T2.(@G3:V6.3%$D:!]YXO;KOCL;5&/]X'IC.^3B)+ "FQ9%'WTMF/!
MU48>1Q$$( \E:YEIC8.%IXUIT;R_5,4SS'-AR5D1HCFY'F%DN\)3PV70D0@W
MMK "3N-GPQP/U0VZ0TEQ*2QX>W)<7$V]XY(.4.2($GMM&=8GE>T*,FRM>KIT
M(]S5II@M=9IFZ(]#_]B<N\]O"W^NQZ?W357J?B?-HZ$4).0:W"'AV-R$H]P%
M;R)NJ++>T 7O8E%]AF^=7COK%?8==X@N7H^J4-*T9^_#QR\7O<N1#2&L>8$W
M(K2P$T1Q\PVPNZ@0"88O>A4,=3WC/0 \PZ3V_(OD\P0C5)"?S;_*]GQ*[**0
MUWG\.>Q%@=O =Z0[3A#8D&)+O1?YP((M_QSX_$.A-T+'(ZG>4-/>@MW?<F.*
M/G@)U1LKK=*VSO8Y:4*/D[FI\O+0Z?ZL!B+F<::.T+X%,P8RZ,W_DOL7!I'[
M1O+P(G=YRWCAO+YA#1=96_$+9#09-8Q7Y0WK1!+4.%UNNH#"\I!-V]$SVW!Z
MPDW^BD?.]P823VM Z,,=%E:!NP^[GB]D4KQB]9=>Q.]RK"-'<-) D\3W]&Y\
M[X=@BWAV]4 O3>$#CSD1C[S7"9^#GJ';($]]]!W\*-4*XP8K?]<O5EW</?Y#
M6/=V6TD'(BU1&%/)G1,(#5"F'/HPV+!2LYO(U,$N.L\/K61>ZI:?KF[YJ[]L
M"T8!DZ]Y #I3") ><I5>P"J7$OQCV<J+$DCP*:A+ ]G@$ 3@/KELW<O6?>1;
MEXA\MFU^QVU9::90\JWED2HVE[U\V<N/?"]S:@U%: 02W"+(S6D4"MQ<C/)E
M(S^%C8RLL.:58]@HG)'=RKK&I/C,L>1E8U\V]B/?V#Y#<VAJ3L4'YZ/E$L74
MZT")5#C)+_O[LK\?^?YV_?A,2*3-!9DE-MHB3 ?AK:/GC5T>B2&29#+3_W*=
ME$3)6R%1NAR&RV%XY(=!83'"MO"XVFF>&EC_#Q>P_@6L_Z%@_8N)OICH167L
M!$24%N!')9H'(@ O#6)/3#'H#-T4UZW+FJ'5D4%I6I$O:Y45FI59$U!PPVQ\
M( TDM%KX)0$(Q&+_A,Y]6O8_"U]]Z([U,!%&-*R-")*!9 +.)14*XOPT'AFT
M%)^= [R@=D",\+=7J^NJWT/N"/ %FUUB<M8GL,0"WI=1: )WF6*=9.P& @!C
MZM#VJW\.VYN#3$075EYZ)["JVI+#RI-,R2ABKAEK=#15(81LW+5DJ$Y]187'
M 5%*PJX.P@!\A8&F1],2UITI<N+?'P'?*SK7S$1J%Z28(8JQ2D>T)4K_O@S;
MJDMHHT;(P:6]@\JST.(:*9P;ED)5M9_J2)U.1.^,Z>HX5\$85YWFAKA^;IJ>
M220Q_VZV,44T.84 6G7G8XH4\2-3J8TX3E8WF;_DC>F#-,Q,\"WIR<W\:34,
M*+T.DXWR^URMOFW:@GXMFY!5ST)G;;=.UQ3GGH04NJ:.QYZWD!N+SJ0[^4-$
M^E2 &0,DA%?=%S64*<0:>4IFSY=X6D;N9(P3[@L&>CEL\<PK,)L3$%D .N?L
ME\UK"WVQVC=W!>8N;L(9PKYP0.9,1.-E*JN3GSF@C2/8^+')<OUH3&T5T2@+
MA56Y<9(A$;,;R;"UJP:>18M_(.#:YQ.TDO>@1L?#$78C6-<\?!F+?U,U:R1=
M! 4G'14] 8'I9'9%95UR[L7#?H0X"F&_I;_1"&"9+%Z1IXP_]EUU=#5$H*5M
M*X+8-R0.7%5QUG/6 ^JQ]0F=7X*S,J+J%Y>%+P FS !#(HX6-PN1[3PO9M\F
M('1N7-$;E[L[[YSL8$&DW^$8YZ!9%V;.?&ELJP-MOU6?ORN * >(_%8PY-O&
M/2)]I=$9UTXPA\0C0LOF0!R\25.>J) K<B.\[TV;'S!%U#%V4]"?CWOZ'AW/
M:*4WC:AK$9U=$\)8.K+Z6B=K=(H2SD"^IGT L9<#;6O%.V/J.;9H:IB;):#E
MX4LM+:\H*:$="(+2S(Z)FA&C,K$MFWAK\<7:; :ZL9::)N*G%W_YOI:)'\=.
M9MP?16WTIY&T%$D16M>&[^ '[.UU 9BO^B&FNP4>9+SG4 OE-"/ (_TS3FW1
MT>#+;B]']_#8C"[M$QS:MKE+6S140A.*D9P$D*Y;;9NE8HM^7-TG7/D1/JS=
MY^X91I7M/A:)K6B.>.H@7O!3R5CPJ*+!WBFU(HT87HEBEK>_X_*![A49OT^)
MH)\$;5]3?\I#(B<<*BI<J>&C):)#5A(2.A5]I%TL^JG:>2*W@14'V!,L-ONZ
MJ9J;LG!7:%'O37,D%4V $+9 G3/U;] "%DS6MK>[RPEP;8:N)WKXU1J4Z'1$
M1;(UV5%ZRLC2O[:H+-E?*CJ7'C3';/:?]&[AN!]PUH+/6_$J@WM](XAL:9P,
M(]TA:CHS(U^$>*,C?0;U1.EA88KY:NASHBW>\O>%N2:SYB[ANF%F&XDXOB!S
M5'.]D:R M&>-S()_YR]6]Y7G(W,"&IUF#\87:I+&!HALGK;5ZY*9:*+&+-JO
M1[%'XYKPOC#"W>V*&@KX7:E_G?BSE:"403%R"]A"F,F05M(2&P*#<F6M [U<
MR]Q8HZEK2 : % &"$P_$C4/@<W\&"[E=Z.@__O!Q7UAX*^X9^3UES_I\LJ[=
M42-FNF#C-L!E'3PN<@+>U>&JX?Z<L;B)B4,G.PAYE8(\->ZB(7F) B;OO?11
MV%=,MF8X4?EMT\X%23!C#_T=1\RH[_V>=H@S&#%7E611T\?'NW#1S*<$,%.&
M\Y$RE5R1L.PI6_/,]7HA,_]0E^N-<]>E[U6=*M<H&E?RI-QIF31/L>4+@1.E
MA,(IU-8JOO^#J<;YT0S>&8;[G[/^G[,/]8&-B.3$%]*0[3),<8JIVZV\H15T
M\T?_W,4,IB>"H9<?)M,FR3.*02)G]UA'[/S*"JWKKLV#<S0P3Q2%@4?6&$CT
M/S6"!7<,#6R#SK:IT-P=BZT6U)87'#.AG@K.5]U1FUI%MZ;ES9A'9Z%E.1+*
M^J/TU&K=?[S4NB^U[L=&3/>>#I@O&!_;XAE*QM0IU!<XZ0.GUTCSZI0ES 06
M?GE+%)4.TB,?C PK0)$,#4I,(D/'(C-2C=B0F3H0&4R;)/&Y(;B\S3=A#'I#
M98E]T2N+79J2TXV2@INW0E%NQY(IQ+VP/W4TP!"ATNNW32W).)__)%1HL,J0
M.^3N9F[7)4FQFR$$=ISYXO<!<X]89<XE(5.8\WU+GF0(OLI.BB8M7:;CE'M^
MFX=X%-@(O;B[9M??Y2U(ZAHA.3F$P0:S+ $3E2!(WMYN=&UF?,#-(1W8=%,!
MZB<VONMTC<G\@_=X9Q?>[-2B3M8,/6=BMS2I[-=;R6UV+.G-)42 KK4_=PPP
MX$)^1L6_TRK,[)94P*/@N*6+A4MJ82M\[_F;W_MJU115P[?FHCBYL<4TCE#.
ML<UE]@+1>TBYGFEK6(A->R6#FW [5*0>)"'$-C]@;2C.%>VG_RVV.A?TUUTA
M,TE[Q5A.!DICWI;M@*S;@>X?>K<Z#Z]"U#9E%UZYH#&'_VW#4[M#1DWW].=P
M6,*.'6H1HF+2'9P@)O7AG!R][BFLV[,0G8?;D8-X_$68_%;*IR8@^@T6I.B)
M3:!F64T2;VKSK=71-1*2YP67,VS4YL #WX>_PO8][B53V@5?]U (M=!6I&J0
MB UF,IDL[/@=[S N2\8E02:$TK[!T!:<!;'?QW_L>8]3&2_8, +1LDVD'Z:4
MVY2FD(KX\A%)Y.B^U5VW\,VKU5.@A'KBC%8+ER24](2*Q$5.2DC1NF!LQ FG
M.?#YP["RP^ ]Y?4I'E+:V3B(*D!W0X>FYFV'TA&>H\>4+ LI@[+&&"<6-/V6
M=UJ!6'-U'1)]<IMV#1V=7@\UO2<7(>F+,FJY=?7TLAYMRX0E>V*=:)%7ORWB
MCS(K%=V$>05:/;:;AV9-1/C;@MGIN(C%!V')<O,%HP_F5]$EJ:2N'^ZJ\"OZ
MV.A N, 6A:4D_-7 6"5'.?15HJS>L>DM#LVHFV:=*:M?H>(6UX/3K??O**5%
MX]8JR8(B+F2CZ6\NO=+CI8E<KY&A$G%:6*=WJ(RM]J=U6VXIYU["H*WVS4%U
M0CA0!%_AU2JL8LEW[084.;[RE=84=KJU@_\7CJ<(A:)$' )'O;TD"\N[PYHD
M62 TMBF0!"4W21;B,1V*+1?\)@N;N75TF1%BE>GQPO85S?Z3J#/ET^P:O&M0
M'CQ04@9 '_6\8A76G#UZT.AE(F++%54O1OO3L ;7J^^"7<2>?_G\Y0ND6XM6
M,#."PL))&SD(4B["Q1X,6CYL!]@IW.;"$H7D#'N O*6B0R7'1 T$2N4_E90V
M"Y;W_WM^]?NP@:M*\D6;ICTV2,K S8!9""[]NU5YT'V=;U22DQQ'A3N&3;9%
MW9Q?)[45_N( >-9JJVK(M<@D!3N^.L:0BQBL<$DL&-,R6#%7,R+A>/: ")[!
MM7,RR=1!5_QK8!RBTS)U\#:;(^9C@F.,^]"=XP1X1THI8?G"11CU5;=TE#E6
M*;:8;C_!& _U*Q508@W6ZBYGH>FNX7YK>3\ "P1*4!E?\HSS'UG]8N1&L$M(
MN-PY_=98[-HR\ M7 >/&DL+6Q ?02R/>))-;R92X88Y)/IKN2EX,!O<E&Q]
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M4_C?7H#!K+WB3"FC=<DZCMQO_F7US5/3.8%7)QH#3P B1(E!U^!'DR!:/)3
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M_/ U&.I4,$52 ](](=PR PM5#?%NIK]52]5GMM-A!BO Y/Z:I*6W'KI1B"?
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M=@!T)<LF!]>T.IKKB+.W8^KXH#(N5K,,KNYWM[B&/?2[C9(B::QJA(,6Z-L
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M3N\+_%WQGT3E?M?FQ_"$26MKPTWO"=T_UZ.'0BK0U/*:,KW'-5)Z@M$R@'>
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MH0)#MK2-/SM=#X77NJY]\R,Y]37U$B<"CP]:SOO]O\=_@I^\ 4HI%MY[I1?
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M[<.C@29L#%*Q+D!&%F9>M/ZT]PLI"LY0!W.R>2<T)4Q4/ B5=BP=^T0OF&E
M)]8.VX)3+RWO?1E3"3,48K\CWSV48N?;0O4TV)2)X*EP7(IAQ]Q1R@,+#V43
M>2Q]KJD0!#UI<MX_78J+E^+B$RXNOMKG8-@:@62)9%+.N?\;H<]Q$6'X4,+4
M* [*M@1GY5YS]X.#A./'H/5'.D1P"]<,S"H-^9IRF7-8ZV"CGXNO]OWNSK</
M4NY8P.ZG +I]WD%1%NB>HLZ1J$6 0%AY\C21N-T6STC&T:%\@34^4 JI["I5
MW?85PL7/X:XXYMV8O,T+V-'$@^?"&D?3]E4.89A <BLA;O#781"U!IBPT7L^
M?,]&/R[!G.?V%%6M9 ;?#$>*@<)9IB@-\SE4K$RDN7V%O.9"1<H3SO1[F38K
M<45'!S_N=G!)L\A&0N&2)!<W9;L9#A1E;?CPW 5;7]3ZN$ANJ?77NUIHHO0)
M4<8J64B&NF&FZ6'>[Y*N*>JEUM*E.UY"$;*:I^K+.*3RC&C$M,-]@#2)&W1Y
M;^=^T-JTYFQ QJ+KRF9&-$+FDM4F\R2EP70E@S6^:5%,P3B++18/T7=GB5BI
M.EBJ2M2JE!M.U/3B_E'#M8$]7$&\T>6*5U)0S95NAM=M83+K8% <=,"Y_V-Q
M!Y*6T5+I7:&:K4KZY!8BX=+;1*/MK//X%8D5Z#YK34TU\6&HNWN9P74#W51V
MS7U5._T>U<X='+M/'R*@A_ZDC^C<J(6"*(Z:K,Y'FES/IY5,[9242&S=:&ZF
M(/31B^CG =J,_^+T>-$TR>8;LART<&&7+[,:FT6FW@PL!UDWRK/JC]%[N9H:
M4SB-X2NSU6;!5T_GV!GTJ6$;3=[4U.J1C+M@17-6DG>@Y.=&8A<IZN0*UPHD
MX9H<^K+K2C:;CI#RK_EI_^Q+TON]WHB4XIG?SE>4;WCY_(L0D!0_!0>"04TU
M./WJ;E>TC&0IV[:X;3;\!U*!?#8<-:F,)[SX C77DKG,PY+6Q:Z4WT^&Q*DF
M:;B-\V*:C7A/&=2!6O">V=1<Z2]]F_Z]<$>E)Q7%-C*WW/R67#(90W(9YJIU
M-N8P1!#&R>E&N A)SEE-MJQ\S&#.SY\('))?$O\2?9GRI_'<D<.@CV*-/R84
MD[TI/1OZAS@3WZ3:BW0S"MR(P;LA2FVRT<S@</#P^Z@+(PRKCU4%+ZWJ>/_W
M'K4DM$I2'Q@:<)JVVJ9H/O:QQ]14GRT_^#4J.=F#<DOF)4HNA4NFZ?V=RBPN
MM)G-S5(D,+/F<S2+&-#N:O5JQ+$SB#C9B+!X=+URO4S[4U&G4OK6J5UU?2@]
MR!*A.V?=0G58S)U"Q6@(1.#>>H5WER.+J/Z&BETM#3P6\-++<#(2U@05@2\I
M:#N_7+" P?GK^K:A"9<;;K[*]Y9IFW5 G/,#J6^4L;9_79Y!@?TQ\=I8NK>+
MDF!),B\V'S] X<&=/>,\8A-I$EN)/G=P@P!RZ9JHS U?P@]U(O&J-Z#>[]$Y
M,V6!7'N0>)7#O7>U^C9\O+GEI:]/DO8K$1G>DDLAD*EBZRGQZ!4):<2>HJSO
MY #=)WNQH,A MQTC$[I3UQ?<1,:Z:/9*,A-00>?<<*IWYE?OW KYO>D-VH$X
MTLM^M2UIB2B]&^47#7\ZEACPGI&D(8@[\/5RT7>RB+-3,A'B72KOFLQ\V&:-
M!BUC?7GNZTO9K2/7RAR4\&<@$]\/C^C!C,&W:=Z-=231V WMA0FP<-R4K(SD
M8PCF^S_7W9Z*GE'<I\'D3<V&L]59A+P* ZM9"M1+D<*@RBLUN2L6V)F)!%Y
MPM3A#0@''\Z&XX,=W>?8E[DC;1NKD4(:)1P"(4F9&@I_)\3&*NO?0EXB/X S
MVL&V%+4\]^78:ZG# J.:UJ]\^&/JS6*C+J*<GP&1\"W? ;(A//KTJX%L9GA
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MDV_#$V/A((5FIPV*$0?&V&/(Y%/?MF:%9@ 8T\2P+1A@[S%B-VOFP#)$BGD
M@VH00(U\9%*%0VZ]T\$<YM1@0\4'0Z= 8?""?_SX_+MD!X]%ZU\(V=']@@/0
M56L78FDA^K?A*JYT%I)2.1;9/E #8( &R]SNIHHW]+M.#'<*MY;=BR& ?FAA
M$8-CC.([(^+G=L),ETZ(2$@\0=,T!:*$YGE#&82R-$U^W-CB)=BZ6!Y&[I1U
M+62('Z/V:5^B(:H2Q$2=6U(4.R?T&F,*\=9&CSQ=,E?@-AOP7"M,O#7N46*X
MGE-+0JU\RR=B?Z[ %*?2"HV=@SHO;C*?.&>$$+88X:_"J*TPD!AG<;/DT,R[
M?D7 'V34H0[#L1*&/6-]-:P2/>DWGQ,8J!F8-IC7YM1D3<8-GP6V/(L>Y!V1
M0&0VA)BUA)D^8\ECQ7W<,#N##!A5% PF%=/V$/HELCEX*"1_$E-8$K^7_7$1
MM*"<L".TZ[+U&Y0^\><I9GGXQJSLZBN*]"WEC?=>HLRUQ&CFX H'+FQ/_8,)
MHYP#47>B=E+048T2K=PX>$= 0E4K03O "9?=%Z!$@=Y@:XEA!.*^ B._<,*A
MTC7!:QL6K,QU=J=29(E2W[<'TY_A/# ]DR.FQ^MLKL;9DQSXTYS#,*BD0N&2
MM6&G@]0<>W!OL32 XR0@&V1X,Z(KHV_?L6C"->+IZ,4 %0S:LNRI:Q,^^R\/
M.3/X=,D,+IG!$V<&[Z&0F0F^5*A) A]1+<.N=7_1'[[^ $NIN]O\!J5JYCMQ
M5(_*;%_WW5\VQ5N76R'3C<(?W37P_[E^@ESV)?_M3UUN__B;/H/"H^ 0BP:A
MI8 OB"@,JYH(#,T@9-?)8/_K/[[Z_(NOOAZ.*[YH+-$?P$F:WPYS?,;<YCBH
MUB3."?4BM:?.@.Q/.)BW?* S\$=<EZ8/P%.*CC6V&H*U&=&9!;G%V?L3KON?
M2% ^Q'Z+Q?#QQ6AS^;VS;)IET\QMFEM.!W!(TS9*,_^=3X.LG!,>N:)I.[^Q
MB V0"\/K8-V%CG0A6HDVRB#X4S>'N$&7[;1LIP>UG=YS-VV*$/^-Y-_SI T"
MX6%_+=MBV19GOBV,:399!.0-,MP\I= 6W;B8K@^CG1Y8V=8?V8LPE8!D@::E
MY:[HP+)_EOUSYON'X168'*-T!I;[@.%$1:%XXBCM>VQW+5*_2/VY2WWL*%B>
M\$ =R,'Q7I+(2K8Y"F.W/EN#U:.NS&?+HPB\27/5<,1P>W1((2X;9V[C"!SR
MLG%.O7%&#<SD?6A'M._T9%[9R9[MR1H+2ZRBY):T*4.*JLTV5)R]4IY,.9DF
M2ALIA^L)YN\>4XH;\Q:LN"1K)<DM8Y@D'8Y(8'WO0.5!?&V-.X;*L3X[H*>:
MJ3 \SU%-NE844_](1I5C D'ZK[HQ84.I2VV_'I:7ZE,U42F6Z8CNR$]SYE/Y
MN,4.Z*%S4PS+B7HFBB&NT1#^'0+PB5AVJ+JPY0IZ)FCN?>MYJ*0?>%Y2SNNW
MUV39XL:#$8J?QO5PW%3$EVG;^7+.+MOIS+>3K>.6:GX850 ^&Z*)SM0F"S&=
MQ<.F0\@#@.+SJ?"U9U.7SBFIB>!Z!D6:5"PM+KC(9LJ'EZVU;*TSWUKW8B<M
MPKX(^YD)^T1_-A4+2IE>@.+QK.QW,3"D@8*!7)!E.RS;X;RW@ZVF"1[#)&/C
MQ<>4YFD!.0,DSG?:9J=HX3NF1/OU-;=)69 >:D>&15^O^R95Y )"*PR0DN4[
M$7=^K$:>X]IV7A7MFS9Y1:U:E(-Y;JK)I+GDIYC@%C[DE:%6YX[QE^QHG$LW
MDH+S4IRQ;QIA#0R5]<.*.CG*&G?5EU@0L9>>>&0D]IC2VB8FM+@41E@U=9:;
MXOTLKW>^41QC#2OPC*[W;0%3BI7UH#8*1N.\KA$3BG#NKAV2<Z[9+-Q'\%4^
MTHG0)\*5AD 9X):%HW83Q_/$3SLEJ>"[(,$BK@*F/K 1:):R'9OP"9/T^V\O
M+:#F:+U:LV 5HCY?.X),T<7#C@0+T\G!3\(OVW4DU/,K]C[+A.T)[0$N^@1\
MA"L8P!:\A*PJ6HD[2]\2!8X)]D4866N$F%69+O<!5T+#7K8;R>!(8]]/$Z1S
MYANY&9:^C;I39X8L86S=!YG!Z"G1%Z*-X"<TZIRX<I4C_#>+P:NO()R8WHU!
MD@A-!Z[:%(*C\W/4,3->P]GICA :1QLG([X3S$MS#0@JN"RI^NV*NXY]-ZGO
MTOO+QVTWNE<"S\7>7>S=67O7-Z\C':B6<$2:RN^VH@T[C!4*:9<$P3$JWG0C
MM25M[<)K5U/+FG_/$B%9ML@#V"*86Q;X4(?V1;;>#P^BK&6R6Z7')"LF@)3C
M/[-=L=1P+!+_("1>)+=0O&BJ!4=^4(*/"L!4Q7:%W?-4,$&YH2N\D*!TX42Q
M=G69"7B8:>(58UM1'P^8T@IG8S#-EIVT[*0SWTGSOB>'B:AC?B,66&M-*L\2
M8LX7J7&24XCA5MFPPNVV;(=E.YSY=O ;('(>!.6V$I1YBF2@;^YNQ6K:<U'!
MK$E%P&7D7WCGXRQ=C(>&ZO!L07584!W>%]5A.0260V"Z0AR^%SSE0B@>5T6&
MI03!-A):CL*#JS$D?7V;:?WHNB< !:_^-W4C(,-B"E&4^JR/@F5W++MC#E46
M"Y&[1DN3R=V&I2H8**JN#GC)D8_!U3N2M&J[;+-9Q'\1_W,7?^;+W!8M455R
M2I.9FYDPPN-R4_NU'@%WYOX6T5]$_]Q%7]SA%O[;;@1159#; U7K.YT'5,2
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MKS3ESI(%I'XIFN%PJL;>)!H="%)R71.QH?35:NF2L=IWV.4..H?:8T':L:T
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M!>25:GL.M7]$6Y(B6+LK&3,B6[^ALQ'Y7FKN!B!M#7:%@$K4VYK/R39#:.D
MEO_HC7,["S)!U468 0FG@\6,AC%OB[8538^=]$@SXROK@F5GGB'P]J.3FN(.
M&X=LX@(2UW&"TGSXK%T:DQ-L)!2GY;YDLDYS$#R(&-H#CXL1&HMAP!$#;LR3
M:SAQB5S)\)U:%HB0 %1^B>.6.]Y%5O9BM/1 +<PA[WB\GGB(HR-P$7L;,,8?
M?GIITXP4$,$#GDZOT#WL@;"G:9&\&I L(=4#WA0(+$P&*Y-L2,PNPQ-+\#:*
M ,Z.0]'($MK75 7 GD+!$1QX?>X8M=$$[R)L& 60& 32;TVV<P#R?5LW;]@3
MM!E.<C/8OR"&#K=7NQ?3^3@$A!/!8!$'&/W"A:^RBS7"R"$MJP0$@\7[/>WO
MAY82_6I)B2XIT7-+B?[VP^Q79[J_!D=39(<0F!6SSA@#3#-X;(-YG(78>8&S
MXZ5>PF!EV[[RK73#$LJ[0_MQP4>&)1^%8Q2)TEV)P173:03J%3K_*+SG3$58
MR*08@\YC@_%GR,'>A@.&[%0?!.!"4OQ.T_,\PLQIL!3.(B8R'XN-B(JGP8F2
M:_!9&"=,.PSPS181B;Z&C-=.RVB)U]5I%BY<*_F/"5P@Y0G2K+;D,(:),']"
M>1L]&;$.2ND@U]=R?$7(*[+VC1I ;) /K/$1^U>=W.!.V$N."RUR/6VEW643
MNUTA821Q#J4:])A@Q/9#J?XJZ2L3*9CP#/:&)<)O#M=)RC&3:X;01CA6%*>\
MR6ZYTGD(4I?]KD[R<QT^N;=99#M?$2^H(HPA\1;8HG7?@L;K*Z:/VT5\I%D0
M?.TED& AX?ZQ?]972#9)!&88TT1@->'YD +0]3Z5U+!Y-)6<LH^P3[B]TR@;
M(KLU#*[T !@X,8^8)QC_-\JCA.VY&7W$>$90?3$G5:PLJ8(OZVQ'51_Y&GQ$
MX$^QQ-LO\1ABBL[%P;KWHUE,)U<T(",Q!+/WD>##(B9:#,155^U?SDQ^C]QI
M'$55BY/,PT<4<-ZU[B_ZP]<?P,Y2T]O\!DV^&10-'-6C,MO7??>73?'6Y=8"
M5"N6/[IKX/]S_02Y[$O^VY^ZW/[Q-WT&&2APDHAY3TL!7Q!5M<!VQYH6,P@Q
MB66P__4?7WW^Q5=?#\<57S0V-S] Z'+>5IU1=,2 G-QF;)_Q1;!5>N2:*JDO
M4'X#&^5[=/#__.6S-H@6?N"?<&G^1&OY(;9$+"F/Q_@X7KP7N5[D>E:N^4Q:
M%S<%&73@%V ["[)0PO]B;&T1XD6(SUR(V[ZED*% <:.1-)586B1YD>0'(LD6
MCCYVV1<A7H3XS(4XP-)(< N-B7R0)6KC*%IK+L_CZSCPUC&&=+]L@&4#G/L&
MF GT4$V3[UBU09YU6;=:.#6=\!WGO+^&#;1LA64KG/=6:!T5%6)]*64_0C$O
M=1XQX$%FBO"P@/7B8\KUM*B<0?_&.VVX4W0A'),0P*IB0]7'6%0>IG\CX/>Y
MH-BS9D0"MEN?Y+$8&%(*8NLOJ>R<TX_*!<0423MXEE-R/6(>T6)/Y=T4DL "
M ?)M]?,@1'Y7.1V&\F/0$"Z<T0KG3. ]XU+R(8EG/L*DY3#^9'+WQZC.I<TJ
M3;4V 7R#:= G>7Q;[Q97W'P&O^U]-YNVZ&K%D1Q1- -,T.MQ/@;?^%$H<G]3
M@>E_A_XVWQ@7UPUZEA'*2&VRF[H1WN)AA['I1#9M<X0TL[6P#BDG=X1K6$C\
MA)=][Q%?* ?,4BW9X7'.DG/00PZB63BC^\+MGF E_GFF6[G:'P*T<%6V%N9X
MQ/&K6PJ<A_[%056!9LI9V!0;S*P%5\W;U2V41XJLJB$6AT< \]VK^,"KIK[%
M;;\QBNO1#A'#AMV2D1Q%3>OIR-B+&U]'1:?$LJA0EJ(;%6PS*FU8-7"O&P E
M1V!NV%T$K]B[#/,/ST%]8<,G=5PJGJ;+N<O7$[)YA+1)X.\(*DE!+>DI*^2
MW;>P5;)*^DR?4V$7W^0?R^2,'GKMM>^J@HN>__2:M9"D%AD TK_E."PY*GC
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M?'T,M9^:S19-I+3C:ZT];M/6<#-),(K&),SQ8%<43100U+$0EJ:6?O&(BF:
MH(DT#AGQF20__I/DBLJ).'.@L3N=<XH]"AJ@0-1I'6"]X0)P72(D#"JJ#986
M.,ER<7!#)HC'*!8SCO8B2?Y!]-'Z%=%8/,KI58&\!B)=^I!;F$@24R,]9.MO
M4LTA_OFS) >_E.40\S,\2.:K5A*2X2-C>6Q[V7URC?V\=*1+)O<(1K!@B^TE
MZ<5U#,\>(_1V=[T@WM\+CF9,/4H&3V"\.=[T24.V*X!<AI-R;.O0\8M2P4(T
M9>2@O3MXKR1 Q=P>RE,[..CN?,)AK:4V]\$QC%5;*J67_'$X+8-!>O5J2V)5
M,66#G9YQ.S)R9<6Z0I&'$9]30K%^HP6UF=<< J;_8LB?"TG'J0A^*@/[9A7C
M'6.LM=/RD(*XQE(_205G.X7Y+4%_>5.716V4F'+A2-MIY)4%;J\2SG\A1*!/
MI&[*B5G%N#-Z<BHJ0:8\U5-._8?,*<9#2/WD>&:=ENMC?:#<7RGU(W7?$5MD
MO0G7M'W1+?KHGD#+9XGO6JKX4EQJ+I:52H@=PH1C+93LCEWH]XI[2E'VD<:.
M$,>Y@D&U',G?FAE"#1=NQ+&')R%WO%>/Y.+<BSL',QIWP.QA@'/+@:6[D#*S
MV/+%J+ZS=HCRV?B"O4)1#J2W=>#;:>'^%AN38* EP@^ ;AQN(Q\1A ]A1_%6
M(B5O\!YU(V%,12[( ^ICEON%^O1]8PPO;,)L4)"BNI4"0*PU.?H,%UP7.X&*
M#D@7-9;-Q7&IC59?4BZJPOA 1LINS-V<^FCMF/9W#?8FZ,1I^A>#[!S%Z+Q_
M4V:W@W 86.EX1/:M+\02CJ.3B0^NPS'ZB1RM0/UCI@&I"FKXHG$,<="E*//A
MP^5LE<.Q8ZH:>2_KHRZKKGCT/\7Z#::C"/>@[UQ\">.H?@\+[9+GZ':T$F6H
M<GJ?A3C0JDG5GPI*D/G(.U^LI)YQAZ963H9:T$]\9S[,!XIFQ=_XJ98^3PZ
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MH'D\&BQ';J<J6X\=_!_^^D]M66^9;GLOZ @@H:2RV-,4/1[\/ZJS'Q2/8Z.
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M&$1BC3?!1GZ2?,<FY8_>I'P)!A*E5\=.5&Q$BNCPF-F@0C&AIY+9"=]6(YC
MFJ)//G/N,E B5$R%NIIV]&?_J6'2P286;2$S8L+&7*9F5%]<M;;&!'D.K\#W
MI-:J)<!H,7SD+2N$\(NBNI+>#&4HJ$T*</Q=J)19Z_8V)AC*A&>(T.^ENL9]
M<E5@81".!\Y6/5A)CZ))&CL8U3ZZO;M[,0;.@E\(7$U4J-L='N-Q':38LC L
M#!QHZAJ/=7TYF;(S4T2A\;@FXHAQ'A(:'&LZUI:#FI*)U&\Z6]AZZ@#2!XM_
M/[1,]1=+IGK)5#_@3/6+V#]&.ZU".]Z72I7H'ZS!S]J#6N.S.)S47?:62OB+
M5:\A"J2+*;;($7?B_/&1T>PYKR)/-BXG2KWQ?) M_X\7?T\'$X-'2Y0-_N.S
MSR^>A9)S:JE#KPONO?/6)T\OGH9;_>&"-LUFTV+G Q\QL 895QG!X0TGV0MI
M#9#1CUZ5PJ._N/C*/WH%IS$=RW#V%)3)@FD@APR&^\<G7YH/P$+CE:/'%1S#
MPR<BTR"Z> 6.^X*9 2>^4")T$R][^@5%]@XN1D8UAZ"31T_&^_[XV(P2GGF)
MS(>P%3+V#(X:]Z$1D F+P_@CZ#+_(KA<9QGCFN0TXJ3E[L:5]8ZAR&&'K#$I
MT TWD5U1,:TT($HKB;=BCN%GLYA'O.;P1*?8 (3]0#T2A/TO^MJ_T$\^##->
M.#*OY=FRPXV=B3E-[@^A;<_/R7NG-JB$"4(!#,<=-3Y /G!K JE2!M\FS[Y\
M2J]^]N4S-36?U[E#'_>NAX(G*PQKY=Z''ZAB;MUO>]:_<HN:G>%1FD,=IEHB
M6XV(3;*DJ3G8.FJ<P,=BVPG;FY\]YBP75YSO:G@%+.QKJ5P<30'K"%S2,KME
M9C5RH; 8GRQ5+("DU4N3G]$B[9M]\LI=]:54FX=X%F9;:G2CHLFEN35SRB8D
M.]V\C,.XJ8@+UZ@W[I%,'@@+^Q B'@451]*[KC!4(@(]7"??=F7-W6ITV3#5
M%!.E89P//$64?KAGPU6?P3;V#TL]OY;T%;$(HY.%G*4^C$($.K JZ!<,1Q*B
MT!KW8*XNV%I1_')Z\TR>E2NWX6X=MU?]I'N2*SQY+M&!AD7<%-1SR5Z##U^W
MU\D&_!P='<'\QQ1\V)' >Y'I@MB!R5FXE!!YJ9^YC_J92^_/E;[M!:7H9UB*
MY[T$K_]6KUIN]Y&(X,_/_W9)L=%MG8,F"F'4YW4#S[HIFAYN*$!>7F$M_8:/
M[>^$!5B#K?OHF<\O7WTG3443 ML4%%U#&8>1H4YK^32I*!Y!#3_#4_()R:G8
M?2AM7SZF2,?0-ODE?#5]UZR1\E[#>/*%;N[#)WT8A9F)#SX4;HB@3?ZW# Y(
MT-$Z68-1HI-(1S4&C'QGYXTSKP.=NW:^6D]_[],39*13[:+;8A%= U(/?VFQ
MLX%+)7!!S &-1@/\%W7-"LXR"4##N2E]?V1UJ.X3=1<97=Q! ;^@P?-=+<KI
M+09=,WZI>2%V$7!F<3S!.!V#DL8M;)[Q(=1.V)6IX42ER$_S#G+[-!T.N8,A
M<]['!XFHHR54DHQ83G&4?#!P/(]=!:Q=_+]<FO";O-*7P2220QUDL<$5S&LP
MX7R&GK7HM^!2WY(" G-)JH2HX:1!<RNC."89;%R*,XRY8>BXP.=LLAO8.ZBO
M-'$![CRI,ZSE!BOE6KGW8 (RKA0XY>*B[W[,R0,;&W<L)]=\ 0/5]6"= 6V[
MCO8FZFFNPE5_=?*NU1X+&UA?H>&$R11CQ;+/)=5:V)9:-[XDW>@4Y2RL&_M;
M7.PPO919 U--Z>%;0WXXCM5JM]3.B@^6.3OI6I.H\$>F-_U8&W/!G%HPIZ8)
MCI-UF;6MV(?C%(94-7@?%;;QU16EM.%IVS8UGA%OV$'R*%*9V,O&[ADE=.D\
MU<Z6#)[QK[HYF'-:<#B7_73F^ZFJ;:#HIN[4_+>=,G%W#.\@,GC;X?:!->8]
M,=Q']"S_% P#Y-A3XY8]LNR1<]\C'  #XZK%/=)PH?YL$MT+>Q;$G3JYT?-*
M;C(0_?4^3:[K6X>&.E7\2^6;[U-;[0E0Y"U\?2L;$ <Q?ENHIY."U&C?444<
M(R5J^)V&P8/ :B+!+5B.KF5;/LAM>7?93V<*LD:8"*$T:0B&D'&#0.[0;"PJ
MIX5(4I<J<6XT*7ESUKX^W^YC.4]]KT"HT>7W.<;^4<]ONGV5=[B/>_<MQQWC
M,!+5S;A!?H?,5!@:XK]).U[=+#M[V=F_FYU==M)&<RAXH]N+:V'G^L27?;'L
MBP>P+SSDM<>%MO"44WBZ4HWW]-F3S=/'OTULCJPF^_P<AC'&'G[,V,,?<72?
M'SNX@>!273X,[>DY3!PIHR^>?O;U&<S3'_[Z[#RFY#_/81BS(GT>\-ZFU) J
MY]FX)LR,DFU6 N+'/NIJ.KA$9SH">Z9\H',?[<ZAEKOCD ]7LJ7NTR(*R/+.
M.:$ 9'D4;,SYV \/K;#\RZ6P?"DL?]_"\L587HSEF4PA' +7Q:K0HIS(Z6-=
MOMHGMPTV@56:<==PRZ9N"&UI? ^W!&.A125'F10%(PC#SA$(V]:YSJ#.VZ#L
M^1P3R\Y9=LY=;N96\,PPFS$AW*,"(RKU*TM"1$9XLOT=>8O9//RH91!S%[@G
M?0V3KT;.I/2;MV#<S#D$_YLTW!:VM657GO^N)!S_-=(/=)B%(!R+G)"\)VK]
M^K:C;F?%^<!JLX9*@>L$RZ4K8CCP27BMFI]NFR:P+VJN\)";0FQ"5?<$F<T:
MPHP!9?K)%U^KMH@V?*A8A*=3B@4W<8WV(2H8S51P_A+!R7O&Y\D0_:)8^T+;
M#?$%")@X)UU)C<C],H06,R))6XJ3%WU:P'K #]ON%+5%8!-\W=XFZ=N%'NJ>
MZ*'>#>#_2'(H#\\P! X F7ODRV9-W$"J/1GE4KN)X$LU&>]+<7_@_BML4_"Q
M@[]GM[X'X=L?GO]=*_'-<U+LT3*WX,Z O4VH+-+2E2:NNLJX.R@+I (6VX=V
M-]9OBY&*&#,Q\&]!,%46=*&O2H45E+NNL];#@<I%&R7)D?KRNDD5O)F1*]X*
ME&&;SISQ]%0E>E,X*T6[_0@%XT:YOE]S\,<J'A:P(X_Y")+2-U1"\OP:57I@
MJ^*&4NK-%.%2L+>X!@46I]_2$BEZ&NC4G31;=;?.80M"C* @:CE.)X<&N"G5
M;?H11!]FIG#\7V!5D3T8!N,'05+9LX:-0> \]%MM$$[NK[*<3("SJBS_+<+Q
M"6Y*+=:[\:;Z]%/RVC%')<%(_:MOBC8OQ$C&.WZIJ*.)WM(FWQ:,^R</4M0F
M_VL[C(!QW3%Q4M]T[>RH/\6>U3EQ1DT&(H@,3 1'+B'B1F&[J#B*H$L[7[OD
MD+F$0;OE>@3?;L1B6)=9L<7W8TB0FXXV!1@4!78IY7VWO^/.[ H$OR5T8NV.
M&@)KH8+G=L7W%9+ZSB1VJL!NQPQ42>*N\$PS>&34[XLH*]EFDQ6P"?-Z#<M9
MN:]5#'.Z-YU<'W\VLE)"4?*D66V/QXRN#+61L+>&0_;=EV3NP91C$ZU\VPBA
MT7\HBQ1_&XH&ZRW;[R^"1O(<!FLE^VLEE>)OT[Y?_L9BPQH2'=5B\ZY[#W3=
MMFB10LAW3\G2X&!+;!7CSETR-MAN'NPZ>Y,XSSJ#!#!D-Q5:P_:SD[;H;*WN
M:(#WWNDZ5JT/JM/U?8;_A[]Z>\XWF0\P_UC2R9I4A'8K! R@) L;0#-4A=XH
M-.VA[44["F7.;[/!]AK"$+(J;_K2M:)J0C\]8452KQG3)GVD8\_7OZ;C U"G
M(]>S)CY0XG,*?GFYA>5>9W>:2AS_ 0^R]Y$C!LK<@8Z!=8E4:B8MG*IN@W)5
M];29,VW28-C0Q5>^AT\/D- 1'2\-]Z*^[G<8> O*R.L<8Z;37.%!NM\QB&WX
M8)F^H=(N6I4:--_H58%WMJ_$D.SV9FDR<JQOKQVK8K\,K)BL''M*+9%+;K#5
M=[.N];#!BVJZ#]7$_8'KZUKP)P?RP/%:=@"BR(V/FACS?]582X,<@8'YSR9'
M1P3(K?$2YMR"N[:0.)EV(TVY,8-P$JJ6GH%ANFOEM6'[!'T>'#WB6I=8#WAU
M/0XR>\-F92E\R<"XS0IT8Y7F I0M!N/H/;KC!FC8RK!SA*:-4$!)?^E.#8UI
M J%R8$$+9=GPU*7JR1E5W8YU-:J5%?J,8(65I0-#C&(>I;N"CPJ&MR""%V1:
M[NJV)<8W20ZP4<)>)9%@=R1^J)ZDOCKTS%+LL*@,CCA"\U>1=OKUNBA='&>Q
MYIZORQ9=R.L[/S5X_R83,J.;K$04B4CJ.?R":@_>2>&1UKDW,[(OM-!J2U92
M_YT[K,G.A!CEH DM<TDRH)@H58U'$ ARI<0"]%7F*_2$DYFB UZGOM!13"AG
MAB^7"V_QE4PMR.(Y.VUQ".RW^#=W.<%'B 2;Q#ZMHPBX:%4E#QE5\:NE^&4I
M?CDMJN*[$!O-)J<\@NNZ1E(FT&3UNJ ]KF=Q7=Y0[;WQ>OV)%:FK.$8Y"4+B
M8^&H380DE=Y=\3CN'8_D[$W,WQ0=_Q4.MYH,HX"W%EA4=F2$H1.'MI]2(4?\
M!@3S124V!&.&L%#[ >1-MKXF@F0$/NOZADIV]@SEA8CH I$!!V#N=E0:6E%R
M 6L25)9"C]848OS),E0P>\?LH3MFF)Q5Q$$[.-7>TQWS5A,4W=33>8(MWAHH
MH8HM/@J2P6I9<FGFMQ</<D,V*Q(8H8V%'U 6;QQ'!1')B<*XU4! ]N\T[-<%
MF=I>!F<D;RQ2_OWO(%+5WH/P34B7@/J#!=G/<%>Q6UU@J#VYZC,$Q7:6]=M^
M-$.JZVO(YL$P/KRE8*09TW38B5+$AZB[0J9P8 PLNH^553M.2V@B]%71ODF^
MS\BG.Q<-]DL5?-*KLEXAR9DBQV%ZH0:9P6*2<(1P_E(7 9MK#,5:C-9XZ(1*
MIXXGX8<:XVB=3DD=EP>SM34(CDG5-7_XJS^."^28:"DS+ WGDLJV\RJS%RW#
MGGW+Z"]AXGC;M=Y19B>9H=/8O?3KUU?H7-BZ+PNF>>7J<"EHD=8$XO$R\BL+
M=5MD.&QQP<BQIU;SJQ2*O'A]0>-^?@U#U< J?,^FQ+BE7OJJ!U\YHPM_>=.@
M0Q4-;\AC4JD5Y-XB8;P6H1C*,4_*Y5-DDO.1:!Y,#"&A2OQ7A_DG_P!BJ&\P
M4*&!34X5H4;D,CJ)ORC?:0&SM+%4IOQ-J<(%'[=1%&,L+]JFWVE]'E)[L<K&
M^VYJG.R2.=&L-(@,V,@/$[Q5N@$]EEX5VXCUP,Y8:_6#ED5X\;H$K__&<4H3
MW&!B0LV#HLCKVPK/$;M\8+<RFI<'TT7B4AAF6?R[+W(*Q\/Z=+CN./I-5I14
MM<7R'CX>'N'E21)U(A)A'ZRRZ@W9T/NV<UMJ-=^4PDR,AUW;BG(1ZDBF8;/J
M+4P]EV?XE0IXKPA2 ;+!82?XO#>A/,SKM/#]MPXKH1%\U6W)&)=<)DP?EFW9
M(C,)^XDPC"_0,#$5C 0"B!&GF74V9 5OKV&?5<[ECD_Q-:H@QKQ@V*>"FB21
M.@(6&<?,LX0L/,1!+DIH;J[$%:'Z(5I*!6_K-R!Q\#E<T=#V&,"@^*0$R)1
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MY3M/4^]FM<[NS9+&,!*$>@OTL7]TR'I[*/WPI"UEBQM)U3C9JEHOWV IYD$
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M+;88+I?U#T8*4DC[$GD"79*>+LP'D>Z0%)K2#0B'TH3W0Q4"Y#9ZJ\A?>IS
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M%BZ#@FD7#!+R,A+*&'S^E?"IOP8KM<KHQ^**0^J0JJ+F=*8C2@- @]J$L9+
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M\_NZKD!*Q>/)/"1X'8_K\B8P=>I(ZU3=,-<2HUWK(Y=B,E- 22;:JM,Y:U+
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MX5^S7NX<OJW4*O7?Z;:=&"FNF/R<P8)"S]I$HG9M[Y9R)E"OE)MWG$!UB0G
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M?'HTMTNM5&UW"N=3X7QZ9'1;+35JLST<GZF\+9Q/CX9NV\U?QZS;#-?3&WN
M9^S"%Q"L@Z&$!T$4/^K<IP?V0VTP*N-F^:DV>*/NJ'C5GD+RU -[L3:8"C;+
MR[7!&W5'?:]6*7Q@M_6!;3 5;):/;(,WZH[L4EF5FKF^6K&G41VV"8N4ZN>Z
MD1_O*YM^W>M:.??6*Z5Z;86M*M;@E5M;VORZB>&^DNC7O:[57U&=4C,'P+^0
MY$NH>NLFAOM*GE_WNNXCE7ZNQ^]) A6;(+H*+=?8Q,H"J.)<N-]K$0KKMWJE
M7+=@0IX;^-8P"*WX0E@3A X1&>@0JUXM65A$7K(&P6ALA_"W.+!^JP)]W>;]
M:ME"L&+7'X3"CH05#.$;U7);?^/:CJQQZ,+*8)<L)Q$X3&SB&[^Z+9[OKQU\
M'OAP'(R)'F@26YX]"9+XU=#](1P3((EGI0@G:Q](R9JB'D]Q^2]-?$I$$.7
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M)<^DA.K*GMPR'#G/,L.7:/DC=2]56BOW1?^9K=I4#O TKP+O2I@42!-2TQ_
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MM"T8;X1?:#29";@9 :)3"V+#(!4!"D::SXU9#ALL6-0;(-UV_KP;S6,Z20S
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MLOFB8S0T!*B)+ZN_TU&#08;94^A!G7OH..^7-7A^.'1),;U"%8'R@T-83S
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MQ2;+QR,SE!)UJCEOF,.A.%+@D4#9&[55348B\/.AP:;-HVNOK9F[2)ILYHQ
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MDJ$9>GD,NVYTEPT)UMBN/49H8J*/TZ&9R5H>W=[+4KLBUD81,90)IQ40:=?
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M9Y<I_P@C1U ?FJU(M@G;'7;5X: Q,9TQ$IV$D6D,>< I4$WU 05^'HGP$92
M7(> KE:/_AI(9;+GS\6H'V8\M:5[D]K J)FMOA6Q,,L,A'$48U1:E@[@"< 3
MJ$K_ /#T+E7I5X:JFL?;%7.XC %UQL^:9G6+]4@^@2H\ABKD 2F"]CZ@I/!]
M0];W#5G R0B*TT%Q.F 2($EN'R2_;R:YS^+T*RNL@Q%#UH@2V8%15!E6=XUY
M5.[HL<*:7F&0**S9FWT^=HTZN]4\Q?"S->KN*EF]#W*,0#TSV'90OO#A*J=
MC3.H<08USB ._?OURNDON8.:]*A&J2>"SM ^6"^L'NV+]FZ K^MNK^%BNH3
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MZP/>'US>;FYFL26]RN9U:/EAC=H^[4VK\*HDCGRJ8U3@B,-A/8&6-&<!8 K
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M6=&45.\Y, N&/!R^27;OOI,2;HT6+Q;'Y1= \B)80=;&J^4_]R![__$.50R
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M;FN.7D@27#>Q+JCYWRYT] _ F--\^=] QC]Q"'UZ*AR\,>_/&J]7Z;P(AW\
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MH=#7"K+O:P$(KN?399'#)0-7QR4U$.XQ=-768LSJ)VOEYJ*O,0E7/N5;=IN
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MI\L.J>Z43Q\84-:RU590/M6WT^,G6;X6XNK=>I1(TLJ,5/*E?*W02Q*V2/@
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M187:93H,]Y$L3[7:44V]*3^=ING-+W$7[^=>0G<&$E?"M(UM9K %=76%W!H
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MK@I.-7!0N_DXJR/GQV/!0$VUS4>-_DVRGV^9=_,_2)1SB)2H]!T 5W/2-Y$
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MEX/DUU DG4HD?1ZD@7QB8ATC>1==WDP>^<?V21)"NU,(WQV9.@%%%=]C/]Z
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M^XX_P3J>-,.?ZR8^"%HL=4,TMCMPA/?['S^F-X151OP[OA^\:4M%\A7G8 $
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M=9=9V2:SH4QR,Q.X&^9'Q(=U7\T=(BB@!KU_RA$\SHF_B*U.5=\B@"?HVLP
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MNQY[RT<_)E.R?53(",4[,Z7 KCVF015KAX7##V,="TM2[X'-';H!XN-VR2^
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MI\2ZE$3B#2+>7]1A+CN:EB__]3A_)@%(E4D&*K9HY0(++M*,V-UR!\2TG;U
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M\F80V$OV<7/UR20#DK9 >HQ 2!^J[PRP!95GIJD;&&MMJ.H\PA1G"O)W$ :
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MV'3U]Q[68"0NFXS_@"3H_L%3O7Q>;**9B)8=>I:4+\RYGWW L@# AT?\>V1
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M)ZCJ3FXIC65Y*9%0B$.,*-+O$4L[ULF01IR<L WQ8GL=%(+0YTC.S.$GI]:
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M]IL(>=.%7$3L*AO>PR7<0_(J%:I-EW 3(6NZD(N(7:5"M>DB+H*_2N7"F[B
MFPAYTX5<1.PJ'NI-EW 1V:MTR)K>\")(G^7=YMQ_Y.U[OU-G?^/4)V7")\Z/
M?FL@2+H*'_[?MUCLVS^$2"IWE8X[*=-NX<9RPY&2*\Y)QCXAR+*O@-AXYR6[
M93""23/Z]UKE.H7G\?A__CWV@2VDDJ]&):?Q_'X-(/S*Z_HEH!#2PZ^]C5\#
M!K_R]'T)*'PR<G"5J/@_U:%B\:O8:67%G^I(76]<WJXV%"+!*5T)7P((OS+C
M/Q(00N/@JQ'^&W#_TRK(?\KZVV00';6&6U!]R'Y6M% 2G @ATJ?F"F^H#E!D
M(%.60GSXJNJA?_9ZB 6A?ACJAZ%^&!+^U] /!=(U@JH!MW0P>"@"OJIBV'35
M (H0= )QB ]?53$,[S]4"4.5,%0)+YSP7\'FJ#P[_/\3*'L?.)?F^PT,_**0
MB?WX*'S_@JZ?:GB?! /B(0;\4YWNDV! (L2 WSYJ[BJ7_= (T-,M47V+I$FO
MM>_/?TD20I/)^^H] NF7\?/-T/?<YPE US_);3SW<?Y)[XTW26<\P\%]]$A:
M=QSG3"&V!F8>GOLT9T!6FFP8(NL'0];4UV2MM- TQ-8/AJWQ+\E;J0/R@R#K
MI7L8W9YU:?+\6UU#6VY!0HG<! /7_ CVXR5@)5/+SV<Y'@+AO]]0ZS[SN5X@
M/2X!$UE\4VLXUB.QS,;S<+:FT Z)??S#R)E6/.IWBR-T<Z]W'NQ.I=^L)+)(
MKHGV(+W^MM-743!'S8F_D2)KE3@JB.9,T&3X!\:.KD056DT*&\5TEQ!ZHI'Y
M,E#3+:ES=/_L:[;H_GBM($,TI-F6N')VGN:NH:$]LB#&'JEWM_GJ9'7;F,<?
M[U '-;2[[12?1$:2LA!5\_^^11/?.#I:[_^^*1OKIV8O9-UB?]]O QE\MH!F
MI-\X&!N*OYGXYC;;7_&%;2WUN.E'Y_W[U+303[2BT"\V\>WO1":2S.2<44G.
M%7T(+]5E<)GSNJ=.Q&28M?21F P91AE_.[7TTR-NZE.*1V8YA9C[B3$W_AEY
M+K.B/A+B7KY>-VMHJW3E(5/M*\E%I9,KY!O#4OLL2MCJYB%?%8:Y8K^@S7(5
M%+NVQ J9^A-_A1;V,6-&)/C%.JU_&G_1V4S9PW/O<HL$YA:R;D,_]0_+!8\'
ME<Y^UHMDC6]HL':DIX>^E7PJ\H7B8EVWH]>I8>*?\TH:+WX=;TSF<HG'IWFE
MS3^5;AKU:KS7+))17^]@H'Y%=A+LICX[A9W,CKW LY[50OB*.'\DDGAV1#B9
M"7R!9PV1_AR6\@4BPJFLYPL\ZD6IC:I6KA0GO%SCQ2<K.U$>.LE5>OHN.EXO
MWG^:3X7[5*F[-;-R/F$U31E&T;W>_OTW&19U,<09CJY"GZZ9,"7&*SX5/#O=
M][UEV/8\O)<O/]CJPN_EZ\ZYNNR+"1G99=[+EYV"=>'7\G6'8EWVQ81\[#+O
MY>N.S+KP>_FZ$[0N^V)"1G:9]_)UYVM=]KU\W7%;[W(O'Z-*YQ5 ^#QM@7[9
M!>J4,/D2L[D" /@GH[IB'VM45TA2[TM2I_%T?TF8G'^NU^4!)22>"YSZ=8$@
M.?\0L,L#RN>FG<_0ZO<W5;7/.#'L\LCF_-V +P\FYV\.?#*8A 9-R#0^U7")
MWQ0J7V 6V86CR]DG4/QS->0S3BJ[<&SY:$KKIYQC=GE".=1:0ZTUU%J_+-/X
M:EKK9YZ0=N%X\M'4U4\^/^W"L>6CJ:LA=H2*:JBHAHKJ)U94?Y]CAH/:_H$D
M^9QSV\Z''!<_QNT/\./S3'4['WY<_)"W/\"/SS/S[6SX<?$CX'X3/3['1+C#
M0W^J 7''L/USS(O[A>[\=<?'O<SD0M3^AYTEOQAF7^*LN1"S/_HDNHM [4L<
M3!>B]D<?6W<)J'V)4^Q>B]D?R5?[B>;:70+:7MJ8NT.8?*VI=_Z3G[B=:^PR
M!]]9T5A[G<Z:55XLI/3_S]Z7_BC*M'M_/\GY'\B<\R1S)ZT!7-"YSSL)*NX[
MXO:%(" BF[*(^M>_58!;2]L]W:X])L]S3[==0E5=2UU;_:Y:C.PN"I';]%PI
M3M-8-U%.X(S8)?I\0:[-^U;0^"Z>?$FFB._0^.X^U-!=]62ZD!9ZF+9X!UKH
M<?N+W0=GWU>CO NQ]L/TS7NR]K?MI'<9UGZ8QGH/9CH6[41ZSB;*,B5W)S,C
MHF11F_I\+X&OV'F4K%2=1&]%,PY-" 5N4&DG6#?HK?>NH?<MLF_?K]7>?6C(
M^^^\=UF/^PZ7?J^J](P^=+GGD-UDDLTKE<$JK:E$/(<VKM.++S.I,](L@Y?1
M5:5)H*E1II*72;\7WZ5]YJ>^N?_6?)=UK>]PZ;?V29Y"\0"]^R[KE=_ATI]2
M<7.IN/_F?A=UZ.]PY?=FF:9Z;"WMC-T>TQN-8J;-YF:#M'L5,Q+C*F.F1'07
M3+96S#.Q*2/0!3)H]_<QE_R\[?X\VL@ZD$:_7]X>+[P27_\OVU 1/OOX_2%_
M075' U/@+S%S'(UBB=>S[TQ$4T1<^!_=0#Q' HDA8UGG=%[F5$36+=L$<])M
M"Q$<$[ ]8D]$9"5R)B*"YPI;%&$DAKT@L%-D% $/!9RAJH;KC?=['0+R0W:Q
M)PB'6(X&9K&"(,3P:?R$TR6P+EE'QH!#D 5DD<T?]ROB$57FO+V41>]A<(#_
MIY );6&-X:PPO[CX2KMZ)IXX8(D#<<TY)@?YGL78H#UGQ]AOUDE6NK5X(Z5E
M%*V0=ALI :<PBGPME%MQK.ZVM29R4"R%AMX6><>$%,]PEFSM0[IX7B?XLP%X
M!% $3J0#9I91#5X)I'C$)@1\5!'1&49Q$:VE&[%RJU$&4Q"!O,_ ) !;B>?5
MGE>@R+?MVYG$HRGBV94@A%GVOO<'VOS97>6;T^797>4^Z9*.QI]M.^^0+D\]
M=I]T>>JQ^Z1+*HH]Y>4.Z?+48_=)EZ<>NT^Z 'OL*2^7H\L?%B"]Z^;?%&KI
M"/'@>V OW7)+MA@:J<]B:,02?M+LVX!H#&"HF H/%9^I ]Y3S/Y6,?L\E!$:
M)1ZI/=Z3B>Z0B=X+?MV;*LZ!YR\\L^V1H*X^O=RW4:]&EU GC]18\DNR\SR=
MGX)SYG/X^YB[-)FGGMKU$N?L]^&13?W'ZLDH%SF&OP^G?!V!,CA][ZP(-\.I
MG,Z+"&>?" J@SQ+D*Y<@?[\KQ<'1<7\+/UV G+AR 3(:=C5N>TQE5<[R+QKS
MDKUD:5F;J2(IF:+H5:KF#3/OV(XIPMO ]BJX&#>@^G$[;UMI9JX6<6(RF."%
M^LE+QVO1- 3.FKQ9-QD42\*7]F1[<E0C:1T625J')97;Y7C/"BF$'L7=O$*,
M*BNJ0DVIHF"7(R/49>/P/MWV4L3S0MU319W[D@063O];+_PQ5=1FU"[8E=^4
MUY=VU?4')=B>OAJG\Y.6&ELE*9D6BCG+%9,UZO,7>:^EM.HUO=\DLDF.B<2+
M.H9U\_1RT0)**_GC-_Z"H^FGRGJJK M854^5]1&5-4R,!D,RH?71.:Z)V8*F
MMHKDYZ]U74NI3..SQ9A>*2N%IIF\;C#M5L(B@5))OZ]4'BDZ[".<YG>7H$RP
M;9(.OB4@S@SP [P1)5N6XSFKQACQHWOW'["Y6V5YRS6?#8?YXGF_>]!EK^^\
M80=WWD*Q5+[F,.8BG3[>YY,K-%OG.L5I4DGR^.=1JCZK*]]0E26@!40K1%?:
MCI@=)%"Z@8ISE9/5:LJTB1:;@%YCZB4=QY_ I4\%\H?5YK=1($^(QB=[?JB(
M^*\XW]#\NM_H51(TBM>[TSB=Z3;3QO5-]S\]CDAC@ TJ%:Y"%21BMEYJ)7H<
M<<%QE'[_.'KPU))OS6<]= ,(;@"-]V.  V$;%]K"&ZR>(9&+AT3^KFUX,^UT
M;TKU"?;T%(!+;,.;28U;"L#1OB _[])I_FP*HU68"D4]F5&IACS/Q5!GR16P
M/T]A0)]]9Z^0PM2Q;/C&QG@WH>VLP_*HUIQ6V8R*,5K22%5-H3G)-EPV^79*
MXI^G_GGJGW,?P$_]<S&GYJL:HIEHLUJ#6TP9K6D);:903YO+%M 0;^87_GGD
M!,,IE^2947C@B,NM'(M[\R+NTHJZ?NKA;;7XSC2 B@1[#=X2HBMK$WF8P^AZ
MGFG$QFW:0;OS2EOR.Z,!71E+/O,+3W7R3$0\^?AOYN-GQN(:QOT73C&=1(UI
M)VM-& >WYY-,0<[5R[#O4_K]4^Q;I"5.%!D!&H/U6)!# H< N JV 3[7- /*
MD<$KSP#)7UVT>4<9C%MOTWT'6.[5-;E0&IH6;5OUIQ^B]!TY/Y_%1GT#E4FV
MQ[?E94K+NWZ#*@Q[P8C4,Q+\5'1WX0+=X3;=VFMZ"M!3@+[M99#;6PKW75]V
M^F#/&'PK$LM7YY2S4C%Y@3MM4H,'>_HC!_LC)7#\5WP(K@![QJN^HF;O6*>>
M$8C@CE7B]>_'7<!=(BDT/W,K5H1J<)+H)(7&6$V1]XPZ()>GZ+HD-[,4G9#S
MRQ)6&\48DDU?!77@J6F^GZ8)')JGIOF$IOELY5V^N%ZOG&;?92JK3+5?G.EN
ML7G2F+NUVBD8<]5FTIT25;&T_(A0U)X:AVHG^50[3[7S>3?PJ7:^V-?UUHJA
M11LU.UU@BPR=*L59B:]E.VD)*(;T1Q3#A=O!7K+9Y&5:PKX]TP].ZQJ;Z&D$
MN%=OX^7"GW_)-A M_A@S=Q]:&MERV ;L,> 9;TG^9[!C;=;0P >K73;4"KN:
M!3O/<N!_8)CEJ/;F$M<^)H/7TM9+H=HR;!>J&S;XDCT!SCH434X^R+ "@0;/
M$D1MYLG[6.2@#Q&,YTR8G07^!!B!V 8R$I&1/'9,GK-%(6BTN\OC:CM!/'6Y
M#$P6X:&%(8]E\%BPFDW?7P?0PWQ=$SJ119,S^<D*CI1M9 +^&8FB[O]90!P+
M=OGEP6KARIP]Z4=D3_R]>5J;W\ _O.H(XB_D)_8/,C.-T69:8,H&#U6#&&SD
MV'.G$# YV'[XI^7P$W_OYPX@NS?YH%,QF(!APL;"0'?\\^+MZ4_\'T20+=YP
MP&Z88+^\AL'09X/?,T7P:'VWMR.P*X DEFV8480&VAH\GN? -\%L3;"M@"#@
MVT!)!K_(D'!! V-C?VU@<PW5TW. R(XJ;/@$?L$K1P@>K*X0U7#!;H/'3@#C
M@I_"*1F]9N/BSH=O*"(N!^7#%DU-UOT-!(J;=^#:@R;1QP_R)<$%A\2>D)R4
M O 2'LIEP/_O/=9P;,1CD\T#7G9O$^3Q6/1YRQ1GX&]@%S93/7C<^]-Z0?S>
MTZ$[XXOEJX>$*G2_C\]>MR)>%3D3&C:3?P^/C1@DSR7:%;T)#8O'-W;95@EC
M,?1U$Z+__J^#9DO;D#MLBFR8OS9&UMZZ@B9/N&=O26+$[^7$C<&K?W&JRZVL
M8)U$.AK;F&^_MG9:S#L8T&@L\1]D[V>X(4>["1LN[^W904/EX&N'/94W'[[3
M4RH@C6W,?N%8%%;3 !&(! N+8U$B<2%BO3H?8SO2_!^'3$QH[_U/IY%]^[C4
MH5FG'AR7P4= ]#V-#40@:W@]JJWMF<_]WB/[6]QZN-5A.\AM"XAGSH I&M12
MR78Z^+PGCV;$H 63$C_\MVU'RBZA]I-\3U&RI?1"YB6WVR<E,#+^>N2@*?)9
M-Q?O4LY:2"6P;%[E18G%CY_)#^6:V$Z,JZBXUC): Z5;0]T%(X^>J2='^'HP
M-RUEGL_)+4L0U@X8&3M^9EMF]%*F7N252*P[6R^J8X*KPI%'S^2+:)&C\[BJ
M-!:*QA4[5:FG0TA/]/5(H5GOVHD,13"];HWI,6VJM"I*8.31VZF4;?>HSBBC
M:/UQC!'8,A$KD&SB^)GX2G+L:J&K4ZOY.+<8Y7IDN0JON1R-S"H9OF8E;96I
MI-F1HJ7K1*W=8HGCD:L:UXVSA=D2+6 5HM@P\35O26SJ>&2A5U/$\:"44?!V
M/D:T-(T3EM##/QKIUH1)4];I'DI;Q5QOI%H1? GHCFZ' DT*;2E9=_RS-F@Z
M7V:R^9B;RA6IE55%LZ5(=^A6218.Q7S'"'Q#%$C[O='XI81VSZ@-/>_,[>$O
MP.S.WF$'CD(@G2('3C=P?AFF=W@)T+"!!XQW<+UUK6<<'%<S,$-#@/8?-')-
MV (K& S6[/G%T*X$RP;_>($ESR8#W_(=-]_X>O,M)ZR%(U/U'?-T!(PL 0$;
ML[-,0\Q*_QJ39W7M[Y-Y4-'HS5F"IBG8!-6P?$,!_FI#HPO8=X8F(C_%Y4S4
M+?$?Q/BC#=$%SSXQQ0GXMK<,\ 9_M:%K Z_Q[$U'%Y>BR<O6/K#;8=UEN!OA
M%6+2X-'@YTP$.Q@!I@$L'-.;L,$K<%]JG&>D0M?_JH;DGSML?CH%V>93/*;U
M$RJ(GU%YVWUKP(4"%P7!$R_>6E^\W=MX=)YAX_$ZW#M8SNH9A>)2MCPAVEC^
MP*Z;.29TY&QH;+H3F9\</ BPE0CH*2# R@&,!)P77A2%P!M . G,7?($4O.\
M#A'Z*?!)_WNI5#XXBQ+;7/[NE[-GL=CZ,BNP8ZVA%&9M>98BJE;/.IG%>KN2
MNQGL6MXTM/<+N ^B077.--FF7A6*7)%9HO0BERBAO(!K"_(M,)FW-(_'!@<Z
M![  F*N]]6BY X?,$( >\GSRP'^U-CY?X)9^Q9\-5"H8 JEL&BK453-G!$0%
M? AD&LSGZV[MZR"'I__W]?F^$MU6V<-978Q_'ZQH]?PW$3R.;K=(?&'5;)>1
ML9PA5)F$;$3(M^XAG#ZR/W1 ;0V"%>R%*1[TPD1BF*]#HPBS.9@.V7A/(WK*
MF/C70DK-!CPY&[QMP&<0^VK8$[7@G-IHX0\RE#4!I[G%IH2.)LUGUD01,]GL
M<!;+LLLE^19/H<!,W3+5]I<-3V6WARR@&CPF,ROPSKDCYD2+-V7/'MNQU\'H
M#[%:&9M/S4HK33#9>!=KC10=S70/ NRE>OX/ZJB\.7KH6@)8(E $3<^(H[V=
MV9]>=F<)T##"[L4JM_R&[O%;I)7(N1-)[RL-+";FIG2^78P#?DL#TL=3B6..
M\\G@ZZ?=%9 H<C.+XO-!]9L&TGS;XS!PMCEL]D\.WS("?X16*6_O%+LFVA-@
MP/]L]JAV#9P(0!7LK)3])W@N@:QY@=$Q,C.@1R\#8^3P"(*!8* E9"$PCQ O
MV@(MELUA^(:-[RUDSR&!?_0=,:B.HL :TSG)UT=[2SWQ+'\7O &&JAHN_&TO
M6AIF___RZ'D04CMYR. 'APS.DI5N+=Y(:<!M+J3=1DK *8PBW\QRD98EVA:I
M"P?)=M]3:^RJ%L& NJ&;!RFN[F9W.B(_\72-Y45;.F"J&15(TH^-_SJ6JG)Q
M:16:J-.GTM/UE+,2#% >0#5Q,S KVW3$\\;^KB!R7O)M&R/T\[$\H#(WL\1?
MFQ_V)P=#:D$X#0:6>#\@M0F)>O$[SK&-S0=^\,[[Y"#&MY?3#<;LHJ@I/RYG
MFYMY[36?__'10M!$,AH_V;/WV=S^2\WM/YWZCT53)XLZGG2Y#5TP(IK&GH2Y
M/\(\!>8^Z?(4F,L2Y@]O?KQ[X-]B$Z[>*_H]97$?K<6OOBWORNI-]N54,]==
MM.9,?7^?G/%-.&.;3?E2J]^GNGP*Q3<2"O]*Y0,IRB<'7)P#GAKQ;KG_C'3?
M5!Z\_N^9M$$@"'=T5>6K&_9SEYCZYZ%4YJ,>H]^)=TK!78I_SJ%J[PPTAMHD
M]&!2#/DIZUX*WCH'RI0O('>VWK.U -OP^7T!Z,=@^??%8(_NDJ(WN*[Z,*3_
M8%7+@*UTQ65;6_23#!U1Y4J2JZMJJA5V=?."17V;!^[=W_3N:W96,_'@\OGK
M 1LEU@$Z+'A6I]08J2ET3#"]TJ(\%>MZQ%;(/Z]Z\2JLWIW^X71>U[A H+].
MO&UE4@F*2>:(<K(TD><$"9O0QW_\AI<\S@?N>@<6?6Y3#O@*O/5AC*YK'B!W
MIC(^J#%F@-_9>#]&-N>T/5$<C%[A<S?IE)WP^]Y'56_74QK>LU[_=<.BL*)P
MYQH$CZPM-8M4"FI!27847L(B5A;5#[I$8=?3'*.UW:[%4QE!$6?IBE!$J7'?
MA=V3<>C^1]$CS?&?;R%F-SO5_PIYO.4A_N?RJ$NS(K.JYSDERSGXBG:S2[)P
M*WETC7YIXI05@JE4)S2K&7(EM8"7V^+OR^.W\!@/3_?#0O_OZF/\?5[C7V@'
ME'Q6;GN<'#P5T_DAZN:Z4X:K+6)Z:M1+M%SW1JJGW\SA1*K8JZ+:I)OI)HUB
M1.K#V[+ %,!2T>.><.<S!>Y,'I\^_]-@."VXD[B%%TDIUZ-6Y1CKSMSR<EF6
M;B2XG:*TKMCK=0+5C,*TVB<4.<Z30'#C[PONX[G_S<,KA]Y-K.U]K6_AG#QC
M -_A[-_CT\:X!)8F<VK3N^/:"*ZX-K9L&[S(Y*H:N^RW'4;ND'VVT^1,+7$K
MK:)*:$2/U31&R:9S+6$^'%:-*0DW&6@5]!D:>(8&OL5)_PDQE>>CF#Y>3-9,
MH9!>K-J5YG14O57 @)+PF%8:S&<*C2Y314QFTQ0&D6O X1]/_ 4!@U?V@"!;
M7KT^9%GOVN<EK(,[VX*GO_(T-O:T6&XG A24@",%ME@M.^-JI;QD>NFU,YD/
M.Q:=OY6=,>E,6Z2=S9L*QT7:Z3JJKR82[&6"P]SE):V,IQ3_W5)\W[;(NU+<
M,BH1AI6:&,.E6I7!5#%64N96P<.YPZ68(C:74*=<6:0*C7Z_VR"!%,,8Q$7,
MD#NR.41OE_;!>;]70.*X[G/SEBQ8PLB4P5.+HKH0X;+@&SC=B@2O>7I0?Y7M
MX3\OOY&$(Z5%N41EI,4:)+5*4C:54XMSS;F5Z3&RU90D<?D$E60&N:8A)PK]
MO,NF+V]Z/*7Y*<T/8(.\)\T-K-6O2W1)IW [V61+$[1-.>2-I'GJX&.QF%G4
MJ$96Y6TN;5=;(]@X Y@@,>+OBX2$H"S^79&0.]9M?ZO+=4OCY:T!65\ZFN C
MV=D6>&."(=0B98;"FZMBLT/%Q[W6K>R4<8YBD_EB)HDV^DN\663X2B--PLW\
MJV,D3_F^._F^Q^L;H?)=='H953#Z,I6=E-5(KL@/9.E6E@M=Q&Q#ZG8LJF=7
MYI-:*2^P54^^H>GR <OEV?#K#V9?TA$H?W C7U[#G?L@T1Y,Y\<PYP-P?4U<
MKSE=UL5-+.BPET& *^QU+P#VV*9[UHN'5[_%'^Y,9 L!&Q+9PFF&]$CR\%2W
M_0+4$_T"GFBU)SB G)FR"O<=/>(!'_*>.SL*N*\AXVP,A1H2W>MU.K)WS4UW
M:K')K?B)R"O K+=%;P;@)\GDM*K!;>K0E'IGV))QLJI$>G.Q6%[SI27]^2;V
M54.7X"TW.*50Z&[@843BC#[2&$>I\F1KI$7FK/OC=SP>.U)2?AF3HUN0F\&.
MJF#:+\A(Y$R_"0%L4F#90%*">J>+'$C7WNX_V>W#F92"#6D#)4%#>'.A*9KP
M<CDG[=I$1O ]8G02'2*=<*FT4NA8J)1<)"=,!A #"SLQ#GL]0);?+!C9K1@)
MEHS\A .@@.+HO\UFT_L)^Q=B\D/896^(=^K!B?NX^_ +3)2.(C18J8ID(,*Q
M:%D(*6BR+H-%^GC)^P^F,^3FP7NM^+*&:>C<0C8=\&59>$':HBJ+8[\=  4H
M;&@RCP20WRN$Y.V#AV;)-D7#3[>/?K46!-)S\T>_2P#\%"QK(4/E/_;ZI@"[
M$>Z3WWEO!1EV%*Q(].'D_9X7%N+,P+C+</ 6T3GN(SJC$-'YO P=*62SS3ZE
M1%#.QIM3FNNCP^GG<DAOOHX$AR?@X1I8V41=@6' &%,IO_^,57-46X;UM68H
M='L^R=9:-2&#*W@S.:#SA4DO/82M J+'=UI](MC>81%@;7/^JQ'-?S<R\U^.
M!-UOMN-"R.QS!F0$C_$XGC<='\T_4%NFUXI"DOTSU^OHAGC #H@KBHJ%R/ZC
M1X9I>HT/'<OK<AD\<]M+!?(28'#)MRX<<V98L.&>WW4#3BB8,]2<NCB6;?!'
M$Y:UP%DY=H#,[<\VZ,,"%N6]PY^>Z(FA!@R-$6P4)#@\7,:KR?F8Y1SLN","
MN396HM\!TA]OP4:3G&</"1XFO_=E;[$1N-B@T9(_"4??O!?QNC;MNOM ,?,F
M!LP<L"J_ 1N@T('TG(0VO[X@[/$^\"/Y7V#]$$G4$O5#YO<VH $6TX/X],QV
M#YJS&7Q+TU_N'F=W\RVEEL\-;":RE,=SO)V@Q0S@;-LU?(R,U^:QOTNP2:J^
MXT+3MRB?)^CG3M QFA?KLIDBT=ZD,ILM22N%S\@W3U"OC1('Y@I= $[U6@UP
M*[]1UJ;%R%@V+?L;<#1\4BY8:#-8I,_E>_O7%VN=ILG7UDIVUB J0DN8Y2Q@
M@5CRTM>Y1UQ\V);'L0)OZT =;K2@WZS!@F#XN[:F0(G<SK.Y+S>FH2-E3G<X
M<X7@6%@CL*TS S82\*7FFV!CT]!\%S=#^BV>-LH9TAR9<(+?[WBKQF&K) >>
M0+M#"9IX6R4$/H9I!:#_21YZT&" NCIVK8,&=;=JKO056>+S=:,U&309-+*F
M23ZW4CO%5.O3;E:!DW6K:D!;LJ%32]B4S9&MB=]:Z4W?*],LEW1)3KAHTJKB
M/::AI_OD2=\+AAK\?G_C;0/?D0VLG_TW'O@%))U%X@0:2: 1+!&)?ZQQTC/0
M\-9LD3-&RO;[?_Y^O%[*V+.7LOCLI1S*K>_W4O[S]K=>U^ CJ=EVW!T9=+Y=
MIC5'<>:T(A<*BVFCY(;U9,[D[!8^7'$H0\_$U*@?:Z/98FBG979,HA1=+<2H
MR%*;C)LB0W<E.#+Q>J12C32QE!6/HW,BWVNRL&JB#/LG'W=%=E:S2*K0GRHB
MWIR+W>FT5=1:83V9,VE6GU>S_;I2J+3<9-^=HBE+ B./WBZ5V376::]75+8J
M5H=D'R_7TF183^;4;&+FF@5SJ= 1K)&D!6?4RK@^.,SAR*JSY @[L1HP27Y5
M;9 <7Z_,(8S,\=OE>C*;2LX9)=)G.J-Q8UKCJU)83^9Y05]VA!S95QJI6KR:
MBRQJ24<*Z\G,=X:Q6BJRKJ.<E:HOA@LBL<Q)_E6UPY$UL9!,*=,8A]).5>0[
M";79]BZU;>9YZ?Y:P+8 SK*]:JK@Q"5U >:(9O 8AC>.50-&^(_;9!46K%.S
MI45)<3AC9LIMJUAQI0NUR=J3^;>ZUYX^]U[W?8Y'D<VJ_1C>9LD7.HG#<LC@
M_YN)>G4RN]F(F]F\(+H(_K/Q.81-U&+;H.TZ#=C>9)!CMHBD^EET65B,T?E2
MYPF*H 8+@KQ"][1W=_@]LR?X:-NV[&_OK$8DH\GT-:M"0TLI_KB]S)<J)? H
M_K<M&8M>]=["':R8B*83?]F2<>A[_%4K_BO9^D&7_(>%SG=T,*6^U\%T"D'^
MK)L ["+XX?_[D?CQV0W!HNAM,?=3']BP4QC[I)?IW40N_>!H#'L)ZVKQ%)#;
M"\@'R/UVBY(PUL<_R_KI:"SYT)P//<\S=22YM&%S5U2//SK5O]:X*5!K-ZW^
M!\\\#!6=0VO=>D4W 'F(WOJF&GCF_Y[-E[S/FQ5_W!/CSXJ&]Z*(FW3VFW'"
MS.KH1L3V;T$Z>TWW!;Z;376I"+'4.^7Q6FC7/I_.?G,J!=.PK->Y;)C_:'2)
MC(%U5TS!X-;]5;&IQ3B8JXC]^(V]H GB1+^*KQU?MY:#I_A_T>?^N\4?.XOX
M<XVXF9?C4YI:Z:D<S1%H)-Z4KB?^J72V'VE$:)T"7QL1+2$5J:Z@^"<]\<?B
MYVM7<POW+.^8@-;PJ@[,+XW!_H&?K4?PN^Y'7]VXO5^(TW$^ ^9^6A?>6IU]
MSIK9RA<8EP^D:UOS.M G;C/B4LDQ%5.:E?)$%:^HV0RL/)?KQ%1G>IF:45SH
M?7&5DF!A+]!L^#$0]P-XY4^=<&F=< =KNR.=\#D3YX1.J MDM5-A5JBB]<E>
M9>VTI_G9%9T=FU^WI*(S8Q4\,4KK>EY.#CJP-Q^T=LYNZ=S:TK^^<GC&=1[?
ML7O&=5A5SQ=R8U0HH]S<3HWE83N^2%[1=)GW%G5,8NLZD\7R5K6<':N-%:SU
M]&(R6"KYC,D\1?<9DPDS6%(]MI9VQFZ/Z8U&,=-F<[-!^O,@#'\LNC6ZH:[*
M%:*G<&.#(IV!.XLU8/%U$$\Y8_O?6\13JJ)E_8)7RQS-4>&M3K"Q,Q/LG5=M
M^XRK/'VH>X^K0"7T\\$,B#UYR^V)&_A9%>$/0#&1&KS?O^:".Y/A2BM,7[4R
MXPY71E<45YUT)Z1#M1T*-AH$ID8Z<7R9\9]GF.0IXG<>)KF"B)_=T+B@B&=G
M/)XNLPN"X7H\WXOEG'6V#F]Y 9,D11R#*_SSZ'&/$W>*GC&.LSM*AXH@!A2!
M8#CP;M!-M-Q%@R W7^H=N5K7BY+4Q5##I=JL,EBUQZ/SB)*,E0J5[J0'>ZT!
MPP6/'1LNSPC)4_ _'4*Y^5+O2/"O%V,)%_Q61:P5;"4_HB*Y57RPMB,L.82"
M#R,L\7?C*^>%Y_VZ:-X&=W??QMP@\&T 9GQ'P<,]>P4SL[VL ;%F<,^\@@SA
MP>!>&DKHHS>X/\F$^QL2BOCC",V.TU_-FTJ%ZW-I038*F$4""_KXJ/$VYMK0
M2FA^W6_T*@D:Q>O=:9S.=)MIX_-"^>Y^F&*IP:3JN1I#=\J"4.P/2<< ^Y$^
MW@\(DFC-()[30H1@5"Z$Y0L K !;<WM^S987C?&C<Q0I3!W+AGHL;YC[OEOH
M=AK=5;67%>R!(I;X=JW><*8T!<$UOR5W_=G>M--<(U$<]E>*9F<8A9O3;'GD
M_O@=2QUOSF=UV"&/1I&;*>?7B!V?.52V$"N%"FM1PR3.,/(XTXG94MZ@C588
MM$X\US'6U4)!9\0VUZ5PHF&FVZ'0.HS5:D@](R8R8K$J+/KU)A%KNV'0.F19
M'#K+,CYB\(@@FPE].2NAK3!HG<:ZJ"J$4&\SA8I3US/QXH+JN6'0.C,\*Q=[
MZ_08+5"+>'*^&-B=&AD&K4.O8C-4R<Z+%-WM%?5,42]&^JTP:)W>M%%4[+4P
M9.3*2G(PJ^F2.9AN/1J)22TGURWW5,KI)I9XQ<B1DT$K##"GR+;TEI9)MJ@D
ML8XDRJMT,0N>F3Q>46*ITFW%)'J4P_+HHC]V,N:(!".O!8,#@0(A?'* BPHC
M33[ [J9'A"Q:IQ!QINPT.9F*_)SI56Q^P,^D])1X&$2<A(>4Z.$);W"0;X6%
MLYG'Y@P,X&^L&Z'?T/Q$%!Q5;(R/^<%#&3MFA1EX -EWZ1257$O+/"ZRPCSE
M/E%P=A-_(!2<DZ@*>_AQ>X^'"-)CP*.;/=O\'H%.]B\?(Q "W+Z+S1>0QGOQ
M9B@W\GKPBA?&Y#L/OL,.6_'KX6;B28@[( 06C3T)<0^$2$6QD_GC)R&>JNGO
M(L13-=T)(9ZJZ;R$^//Z@SN! KLF_L])T?\; ;)BWPD@"T+[?Q4^YBD4WT,H
MO@"BE'ALF3@K=-:%F>.>L+,>G^Q?QLZZ@^L]5-#&#9!4@Z%=SN]WNVLB![-0
MGDTG!MWM./5,(!7$[5=_BXJEV!VL^QP52;Y#\7=?ZCI[I>%&'-N^Q.VE-;*P
M=U9H$76[10LUI]_6E49\5:\U\@(F]%H^3%98$?53>I_2^Y3>2Y0+?D9Z]?2J
M[D0JY(#!QTJBNR"95F*X1;G"4^>]E7EM=ZLM6B)G\A//C!!@%WK#JY\$9+'L
M\]D1?X7:><PK6>_%';^=5CF;3>#U5PWJ&S9R1.I";B=%FZJ0$+6R-I6"I!A*
M$XVLG%&ZF)ED!Q/2AYA*HQ<T"IZB^!3%>Q'%LQWP7Q)%V\F5:]*R7V JFC/H
MY-N5E<B[/K(3GC@EB@\94:B*$J?"DE717, 6]3/3&(N6!58&/AZ+8A!3,.R)
M:#XC"A?T26Y]#?J22NP.EWM'>N^\)H@GT.U GIM[TIP'P@RT8 -*,AD(\MN.
MCBIJA)4OU 6&CM>$/)G(\7-.\I&C8O@I,-^G2GBJA*=*N"=3Z$PJP4K0B5J[
M3!)HMMID5A.QW1TM D0J'#L%)7?_D8^.87/JTZOZ(X5UZZO,EXJRWGI==Z2'
M+@% ]>H"R-OZABK+;$=RJB15L#.U.5'K3BT]0)3"7]#T!8V0IP _!?A;"/ E
MX*4^+,#C2(,NCRO9(9JTQ*0Z<"MQ2R%]O"CLA4B\"Y2]@5BXS/79<]><7OR.
M[^&DSW>_EQT3'#$>HS&62"=X-CY&DRR7(L!_DN,4A^)<*I[F@CND=[GUE[K
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MF5!(Z /&0X#!;V8B7'6WKVDBH&N^1:=2PQE5T=/"(KY.CTA3^O$[%L4?PD3
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M9CU6E42=]_)=.SZ^Q6KRIJ$A-G@@8AO>OR\'_=TU;H6,1$36%X:Z\/O% _,
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M.Y/AM$G42D/2OV)U.#)2:Q/3E))S*9E>MCKS8K-(#%K^]8_#D3F]V'-3M?Z
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M=7$,PS_@SS,#AN=E>/)N/I5AQ%[PW1K "AHG[+LS3HBA&Y[E]\XUKQ>DQ\?
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M02]]+\$TJVZ''EX-Q=PHX(,>JOGW0UT0Z)_N(#C4BHF!."KI]D %04#2"S1
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MOBQU<B)932EVF^.2K6Y^WE<6B&= 4Q\)@ULI0CA-".5'\KA+4_6YE*!+GS.
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MLGMGKY#3Z!*TNOE9O2%.5B.C\S@]"*-*KY8?&-Q852;IQVBQ%']I)98+9VC
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MTRL1Z\ZB[_&K1JVW6C[3P[32OQMUTTSAH6X]M_@X4B"H2))^BUV%)OF/)^7
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M=I5A_\.<,)M;'(A48\%S>&,3S>DJA"X(ZJ_+E2\?$^.Y$UE#S\1%'6[$\PX
M;(\AUZJO(<BZTJ*)']7Q'K7N?..XZS7\3!SVVRH3<JT'BB8)"?+,G8"FX]+'
M#AZG58AMH"(-;  4G68H2 Y:AMOOM?@7@T.\.*>4(J/5F%^!8!,21\>'*9X6
M1 8I$ E>X"0.*I1QCAH.$X/4D-Y3("AJC4XH#Q1HIJ-5)IAX/)4( .Y3,1_"
M^[=X[G+E"V%S@/'N*M5LEDW2M)2 M"$*4+DF)9H?B"F&%P%))1.DE&(Y:I]*
M:+?,:-7PNCGHPZQ31.\4[HMR &B%CGF58BNBX6]UY&Z5\/:*7%WX[UAP^()=
M.*7$99(^-@B7($_3637QD.9.1W/'\F&PB?B 2@Y%J!4R@&>9 <.G!G&2EP8)
MBDS%)8%F$OO$Q+CHV'8+:!&6(G7+1;RN(03 =D6%UQ[9;&UTBT:ZOF9C$3>M
MTU'4(# E@%H]@'.J82'=[-/-,8L6CT4X8D(D!3%%\D,.I'A6$(>\,& $GDTE
M$@DZ)<;I>'R?<-BF 8$F3P75ERE<   13P<E:H@@ (3#(F^XNT]?2O,ZZ0AM
M&).*N^50JMR(5/EA?ORK<PO2H5LP= M^TRTH"&P\3G,)%*MB4*E/@D\EXR+/
ML7&!% 9<7 "#;;>@8%CE>YYAH5BC N05A-MRO8+WNT[!>'XYA@S 0F)UG1NP
MYML=<0RD (C9.'*,./O<*0]:;Y7 >T4YH.?*A_E+^/LOZN]#>SE9RO;;O/S2
M4N8SL(7G62+!G469G:HL.=FA!ZX2[P_/%%SS;F=*(N3;JC UP6_O!_]V$*MS
MV1PB>-%A%)ZHPGQ5L"W=^\!AJOB3+=Y+3JT=QKLOW2S#VYC[0LJ!S*NS("$W
M?F,0)!U+<6^-\?1Q-=_[D!-\J.H+#\K>[U'TZ-^.Y$*]&=^5&.N_>TDF_R+A
M<2J9_E[#,+SPXVCL$_?OS.-\$P;O#0$." @^?MJM@<UL+/7FG-@3G\[E3OC%
M>P=]YX#OCZ;^'FT%1=D^'>J>6!4GWT\4=23Z_K_K?-!/HW* YK!_^C::T+#8
M/OD'<?S6$/KG3%]_C_^>?)+S=T[]!>S<F-J__T<4 1@.SPSAM<'IE/7IPXVW
MVMJT'2C(QN1KYJA76#CTN<$ME  FFT[7MJ8S9,/7X@"]S&>T$G\UL^E&ABCG
M");^F_@"S5S\DM]&*/_VAO!_D"N?C+(N<!5O$QM%<2%[#R9[/R=>AAS__!S?
M[UW(""K*$NN, ;#,KW'Z+6>%^SS">>"[8]_W?)0A?[\9_IX*^7O(WT/^?G[^
MOG$3Z\.&UW/H&,Q]\V#$U3>/=I./)U,#C(%FHCQ--$ETW8/<&0./3  IE 4_
M41;09"@+0ED0RH++R@)_58/3SOCH,@'^"=\-"DPVU_-..DY#86TKH]ATT\&(
MOW(X(]GZFW V%8J-4&RX8H,*Q48H-D*Q<5FQD17,<4'5%\>W(-"3"?SHD.>'
M/-_E^73(\T.>'_+\\_/\NFX!T]+]_'H_]_6+0@ _^X.9C2%KOU76SNQ0RC\X
M@_5G%I]<[V[WD!ZE?-,'4[XWZ><_,_?[72"G47^_];UMVE28WKWYQV'CUK_2
MNM4;'IHMX!:D_HY%3C^_=56;JU<?K'A#X\['^D+S&A@?V(GI/4!S.#BJ@[/T
MGULS]BXA,'^OBS)"G'^U '.HHW$#*.D+C4 @5-G$J6+ *V=Q1NSA/IJ^(LRM
MZDO!/]MN=V[%>NY>6.'XLRH<F;#"$805C@>Q]<,5CG22DEB)3/(420L\*T@L
M/Q@.!CPGBK1$#5+L0#AQE?UGZACS#Z5RINPU.*OG\@]'+0[[<.57*A%CF;=K
MO\9;M[4-7M^1T:O^?=70XV(D]9:#X!]K_+U7;153D+$X<[ZWL0R4*+=ZN&2,
MOMFS452,NEFL/#O@V/,"[DT_Z[$/Q]'G>QOWD:O<^"S/PIXO7UWFFF>^ K-S
MDN99SN\5#Q[]=.\*J!/8+2<[3%!!!;4SI-?^?[^2OXYT4H:+,:F]FM 8M *N
MJ"JTO.,*:'NN@)-1,N+5K]^9A3J_305CTT(A2$AT3 ER%7?P)NX4D#]I&T].
M(O>NF\+J-DJW.*E@O I4.K7XO&XL<?4G(@=,T9"G3B?F$&5.A#*.\77=&(,\
M\2&*G Q%7.?#E>,(ZGM91Y'%$$]"5G(YX_U:U-V3<I/$M:,)Y"9P/\X=Y:#!
M&)J(%S,1KP%=2L  J,WR:Q;B^^F'KOEWT9R[0\>&!L=G^X>YHC+8F93?2)O<
MLL0N?4K!>V;4!&(4PM(01.NWFP?SK_]%_V]FZ]:_[[[.6?;O+S?:/K:LJ?G[
MGW\6BT4,OB$VTN?_I UQC(:Y_@.DD6#\(PF6\ _%QN-,(OX/I%2*(ME$/$53
M%)V@X4?6A*88DDQ0$L6#)1.E8F/K8%.H3][(^_'^L6Q(1'KB5(,X0Q=P8IJ$
MYS+(0PA<"S@MICS7H#MK-:N/-!S?)]"H;F$*;(@)9@0MC/E;3(6T\;J>&#A>
MQD6K(;S>L/\"!S#(2Z(LR7&)$&Q71&9?4QG8FX>79Q@%#F 4"<7W/TY=Y&?A
MANV7FX.;7R^_$&:^9XZ<H\0L$+D83(S^&ON_<AR\>-[$-=H6]+ELBX-616:E
M"@OS$_9#B-COY08&VS"X)4B\FX)Z#2K_+0$D$*3Q->G[9M;H]4'BW23?JU#3
MKQPBNSKYSU' @V=]L&%4((P*?%)SC\<Y)DG2- DU^"3]CSBREE'$S"B:H99@
MR4IGBPOX$L^\8:C.7 G#/V36G8,NPU=N39W8C$>%*_ S*-I[C.\[^:4X%K01
M(-(BKC&F4@S[;<W_XHCU,SV:J @\!%@8.;@5L 65SKZF5H21@\M9A_\P)+)(
MOF CAH&#F[=;+LY-V-")% 8.M@,'-$6G4B2+ @<TPS 4)=$\-#ZB[+F,#]Q5
MR)UJIUFV <)P0-!\GITH$T(B&.$ 2*)1.L&E4F$,.!BT\36A&L8#3N&5H/^A
MF6]HWU<.D3 >$!RC@B*_FJ1S>R9@&!#X9"H/F6)H-H%3>2CXMY24A!HY19XO
ME^>-.H&R-D<]S3?#AMKHJR:1'AD ][<-7?K7Z6KL1,,(YE5Y]+$E$$^F4JD0
M;E=$9U_4#$*?_N5"9\E_J%18#1 Z]0/IU$<-K$-74.C5_Z -P9S-K2\;IN78
M$'@ AZ43%S4K;@G; ^'X_++!<$N0"%!0X!NFP"U!)!"T\46A'$8% JB^7SE$
MPJA <*P2R!:^F(%S>S9D&!4XDD9_MD2=QG HBX"H <$$&\6<& !K@:;IM2M$
M?F8[N?ZU)E;OWRKZC1#.R-**K:X(/(Z:2H:Q@^OT:8:Q@S!V<$MP"RJ=?5%_
M"&,'5VM\W![<PMA!H&('\=!C%,8./FAIQ"\8.SAL?(11@:!Y/L.H0!@5""!$
M D$;7Q2W850@@(KYE4,DC H$Q]Z ;"'LRA!&!8ZKJR?.I:N_%@Z@XR3Y#YTD
M2:(/3$L< ]0OB$C/@68#HK'0X"^=9IZHU;)?"!4@KAV&"J[1A1F&"L)0P2W!
M+:AT]D6E(@P57*U%<GMP"T,%@0H5)$,W4A@J^*#YD;SHV &:))-.,M(*&1 0
MG>%9B*8J:&' (&A.T3!@$ 8, @B10-#&%X5N&# (H'I^Y1 ) P;!L3H@6^!"
M9TP8,#BJQLZ=2V-_R]./JP!.I+E?'"M^IB,R=/B'#O];@EM0Z>R+2D'H\+]:
MB^+VX!8Z_ /E\ _=0*'#_Z/F0^JL#G^O*@"-&+N4/7%+:!X(;V<8"0@C 0&$
M2"!HXXO2.(P$!%!OOW*(A)& X)@CD"U09.BF"4,!1]7E(5;]-&7^XGCR,YV6
M87 @# [<$MR"2F=?U1/"Z,#56AFW![<P.A"HZ  5>NO"\,"N24'1-)U*^4P*
M*N7:%%1 \HMH*HP'7(?/$QH'_Z1#6(01@:!!)!#4\54)'(8$3@*,?T@V# F$
M(8'+VR"(+X2CA\.0P+'U][,-'_Z _CZ9JOH* *)CZ:)"-&UX.-2$*(P$7*^'
M\AO*_HU#+(P%7"?<@DII7U40PEC U9H7MP>W,!80K%A .((XC 5\.+WH?#.(
MX0^$/L2-@0Q91*V!').A!RT,HF@(FD74=0L-%D#]@](+ <TG7K<RA=P$&!])
M2PIC"M?B-0UK#,*(0@ A$@C:^*H<#R,* 4S_N7*(A!&%X%@RB"^$8XO#B,*1
MK8"SS2UVK0 /QB=_GVMC-*;88+@"*^/B^/LS';%A\4,8\+@EN 65SKZJOX0!
MCZNU?FX/;F' (U@!CW!N<ACP^+"I<[;!R4YF%#8KU@;&9GJ:!O[_]JZVIW%<
M"W]?:?^#-:.]FI%HR$M;VC*[$A38X0[#(&!U]WY"3N*VUH2DZZ2\W%]_;2>A
M+2\%TC2UTS/20&G:Q#[G^/@YS_&QL]/3S*V'8]H6QAPB7#FA,4;GU/,H#ULH
M9#148VTAHP$9#04UHL38*#I10T9#04RON48@HZ%.J"+\ ARY#!F-HC!_IVU;
MLS429H;S*SMT67V<OW8+VDRN$\HH(*M0+[VI.M**8@C(*JPS K$AJP!9!76S
M"G#$,F05'H4;/,AH-3NR)-NVVQPE^,TTVK K.W+AQV @%B^=$%%D_23>V)L,
M)W&"G#3DL"%#H!H+"AD"M3($[8YM%SR_LTX:46)L\$G7AH,5%,D06-:V@.AR
M$H$,P;JUL>D9@B)1X@;P,9 A6")#8%>V"^K#'DEY[;.H%NA'-R3$LTD#X/GU
M9!^!YP>>OUYZ4W6D%44"P/,#SZ^,WH#G5XKGMV&[).#YWQXT5+9?TGXD2I.C
M 3J@C'A)Q&+QQ\*E0Z?1-0VQO'I"$F[LXAO?F8'V&?\3?8]"BK?0V<@X," S
MH!K["2<LJ)8;@.H!=49'T8D:<@,*8GK--0*Y 75"%>$78#\DR V46R1L5[8?
MTJF$ZSC@ #Y.:#))".+H?8_+;[B5;U3$0;S<IRA?Y&-V>&>X^Q5+7B%CH"./
M";L-0;Z@3GI3=9P510>0+UAG; &[#6U4OF [P6Y ^&^?WOSQA?_([^0%!#.A
MXU'VN$:J[YXC'IO9L6G^5D$_[>8X0>;TO_ MS<RSR&;+G[_^,MO\J9X:7A1$
MK/?1E/]V9_HU2N&@+14W) V7$?RS@0?\T3T<W.+[./>P74-,(Q'S^14S;Y80
M!.).SFG]AF9>"X$\D>8UOFO,R"RSDT9 !DDO^UK^'I.-RM^,8DDX]Q@)L%BY
M(NX^=U^I&FZE/=LRVF(\\#^SCC4M8Z>U(F5-35!JQ9FJAL<<:6SP\?)'_SD4
M_SHNOQ0VF1+NW [")'X"M1=:Z[RHGY.@-/H'4Y%Z%682X'%,>OF+V2X+R692
M%??WTG;-ZW'& 61*G(Z4;MMH.E+\"<N?F]W/2J66C.:$-"^2F:$A'K5;.*^W
MG8R6>]2[Z-9RG_9JGDSGSKW&\^K<MU>S"CIWKG+%+>0\RU?<0L*[[,XMYJ?+
M?=IK]+%\VI2EK<0]5P,8W>>ZXD:!+U;+IM3@EVTW1XI5#LU*^O^OCU;;W%U!
M[]:QD&-EG5%551R="2SX^X>=#R7UU.D83C>']WF48QD<.:,X"JB/\M!!Y7%[
M''H1&T=,<M3N/3HG \)(Z)&5C609[[\HLX3AD.N)"92LGA&5.8-H(8.%MG-$
M ^+/V\E*YCV]1]CIY-HE;*43HQ:FM.KI4V\KR? 3.B"QQZ@\^ 1,9F4FDZ4^
MM+88<2@/F,C*3"3/:NIM(WR&1J>1 78"KF2=P;LN<'>EWJ2MNYEP;\+;D\KH
M@ >,$"*N+434P5R^$D9N:3)Z*4+4J-H,=I6#:K,W+T/=47H9:G?;[(AEJ!TH
M)E.M7 :VF8-2,@4UHL38*#H+0RF9@LL]-=<(E)*ILXI5^(6"6X'6;]$QE)*5
MA>$[2F-X#N %AK=-*"73L\0%2LF@E*Q.>E-UG!5%!U!*IFUL43^]U;V43+-D
M@ ,D'20#WAI(.)5M5UTHD+"W32?SM9 ,4(OPA&0 ) ,4U(@28Z/H+ S)  4!
MN^8:@62 .G&(\ L%-X:N7]@(R8"R,'QENT<7PO"\$^UR,/S:K6,S24I(!D R
MH$YZ4W6<%44'D S0-K:HG]X@&:!6,J#@-M::6R$D PH%$FIO4-W:MDQ(!BA)
M>$(R )(!"FI$B;%1=!:&9(""@%USC4 R0)TX1.Z$# 0-) .*8'C;LKM=LRDP
MO,UG?,OR;8'A&W95"%[L8,VB(.# _/"?"5<^^C$8\#N$PUSI\61IG>R('07>
MUJ* AB3?'USNCRVV#A=Z?,8O<+SZG;=R,JY 3N@"!_Q&>T-&R#7W GDT<T \
M(O9=0[:SA?A\9&^)W0UQZ"-\'85#E(P(8F1(8[&;!/]6G_^,&#JBR?^&A.'
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MC?1\'#S@+>[AFXCZF71VNH:33UT]4\@I:ZT;^??\URBY#O[X/U!+ P04
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MCICIC0X(0;5*F:?#G%-3?@IY3>/8:B*.3N2R4+=O0>L?U2JC^ +9T:&#-!C
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M)>XW[CDLK:>6;8]LQYELZ_EX&)=4E5D&/FA!CB4"]E@:&96EQQT60EH8&]_
MJ#,;OD83>%?=Z#XT(.CL\>"BD'!,4Y5>;\U<>MUIOM0?8O_0J6A&,[$"ABX^
MAQDT$41:OHN(V\G4O*@Y"&C>VXS6#>*Q3W=H'']955,]?'_T7H+3_GZ(QD:?
MJDE-QS00F_TF_=TN3S0.$@K6_V+O'SI0K-<#C!U1>J/LFXW?6,OLJ=0M\UQG
M%0G\4D5$1O!=:=.4D:N7(M,VR5Z07T+G=7!T\XZZ.EPT.6N3RE^QO(%RTO%
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MDJ!H,("9_P;03# 35=2O,Q#(53[$"MYSU($!W(*<]KSY(_GY&$"X_3QD" /
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M&$V)*7F&]CI+"01>KPED%V;=_+)$IHW 3 C3@TAG%!]Q"I-A]=L!5C-_QRD
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MB%E!FZ-S%ELW=EM)#N6X4#R7K& @@K+9)F]PR6&/#>\S=U)M^2Z48K]SX_@
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M]F4QY_71YY8>=8/)HUGTNL56W%L;!V_'Z%JVKR:V#)FEHMK>"9'!P4V3;8[
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M:9R]R#)G@%S4"W$2^#4_4E<6D2$D.0OF[8EZ8 M#6^A1M\0P_/&D25?BR8-
M#G-94^H:(N.Z%I=J]U2?XG7W:LMD",=QCCO.D*:?/'GR[,I0_ _JP\2$<R$]
M1!"L:2)[W]!X]I-$VO&4PY.WIA&PZO2P=;_";4]CW<\+XIG<F@;'TKTAA3HY
M81H1Q2H.OHR[!;R0R_#EMNN%2%OS: KA#$(T2>1KDF!AA9=D>(PNS&4$K2%-
MB>5&[68$.]HZ(I!2GP6-UG7 SD*]4W'-B[\>$3I#[_@#/(U 4E_N#BP.Y@Z6
ML*J(K(+5F2H0&8]\\MON'IV-EGIR>9%F/>?G2U<5B)]!OVQ]4U=+"<\\NVZ?
MS&/!P476[A 5^TJ>3HL.8*K342T\Z5G8AF,=R@&2'AD8=-O/O=J3;75[L! 9
M])I-)<B,>#_B(#;E['N5\RZJH="77S[H4, 3V$5+H!+819ZV/8T2[_7>SW_U
M:L<?WOVZL#4\27 X0QS80DZQ9F^%Z"Z4.6;N;H7S, B)/"*,:IP0Y5K&G8K?
MF0N,>'3-HV"417+/,IZ)9N8>)M+QR^];$\XVWD[5118D6_BM?WL6Q]E5N+Q<
M74.K)D)&WB??I/\TX(%JDOGK\/OOV<XE[!4F&6-(G. $;)D_X+8L+ -'-G9+
M=8/V_.QE4,'Q[;ORCT1/8F+<,R0BM#,F@)VGS,2T<GA D\G;4]?SWJ2L/;^V
M#[6RD"),$"]R=:(HIZ[\0SG_+9MJ'^.>2DXZ6M$;E2<-:SH<>Z/-'TFOX[;Q
M@-8,PPH6\H\F]0KE'Z&"C%41,*OWK_+G-DW'IQ1-DAP@:^)8X>RITPSW)"O^
MSQSD]=.,3C%7[HHS;0,<CMK$\SGZ#M<F+.,:)^22S125G\&],SD(G']J*-*O
M97#5EY(OX]#S'SW7'69KC"2E:HS<+\@S7']?^RR Q@38I6J4118C$P;9!Q)]
M.$(4S-3XV+FZCXN7O.+X^LL)G_YD'R9U7 !']@9_'3;?DZJ6+?IUEIM;44A8
MJVAE)U8>RPY*NJ_PE,?YX/!GMQ\[2#*'5-OOI4U%H'J&  GJS;6#;/!VV2*[
M#V6X(D@TN]..=_9EF2=A5?D=X6KJVWOGM6:,8D!^54)^QVNCE6&Z'0]S\_G2
M:9,7<:+(ZEWHCQWB7TG50X.Z[;PAZ?D;RJS-[=;;A6P[JH )]^UM\1Y5B&2+
MBR?M?-UR$X9&A:TIXU[(#7L^/MX8CLC:QPH%')5C(I)1A;6K^6LI)_FNG>*'
M!Z\YB@3UZ+!9=OWY$;D"* >!".?P+(MY4F*50:O!8B%[Z5%P96\ZA+3(ABJ9
M3C*&A$5*]B6$ PVM[:&KS-GAK+'GI:Q#F63.'>,!%"#-/(A5TYE.Q/R0O=P7
M+5_98SJZ]FM.]'QWW!&?E&(J304.3%>I$V=I0"[SQ623.D.^RH3[AM8G.MV.
M4FFW/[Q27&YX:,$4I\") 9MRKW$[DJUI:^].3JY5.#TEL7SP-6J:VNSY\*LK
M[\B=Q(I@%%C)?E]U>(.%LQ65]IX0E$> =3N2T>G#WHD@$<% L3;<1VQM7SB*
M+U10-05E1'OJ+_\>8BPYC(3<[U_:T_>LGX:7)6\798;PQO'8"WTKE-^OQGZ,
M[>3S$H;A <2.+2DG0<*G.7O"Y0+@;(7]6#X8JVX[>WBLUS,:04+)\'A1-OJY
MT2$18[K^P[&M@4&E[TAE#YM[NO:QU^QF/?,( GQB1[)"&R68D3E;1?K2,&KD
M!FUU,*_937$IY7>/VC92('<(CV58$T7"!\=+TNO]>'R'Y\$?C 7ZCU+Y228@
MZJH36EOU"=1%^V-RJ+PO7M\5BEZ<AR=:"+Q#/]B(@ZPCV?-Z]7NCFU)>Z7]=
MM\G5R_U:>H-P8O++9SF)^U@KQPIG?>%>[:]Y@TIM-/=KN<L7J6I.OWT-YR;X
M\(_W"(6L7W&^HVG,L<<X+UM7F\10#Z-ZG? R?D*IQ<Q)G <NP^T?4M=3N[&P
M-!IO+3@V]I2C97F1YT;L&>4!A0^)!Z)7K/-*,"+ ;;UUW\# 9:R36RO'Z(&D
MX9Z/CZ2BZVZ^ \V,>FVKO#'V?%1Y]WS>#Q6F3ZJ]S1[U(ZW!AC%NP&7D>0;1
M.=M>,00<&*^8XS7*$!2[_L-2Y./%"Y-->]R]=>\S[='&!TAF*A,;AH125.+,
MV[T$R=C^TXZ,1?$31,N^;Z)3FT:4=.I2XDR]U:B9RXV>H/IB7FU<AGSNV@BW
MV=76=USOWWTQO6*HC5R8I9KRA+\:Q$K";3RT)UZI"_<>!^VWL'^72!JGU^(^
M<=_W2=DY"S^ 8IZ"-))F[H5/ZG\K'3Q*;:M,7)"T8:^)O%5@_ZR[5'68P)V,
M7 RQIE^>\RQ!0M=ULT;_7!KG+BUY?4W))<&]8C#E>-K$WKT*;K\'>9'T<@"1
MJSQV#QU WQ4PH,B*HF#.XXA]JM5I[K85_[Y;9'2A N;L4OREO#Y!Z!P/V,2T
M%*<-*DH6O8;=HHR$.X$6EXED'O4^+O0E]NG6GGKJ9BE4J+>Y7*'\(2=NX4:F
MP,J-R:Z)@D9!#_LI9:95\7PD-$B_/L<ZIB('WH.&U*<HE-CG/.I<;:\S=U6D
M=8W=SV(O(3<SS!@5U#'\"&Z#^UW&:-I2PO(/W6VS1D=5ZY!0*W_TXWH3NE^K
M3<#=F-1AH[LO+$5YBAYEE>C07[O]E*Y'CON>/S?&=XI=3OEG@X4B1URK113S
MZIUDNI+;HG:+ >1*)3 R0U^Q_EJND]L@]T)[YL[/4>-QHMHQ5S*(30\FA6-]
M=E_S85][Y3]>VQ\W-N)="EGHSZ[6OI7UIM0O5;7O[:O8^&CU0>U<B?YC)P/N
MLPW_&E[I@[A(GJJJ@C)OT7^CAD''#BOND<L'ZME+6%6CW/B^+D 4-::3=5P>
M?"H9>!9QU&**!S2N#MP?N1="R:7+6S8-=G:&\)BW_8AHO86=']N+JBN$ :\Z
M\KEI>G@5Z"NR?DR@57:\5Y7415K^L_L>D<.F/8"$;)I;PR2X>B:+/6GTK"5L
MF$W9 KG/,VX*?HAZ'5/*+D"02;=EN%UAQE]J[ULQB^[L[73)5^O(Q /X&0>[
M(<C1FDD3?JDHA"(F[*OM,IMR&&])BC/D6+F2Y6%0D/E#.7IZIM4<[>@%:9C/
M0@TI38MY[?FSCEXW)@>SZ-<-]*WB("NQA:I3:3J(F>9'/94W+4>H2IM<+Y[)
M=L.V4I$'OLM7Q-@/,B#@!B"Y Y8SKP&$&CD)KS"QB@WB8$ZK<G_=\TAQ+?Q7
M\$N['+H.&IWAM8H,1YWB<Z;!K*1&P31.#WN:FHV+X:\#TSW;X0\0IKLO>66T
M*RKWC M-$Y6INVL?U28](>F@8R)H]6R#ZD\7,4N?-9K0K(_TC9]Z!ZDU#D[-
M^>\I2,IY[_6N_ME#1;\WW.9447.&5Z%NT$'<F$[W).,Y?!_1+\/B^V 7WMSZ
MW9%B[68^,G'/05^/36"G==/N]:CMT6&))HY>9][QXE8I'C!GT8L',"'BVI:.
MG#W#M"/B5*?/6>YS7I$X,AR4;SS_W5Z6&=05IW4BCQ5$-,Z>49OA 3\Z83CQ
M?WXV]CBK,SD=7<3)<QYK@5?^7&7YO]=]>I&@>1J[6]^*6\/FC<U.RR3X]>,!
M)(6[*%RP+AZP*[B*!T2I_S$'A]#!N6'P@!BHQ2N<N2]_*;H:RB4B>@)>-G&%
M-G']_AB=J2V#):G" Q8__3&C<!@/2/>760*.:\DD XDW';=A'9&1%X.G.M/
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MKM-/Y!H5W1Z8473EA#4812*? +W PJ*ML^'5.^^$@676:^:G?8Y'U.>O9/$
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MGK@&]G-0KJSEVVQ3B[8G8/W\1?[;8QLLU+O""47%'#U)N2KV[CFW@F)+5F(
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M R;+UF\_O;X)M/F;,!^?!&D?,GYT,=9] &^Z4OKIWDFR3GF\_F#IIH\F&J+
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MJ2JL9_%QSHJCFT?KH!59TV>]IV>^,,IC]>V_2)&(ZH<\A+OQ*7>QEE[A0R:
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MPIACAC\K"*(7LHWR'*Q$DU&D+V6'FY^@\,/!W!SWY9O:(,EZ;:DX66:V'7A
M^3N[X\_S9WM_]4$A>[!:EM[TG6KRMA4-5-?VK'V5R:&HBW(+!&/^X2@F:%&\
M,K(I^M/W>#0O\K<OC;Z)06#A?OP837*&U87CYWD)5J4:WJ66[^>&%L%SVU_#
M/GS_!I1LMR(T<W+PN'W7%2X=HW_J#]&^6(N*7S'0^V$2/)@7]HS&^1/C'A$G
M-ZO2E6YTJZMF<WK@78ALNB/)HHZ!K> _1,BJ>^^)<0D\";T35,3E'S0A0RQ
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M^<JU4KSL'54C*?F?D,@O1Y>U@P%CS..JPUL3#_RPD@%5>&JO=MZNM=&$H/5
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M'RQ#Y351X:),<HL8+2=MTRM*Z<8Z"VQR032"V=P;;O5;5_!IE='R*13X7-F
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M@,:IGT-J_*M*GF.B_)LR7>BZ0VZ&3C7>ITZT&?ZH_K ($%1P&W&@ *1.\[J
M>UXI 5\X19^U(@4I-%=%L+342,IIY[/.K8:9O[-E Z*\NOK=W6$&/@(S?(DW
M)PIB3$1I:3W2_49\E;'Y)P!M>>^O7M.M<4C2/F/11XAMO'Q)JJ]D]!]/%/M/
MN5I1XTA?L)3#NU75>,SWXMA0](7X_BM"0<+=4OZ?@],3W*Z#.YMME%L<'A:T
MD,/YN"#GRM_?IN6BE2;?8]./ZJ/8X!8;8*@/8=)3V8"$HR.?TB:A#ZACK3_&
M<QE/6JR8P7UL0 :4=G('NIX#FPDCX\4@PZY2S'R4*0:9:HDG5^,E9)L:\@(3
MSA[C@O%:#.RV8_/A:SKEY)-9'0[GXFLE80BWKD&=03-GU4ZAM/G2+T>]!-(0
MK/C_@"#_#T$OA>-SMR^L&>VNL &U,BV)V"PCS^$#F9U<^C8;0(B'<G>S =O*
M'S: @_0M<38@N>@J<!DY)V8+'>K9_+;_#+T<0B$SHS"M.UY3A%HJY+\M'.9&
MYVXU)%*U>AFYK]B >56ZT>#15,7T8*S^7S-]_]?L7Z6N>45Y:;S+;LWAG!G(
M2-^IH"EO5Z'RZUK&5,'',NDO N?>@E?WZWO'L@JE52X@B&Y]1D?>T#KRADPK
M\R#NR!N0%,8#*BN7RGVWJAF?W_B'J@:C6/)F:=>62GPY\MLG(U))VY\(K)$#
MY3O\1$%7<UTP;VI(VG<,'>AU,+\^"9=-]]DZ@U2)B35X<M;13C]"\"9#,-9_
M9D6J6< -9F.S;NE\)7A_*W%JFU_3P;;<E7<='C!?RH*FGBF(!?\\OQ5OQ._E
M[]$"&D.<G)B7M6HH0;SB_.S0*:1C?DF^=D>+H=OS@@T@=T+8@%9M-+7_(.>3
MVQ*T7397/%BFN%)FRD+EK(1%RF(H&A%&IX=,$?TFC?3>V2YN%V6F-N%P]S07
M;J#J0J,&2HT?/#TQEA [C ;AJHD&PE0U?,_@9HEG2)9CK]\41+L[^=A:TG+J
M#O<\CHXI\9S$6;]V?.-()1!O7"RRU9RP=833M4[R[JQV7TK_>:OLYL!R$S#V
M@8H9XFZ^O-..]1RCXZC)=O[UD[A_E@F>T]Y2WMI0-PN'1=[E?(S4GGN_=)01
M_&=#=X&_1B[8_N8T*,<?)OT[5=LNCE719'2^[%0L)K*T['9:42NV@1;=U2(]
MCE(NLR[Q\I/25%J6+]V8>;W/S0:4!Q]W]+8UV"[W5[)4.JVFT*<RPGMHWFUX
M<HSA^ZX/]KY-*@G5.!Z^K;1>0@^X,(RZ1+M2C.3*6%MFC4[(*FUJ9MYP&Y7,
M"LUB.=#JE)[Y&]VS7[4.E<2>G],<0H1EC.Y6T5_(:^7O0O2KF.NK=>%!JZW
M.\FT.Q3% '+=I,&-.(U>61)^^J';U3AZ\MHT$TQT,%%UX+#G!^@?=?A=1K5:
MQXJ8.+^Z-ZX%L^]+OY<X1#WX0TF[;!/>SWQ[HTGAR&!3!B/_0&S6_XC5&D![
M 6,)N6ULP#/7\]3)>!_/X ^K;QZ0>+0F,KC=SFB>!H/=^$.$H3IWP^=9('W8
MY_2:H5MMX8;U%&S4\$MO1!@GN,SI14>_,*:D+N-1<KN +,J;<[/]LA_W9*ML
MBY@3PY_F0#+B] JJUT<DU#_66,'5\#Y\Q>W8OW4<IJ8?2RUC Z;#@>) R3GD
M, D:PW KA[-DWG;$O5\P]>1S=K;4&5*(5XP1_Q.G.'#L%= %L'$T-A"([?.B
MU.,XUP\^9<PW'7"KJW==ZZH\=><N;BV;+E_73>_5(*LH"#5RO 3QUA:'XW'<
M+QE0]!)3]@95?#EP7[*.#QNO=OW=A972Q@S12VOQ4;X*BB#5![.0JZ2CW9 M
MJ8^J,.3/A/G<I7BT'7[7QZTS<$!P!JNI8? I.MB$&NVA".,Q<^88!LEA^5B#
MHS2CKBD]&6B"@2E\R?,">-/%B-=41_GUTSFED_9I'#D*/T!EHB+Y1(/%V]PG
M*;?VMBG81!87&]#QM (T.KL6&(@F?EQ[8\?'HU7!RU4;ZRS+U9ZLQSE]K:V:
MPW6)$DVJRZ2FMH_0XJPJQP,V/$_W+*_?+C5<Y%!V=DXQ)?\HU,DZ+1I+]>5B
MM;?(TOP7AV"=AA)4PP^%GB&3,?"B]< -F*>!9+7)H.&,NDX7M2;%;/ZWR,=3
M !&^IZ[9%+X]]$@K;$@4BJ]1N2-?6]J"]3\MD40P%L.<]O_^AU2:G2Z?"(7[
MMYP=CG7=?UJP^*M0V$-C).0H.QS:T8ZU^WP=ED:>-WG;@:LHN41):-+\$V\M
M_KE4,:F$G[.?:1Y>^PW*;P1OE:(]-1]#B4IG=D^U$G,4\#4+XNL201EQ7HXR
MZ-25_H&'HGU*DHU"Z1>3#Z,?*>.8J5\%HUC\M$BT9Q@)RN\9LK)9=.NXI.3D
M!_5DLV5)TP<Z8FEVYBC>H8D63M25289>$3+\1SO.>+0&Q0; G#N]%:VNA5/B
M'O$>FQ401(UP#X5$;^)),PPM$B9PH#WC<4*.""4L\24B[$H7Y)8O0F-H]+7Z
M.8[V>%3A6[>LM-N-W@E1K!E7A5R286'A#,W0:DC%:DIW4^:[R]K^E.BEQOI8
M2+:*13PN^-%#YFQ"N8/S\\.\[PQ?9ARF!;S0F^%874"#F:(%L-%*E8;B-8UO
MNH45'^S5 XJ2LTL\S#0CU=N#A,PQLRAN6F@0J<Q(9'A)3L?GR?# N?D^ ;+C
M*Z[X+TC8[3QPDI, 1YY@CH'LH3<2ZSR..HDH14(L(TW^?;!0MW?YK7]?FPUX
M>-U?DV6V,!^L&/@UP<;FFI1^[B:3M*FRR,)^U:.H/[7(D$@OGP'5N;S(QGV:
M^'YQTQ=4?:/L%XG[ ^K*:?WUUR[3)P>65"("%KYC/]+NF->S^C+629T#'^/#
M!Y1[?_>C4K?3CS4\,=S[FE,;61(^!.2M*=-P^4)LD^$E>)6)N%[;@X.>%#U1
M3S:O_<BI5(K+ZRCC?W8*@-3K221J=0,!WE@H9)2A5[H><C'5MW2=;I:$2QNL
MC,'*@!S3[V]KC'=Q"((COO"<C"A:&:8F]NC)["<H3NT&P_ [PW&XH.B:KK''
MKOT6/AG@(.TK"LQEIR013$I7BXUV8G&S#T5P:;@KV[,6+48[;SZURUTOD6*-
M]OIX4 66L/=#^A6E-#TGIKYRGTBC@1=-IVJMX2QA:^U::YOM4V;;2XO\CW#1
M3/ME^>-Q,VW#QW*X *BU]^%$PS/X&FO!;JTES%F&)$GNJ=V(+M$6H3!!>C-_
M>=!N6%C6P1F3.W@[R$S:< _YW? $:RQ'G9;X%<KA::A(V4LM(M!:VQ8HZ7?#
M(KY9%M5S;":9K3SC1C8LM'$A[S1$].!3]T)I<&"<)N-7 ^&"[)"UDF"LRZA5
M]:_EU76"'$4"[=, )^"?.>""L18@$F;R:0RKN\EM4X4;"Q@MG+;V]7ZY5^=\
M?0_9"U1'-R4NGT;%K5V3^\M[K7_I7_H'"\B>^3=02P,$%     @  3YW5I:W
MIE2^/@$ S5@! !@   !C9W1X+3(P,C(Q,C,Q>#$P:S P,RYJ<&?LNW=4E$W0
M)SKDG'/.0:+D*"A*$A%!<AH5"0/"B*0!!H:<,P(* I)!,LR0<T8$),N0!P3)
M,\1!TN7]SM[==\_9;\_>O7_<>^ZY]3SU5_?35;^N>KJJ^G3?_KI=!5 _U=+5
M N#@ @ X=P_@=@'P&("'B_O/>T?X=R\!,0$!/CX!*1$1(3$Y*3DY&2D9&04E
M+34%)0TE&1DU(S4-'3T# P,Y%1,S(STS+3T#_3^#X.#=?8-/0$) 0$)/049!
M_W^9;KL -,0XY7C*>#B\ %P:'#P:G-L^ ->=G@0X_T& _T(XN'<Z$A(1DY"2
MW75 4 -P<?#P</'Q_M'ZKC7@KAV 3T- RR/UB)#.\#41KSN]='!R'C&?1FTW
M@]$$FE_FS8<0$E)&)F865@%!(>%[(K)R\@J*2LJ/GVAJ:>OH/GUI;&)J9FYA
M:??6WL'1">3LX>GE[0/Q]0L-"X^(C(J.24G]F):>\>ES9GY!85%Q26G9M[IZ
M.**AL:FYI:>WKW]@<&CX^^34],SLW*]YY!IJ?>/WYM:?[1W,T?')Z=DY]N+O
M/[AP '@X_R?]#W'1W.'"Q<?'PR?Z!Q<.KL\_'6CP"7BD"&D?&1*]=J?CE0XF
MIM=(SJOM)N&3,4(SO/DP0<K(+[LF@/D'VG\@^U\#%O*_A>R_ OMON)  <CR<
M.^/AT0#4 =<O\V.$ ?]?XM(#$G-^[M5P1;YM(V,S=<R^Y&7DQ0NBK%O .^ M
M8'Q_\/H:C"FX?',+N(&YJ1_NPN*-\Q%BC=>UL%N >B/7^6GG0.)^["W@XKKI
M%M!9>2-G% /X_UO_W]]Z2O%@?D_\<[2#5!G_J1!NS95%^=)VR@(9"%JST]_Q
MPF-JVG3YS@FX=X%_-W*'S*36JT_/<@\:CQDR%S\ZW )Z3+[!QN=N'AN@"VYH
M*U_>!'8>L<+"WTY86I#/W@+"RHUO ;G55Q&Y:]I7 I8E5]>P#=E; .EP?BRW
M7.>:R(SZUNXM@*<$:W@+(#$MN],2>$&AWE/GE#]$ <8^11C<_7> (= -/>R_
MR:G(%*[#L_J7,"YTFG/N\>DM(&GJ2E0P1BSH_Q?\?T,P0^.:C<.Q4=MG"8=C
M!KM%PI]*0R<,@V:ZJ^ +8FO8G.3./;FO,D5S$F_K)ZL$PQMT@JA_$;$G6JZK
M_TN$F0T*?(&S= MH4?]4K5(8%O^?(Q.IB'"!_6=.I)G$NO(OJ,+_'4H+6<.W
MA(W_AOIO%4SUZ2UP*O\[J(G_1CD"*>CS5J-"SU96.Z?(*KNE@>1.IZ/"O_?3
M,GV@_Z!CHDH*I,"&C/3G<$R>CLIK93R?WG_3WI#\L<RI\.$?'=6X"'96L: =
M]?]T7IOU#?K2D::( M"';G_^O^4C[-+=+OQ) W9Q0\_JA$6I>70(AA;?$^KV
M.T_\3U%H>GEPI%7,T6;7/HG0YG8$D&>*!2W\Y]8^'B>&/I^ >H#7+K/9@=;S
MNYG L_[L^;JT5_?M 50\-J5;/XQHHM[@4=\O;D'^/^6PS<78R'S)/D_TO288
M5F=%U]75]:IX_LSDDX95H/R6/TZCTJ%F$L?*?SXI;[#J \H&B;)RL[)Z>?XE
M<OW]=3_H2QU#?$(>XFSAZGQQ[)"Y&R#R/Q_ HV4P$>Y*-I##CJ[<.,B<B^)M
MS>QAB/[\ULH^OE@@J&?U:;;?5L)'"YS%_XEOLJ7;"DX7MX4H-'^7C2GT=1D2
MVK;Y[1N8?2>##/AWI_.'6:FQSC/A_)AD DV/6P#GY"V@"9:F9VA]"QB$=QYP
M_7[(::%);UH43F_XD. ?5O [G&\"#WAO??&;*C^N'^!B5Y62'+!Q63?"KNB$
MFJ(;8RJOE.S6MA'"DZA=#5+Q:N*@^Q*LOLMK%@/&&KI#)EU\)_*;1V2R5.ZJ
M[WG6/1/H Q$B-5[DA=(YCS@HH+T8L'YL'PSN;,-%*-G7,'G%+#AU]8 ?K<VF
M>IZO)/CR?0]WCU1<CGN2<LP>S*[\SZ$:B47^Y_WBQFG)UUE:3?$%KC3]O;E[
M:#;\"D#4](G(UR B>IS]Z8$T.N\M$Z3T!S\JRXM-@[OH0G]E_QJ5R 3A>X8>
M1MN&^OJX$"24L^^7NFA,?'9TLK<P4E1HT:4EH:F92%<R(O =[*.*FE7.*<+$
M#C):NJ8C2FR@]R;E=#RO+053EE$*Z1<]3X/*1!YU T(?<CD9VE*NT-P(8,<'
M.@0G.[B06*.5I^B\!GAK(C!A8S3 2Z#%FAD%^2(FS)<B1SDB)/9\48**!3UU
MEH$-QN3JHBF3U\H-*$#+]V>NY*&&%38[Z7-4K\%N;IE(V1#^CRHJTCK/MP$O
M"@[=NB2(9CS-1J(OGT-0!N3FEA1D3X L_>OKJ^+:G_5#O[O^B/6B7N2P8T.]
MJ3!?LWDT;,I@,$"5"'3"9I1$W7!<EW>Q"7:TRV<LV_Q]D&)3X:ZYM2EO\H:L
MOH8_\:,=?Q.7Z010W#IP!CD8+T<A.-*#3 R%,FUBP<\P!$MS"8+)O6Q_,G4J
M5Q.4^);@$K8:B^_EL^>9Q-6=P%S8D5X@53YZ+&/M$DB#332<AK?&5CYRR#6(
MKCC?W+R?D#"A^UM^XLL-AO(YI5[PR2C#[^,K#_1H>-I-V+(\NK@$0V90UP0Z
M\1>=II6;O@]/$6XXMGQ!.""@RR^LI.K0YCUUEH9-+;J20JM'09]"28IW8-2T
M(Y>D8HO:KB4%"[+'B\NJ*?%_Z+6>.)D$)PEN#:!P3D-;!HJR0TIWS%=)O:#W
M+C6OP--MP$OUJ]=HV_: M24?(\3/_5,K&Y<>M=<U.7C^[*YLD;[D'CR_O ]5
M0D.D8LZXXF#LJO9K5.P[?[6RJZZ4T>'A\9G6%KF,2XC^S:JG;JG#(6Q1R_<_
M+1R+,HH1K\OBG#SW+:I.DC6(R9'&= YTAG-*-[9,G,"H=H"4@G->5F2E!X)'
M:PKRB5Z_]]^K=K%*L3$HXCZ+6)12R[JTA82L:]9@1L=*5J76R)II[=9<_#\+
MS*W5^Y#6,5D\E0TVR)P@KB,:/@^6M::JG ^YY\!C3)[B1XI#CD/$?41<G7*C
M>/4$&XMA6Z,::%VA6, Z4.%L,[+.1JM:QEAS:!T.A>@<%,=H!B3O@^^+R+HV
M]9\'O3?[HQ[*=:3=1G8+>,5&=2WT%+!7FA]#2&^H"?B'_0+_A]G5U';G$27B
M%E"E>Q7NP:E\"P"";G9A4H8<P]J2F@P8@[Y.)@B5_G6EJB\((VDXEZ$5^7B*
M?VK_I+=LF-V(2V;T3</#_2&R$9PO[LL5!?O.HJB5L%SZBD!F4">CFH"3.S8&
M&/S3RI*#]4$@"J4+1O ^>>:J]O-9&7X\O["M08:[$#<?P<F2T%DTQ@\RJ(FN
M:EY+I.RNA*1,[I_(3;8]/AN*7Z21'268(@Z.8I[.E7H<%Z*$BHWZRQB#73E[
MBTU&B9NM,77O5K-8<!@=FV,<\L".956U2FF)?Z&)8M\9'J\EK]/4VB\@FKAQ
M9@<OC;$#'+1<S"L0W.\+:R=^"TYS+4$S7Y;[".8;+C6L+A0AYZZJ:CIC!$QX
MVRVB71T"4"BF,<Q+DG&X!")SAQM]XM\QA0)3"V:I%2$46A<$!UYR4L[XV!.$
MXL6QZZ$'!Q+7U9&2P,[&G T0TS+ASU,V?]VW*G;2XWZZ"S^E<![Q54UL/^3$
M:/IJ]U'%VO+68J-=5PWP(&Y3?9P\K'8N3/7.&:..CB[@35^=B"<)6M*M&^$B
MA-,>J7%FR5 )[.]*K/;:Q_OZ)=K^ZT!J[)0MO'X*D?UR).2GIH]J"HD;X -O
M_,.')CJ+$\%!/4%J\/P.W]RSVKNX:_<0\RY0^&=E:G\FK<4P85:>LUX N$Q\
M\1;@V.!DCRRDDMU[/\3B78L303(S%:B,K>X-O-\VH<:#U>K5"%GH-<L14(Y(
M+$-LZ'.TI?]!QV.TCS<=#A.8+A<!_O$,Q[GAG<X<WMM70N60Q%X_P=0U(-VB
ME97%L&,U6;S6Q$'4Y?WF!BF)23W>^UIO$M;Y<#Z]VH4A&A/@,")(Y*#VVNPG
M*,77W=0_YV:25<G^B@FW@+T(\]?4:0-/T0<E(K> 7L2G)BX30ULJU"&2R9:+
MMLUPC8L( M.<MD>W>:\@S3BY9^>>'SOD"'SF;63C@AW\HAV%$RJ>5[!1(4>L
ML>&5$(5G6-?570-J/90DY7@EO"6G>-;=7)5) PDIXA428]2?.'C8G05B>=QV
M9W1GT2WUZ%L O"1.C5,;M>1@0 "BAMCUIJ:Y5T""Q4Y%L2\2I5T@\M)I?&KF
MC@189OQ@:[/$#E%L=Z H5*^I<[+R4)7$$=WAZL#&+%>VFF)E=]9@H374'>,+
MK65C>)>?7U>KBKL:$*H).0\+E'_L6@ET\AOXTJ*5_7K-2IW6PN:ZK%@&*?OV
M60D$O^WY5W;&(<@P=X-H\I0ZZ!9 B\UXCA[-25US9:2BWU&6#>3N:)CUZ@4Y
MVH%D:A"/A3Z.30T%J8T&"9L1U!$^5$O,;P*&KM"EHC(BW,#\B)A>DRFPPY2<
MJ*($/J;?@X:MK1G MO[*9"+*R&0Z2=DL\NH==FT]D?Z*!]M8"E'I>6&P>BUJ
M, ,OGH,UJ(U")S7QH^5FX/[R<'<EU8N8K>$D83'Z^T0SQF8_YF!LE8%LMI!(
MPUS-YFE)>"*^D]GD$H>&46I OF_>"\R70ITXLN'[! V,0CR RGV5LZ0967#D
MLA F(];S <O5@\+MQ\9W&4=Z*V>9B\=/8A)DBF@]#2*$GH^_AH_>FLH_OXVN
M9P4N%!T9?R6:#^GM5>;,H(I&FHME/9F;,\Q!KO'ZMI6'$7^380<?%R@?,(\1
M"]&]O"Z#FJV!]Y: ?<ODD[(&%,N[4ML18T!JGMG5!(NVTB)__2R]M^6R+CSV
MSU)_KOZ'V<4ES[(Q7#$W/) ,#?1*^(GH+HQJ=TNSM:850^_=TA9517-@U^!)
M:J<D]CD)3.H^AC.%D=PG03EB.F,\8200QR<S8E<RLMZ-U16[VR6+-M;,*0X)
M\Z32#;2:.(6>;$<D %K @YV8B_3+L[[4/M:5,-EQ@FU+L7&4)(5DU/X61JW.
M<^CW$M_@F7GBQP%=DP+7)0 S'V][O<;<E5F%!43K"$:)!"6O]$SNFA[OB/(C
M_7V?Y/?9F>H>"])G?Y?_$N+W0J:J*K5KY8CZKMZN DZ;*=@(!7=N\+C? JP[
M2PO/Z)2IZ&!#E(?7$U?]ODM^0M&=&T0^-W]NWK0=?/3&9UA=8=WJP @-5H?;
M$F893<,[*7:\6ZJ*(+(C\^+\;>GSKXX*I+4>AP/EHE\\=.U](+KLDH2-1V?U
M=#**O=MO,RBZ;MTS8JF4X,G1<XEUY".?T*<3B])9W7^=W/V-Y7BNJYK&)9!D
M]D9NN&01DHB*:W&,R9\05U5NR=1W+T%JNK$(4'F)Q,GH# TJV5%^6$R&H6RV
MXJ[\43941K&]?NW];<K/2@S1%(FQ+Y_.PH_."6@/J9_:?5'F<Z7@#4Y@YNAI
M7^B"D:CRH =<-<!D?TR1LBTQ/8V)A/MSG$9I6A]T%[MD[!/Y4W0%RZ\>8:76
MN&*8Y#-LN:?LT_].D+]?GK<==WQ?F\(\N-GUYS<)Z5.Z$&-:17KBBT%-;('+
M:CO3FGH_<9L)RE>5R#ECF0'SS%;\$V*F/-TQQNJC"<GF8UE!.FZ"7[JL\?T)
M[R"!O7V=-/#$L R_P2C$$J_D7:*1TQG@Z%*F1Q]K+]"JZ^)4I[7NG$],:>;V
M?M!);&8[E[F#>!%;L'86C^[L6>;X*7;#9?,L>:?'-^>>V'ZZ9UHX_&F83.<A
M(6H7GKTBY[=QPSCI)BD;6U(3IE_HQDA ..'&(D_]]3WALM2V#E6LW H-)+2+
M4WJZC<<5E>WFBO<(6[WV*;^I<]H^W6GOD-O"H3'=VW6<\&Q@CO_5ZF:[Y%D4
MMJ0"*SK(J0"CW'G^-ST1C3PVTB-(SN;]LL2=8$>M[N_T3EXFR-^AO=P&J[*Z
M0KL R:<P>-C0%MMWB-_2,F1U?6^5F,<NM-M _+X9/@-1I2D:W#6.AR5$6<5S
M:3QIRYFH<&QMS;$J.^!^0Z+[-NUS(9?(->H]@$/Q*U5NAS14Z6<'!Y2M>4Y<
M31";L*FOUX-LR.&9\0(A1,'4+)[SFQ3P6IT-3N"G.BT&C0CKUQG,:H"9TQ5.
M2&YW!UE3X^R*QH0:NU-F>/KG@EVA9_[S0E&%&:XB;>^^9^%K2)L3$C3)G=C&
M7DI?R?UD>R$?R))HOU^(]-=\\.-8FP!>5F?^2OM##9\$CGE("."$P:4?6#\7
MI&IOE[_@K QX7& I'I'K]=I++GNTO2X(7U15HN[=A?9W*WIS*CRT>JRJ&55?
M;J@E91[J4:FE%;:\S]+!50[1D;XY*2ZM^RKF.M\U7O79PM,&G5]Q@7:I_1#:
M!=/(,UMT1M\Y)C+F &IZ(Q;Q:]B]:G'8[95K0"4K'TE 7#&O]@^2X=T@P*6H
M/M9P39SKA@96Z^0]VXF.@X\7$G=SO04EIYC:^DI470CQIPN5C4I/K5&%[D'I
M7-:(954@5THNGHTUVZL-?9^LKPL5MY2..P+; TIKV!/W#5'M5CU<Q"5-DUXO
MU[;:IM]Y[E9"[&X$3*<6!]GG?-6%CR:B1UY1&5K;-N=QA0$95>_E8V&VLZ<<
M"GU^:F6<1<7.R,J!O/#&8%M1!"@[QM7N=\.BFTQ5X)_JKVV/UO9E^OT$#A(K
M?EGM^)GLZ5.,9D^_7D^C,K%_X!*'5MB[!:Q*1BHTFK5PAM2L6'?-5OIX><A-
M#^-L#<5O>CNA3N)U#%.#1^^KZ4X&<F-CNW*)KXA\\W8RY!/MT2HOIE>#K>&\
M.X*U--_MU$6E(UZ1L.!$';BT8'+#4%@+5.?\!1P<Q2F8N6N%(6<\_^M05#WJ
M=5U.-5^<7&SOH\J79D2-K_;A+;0L$38=2+G-J,:IHWK/Q?'KKG)@J'QPP8HN
M$9+V^](9#4M\ H>"-@OWZ8*MW*KD?*=5QN -]8S7."'D<0^K8X2;_M$MX UP
MW-_=2[I7['T^4X(4F)3%YH=+4E\U'EB82LS&!8BXCA/O>,#%#(F^X?V<:BXJ
M6"[YRSYIF5B_K'X\;>/C^@@IU7N/42\@#3S;# A&QMKF]G?P(]1H&USB2>>>
MSQRXOJG+EBW\TO%KD8A\EVNHUZD7%E#^)TK=,3'R;%F&\UYB[TY+:;-"=^"4
MPKSIEO<M0-4*?/2D->'PON#><>8?B4 VB//!7+_I,>A^F]H]+7U[DG>VHAH\
M/,VW@)Q7DLRH6)RCK6@WK^I03A&L;IG37?@E+/%%Q5-999C>(*>+VF(VS>$-
M;0F/R'(EY.FX;P&FW^1_/P2@OEVI3:F:KU!VT&,/.,QL:N?DE$Y:]Q^;8:AB
M/VXC0Y:9X_O4[4'R%#U:U .E%94UE*O7=C[HR]XY9&[$*<M)DWT;&O6]Q;CR
M"S*:]\A:4G53/>,+QKHX^E+N2@%]&,T]>W(+H- F6&I;<6H(6OQQEE[_ ?K+
M]?,/0_4?*]+<ZC(>P_E=ON.]\6RF\.D;GBN-IMQ^SKL\Y"X; LZ#;#GJ9Y85
M37\I"WWD23$)_FQ1]'X\! <0,%-Q"XA6XYF[$85,K3%%GL9+]L,HWB':'5_6
M=]0DFNCYEW]Z/96YJ4"+?+I@/,P,;&/[[=[U+K<0#J0"+7,D[,ON&B/T6C]+
M"I+DYH H;<;\4U_L=-!.RHUZ/)F5K+!KFH;K"F09-+WQL6I+EC5BV&(OJ#O>
M?4:5YMEJXSAX(X_-+0$.HD;\@20VVGG;-;^P1159!HB$986$ RT0TYAOYQSX
MHSQ#0TJOW- VD*;*LS,JW5;D+HT0=SW8OR&WJ3R/5I51!N9YS1@)- 7_I/<E
M(5VDR!MFQP$:0Q;.?-%$?>K4\LV5?]3<RD3X?9@8&SV067##<+U@NM+LAT-D
MW*]#X]X@$%RARZ0S54C4<:]E0&]#'%35$$6HOG>T=C-:?["W^.WA(#/S5ZK/
M5[(=W&CU?EA(@VX)=N0A?$ZH?<J+!C7. '.RMOUFH2\L[E8W%+,P ?QAU IY
M<7_Q?0X!DRT3U@9=T)MI6U2Y .J0QB2TNGQ[T-!T=CS4,&>V208I23OKWFSY
MZMIJ^_CGX;O<*JCHI>+5 [1;69&SI5O(:!G(:%@N?G]_OW_QK/_GP/=$V3B3
MI[5L. O[1HU[AVC,28#'4S#%0\\EAWTOLO*7LAWFS?@UF3RMYY+-L6ZQH&&A
M2E&<X_-XA '3E11ZJZ_U@8I%VP2\[,TD:7>IRVZ9LS)S<]M]FV4W:95^IA2?
MO \TSR3<XV<ZRZ#R4S<<-[.W /PI_5FO42VR2B$@(86=2?J5EA&;X2;?4XON
M]UJ'6:"CZ2!*5$!Y3RZN*MGJ*)'YQ,D^[KUWIV%'IWREHP)[<V4A>0[I#CY)
M !V<3T&*S-\"R:^_='!"U3$,Q>UWR^;0[+OU%#:7W=CF _L((6:GY"+O!4YE
M[@LS(8!#T .1&.%BZ8%_;]N996S?Y6S_5-_E5_U^X4^B7VO2&T>)B.9BSS*N
M>Z^^6<9LW3PHN@6\OP6( (Z^"^<CQ(0+A7#+!)N+1\JJOF2&E^]0$"%-)QQ>
MWHM4@79]'EO$M#*/ FSS2ZUWD?8YY2[%UL[R2<YF3T?!COP[]<^8#NDU/G3Y
M=)7'BLC&!4^WK-:%#HT_BP&,8?3#S\K7XFU']%IC>E\VUV>R63472/-+UU$G
M#!&+X5'KX#LR#U71]7;6CX=Y@L/2 _&;)BNJ]_,G(S[+[<TFRT[1<<Y]3&EK
MYF\P\+ -+75I<4M] P8CR*Q4[N,H,-%5N ?IO/"A2RBD*N.$9UC>9-B566S/
M*:<5=>3YM^[-IHR5BUUJ6;VA2^_:6&4%7.CUP@@[>"$&J/'P/=E$QH6JUK5Q
MG,'">.=+'5 %^"M3F)B1]B;A,3Z(9+$.UX*$CU(S@ R=L?8CEU*6[$^U%]=^
M@(=I9Y;)#'A6\IY@R\?X!3K^"F<&0^,4C=)AH<R=4PY'@TF*FLZ.ACJ%EV00
M@KX1KJQ[P\2?^3S8.8E46=?4** .]=@2],M'V-A2J^XU?_&G,U5%$9L86Q43
M6FGHE/17OM]C.AQ.-#T[MX#ZW-A*8'^F4-@-=W5D&Q6JO.S@L()+G\[6'+Y#
MT#/_C,-4P"/]-W.YROU>]ND.J>OT@KEW4(^2;4NXLFEN-59ZO$<^*<MUQ<[*
MNTF4IQ?0%=V%!%RV^ZXOB9^268W0MX=LLNQM)([J16U0L G*--U?C?/(3'PZ
M*R8W(@R67=AUU9BT%^?HKQ@1<\/A3K/GITG2YNC'4S/&)E?HH7M1"@F$J=4N
M-^09QG6-+1TT$#=]TP?/BCI3)&0O^%3>-*,4O^L-'O2Z=HF)73%>9UU9K1F$
MYY(CEIB,$&A87Z5,;ZC6-),)W'\$5,GIT&1N'Z;+8A:_F&0<FOYJ(<@ZX%')
MG:&K'VPPLH97[LT:72@8+HS5R=+"W+N$7/S969VQH7JN1N*RSJ:.ANET[AR?
MLE6WHMB92+ZD#?$I#M*;:T=OJ]>=M+AE?X5W""C\G;95X%28E?R-(&YL%)1A
MTV9W=J?=/^KZW;'Y7+>JX(:^;04)9#[H1-@-)A9$\P+OPE3>WM3DU.9%!_3C
MRH#R^G([XSEP2G9)X_O H2$<T=$NX.I:G&VD.\3"0_^E@:@8=([LCTBW8\J8
MG8W09>2G^U'6OJ!B_/;H.241](5,MZ?!?'W?+8#2557%?U62:?NO8Y1XFT(Q
MUL-<N>/3>;IEC$5_'<LLCXBLD80UN9)-U0>2S99#2BC#](E_-<[23J!$.X;C
M%A!9)7EP<.C%_R/C@W4!+C5>U 39ZQ>XN$%$3T\<,1+)G$V9HLX->A6J@<[;
MFVL$O4+G8;Z+VAVBT4W8*9> *NAC]'GD2=DIC!:KAD2"Q#9S5"!@6TBFSJ32
MASX[-^:Z.%KEGWS%&*+@DW9'_9F"B)[O<X8=#3E4C61OCQD*M33Z@_"OUW-\
MJ^5G8(X6AVK45[+HF8RHSGI5@U7F"K9G<W9P"YJMQH9+%1)>NU3R&*L/A$0'
MQVG5]HW-%JLK:?A4R\*OO.6E'ZG-6!G-P4=9R7RK3]GTF-WLS5^E;'K%VR=W
M[-SC=[,+#5*2)4<#V6Y&.Z2P1>B505;U6"B,8[D1)<KLN0NKL1@!%X$P@_<_
MUEFR9$$3C-V2/]4 "+C?LBE'[JVCK+BB V4Q1!&JP&*0'RPV*.7BE(("[,6F
M!(V(E)\C7\7' Y'PMI01X:7F?A7]<:-R]7[JAA1"9C$7)H]<+BF^3E[09!K!
M'V4_-[2*IOK^XQMYV!:(R$U:)HEX'2IY*>^\3).U]K'!EK<FZX8F .=*M.RQ
M3XEL\HZR1YM8M_8GU6:=8,+U9E]P>AYZ<&]['4RRW<!)68=-V4:C!E8?M)$X
M8%P,%RIRWB#)IC_B,*-4HWK?73QBM_LEFTB[8V;+A]'/*2H8+ *QZG6)G6JU
MFS$-_8SF]WZ&1ZPEH/;&H]$'@$*<Q+L88 C"?) VUPU%]H+>UO,_Z@:PBHKV
M_)Q:PGA=5[!+!<B@22WF)GB-BF,>Z]^C)L?TTIF1J<4 6=R8@^)-O<Z^ZC=.
M>'Q\7_BYK981\X:_3XBJZC(-VB$X3Q7U^V14;7EHK!RN8Q?_TEMIP'N+P4=W
MSG/)[U[AE!R9C9:B@). OVZZ(7OL>7),:@1']X:Q=Z# I!R%Y:$>8N9=E9?*
M0XK^CPK$QX]SLGZR5Z.$\9[&?,T\^RQ1+YB4&5^P,_%$R)\@^]DVBR*EW=AJ
M,[<C<V$KAC#C]3=+4*-E6G9# 81YP6)$66PJ>.YNP1Z$DA(Z&1K+<<">31R(
M51[>N0O+X=LCUS?-V78NT>K-S/R,;MIX@E6?7^CP2>0-#5D?:5<)XTS_[^U'
MVUJMP<);JJ(O'T.V!E,7+3J2J[:5 \+A-*V?)U:EP1*DX:0^<:^C=Y-$ITO+
MA2^R^F!U]C=E"GTKI.;.WGZP7BI63<HRCAA:"=EV>T$+LG[J1#NKH3?AV3XA
MSU<!8^O34%4L&,.Y,NAG6HG21"M$GL2+"YK"T471Z:Z&2Z2B>F(_RZW"AUUK
M:757:ZU##V1?\&V"P^Y"0$E\&]U:8F0@QPS8DV0/RH3*:C=:WAD#72VT*AD=
M$TP4X BL>*H][-<HNQC>_;F[@H.X?GGVO@T+8]C,;.E#1K=:+.L2-#TN"R@G
M:' ;&U,[7#[;;$?%B!&-^,WM3:U;J(+71Q;HT?I7ML+-S4V1_<JC\-1=Y2<?
M>FHK*X@GZF2=7GY(Y08,#;X>8(-CF=!Z?4"*-CV7;RX^R(#E<8(_RQRI>RE#
M>W.F\4II-V^M!Z"_D7Y?V$L/#^A?$,5?/<:ZKF>IQR1!'V&] O(:\M32KI/+
M_G3P@/(1K9H9/R)>BXGLU6DW3^.&46^XSS;I=#I0,76O/2 \TC?K;2E).#&@
MWFF9E+N&5Q:O]/KSP1LF[XWT57X:XM9Y,="T3*1N,/&02P3Z#&M?_NN*%9-3
MCR$SG5 5&=!70XUQ$6US.2$FBD)VY!/6"H]24.^M177/3?B6 :O-@^CX@WK,
M+6 ]I^AUI<L-YQR<)9#+6=GX&**AZR96*=#4VO#+9@5O-$7Q/*RK2T.ZRZ&C
MQYZRR)S0Z/XC=M:W\A-6N+S1O$2EFGCJ:8QX6\!((/X-/_:# =F?S(H.@L@G
M/RDZ;@'4VWZ^ 5;&.@]Q^&.<XMYG=$F*M"I\]]X7_YAX%PGJ':.]JN<S!F"4
M7SLG4RUG$9>5ILLH77O&8?J6Q@4&FS#[4%\H-7W\XML$EVT1X1HN54CUJD&<
M;&[,C20&%EK9QE35C>H%"?S.C?V:9MECSFVN.L0J"[LO_2TECBDIT VRB.;J
MYH#U=#*JRJ#B'YO7SGR=:F-S_[JLSU%GJ2NWT5BSF)% 7& ^R<WWGM"'*D,E
M85-M3A, C5Z7G-<;M/P!I(-?$K>1\&#>9G[YB:TW#+&0^U30[.BTMR E7:'#
M_(1=2:19Y#/ ="ZVTY&*:T=/UL^[Y*L!9S6ZO8WD6];%EEG,-D_3416O?7Q;
M'\@1IY& YQ&W%(_VM*SA*S4/[,*E]"Z,#JJ"/AC7G:WT]!\5Q,G?/:)= )]$
MOS9N;32B3A^.)PV%XQV[F9K(E6-$5V%1VGU.;:ZKYJJ2I38&Q=J%.\I<L6\\
M7)6?_/BISSZ4HNH6O&&3][0FT!>0Z),?_ 78 R1Q4:-"ES]"D54J;YFU-*<<
M>$Z^6V^ -RX'FO.2QM@8/C3DB]^/^^+)*;HN&;3"(*[*A2'K4B.9:1.$TJ&*
MIM^&V(#WR7R*V?H]Y%K$G$R?@#A^Z8PVJVZJ6/.6_?6+P8?(#7:M,/=68V.-
M)TZO973:VM$)R7F6UNV=R!YKI+YJRD724)8E"^.+;)_7GX(*[U71CI\IS:C:
M^:_[C],CL2^[15&2E*-?.W)7GR1UR]99:ZLO.$AK<FX_UF)B,_AN,#K.96FH
M&82&$4"EL1E<L2?EE?XWU ^(=">O5J2!Y*"]<[]:)Z2<M&^MY/Q#?B7SS\/J
M$M=?#X[TQG\=H^A7**UZY,M7*=10;"-LGU4-P?0KR,SYD-\"CJU)/<_<- Z_
MP\/JPOGO"79,Y0>IV6#;+^6QZZ@$1.6OY5P"Y\SG>9Y3OR!U-S][J_\8RD_R
M-M!H,/SP!^BRFKRA&LUNVW-1Q[T"K]T".+#EQNBTSF!$I4(_D_ORV(THXM,B
M*"7*+CR3A[4FV^I50-P$M"M^1<WLSS=AO*UJ3B@=9KG@KI;1#VYCPE ]:YB<
M_'X+T,94?>9 E+50M5>_EC_;,VXD^_V*F[208U[H&_8E>FZ BZ3M'OJRI\&R
M.*/L3XN++<QMW%N0[F/J: KQ/M$/W$&^_-?C-%\'5<TJ)QX2>.80W@*2P@>O
M/]SD-[=LJU+\4Q$E_OU]K2E4(_,5HW 5=' +6.+Z898]EP_)NGGH SM(W!0=
MV]9^]<CVP?HX,K8G!V_F-%[J9(7:I;&%/<8KZD1?=O$6X&#%'-;I\F6#(.R>
M:ERMR*5)0\.#B+;&[AS*UEJ,3__(;J7"B(W;7Z[ZISM4R#PKX22J]UP_F!\,
M?V/.D;S.OU)8:Z6@M!%]/J<*AE7,%Q?9%T%L!_<5P Z_^GM%Z_ 3^:FR@X6X
M<1\-1"1CMGI8_Z S?H$=/E_I^[L7S_>]LD]A^\2;8I&7_9S\>8@0@;DCMU_,
MQ?.558583U>KM6)$.2A'N7%RJLL[AZL=B+-+85]J8?M(=LJU2=-SA8[D(;Y4
M[[TA/,(&J  Z<B"7\DIR%<R\ %$P;6NJP2P=1H%E[WGQ!%0@TI8*D)^W4K1(
MS_E$#F+ZV+>X#WIH3DKBU%0AC[M2(6ERK?/OUM$[YB-ESW^FLM_SWDMJ\(\K
M8#S!;1Y9028^JD<O9P2J2J(6XAU-?#NZU\P]:[S\/[UYQ;KZT!H_EL!<I@[=
M9><S8FL6L 9D@K[$</6U6QFA*8L*MI5G#L,+ZFIGP@1=LJQ<2A3$>?GJJO"D
M1)NNB@Q>!O_)4?N)Z,0/G/BKW=<JCF>$,4T,6"M!SYPVI+*[NK\:]CB+*D&.
M=;SI.-<@)-TCVEP*PFE9@:^$6'61H&)]O=@&4D[AI7!FL2\[=<XBTK.\BZO1
MD="D(.K^$.C, $3F+!,QJR9\]2C#HK43?1AVI;*V)'*TKC<G>UAO YKST'7?
M+"@U.MC+!^#6ERG.?SGN<LHE5_7YZCS+Q;B!#E_JG\><W@*B%KIGCYY(YD]5
MG6#>V'2 )?=)&D>ERN^_?RA1HAB*,NCM9+_RF F4<I:_(9]5E0'#"IT,_Y3[
M>W @9K^>,1TM#N'Q*<PO12$+4XR95UA4 $0=6+:S6/1Y'%1/*+(:GD@-D;&\
M/^KCXHBJ5)QGVS5O.,QA7!PR=F,QM7^O)$(D%VI_^0HB?6@VN9^KB]$LSJC8
M24=JQ58O@BAE]RU!&[\B2!ZI"\*B>]ZR5ZW9RA5#B9LQXS&J%^(=O$Y_GZBQ
MSNR!$9W1R 5;^1RP>%N2.-_QHA2>_U-=S3Y0A& ]5'L=2&-]I7*=>\7ENZK_
M]/L#OOYEIH;</CTO5_D,SYH?42F6NNQQQZ+A%"E1@/$2@:Z_3'VY"+/0*YDJ
M6RM=.Q3%X\=3#OZN5OV6WNG'V\K6WPGM,E\/<]>5295_2[^(V7=M#.0.G.3D
M0#-6NQ=J%D(B^_WZ$15FQ[\@8'V%#YH@P3UKJ>^EC^"W ,;U*Y%?BA<?SL\"
M,(+1>9#![G-E[7YQTYM=PTX;<3B0%L[)WA&R ^*/WPI[UJ&!QV/Q0C0%YW53
ML\E?Q[7.X%,@)?0=QC;/XPUF.P7K\F1JM56\62 =SVM36"BUT>\#K$T8]RX4
M/X,HC_?<<,W*2I5AD4!JR^O6IY-0.0<WR:K] ;SOO&]R+,L4[7BLN3(.W9^#
MD79=:"SA2G\CD\)L@[0SD4[ZF,L]@M\(K)8=B%]Q4>#[/JE,\V?Y=/+"J^15
M]?G& 5NF"35J%^7EM'5_Q4JHC-?:ON54MV7)+[D':L#&87?Z%-?D9Q.*22%!
M5T4FS8H,*R @/E0?A#[L!=JA#QK9EJ"6DU>&_*R_+]IF: ?D@SE1IR,UM#@D
M B:_"!;&= &M>/.G*\A8W8F*DPFBD"O7BMT,>1#L3HJ"-E4I*$G)RZQ%*]E0
M>J()H$(7%Z0M%UH5.&/:"*3I(#?'/D<&P'IRE!)?I%OMNK#P)Q&_$/E&'A_.
M+[X9P?*P+=@"R' "8W/AHF][GOG%5B6KE\82J;?6"L99$0^Q'J*^&/9Y7U$G
M^OF#D@J^O\'R4+4*]@&Z?A!(!:>:SS6>;N/XIB<4X7:E":K8/AMG;Y0'@C,?
MX5<V3\N^@O[H2L%AIW5_R/4(2[>N%>M1U?W5QJ7Q;_]->96+J;R9@BD)F!WL
MJ$1K:0\@&B%REH%.XHNG/#89M3N+00<F='#C')Z29?,9LS+7U\!!)1W3T+2/
MR 7N36W2W:8O(EMB7;C:27KHSOZ_VCWMCA93<)(#*'!M):HE-^8D7L:/;V6A
M_:JHP%3)Y+C2/ODQM<Y2UY@HT4 G#O2U*SIQC0-=.XN@<-&9*9F%ZH/77 WA
MUU8_.A(,WY]-;D GX%M2!VQIWFZD>@"JP@YF*' R4+C7EYXUL')MWZWW=<=/
MN4N#NA5+HN'X;.GO)EU#;QTXHLF)6>[RPXX'3D"J-FW7KS![EQN!V<]\S2UU
MZ(/,\\373C]&SLJ&NLR[C>1#)KG6M #KXYT.N9$*?XGZ)%FP"38R_;,MKC-%
M55FN_NNC-H=>>@5TW_<T,MS9\4;9/G1'2R:)W" DHP,9 G]VW,,\LR6;5;59
MZZ3_DWX_-A[O>XJ_2I9@+HTN?<)G"\:-I,L:4L"C89$N6/=*7.)ZO$Q/2_96
M]$93K-DTHMNI9KY_8\6R6^9"X(NP,"UW&$W(2G\F$@N[?(X%HX1BWLFZV%#U
M(:U9ZX;^2M26@_0)$FI*([1<?!:MV.@[#QE(.)10;9=KD4%M8(K.((F[OT\P
M^EMW $JO?,&HQ\5?J-G'Z6/:ZPYI*T"(] /1>*P9^G  R=FX6JG>X\<4?X7W
M;DJG0V "T:X)5E6W=V;HJ_UUF+QDDQWZQ&[0NA,0\]#?)G?_]6K[8UL7?Y<'
M@6#*RN%:,'.\^$",1-^R0?)6;I:: Q/$0%+H<'J%6MV9B@*+9SLMN[(G28>-
MX6!/W%_2>S2E-@'*E^A/0HRDO^S3WZ1A]B:E8N'F2G=5=Z2BV[X%4+W%!I1N
M<]%[V7CLQY<HS+>]Y ]DRIS?$C^+\VVFB=)Q2!S!'T[KPJ\Y#)3$TJ$D$R+[
MVIE,:S&(I8U]=]":/YALQ\4^WP DWC$TND"H\?OYLW*)55WDU[)^@+]CS"T
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M0D<,/R"[UP$EEY57_4]\!-C;Z0U-7QAJT@/^*UO? N*O](7"3SPSE_ES_NY
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M7C,/BV10>DI!W%*1NCWK/)%5J>*\J72?<O4=G[V/>F,V$W(I"9M',L#D%G\
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M8YY^ RAY3EAM,FRSN=RP/7&HC2BP# U!O5&564Z@8;+IX15;V-"L:*H<?G3
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MO9"-L ;+-W'EYGD2D?!'#P/O?*_J_LTLVZ&H9(JIOY_E^>EPVMS8OI9[J6)
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MU2\)Q9I6@@_+]R4$/L[L:XGLG.3< /[TOH/NV7E7M7FQA79KU=.D>*M!:1#
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MS0T8_=HW'O=@V#<H4#E#M1CS2G1QG$_19FV"/\,UYIKQ-'?>UA4)5,)D5\7
MGQ:8/BO"M;_[H-CC[5MN]M 3];.,.8_F7@N5O:"TE+2G/!-,TV$2$0UA!$%L
M/ 2,WQ9C]2N]2"*_KH6N%&;2FZ36RL7Q%H07*?0SLQB+;=;7^F<J48&X4/\Z
M]P'2/B,$WP!&Z>4/.8H,_M[ZCCM\ U@8E]^HD#\7LIO2_T<+0-WF.3KG5A+!
M+TK/"AIV;1T1F<NU(S>FJYP"WWU(Z)%-S=X7?YOM,EU8H4M$3T/VB,"[6S>
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M1&7OW:L:.OP2.SWOIP@,OCS33G L@X5W"+V8%)Y,PCJ2JHJNHNLA@P4[SC<
M,%S3U-WJXU5_)7HG"YTT[@.$VJ>8M)/&S6[(LK:9]#41ES=,%SA 82+V/]N+
M\)-+\^]*RD%M. [I.OS O>I#6OO^HVYX)6GS$I=K=QQ<!@RYXC:!/7(BOM"
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M-J?J&X7$6.5?^2>B&=FG1:I[>&T]#/[9#FY.[YU$"&X ]5%_$M9Q-IT"L4E
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M<0)EX[WFC2_YS3ST&="%P>H-!3MW_A75XR+_2.+!_'_SLKSXQISKCP_!S"%
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MKO)OP8WD5Z$HCGOC?)]#X4N2G$E%6/UJ*OHM+BL3D)NG"GM5XI>P!USAT\[
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MRA2D?C,W,*BM)Y/E:8Y;YHE6V/>;#_XMG*EST<[K ZY"RPPFN5/OJ:"RG<8
MOS8I+2GKV753KA+O24LS4;MTFY779P)NZDI_RR]?@S%><QFG6MY13#CK)O!T
M,JO[UM5'^XZU3 !YG??FVVX%'^=/%CB5F>=B%[<&%S,;/*_;CC//HSL-RWRI
MPO4Q+:-? !/HD^SD.J<# H)]V"I&@C/T?-OW*L&^FG!*^>6JIE-A,9G[][I5
M0[VL<\3HIHE]Z^/Y96#YT8?67OJCK7!_^@#\PQX2WHE;)>&+I><=:RKVPZIM
M E;GVX?>+U0U[HEX,I5L CML0R<@?CL1D-O/[472)4B,8TO[>JZN,C*,,$"
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M2<Q982X=8\PG!AS'VT!;I"Y&Z^B>&4W0O)ZV1@(PP78'\D I"3$G\AA3289
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M);SI_'##,N1W\^MO9.AS\IE_XSH'?NHC&5>$OQFX9_#^ULX>N/Q&?8LO;E+
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M!MQXOUD'TA-![4/.57];3O6N0N[M\ZZYIOD:S=../$.LR1T;K ,H?[A_&:1
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M.*Z2.WE40A\PBR=):HD>"1A)4%S1:7Z0)D<X6P[V)KD.YZ#<L\RS"+!EW_+
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M!;^65YZ%2.L(Y?#]@H"'TI83@:D@DFN !YADSYHLC#)%C=(%:S?@%^CK\WO
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M&Y%@'3]IG],]M_:N0G&O0$Z/%R\3$:805C'5;Q_?QIG*4JF066Q;#"%7# =
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MOOL'@9+?O@KR7P/86X+!#-< Y_HW7-('X%*H$Q:<*F]D>CRFD_0@9WC$*%-
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M^2BV5P"G\Q&JE*6I"..>K+ ID-X/D ]ARXJ3_%W67?"K0>A#3.$'.@"TG/)
M$BNMC5DX\-@XQT8<?JR"RJ3XR0.9Q[Q\??MYD9WYY_9FZ.=]=]JC\1B9'WCN
MJVJ8%)'D2^]7^GV&H'8O!D;,V1N]6OU<W1M6NY64]&MH^CD99C6#TS6T1D3!
MOCC#LV>XB$UI6MR*CIUJQ%/(7 %>&UXUL6VW*QP%ZLXBC5U=T030?6#P2L"
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M_+Y_I;L&.=&%X#=A4CW M&Z0GV1/17Z-?4U.#I-\\K"^X'V+@J^_LJ)5Z6@
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M,V80JCZ1_JH&XR3J,B+<A&<=J(,"Z)PE1BQ>PP]4*Y 8ZUH2 \I-C;J[<M<
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M8U9C"I_O][#^&?7J\WP;6X" "UUQG& %=<V5Z?K9SV5!U7>C9 5CR8IAH#!
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MF^-[K:8:8K0U +< AKES/]U #X0G-]-.V*[<[#HM*//1]Y^WEF-37Y0GNJ8
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M:H.%N:0M;%Y4L,V09X"0HO'CF:UY,),,=GFG7+6^-"C*G9'F_3'DB,B=,1,
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MIV+L=)2BV"@!+Q\N!WU6]W**0";3'R'^9N(?4UW(W#.*P+8D:U]=O2S]%I[
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M36,M42.&H)DY*+4'VCPI^"KJ\\%[N)#\C?1AOS$Y?@);Z/+C&Y7;(F.8W+J
M8\]5;/?4,:MV=P*#[+4[BV$T.46K^#</U(.3D0AA5F'"*X,,-W=X7GUGG*:-
MH.R &OQWU[=#13HWF*&/<P5BR7R</X>.>TR:+2TUI'D?;CW@1AX,W)M'32["
M4M+C[#QA$M+;-=K@K4Z;=GD(9ZB#$Y2YFO2ZKL3S5W65:Q]((0O[EP*/1<<%
M<!3R#"LXI*@-W'_9,D<UN#<%=)Q-(RB5_KUZ$<QGC#3N+T)?:1U*#-L%!AO1
M0#M%F<,ZT9U$9V+Y9!BC[LIQCQF397 <@ZU)7LZVAHXJMRRIT>\8=/';C@5Q
MG8/^*(1.BYORGO&[[Y04O'(Z<@0 FZ!WZ-M<#?%.+I,W><]Y6MK&=@";N>1A
M^>E7_W&N-.*?"NK$W_5"%<:,-T.3#H'F1CK-K$WQ]KYQ\BJ#:G[, <9[,3=4
MC^^TY86NB?^UL[ B*^C_;*S]G\H8=7E#HW:D)81P(.)0];T'1-I,OK\'K.9D
MWQ;5#E)@>6U>K[:<UT-UIVNC!1Z2BLC?+#OA]8B/9@G".(I6=2KRU.[VU!-/
MEMJ<4XR9-+F; ZS#;PCLJX)D9IMS]$%;3E"]5UU Z=/MV*1\R]O];#0HTNT\
ME*@LKZRTI1P5K'SQ?$0$2KM',4;I_4[]I-8,LU59<4..N>V)Z*?<G;?^$_[[
MM^D!D7FZ3]_W(A8E@5-=PH@@0\Q\Q'K'OFO"X[X3ITM-BJ^4\B>;.BN@($^L
M,6T^5_<UM4=G;]@W W@8U8OM^29W=\+P(.UMY\N+]A_#)!0R0ED\GJ<$W$5;
M;5QN)2UCSSAQ R8?1 HO[3&.D3ASZ'@<,-BJ]N![#03< Q(ALFZH"2)3[.^]
MP%OC/D;VN,' ^!B\T91[0)AM/2XL3%N\Z1[@)"A0\MF#49")>[KS,?)WV64(
MTYS;QGQ47L>[86<?8<J1GYO_2(I>ZFJ2X![P$&S<UQ[=? ^@>9/YP^G"+/>U
MM\;!HN^HT,LE';=E[8#2LO22&T$LPWK@>VI6=.ZR)C.MWZ"A)(<@7HG)GIQ&
M=2W%3CLP8JV;%APQ$/I^MCFF66U2K-+Q_8O/3'?RNN0/+4ML8)G]R19[V0,7
MS<06$Q5/U#W"%]\@; !+],!(FS!A<;[X6W,23^JIV+!H__+-L?RM1BLMB'27
MUA0?HHN.Y.OZWUD_J/Z V+3<Z(3L"<AG>7!]Z7KND$^'\:BFG]<<'GEJ]U $
MH#>!TKAUPJMJFA.\44"F52MY>H$$AFEW)-WL6;1P+)X.%LG-+2T\6AZ;D29+
M&32?;SEW\QWMSV=+%HO0GHE4?%FM%::\AG,N/C[X!1ZO-LW)C_.>#>D9![@0
M(G!MI^TH0BBA0INM]X[]+TR7'5B=P)Y1#X,[MB'VV-&^"WD*:/RU(-R[6]V3
M$\*;M)Q/#9!)68%E'NI '_TRL@^JCN^YV?_C+2<7I(ITDU1OK<\3KRSWYW?/
M5OK\T#I?;J4\L0FG$QGOVOVYB[4^QR1.(DGE=BS$E&>&5H$GO9U"T35CX488
M<J/0-8N<*XJ6;$EN0%@(8O5^(=7;""$.3@M63[!^?A_%>6H_5-=2?V970X9)
M#0,+%XPK0J:,K?C1^<7?P4FJ=?/<W]Y'"VBO$7WD2/H>KA!?/N:$-YCZ]E)U
M18588VC<9! W8M<,;6:)-;J8WT(QQ0<&-@F&M0SFX_4 KH#I1[ZK#0=67'7H
M\[D6Z/L22VR4Z8%8SK!"( <Y;CA8%I-]JL"R0T=[2:@S!Z(]-FU0^3#ISG'0
M\6;RVTXH,2"BQR\[.@4"7U$1GFGZK.DL,!H.P9'BG6O$L/8&^":%TE8656<G
M)GW$FD=?QYKGA5T,^!\88<P_)4^/ G%:'";&5Y]T6)-C&[7J.M.T,*I-E^T"
MLT^MX,,W+=&O@Q)%>SC^ZCY8_;E*KO ER/W*CNK)ZSK9'O^Q(J6GQJNX7048
MH0.""HL@D@[,1J:GLZ0G(F>SSD/+7^H7_^I*3ZTP5K/8&NO59\6^$/2B!&XY
M5 XGBH9\W'LUU'13^,^-#NG-%R!K$=M#P^B]?>3AM>D>H_V2@+N@>Z9WLK+Z
M\O#!"X<P>:?9>0'Y$:-/, 34+3*2&^#3\\/#2FX %F?'ZI1L[R<4 )^6=?5"
MDCFXY@D:O$.B^/AME.I;;42'Y)L0"&=QDAU!=HU'+.E#R;GD>1VZ>)OHJ -Y
M,ODGV;-6SKL^+$V-JD,I[$SAT#::1; ZLJP>9R9(W:OT,?(SZV&-(_%4K&&=
MZ=_S7T,!;8Z%0Q!P^)3 D94;HW_?7O;KDX:G;:KW )/QR\!<UM[J()6%#V>(
MOD*L3.!G&$L%[S(3$?TW$IY!YOQ%_#"IK;#'Z]#!<0[4X6'DH]TAK6EO0S $
MV(-;? _P>S9I=U[[N*$-U#3,UO8\:F(,DG0/L)ZNQ58"X6<-R@)LR54/<7Y=
M/:_8;&R1J%NR^-!"=?)#FE_.(, A[.FT^.>#8W=_Z%>-A_89;'LK?P[-Z&*3
M+1;CJXRF.6"Q- ^O,Q3?2*XWVZD4LI@)7W#";?'%2B^^D0??5A4%4RD0(Q2G
M7.;]9BS,_1.XKR8XMV]USUP !<BCQ)0;/?3LHQ'H/P%T,:],QO6\GI-F30]]
M6?6/W+L+=,*[R!?$5QFQ(==JFNXI/B8T7Q3\S0,RUG>M)\UNI\[^4YCHOV]
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M&Y0*"'N?\)8NC?)GQJ/Z):_) K-Z,L3O:-;G)29P'#D*B+' TQ\BA%(AY*J
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M C>^:V6-?XYWPVVDAI"_?#*_V5;S-B_(MAS<<JG9U)1X#GG#N+4(59U8?C$
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M*D>@W]/BE[G+2.$1;U\WS<*-FI9U[)W$0K,VU9]=7^.%<3=/:C22(T61.-B
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M,%Q\\Y\.95G^]R6KLS@W%W_Z'BNG:G*M?K7SD]7G',O$%QJ!K.3@RHU4XFW
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MF3B)ETO[0JQ]VNM)'[Z=LV!#VR02@;J^Y_HW_(41V 56E$X$8T;:VHZLCEM
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MO__(SIQQEWZ,OK!U)?U(B59[L_+<J&AFS N1_A&'I(]U7XM9YXG_RYO<_";
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M>'D\#V6FL?$&DOS623YPU$!F=6,S8751^\5T0<.OIKK?)A_NKR- 4FH1"U-
M5GPY/FW($C4OQO:L]3R#:5\VH_<(64+XUEJ*!Z^!H[0U)LN)3[XM;/]Q<X:X
MS4@<"STNS!>?W!IO)G2'7,>X1Z(O*?7 -W=16^$54(/-(M7/*]R3O@(V#@<
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M:\/=T6EG57=^R>O:Z'^R/?>_1+V54><<=.LT(T^FA%5F/1_GUQ_W+G2IK%E
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M6KA0(O65 \+@WL&<8PKUPQ6O >FEYII#LT_G6</<IEF>M[P,K,  V&_]JBL
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M! CPXKGOW#ON>&^\<>[[?5;V_).]]MYSKKGF-[\OV7<+=^L Y3,U334 "QL
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M7]S":*<\PAC03QJRYL:9\Q1X(^?DZD6&F;*QBU\Y#'GE1G;S680L?*:8NQ)
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M6Z6!E_;.(,Q"%*?,7\Z?D]SX7DO8 ?PG&RKN(FDIY]V7:KH>=5A('EH$]QT
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M2$E>UY9&ZR"J<UJBQU(J:B)>?<E@UN#,<N9(V[+]T:DQ8U/(B!N.=5Y%B^C
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M51>BC^SE8'[>D5CK-\XXIQ?KO%V>B1!6=.BU/*JU3Y'^.UPIO(/%Q=MB8;\
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ME"8"K[,W&#T,GF;W3S5T/A2"4;OC/7Y0'.7\BN/2^^K<2F73>I%W0S<5;1D
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MO'I"4I%Z;Y\I>8:2Q(1WAN?Z12\E W&,9;\R"ZD=:QG.P25D_0L$)"_[J[&
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MEBP \^CTK;!>W(.O/O%4S'6WYS3*\/"FX3-7_/KC,-_MF D]C$FDD6N.X,7
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M%#^[@8IWS[YZV)=<^D/.?.'$V]"S)'V?V3B3H>P)TS/-AR-M?#+2ZS;>*7B
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MF+E3MV&\YG2% 1Z&RTL<1Q\-:9GN]3<U>2%/W)#N03#I(W>A7L7MK-]'\5&
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MU_C? NM(*+E66.1D6*==0:LL]XA37VE_!04[]V(Z[:,J<_@5Z=2J6AI&^)+
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M>,[!JP7M1"2A,;49[RF!E"/"2A9A\6,AIE]YS%"7@-KO $K:_;<G[)A )"2
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M>CC1(GD_Z5: >7Q)?U.2<;@!4@CZ#!")X[J^3;-RY-XRR"A%HL-W\I5$4XO
M47;\$@RLD1/O$U"&=@JA3:1&>2'+Y?FRO[2\:4**69,_^P<=B%.^=N'OK55M
MW9W0RR="XBF0C(G:NS%3N^T -PT%*WIZY [B<-GR;#-BZFQTXDVNSG'HV6,)
MP_:4_FL)$0D=XGP!$'WH #UUZ%7Q0R2Z5>@8"YI=;W/9[Z;RI17]OMWI =V;
M(ZK80AR HICL6G7(DF>(8XHH^46PY0ZY:I^B^KB>@3L(3) [\>)AE&![:$BX
MGFO88<=AETE.(!T5[06S#>1DUQ]?/<)16R5"CF*I']UL.EW]B(.I];L,ZNN
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M,;L$K?ZIWXSS>7IJ-]K]/P @<*UB]=S*T_B:INK)T1BFW1MXJFT]9?SG^LQ
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MNSMWL-YTXL@Q4J6(5X*C:]3'2("AF?>I!J:&TJDY+L;ODJ+M:KS$-\\K,BV
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M!YWJ2>?O^>I0\79>N".+&$K#6X#H?@)=0[V!)/U"8JNQGP](/0A^!N9*$A7
M9$0=&GUT.ZP'"?[DQ$+HM/WIA+9\F0(<TBNRR2!V![ Z#UO_^>,J3R5K=XP$
M.NT/*-MGX2]SG.!9=S:/Y*'EQ_HHT%8^EC!($I,<5& BA@-LSZS=:UT'_V+*
M<B#/;DIF&<Y5'0 MR9P1RXCSQG=NJM="*;OUYLP?#"]]"'XTQ6\GF7_O:PL)
M4].YI %V$EY(%=M2Q?YEW_*81IIM)?RD5+[^87XACNM5W_XG_M?B]A7CDH7,
MG61\="YM 0A"6Y>$_MMHTV(E=M9WIVK4:)H?VVUX@%-]^]S@?1$8[_YL*E%@
M>\PS@4G0?BOIXOSH9+'<=SN(=]7%W*0X%*X5739:LS>],&@Y_I9J/=4 -?I\
M1^P=6Y 7,@%R5>3,TI(@@)(L=;/I.;9]E1ME2H RS.DD#I6%^OBHH L'N& O
M\(8L%RFPP5YX!&$-[;#[DF1V5=A.]KZ8R5_DT>,]CLP%1)=042B$A$!-M.&I
M;ZM3"^*UO%2>@:+('W*Q)6?W'(#*KJWLJ?X.W;M/]RIGI'%LIJ[_93=T[\.4
MU%N6+1W4)DP1MRQ,PT[&UI'$M[I.N!CH+Y6AA/S8Y/QE[/_+!URVH&]C(--&
MN\Y]<:.B)$Q&,?X9DUH3Q6//<:L$R$5P7Y@@VPOHQN>"Z!_^]'-H,34E2UOY
M$7)_>RQ\97[504W8E2KT]29 H24A-. 2-_P8DQFT&F4"ZW@C[+WOHP*4[/+8
M[=/=,HGW'PV>=C\UKUX\ TX/:7?^^J'+)?N$MTRB@>M- >0W(PV/S\"2Z':0
M6);\_W3HA2%PK63!</;D2"Q+>>=?J/PWR:J8X_OK/TLZO;\W=DS<<'JJ%F3)
M!W&<)Y ;RC1^'R9%)-8YJ#X88TF8ENIBZQUHZFHQ-MI@F70Q2C2@ <"?KGS2
M -BJ96"G29F?U$;@ F]W&FV\A:\OJI</!=SCA TD//Y^,]_C+6!&C^IIDA@<
M._;PH-]&>ZX@_. G!P-)SUUL>50*F8C37Y$_LJ NC[RGB?V[$;YA*.,G/NX$
M,M=9NL+*#5F4QE!"@2#)^94@I:56,>L@_=6,]LEMO)<$ ILAV/M>R((V6_T_
MM7J*>=O)8)C\M4W9R@K+(%'!T"LVJXS%OTXN3DWC_)(776E]&=P*9:*^'D;Z
M/F;6 ]2(99EMJ#7*;\/]'P[T=5QWA<<B=6">$$\! B_:-J&R6 +KA9IA;T\K
MP3^<L'5> &&5P;(>*8XBYK9Y2>6::)C1WBTXR5&[V%2^,>79U4"\;'1G6US1
M/TC!;D7>V8\)H?$J'67 9Y;D7N@OZ33SIIET/'H1+N<@Q21.Y?2+7SBX3VX(
MX=P+N+<3MF)N$$9?&.S->3K;\BZ,-,Q3CF[(X9%QLQ;7-JAY?R(F1<<+@5"'
MGL]#S]#6,R,<^ 5^2) CE*^T(A;UK).T27ZE"\SA82T5RXH0$-#/7D$X?C/(
MD)[ ?R\6&-!,[].3D*.G?]58T7$#FS&+!+FP*6_@N=I0AK65TA$EG"\>_E8S
M7#!8X:_IZ':*)EV+GO'K9QW"%+$,$G+$\Q.:<7\HHMS,8)-KB&/<SA/Y-.@@
MG!$E".D7UB"V66&_==P@Q-N;HX3?\Q_JD3X#Z?<>>?PUTN] T==\0;3B [L^
M+FR%S773AX<<?.L;;9Q[VS:6R=<K=O7?";Y1B&<K0':R1?QZ</8>C9DR\KRD
M9,1.$Y<-#/7';LB: ZK0ARD_"/F!7FN]HS_,DS5(1+"@=5S,E2](QE=D"'0G
M8V7G=JI)="=U@O&TLV3.!&5$7Y\Q)3FN05\:[ZNQ=9<F@L8M)=2Z2,482F .
MJ$54E008;%]F.#C*8*46,?N0<@LM&S7!SV80*KDA@'<<:%!:4D%S/]B[HOF\
M[5L2<;S)43F*@RZ#(U"D"0!<F*:Z1S-(8=<^VYZXU^FIS!@R 2X$V^-G+L#C
MJ#X,]5A129C%V=,5',XO2W NV__)R>>:*8CWU5MF9U ,%^^H;L-T7@LQ>9K
MGY8(3A01)$!-[!^F$[[0M;">O+^7I]$7,))*0,"#XO#%_(JF94:K(=.T63_"
MPLT]0.#4R?>!$H@F@PEL42 3*%Z&U@6K/S&T9$:4Y1]<4PI4Y.G\,+<S<4>C
M8 ^W7SM7(9J@)E[UK> /]2S3U=U7^>;5N]SZ*<;"76TTB(M+@P""2;^SDO=3
M;9;?3KO9E\BU(/4;=\@;<LPB/% ?9M4E,@]0F^,?X&2O?; 3^D1GJ?5OC<JP
MP8P^SL4G,#VM@;,(!LO*CYH<]OD4Z8)C4"T=71LBX#]G3W3A?G2@)_KR=#F_
MH-1[PS <&XEMP[">X9IB23&HPIO1)*:44W#V+LC><MY/N7@/XWI>MG)I4M'N
ME0QQXXALE??/'K'+"8<WWFR(+%KWXEU!'XMAG;"DS:%,!MDS%D8TZD*.F-]M
MW--9.1:N6U6&'2 @]R6VZ-K:1D%:'PRJ]9H%;[=43S;U@]_E,,M.S)+O5<EO
MVJE%_9E?47.=!0F,5M\_)'S"*1QT*10$,-73_5G0Y@*PO13DYS^<K<IM-Q,]
M=+_&[C>+:4_2O0U;XUYW]EGP 8&KVDIC^8@&J#S5?G;2WW-18&:3CC^*G(G0
M C.,:2<:N'9."7ROG7NLM.)E<+398I2PC^9)ZS:6J?K:7[8*N(^^%SNB$1H,
MM;)$:3*'_#N-].2&FX3X6*&E 6=R;I%:-F\^#?,,,.AT91P&+A\8NNF%/0-?
M1"#N+W+GTQSRBC]>*^Q^JU6M%=_)3)4 PU]VQ AUEG^F\3F1FUG948[[L\2I
M(D?T)FBOSX>RBJ# <T,73ADVVCM\Q%XZ3[Y)P-L"63.#4P(#1*F6,;A.TQ18
M.%DN<D<GAM1&)//L(JJFV;9ZL-FPZ>4/L?@#W/_.N1-DJ&E;9]Y+AY8L=CW1
M3UL\,)9]+^ZZ8NQ/8G)IO5I&>)$65'B=:&1V>VA]P4+8K!PCU=6Y$?=JKLTR
M'F\JY1ZRW"&C@.IM_*NTP"A'OB(PCU2^_'7\EU3S:$V=4[@0Z#$M]L,9ZI]>
MBC2^>+,D"H(.[> ;?39]L@":QK,YQ'SR];7LQ%&47<FWW :<#F(YO Z3F)WT
M)TW(A B7Z'#!Q_)]%'#\ATW),AP(^6KT&CRP66Y<=2I(T(\9B<\$D]RW@06,
M67Y>Q);\W>&7Y:HK1E)'7E<)CZ1D-\&ORFSV10CQI[KF[FI1IN7J+7R7L3[V
M[!@:DC(A1<_HB/'B=Q!#-[J=[H'E>DEOU5V&+)=3ZJRYXT3Q;!:BGUUF$:#\
M6FA[CQ V.S!4"BVJ"'&WYF1(6]E^N^Z5&T\I7)A.%-J,J2).L;OFPL-&^Z#@
M-B.OZ$K]U>,OTY\-_G[:H*<D>7T*9'R[FZXVA05Z(6;V*!"0&]A)(\+.1Q=)
M"VF-TMFJ;9^D3R VXGV+ZD>L*<?:M(M%43%K^QCZ'QV A.FB,HF_7U+RMSO>
M.QI7?/\_J,#X5-N+$GDMTH8[ZU["]/AM?J'NS.J1=&Q?0?DOZM&&L,Z!!ZLR
ME.?I.\JM*8%I!GE)2"Y=W)%CQT8S!P\NMKMO$:<N,MC4FQ:3,4TJYK43C=P.
M,UJ4[,+*/B]3'F]]^A^5:_$SSM56S:I$N/GL3T7*9T 3)DE%8:S9@RKM%3?0
MQ2^2V,D&CP**"@P-5D%+*RN*[*K-#%W'(Z_%6$[.U]Q*!YA2ZR@V<1J(6>QK
MO\3'J@7V_;H XYB\31492:$_9LZ'B$TA<$O'1C[+? 0[JEYX]''/(RY1C,@\
M&UGR,-,\$CI>\OA<3-/6M1=6++0*VI;8?SH=&=P&;0[]6$MB5R:' N2E/_63
M:V/,0_B^C](E]\DF_4>GBW&RHDB,VE+V$YAC&>P+C]X*-K%%$M+<JQ-$0&@L
M)4Y^9J-=L_@O&V9EY[+HMTY"NKR7[EZP:B.H%55^5M)?2P+F:).I M'3V39L
M%"4KZGU^Q]CZO>HB-\YI'"$+?0;>:)H\*'X9>#U>FV"!1L'61G4^P(<B&74=
M3;5^\S53HAFQV<?(E3YT'CTIRB.0=6"D6FP3^JG5FO9CJG.25RRZ!Q\*H@ S
M2[0OW>P-FD=^@[&4PG9[RM:)XSOA^AWX_4;02R="BM'WS%A_6:E".^_5WRJ8
MGZ*>+02!&^L39KMD4:M4.LQI"4%Y'_6:1;\Z5[!W+;\6F$RU$ [?2-T,\HE'
MK,S<9<=T642;^=ILN*8TJZ&@D=\YST.0KU R\%N$HOOD>0^%G70".UP13[-_
ME:WX!#!EZ]JB%)F&+:Z6\K$FIRQQR&E6>8\>6B1 8@:S_H3Z1(O[[Z,[JB+7
M!S7/-?76%P&&"L5&/#D<;D2.4^EBAJJ['?['D9=_*G[$4FMMA;R%O!!_$POU
M-L$@-)AX44%W&S/?8_0&<3RTL;VQZLJNZ([Z0=Y\[;M:I[)(D"QF=GG BHE3
MF>:_,(67.-Y &E##FZ4:>L7/\;O(AWVK,F3MIY7]G15U(ASY=$<75^SZGBA,
M]:KDO>'"PLD0^R@]]YU#@37F;36!"Q;FZ7_2$?R%!/Q1<02AR\HP9D:_N1/C
MQ/LDHL'UPN--M1#S%L6NT$;IZA)?@Z4:R7$8AN@/:@+1T'8]0WZ1X5JG3D)F
M)NB0$//VVKT/)5"S@5O(Z?#E^AS\V][6XL]/<0<>U",4<1$3'_?29'91+7)@
MA[S\9X^/9GU&]J[V=6GV";U[LAB_I6$'TE.B,OW?$G6@+P0ME:53 PE<BM:B
M_-=$Q)-2B/JD=5/8#@DKY"-3R5%1\,><)^[52'Y4-6RC)ZRL[MQ-]63_#*TU
M.9=ID >2IVR0GN$4<$D+[L;5,-/.SD-I<3$5:%&*UI&5,YA=<XC;<,"E+!0>
MNJ0FPX#>S4E ./(^36;US05Y8N+,!+K_GF9]G'.::_YTYT O:P@6YY?$:;&Q
M(*H69N:8)9S[GT_8\(%GH/X9Z'Y3>?>-\1D8(:0[)VS:9]OJ_F[X@P+JTAIZ
M55$<N);J0=+[X/S(_P+G1]K=IA:5?,4?3DSZA_B["<R3V?_'H/3_,^B2,T^U
M K&]0OO;B6IAO))13]MVL%=*<V=TR^\=OS=B\>BV>Q04D&.T<U\^ V@']TO2
M&XORS6EC^+_=![[<.8?;8WCV <Q!RI45?]L7M14:SJSZ1NG$GY:J)BJ8IV&/
M)=_:K_-^6 6/ =!_=A?OKL.G_#[:G0D:G^;J7>H=>APF<ROF]Y&^^R)?\LJV
M W5=L@]UAP*-)AI0F1+A+KHE5)^&U?VDBB:11ZCS4<+)*I<_LA7_NUSRD$4=
MX,'N(R?V+E?OO8>.A[&/+J$NJC0@UN3(\ARK=/Q^1I6\>Q/D/N9%L>Y5FOEB
M[PDTY]Y>N?AW:57A\]8FJI9TP^*,(^;67NBMK[;B^ES3+6AC7*RGV>M!,BO5
M35%^>;NN2:OOP29\R^(%UCAD$TV<%N9>O'0;8K]/O&2X!$$W4'C[W[7[1[S7
M4/KS..LP$LWC]?[4]<XNA' RI4&CR@F7X1A;SC.58[[:COE[S9CP*\CE\(<'
MS@)/U]]3NP/U]5K?6A@EJV#=:*%-_@&VAFAKF)'\^K4DP[DV[^WO8Z]59MT-
M)<DY-KX7^?>TH-68#-J_Y!&.%Z>&]F@?P[):I%N(^K<D:N\0.I W$I@AV,PV
MQ\HT=I./<M>+F=A>>C=:OBQN=N2XNHO+NJ1V?3PH]&843)_,3D@ZD/"YU? G
M+&O$JP?IDK+;S$]G?'-AWZU7*#..P4F=74^7]/#\P$C]QLXQ<1&YC<R7?O*)
MW0$4,Y?>COJ*OA%\PVQ?K1/X?YJA>_*PJR9U?!Z(TJDA8X8#%K=H7<W&<!$9
MNXH]1X(?]OF\2Q)N9[A>C[4\9&R=?Q9E^Y;,@Q%)HX^6MU_I>HPCFA%M+^!D
MGS<8(Z2LJ,"X$5T)$;WU16]BH+>]OB,+#NVG;.M^OUD1^&1=3_I]59-KTQ1U
MX QY,H1F!J,U6':VBU@J1"?&N_^;D:$?]*QL9Z&\XDH9SU:;^%W&*STW;8&1
MD561X"]5W_>5.GX@4<( [X2[TZ[#F.%7F6SV#N1X3H%*=56B[?]:")+, JFY
M%G59%V4X6G&JV2V&B26#MP5'O.W33:P [0(=K]?=1OAG1DWN&-EBD;4P*!F'
MH.YK-'E"C[]8O5CQ444OHD*P-9D9LC+\^#>$CPP,K5-D>N;FF8R/HIFU,(8,
MVCDG1[&%I>66VZ0Q_ZLWHUX%Z\NSY2WE2UZNGV8<:A6Y2J"CR_&:,4R:?\XW
M*R47@[MI!5%&>26F3OP@>3:4R^$E5M#1K37E2IM=.M6&Q0NV(A:/T!!1J<-N
M=*N2VVXDOJOZ6>]E<]O2:_UCCM;N5_6'O6;!(.-W@TP,7_"V9 I$TL\% MX(
M3 ^+>'Z:GU>Z;:^/3]AFN>=:#,)8<^)RG@OBL T@GSBL'=R$V4Z=Z#(?)>HK
MH/4[4GN!&43\:K_$"81I4E_T4^,NKFO^1:H\AFDM.9_ D;O>Y2O:DQ7Y@:(K
M"A+$K.'ZP=L&$->'04(A9A#(CI8M=<9MJR$UQBQ9_*];B"22MNGFJ19E;Q57
MS"J6^/'3-\49OI^&K#1,6T]#COR^D]2?U1$E<:L1Z+[SU;>KUUYGST!7!3#*
MU%"J=YLC%8(M\M.0P%%@H?='C"&%1B4Z0=:YT+C>M_782#=E<B^Z3].9/:=[
MF7_EXQ9LTLH+\!BX>E*L4X?P',3<S,_MK#:TO_70DL&HNFF9&F;Y'K(F]HFE
MF#2*$68O@IB70F,EK='ZKHS1H+_#; KEW4F;8.]&ZM(&O_.&<;36VD<MH<##
MUX@&]XR4:7-2%I*K9#U>).FI*!!\ ;PN=WD@Y0W*\Y^KE]+:QG+PTVVOG0=Q
MS0;0R0SZ8U.54(3V,:<JZ[PNB[I6/A89&.C);5-HL7%4X+Y$/89HLO9<8L;Z
M .-5,_:T=P&S!8J,-2S1G^5<AJ?#!CH&QU5\YO/V16E".U;H#%7R^L(7?J\3
M)+&^R<@6X_3;7DP2V4$[I;$;KN6*$UO@K.&OWDIC^?,6[$;1V>N^,-_SDX[(
M^$/+.W8.N.BG\.V]O!?<(;FL-QU] -IOGR "/=C[5?6F.*S7TF^QK3>\=><L
MJ2UT=HHP?PLA5\VZWXIF%"XIPMRTCB?%I?"7G/I:(M!+9#OB]V5V6;?*JPH,
M=U]V6Z!KO4\:'4^>SBWCS16'L^6\04)Q&@KIY_ \?M-5SW.:SN3-1$;^%9O4
M!/4$Q<]&(D'EO(<L: 43I20Z<U>$+[TR/R6J37!H]/JZ.VQO=O4DR;RQ@B>V
M%(R\NJ?<.<[L:G;C';=T='B'16<9;D*D<;RUBKDU="FN3[,TTV^LD$J05UBV
M)#@]0%IQ>4$L.<EZM+C)RK(<EUN_CI!#3Y]NE2DQ-!S'WXF\S&VV*S1[N9SU
M('*$<XKU]_MR$ IGJ8]551;6KS.,.A/:,>\TV2VBUGKU_GB&BI%4+;4"6B3I
M.#34B#MAV3/%1<!!I>/JX?>/8X!NJ(5&\AUZ__K#URJ$1GM<P/'")J^(#!KF
MF')\R\Z6@=M.F8O'.95PQ+'#JT%,U@Z&!)D"$/7]!$9#]T.&S(.1K+V>(,+:
MB%^_],>2V3'1Q,YJL(;EM-[<T>-6])\/A,DUG(>)P7 KL(_67*:90-@&5."B
M^[[M=P&(=6Q*OV\HN3=X*0:L^="&"WL[KE>P\0,C=(-\,&9.O[%FA^%5,@:T
MTNQS6>=1<!K0$5>9E+N3F?R!'/W^NB-?0F3.Y=\OS(3EK\L60F*9I"79N_/:
M'IX+4=6]=M9-J7\)7E5UP9$AOJYID]-^/,V5V':B#_9?84CRJSWQE_JW*3IM
M#:F]ARJP6+/,QFDK.+4_\BIW^HIMT1!797HTH:UM4O$\]VT+JPL$)'1/I.68
MVUC=%BY4-HNL-Y"L[@-P]\4!:L0.\TKMX='O:1MGD0@+L(.]"0LR'<_J/(NP
M^1E8BXPE\=.Z_<X0T8?QS?'F)^3?OX#6^4WM1R)5R<?_S@_-O$W4OW@&8 =7
M<__[G_2VY@EGRWX^L/K%C&S>TH&'$&#5,K_@?A;[2)I_K4_XEW);)\]:^7HK
M0L@2)=QX2V@S=$^<+EQ5MOYPX*_%X)VYDL35@=Z$+4CVP;JV$<&?H6X>;V 2
MMB\5=G IU&L=2ZK_.[,PE>]!'90D.UO6\PV'^RX$,;KJO+-:YE*NNO-O@I&W
MPZ$]&K#KI)F/(#E,3H[/:$W&?1B$'/L'_'BT$U29YN1K2:YO#C[:5BIBB.L^
M,*H[_0L[NL18Q"E;&@VS,#N_)V8K/BOH_B$3MM,VZS!RPQZN,R1-T0=5S@.\
MPK]2,RWYYP-5)LU-DF2&;>H>0O<Q4)OY%,KPLE?:]WE;(_7._9N2EJ9L?3G'
MQ6R5;V2*+XO\N$V? 6RFO&OC6EP;OWH%:RV.)[MK."##/+_89H/OJ/H>?^XG
M=";L2.<#K/S\+'@B.#[,M!9OT]S$(XM [T+)\+U0KF#R]-TDMJK*B9!85_>M
MC@_=V*\9]Y9_EM:T]_?[9UEA'.N")'SA0M]-5>68<3 ! DS;!IHR1!Y?-54L
M.&MY"VN02IHWF9IP2Z4C><&OB'$9/O]2:)GVKU];=X$!)5!GM[$L/:\D\(U!
MQ #ILY4RGS;<TIQP!Y^J?-?1[S.50,/Y+]].ML*^6D(VUR(5U6J;_5:]GZ[+
M3O!0F6V@\NF2V7G)EZ 6Q4@.#ZY;E;C+K9AGP2I+'R),*0^PZGLEZVJ:![XE
M/(N/5ZJI\QV<8^EG3E 6%TY4VU=[$:?7[Y0B<'TGN_6!E9Q83B3(YS^.M3Q1
M@;TW-Q38D 7AD(M\TJS6QL.FO@'10/A&1:#_E@)MFQC>@C42Y!3J9\V&XR#T
M)HFZ?_>.].\U9^[QOZ=@=7)6;%C_BK?H[J=[,\;==VA6[HS@L@;./",#&QPX
MRK)BA/U9._'(XF4HB[ 3%+C[#"/!"3V(98 TGA;_>[_5&0O^W0P/TR"%)T9G
MW]:NG>244$5M7YWA-X^$DT\QYFI<TOZ5!-#Q/,#J39]S:*9J&J[?<CM.:C+C
MMW^6YFA)H/:J9^!*@QWX*+)Y?YF%V?/;OH1._!"%WHIN+D^=,3V/S/,E+_XH
M+K6@:KKS&/;:_;2<0#59C*:+-$_H?(5>-,4O^G 5JG(GWYM7*%4;4)K+93D.
MLM?P6@5Z7=Y65$'\#F35OA"27Q[W;^W/CC)J-:P?X9%!%@Y<WC1>Q_CN/EW_
M]6;5-?<YL5K&YO;JQI?*9C0AN1YGI%3@BU>7C+*X</Q6]UYG-=:X%M<6.JY^
MU"#A%_\796\5U087= V'XL4I[I @Q=VU+5ZDN%/<W=T*I12"%2@4 BU>W-TA
MN!0)$)P@!0HDN/,][W?Q_]_M>]::ZS,79^W9>\V9V<A<RF#6O,MV99#8'!4+
MRX&)[[?7@]8"B79U*0J;)402XNU1LX7U3=% ?S[FL34*W/JW;6!=ND2"PMQ]
M#-2,9=/\:<06@0K&U-75[)A-"UB6N%7[9-BCY,_H2>N!$?^D5Y"7>T5[4)\1
MXDW'N._+@H_[<V1HY!WROSPD)4 ZW]^ *5T<HL-U4Q-1PXL)83E*Z>\66;O'
M>_8XVZ8D@&7[I>$7?UR\?+B.OZS&#;B^CPRZH/.52RT'1>/99DJPV>>I;=G(
MCVE)8-8+@"5?$,G&,+WD72=K!1-7X(^WN,97][VU_9B:XBV9R-C_2U5'5(?<
MS(8JQ>'HQN^ZO/'(R*,:WWN*9QN0<CHG8J%'K#+6ZBGW%1;)#EX\;A#V3Y7B
ML&D4Q0NQ12V%?YHU'MT9;59!I @ 0*6 .Y^EX+/7,Q9FC]]-N".5J/-TH\Z)
MT23NT)*?NMZ2@?B^J^AC8]3]=\TS@ 9@#,1E)NSS#.*:WOF_+:K0L8T6]@%,
M':U3#ZA6Z578XC/ I-LD4TQY@/EMY!(P#6?S2>1_AC?8J(&/K4^4#4 .P8W-
MU,1GP&#[SC. 14X2\!3Y]U<"@.-_$0]ESX#H,K/!_$:^N'>286L+JR8@P1$D
MD'QY7Z/1:X.Y]=12Y$'OYJ=;@?.7L() [Z$J/QY1CB(QBO&G+[Z5 [Y!TO0#
M4F9^&'31+@L1FS5WL.+BIWDX^](IS0)VG.L(22Z%G%/[E->\I[ALTY9)9H,-
M2JC7V_G\)D0C9I#8I-$-XY5$:&G&_2UQAX23>J+[K;>I [IS9%#[$85D_9$)
MN)X&;[H^OV%EA9L_:)%T!Y>*E'!AU7(7/Q"=B2[1 T\]H-P99G '*?00_8X2
M_-FE6Q;$T9D"?&..*W=RR5;@5"F2T3R[-^MN:,S3N"H -4I] !#R"QS-[\\)
M_J?4 VALK>]F35V.Y/BMK+ZI* $D? \IV:F!U%0%A%]U40:?MZM,5@]->++B
M7'D&O::Q$L$-9F2T1C',Z>,@6P@_D<UL52!B&S,V;[Z=*,[W7CT"EQ/Z1U$N
MRT>X'@,X[?3)<65J[U8>@/^"4,@LZXOORF=(R$'X6!50^5-MXBVC<$AM$4%!
MU+R#Q'27K:KT%$NF/&%?G?$B4]0*1'P2$(SY#(#*O.\:S-$L#RK@.:Y)]W'Y
MI4"13\+L[\I"W&UKIZ_NWF=ME*+%-E15_ Q($.:1TJ[_X^[.MYL_WCK_*4[1
M6-!S.O\RI.]$7M88V"U.+_8.<C(5\J?)JH6I66MBO=>PYL9AH)S]4Z<ZBH/6
MT3>)O* ^61E6';"ZNC8!UAU_A,?I<\Z284LIA[Z2IYL>"F.T1.8GVO[I? =J
M25;'M9TIZE>YPV:FLC,*O:_WZ4, R2<Z#241?7++^[D*#D EYA;MWZG1WEHH
MM&C57IG FC=(K4@>68&#NY)?.?H38L'<NLXTE5>+ICQ/8_%&2I&#]XQ 1]9X
M"71'J,OTA7$3WK&J&_?).R_H[O%Q#6C"KNUE 8/0E)3?L3R)(X2I\UZVT$/D
M<LQ(K=NW>::.>)3E$>K+^)H)(BA'DK.QX'J13V)2_;/H,.NM-L2H(&WJD:6)
MT!10[\9JK'"45IKBU??[26@.B P5_!MPY]B"(J^<I"C0V;)@$?B&6S?BZJVZ
MPYB5NJ&[J3$TF05&++A*BS#&%\PRIW]H;6AKOM=I_%!N/X84& *P#_,1K(:*
MW=0$E3XVXXU6'1^K:="AU@HFVVVQ#/W$)0"V2&PUQ(7+T?UC\-IQYL&)6M [
MI\F=D=%$NH_$G7Z(>4A)NR7)7YYM')$D4['Z(Y_U;)U^O8EQ=(';/&7@;]2M
MK:''5GZ<?S[>@ZR?%KTYO6B8>?@H9FR%1]L[C\Y9WK6?U &$=/R<RAC:V$FX
M'GR7O_3W6CL$K:CS?=)G;*]KY&&LR*RH4+KFS%3E[5-*"[*T,&-$*O=%K5#W
M.K_**S7-M5F2IF#>;6]0UTV]M)#?SHU]_QA7(,(E"&^P09$)7YYSZ"U^3'J:
M L@7RC5MTQIWN\ZN4]\9E:D48(<W/=KXP@OR .% ;T"V'*,A-EX>MML7VVU+
MM;'.%8:X./(9F9F"B/(%F>DBJZ&CF%XQ.4>ABE9BX <)I^U30D=M1V+J]S1Y
MS7F<PS;X19$-W*X[@XF:N" .$.91%$*T'KK(QL?C@+_/-*8CM$22:W,807-4
M<\GX;Y)'FK=^DC9;=F9NP--N?3B*]#A]W&Z3OM<V10)@'<D1F DUYTFD#&C.
MHJ2H#*US?#_3*CYJR,A,YT=],*F#7/Q\$JI;5EP,^>$5B@> +A#*RX1]1EBT
M(9.W/K4W-Q2OKIJ\@\W$B$R(>9&FE4E7%K4!2"!?(6W3Y(<]Q(B%3J*?%M.;
MEE1.P7QQ'B9&341$CHA1E\"1;6-6#NGU2K3A,7[ L##:EC\C;J<EBO-D_!T2
M$A7$$TU"]N'TO:I/X^X7D-]?HDW)\_SJ\&D+863-Y\Q[\S]^/"Q!NV I6KP?
M$AA9L0UIN;X QC.G;B;4PE1ZN;%J<2#D6K>YEI.)WWZ)Z!OIBK?6^D%*L$_B
M=L<&X G.2!PJ1+^>1[ +;<+ZZ7AE3V]_6VK$EO(,J(Y6OBV0Z.NOQ>ZAT\;^
M=&AB7^K"%'<(VUY+C!/R8/JHOQB-(X-S(9U0%[1O?.,LY>3JUJ_J:6M:2/JE
M'NOEZ:$A)$_(8B4$]<,4Z?#YDHNH_B]\]W8!?Q&>6?QKQ9(Y-8O5($C_>ZW$
M#K&X^%HN3/\9<$P#$9GUM22XJ7D3_0R0GT4SI:K:$STFMLD"I!Q&]2QK8V$)
M3,E+]V@EFR";TRDJ8WDJFWBN>E4.WQ\\O!O.S6!HA;HXPS<,)#%,^:K]+ D4
M^$X+-OB6#=LL?Z"9W1-!6ZHNG@%QW1QI6YMA6@,M2IN5'\)*<)E;XFTSN;<"
MD/P2&.GK34^DH3+(JXJ:PF3*@^:OP@$$CEFU7(W5A23#PO:*>H2!:^G@1K2^
M\8 2U4"=#16'-T=7CM^]VV3P' C^!57)B*G.%+2^T@@H-^VKBRMU": @SS;=
M^V+[1BAUYDIBI,(@.>2G2YW)JM/5DRNO6_7U$/=86=&)5>.Q[3Y3=+ #564/
M:=7YVJ&V\7H0S#NTG#ZM<51P/Y'_OK D_."J +_+1NWS&QBB;0ZFZL;.X^5!
M(ZBZ"S6]=E;KL$5$TV*#,QI0V$:O*Q]_;\]R33>9#EKGFBH3ZP PW(R^B1)A
M R&WE99XIFN]UUJB266'WO&17YAT[[M]6G>-$-0'"7?LPSU83<FO H7Z9461
M-FMF@=Z;M"JG?#12QO]XY4>CFB.'#-E)W5[Z1#JB[^=I#>:H#5R%A F;O1DK
M'@WX@K>9Z9;-:LI^8^H.N%5T/PBN^'O'EEI"&V3#G+-MQ:TF.'GMJ3(E<.BR
MT&BYC'5AUGM0Z=3-L\BV9*@Q9[_FVM#")O4U&]\1W*46O7Y9B)B.8\0/IQG
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M>NLEFH^0DON?T(+#JB:BS ^A#;7HT:821RF.:+YR9,Y/5#,.C;&V3?7S9W2
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M)?=/XSW@H)J30U"<YYHH_5^F857"6H0JQY[#[M:F55-QPEZCMOY,Z!N H9K
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M G+ J:46JT./J< B/H8M^M4$5IX3[)KFB&)K]=)59:KLGS9HUK^T^8O O<\
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M"J$CF@[MUX"TT:U((1*F\PW.521Q#-AG6J8](21)<XJ=U#3>[:/GMH1-?_1
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MG6[:NM\T"]*T&,..N.;>?Q2[*;>&>/A!'X8=Q\!F;>]LZ^?TQ$V+ORJ=G@<
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M#7;\@&;(I'"0E]J4Q)W\ [LSPN1G%8@XF!H&: *5(]^O^M#OVPPL7E@C'[<
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M1HEGW$>_/D07MF3B.D(]0/76J:M>"F\_.C-4X'.2Y7".8\THJVMI:$X,W:?
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M;Q@I7:L<F+5MCJR(MPY)G0Q@6GZHY2D#(@=\1;TL*.T,)EQL(I06,['2&3Q
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M3!__?23;^NRP4W #@U_X, E*:-Q%]Z1M7=)0A#:A\VZ:AX(@J8^!O,!HO!0
M0\P>RQ"67LG,JHT>U^/8:] N[R=Q F #K=0;T3B+4I2!L]^2T*"*_8QM0L$*
M)SU[&N^G[%\4,-+!+L*1V]-Z10AW(U>>J3&R;R'@U",F0^52WD)@/4HGM,9P
MMG[/C+T/V7:@RSE1.S<U_\2@V0^FXC-MNIIWED%%Z/8/RV*80XB82'IRL'0;
MS"]  FSW5E)4&=9A$X)I\?TUIRZBL/JG;7[KC]>O-_)\$+N.A*O5/Q[<+V,S
M9@ SC-^2U[+,:F'@.#@P 6])!/;K1[_&#Y;G]*XCPBV89W'$I]\C%2?( 3ZT
M,K(;U-7R82+23K&I??PQ=Y)0430HU.71X;#;R1<L[M!K53_ E0JPZI:%<DN?
MM_:"RWO?/OOSH!4W.*$:$[,G+C^G*QEYJX-6E<-3KIAG>06<-$54UI=<R#3E
M.J5_W!C]\#TRH,_"\(Q7?_-WV[7?Y[)BP8G;RMCUAC' VR,?MO0[I* EQ;75
MM6@;O.CZE+=)/#A7.N$:?:C0D-JFKA#QI2[XI$AMG-[3NA"1^L9>_7WY]Q]C
M L-X=5P6UG"0](5>]XXQ:)GY:W/66Q+(S-Y8K2$%1\Y+<$E?X2KGD3BO 9(V
M7E3)#!A^C1I";%\Z'6BP&_O=L41NGX[K MAEIQP>]'BH!7"S^RUXI;F&J:6V
MV+<OYDRHC ;X 49FF7^6Y+1K1I!^4\>9Y(U3>V*&WEEYGZVQQC(0U_Z%5>Z3
M6 S^C'P;:195T"V\]/L@B@/IXL=J;]OW6*#N0?$U<RWY4XCGWW?:'XXPBV6-
MA:75/2<ZZ>N@/B0X0^ST_2T^F(Z#(K@87-9?_L'IB1X)]Q2CY1,Z.U.LK^;?
MK6%I2V86LMD7<_;3E'IR6A\#>@QSUK);M.].YHT7V/GI^TR5@Q<!&(:NA%N=
MV-ET3ROBO=783<YVQ^=I#D;V#P!T"MDL@RIQ"&?^05*BQ7/^>R#W0OVXGHEC
MB6=T,Z$O^N>7.E!/V#2Z%$(J/[VI#<Z !WCM^^-D(6>#G8"+NGCSKZ?T:HL,
M#YM/K&]];(^U,RYE%YP_EV0\=>,IBO((%'*+3FC!MIAWIKYY(=1\OR[A]8.,
M1BW3MK""9>'Y3 !6TIG],2)FS(3(?H.@\RW- UXVO]$MV65H%S$FAYK"12Z%
MF(H57.75$&7CJ62 !0/HEL[3MG_.M 6[YHD;HJ_M%RC>L?9@'<UG"Z$WD5EC
MT/ZSUM+%).=A6J7V+56BSB.,]][UH(D"G@MV^#8GG=#UJ7>+GMT"A+&7A<%I
M =6>^P>CD@N.=Z<5< 5LN0_>EJVZBC;M7DPQ%D/PR.W7$.&VDY&2(2LX_HM=
MJF6.+'@_A;VQKP>!BL'-V=WK8I(=[4J:0S<!6Z2/4I3 QMTC-3+X=YD(^G)C
MAZ-BF+WNO<O1^FQG5!"(S+!OVA5KF<;TV9]-*!=3CJQ1Y^,JR+#)2Z+&ONB)
M/SZ,VE>>YZV>:XNXRFHRITW_K>Z3NCDC#R!<SY4ZH/[/AG(J[KS\E(N$2U86
M:Z8;V$46>^"<HR="!1BUKZ'@G&3]J7IM:Z8O'BH_#7W!+;!G29(O??H4#I&5
MY!""3EM*B^BV8.@UZ\:9YIK1G'V?\QMD\:M# 8HV9Z6>Z>B#:ISY<U#;I\B7
M<F[,_DF%<B^(N_.KSRMLC8O8^?J? ;-0?"=,-CZJ[@;5R\R1034>@QB+>Z\_
M)JDHZ30O%)A !S1 .Z6<$:0(E$)(KVUW_CO'GS^OU2W9F?%W-#<'/U.] !QF
M ZF#4:[@=*]UK]QI3-[&CP':KFQ%*WJ R__'H/R"+M,&TN$QV4&*R(][4U!A
MHX.=R[%GA"L!#=>?^8 1#RT3P$0'<\P]'[(Y^OC$R/SE21ZNV$:;%-G:^^OY
M_;3O0YI'A<"GH$2S @?V=GRB/U?,WEIS+=F@4+VFTM/B$S_67WQM+EB:#I^8
M:5P;46&#L2F\),B0%Y03^B!LG!$QP]-_Q^S%#4DC=+3N"T(/SNJ5^S)/D#G7
MT$J1ELFDDL(_YL@]!2W>3V%"J)].)>'REYE?[D!4"M&Z&@Z_>K@HTAL.*H2Z
M#QY'3-@NF_EY\*GAF.A:$!VKE$LCP@69-OBU%/)VD9,C[-UZWWQ+?'=NS>]I
M@_IJ^UPN8SZ^:YO#*^O=_CJG 9?0(9,/DU+3/GA?3*Z#DIK/W$-0/^N*K@;S
MPEN\7,6[]@\Z2R5O?UL+"H37=;)R_.(+\^7\,I).!6SS!^9-"/L5L$K[ZG&X
M!,,8_Y<O\21MB*M=W(:7P-0%Q?-<ANPF(":VFO:<0@!?\GF3J&17O/MY=/_%
M^ 5LQ((L*.&>D))H;#R'"?;]B.Z;1G($"H8:FBX I6N\\T:_4%DTDG+J+4ZY
MM5R&#:D^<JUKW'@SOS7J)\8J!5>'4 %E<?5H3AEDA>O&3MUD++SEI.('X+Z?
MM>I,"MLD63#_EB%S0]Q[4"Z1UU.TU2]%!/_\!D?NJ1VM.V8Y$JY?>.B7TL/M
M''W!8 )'\7]Q+[GDY1%R\W]?S7>9S+_GMJ_U@0HTX#)VPX\?=9^G K'=L7#G
MT=(K5,#W.Q6X7,KYZ?I9NI7,)V:V[V>*!Q_*&7;1GQ'.#WXR$W<8;GE[W@2<
M\GPU776N;M$=R7762BOA,@01-_2^E(,(SE%V[/KZ1//\N^5?;84.DP'"AE)B
M;AKC-Y'ZA'54=POF)' .>;,ULZP(E(T1LMD)SW'THB"AC?"GW5QDX<D_?,2+
MUDOG\OB"8T6=XWI'EA>(:]%0*,\%=FSD4XF.0;G/J+#5G^!Q4+$]5A-\$@C[
M\S8D3#'P\LK>EJ?=<96B^,WX>ZTQ.Q@@6,R"$7F9G;^B6?E^@95ETP5&)N<%
MQJ@6@YP9,0D2NB(7M"!DR+&8("46Y49FNIC9["X<S="J-<%4Y.J-(+Q@#@/M
M6(QT:O!@UAFT,6H5J(51+9>=;9_L#:UX9=7 ,5_6XXT.H$U<-:YP_<6J<W%+
M>.\(C&>!4\&9QV^ISQ*+ .RFT\EL *(^YPG8.&0H^_6817G&'8@_7&3^J<Y7
M"_[SA $&2'5.BZ6_YA##1].P-^-UYB[O/>#.>4O2"=C7K6(9AQ[?PM-OL8J3
MJLBF"D]%_*>W$OC!NQ*&;4Q-;:7Y="E'',Y5I6Q7VI+P?LU];J#DX-&N+R'"
M+/-\'#D'>@P,+2&.='\?P>:-9)Z5V#9X$:0(DRY'7(6N+G4A.K37,E7&/P(1
M,CB&8_/0FOV$&842VPM,=1U?U2?%XG7+#Z"V*_F#(7?GWO3.V_"#MSN.(9?6
MI0+6Q%[2TV$6@]"-0;)U(H=F1\-SJW8GI@]C^OI^A3(+O]+W\'E; (VX1-=8
MNJ)R%*L2IR=PR6N]>?;UC*/+J ?DZX*]\R,IK _9Z.'MY4WS.D^DX!%B6GNG
MTW1-D2-^9%BZ\\3SP_WJ'XL#D\#.AUR?Y2 .K+/8.JA8)2.\GB/")$P=)P8;
M_R7+8'":M18,,:D2U\/)]6N0:ZD %R@X*A$:#]&!_*Q]6A_N'/QPM7="W46<
M]9]I1/BLI)J@5'4#*%:?4;(7>7VE2$Z)>^.5Z(O6:-O> Q:<W&"/U*(@S+]
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M]\:&;.F820DCCI"SWFO_3+[O??>/-0V]#5D5Z8?#^[4\N?70[U$>MUU=Q;.
MB]>" ZO8\+!V"H&,02CW#LW3]KZ?!:"$&_6)(N<\,=>)T*0]<]P%&.1>EZYC
MMM6SA:T@5_=O6YFH[E]KKP@R9)Z27CCGXV-QMYM$9"IEV?GRO()]12N](-[*
M0 ^XQ2JT)8_[(LN 8J 56,FD('">)3$_^4X8&%+P5-WPNN;XER5#Z^+0&AIY
M5& E5Y>;U%-KX]E]D92#4;"^W=B8:IZ H@S68X>*8I*B?4$!6.PQ<I&&L/>N
M),%P.WX.,K!,R">]<C5<')%M]E-]N7O\DF)3,4L;*VV97>TV/;S?$3WJ_I#I
MCFQYFQPD,&K/B)QRO),"D)Y 5W*@IQ6TN2A"[XEN*5O>E0^E%[-,O1U^]WW)
M_ZK#_$"^J(G&&82LT%3,*CCH(.<G=UOYKD")BGCR#L2H[<8)_:MH76FB()DG
M$05/.3M[>K^I3@VWE]70E?P@N6XRW(C/0RB-[^!0=62]\'4Y%>@#Z0JZSYOA
MRG7!1/9%>\.'7B/.31X\D'*NGO9>[;C.>O%-/$U4M,X_%%;3E=->?>'F"7Z1
M/NCC-*A)2/: -D$YNOLRZN;UL'DM:P5F,G<^JJBKZESH[J#^:^G7ASC=JQ$9
MBX10_B/VZT"DM!^-["22CV#V%&GT<XCJ51835Z\[89I:/;!=2=A=;3=:\S.2
M'R8,M]I)M$ZJXP#17<R> _L6@,/L0_D/%/CH"&=R:7W\2&[EGOZ.US!^ DV?
M9'.YYY'N#Z?+I2@M_ =D[M>H-Q6!NXNA!X.!JN\??<WKRIDI6=QU+ VR8%ZO
M[2%<+XF'5'.2S+0=A TO,[>,'%'6BJ!D;C@J_JN^-!&)<.D;?A1QYPET/6-Z
MIWZ"MO*5.DX*RQ_"T"<D.\P-O<U;-[57\+D&CGDC_E'C]_)<11M-#8-([<;)
M\],*D3!TI[O;(]4;J6[KQJ+5!=II?4]B@(.Q)ZCK0%3$/1K; MT"]^Y?K,+
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MZZ-6>FI"/B1E:;N2AEC:+A=LH'<:ED0+![3JX0 RZVH<H%2OBP,(LW# 7+Y
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M?FEL)O RJK@#<"VZ6EL(G3FHS% BX+V2(RMF;-;T'O[=)A$L(V4MSYYSA22
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M7B.5IA!WNGB6AV"G-B,P+*# >^:9$D/;2 ;+Y?R,D1>#\UT< 2'\'X7PO0Y
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MFJ",E-AJ$#!?$S,//:6[V1#WA-Y,UX%WY9EY[GFAYX#>H=+=B+)"%*S%YLX
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M+KR>9,@9M+MY^FWWZLH#%+8>:N7@!,V=,"X[GZ2?.F88H?JL8OO2*[E'E'%
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M\O06V'OS0*5=YAW=)>E'8&$VW<28HGY>^N>0F!VSOC.N6(5'ZU=)'![RM+B
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MH2"LG./8@..C?M?SR^8#[@>%OUT\/^+Y@R:9>%3D\74QQ(X$K9.0RF!F[M,
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M!YMJC)SEM%0T'2&G9UH(*$Q\:'&S1<9B0;:IY7QAY4A&%*'P&+@&]*/ MSJ
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M+ADM*2UJEZC+@>>2/)'H8;AYRRFWN=<%]. >$/KKNM=F\CU 7"WA'N#)>@^
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MG?RXMB\4K8%PXMH\S+4E%QO83+J9.^MX7.LPH;"PH"(I^0LF^- ]X'#)$WA
M6OD.;?X>\%'&7LLI!N95U7*(:^^%UT@'7AG&)Q,8H=8F<2ZCCF<8J/CQ_=&/
M'6DT!*46)EO^];,R@9S:VOC]CTDN>N8Z&VF2S#T[P)?9Y>]C39[0]RV6Y0]_
ML'A3:OX^Q>7#4L@W10F\P@&/N.M'7KTDW:)GOYX@BD4W5Y3'M/S384VSUSV
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MCY@HJ&%-FV&P/9B.][J-J^R!#Q/754>&DBG'RWL#C,\6JQ0@(GI$JP1#!_0
MBG(+0MU*F"N7X9N.3!!K#U6:;-4DW,[47JYDKP%V!#4<X& YLX./@NXW+;:Q
MS)J00 *,9Y)PQ^8Y3.4B72AAN4*SAKFJ'YBXRY7D2IJUZK.OQ@\Y=F&UAG&B
M#<^G\,?!1@,"MXNU:#?;7@BQO1Q?.8Q&L$J1V0637DI$":7&S_NP!=,QX:Z%
MUA%G6A[TCJ9&L152J7'6+8UTP-&,,]$[2?DM1]VB9+O&N.5)4+@B+V;T?'1T
M0-065'S471')GC'%PZ[\@KUU#,5$ILI6CAN+74.NJZ-V#:JCZ=WTL_"A \U;
MI6N@DE.BP@!\X$R^*D4:8U@ULLH=K\R^=PN$B;(:7P.X.GV*#;L$?3&F.9V6
M#AKW/)<1ST[,'7G'[33&I!+S?,2N,N>"YT#SH#WHWD*>.R71WEI2ME7(#-(E
MC)N08<\W*YF$JV#B1Y1!1AIYY2'#K+U.BI3!3!'UV<[@R,L"BEO\Y/J7&8O7
M.*U)A*FGDR[A4V_S2$1FW_>^V) 'Z"-7![WPVQY^HZ"CV*ZL"TY&^5-%ER]W
MG<AP"_5^K2\B1GHZ";=4N^'M5OCMA*G4+71A_FU)7=N.&D^/-V/1P(,CP;43
M97Z^.U*!'][<Q8D93;#NWCHYQ=5S0"0O1=SK$00[*!G1@F(/'EN^7L _6UW#
M GT,HHK1JZ?#JGN>T&2]C$E5K^GL5G:6;H94X")0US[%I:LLM*P9;]EIHY<8
M##-XVZ1VH'%;6)Q*(,W, 3'8O;X_2O^MKPVH,MQVM>=5M)CJS94#@R?-8P]3
M#\N-Q45ZF0XFTMRYG%&#_)7TPB"=@,6J;NX;&_53-!GTE(9K-D%:0RD[PN3R
MP<E3^XFW;^'>?*IZO^C#FJ-6@F9VMEG5$VUD !@'<D,.C9"-/X>13,H]\$9X
M\U%)P9@AT42YJ=5M7#U<U:.0HA;=@"MVN/C]>&MM93_$E@KR#L6SF]&VD6^?
MC*W<+R6FUTT;O-*G!?J':A?XG9SUWEY$3,L0@BJE,-HBA(_HEZ\!B(FW%]UO
MNL?&N['T)8QMDFNZ9J^:^90*N%N)TTL2K<0!1D?4RJR2&V 1M6TSC.)!=]>C
M17.8T.)>8&W?@(^]3V\L+*'&4_2[&6'%669M_@Z^-E>RCFL\[RSM%FBL/(%_
MW&>-B.(R[O43:F0\6I\\SGJ"O%,[G,%WRADB6N45,Z+E<]DK[K,%.(]8F]L^
MO!,W-!'.$?P0!TF[+5G"2(^7YOZ98K$9S^9#$KMS'D%5"!5Z'J=SYDJ1+;LX
M1:?P80J^>O'W$!<1PLVJR>[49+ZAX Q-XLX\L)[RTJ/_117\<)OLC=STE)/J
M?10S(?L(H3,!_$,K^-"S0&U7C.T5\'9@5EH/)'?6$%)H;^H <SXFA27;6629
M>4O)3<95MYG/ ,T0\Z8:9981CQG1H2*Q!@,>+3M?+( UL$3^]9?#8]OG(>[(
MA&J6]XT0I':978G .W#1W=0'."F@^GN9H&R-X/0%OYC8H@LF';X8)LJOWL.6
M'#+TII0FG[<&D!$$:4@$KP$.^W;0F?62\\&.IC8\L^E)=AG<]F7T0=?9]<5I
M&<1X5TN[3;R^TPXLO5EB<O^=[[5C5G(6RD&$;G-__P_+%?Q\L2FKD8&BD^@%
M_[MN."/T?H'=Y-.APC?H(B/U%P>/ZVU_[G(>*NYBU H^_5K]]IU"$DRJ:5XB
M4V19UYHI2";RM 0DR%3T\HFX;)GG)73AXLV3YR1DG;'_K&XN;?'%SO]G<<Q$
M,_C[-,U2VZS_HIMOXZ?_+]BH8O=KF;H#]5LKV*TSQ/IU_RF@<!6=9;>0$89\
M0-P:8#&O)?GU+:E [C<D"I<A9DQVG&AM43@L;KP-?#2HFG"M7/0-UTX9N15_
M3J0\-1J1$ >W@O<_"U4/7*(&!OC 4B]E>R3S**AMYOH6]Y&;7H]5/:6RD!;[
M6<&[;((>@,55H>*9:OM]Q]%ENV]0NNTH)X]:V9$ACB_2W_DQ5$17<.L/*5NI
MJ^QCO>U4DV-7^?FZ:K)H0%3[7C6K]DZHNW3&BX=-XQ(+P7OKKAL.JV"*IC ]
MCZ=WXD.UAR"QU"BY<V5F+YS#R&+5$VT5RD<J[ @93B 80BB79QA0ZV1,JZ?^
M,=HBH*2W+31<['AP\\G'I?N@D2H?M1YBC\5 (P#M])QDCMH9SE+F!2ZTO/)A
MWK=!O-Q/(S=\_,=TFV1M\R/W'$L6V?W.Z-TNE_NO;)\;;1S7U/[%SF[NLH*F
M&%8$XC(*$BJ"E@PQN2EY6EQ=PLH]T':XP@);V<R^F6WMF4VD5LZF]?<.26T+
M5',FU5*RM7.4PEK%\C]6=39X,E,JQ75V[^IYM'X[TB;\DBQY.A+.?$=H2>"2
M/ [XNJ^]L,\=X9 +-6@'W,*JT3FRP])-]Z;=@WAF93C7@)!( ]*#E7+F)$FL
MN*"JYJG!JZL6TBT[&!20DI8QOM^%! $?4#4!Z.@<4=DX/FWWAMWS[P']TTN
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MZ.Y%RAAO<5BU;)P!'W=%S-Q[OB!V:U\LN_HAU=C$!PK+5D#.[PF"#-[^+4$
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M@T1I=T9'Y[6RY7MO%]-UYB;9RMQ=Y#[_2'? >)<\R GKHK!]E/_N<&]PDRY
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M@H"J.BI#[$35&5B(=TMSAO,0.$PUTK8I,U1U*B2H,E^%1V22\:-<<GKCW"4
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MCRSZ&U'F3;NV[N8ZT6I ;EK[QB1"4+HAP9P9 "AP%XM]<M$FWW',![*_A[?
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MIEHM<%AED- ?3IGM5IM+9GPOR=?)#X&^O$L>_Q-C.:!10:]+AZ<=Y,[ZZA+
M+_!55K6LI-F<LZ:(%H2.T/_$7%,I(LCK*6A%6?A]LT,A4X$@@M):YQ@XP6\B
M^C5GH0(<?M'W(Q?_ J'O"FB192#?TKN%Y5LP*!V@T&(JGQX[D"YR<-"OZ8Y/
M'.QGQ4JDZ'*"AH:=%-(ZG"T"-O8L*TQ3Q\R33MFY[':)XLP-A7(=RK%#U^^%
MVF]-#_R(Y0*B#!<,L1L@EKOSVB)5D[PS'1P]ANU..AW3SV%?/C@@C;^EC99V
MB5E5&RX$3.*<\8Y728,DJUJ$?-H0P.821)SDWB5ZOL>7F4+[8>=R/4'93B:9
M^PA)VNY7SU1N\:LUQ,8O+>'*XH0GA_\<5ZV"<)N#)S]8_%M'W\;E6%R_61%?
MA].0B56HE2Q";ZE\S!#AIJ9+_*Z0HJL,QZI-9ZLV.^B'N].#4K;OE#I[R=#E
M:5MM.+&-BW[H@'6:49/]J9>?Z?+7[NLZ6*ES N6?H/78\-DPB<B67);)K7&?
MKH)[KJ8N8LM%-[E9PKCC6I2>/#)+X**-[>6J#JY&12:&,]"-HR^<'?R,6]%Q
MT7%N:!X[<<Y'#E4=';?S7EQ)<0=4^63HBPJK%LTSDC7K?_Z,,F(E.?4]1%7B
M UWQKJB76-+ KF(K4!$R3N(.YC@%2#"*K'>AC7FN2NL=ROH"_I<+]O@$(.*W
M:/GJK<GG2T!"-$AXZ:J!IXWU"*G[OB&+P96$H]/KVN:T/5%IOW@^RBU^F95\
M:<3SX35Y.IG+BV;93!GEH[7/%><A>'/3CGD"#[K<$UV'""%UWN\I+TZA@*?$
M!H:@#H77'>L^EO[=V;/IG25_A3$WG3%@?N;\^!#N>3Y-;_06M&IPI?ZY3+'V
M<T_+0<;:%FB^R/.@":]6Z(M1>B0B[T ?P9E7$1@L>SON+>GQ:+/-*JJE#G48
M+< *@AO#E\(C6A.6[LRN(M3#W&BI:](F'WH6/7UFXB_H_4%1J\2Q/.5N?20J
M9)1VFA'4,#GH--Q4NO#[2[9WR]!5C3,MG;Y7M(%Q@;99!JKF6_I*.9OGI=.:
MG'?0BSZQX&6;CE_M7(KN&N*C-?[Z"\*VOZ&RH+9\2-!\0X\5C1?HRS@$!OL4
M$E?%;53/134R#$2?=R73<*;> ^,>X3GJ5W[ZCKX1O 0DYV[IL68FI=I@<KJW
M;\0:^8;SJI\.AY3!M-OT=5="0W>X1%:UFX9I:L2?Z;[$RN$JWX$B'\!F5:</
M^^PV9AV;5:<[Y.#(W?MB0J?..Q8'I$?:=-]^05[H2A-G]=CZ.8B?!3HB,Z%1
MJC=@OBA+YJ%:?\4?&;[M<P^[.V=A'R"B?G,P<' 4[=@S[9(S=IU6"%)M+UX0
M3[DUS8&/'/U['?Z.+] (.WRRSSU<N);J.=&YN+CO*9-BT>A+1GK=H&7K]@A
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M >F@2)5>)3::B!2EAJ+22XA("U*B](Z ]"]$1'J3W@*1+EU 0!(@)$@GD(!
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MP)Y7Z'TG(AR5A,7T5L>_;0VZ0^A++5OC9R(;5'5ZX<:XM7 62KE<8,'$0(E
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M _SR2'L,:UJS'IWZZYWP]3JAXK@>_W0GNOT$OD ]$?&\X/?N:/!6S\6Y,A$
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MS?/TH,Q[0'<OH?OR.*>!M8I<0;(B^&+KC+J&]D3=1XNZS;&["B]ZR.,UM%<
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M42=G]_.)'_I9^R9$-LE2D6S29E)K7\T>;S?9<]HS(([>PXCRA=-C&B4O@YM
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M'<ILMK*&,IYST%M"#?VV%Y#'%:#0<J8-\Z'9L?FGAP)"OE34P.],:N,"[\*
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MZ-US(S50SG/OC\#?_7'_XO:W;)_<4WL4Y#7R*DI9$%Q-@=94'MTR9&N(>6G
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M%1JL'FR3K+]N/^U F6X9PDO?_N@'?=Z2S\H!Z<L;.K4T[)!C\&0ZX8KO5 %
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M3[3;+;$@K$[TT@BUG-RMZUIJ@Y[1026"9;7%UL;I6H^.J)8LN$EUUI@R)V*
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M(+"!+61"/C1.F1=<.*K,MER&K.^"_: $!]FF*SPYUERL!'BIKJPJ+SZEEKF
M%KD_P0T:I@6>[59@J,'DQYM;.W712S7%YECA;HQ_JAN(Q\J3=YV&QMM61CB#
M7M>X--O]<F *PP#6OSA)9N[^</P#;WG82N7;(9 GK*[%BHGE:&O(/[U^4+2K
M@5'ZG,X1W#4L'Q".%:T!)YKGK+DRZY>V+[<#2?Z)/8W^XTO @V?L#53T)@-
M>#'/P2Q/T9HPE=67??3*/#TQ,X-YW^/]Y#9$6ZW6XG*Y,R>*U,[HK#/[_ZJ-
M-X0B>X]\MOLIA@5/&-]>V4J@*(8J]>O;JW.6%H2+C-/4/!-TX^ED*+J'$QZ
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MS*QMOO#MA?46M0X@6)>3XITJA[0F!A?,Q1&S20>AS;N*B\E%L9C>KBR^.?/
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MRQ/0\W#^(A7GH/,X.R#8P^LR6>)T0C'=\LDLL^SO4L&'"I_.(A,FT6;PT+@
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M&"<KK.;"3-3[!J#M-*C'ZF_#^R\*QBTMW=T*7*<K))^<L@B7IR4$DK"SEU,
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MBU^=/N%..\JBP0W@;J-3VTI%5R4*;-R$0CV;3)V<*+D?_EG^!7BV(Z2-M-^
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MQAPCX-IEXZFN1,YBHCJ\=;8[9Y[;PE/-/X9/8S G/JBX'0133_(JDZ06*J[
MZYMOB"9,6LU+T=EM74.\.B0B-;RC#IDL5Z%*.#=A.%"*+D?T=L/I?=N@C^I0
MDX7ALO3>=89J")I/"X[3#ZF_K,;D=#W"OW//QWVVEV8;4BW4;:Z(=&U;)O&=
MUZ^(?S$A;O_'[PV2(R)*B\/2[^ #_=D@P#_T[TQ?OJY[X=RAT*<HK2[<730P
M0DR#^!(R5F8S/M3DCNI@GK;N\>8A<0[]X/+V[HHUN2IHW8+W4@,CVLW,.E)R
M$DO8BV/"!'[;G#ISWZY?>H@Z9LC7P']DO9\\\2Q'Y\S[5:<<#W[/34(+S0&[
M07*8+,N<[580A@+!9UN7D#;?-N O;DS\_3SUMW-Z0#W+"\/9$S1P-[*T&U$>
MX>^28X7.:\>)56=.;:O6M,BLSFU*ZI6\*6+/+Z%!Q0Q\))0)=W':V_Y'/Z(-
MYN(:<W'0YCH[;XS6"A,G81+MNK4_-#2VH1.C1FIK^D'E=6%(+4F]XO@3\8/)
ME>4Z2">,%JJ*T7=@>7\L .R67DK^,;_ME.LTTH6&/'0A8Q#+YW"WK"I;<(L3
M_8C7']3-0M[*"GT:WVVX)(*I7=&*O/"")]#DH!SW)-RA?[1DSM3.@E]X;3I9
M]2S7#;<Y70,(G$ZGK@&TLD+B77.!76X]J=OJE;'O\!>2S&"[>2C77EH8<RL'
M5 \->5<*HG:8NPK-3'=8Y9-37D))13 =_7K%2.!_+_P/-.[#29#$53@(;\97
MU**Q'J.W^M.%;7R?(TZIIMV HO*VQP2%/#T,]4("> F$2ME(Z5X4W?:Y"<R"
MQ4!UB "L_?$$]ZX<:OVEI>)V-MX\CBO5Z^1_T9C3I269"#[)OY>/:L.) ;;_
M%X)0"AP%/]0\.;@X==SA2\+<"%". XMK0+EM6=7/'-P)&-5[]&53ZVHH"U-X
M+G^S4WNRJ+^1"?@=M2RS \8C4+5B1S 0:N>Z6BIID+Q?5B-GI^*L.<08UNY7
MJF FCTJ1X@]=%'&G\1OV0.6MRL$[&?FV["8/9-403#ICYNHF\)=J@DR&CC^4
MW_'K",EHWQ-Q-TKL;<XM'=)\)+"I\$'OC[IV;M0C$EED#YC,"T@!M4;11:\T
MU,5U=IZ>H<T4V5PE%*5[J+\1/)GQ2 0S'"W30)DQ.2O+4;@GZ/B.0,6.DE:)
MVCKIC/JHM'63L=,EH8?T*X^+"129)97;W-_M2[$&4BD!H-5T-Q&,E4/%=_#!
MPR]Z4I:D,?YG)8S&QGGC7CK?\:ZR.8P&9&VR*-D8WR>WZ]XS' '=P;*BA4*;
M(4@(,^;T0+49#8_B#..E4Z",5I?AH2ZAW;9N=Y<4I7M$)+!Y)T"<&N]/!59X
MPNHJ9U\VR,59,Y4[W%"%MJT^DY/J/+TRMLFMUVRCUDT/-VRR"Z_N[0("R!2U
M& HCO.0L3N?6:C*?.?CX<:##97RL^=Z]!;(BQ0^.M0G;@GC0&F>[5VB6WCG(
M!Q"/+W=[@I.>HE>9PY)41:.DP337_=R P2?%/Q9*HO!>OF'UTND=S,H&OUH&
M;K?2724$,6Q=+!9TIWRKH]3@EW1\EJTF6\7[RJ_/4 \S7>V(HQBIO?SNXJ5!
MIS51]@K!6[9GE8S< /.^4MW(Y#/Y^] ZC)\K[K2@1?OLGB&=A7K\-[#L%HPI
MO]4\BNUP<B92E*I9+-V77?%K./Z] XMR"\5+,WL<U33<#L@TBT$:ICY%C592
M#A>UA:D)Y,<]2R1\=MLOALNH(JOG;<LF_GK\+-]+T,.K[[6,8$JL:A7:HCQ?
MQ2O0@2 ^1\W.3GRPRP#ASLW?_H5=M9KE/K_O\=6=\F'8S+(9QM(/K=+)H!F"
M=*7&E$/JI7L*I1U;::6M)27/1/C,S5WG))R)O[/=?F>497E!\3\1UI );8=8
M#L7=Q7 ==0<)32BGY\TE*ZR2)JKNOJWLB1ZHE+WS8(30RNP:T,5R3MZL?@UX
M-9!U13W9CZ6ZRFFFN93?:LQ8_B!4QA4H@MRMK_.9*G?R<N42P>]F)6U@(GHP
MK?^O?2/HV8T^[+X&)+%B;IB)N3CD2GIQ>B+Y?/R2*6@61@:S \^RK[H$(TU+
M#<9PAV2ZI_@.!8-NC#U> 6NKHZJ_>-RE8\K\HR[HVN H;> -%Z.0]<K!@%52
M(3!R)TF"J;$I9UK?]K<%61XT':':QI&;>5S)DWL3WMY_ZL+'Q'24A/\K=_']
MQH.0FBS*0>K&V.8DV5<_/OU,E 7F/A[TVW@?1.,@W1O:+%?*N&@RA9WIV3V]
M^/!.)B&QBU+9K]R\S' U'IOD>N]FB2"AJ]L&^KP=)7ZV9;%%^AGT'N/>MEJ=
M8*!LHW)JR8(30^EBWST3WGV?9PM5AS^/KY3\[_B&^/+U+G&BZL*]5H4BW7VY
MAAB-:4W%1_;*N\;\RGP.4I-7@H-[Z<L\3FUJ,95(.!%&O9>9 U,UEYGE6Z7A
ME<,=SK^B)F\GW^H.'?A%EK 5M=:F\+AC?'T[*:A.Q=9&5U_82RISL&#+.Y!3
MB=HPVR_G;]4H32?V:?64V)[@I7X%6KGPM7X>D=,#B5A*FTE-R;;!A4RCP\ G
MV219-+"UC)WED]W)*<-,S(%2RQ@6#\'=.'U"9FDQ\BXU89Y',3.O/_)>4/Z4
M2BS<42L<<J]60'F@BZ&E)XLKBS4.H5+QM2OF+>'!+6<ICGLM&FZ*5]NPU?@-
MT9&LRPPP6NLP>$?,D QU#4""0UNY(>8F]G22>L/.]U.>NMF( 7B?K#2^\]OE
M:R@;'_Y/^:@L\_(K5?#7>]]2FB][I2'=C(-OU%9N@@-CJ#XF6T! 9J?TLRGK
M=]^"3Z_7_?EQ?!=?V33 H11\)7L9F-?24A??F2G^TTD]4L#&WO-5/T=L5,7P
MEYD0BV"4^FD::K@W V(\[LG$W24-O7BA,^ ^UY-UZLEL*?-2 IGRA)LY^1#8
M6T[LF[1"%^<%I,1,ZXP)U631E$P7@R(M!4HH()W,6VR':REZK=8087FP*,=7
MSW*'JTS<7:@#QGDE+'.^"T0R5BL0Y+H7J#"O@[KJ[IZ@_!4=P?RR,0+\*9M[
MX4'(MMIIY7THDRS-HXEOBVH6.QH"\"VK@3Q3*EG]Y_H//[%73YONW23517_:
M?F61+=M+TD1- $W"*DE@T'1G78)OYIG6A%?W\FETAN#D7NGRAG,ZNQ^'38<S
MH:#[4UD[?-W-CKIQQMA6>07K)9$FMZ' 2@O>;6:J0MS<\KU:(3H3^]'N\K(,
MOR*RA^-=P_G/Q0**JRYI>?;]A>W.G_:,/=UX,#7<[3J7U7X-((*^N+BS%Q\A
MOJ>[- &!**XN/E)?+9Q/5.A[:_B!T(E<ZHFN6]3-]LY%Z]6/@^T667J"B!M0
MD\-M9 3[O2];4!OANU-SY@I+,EWGK)_P*0LS:J/N3M3U,+_>'_37:E.JN :$
M?;DJF"&@Z]4?E3V\!OCTX_JC!WKKH'. /:SEI1J&O1V'ASJ(#IKT*YW!?.QI
MY,R,MC\S3$OP%+S]./[S*IXM-P"OKP^P V7#C*\.Q_J+G^#>"Y7:CN]K9.#2
M?\R)ERY^:L-?'V!T+[Q-,?V>#P&<%6%40H-WZ[Q"/YG=09^/-7<L[V@L&&%!
MPW^0==*&HRPD^L-[@^@6Y)(SK,*3QI;^$+M8O>;O,E\O=Z%-..9I^)N%HIE)
MJ!L^UXYE+,6$6$2W\ZU2^/ED.S26=G^23+PJ=*RN$8P37G9@;'P0Q]?Y"F/Z
M_>FEL.]X+T-6%Y!A>XD7!6KX,8=QTDWJHG.K32XM..JI:.0/YA:J[>Q[6/W)
M1KY=!P"XHLAM?8QB"06O%C5;H5V-T(41S>K?EC 0/0;E8);PDYU2$3G..VG@
M.40<M_:XZ/.NYN")4)UZ>L+):X!E/.4V[O'5)RQ^B5/CX'"$E]-/09- W7V#
M%/7W@M_PHB6?M-UG>H=?"PCH_CO@A*Y>NOA> SIH68![N >8PDZ0(-H)@Y!"
MU%>BS!,7ECKJ6LV&/?$?X_=S<;,$<-R[.QC(8D%XJ89EQ<0CAVDQ0EUP,JA*
MGF^ P<B>.!_]O'&UTZ<4ODK7CS_NMC.K0/P!YWFGJE/'8+J@"6W?]V/ ".]6
MVHG= Q<HNT^Y&/N+R0=W<YL; 8\:U=AB0.--4K9O6#X%14[W+%?#=G/03JL^
M$4%,3Q$']+XP8U3J>P'!O>,=.5#[ZL_?R,0AHWUL\6[:/^@Y4@O#NYQ$V+D<
M*CF-5KT0B.\BDPA4&F&J[%S7;/IZROB%0,N=;[>Q"UWXWI,EHI6^%74665/L
M[/2L54L0T;\GV<LZI,(4P4JNPAH3!3AW/7TS61-/@9N'U 3EK<[F_!S7^!;M
M<N;=Z:GE7@3^$O9 F)Z^]WL1U 8%.?T2TL&PE@JI"4OV<DP1K:D XIGD)-QV
M;O A\OWU:]CQ@F\5UL%"@*5%[=A;W$7MI88=IR07.@6(L\J&%PMSI,@1<F=W
MVT.?7@,22+K@IZ0-UX!1#7F6:!#1V,8-.J/XND"<-2D;'>JKBYI+/>L%D(<D
M7=.U!#\]:-W?QKNH';>W4U1J::+X&\MCP(XLX3!4:<F^.)/KL\E07*&?C30'
M&>E;5>MZ;VYZWX6N,4\M.>KU?'VPR5_&;EG\U>%(E@JZ=V(0:OLZD_U4_K2R
M':?-9U' TX*57\./WFJQ$[1&8\Q1BFVP.V);)5#@JKE,I_?1@X'3)ZU^4MRD
M&_QME&^)VH9ICFH/C0Q^6WT),.95%C"6DX.MF S.MM9?Q( "=<,,98MGE74^
M?2J;:DTS73OP+$M5]V.)PLGY[K0'2=9.R:JORGD\0YG'?DVPV$JS36LL7EP0
M%4I]:,:FVZ2LW&TPY-"*=U7:+%"*54333T ]*!T\.ET\ETD6[*L4OSN49$>F
MV2E<=M;=MR:]^:%<5C=D1+*$9!)B@M],X1ZBRI*+GPW_>?RS5J^A1:V7>\>B
M4/ 1HYJ:WR;NY(:[).;U_NEXN202<NBHON\-.Q>5$L+SW?^ST7'1)9W:-4RZ
MX[^^/CFP)9DR]7Y1(.<U-&(MHO]%3,:0H9P4N]M4\VASX'?HP]K1F@-FA\=8
M!0IY+C3/6(JIM^7#+T8F![V_@U,9P\UBO(]*(:?,J/?\=IT,4RVKRE'**4^<
MA9;4O:PR;PN^L/3;I&U('YY%(E)#CD"1"#*A+G62@RB9 ?$P \6SA$QV1LGZ
MWSP7OW.P)L[^ 0.H)BS^=D(6RK'[''RS@+4I2.0Q+,HSB\I1>B.L<.3D,I#]
M14V3@U> 6LF'/1A!QVW5M7B>,+9ZTN->?_LQ69UK  G_=A;JH^E-QM-??10(
M#\=UM+Z%'T4SEM?8R4";N5-CK%T&H?/<L2 V#('I40E&\T+&*T%AH&!'9)Z/
M=Y]VE3."I60;6.O) -L#,L5]<1/,^^%;+5]?K\/:.B4KXKH[Z^ZNL1B?04X2
MDCCTL[0(P3,)K4ATK8>D+=Z?[)C.;?CQM& Y[SA =*&9+]\W3W,2JB'8A& ,
M?-VQ?S8X)K!:22Z1Y5JIDKA[_[SPK>W"6[]NRUF,*T(6<O= +#J>?BL)^]3^
MFY&L:N,3=6OW72LK)SC+(_*?"W[T,@U#X!"0$#@^#,J.R,+';/1I3U/87WP6
MZ0$JM!N?GJT$FSN@[2($!"4L?$%;R)YGC5YK>O%=4C'33_M5$!ET/6<XII&]
M8R$JAT:#ZCN#U=L^]0S&F7S?4YG]55@^RU9A5_:?#%N<.!F/0?6]D,/W(%N-
M5P7QH0*6#>:FJHF=@VD7ROKDU.EO#]\_YEAAFF6->VJ"QFJ-6QG'XM)+MS0H
M.DDR'OG</UFF;$2BBVE9J&79BCY/+7?-Z:FQ=72<V2=2;55&O+E\_8[IFP.(
M)Z2W<2@GH'S>#&,08,0^?FQ=1210,M TF% X9"9A2!(G?* /E<G&]/2JH%\P
MP*.<:^44SK2;TY4;XS6,4C5J89C3X!')@QCSA14XU-"BA$F1E[0PAY!U;(00
M[SO&"7'[IM(+> : &8Q-?<]9Z]6:GU\\;Z;L+_MF2SO_3GN;2;YO_B>S6]04
M6CD9,;#GT3&^Z7^5DOK-Q%PL;3'_E-G#D?S^KY>Q9_$\X9UVF4L?)/64 .Z'
M6Q;\8(J<"2J+*@A!-$&4!O6,[6I9O?5S04E4D^]\/5:%%\6GAG9.#1<LJQT,
M&M ;%6*M=;[7L=39EZ05(9^KE*BQ,<A__F;%*O.M0GG1-!^J%Z=6'P[;9:'#
MO>=AD((1.H"XLU;""NSLRN=-G<X,SCK5)V+?"<]4?[E])Y?_6:LQZ]>$I@=1
M-YS1=I&NV[]P-P_5 03Z)BX_F\A.E'(MYZHP#6VL5_]"BOI!>8N>$"]\<2_M
M] 8P#[7>@'<^95TP&E)<,E\#^NI\67 M!3<H?&C(3'(UE8HQ7(M;@%TN0M#J
M1W:PDBT05R.Z/-RU9L]_::#3H,B]L2SQ5$%-Z,O'N_1<W,*[K]0 3+/;P@.>
MI=S=!DO@Z?*#VDOU82*S>=-OZ7D%$7$!4JD^7_= !TN$_1_OWN]E.O,\-K3L
M<&>F'<7:65DB>$Z6*;;F"M8'%PX=1.>WPJBK@L/W\Q)D._\DRVD:^GP?IM>Y
M20<M+.^ ,Q/6[N9C=O286M]LH!CLV"#5V[B[#ANX)/U.4Y/N"7/DS:YD\HXV
M&W^'=?"+@2GFML!6$Y99)B);"-@>HU)LUT=6?MG<?>UP>KYZN*+8A4ID%H*S
MK) 6?CN(0D-J)5U!XI%-XNXOXB'N(84/=[RM"*6&:<9&Y1\,AWO&4\U@RKO.
M_%OAKD6;DHEM<Z!TIH^AQ\=&Z$?-V4F"9^?!K%8%UILX)O15>2?)E9 V.C3T
M(':-3F&ZBR@_8B6B)LYYP)2P\XU"E/)!NHO:GZ9^'OP/:.80-,%9VQQ32BQB
M4$@#_8*.UK7(L7J+RU<P5UGO;23PLVPUZVW\I)B/$HGTGEC% M^RH^ZE!TVC
M)SL",IU3@[R3QUN[LENN3\V4V5-]#^OJI=J'#[=YLN^]GE=#/X>JM$Q\F]ZS
M1CEM5;:[YI1&4/7Z<KP^JNW93>;1]W;NI4=F#*+*8A&E3S"?=EH?UDUV+^7P
MS\F'M;_"#=<^NOT61'3T_&.O7[M4[YOIFWCWFVBEP<0$D3+= S,9"W6Y5N\R
M\TF+,,(D?P]= ZI<YF.S!$6G,_U?LCRH*:=R9+X_MC8J/N_\:&Y:NS[5(,R4
M3;BU;BDG5UG@,M>H:/']6^%E\:WDW]#G-RQ \!IPM0D[=M<F9$='JZ'?)%DX
M&LQ=?0(1QRME,@Z2[4J::7B;O_ 0Z+D&)"N$,7HCDZ99"].#9DP,H_9 =[ &
M35/B.P**G=-"WV#66R-&?B*S>'XN'$><2]#!WLP0EH* U&[(.;?_V56 N%_Y
M7N\U@*L)J54:CTLUG:8&+Q7B[N,\Y(BN 0U_S0R]!O P[8=D^QY.MP>Q54\V
M&Q8N8U*V$2?'+9ID_(ID,9I:LPFY2]#.^SUJ[-Z//2:^5:X.,RU"Q<?%6L ]
M$MX6HJ'.=S8B&)\;AJWDL?WD>V-*](?G+0&R_FV/F_DDS9S?ABB"C+UKNE4(
M5;J?A+@KM@R<E>N;\FS@-[";2,Z=OZNF1L BJ/5UA6F13* L">&+8UUV%-V9
M&O=];GH743>J]-$XIX%4_;?=D)'(1XD5*Z8C<P%JO %?(36T12H,88<6A-N5
MF9@[NH+B:4K#9]-Z?N>&OE=L:)XR(/5!:7JTL1D6_<MA2#LZ/-B3A65FUA@3
MKEX_65I27GK"Y[NO_3@.00>D#EEXC'W*GB/>HD0-T#.GF2@&]"O?E;M;J"//
M3,>R:X-:%$I][#AFS_L=YE@8QC%IY\SI4G]P!!IHLEN2FH]MV+NINA1PVV4B
MJ!J:O_%JXF(HMMAL-A9TNJ$PR54I.=66^#!]P+*9]"O5KS[ ](]1>68G1-8L
MLAW$B](*EQ7T//=,!Y+U/9CCO]#HG%O8&E,NT%]-OFLCHT;X5<)OT!$JB%%<
M/?C@S1##\'!QV*MH(7U046?")?//]N%KP#)'F=H3 $ :;ZS)D0<_0PM@'XG<
MDK45^.H;?(S^)MZ;-J_Q,_#2V\[%Q^.K;>7R2M:'?-2]II6>\340R]2^2]E!
M*6Z<:XNCX<NWS^%#ZP--#VX)?[W'UYC[#B2&:4=IF39CPA'SPQC=LZ7'8=L]
M),[<NJBLJ'&5N%,Q[3NM10_J>8R*="XGU20%"8:DSN)G?59I#MI<WX%(4,P%
M@00%WS>G;&6BT_7YJ%0/96.H9)/O]+^7_T7?-D18-/KWD^3\N/=LD/'D4/&K
MK]! 1#P)Q'@K;3_U6VUWRSI*[P&K2/C;TLXG"MW4:Z)[]Z6Z_1?]('M:JXQ
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MG#OS_0U2J%7H&N""_5@>4M3X";0E=%5;WI(IY8JF6GG;I%5O)/E.G#KUUS5
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M.QIG7_*,I_+]R<C*R)E!PBV!8<*<PY%!;+VGGX_GBQA5QQXF_E&C-%IUKUX
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M9HD$%=\#BV8A"GJPPWPWJ:>Q="'5<%Q5R&1.COT%\);90BOHG/OU32;[6K4
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M$'7010+$A^S J4M S(,%ZGZG<F ]JOOBA5[19P)K6M1Y#K%^"EK#X].[Q(?
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MH3$_8[6RE5+_1%<R0G+*X%[:YUZ)$]S/"R]/635J KS'6^8F5]!SS0P21#"
M8#;05CY7W^.!X_06$;_1D#Z91B=*I\BE^M9I\%5VP$U5MZ_Z&.;3&\>6I7-5
MLVN''(-NBI98'O'% RY!1.6!#$&C#'J>G Z5FB]C]4LCVNN9&L/*>Y<U=W7Z
M;DQPS<>.;HWB#SOBIN8,<>!8$LP:[1;&"NEJA5UH^JEJ7M)56(*H"341QYP]
MSZJ0S)9\E,+SZ+6Z(X!X)K(/-Q#NC+!$-TI8#K]P\-AZ-"0QY<!U/SGRWH7W
MP=WH,/;\__-G'"\(E7II9KC2RORI+:+FS,??VHAYUQ?B,GXR3F9-(BF4\U(%
MI95^Q?EM2CQHR_PH$/HBC$6]. KJ^OVSM<V3=],_*-<SP@0 OIR;NCC[=A
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M 9Q<HLZKAY$.2Z9P$^QQ.\O+MF56ZQ<M>LL$$H2XS_Y.>>IV3<>$[I7W(_<
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M 1F!Y\"_,LN:J !K8/A!T;P?$%T;SO=R4-7$LQC5F7CCZ(5.<;?FP,.(J\W
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M8!HIQ95 A:B NZ4TY Y:A?W1?S C:%-"+%EI;DNKN?!R/?NBI*X!*J#H"14
M+]JFW>;/^&_:*>NG2P7<@/USWS_W_?]EGXFE"]ZW\R#YW=AW0N6S6!0*)'(V
M>4>O/.]FM1;D\@([D5;EGA]O!>V)K\()U\/^9Q>2O>P];/7I( AGR4P%L.H]
M7ZR)?X/^^9W@9$Z+W3X2EY<#7_I$97G/2R7AXR$3+(@D ?ZC 5F4#9NO!_[1
M6S1NND0%9)G<HP):/$ D/>E"T+(0V0Q.(H.]2*PXFTCR"A40XH0&'K-[Z),X
M-?Y7:_'OI%C7/PK^YYY_[OGGGO^0/4@3Y'PJ;,<EF-*F /ZI?"SZ=U%NSFT5
M9YV%(J?IE=<,;]5R[+A8/TL4+6P-N&4^V*9LN%RW;C<I^UV.7)F^5]/Q\X_Q
M'@5_GF92>G(!$W5'-9X*>!E<'KGR:R.8LN5NTC[4-CGZKHXE(78%INF-)4G9
M4P&9-E3 '!5 Z8PCF-&0^'8'%8"D L@Q;V$.:! <!UO4K@YS_UU0ID8[:#$5
ML,<()O[Q]88)VCD93&G,X#+R\(_7Y3E$_7,D*B"8"A X^+[MP\Z^@L15PRF!
M450 C H@<H/03B R'2?ECYL/9/_R</XQOH&[V8A#"D<E+6_=A&'_^+.M]M])
MMJ4JNDMA)@6CVNI6C4QH1+MU#'9\1IK\Q\V;K_Y>,'+^>PJ,QHP_^#[S4CL?
MN3OWMP<#_JU853CX  &TP^QT827+P,KW[T_U=X(=9+ >T>H>RITMZ^D]<8D!
MV-^>ZF_DH@RWPD#S5$"W6K%*1HBF]RJA>#&0_ GTOQYE4CT0[I*S7LMATWQ?
M4,!M]TW&B;4XG[(MWEM1*?(9<21$V):UT_26V+^J^,*_OH_5?R-E_F/G!:(@
M^BLDX!']?XSO(KWQYTIDTY4/-Z_$S'W>\?XQ55T^SKM<\E+1062D9L<_'=&U
M]?PX/?T?^KS<7X1B^&^L^;'0.OSI*J=!5\E[=3%@K[38',4UXTJ:SR<D1_70
MSDHN5JB;_%?E-_BK;AK_$[SAOT$FDQN#V%NH7QE6'[/>N;"31N>ZA@TT'^S\
M77;]_MN&/3NM-XD5<@79D5NR?T(>G!,50*#440&E,:1^WWZ('!5 @M$JR'$M
MRLLF)V6" TVS&LE-W4&18F4I2O^H7W,:C%"OKEV '7%[,A^F_#'I+QP)\7-R
MZZ0"=F37@5AI2I!$-J@YY1OIJ\GD2SZ(R58:?N Q@1YGO& Z:$MO-8*U&9)=
MR[B!G^H7;."R8%$TBGWH>73PXE+JH1E&718J/-BD"%4<1?"5<L;^.C+*[1/P
MKMG).:/+JM8"#!?V$,F+>N^H.6)B,F)0X;C"D$L"6.K/3]>(MBMG0P9,ADY.
M$^!;.XBMUWA/R;-]=^*F+W<#8[S=ML"VQ5!17/[[Y>]X_AR1G!+(1E]] VM]
MHIM:6_W4B1\8V>CLY\_YOLZ["C;.M? SXU="2:!\R-M#JR'[H3TB9$MPQ&7K
MJ_EXI.KI::[(,V+R"?1/4E=@#MA 96R7.?-YE -W)_RK=HYC^7J%W";SM:0%
M8H%\?."X2/W:T^JG ]+O:)HFW70@HBJU%]*K!P+4ST!UQZ!JA58.7N5K"B9X
M5<,$ZR2IR#AII0F9;Q,6T.:,982H(=XDEE9/!/D1--I]SGRKW+@C4#_*M#09
MZ:(U_0OSC.5AT(OXR.NCS_MDBI*OZ ^!.%69,<P10/K]N'-35@XU9AF5UE=#
M9D;*NW]W5FC]W.(._A)TAPMDMNL'/+ ;EVHZ2V!M4:@_R$#%!55'J=GJ(6IK
MW["W3:DH"_]\=/MJMXJ^M2;WAVA.%9-EY,\6CH3QNABB *3#7\*,I-<TN,]3
MPMR6.*OAD ?Q-T4.5\ESM+R\>F$^,%?RYULO%^& .^S5Q.L#&& $O*(FZ0#+
M,L=D<[SQ.'3![)VTYU():?5^C=;XQ _CQ6LM+9T2!01?G+X!3C1"%;9P>7MO
M'.\5)1QI'"EF*>G2]^;]98MMEW97&^\>N41<PWQ7+(63=+H1QP_'\+$Y=KN"
M*O<]:U*<M;P7D[4\9GK -T):^)2ROZ[UIB7MQS2MP#8*IO3=A%@/GN&:&N:Q
MX7!VV4_[,6!S'%,NR<!!@;NRLF*:M.41WK^K7/B"I^NGCN(B=P<Y!_'4%TT%
MH'+F.R)GY[JRUZ]YD7.L7U[]:"FNU7$G\H9IMQK@U+@U41YZ#H]M-2_*60"%
M:W=R&)@S^,G_9(!5=KC4U=[OHY][B?HD*@R=FY53Z!@(5+^*7Z$%R0G"X?TQ
MV2)%J)CP35.K.Q)56P+B4Y^?/0= .DQ4U1H2$QP'P$D-;L<AXS>7*2<('1B:
M!_ SX9'A4#_^?-\LQPQQ>?XSPYX]5DSW7UD9QYS*-EC6YA_5XOG8Q*$U<<=P
MI@]9HQ^V!SM'NMLX+MM5A:</DKN\UZBM75G'6CS4*YI"IW'KJV]\[&9"X$>M
M%0> ?34YT_^L&<D#YQ+[6>[GI*.9'8D[-V3XVHM8R*_7S?Q/ ^W4<$Y]TC";
M*! +!(PQV_"I N,2"5-/@XV3=X:$%DT1+"DA0L9*0LOQSQ(3A!57Q0S;C"Q&
M9;W6=LC2NPP=ZWU(U(.%TGR%%K<H,]Z:!()V5Q-G347#F59\J> KD0PY733\
MA3U\]IKQ4R'ZH M.MFVPJA9<6*O^*7,F=3 ;(7*\.=4MHOI]\EI64DF&V&^$
MR]*/Y)=^*];B-[XF\]I1 9= =I8PC'881:BW !*E']7!?RMTJ&4Y=E:_PA1E
MWETA*+CBKO3\K2[VR2M@I78T@JL,P@S&'48[2U:[<+9Q-+&-"J;VY-8V5@>K
MFV?.U('3I[^\\'DJ&G;@*+6/M.HM<YKVWRI^27(BYXCBW8+5K[Z:/3-L!=F3
M/D<%.(,)H>;82K^0E8!>Q^_9.9]?B#/L:_*<G?E"MP:O2*Z&8:0GQYM]DO.]
MI,CD7U_*Y/HV31==^GM$2]YDR) _>9)-VH&7MJO@[,V2JM[HU;T88ZG[$XBB
M-VQ,; IGNV^O]M?IK+S98U^?.]W$#VJ%A61PX]ZG%!7H?C5C>%EO-"$LD/A!
MQ;/8\6=*N4'H(3@9&2'5E=R]Y>3[C J(-VF;.\!3 5F1+25;MA1-,#-LJHL2
M*L$-.JVO3ZX7[K(G>]YXE1VY+"R!@85G7!G/)HSCB7<'MQ%WKO;'A6QNJX+L
ML[7=53^ $?>[!XOO=WCIQK2C7S]Z= OL;!)!$)WOBH2J$>]!RC!J!T5?]6TQ
M#(K.>=]K@PR$=<\'\DAPM(C2*?'_*$6H+ERPOX[R6_W18(%SD>B88Y$MBT-6
M&L=@R%K' \]&]ISRQIT?9C)$L(ON]'W+=WB>=0Z;@5AN1#8#JR_B4V)(-[-F
M"88KMX/;QVK'S1P:: CV,,+EQ43K]G3GJ:MA?0TO$H6X.H"L(/LM]RYPE7:@
MOQ!J(UF>P_]R;?*,\RR]0^[NT]&T=Z_/SL5WN3I])-@2A0DY+5:BN.NU181E
M)I^5-EJ8GWL[- &7Q[M^<I6^9O.+^)33W?Y\Y@5 :>'/$!U1"5$W-?(*1;.6
MHUJE["QET&U!S5T'KH_+W1H/K'XYDD.3K%\X:'(SS2FM )%Y1?=\MY"Z+0=*
MIBCA-(C1?TC9JYUA1D&?TDODC\.DRZ]C;X\DKS982IH'?RUG>\(8HK4/:#+B
M31)B@Y^F17L:&G@P'D8?]7RD"6@Q;6$QZ8"UC^J%J;R!D*877JY(#ROQO\>X
M!8'H$":XG+:5UEK_FWHFK3Z^]V73/*IWMCE$&3FNS7WXV1#!<UMX032R\W[0
M\M*1VPIA:_'!TJJWR>8447?=GYN@B7.4YC;M\;;%])1ZK")TU;/YW=^)?BI(
M8$&N=Y_/.MSN[NQ[GD'C,RYPYJX"O\:J:O4SZI)N9V+\5; R+Q'/[C6]#K05
M=_EU^\)526T5%8/YN4FN/3]F=%GH?J/9P%,<-O#ZW..*<ZZ]:B/8NKBTQ"IQ
M1+26$MI]MISG@+OZ>A._GME9Q*DF&3<NJ2]O?B!,&4]><0:J0+_?5BEO8$=D
ML+A_S!TC$Y&=8SO7=N3]S#793!)LV)$TSL$D37[]/Z<+!YI3%&@$;(B&JV>1
M>Y<L;U!.D4W6#0FF79"$L]L(E6]MXMC(!Z8&XXK=8G?8C_9Q$JW^2H1@G-=\
M9_[\LWUA/%->PQOU!@Q/6FCH)1O1^(?.._(ONYL9N)MN_I+8NV52D6@XY.8B
M"-^LF+Z-%T;3'=E]#)C2I^?Z)1%"HS+OF /FF)P1/ Y%^L63D[V2'Z8M[I7_
M,.6M,^0,WKW%2R0^'2PN?))46T]*)6MSF3(A"%BTFO;#<9.6^NVP!3<6AYHG
M,WF!>1L7O7<O=XGKB-HKG@YO%DWM(-@1[TV1'A/>6&/ZI>\E;#;%ORF<=5#V
M_%W7$*33<\XYJOI>@I(NX%3I64!<FM!O#[>P#';<<HY(UE>"O?80=M%8N[[B
M>R27Z;.E0+O'.L(GG>)PX\UJHBT9=/C:4%D^+2K@05S[T-PCMRL?CVK>6A0Q
M_=[=^2CUPY8W\'$ZCYR+!PUJI#UV8?2443 .#KT/1X\59I*#=@UPS6.J58F'
M]= 8'B[G;2WW1JVSS]G0H09Z[LA*[<YK)'JB(HD[=F?(Q17&1LC WB'>&W^A
MUD3L;146+N(\+TCGJNT**46BL9OVN5 5O'Q@&0J2<;QB.$@"*83E.$C9&$'2
MO^0D/3ZSM,M,G.A9$2E[1NFIJ==N8SX!T6KK4$C>(:A8^/GT&CH]F_GZ^6OZ
M0;T'BJG-_V[]DJI<G5!-^O$U6+.L*X\0KS]*_@9!H8.[\3 ,,XSU0+)WH24D
M3#VEIV<MZ@R%O6GA>3MD)NHD(#HZ0=,GKE4_,@PCUQ51?#7HUIO,V9(<1WE3
M>9/UP3#3Y\*)L?<K%N<+CV*\HVDDG3^P *J MP]Q(VD6S R4;O1@A$>A5;K%
M96SBV]$7F']>=I\<*"][@S,)VW=C=LAX5(FY1M+U#@%7ZYW4:(WV&UT03=!W
MGS!FM[Q@LGEX= 1KN;(SI=%?#'HU*4)(6Y@[805Y(Z6JB4:[R*<!D%<]H[S#
M&01OW?OVWBV:K9>O(T#4018"/HC_C@=VEKBC%WN=<C:X/=>JX_1&9N;K&P/N
M6<Q,)31<-9PX*:#A;)+H=8+9O)AT^;?G0#0W9[O#:&?MU[6=M=5O_KKQGV0X
M^0Y8KX"]1+^7NK6#*ZUB,%@>@E<']RAIO#XYL+2IVO:UH%'ZQ:7DP:^\51)7
M+IR@; \&/#+TX%]'^8/&E_G78 NUG;[(X.^$AY.K-S8J"6%FM8-"NMC^[#;)
M/G:^3YHB)J)?& .'Y3!S/.I*Z_Q7"0_PNRVI51SUTM&J5^QY/LNFC7MDG*O1
M92M/-O(4+XV<J>6_P.0)KWD9440( H48HZ32R1TC5C+#VU:^$ES7DX=DXQ_H
M"3R^_;0;=!,P3QS;SB=*KAU3(O#R?$^L,E;,\#MM'%G?NIQX7=@,M.([X_/O
MM#+N]AP;CS3&*-YUGZ/%WW7#)5WY%X3#@Y#1)HY5"49_?@>!880$1U-J3?:2
MBZ?([5G/:%?UK<Z.74Z5"KHEP(G8Y#JBSO2,XQ@_/ZXTM!X>F8]+@]05"R>^
MK3C!92XG$;S<LVQM$<U(%_KK#(R6C%[(XI/+_0HL(1O/0LI(4E3 V9*^FVW
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M#5V6N!NI]O_R/M6XCC_&V4FC)>)X4G ]#=]Q5G".W!*PIMO%V,N?'R:(KZ1
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MDN6I\$%?(9B"+0WU6\6$KV?FQ=^)?=(OK]='P6?MF"#ZMME:ZH\IERKM:4Q
MEAGRA+<UID$$W9Q+XCK/X(01?:JHI6+4JZ[F+\L\8X<@.I""]:1=MCV?4=EX
MZ$^];XD8@>.5PR'L'@$%: HO8KX8?FE_/'GWG%2ISB?[PP(P57%,H.3:"<^&
MS(\Z:^?9]MQ"=X H!3&)%EK$B+P_55+G,NN$!#[\MR_M'Y/<CVO5.$>9)H\2
M;?,2\M(_?G(Y5CS<]ZFA23ZA[<BT/C&:.KL5[DYMXZI&?F![WJ OU<#YAN)+
M4_=Y/BEMBS4&P"@"@)[E.G_S'+DY"CY5L5M1!\]J(<YK/+\OO]NM-)3 $U(E
MKTQDB?J# ,T%TSE=LV^=WM_?B?E.9D_%72KX'A!:@G6+OG$/:,_Y4S7]I<4Q
M4ECJ_W_ Q@H;;=II_RL;&K>@@DGS4\V GS)#5])"3K &ZZIVER'5#75QEZ0@
MR7N $^T51=GNEDB:O,.@U;RG\AF;5H::9L%_TZ'T7SJ$V4N]&KM1(.';6Z:N
MGV8,>LVI!(SD!??)JP]\]NT3-&NCMZTH8OD.8Z!&K=D0[QR<: O1IZ$?_'JO
MI439R2[)L=D.L^_U;DM%+/0(W5&VV>/+=T$//%.1X?B?0L"%,;GF.@>C.+@6
MR:-%NW'.TJ$'-,)<;N<V6HL;J2]YE:3.2H;X[-A5?2YYCCE@JK--NZ/K2RPJ
MVI(JIQ09[V,9'QD_#;.*^?:%L(%>"; N4E@&^?AC_C>Y?EU[V,'W:<<O7#VG
M-M$2'0" )VY3&*D"*THA#Z2)^+U.K<_]H]#(R,X?ED4QSL,C89&_LD(9<\';
MVV(\3QG%:=G'1J/XX3* D3%ZF0:57&(C1(L.47+W\2HR!BD)[18O#(I3VV3Y
MR'X.PX[D>!IS$\ B_'+PR"F]'@BQF\Q &+<7;$AY9XZ6WUBLO7C6)_:)S#L_
M=B+#H+"BC'6YS:IL2*59-$?DTDC-_\WKU03M(Y!5CMW$[LF>'VW#5/F^KI*3
MJ^MS1T1_YW)(T9Q+L0O?F+=.*$@!%7H;ONZ$]@ 33<R"M862O&<'3#WV#FCI
M'IKSHX?Q'PN^&F0V2OCW@#UU$4=]*X'>4MEE)@8[S7DS>?B'WY@PQ>-8>N5C
M6HA:([@2<9^^*V)D%/SF/-=OL+(D7+WKST/_)[!+GO6E_^%=FOYSAX^[@.D-
M5BL:QC"%*+:)X[L@I5[G]((?J"2H,85PN#PB,S;1R<"WORKH)>A\.Q66X[QQ
M[#HUBUNJ;V2RFTIVKE.@VI3@43;1RV33M%&<]2IF712P&N]-2X02+I3S7.>)
MI*$>EZ*S@[76JL.&[9TJ4E*.NVPE3B02+J/*$<^[R)E"+3_SB@VYXGWXN3G:
MD'@/H--BF=F>NB*/@ C"K5M\";L\Q 12/[H=%7228&IO/SXO7/22]+658%T#
MTW9Z:^KNIHN_21SEFCI\CIGN]1R2R-?'.:0&#QS#N1R$2N%-/=!]Y.R5+'"R
M^^H\CB!B[4I2]5#B2<%GAN,LBG6;C;=1[[U&6&)B+ 3'0*S(Q2RF5N3'<)[R
MGL,JN)&B[04YFE#M>*T])S\O +!I@%^+ELP$($!/D29+LO-\<%1"6ZGML7O
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MN1;GXW6*31!KR=Z56N^?*T.N/%TK?NMRMV$C3-;&V)BAG/S4;P^K3D^B-G5
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MB[[A>J@\Q&]YQ')J&7=J\5[EGHX.F?9YNE2PCZ^'=> 2JWP0Q?Q4+[*YRA3
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M(7*6K*_@Z]I4P/%U-,=!+];BR.:]KF*$A5-V''[:S%!:)\P5QH>^)F[0G@/
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M(\)6FF;XG9ES[IQ[[_\\,_-A/IWJO3[M=U75^U3M5>^JJKY=OMT"43S5T-8
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MXRP$L[%0K-%T_];(_T0IIC%R/N!WM?25F%5?EJJ +G5R]4A_=EP#BSO\%D2
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M7:[N-S$(4OIANBV-(P5SQS_"M([->0-U?NL\#K;!6VT8+JNB0TO>D5O0']Y
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MPDO/94JPTZ&S\VO;[T;J11VC\>&3NE0#B+][$S^>^!2HG9PZ/ 'AZI[J4(!
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MM,0MB" N3LJ&E(W*38D?E5T*=9HS34^P1=5DG$ ?,B1I%0E\Q.--(P7ZK_7
M9XAP-/4M:%B9 O+0'TKJ9OP]L.R(GF*<>[4DU=>3.T<H[=UX&ZVKN+[VR//[
M@1@AI.9PB%YJ(7'WDH(4_? FX6/X;B/;H8^9^2%L^KVUQ6'M[EB P.?*/GF-
M+KZ'IJWYX)#+ *"S$C/42Z=$^].:\NN<@FJES>9T.?0$O&NE6MYC=AX'TF1=
M8&<@<'K$S5=$'K84)N.&P;Y+B 3[3?0/,L"39DTY?W7BU8=@8045??:/Y1_@
M?!5SM5-/]L3-2P@@GN8ONM,)UK1 .,K"',B&CWNLPF]!F2?5+HMS#PKJ-)7I
M;D$.OS"VNQ,C8\-O,\F.J?!$AI4)(9Y99H [JF2 E;+%AA8(GMA_NM"%Z_=Y
MQ*%KSHFR46"-CS(A:KB-CSOTFT,5WM((-!I*W>M>OS(]&JP7WY04CF7S,]U<
M&[Y)NK;!\ZWEE\7X/H-P1=H.J=C-9DY1_()1PD.M%R1GJ5?A5%Y=CM=RW[<%
MR<E57P5N'S%%L:;_RO-?A3:NG[0&OC;>HO$(^MP +U'F)R'XNV\:JJ9(==)4
MVIIE0"'6K/-UDEJG=8?,)+UTBTI<1;:_/D,A- C5B< D(&.#>LAT2L!1 V'B
MC?._*^N:JTU/RL\Y\EA.K*S&8Z*C3WT(> SQQU]=2C5DU)9(L">^C KF\B+R
M'</'5K8D OV1,+QI"C@*7^%&VT4-=CP)SLFM4H+6'\CD9E8L,PCK=GVNH\GU
MYV&N^]&N/:H*=>\$"JI^LBH@P^+@;4VU3H,O?S@O21%O*R3LKJ;Q>WY[9&S\
MJU!C9.^^Z7KLL5U7EN9-]IG%]M50Z0)G*W3K%A2_#$[PKTU*:*[^X/KP](K\
M-'Y0ZW6OQ#3#VC,'$\UK)@@-RKO_%A2W9&PM.T]ON%24=<TX$,!%6++2.&K[
MD7K!;'<_G<=(H0SD>W*MCM9%M0ZFP4@O"I0'PQA1;!%23 5RB\XY(6W1/K"@
M6=V"ZI['XRI&A@YXZTVGO[RI?BIQ=M^"WGJBE>>EYIM[VW/""==6F?BMRMLT
M>KYZ3,QN!7T;_JJZFK78K0G?[Q=AA!W:-)V4EQ37?>!-_:VH=O;$U9LCPTF[
MYAMA[Z236$$?=4;?JR4<,K5?\/#A[S:7 LCPP5$ G+/!/5,V4ZO^X>C-2H;D
M=7Q9SAO(L6'6&!8-G?<'H4@5UNHBM#_J-.Y:\\"&#!WR"0B;?HZRS@BL.L@\
M")285JQI&299O!)B-PK/2*#BK!P;F5NL#UM7IFX.C[H%?<T=$J$^H)9J:<3-
MM#!?$\BT#=K5@O2G)E=SB?)&]#E501X#WHA>"LR2#4&7M^.GID)&)";K,^RG
M3$K@O::75NP$.(Y7TK-0,5#:>WN%[3F,%)IW-DP6+8"2B90:R524L6QT=\YA
MZR5VD'PM8C?V,QEK*[L?$2$6[F03^]=YH#<"0XB\S,.A?&ANU;7T<I4YZ4,>
METF^W;IE9Z/T]OA8+2GYEG.,)#F=N]Q-]UOB%#WSM"$ALAG.Q!M/TNKGG_$W
M7,:YH0B>CE_6CY$6(VQT2L1@374@<-LF)G\TJ?Q'IJ*@+DHYROEKB."D5E\J
M@[-.4GSA^@ .B6C?5GJ(23>8I4O7SS4P! $^\:AH_Q#:DN>RX;R\U4>4J1.Y
MIQ7DQ+6+<V+5'RB*/[U)NI*&IN':)EA;OHL@FH^WE4_&K>=0Y .,0A4#]32'
MJ,,WL7TK;O3*CIFTX*%,3<&Q?E,*8HEVY3,V\_-;$#9$&96:?>U\I\)'K@H9
M,\D)W?-I4W,]*^\&U5MZY7V.2U0NT6HJF<0HNW.:*Y#A&1*R)4)AX=HB[F9R
M14?=CUOSDMN3J\NCR.N-$7-AZ0Q^8MA0ONF2\JN[J<WHV][62%_(?"W;UAR:
M.=S[S>I@_;TS^]](&QX@?"1W*9S4GWSE\>@2S#BR1*]&O<0UG%*(90I:LV)F
MK7&"6QT#:QUXHI7@1%2CIV2+U?/])J_G/OA#_^;7M%@T5OVH3 Q:T[Y$NTS;
MU].7^00G6J[F1Y.'ZLC68/IK>9/D#0@NBC=9V4&(;4NX$7E3@M+(<,>#NM=W
MS?3DN7*_!'642L12.7O93!!P\^01P'1>X%?>@OI5/3SK[I+JZ42J:6^2\\&2
MSB?G&C7V2@Z0*JZHOIU@HHMUIGZ89EH/F4LP7;=31VI&8+D9\0=9PO-]HU29
MY:W0'1X51P71B715]O/>YK,(R&.4S*47JCX*+5;14EOG+LUFUYIRRAGM)5P1
MTID- I5^]#L0?!/Z>,2:&F!RP; A<R];DT_\QX1.+N2K@5=Z"IP59P_(#.S2
M34^XTT5E%4!!RJ-W"4F'<VJOJW>D&/!FS!3<.$@_7;MY)"T:XZY+]VA=:5)0
M6,DB(7$D,82GWQH;^S?%ELF$#8F47FH/8RH3OQ*EYDUGS>:P=#OB)G#8.)#X
MEWA-9I(+R%OXT7F#2O*]2FQ?GKR>6H91R7]Y".L3_K]N69@0_L\;&R A&GT5
MW/_"F/^G#8OL_\VFQG]9P;\; 8B%WZ4X@HBO.((:6_9,1YT&]-+6^=%>SO\X
MBGY&LM^-@[V4;_Y_7K O[9M^:LZ')?8/]/TVC7_9G2?H3=E_G%UG1M E/DO$
MPHNXA_7SWZLFNJN#>?;'78OO7MS[H;V8$T'$+Y'/A^526E9T[PXM+J9"K/X
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M(GJ3?J<(SYW\<H&2I#:3-J]?(&:U\2HS7M7.QZS'*G>Q22M9(KHEMFR&TYB
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MFL/7+/=6-38D2D(0SY98X[N=]]RR[VURMUXE*'* %/%1^C%V<Q"1;"+8 L[
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MZ, HCP+5I/+!9Z/;]UL@ESER\4-61,1&>3$N-+&^L%4I4-KQPNA?C>B=WS>
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M)#5/G0<)CKT8=SGQ]VSWL1EFZO], /Y,;)![6B#K&;66+1!F);0GO/K;7:B
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MM= +!BC >QBR7X,3/#8%ZV@25( *6+YK8F@NF.\Y.N +N_3LL69DG=W4EJ]
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MGL/K)_C:F6^CK2.2>]KE9UWMU-&S7Y<B7G)"]HTQOK[WNYH:'@^I 8M2JV)
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M+DTF9B!.UU0HS3B)&P K&"8U+3Y2EOG4S0-$UZQ:W:2NU,)D9STL>AA+#BK
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M[I2_[P8 2OA\S8%M0 &-ZA9RLVX =C> WOYQD"^INYILR<N>8LZR*LX0F=^
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MLR5KRYQ$:R?I?MV94W&""K704]U*&G]*259")\ZL]7,0'H9_'OUM[J+5!41
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MR7V3>"U7[@@73BHZR,J-*%YT!&VT_M1A;W89(4RS2]8<_CS(*9VZPT/^QYV
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MA+>TGY[U H5?O)L5Z"^<(EG?U@0C#K7QM7\=B9#R: I"\FPDF6#F4;[SZW>
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M$%EVNQ+G7,X9B%4EGY.(SZA^N-Q,]>'QJT3.^.?/U#*VE7L2T_HP6#1H"N*
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MOKC] MI8)VY+0+2K_T4;0J7 *@4V0_=;</8&,<_?<DM&;2R16O4\W62MW^-
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MX$9CP\D_6N^U:^*,.T!,X2V3B^4=(-]!ZP[0U1R,R0+.?E^ZA01OW5OPV1W
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MTN EUA8YNMN.) .<+80GM8/'9M>%G\.V'I"=C'GB7PQN)5.W&-#"I^]A8#'
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M7WW4NYN\2FF-RR+B*ISYS5;W$Y6]U=G2\)Z%Z3%6<0'P)_P?8T!(E5"00[-
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MO4?9X^9=;**:K.!&O"3ZY@\QM75G36CP1565;J/U+%9N56!!1;UJXHH9.VF
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M[)X04X0,;1+)L $>]J/N!$FD*$TBPV<XJNI4*\@MZQ7N!=][K$-U1_[5O4<
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M'O69^Q0E7'&A&&1KD:R?"4K%<L)Y5K4[0HUD94>1:6P4B@M+M64#(;H,J=8
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MRPH>M"$;\O ")LI,027:^T3&9W? :L'DT6  ^'Z^_N+ERWWO["I;QI8FQ-D
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M8X_U,(27$UOV?IB:K"SG 6>&/ ^<K:$YY#GWMG:L?*':T+XG8W WEOL=!21
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M%Z]7[ ]V1C2<H"V=*&7TL[N[4G-U0$FV 1_K177"&5#R]GZC26SCG![S?K<
MI-E5_?[9CC]-!]<H M3C(<Z6*N6K*3VUEGBDV4KQ<Y' .HD2GW9;@3+S&:$Y
M,B$AGN0%HA'.@Z08\ /\!!KD7W-/51W4^SKNFLZN]I$J")10.-A>\)F.W,.R
M7E@(9'E.S-?OT8 60%5(1/! XNZN0I0:NBCMS+/:I_-DQ>%E ;V^T+R(Z_%Q
M;[7K6:7.6EC_$;8^JOX.8VOVZE"3?TK5K]UKE+5#+BTM*M.LQGQ*C7NT'$1
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M'-PQ;KQZBLI7GNF@WZ<F2@FS@I7E$.[/O;+83BI^SEVQ:4GQC%FB#]^0B7O
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MP'<#W%?K)";X6P/^1R.X=K5&$E(R\NL45QWJ:8!K!(2$UX@(_UKUU=6@J^L
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MWS#_HS5#TL7D1'U=9O.9_C[=S=X%.4VVUA29Q.J^C@U]/. [ILK]7MY&Y*(
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M!P]#CA4-\$!1V?SI]?_4:U+XMZD?V7]7"Y1+_0^5/K+_F!SZ%^]+_<J%BZU
M%*.04:?$4S.)^^[U[D_-BC"-73_-EK=I"UMT#-XSAD5?+V_146I7IO34"NF
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M)_JK)O< A SV-<(5C?1<E>!;Y?3YRM)XH9 <"CO;_*9X##Y=H1W;K8*(BG>
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M_*GAC]50XCOU>:9GK8/&73,3$WLOON\)XI^SN3_E_TFA),W\#U!+ P04
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MMZY<J0AVWH9X-!Y%RX56IJ Z^IAD&O3F$7S9TCN5/,;C_BK37P!ZQ"G^@S>
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MK_6W.,;&KUP2AZG'7$OZ:HP[UK59('3J(>#<AJHIZ[CAQ+!??QLYRZ+9IP(
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MG&HFL0-%Y8_T1'_3E'$4/)*@^<W^]D_9<5:=&*J%VGM0^SO!Z*./2>->@<7
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M]\8F!YNH!2&&5Z0<3>MXY[6#G[A3MEBG=QYR"E"[X\V :[HI"&?C%*5 (\;
M[5,]U;/R0"Y83#?A=^I)7/>[0<$4QJF>:AU?=EF G.*I[<TC[G="!X88S8X1
M9I+:5%U9A;).N@C/FHGK\T=,#$:O+"CE1/I4)"#YTQ\"TJ=9?)CW1P5PDV@;
MJ2'47+R,>('\IV9XF8Z"%*+]0%[B5SMEVN3[![4MFY49;7O]Z=%WJRJ47OZO
MLNC_GXSZ ,)I:Z#NTO#L]3;>LY?.<:1.^UQLWGF\6DU3N*,YO3S,X;$QY#<E
M[O <EBE':QO7:6S,2L&5'0W ()D)$9B12!*G3=EEZ!0(RD)E/OI+;[[4]:&'
MQ2!,*'%UA^6JUE7WD&M"D6>9YSQ$'ZQR0N#]3:Y;;;IZ702GU&\!S9>R_()0
MO7*S8@()W6(A9T37) ^_@QOV0?!:>L&!$I<FL1$J&$F2H/Z9:9MN'.=[<_Z:
MH."K)$%;RE%IRE="6\ PR$VX&-ZD8Q[Z'LY9H)[OX'WSL;Z&CL3#U8S9_=V^
MI+[D/ST KTD#=0##Y6)<4:X;+B&8/,'37 #"V&0BZBL,5FS;$KH-D0::KJL-
M:X_BF^ [Z*^OT@\WL8&B< U\%2J!TLJ26-6=KA=>X6:3M'3CT+E_)\GLR</K
M!?U7(RF#1QC(#IA)],8')A/MKS+N;*E.Y$S5?T?4V=9\R\3UQV.MA1CB\CMG
MJ5XQ=?9Z0)YL9?(2=K*Z'*1<Q3J/9)84G$WYDE$U3C$,-R1<#_1?XBA$+2@Y
M<$M(\G]3VZ9DQL5Y]/II?,G1P23<G'.>:93YIEZBZE$28U37"#VL*6-4LK8:
M[/4[?=$F.$V"6./$J.9^9[+73<$5?/CR3"?7)A_3S=Y]V3M ^]SNU[OK%#9<
M?SD#&,@&=,J)]4K\JH6:F$$3O+/CCF3S^D+'9]%0:^O]ATD%OHM9Y\T.\R,Q
M;G!$Y<9)1/B.,%((2B%2Y$R['"70\N$"4&X<P1HK5@*^ (@V1P-P2/9*V."+
M5H(X+ ;%Y,=?7X")T4I=?LXL<+X,I9.]"<[+E/YZ_ED*R5M%7-?'4^_F5!(U
M^C0)+UW?BOR!2:EGWGN4O)+\0)\9P8I+&&\IO4L^LDX )4Q@[CC3PJ2[]$!?
M5'EA;S=+O]TX^(EP7(BU^8I;6"HB9+;C,L2Z_'37PTF\-A5;!X-NC?->O:4B
M>0T:?5\'[ZFUV\NRL%<333S4 >Y*BDB"Z50=I\PC_&%;4>ZF!)BM-WL^>D&W
MJ./%^;[D?3@JL^L[(@QTH_ LBZ3MB%&F(+II*X$V!=:?3]9;G#D,2E7@;*@X
MA&4>?#CD1MLT(MQR@^0X%<P(GA< NGI=Z0.4=^H237BOG,MA]R3YB/L["R"]
M:N/='-_%3,3'0. TTJ;$^?Q>:#<72\U879E"BB[;_K(!,[#XL8GP/K?!ZNU?
MKY+3MXNS:00[V?;BO)2IG&:L>/$5J1&5:A[NG"EA#?F--SQN9OWJ'[]*1G5L
MY3TE!*$CJ:6AUX^&^D(EB6T\9XDK%X#WMDZ;KDA\GPO":2&6-K2%XTTK330
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M%K,#PFSJ0RB1E<2'EGV@^P\Y$XK\]JMFLTQF>(C)TAFV^P.Y RXC/C=L5GE
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MOKB@]+*_6Y/;!:\*4E.A)>8=51 _XZ>WT&?K"6#.?)CA8X+=R)%WTSHX::C
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MG#T$#4YU]76JN1863FS,5K[''1N+U]H9#Y(\ON*>&2 D\1\G!6+%9@.WGE\
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M<.X]!)W0D:]Q,Z[PF^F0;_#7K,I"(T(UQU^6\3:]7.)UC2)9$7%]!]M9KDH
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M*&V[V63:+*MIC!YSCGZK$_)QB[&3MXHVW>W2V.X((7."TPI64IR)ONG%%EU
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M!N6O()N,EI2I;-55>+!^LJ_:6;8$MM2W(4@=G8U0=R124/ZDZ#X';[%Q\ [
MN,*I*5J=+O4=.6GMWG 1:O0U^"IMA:+]C.*=K25*17!M[H4'$)2&F?5K33CF
MOIT_[I#\-+G4T5[#*>BMM"0_@CMS3HT.\$C18T'0;:HFPQOZ(JN W&9C-@O.
M!M]F*K=;T_WJ7TP>2:GR>(M_<S?Z^J -@.AAPD.V),.Z!)$!CP!]>'^SIN%O
M!]Y]/39OAZLS>3?<->Z7M1/H01.J7:DKDRBRA.K_(Q-M>09"]D(X IB,_N!L
M3N!5I\"T_[HN\_]>3<<44ZC;\P"PGKC$[/A,8M1KZ.<R(4SRPL18_&N4_&Z5
M@6[.A9P?E_VB<L&1.JBMYF:2 6,TC<2M")EUISC^0$)[%WOHJ[O7WN6_#WVX
M40A8U@D4R6.+[\!2'[>W!^]R,0$WKE'(BBN]^^* -WYRR&_PM8\+EWB-]JNT
M<+&VR[MTF.MB<?.##Y$11F^DKE"QK+O*K4\=MHKO(V# #";3^PC O)/ZPO;;
M'<?((%RN!4$U%Y=!T)$&L\(F!I:LCI"RC.-C*2RIS@GEX^D6=GU$.!T+ERW?
MN7;.0"1?RX#@9WOK.Q-Q('[F+P/M:63?>K3;M(7LWP^$G2E21 QI&5$3W-=T
M"&], )"&XD"C63'/:LE0O)A&%=T^12.&>$5=:]]]6D_U(F<8;?R7&'E,*1J5
M*5.\ZH#% +2IRDI'32K3!^$.'C'K+[6&Z+XXI+4:GCSMY=N)$0M?0JV^K<\%
MTCPLF>%UX+@'VJ-W=6Y&+TGB#&WN-4]"MCB/.> !T]1R'UZB8,N\$_J#N1DD
M$538P?L$MTF^;^+U8?H5M4TIV+!G(Q[YL:I11>GG #"P..8Z73U!&?01IV>.
M(B_EW3BMTQ)7MZX$*8*XO6*HXD]:)F>\]28974<]H\'%:-,2R)W\K85.%JM&
M4]LK&>9\/*_"#I1' $@-C>,JU@:F%\E1NM H7?)'$F;H/#-C2*WP?=FPLV^P
MYH7F#]($@Q4B&2?C6[-O?M)XT7[<Q<"TJ[\":3<YV8)U2ZM#.Q,$/[_V_LP0
M-7[>0[8>S(RJ&<6<_^P?;LVC/ R@F_I\;-:72Z%&H$;?;AUY2=B SRD$^E75
MGON.K:3X4(J:ZY;/JV\PEQ[.%2X?X<?S^;/11P,2O73#N#/%[9\ 'C1L'BS*
M))=FJL/N1X 3-%J"'CX.+D*&]'JFJ]#T4>D.F<[R_?S,Y-5(NS%OEVO]/HJN
M.8$;/9P$[5)G:,G',<.VZ+>TI3D0)S4;JY[-]PLF.5>^1C=1N&2?$\Z*EV4_
M-77>1\4+IU?\,PX>23]/FLWL)_):TL9)N4G1 $*D '6,41H(3:0%,AIQ>"4W
M>X%J^V/?9^_J!&S]O* %9NPXK;-N_QHCWVU\6H^)=+?Y$6!N1F*7BW,?_1G&
MTHBU _\TQ]%HMZ-!7^'BQ%<_02FTL74-]<" IV DN("WH+]/8.>#:ZAZ/?$T
M86+XZR3S3R9FHK1+\7/^9,DJT#K!\4UEA@79+$KWS\W.B8WF/BZ<.WJX1-8&
M#99]XKX/3C!AV**B7QI#3L;WI*-?!D^M(OTDQDC>RT#@*?Z=&@2I!=S,>:T(
MI(DF9XK@+() -.4RYT6;!@<60X?IZ7;1I7'5X'<5VWGU3!''D!RZ*Z4&ZM>U
M\^[V8AR;T5GB<O(YCL>9PM:,S,$M,9%"6IVD\1L#_JWK:HM9&Z=]L2I<?!RO
MEA@:JP;B\NS^XE[=6'?VAQE%'%LRO8JD9_A>P_0U(9_9.OUH#'[;ET9-:8;G
MY;#PL0/>&'N<]I76V!C%(EVZ8P=-,8FTCDF8KNG)8@%(O5M+O_<(X<E+#B/9
M&4>^07A3U:8:_J(][$OOUH?,:;TX42:;K&W;LY]]!:XC2!.H,]+E%HCL,ZJ'
M+[<-IA:K<$4^T#B8\D&(ZQ0)%M4^CZ.WV\CQR(V0[%[K"YS\>G;@]^(^_BX0
M7J$!IVS.([A3+MM/2P,!-]5P#@)H06JRF5P-D$#;AB9?*^:P]W&5IZT:+ZEV
MHO4:D/)7ADB7]58F( YF#H5BNG0P6T6YC;*XB$R;LCXJ]]F6#7VVWY#02A
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M\P3]BLYFH<=5% (D"3-U>B3YR<&["OQJ M=%29J6PI05NW[=MS[GU\CME ]
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MMM^M\V#,1:>$/'%2K\7TY;PUINRKG%,IVO<24%B];%B3!F!O@E*STJKGE3@
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MJRZ %KMHQ'R1];9#*^_%(OK9JC5U#D)S P]'-;-_;3=U?(PA-&5ZJ>&Y+3(
M77_;9YH /I4%)DCV/@!^?M^J^9I:^@$ ",BK$?=] !C<NT%RMV(D/7F@8)0H
M*.,BV6(3J^ 8#:J8X+POH2PZG$>H)*^'A_'3$?RWQ4HDM>-]4W.D-Q>GXV>>
M'LK/#NE,,Y^Z@W\!>NQH0PZRYRZT[S0I \=,20AHSMCMC7U! [5SYW:4X]GA
M;$']XO9T4UFMNU#-U'I2[>*;--F;6H.SA55E0^"(X4"+/EEP3;\YZTA(R- E
MEMEUV4)'9<OH*Q/3CXXVV0X^(2EF0UV4SJX"N=+]0(F=-;7U12?N%P3U0^<0
MRAL7-,D>#0;ZY9(_,$ES\A"25]M4]].D;(EEP#C4&Z=2'D8R?T0OEUS$4JDF
MSG']2-[$LAV9PC#Q$$U#!A]\1VK:6_Q;W,7Z*J<F,W[5/U-<IJR1. O9ZYSH
M8"U;413E3A@1%HVP'.)W,YRL=/>[RU+^H96(2\VD+9I,\HTZ,+]"R]#K'+>+
M;5SHZ![HZUY6HL]LNXC&.("Y;Y,('006S%[3\26W;.OA':V%4>>T^&D/ED]M
M8-!2Z^T+"GS,OMR#D1C(A[%)Y3US5A0_%3&;X76A>ZH.=W)T07L7OI<AX#3H
MN,H1?0!T,B=,Z.TR1.IXXCT+6/7ZNY/Q3CLY1<PW,O>OSP/ ^_PMZ[][R>[2
MVF U,FIXA<L\:R#D%C6>TA[" ,^M9V\D5,8S7W6.VE8GD)[])4P;CR]NA^DP
MII2]D1FU!$N]C3T7],#<QV91=_;"4-#"7ZY-6$GRPI%,D0#NSW0O1[TOM?"N
MP66FQ6<E[.4<E[J8\+61,A\J>;D4VF&SQ(N2X9_>UZ@@[?>*,K K19F ?Y;/
M]@@ ,+YM5AT#KV70N.2+#P#+>[%KD=D\V'][O"B,O^5\FOPSL[M/L"RY!KRF
M1^.2<M_1_,,8_)_UB[P*53KJ8:,H[9: .1"22L!WR<5K^DX#^@ZZUA !W7#J
MD8['N1*?8]A$F[R!F@#/B- OG%T07.N0^Z!CZ$4>,/DO:LY\6T+0O_-2,UNK
M7'WP^0F])$OG9KON&C[OB>:G[9D0P14*7;#_[32O0$NFF['/OL.*7'+\QS>T
MZ^'2?SWZA:Y*05]3]9^TX?*^DN)L.Y_XIFF&;6F6YV5+VV@/:Z\W) E3)\;M
M3,'T'Q8U TNY<J]2IZRRLUOD:QCR(Z]NL@./!(=;0@OO*Y/8'6G#@.M,:_J\
MQ-Y[*6+<$\5T+4><WH3=QIKJ=2)#]3DVKI,.T8DO ,?/A!A>QPVW;5L]45DC
MW(*[4!)TM^85&1EZO]E2^%EU\W>,Y648=LJ,&N7K5#*20^MTI7^1'OM?8C:?
M+2_^;HG;F1"E4F*1.]'G:YP+S-$=W#ZNSY'7Z<C8:K)D.".CM U6' ] %V4F
MRE@T\HS0D\E),<U+X05(B8M>E_Z6K)5:JD[5QI:7?9&KMJ>=TK;*C;$DL$5Y
MJQLC))<:8>_+FNWP]6N:I:G*;,7%O<SK^[RC]&\,2G1NXVXY%;%2ER6.&+EL
M$8F"K\KPR$B?>IBIT3H;QGL1#%<='1G()%3=\8:.>\/%FTFJ?5[4%S RZ.=A
M>)D_ +PH$KWI?PU2^I['IKCOUXL.LZXRWO.R)J^3%5&M;/&$MW]=3_348;:S
M4]V6Q=S&+ '@G;XW-MMK.)-U8/_>@<O"]IZ6^@<^OG,16%I+C\)[P2Q041KW
MGUO7 ^#2;\;[JIH^CQZ0FUQ-%./9K%WN6"*G;!R[JJZC]F3O 0#$I5L=/?FV
MW]L6:$IP=DN('$+O=6V2]"^7M=:5]\N1CA"D$_2WC!D,6Y_F9E5ON0=]EC"$
MO!X><#.[Z)^E^0B,D[4!,0EB.M,V;&#BMZ&U_XAPJ/+L63\ <!#0T:W.PA$6
MYJO"FP= 2KO)[V<%&5$AG3=11+ BY-P?%,:TR?E5#-(V,5IRG14FX4(>YG31
MU,P1#>YON[*+EVM8&Q!+?^Z(N[?[5AQ0.7?E/!SX]P& )TWY .C6+ P!WZ(B
MV_J3M\?G\O9D621L&OZAT]\6;2HKM$L2*6LY$G^1!?P?'^&%'._VI&C&=(\8
M?@1.2A+3:P@*1EYJA@1+;IZ9L"76S3#517_6P0G^H",J1T._!1B5_Q8T_<KM
M+\*DXD[#4&\(4;3!60'<&G!&,\^8M];%=&B[M\6S'9'1>\.Q-ET;I]H<;TUY
M--_EON/*Q-^5?D9P71VWO3=523VNM50!W?,K>@ 0[+F-:.JEE/O6W>O$H6D:
M%N.:W-M$'7[D/\-S"2;E8LB^&##:TAGX_EH#?;:R6US7!G/<2)2FQ>;&35#S
M]]\-25B=(SYZVY.JVV*4^2??_ZJAQ)GCLV<\F4UK0&%$-.5[@*4P_0D^OHL&
M]"??\A/8EYI)\U9%)SJ!LZ65#^RT0BNEQ4\%XZ67LSD!74,0@4([[>B][CM#
M&'S[OTQE"L1=WV-:F3N"@S@NH"LNT:W-BZ&7-/"5'+H6NA-:ZB9FL$F*!=]Y
M'J@VE@>S7\WTH_#M/4N$XQ%SLA8+\XX-SM8E3NS,O/N%+_5PXEW,2Q$63L)S
M^PU@H_+7F0= 3$Z/Q]6"I.0$3()=O#&B;EEU@\+'!-XC^,879W%(N"6&]NMT
M2])9_%\%UU]60H.#8^;>GE-?^1:708?K=?=TJX>SQ9.V$VT>#!](;Z[BK2S<
MZE@Q%UIH7A,5SP-W=RP]RG9O'3N,DPG$831?/3^O$9K(;]90][>)I( ;HA\%
M]Z;' ^#[HPQ]Z8'X5[JO-^P6&XN_>.0CDR%YYZ:[.#YGHNBX,:(1:_5UYY60
M>7.@SN*X)&5@?77%USD1_Q5_AU;5;/9)E?%1D;#Y1&':G")*:Q5K"ER5GIHR
M5OEWNH,WZ@2:4_7,?I!#43VK."OIZ*IBC5'M[UBIN\0I.-3-DJ95W;"=,N+"
MX064Z"U84;O#6XEKZ%&>/P!&"TEZY%_($^(T6+:?I7-*=4Y4,3=6..RAN:%3
MAS]>/XM]9J5/A^=YV75)/;!2P^X.;XI>^EP3$$OW1AZ',JF[TB\;9%#-KF-(
M[AEI-? L8UQ.2+A3"&>JHPR3M=D^1XG0N2.FR.%D\?9?QIVPA X$#9I;X]%1
MT1S-U'FMPK8>"1E4%$9)X@N53U65;UO8JN//?/.XKH PE$0/43LDF2>N,-'C
M=:Y%PW/1RVR4IF^RGT2"!5>[!N^!SY-WQ_H]"LOK=76AFZO-[HM>7_[-I2[(
M3V'AOO81_-0:M,D@3$_SO9RM7<+O<]W5E"RX=8<-#[_7IN7^B0+'.K3#!U52
M,2OX6KA'J:\['N<O'&6?6K%)%-AA)#!<^\3YL'5Q7_SVW-!B=[V:SS:B0C=Q
M9"E*96529\ZZQJ3Q<+!(N$11UM0X<&NBXP&P%N'*!R:6H'=D.)IT^#XT@6K+
MO/>'#$*1=&U3(PBU#<',R:3[&,=_*FU$KKY!L#W3RI33*,NIV.*SU85\M$K^
M!N0^\C8-G20.$M))A;CD3))$T]4*JDLT7T)VKZ^*-J_^7UOSQQUBHI;WW"IJ
MS:?#;#G.OE%:BL?J.8,^:\FQ>A@$I.T[ZZ:Q+[;7F68Q!XL&&/2+ZN5]&'$T
M*O"[KNN*H\67, _J/-J7%95%>!:M*RZH<*(/5&Q_#K1,R5"8A^$K] /?&XZ]
M''<>)CKYL$EZ<5%&S7!>>>*_)V4804)5)3^JCTG427D;V]_N13I X".O>T,Y
MGLS,92VJA'\\83KAA\9F:O',R-3EY,T.&:&\G8XWHNNX ;A$1^=*I)@H>T4N
MRQP)WT1>DSUF#BW&##4AS*;+\O6($ED(M'EYB(R-;FH<]DZG)S??><PT2_7)
MU)OGKY><MDX#4\#/RV03X@E()WQ;W=[Q_JZ+8<#X^,MR\,N 6G=[J<;59.",
M&QH\=V/4[;6C)$)61K$XW!J$XT6=7GKVG<%,B/K2S6M\4''!K0J\_L?(,%5+
MU+/#L^9Z\.0&Q'H&7#_"M_=COG:XYX1K6=N6:#+; ;*)IH*; *=NN_9^9::U
M2H-6.ICQ(X.TT;$IY+^^%7\+FOBLFR/4XNJ<.4->PE3YXW/#6\@?4,H[$[7S
M$JW>)IQB-".Z^0'PW L? RN5=NMU5[DCIT4CZ64^F9A[T0_ VO$WZNE8.9=&
M1W$??MDEW]&_PMS@Y"NQ':C;HR\EW*D=@HI2UJB ZD(7]QL(T]!T<0'X"M0=
MM):0'3BP$/@H)1SL'Q&$1AF6)KK?9\UP]<#FBAD@;D=*J/ '0/#"X?^\$9WS
M?+Q:&;MR/P D7YA"2&YP'P#830S^RDC@ \#,#W+_WF!"-=]V!T9":/WV]2TW
MF:1!0-OSP_%5GDJA<=[+8AU='&&Z0L,(11L-@! .*:9P9;K(ZT17Z.4YC]VB
M3![L0I\<</A'V##%=E!+'=>.(O8[?BYZH]A4:2%:*EQAK1%#V\H,%R=Z4U@<
M![.HD;_"K\)X$>D[AK4J*GR. =B6HI 3!PQ)M(:Z)7R.$G(=VPZ8LU;]%3*W
M"MDV2;74B/Z3K]BA<!0(L3W?]4DF46S4,+Y M]WB12ZZF5O+@#\_#M%7:?]*
M5X*@J8X1PYO(/_;Y#^[L8-QC!4QJ]"5<Y<K/4RYB01]C<U0%'(<UVY'B??9O
M:?&M^OE36LKJM2<$@?M^7I7EC1)E2;"*YV_N#WU,C3G!NZH"<8U?DJ M,!Z(
M>>*&U$%B 24VU5-0"IT\512.CDZR_W O HD//Q@P\.[(%*(BW.Y^N]@HJG@M
MA&)]NM^M;A@O0[ !>6.4'M'\;7ZEN6+XBL*+&TSQUL+,_SL<%0W'K#>H;T\D
MQ6.C+VV)F:3W+Y?>E__HK,J*'?\9:AOCTMJTEH3V"V!I<*1-)7M14ZK8^MRS
M:D 8Y[12?TA&98$BTJ6^@3%';.9L9(#2!?7KZ5;#4U61\QOM.V6_ 'PA3L<9
M1XB5&@\%5]LOZB^%I'MQZ5S.ND)4=@9Z%!EXC5Q;'UW/)%:^4WM?"G=2%V@)
MSA'X>+ ?]RH8YCM+'>W]-=/83N9@\7@W +ZVVYM#02=*=A6RVMY:.-GP^M2H
MB/3#WY%%KJWYQA0M,A<ZBR2Q$PT&D5C1XSTY8CN*'9@M'W'7Z-<)YSXZNPIG
MIF>5(;D:1/&P"?I]IG MX[6$6PY*@NO]O)>Z<^EQY:+-;;&.[Y8;D93_/HL6
M;#-=.'0L'MRFG(>8I-R)*.Z@_ZZ^^+?5A)!+2V6&W!KI0?@A\O=9X2@KFAY"
M-=28B/JCZT,&RWI@)0?\T_]QL@T[N_].7TG___R2%!P]X@^MB^MKX^/6*XK@
ME_:Y&NSI?R<X9>8@;I1TMKES09\H[""C=-I0_4?V/L2VE.J3TA%3#O\4-S<V
MNU7<Z^QH>D<-19,/>E:QL*N,&9P(R:\T/UM\%1J>S/7>9@O,_LWN/[IJ5N;=
M.EX959R@SP8 2';>M. WKK>F7[*E,]0W-J33B'^QZL&SQ!2#BR/%8GUUR;,9
M58W.MK)\N5K]G$ <+3ZHY4]P00W-+;#"(T7R\]<]6[2Z=O28CBVS!A9E>51/
MKBL2TFGN\+QE9^#HA]\5JTD]_<!&O:-0]+QZ^%2>[/D!K5J*&IDV#L< :*#=
M4S>0]O2XONA-RU]'0MN?O_G__%HW<^B!QS)A83]_QJJF,TA/(J./"#WJ&/$3
M53BJTXGY_(;CE;? )D5$ H:76+5+2-.6Y7?^HK R4C=55O%O"[/HM-7QU9TO
M.=J<>E,N7G[U3H(>8YXGLXNB-^>O!Y[\8-JPROS@F>[L=S%^W(SVF$=B=E=L
MQ"A2[U\9D^,6W$DND-/S)7U0&:V6C\?]AVLQ 'B%PX"I.J#7-&,=IM#&F[?8
M'ZG>EKKSGC)TJU4LR,N,:*"DLW*DJX-59]:IGJ:QC\?.P*BJMU9J",NE@626
MD4**H9G^#W<K&<FV9:GNE8:+R65KD>.BL=-JWDCZ!K"42&O3SG"H;F7$ICX
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M D5WM,C:WH7VZV@'?Z7,]F@=X,OVD,7T2&6H"_M1-KPP(,<TCN9426ZVX@$
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M[CO_0V,:>KH5X&&Q\&C3M8%*=\5'M\@O.__N#=:C.7\#?0!T_C=HR77FF0?
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MS]'Q\B0Q&,SRA=V.K:>E4WF$:TH[KURIJ/$IW^J9_EG:]#A 1F+<?FWAP)Q
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MH?!W.;4I08%[#@#D&6]6OF4HTDZ!N^IY#T*.QB% W*A^W2RM]HD@K\EUYX=
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MUI2%+@=,NGW?=?BDZ"PQ+Y7>6Y1*$!GL?SIF5]6M9T_0"V:BG7M-B3F=+R!
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MDLN\@(7Y>T&<6.\^WZ#KJ2[*T(E]SH(!<S@L@3!%R+#X.;XTD]%(YT[V'[J
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M4#^^6/',SL'XZX,'^-L"$O29LPP(6$2XAESU!+TU$_&(='GERYCL!RG;@58
M>B6.B?9?_]1QI,,UZ36NN!*"1 .54^WXKSB22;L.Q*+COA$\(D*O7E A9.3$
MOO9(.N=PMLM5CP<8H(8*0W.4-5P<E#Y#+R9SKI=.I3,3U1ULQ>S_K! +]OO<
M/9&_!P1[R9?I.-*8Q!2B@?> KBRZ0M3345VV[^"^,/'(<,=SM/!D0YUK8]O?
M/<D3A2TCH%?'<X6F0[MS:4R-U"G]Q>+2ZP^C?4$5)-!?.+;.=$@9LZ+W\LLW
M$BC3Q]5?0<YP!L&=^0)B49"Y"BE^:4WJOVO"#Z!U'F5-@U"")5),,*:LNS4
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M*+L1$1F("8UU8\)7PW<!RVB*E+KQ1?KPRJ9C>K4J9-C7F+WOHXCKVZWKV=R
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M:[008UPB+#8&JPYH'[#"Y)CJF"CQ27"DD_ (CV;K8VIU:CQJ#!.F(XG J[!
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M"Z"#W^ID09QQYI5QE73I\DUBB?2KKT+*Y'P<].:\CU_Q[2N.&8(.&%"28LB
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M(_0739QI/JJ^R0SS#]C.30;4>.EW!$EH HYC+$R()\.@G'_2( DZD0Y<260
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MIDP4/+M(78H[?Z;'&49/9:D7U_.AW;-],='BT*[)YR:BEN*&#+S?4,GF3*>
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M;R>I@\A[^=FUW1SZF&8SE6Y;I0Z/PPTQBK@6=:^2,9<3DB %G2 E0RC=+_;
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M09?6@I)?/W5YKLV3.\#@+7?0)[75KUV9[QNWHAIAS)+Z$ZC%VM^2R,GJRIM
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M*X#$+06B-D*)'CE_%"CZNXMH:!60)>Y0DO:+EA$!&_9J0(IQ8 5B=WZU],4
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M)!=Z!SHJ:,AZ<'MZKO> /3^U\?$G?'5UB1L%XU-%.;'LC#NL:\ZPQB\JS"I
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ML'Z?ZR;OU_4B.>1!MZ-$]YU[U+[6-#M4Z;P<S,>C&1F5Z34WY,+\C:7O:,
M' ;O'0U)14*6;@&AB[A0(,&.1$SARFP/%/#=+"@M*[J%U7*OE1NG12;Q5]'P
M!QT%MC&U^LO9S5EH)P-'OCIIL5[[I/J[J>H$7Q0,?#!;GE_R"O/R ,7C;45T
M)''1)S]JYKY+=W1G8SG%$/\VPM4$)3WQUT(\CEHK3S97AU]7E&NW,A!C#)%E
M$QOPE?[\$>1S\.&L.5<L7VQ]1TS:L9R#M]>R35"CM)E-Z>*NI\2U5V4?L-ID
MJ<,Q]$N\(,[0^Z 8>\-DUT(9/2T)Y,*IAZ?3["D,7K7M5@5_8K;5I^F^&<"S
M+^PYYJDZ8VQD-..3:GLW/<]O\E]\VUQ1W0G_%;Q;.!U5R;I>35!(Y_MP]/#.
M\E,8H>-CGDWL![+UN]C@7@2^OPR(,V!E6=>]Q_3F3+QGV\1JQ5%E^9<A2=NT
M\*Y=$CEL]W58#TSV9A+[O)OAJRN_H<@BB3LCI6U]6'B9E%5V'FRR\A7:>49]
MH)Z/]!FNK<GW\-V$A$Y5?P:&*.$_J0VZDZCMBZ:&_9IQ'<':XH\318-I1M Y
MJWDN6S_C)H9YG<G"+XN'VB D_CIO3BTF3+JTX76,O:K,WS],EU1J;KMINL;G
MUQ3MZ.B43W?)SA/(IZB7Q@5M/6M!P:!QK]W(XQM3-&BJ!O6\7=,H74+?66<M
M5-"]B#DJ8(JY\NLUZ@QI5U!VZ*3ZHFMR"?-#+KV@1B4LW-CQ,_WO$'++@"6*
M#+%RX:^IMIV?YQLA4V-.");AW)3U@4(UZ#YRODDW]E_+U"SVH>J5 L@F]U7'
M%0+H0X(-LE2BHA*[D@%<VQ'<834Q<)3;@F7E^Q:K?_N52 ?Q)GR?J[<&\MWP
M+#^JOD_!S(.D@?F8[2=?LC[Y3XE'8CV[/452;H=^'2:/#J="#WC-8O9G-4*5
M5L$#C>/O82+5I**?<&-]BY;LWVC&LDS,>$Q.;:_953LP0J,I=4S4^DU@CI!X
MH.HM8 G,"!7M!,;> AXU>A1B[O(+.,/SJK'3'G9HJ+V]=V.A;63"[]PWWE2;
MD3=LD+Y7&!;UD(-&_B/:%5G$XVXN6Q$SS1>Z/8+\:Z3>VYEM"#W[4)>UQ%+?
M4[NV&I_MAO*MH:/['> 4AFPIGBI]U)J[@PT>,Q/6'''?Z:[KW#N@V]4TR' 8
M%PQ&NN]R)]P" KG.4SL)&&@GU$U/E1"G^)!U]/[[>94ZS_6([D)AE-5"WP>[
ML3^)\Z7(V2_I^Z4!].S7%$GHA'>ZC!00*E&S0H,O <#Q#Z##8P12&QOY?1-+
M5 K"='K+1*)=\D86C*"HQLJ*&6KD",)F"*3>,4EQF&CN24'PD\QNI>1;$2'0
M2VXJ]WFZB:T8M/*T\%JJ&OWK%I"3[7.W/+N,6'Z%_])B*DA90N.9ZE9LS-.4
M)^\3SOW(XB<..Z1"N/UEK7'_.V<.>8X^M5Y&Q5M >]^=Q]:\!0B_.;FC%@QX
M;5Y8?7>1V,"Q^F\Y7*81--%_"W/>YAN(7W^C/"E1-7L6-O*38'PM';Y/]QS
MIS#%&DBIK3 )J2'"0-RODGF<+"3!BD/J1^6>FR_[X^Q@B+/*6*E-0C$>'51
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MM"-LUL_6:DK75F[S-^P&PD,%O/*U#_!:;T8ZYBZL^!N.8 G]@;!Q=P3QQYW
MYQ.=];^=*B!.K*R6X!ZQV826793^I2B*'^)MNDPA0S^"XG$858FPJ$O6@2N7
MXG1_)!5;J4<08KN U,\K$343S:284JG*%:Z@ L'_J[WOBFH"BK8,@O1B 9$N
M':G2>Q<"(E6IH:BAAP "@0 !%*1(+P(*T@6D1DKH@O3>$334A"8]00BA.KQ9
M:]::F35?;[V9K_G8'^?SGKO/WOM\W'7S3I367")2ICF/<ZI"NY?9=C'91M-7
M=XFU^PRRSLQF;NOZI][/A?A@JD%XVV\C-8]BNZ9M8\64BYV/4*=7$FF9!;U
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M)M=(_V!9H;\]D5#0E<S0 6.X^^?,,*=J<;_"R07B9_XB%[O.JZ_/]L:"CWR
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M5BO#LG^4H#NT-&\, 3UD_U49<$?S4%ARJ:+#"\^>JY_/4"0!VY,WZJBK:>E
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M/A6O^HV=+OF>D/^)AZR7#\*R,%#-,-Q8QD&;QR631TKLP,[^ U!LH</>0Q'
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M%'FDU)CPQZ5:O2$YN'FM2GJ)M>+/HSBDZ"%WNQI99ZLP!@\1QL5H-Z6>R92
METYP3TQ,JN[/#X7,]_N5@<\<1!!WB3G("W:B&X8XWSG+@%L*N[^=Q;N=$127
M77%7#17 :":+3*O7XG>]CE+6K1L4['/-;X;*G66$G^=?$H<>ZM0C1TJ.H!4=
M_D,/Y46V&IJ?%$;HY[TLL*1#-;Y86=FDF/I,KGYV?)C4S<!E=R&.*TV$B8@I
MH:]FP^(RLY[B#94?#V3:Q,MU3E/_2)>*ZGYQJS3KB V)YMPQ)D:L,E#8_B'$
ME;N=Y7XJ_K/?6%5[9O#+Z9/*#Y/[%TV8E(_BAUJ?+9U".7N[OJQJ^O:I>F:\
M[Y2';+DH+ \N.^ZF6]57!WM.?I[\#YGN0RCA V)4@.+-+EAU.OT".[?&5_>K
MBY('W;X^'F!QBOPHLN)8(2+4R7Z'@7VV#(^2N30[G-ANOZE--GYO/H])U">A
M4I=#I0C5M.[;.8#,1>K"@Q(_[\%^EZ L%^U82V%^07V3\;ZGD_5<#F--ZJP7
M^ME='3=EESGF;7Y![FQEB?55B^U)G(",U[6FDM/>*3YKC*(A6G[L/7_NWB(Z
M80_/Z[KM=L9_\-8+X>L^RYK<U&I5=8<\=TEO2)B<!T,M-:"YQ@Z6?3->&/XF
M^,H/0!YR:8@XQHXG+=]",*\L,Q(3KRU>"8%VSL0H7IA[A7F5#4$_=\D/@D7N
M:XOV2;%P:/.^_-OH.A8=^P_@&@+N#I6;D5&X4'0*9H73;_;YI^9HKCH_TJ>6
M;8L8XM:4OL.AK^#0.@H(_FJB&J9$.8Y<@6R*T1#R\/>J7N+&V#IH7,_L6_$/
M7S7A?J9!C(7.I7Z%U&Z#/FM0![K?$-(XS]([?";(!%-'3SM,JGP7./B1HAY;
M=1$(78G;$4*9$CP60"$E2_LL3P,=X5D\YC^?9+SPT1B@F#K7]1W?-/1_OI[M
MRD=O'-K5QMI->(=_VL(<E[K3I>1H<Q"%,&6(]EHW=!7_1"9!QDQ^IK^>P &V
MJF9DI!QQH):BQVQTW%'C+^WKB%RFO]#W+>Y^&5)RX3!5_W+]R2$W! J%HI^+
M?NUTO!V%'J(<8W@Z0?$K4N/:UZ2?D%^;$E+XLNRH=[8=0!PVAE1DW_9UK:%I
M5;1YF"]@]2.%)9#VRS[G:C*0:2V,/O0A,=N!R"71'8C2A[8+;RFUY9*VSVCR
M/)9\Z#PSD9:7-8@X!L_JFF\^2&:H]&90F;J!'%#<Z\2VFUYFJ DP1/\#X(R1
M%/!A\^9LD^;&R?4FNF#O*7U?[Y,[E)-??(S'>877/@."27KR:DZ2=%-6O6+R
MJ)$(,'055*7FA)?+K.P,9+_VX(;OROO1@S\.D;3='%K#G$ ?DF-C%MZ-2U?1
MV.WB;_WY@M6J%7\/^G)9\10)5>VJ;J'D4[+GR/<I")W'N/U6%]&:^2VK"*-/
MC0O,E"D)?^MTM4DW0KI;OD<3/A*9P%5NMW=8GV<FX9%F,U7,W>W<46!"E=CL
M\Z57?4QB/'&C;B8)M>(!3HN&@!"#>+-IDUMO[EZ+]']Y@*,/QI(UOH8+@N3D
M,@,:#=UX@'1O315%6WTYX0LD?$$I]H:XNNXSM$P#*W1OAE4E ^GE+7'!TV(
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MQ8(,U7NA3F13=FB#]??YW]]V!"B\I V3'YI/ ?&_%?Q#+40Z5)\7SLSJT.-
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MZ-^F_6G9_S?#WO__LNR?AOV/73, $ER<F^#A4@!  ,P8EH7RXL4U8$1WXAK
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M';6ZF<(9\NP\O]P,DN5RJDY SRI-B:2]VN\6:'1\@Z=C13 RS!0I][EEJO;
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MJS#BI;QO-?:CM]DV3>7A!V9K$' "V;-CN'\LJG-">BDOL&H8(\\O!)[C>$W
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ME)N""G):CS''/R#39P:3B&#PZ1]*W_GQ$&&8Q#8>4[IAN(_;)F"L$#K1KGS
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M2C2;%JSUW*[6$&:B2#W>(FEHH\;YT:8_>?P;C&ADZ)U#V)'MC<L:&H3R1*H
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MG:*5K5_!DMW?RZX(,=)7)BOC]WH8OS6:/=SB;55Y&O=MT(:QK@=0!Y>'/==
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M6FC<>9E2J!"Z-1:?ES+&HW;-KJQ#]TQR-)1I@3JE._O!$DIGJR_*AB]-=CC
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M$52?F(W,4T>.]F =,6U))SC:#"-MRR:KW.9+T4,'[6(WG%S4>"-\FOSAMXI
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M\]^M<0$_M?JG0-C 0_-%YDS6*;/A&H(=5*"/[:,> KSK PG$C@E16IP@0=4
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M1/V]7A=9A(Y%HU@GM5,GNJS@.A&TQ-;T;Q.NMY^LXULX1]R<I _<A)C%E 5
MQJ>:(4(4 !LI WB'^AWLX"A06]2J.:4M)T2)Y;+O ]Y/AY@'A*A4 WC+1+L2
M$CCGN2>0K%L^6C("L21 L^0I;:S]4Z!?GD <,9#<3P0)6 =( E9ANH2]BZ_Q
MV5!-N[M*9H7JMLXW;)%&2AH'P*-R?"&6+9[]$Z)W<D:[ZX(IBLS\-X@F;5%"
MHD:]>8^,SF7E=J]2[5VXR[_UYEGU'7MQPW(D2L;PND&G<YT?XF @J?_X1LJQ
M^"!WI0J,1[+V+/?G8OYKTOO_48OYF"<XYDEU[CY)$R3/98YS8I*',9Q-,O"+
M0##,-GOF"N<U+7#R<X@"9DD*KIO.F,NU&#!=H\W8Z<? I'@EM040:I Z[.1A
M>"%(&SQ.L$J5%4$%V>Q XJXCS <26X.,A$BSSVO SK&D=W!'[RTX9#OTLZ]$
MY6]+[F6L/]?B)\L __5=HQ9@:@\!I5U(B@GXO?^?*S^W91[J'001,U-+Y^;[
MF0%N*^\BU@'F=&ACNL+$:T(4>Q:)5!K;PDDJM5G>I'6#?^F\8WNQY(VD[SL?
M*)EM.J%6H!#F'<RW!%8VG>%B5HK+"F!'QCNK'&MVN+2\,^A2V_UY6F3M>>0F
MSWC.7N@&:39\UF=HFD8I&U-P0"8"9D&L^:%O<3.]\8FYSG[@_25"F&7(;6 L
MNJ]0X;,89CE5 AH2QR*+JN8N,O($*MH&GP%JXAZPGG+:&&8551H[]!H\;')>
M(1V$@ GRR.O%!_ '!HG1-D'D9!A$P3P0,E_;(,Y[IFM[63<U0$=F*'IA7= 5
MY<SHD8&C_0XO^\K%%F-V[$V+0>1N]20)5@+A]+5BM!)0OS(+*GJI>?0S2^6!
ME75@C\/1^%T5*D^^SC>IL=%WE4V1-++OJG/UZ6PZVX%3*JRSDWYZ]M/I,7<;
MX#I^C.3B^_PZ?C.NYG_9#L![B>XN:B 8C.]U[=9M((#).C=X]%_\+=MY/=25
M>4N2/'_P&;.W,U7/?&S24D]SRAFO__#0SM_X;LF]3ZW=\S+EY-8?DBU8\N4#
M2FX0ZTB]U[6]R>/AZ5[,'9WUSCSL W?MK>G,\>$PXQ5(*ZI1(R]]RZ*%V<=]
M&RU:WLBNW?+V2R*A/,/IXW<TQQI:.9"9FZOY] FU_<GVD,3+"XLJI*./O;XM
M_MCCPF<Q,Y$UG2"+P]]S,G MZEI./<FIJZTFD1:&T]57^R\&/%!2E9WT'6HI
MG#_R,>!B37C@VMON"(IU@46?:ZNWM;N1N"TCT<IY?27K9HWKX)&/7M>75N=^
M,'BKP2*7FG VDPJ-2&*<CL(0NY[T=ZN-.C7=&CHJIV[F>77F_ABD)OC5WD]_
M>W;>67W4&E2:3*]]U&<.MC=P%>LJ4I*W[QMV,*1>M)K^9V?]S/^K5?_?KU4S
M:>.2/4^9)N-&+FD;R!VQQ9;5:D4N4]O]0[M[)].*D-5/0(;<NS57:YI;!PMB
M^9]+KZ=>T=XH1)WZ'-9:*IKI=3GF1]P]N8T40'8!7( .@?DJ"&^.3$GWSL:J
MRHRQ@H/9$0UO<[DC#?W=9V\]+/-1\+TVVEZE'S<Q.*$QY$F"-=6 MET\(43=
M,9Z[PBM@\'XJP(@U0%=MIG(Z?1Q@];I [+3&,':6!M0ZD8,C =3!-T(39"3+
M.^\SF3=75IT7Q(VE;]-$@DZ"3^LD1#V?-"MS;=<9[!D,5-O]+F]/^^&BZRI2
M<B&#_4JR6[3Q8_1?5\\'7=M[>US]8?ON-?N;#K:.>:Q^0UFQ^US95AD[B>GA
M<G+<KUOH4B;M-6)H[*@HLPJ,EW+.>&*TW"6QN#HW'=JR9,K17ZQK75/A[PV[
M#Z'N%* +'?;3!/=2J-/VF&QU./[/K>N.?[,63XYG4+EK@'48[<-.O[&SXER?
MQJX:B@M&.G4<?]9-),$)-, )3#G :5UPA*8]R:WR<.P_.XH<9:&18_)=<VOV
MIA,,[%UBE?I?2'.:"*\41T[H GE'7CW'B0,CR-EJ*GT+L#"( \\"I)EQ/V"I
M$0SO&#!G>4UCA7_E3$X%+@/*J(,?4>=!W^1I<_4"_C9Y1,/$I!EQ8>4B>L^P
M/ X8V<@002;4]P"P'*X>VH4C>?"6_,:KO9P_-]9Q[<"\3^[%=1,'Y[P%PZ2F
M\#?2]'WX^TIV<@" >%>#0: ;,L8XFHC!9XCO U(AG"WMJ\K"E<B3_:EX<8&9
M7A,URT-63N+F:[GL 11:O.XP_L=[P+,$]28M<<"S^/W%XZY)'1^?*Q_9IN_R
M56&I=S@ND67 O#8G"2>4R"Z*.>PY5RA$=3*S?]I":!O1VKW)#\0XQQD;3)HV
ML0)!JQ*/R!,!JTFU@J@U!$J$028 _*F_#-0S*N$?6^H"\SEV0M2A&"(\'PC%
M!VE+':%Z(.:.:M5Z0O4LJ!\[I47]Y2R5%!U?*Q94[*)Y-)NE$A@6()E9RSIJ
M&ZY5>'"!;\N,.JPQ483A27R'NE=286-/[+@M*[F0M-+=>'Y'4?9D9Q7^AG)$
M<D>>Y\*#&$\)6GA,I;K(J39B9H,/Y4=.6CLW=JG/IKQ/[RVR/S7XQ [FOQ\G
M/V>+%@%L7NX+M-H%#G;:LE5P86ZK8+A,$9V-!O&FE^I*&W''^J/UN)A,!O4.
MN >*TNKENG_II\;__$W2WRJ>X_C?+YKZWV9S]U^KGDG_C&/@J1[,K'HT-L$7
MV/R(YQ#M"Q)4=<94CW 1NOY3>8//]#$)CLF^+42-R5-Y4F9N+!'DB,ER(>K;
M?A I>EG7_NX)A!(302FV6X">$@^&^NP ^J_!";;\NA%[X#3'^/_$1NP'A+V<
MRU6EV*PT4KSS?%U[3Q?;QT<ZK)P.O5!L&<,R2ZA+J5\ QW7C )KGF; #FS3\
M[-B)GS[6IR%%R=5JI]I[O4S4V!)KBL*MB?!F(I$^#6A78N[:[9.;]$-*>@2)
MDJV$1LLW+_.R^'7BDO+H-6'L+S[%6/R<9[,4# *^DK!BCO*C20C0\3-O00JI
M<3P$-29"%, C7DLA5/B,(Q"B=$'4=-?BF/'(RK*R"9XB78A:=!W0F+?",QQ/
M^A_-HK'DC>+(O0B05W:(@P;?&*DCK.2<[<Z5--&U*O!0ZPYX6,RG76WTMFNG
MO/VK-QL'"K,'"O!5=[K1BUWQ*3U)N_XH0Y.X#>,TN,#[,J7FMU=DE3>OPN/:
MZME&$3JC'T<I+VL^NYRVZ-IPJBA''!PQ]*"?&+0#AF'(8,3VMZP0+:7^<BEZ
M8L=3Q'144^ YC.4I[(;^(]]&:V#2X; /T,PDAG=J1RJ\SQL3XFZJ!UTE[9[;
MAD$(!+D$K%_?6_@02+G=6)Z6V:@DP03ZZT%(V3,(* ])UZ/0\*99)JG H/_I
M7[B#9X"(@6E160="@/9PCANF/* M [B)**@8&&#!UFXJ=^/<(O0,6K !1+^-
M$]OV+]P!7R*W4=L&D:.XV]0QR9\53+^GDI!\4M((M(<#).[Z:LQ<,!J6(.W8
MR2, [LE#V.?DNAS!@M_XA07_KT:H]/^SC5!J+%S =)TLTI;A9%GR-O_#R\>&
MXCM.?LM><'VQMIY? D[,UX+I,4&$G/D"F1/-V(\_?LC-M_:E;UPKFJV=/-VU
M"5FJ6/]S=9$2/9Q6-J;E "4S7)9"=-W.IJZ&X;3H\7?3V?!.(&AYT@PAB@K&
M;.XZ3MO@G0!I;##\G[4):1M ^A(W>B'>)A&$%P//\<D^%E6P<A[P=L:(1AF_
MCK=2G8+INV9#%BSNG6T"7Z$-8CP%P%9/1H,D 9033"8)4?BZ>[$K.3=>>WKW
M%K4?=FK\?KX\XF/Y^.>%"]#/HCM^.^M<07(QF!6QS/'UH^:LM32EG.?Q1ZJ#
MJM;.-ZG&E]5PD?A3W.L)<;-D20WK*)@HHN.!S<#C-I]QMQ$P$I,_4I^\K,M%
M_K[_R?2/_J>8?['_Z=<;69M%+T.C86R+AZ3.9,>99I6FW?TM,TJ)EG(E#^-W
MO:_:N%A9:F60\Z(KZ_8./T(?_LM/VJ_*WF'3H>NV(&2WU-J(?<OZ=H8_.C2]
M_K,0]=]LNQ(,L/IN*%1!\$>^LD%(KXSBW< ]HS--B5SU>NC;'  >CJ#6Z:P3
MHJYSXWEF!1/<S4\%/J0AWRR .@,JLVOG_"P?S=\"5>1ZHI&"Y+GFD%N_7.K#
M[#]^= Q8G^]V"+I>B-K^.0G1!\3":@'9\X9PBCJWQ^?%/VJ%B#WV7FL!P+5=
MM+\PSQ3Q=W;"=Y.Y,G6PZ^0#P1+&(!P\ M& ,GQ3S,&S UB[NY8*WJ5FQ?CL
M@C2>93UWN;.V_/#2O7/FQJ08FEX+-+7?W*4*6M&E:E?+BDB?ED:]<S83Q]M=
M84<8[9I_^.VAR!(_@%>2FYEU2* /C@\&#C;V^F8#I5[DNKTG3FR(-[TUU0(3
M51:.Z^2&]56OPLQ^G/,[_!JL$AAO1B9L (9U 6GV.VFN#[&= "3$Z_DF_!\F
MR,;\2$3>C$$22+"IL^-S2_Y81@)!#NB_.I \!/K<&L&I&>J0"R8',^!C1OYW
M38I<H][L<=%DW[/,_-CG?HQ;#7'!0\=5+E^4'5=R7>M-:_OMVFFUF"Q2"5V4
M,_75VR_L3DK16VL#7V7'>/T%VTKE^I;VF34(4;^\X$Q?'KV]A9O\GARA,YGM
ME]ET>"\4P[\A57?_+%W9;\:>YGK+>.E<-S$5>_)_6#<Q=BNU^Q5N\KH\2>#9
M_G/%2M.L$?M[\9!K!E#4-QE1X9*&'<#T5V@"(*2]!;P&0&;*)$-LKBL7^G==
MN;T;_E(['/N,Y[1H8T]SLTLGN*OF'-O<>O$)];^[= BQ5YTK1V:2:TC]Q/^S
MEPYADDN@Y7@;:4&*^HPZ>IC>GI.R-=:8_*2.NAWE:>,MA?.8:XIAA<5TJW>L
M&K1LZ?-,47M^G"A_56E/]U*=Q+D].SX2VH-5_/+1#@-RU0WVTET?BQBN.GKC
M__ W/E?=(68#3AX[1%)'4'7(;JA(SQ=03IPOE2."Y=#BH2([>*X#AE\'+W3&
M,M(IJZ$ZP2 R/\L+GH:&KB"<6)PVFK>&2A$%0/#K:Z-\_3@QO51%I^@CBFK,
M^OKQ[I==2Q;FA7-##RZP)VJ9-4',;W1)ZB ",'F>99XZ.YE#9[@&MV_S=V'P
MGP]&M_;W/39:<G#>25'+R5U>ISSE7WPA9GK[9(?]X6GVJV]['Q^=4UOU/<^C
MY2:MFB_S.]U\T/F=D6:.80J"XF!B.Y/^%=R#.4JM??2O7NN<_( B9YQL#&*C
M(R"KK\U=Y<')>:$=DIM+OO2VSEL.X\>CIUSE8+$&V#H-+__8,O#U:PKU4O3-
M_%5/-]UW?K3Q\)*E.].DGVLU;^$O[?QV]JNH#']A15H%7P'>Z+J,>Q=V#+^?
M5W*24"X7D-39BW&8O.;=*S>HT2U$R5"[W\2N:=Z-EN,<5@_$+).?M/*I4=MF
M9G1ZR76R[(5;@U>]AALIHXW3N=KHXQE-[J/F5]SY>T]UM;=VSC>0./K:=+F!
MV"L4:@WJ'?RLCJG>?Q 32?\(C:<FP:*"9^.4U:.0I*^'3W)I]NNTK9EY1?R!
MZY^W?F5]=@CF*)J(>[[NNZRXC,8TQ$ZB(V%5GL4D\+BQ>*YI'T!N+=HD^5V%
MY]/MC!G3"Y>>:I/=8VG9 [:G0K=TQ+R&&Z'"S3U$WDH ,[!,U3_651<G!6.'
M3H+D9\[]OK 4KI$>B8&G<)7$C5CN #7*3Q,^<@5H.S#&M^,Q[QK'H-TD9K!G
M/!(@"0$W-J><-(:I&28/-"!_[!JM=;W6N )%E=PF=Y\,K?IVIUI[V_2G8K+S
M7GP8P?.6_O9)TWP-[LL-; D=.O/"ZW(T8:0M>4>*VJ;,!N8LK.U:2)HV1 #@
M=[_#<G*XHNP404)9&>Y!N"=1C^/5>^" WH?@YC*?Q&7\J&>1DQ$[IL0$I-\'
MHLK-W-*\DE"95D:[M(^M&;2#9%/5?G9KZ_N1.C\=@ZE9(6I)8"I@&&PPEGE^
M&BJT38;JB3U$6$8;.AA[')JJ@;9H/1.B!J.1L^#K7[C@@\T3R"#K!X&LJ"N'
MNA<C!$!2VUNH0P8L T0\EL@YKN'*6PZ; A ?) ])51 1+W*_P1_#.2:!=I@-
M@O5J-X,D!MC\=3FWA8E#Q Q!K@#,%H,U&#' 05&7I:GOKCJTX..AA,WZ%PPK
M^PO*=*(:/&,0,2+#S[4H.HTD4TBZ7Z'6F?)!:<_C9PL?O:VKF\!Y<7> SZ0!
MO_UC",SRWNF=9AOAK?K3.<B>3-:,<RN9=<:%:K&'/D!8DUW*-9(",R\:BF5:
M.F$9MX!A._SS'_RLS"^?FH(5G*RD/L%QI+  >TQWXOJ?(@OJBL@<ZT9 1W=Z
MT?"JZ/_H]<09W2V(!?3_M7>MX5"F;WQ03IGFO[6$RK1_V6+(JERE\"Z%RVE+
MC&-,K?QIBW&L26/>5301.]%B44THBM7L%F%C7J=(Y4Q.U6@0#9E7Z_":D_]C
MN_8#?7#M]_WP?'FOZ[F?^[GO^[F?W^\YO8-.4)=3QCR@"[&[ICH'V1]<J6@/
MWS*-O_G VY[D^T;!:X0_\9R>WWCZS"15R95"ANM>2H"9#K+Y@/%<6_Q353G]
MDR/<SGWJ:-%8N*2,D-81&=IT^_7,V1X;$=$U+6#OT:PK.7'.-H\%PN)4*:&)
MFD@L'64R]"0!S/H,MIHY_8W.<=6CW@NXP-.9:1YJ<OC&41\$[?CKQ.Y8 AU0
M+00/Y@/2S*XEO:A(M\\0VW??T-NVY^P+3M&'F)2GY1&DV5*2VZT"_;*OAZ]U
MSW*?/UV\;GPI R, O1WY;"E&E9G9278CU;#HOQ00,<(Z>.J9U&E9C!9#OS_@
MB928,OEDN%N2)XL]OKBS^1'Z2K:5T4[$1^&U5Z'46NAR?\CMAXJI/N/68_XU
M@_C1Z_RJ\6HVZMJ*IWG4>.NPPM BON'#WKXG5-W&.SLZGMU:MU.ZEX-4+C5:
M_,GX9^@O!AT<)I.4:C]@4Y"23_BZ>@1+X(>6=&U*=3;2N.FSJ;&V];(&8#^6
MQ" _P]).861VC'=?R)'G+DEV8<I0K4"EYG[A55P>[EBTJO?,H=-+WF1FKZ,'
M3'$Y',GA,E0G.5^@P<4]LDDE=:?DOXQ:'SR;_B".::7BV2_W[IL41R<<D>3?
MQ=V,S3EC&:BX3F;<P9/I13?'[8O38[VV^[87<AJ4DD9'ILHQN2&8]<6XQIX-
M^QHO3S8FF),*!AI:9%N.Y]>$G/Z 6WVGW#Z8$7G8X=?VBGE[W9=P()%9AN#A
M0 2'[?=2G1.Y,X,#SER\%::YMNK\)E;MCY;68(!>9[1!>#HL)IWR-F::A^6,
M1U=T!6MZ>?G=3KWZ@%Z_W6RH:MN'9+$5??>4QX0IQ"R!-P=YIU?,&IG8LH.C
M62;;IS0V6K78KF6D31]D_T:8F#'\28ARK //&-K;#=\\-.4*O^4A#P%W*5XC
MPV"9P6-4LR( ^\.SO.B/\",/QP/# W5HY7.0 E)BA(Q6PG/=Q'X-WI]O(+$
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M9YGLFG:^8?^D\CN4S(?.#"CJS.#:-F_]TY\=0Z&\#>"C0/?0TH-;FYE@F6(
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M !2ZTQ<!D=/>E07'SU,TJ[ACT L)\UC'[D2(3$W"PFH5J@"4BL1(,")PR(J
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M[6C/,8/CK:1AS"/ [93;@2/Y8(<46IXGAQNO%?C^MZZB^IHGD.&I*2'+UT?
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M J3O4=K9#I?*4_@.G;9_O5R/DE[^Z=RMMJFVYORYG>]K))DH]^$;)0>XV 3
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MZG J9G16>XU(:5%6[DV4&SYN/. Z@'], .@P16PU^L:1AJ8]W;&#UI=L_<3
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MO#\&10<C56;7HECQ+ZZB\$,MP_77R:Y4<-=%'K[UCR-U"I]6]! L"&F;]<3
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MM%/*QG@NB&=BKU#_F)=W"\L2*7KSSPDN93])@^F_@3W= L DJB.>E,K%L9X
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MH$"EC3BFS;I?3B'@1<X=H/+E157IK00NC!8*SNUU9RM(#:]O&WMBGLKN8$=
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M7ZWPD$PQ$/%^%5FD1GWJ!7T48=.LAHQJU^X3T@Z9&I5X@F<^GP?%LWSVUU]
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M0*C?R+^>+DIJB5Y_C8A96ECB-1WFC!?\34ME(]_/87\'0%K,024:0KYN6]7
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MX-5"*L-+R:;7'<^E'.7/[P6U[06&=E  _R&GUPJ)T928F8E694'!<&=^73.
M6JL[7(_(QKV;]_EZ@KP=+I;CE@73T!Z"^F?C\21.0AQO%RUCGXN1,PI]$/S@
M:R!%3.#Y]=B\OSLP'$Z[A4MCGY27-C%= G^26=*"M#^HYV4S4Z.->?KG%S>-
MSA_[9SPL.J\A/*AB94'MH2I/37[.Z6+TR@T9HFP4Q@D;E[^/4RDW=H1QSU0"
MQ7AW.%J:&NJF^(]M( FE;8?!W,_N#0J[3QMEQH>PU#]Y!E]XT1E>=,V[KW.K
M6LFR?HM8P;O)09"5@+-$D0AN5UF6 &N%"%$FP"I#Y$AOR9PU]9]R_T:9.,D%
M@#R"NSJ $\42+4^!W:R,]4;=6(B9N5A);=:EK= 12X8&#](F]SB7?]0];_00
M2@!7_:H::6EP8X28K66UB/JV<]5,CL1'5Y6+S9I%,XR8TH!-@,='3UR$1D<X
M.H6+/WXNC4&:E._--C9)=^,(+OKUH/QO)NX *+[,T?P+O+0_-ZPYCH%0SI/
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M'4!YF,4[(T_X8@FJBKT9)F?ADO1:5"O"WP2'JBTG*:P8;T; '2FGJ'IY>SU
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MH.8L9/[Z_G@EAX_=M*N ]Q.ZC[IVK<DS@8"758Z5GJC^4,(@*!YJC R?@4E
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MK(=I%U-0TI83N5/U67I4%9L^%RD9?:6:+.-=+G]#OMHG6X>$,#R[+4I[//2
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M,YV=EF,A17-SD@M_8"X0[U(R-OF'IN1H1W9G4<8D&K<UO^ 6TG*J^E:F#3P
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MG#U_?CG_MI(RTZ]*EFC^&DQX5>T53S.#R,<>O*L9KR]9&H@V9HCJQ9Y2^S1
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M(=J8X?!MAMIL9<F&V)W3D>W1QSX?>V&.SP[<-.,8FYOZ3QL/4!S]7NNXLXU
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MZ^=IAQ*6UI,XHR&MXWXJQ\H.*[V0AQ,Y5:NH="U9\3GL9,7:#Q_^+6* H1
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M?9V!@NK.'(^+M/!47 6'/Y.&IBJ?#9G^[>#^.*Y4U0\5=I9Q4O6]7Y@?NPF
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MNPKY5,A'KNN(3NFD@M<KY<MD8,<#^VGL6NCM9)Z]?'B?'3A")"/]3K"ZGL)
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M/PCZ_?9__3JS)34 'J>FT>#W9[_:ZY:'C7%^F_UX1W2C^]*R:>$Q5-^ R8A
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ML@"; (Q-QS<&4>SM/:\,>7@--TW-1ONE?'HVW3KXOZ<M=T[[3,&4AH,)?1X
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M029(IVZ9>)-KB[=MNI*L0<\M5&4D^JS/VB]'QE\+7&!U4*OB]<+==YM]T#S
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M2;AG1-;%EKD%UF76HB'H"-;WFW-P@NC2<*ZG\M%LKIN3^/.T =R[80L8%93
M3NH0F<KP<@B@ Z64'8<1J7 )+$\%5:T%5^AVM8B?*OQS49R 6)\GH]RM<O!
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M=S:!VQKP/*PQ2\NFHH24A1K/I@=I"Q4Y4RM!MPOZ@P-7!F0Z7F3;.8RV9]W
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MV(I,*P9$PNG^,R6G(F^HAQ>5/%1;]+TQ&^8?+]8$Q:6.HZ*DA@G;#,H1EWS
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MUS9]A*)4);H@F&M@SEVLM0O^IO!4UX=8D&J,(W;\<1YXSP%KC $_3*XW_@%
MC='?I8CVMR1(2OYRSXV,'0+1:[4M2H[F"KC_[%G G7M!F=F0H(/#:T!\?="M
M#7L T(?P@G>MT-&>R!%]UW-%OJH'@(.5U0Q>B=7&^@C+JW%A)JNXO62K2?XR
M^C 9QZ9FO_LG=UF2GC1H*4D:!)G=N*[4-4KIIH(PO,[3#\_7]]/$\&L\L>%B
M$U7"A&X\X>Y;P9_PWE0_=MH?X']9B*USN;:X%857D A.LW+GE")F<UQ]+F?4
MW*7)C+L=H<O!(C,$3.RE[&'&:"'/DH<K*JQ<"N0:I /5-[0!(&93YT3LG4&$
M.2UKF,/M3(O$KZKZTK/:%I)0BA$/SXQ#8W/<4% NJ<!$DJ?+8HK$V$OM<FW+
M7^Q,(5,=VJD0E=U@9I-ED?T&E"3=<EPB;=O].#0ZDMNTL/,/P-$,#TJY+2J'
MPQ:_DTJ^ 0X:,+64_+MQT^0'(LB\JP[ADA%/_VUS\ZWJC5AFLS.CDCX DK/S
M (!K(VP[D1+](4^@G;.9YHLAG'S1Y\OZ2C!QJ^X_K39%NA\YWF3^8G]AUH*A
M0M4G7+/'J=! 6!'Y!B-6F8/TK0*@*HO5/ EN?^E$.=/4H-2/&5@$Z<OM&S(W
MLO-7J5@_-Q\UH[+C.!>N"JGK$VKW+L](D\%- <?LOV5=8*4]ZSBSSMC=)'U;
M! O]0"K(6P0*0:;]J@,E%UXO>&X?_B:Y6(U%GPU&2I@$DK,OZ';!25BY?XSN
M1! ,&<9MXB$-:AV+@&@9W88O>D&.A[4;9^L^NM1R@M(#U4P.E8)Z4"XG"AD$
M,)&=%J*+$*$$:P_\]:5"5P_VL"[4>Z3DLW9/E79\FC> -/ZF&=!L$WTC'C'B
MS<>LZJF.NCC=+P=/(*C!*P8HF3@,:_V8G>3$22J%3:GZ_:*8HZ[I,^]V?^D?
MCPAL1@C*C%'.I]"BDQ"!!47-8G0LK !_2?!J<6X_>S![@K*SR6;-[K-."D/=
M#:P00I/F$ZG*<IU54NO6VQS;?]M+Y8IR93J]QUMV[%W8;J,9\?1R7E"$F1&0
MXC@X^ V!0L8KV!A01R>I[.B\!X"!CRD23>/LCB(8N.=?N)[2-F!C77":?W>U
M^HHNO';_<O*KEH.XF!"I?G[?OF%5K4A4*-'"CG)^K<50'?#$^S@W?[I> #A"
M_+$ 89H5W&,I,CZ]%^:3$ID ^'6$\4/1(/2W8+J*! &EKM 0RI7L9RT+?F"H
M1J6B]]J4PM33_1)3BQSC-Z,"F5^V'8][&11-D"L(:.H5.[U;^H;KS,Y@'5K_
MW:D)VW:LV)2'^1?%N5'DTS#1"7X^VI438!-;?"5$=1EC]!;!3N5"=7)OL>(+
MXCV7/;W6TH0S:8IEF3[%;DC^^)V!+]-\DV/V+?H'*F\PR[\'>_'J3F1G^MOO
MDSIWRAI1FZD]4+0@<F^"S<+!B8-?M$B.#X!=EX=X ,2%\*"2#P?C%'7+76UY
MD+]C:OV4C%]G#3G<FEPO/.?2*5X'0%/'%5991P+)Y?CR4+QE-:LA"^Q8YQBK
M&[4ZM>V[0!LCW\8I#[[7+>)_K-K7TKP+W)>4N4)FY($I&/]R\/(@C.DB$F+F
M[ +W.0YAS^4.ZM12Z,K),M]@P>>N6DLSM,5_G'?S?GXD%4.#2%3R,6E2IF[,
M-FS\/FFL*2F!1_/G@E,R0^+TE7FK3^9B+N#714PO78\ 1A,( ,^\F%->VF&G
M7.?N2"[MM4MA5B#Z^.?]H&B[>%<Z-+N;2;'5&E *"-J"*XR$/$729H>7(;N7
M\SUYJQ&U"IH=-NI+Y12LDS&*568V;8I7<D<CEM7(VQO3665F]V$; 1@;5RBI
M9LC?_,(H#T_:JPF!&.Z8Y ]$TM5TCLE?BNR871U?R:<F/@ (N=#M!+%VV?^(
MZ^.O;M_=11\ SJ5"!^OJ_<4B!R6.)HU>8E\N77#&_-C9(!9,PTW(!X!^N[[/
M$)P\&;]$N*G\*&O.:D/?3V@5:A835"8V7(V-OVKQ.>-]$6"E)37Q7@'(C"89
M".%,F=A9_ N-]F@)UGB5.=X1>?N<-]ERFL\9KBZ@6#O&\V%[6ZQN 2%RNE\&
MOA@)#$T6A&C6HV6&3%N=#;*-D=<P;Z6-*NX_$H+I'=]Q,RH8C4?_H9T:*J\_
MT^5?TH HN8'N'Q\I,\]=R9Y*GED-2C^I&_&7F&A?1C#:?1EY^D=GP)[-RGNB
M#O"&4)'L5A6COU1Z5^ G0JF<_Z:0TE-$Z.*JS7<YB5M,C3O]><HEW60>;7\?
MLPUX6G<"O;%K$SI4V$0_LD86<L.J#B1##VQI-;?%K*M:;C@M\-H<$^&%Y\=H
M283WU;]N1--\@[Q 9B7R)2K^8YTV/NK+[,;(\QX47*/&ZME<@*.S27(1#U1W
M)(L0*$C)J*]B=9=ZI6_?WR.-'$5YQA<M8(#?1JJ/WSE'6)".-I"6*&I[6!)^
M+@@YQR=XA#4=,@]D@G@B#SS9-EURZSX1@WTT8TV^S]>>%KXL\)+IN@A._@KG
MI-1F),O\)2.[9DD_"(/VM@9:K8&_N@BJ[.#3(UTOX:59R";;4H\B!YG)T:2I
M_"U^0)B _5!AHW+JKL(#@'%]"]T[1*6]RRK,JF+=_&^7_"+<"5C8UI^H'!T(
M\4UTM$:>:M,N;&#PFMM0=;&(48P1@M!O0T+[?B@H.I?]ZF=4@9OD[L1>3:$T
MC8M'$C%*E<UPNQ[./K3)B^0;M)%WO5I5--EEISEA$CBN!NVO6?8[*LTYZ^BQ
MSDM^.$XH:VB_U!VF4$&9W7Q$/0 &E9AWE2-R8[*#$>RX:A5N-_+-'=Y$?HX?
M=A1S[*@!C274,A$F'P]=.+NM7MQE-).I]$G;,@>'6A;LZJWPH,A3:YT(+R0G
MVGE<'<1HDQYK!7"/RW]_/*J(%0]QO15P*5!$IB9>)1O:+*DT*UHO3]2>O*PA
M\?$FZT PO X(XM(\EJY[K\M]$"8 YAK9E%T(=;7JC;WG6[SJ=G^QJ/CD 4 D
M].6&CLQE.07JCM.GECZ9\"Q!(X."(.%WPF6WP+;%=W1W!>99&\JIMM+M)E?D
M!@N:*^ (S5IM2V^D$^V?3*@QIUI@& HL^W]^"_6_B[7*\!:=NS(VV@A13_/S
MY0_KK9^YOG\+TT.LM9]J,.L<?=RC_J:J)+$<II @$(GD@SWK1,K$M(C0NEEJ
MY7\[_NNU&$6EO\^7O4\$?),.%=7TS.GP+A"P98\/H6E+U,\2H3ZBUJYZ_J;1
MKR<N,0<+4.KL/_U>M6_L($S>4@#'%/4[IIF^6U\/N"#(-#%QJ]/>F2)!D).?
M=ZFUL2H[8^UM$#MBR]JVM/4\T6:A=#&#O5DJ=V/8D0I$UE7N W4ED!TFE,3J
MU$WH![*#74^O;AOJ7<M77GY>@[\0WOWAS?OA5*.3],<N#I_DE 9")KHYVZ\;
MQ?;)9<S[1HMF<SC:J4_98B+XE.KR>N\E@::F'3IQN(<=F9I^!ZUU_:M=H)-X
MMJ)+\5E+ NK->"Q@:M7VML4]A^<9]+6X9$T?_TMQ@T![EH,PGJ_MU9[QMC3=
M]+Q;L(X7"/BJK?[^UK--:X+2Y)@=<NU)<+6TK2SRINQK3X-KG>N*_&O/_>XK
M,YW9:@=2>@+ 7GC2[T=8[9IO^W<+R=='/+DMS_,YK:=XN@2SC=*YXXA\;0,<
M 1D$7-TJ&JBL2(2-L(VA[O([*25Y7L>,X_E]GGA"1H[&#'RLL2*R7 $" ]1%
MS'6P].^7C2O-:YW,/$(^/GCKGBP THQ3<OJ4@(JC31GD?7UUJ.,/]\#@S;*]
MVID?'!W)^Y<Y&@*G! HZCAR[#%S+8=(_:VP4AG/Q:ZORY2<LOG?VPB]N7#R,
M]N#)+=.S/M$>1*?@$]T2\-;@)N>B\#O);D_#14]0HQ.TI4.7.Y6 X'T5M\^(
M)!94$UQ_]A@5"0LE$E%FT2Y><\UV1]0_L@0[J84>'."W;9J^_7[Y2.M]19TV
M9U.+2L*]?/9->A?:OJ(^=J<U=5 7(7M-\OGP0W_;):DF;=CTMI67DJC8XBQ!
M]QQ0"O,2/8/RW+Z/I.NN EL]0Y%%R4]8ZKN6Z,O /7ROP^N8C@$_F+-D]R?U
M-R5B.")M(Q&&"?Y,,U&*7 A/+#=YY>J2D^SEUA,_+VY?\&$:A\.J%J.NG.DY
MH2QGF))!@IW8Y6([8]\8JP"!'FHZ$A%05W,E%*2WZ$=8(O@6VJ&;!-FF,WFW
M^P$/X"MIEH$A1;<$(+9B46ZV$IWSOF=V^J&OYXR$U@=)ZT'!BH3I\0Q-8N9J
MUXI?B$M06[N0 D8TR;^2A 6CO.0K]/Y0'1KPH\"PQ2J_-X#BXR[%* ?-]741
MA<O7QN8M6A?XT$&QJ_VW'[8VKF>-EPS"5)L;[0A5\M?(P-TRM7_5.0LZ:"A#
MGRVQSA7>E5;I2CU\+)> ,YM6NBM;1#8N</@ H(1XH(1S4 2#0LQ'=/=$2XH6
M?CN'60>\-'],_P;#&B<;/5?I9UH_O=<FSK_T/LWU3\:H5+M0NV=9;N;[E\ 8
MNC'T.DCAK>YL I>1$!><]PF_ZEGO9]GPD02#)S.,MNB(X1.M<,S'C/$#N1>_
MJ $)BM*,8V^'P<=> L5=Z,P=?>7EX8,+6*Y^,_VX)5RWWL[DBS.CNA79&$X"
MX(B_=%WZD(O5Q[K[(L6W5D]CN706HU:BM)^?9WBH[UN/U_YTTSH3]"[N4MR0
MY=_Z8Y<Z>U44^XU_1#/)S+_D(+<H#'I\JWGVL<<F'W; ,3U++\?O-5F4\6&I
M,Y0%_>%\<QXL-25O[LE#:36:[?TI5[TSHHK@0"&@[_"_T794\"\DFTILCI>9
M#O*#RN!T]/19OXVZQ&@9WTR3TP,BWH/K^!!;0X6GH>'W,JB*\&M]9K,.Y$V>
M'X2U]%:_'?Q8_//:^!L-2H*074FLX]=F>)X(&Z=;F"VA3HL-\>;P;_W<$^.%
M.G^2H]41QOBSL'>XIN*>ZQ1XWINM"'3BCNMYC5 )BBZ;9^A6W/(9M"&KS=&N
MAM)C@G*\;U<Q0N&_8'0<(CGK:U4""JU9M;#&3W[A3\^?1'+XIE_)RMU^Q77D
M>;M?G>NRO)Y;-OTR\JB:X>/&V-,:-0JM=0.QT4-)K, $F"'33VJXZXINK>L9
MJ.KYXZ;/-H_ULOF8[>4&66X8ZT+[-T7:H7,8W4IT!:R J;VI>5GX;<2%7O9$
MS/+:^[BW;<YVN+M>%!'X.GU%Y.>9+,LAT0@A$=B-"FA>BMGFU8*WH?*TXR<9
M\I+W&>("8SWR&!L4WV J&T9B]LH=)!SD2>\VHA,@$M5YMJHU'Q#Y%BN&GD'V
ML!L0I,-05L]]5]8C+],G$E./4 CF/X&'?2)V;6@@1?)=")=M4]/)4IOQ,3 P
MGMCXQT,L% O)/+KT=MIKSB4J\K7FK=)F2!O^A+Q1>4Q VDVH=#M+8*4)6=A.
MA?,-JU"%,(.Q@RD,YNH4@Q"?N98<%E0@(,D-J7C\H'BL<=\!5 [ST^JPR9[.
MW=Y'[LHT2)OLC\O^;/R];:T+H(CA33WKYSL6$733BX;BZA*_[15G"7PT(1<E
M&%]4!4P#17?1;VJ)-XA6,>F<[]UAZ\TRZ>T*"D4X&[>R2\9<]IOBOLF0&TI-
MW*(+X88HH8-V*5@URER,7"S9LO'NNEMVOJS;-D3;OOF0QDE\]MV9^TP.)RDL
M&$LSX'>8'Y!U\UA4#T$H:7$ET"TE7-RY\*)*T RWZC*?F^^I42,#V[>^\&%P
M;_0#H#EIBTZ*(H')(+TD>ADB/0!BVG3F[R@K_4[C[L5P9<&3HI8^]YSM"NN\
MV6SZ%^85NO M*G,PE/Q\9:"JT@V.-PSE63?:4/22%-=F?H;UQIR&CVR$9"'W
M9@O?VAVJS/ ]$[;<FF5Y,P#U6GT^K\HBQIC\&?MU&.$H08$F #3W_Z$'ZK]]
M4)_O%[+3X2'3_TKTI=^2V6S,BZ#B^$=-$X)9\YR<E7L-=@#L;OFTI%F"4::4
MO*_@;%AAXQ=HEFE'<O.';%%KQ>6= 9S2,YV]T?%(41SW-W0 >ZD#6U%D5C)!
M7RC\O;[,,ZC5(FI-M_2/M/VT>>1JN_2NQUG!F[:W34FQ7-TA,2 <17(7N#@Y
MOB8 DH[0IQD,? ",J*3X-[IFT<^NHVD,B027OQU)]>MMK*ZW^5]N @*_B*>@
MZZQVE"-+73>9[M+J\UZTMJ[89_@MUN6N\HQ'EEIK<N2@VIR CPU^C1$J$-]&
MNBC%/@*Q1>8","=+7;IE%A#:^2Y:I9H31#T9Q"+E_+[/7$'W+6[N>M/(DP',
M-V3;4[,+;.\T,A#$ %D1>^U)>+]R61?OZEUIHP>2_GCDQ*0KXWHS1,HNPCV=
MG/_E')B7#@Q^8]0<^))@@$T(A9_Y%:*[7-,C<+S)N=#%LZM"?/1!7NDZ.0%H
MM1$-!9^?)C('E.I:ZC)&U)'0S=BT7&]%-(/8!WH)?4%/P769JM_G$%#1DS6'
M?% &A_2Z=T0_/@/5:L*9=))O61'%C+Y(OW0/TUU"#R6Z4!]Y I\J/0YTG$D4
MELR78GYU^\AXU'&S)FF><$],Q][/$0MK+8SPN,XW-9:-$UG>B>@E0<\,R>M#
M$Q0U2M<'=X.J':T86O3 !U1C-\"GW"Y]SW0_EP],MH/F&H!M8FHOU7"Q*1B*
M*"*N\RU9@:KH@*#=?)K!"=;LH0:0=YT+4F[!+VY-OTW<9IB!FLN9N!'PW",Z
MGAO'I,M]V[V-%[U1AU&>C9X9K!+!B$G"/2+ILT'?>)HC]%^HII/*_]$TU0\[
M?SS"304$8@S1%GPP&[U^,Z,3]A]Z.\E.2A[\68O/^3YQ9E$FZ9'RCI6R^&20
M@P^[=98EB8N>I@!8[,*4Q=$YKO8H&D1, Z(0+T](HS\#([E8VY*7]\RLI?/3
MF+2H[/#*)UTG$Z[W$6K#V^0JD5>U"AJHWE._X-)5H8^%R.1C;W<:R_[]!OLR
M=6GK5BQ2)W5 VMV^[)[9>C53G5>1P]ZV_W49G.*M*CL (P]=X9X%75'@ -?
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MK;U,F[R!>@=,>6(/TBVP\"NNO.X?)A),P8>>,2-F2,'5)N@\Q_*CPA^_5QX
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M=XEEV_5"1)PX";I4/7RNBBT=['J7=J=$T??>:L[11]:?JIL,<G$?*/+63W0
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MAI:(13!FP8H8_!OL=1.FYA*NN!+^<7-6#+BT$QCF-+1%#G(- %8CV,T@)]>
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M;T,F2WB94Z>OV!JO 6WUDX\+'IQ,%V0Z[SXU>EM<55JPXYFZ2(*SPP+1A9U
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MM/X[7>#?F%K_%TY^_^N$G/_P_?\9OH>M2%I?70/(X%S8]2QTJ83QI!M",-5
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M@'/@PC 22IBN Q.=RT8TA:%&:F<FBT-]C;VHX-- +SS[@PFWWBT2!:.O6]>
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M,$*4@W,XZ6"X21!2.6S/9K6+\B#L;*[*>A7C^6]:?DRDC&I]&&G]F2<4A-N
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ME@ 0FH=)/O&85F12=D7U7?AYE<'EQQ4FQB5)=K@UG@CG$POS]8EW9T;ITNF
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M70IQSX5!-9,U)IG7S9A$;%/OD6?D\AA3)TC>_^#2+;UR6U:J:#F'VBF0YDK
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MK"NZ!_^#&3Z=SAW#9/\UBRPJ;IT K&(Q%M]P3MS^3,#2;,YUV*!C_IAB].M
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M3E9)U?$IT9=]\$S$Z+KE(@V\6,#[HKUVM;$8A'6Z<UI/92UN :O? ['1_QW
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M>0EJ)_P ,!OFU'=[(1'+KOXXNX[-YNI(-_Y]]=9<<B"C2BGTTB^=%CH7R"2
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MB-PU0>6G']5BDPM&SXU#/@>I76D 2AD.=UV^LGQTG0J0E_JK?[*I?767:SU
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M29-A[40CIW7SAPRL*2K,JO.J>%3D++8%/KM___8]"DBTJ)V]!&GO<4'?OV#
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MF6_&]C\7\B/L?0/:JDI9,IO[LC1\+[S493]5[]G3> 6#2/4%ZVJB<PP1H!<
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M3,\8CJX*H?<VHS2!T7ZL(*#Z9(O^!IB4+[QFZ5LY=U/@>H(M0E%7/4$NN&.
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MTAO[;0Z73U=.1Y_Z65G?'>N,MTDU%!7ED1TE[0YG_E=9+!V7RH0,K.L C>O
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M%S=,5B1\$B_D^3,3>B)N-G+AO)*.H,&^9WT)1TT?8A'+P8HJ[[<BW2;8K=[
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MR:VEQ:!#/K:[]4[3Y)4>IP\(C)B91(WF2!>U&_/A=AX^%5?6]6T@'G_^]/7
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M>U@0N.""LI$064V(_#&JP@JA\/C=$P&N&R"J[/:Q$KIRH8YX)CJA3\FALE*
ME7?0PZTG&U2$!=QF;Z7VY4MD:MKW#!-6P&V:9C(S3NELPU'R1[]XGYI-=0XW
M8&H$1XA,.)>6+=,V'"/T+EE<-;1M*J"GT&8ZCV;W3U:LY)O6R52_('JS*A%C
M P8-6ICU=4; 5QC('WL)>8*G-H*TN9GJCPXE__#/]E- DXVM 91WH]23"=)X
MRRULN;H4JZ7.F=I( DS3MV2,M4CX%\<]K-\?4E)U;^D9O=/[$@))2SQ:9M[)
MNC>O1?LUG)59+TVV8KPY1P;#0<GG@#Y([ 4';A.U,-B:;0/S1,P'@DI6@&J.
M%4\6P!YDRF*5  /Z!<Q3J8W&71 ;NOB--ZH7$%ZYQ1WD0T/P_^<:O++/?FZ0
MYZN:O7/XI9>:U8Y3F@I1C$.Z7<[0'T:2BU?@4"ASF"9N.Q^[P=F[Z130DAR4
MX"WSE>'3VBO127F-.]^)JH0Y_ P(O[-]8WSD<9,Z>UL1OE2[(<R")^QM4/V$
M7&U)^[:74:8H8^]%T+NM>W\!CN+J.\0E%R)5#V@KWJ$K>1_N,3JDJ[1V6_0H
M=NTY^:HPEI^N8%<R-_5XANUB/OPS[SW]W4IXJ#HFEK#2%U0D7]QORT@(*?6P
M' P%#RSCD<D!8:M'!AM0<41!0?3'U>EA+1]1-YAS9[D%MI..H%/>@"-FN/]3
M!5B>]]BQ4GSX=&7%OLJ[;''A7]<TJ1<!_A2\HFQ!N8H,G[?8_D !%RN#EKL=
MKM50/W%.4.N2W.'J<()19S;> :+T6)I!(!,V@+B%DCYOLMH]$,K4GA<8#>6W
MSR>XT-&+'XW\6$39I-=@%O\ID+V73<CYVF.A-YH"+0,&]#E*^7??9*;ZGWQ.
M7P0W]]R[+HY0),0.!I]S& [9T%DO\2R;2[SW]JSES^16V"#)I/;NT;M'RD ^
M-B8T2[[6:#- (0 RDD[]:2==E"L/D_?%0*]<\<5G,6 F4(BJ!4%4KUO?IW6*
MRS3/RUDZ*^ME%#6[)FDZQ50XZ%+-HRUTK]<P_B+M>C(O;R6"8\&UO3VW#=C8
M\L7Y6X:?>7;X=])9M__%:]#_-[$C062&*OP%#)+;M.-:L]3K-T/__"B30=I:
M-/SB,121#QXJNH';S! _JKD"E>QWGK+,A\R.?$*5'W*>KI5&]]6LS<_>4@Z
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MK:V5%P4GL :M=(:7E6?W3]QM;*7]H<[F& /=C5(3CD2M/%Y:P!1NL#<BEFJ
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M]=Z.462@L:UD3*1['37$5H% L95!0PA[YF5BL1Q0D*:"6G?6C?_SO,1A^B'
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M&Z)]TJ_,MGC3.HO2RE>%\MNN!%DOJ/.:M.U[VN=WW3=$2!JCIQ=O17&[D6X
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MK"8@&751U]]M985<"OAG^[RQ",IZ&ZMGY\*'DSI@K,4T#CKR++?TX]6-I7]
M\?4*QC."EX"/>KY:'K;=OPU'W7,!O=9+OE$?]%39$\[&_8ETNO*Z%&@8@CN@
M8X0:#A;QX&W*B>+SS6YWLY?U@T^\/[9&8_.E)F?'&_7YQX@,E>YJ'M"4LP_X
MA#Y>)MACW$@&__R59M5^!'<;7B$EL'SPK,& :47?B?^MK$)_4R?LVPZ%$K8
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MUQ66.2E3F(K?^V?@B8?C(W:/LM@&A"#T:V*)JO5B,IUV&O/53]K<;:R6]<H
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MS"Q%!&A7A2Y^/E<R@W.)TJ@89=T9](B4#IG*,K:!;_H82&9ML=P8708M=%C
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MS+]Z_+^]R:Q^^?;F?0?6]1/S%=W*15*Q_CCE'QZ71+1P>NSZ<18>PP*3UB$
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MI7.@4V9&0^_&8F%12/6K=ZV ;KTPL@XZN7U5*'0[ 47JK1. )74]/8;BV!A
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M<CK.I<BX7!(?:?M1#\U@4TX&XAF&@T\14Q0892'%B#_/:>6%XEM"8#BY_OT
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M[TN(_KL[G6O-#,!B'$;W/7#YD<)?<TX&QU[DD7'*G15%'K_TTFO1^(V <I'
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M127AACRM- 8_QG)(TFAS&6WF= 0#KI_8C1V\^@D@_](@4X.+GG#BE;4JBNU
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M7G +3@!8A"__\R<7L?'Z?5XDRXJTGT4J6I"TX#=Z, :D]9XFCH9/Y)UD1N^
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MZVE$)DJTYY^!W6E#TM*'5-:H =88]1:"*@GB;'3]8,:9-POL-CTC?]RUG+?
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M(U!%&HZ[B5H3%+/Y/]?;:(-H01W]GM,^HGI;^2M:\=6TX:S$^]3*L&O[5$T
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MS#"!X'#1XD\T7+'=V8S!6OSU[TUEGSQL+_UGC+31>XX!--[#&QF]X?]:FK5
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M)#"BRJ%2=MJZRH[)4%,\8DR((7]1B@T%^D? %$?B#/!KCB\M31U3!MYO$N7
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M@?G">$988F(Y?]54 Y_0\J5=6-#AP>\NZG_+7E:HR.V]<^([ZEX.4?L4!&
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M!1APJ<H=)2F82R'2.Z6[L^MPM_]K_\N!3@+?4LEFWHX_#=Q8\^,#X!N6QK1
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M)X)NC&5-X@WO;V76QAE&*8BBZ&UNV?<%6\/B?T]UXR<I!>N1/+OV-0]DNZH
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M1^9+ $E8Z24 U$V8KK^ZVH"9PFQADVRXFB^-.YW^PQDK(82F.N6C&[R/W+[
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MK)X$&?TU[-)]D;<^,G:H6IGUX5'_WZ;W>Y3A#!]K5V-7;J5K9FC,BKB2'OV
M5'Y,_8%8-)3LI^_*M%]A-4S8?8_Q!;/WGSO\)"BT8!@B'+&@&.@=!(QJVE]X
MV6)X0C'_G6,$M-(F5<FC+R7IR_C(\4"A;QH:'C]-G"ODO\@1[QTOLX18#.5]
M[,R+30K@[VSLZFAJ^ZSE(UEBVJXZP>A/[F 6]_(#0Q=ZH4$D)$#\&^DQQ_X3
MJY?9NH#Q269$[S-\&+;+,-=:A0IC$B>]S&<^K^2&_F)]>.;R1_1VG'X7K;?/
M&#PHQZ3P3N,][1'PM4?A_JU@(*2#\!(O7P:9[P_6+T+O+ML-L1G?S.XM%FG[
ME+X]K</SR[ TN:;ZD&.3*Y=.\_J,*J_>%/@:@?JB3.DE9A?W&"]3"\DWFYEF
M8-(-]NQV0E/5U=DTJ!XJY'\T_G6D*[9A+)*4>AY.?U+4!^=UA3/U\JK5[C(Z
MHU%_ZFZG'@R>15K_M![*;"K#?*G1-@8X\%ZOX;@AH0J,^A>U/"AEL%+]I6CQ
MP316_-/E B6W3KV5'(\AF%/&U@#6<R&CRX.PQO=P1S@.*[>W5H*?P 5-J["Y
ML6<^S3-^Y^#B4#MX(Q6-V$%(FWK>(2](K8EHS.J_KT.^->_\@8%VKI<,?SAO
M=86\20,@%EO,0?R)\AVD 9;N+PQHL6NEB:;":0314?C)'M)/VWMFF'+T4SKJ
MU3JM!J:\FH;>HXPE"H,MK%V,I4Q=#=!Z,C(AH2X._2Z"<=^3F"C(JXP!]X0C
MA1<K/S"D<.&<L%J#XO&7 +)C$(G;? #OST6G!$$XEK_S5L<,<<97YGTM2\Z7
M+^G#?$&]EKIWLJD>C+<F'+-<I*VU82Y2]NN3ZT6)0N;XR##6L %WG-#2]]F[
M47M'%*VB+1;2)*\.64=8V;>6<T :AJJ\,O@N'*@''[<JGG S+%')SY^7 [*Z
MC;7:Q6P_X@K1=5.,D&;#F >-MZI)VK_3E<CR%@28?(!LK9IBVX?FL8$$_MPS
MJ?;H^FX1YJ? ET-@YX[VHGV)B:X-/]G5:XN^7?)KE'-"'Q@*7H?9+R%9(4U'
M0R 6 MAA+>FT6\H?]3)4?!#[>U^@=G+)9Z9SC._)L"J59!70\M/&N#L4A&=?
M0]+O]'(F#8'8/0CJJ##ZV//KN2YE=XN\_1Z]1;&W4PM33S]<B!U.??"=,?_/
MZGG,?RME2([J!XL60,\PRG\'F8/6(FI<D S^RD^VM-N(7VYHNXO5;+3INO S
M\XSSYHUO[H_9D);6FB/@CLH!:R-@)O$6@W@0)NTW[PV@O$RUJ;3I^FRIL&O;
M=]'ZIV]3GMQYKR3)*I"8+9IW1IH(P"HSXSRS]#"K,Q[0)V(?52C UWH&3(-L
M5A^<:X,?K!V$54]X]IC!,5]O6N$B,'#UN9.*6;\B2LC]2T"_R3/1^C?^VF+[
MHNYE65[I;_67C )2D+L**9]5$L*PLA.#A?>P_,#;<W[TO(-G+UO?1/Y9,WI1
M*%>HF4P]U<!G')H87?0V4_$E''!%BD'#=I5I%/AV3:S:3!GC<LI=G&(4R>O]
MY9;W%(L_E:_/1'HYDWUY=9&K9/<)'PH%H3V3YL]ZH^Q*5IS/K+)SWK3=2MA?
M61;HO7>/W5'HE_NS.U9C'<F(HMA+@(.P >7$:M(X%UCV9DX:ZC$FMMV;)WZA
M?E'+]4[$AMXE@#_C2XG&ZT::'W&W(IN@#OBO:T@&J#TF=Q .<+;FGCU1]GS2
M/0?<&LK]R]8PE*[D^H+C57HFM)^@W#FKPHD_6'-G1U\[B(#QX4T>3Y]L3CK-
M'X\=7'=M6EE8T:*]EB-H9INH_4Y7D/_&4NKU%Y/7#F+"FA]!);%.X?Z-Z+NS
M!C%*@$**&USBPOMJ#FU9^Q;=@\U$Y<:-U8M+0,^HBAU6&/7X$D#N!Z;;N:G9
MC.92=F6XX987;2TQI22Y.!1LKQ SE&NTM/Q3T]KLP^L:V\F4)BWF@M+$T/I]
M96SN8_SMCP0'+'N$$KO_*N=QM97/YHS&_)_8:M;WW](^V^4MO')AY!50ZJ/F
MH%_IM*A/1;)"7;!=HX54>$\4DL)J>X6U?48P\Q(PU%F^7/U#7)2P_K-AZ=O#
MQ;XMGLZC<.HPNS!J2-)3$!/A>?WR;EX\5K^'9Z/V$I @?;"WM-N2^(,V\%VM
M;%5[0EFBP7U9DNA'2NN$D?EDD,/!C657HM)5%A)$6Q)IKNA9:KF<^9^W?I!Z
M>W91)G5I1)94?>;TZ$UA#S-Y\KH5B=VBZT[8UM&XA>X0AP^F;H6^).QQ8EN?
MVPX;9 N.-+@\?OC(KE7(J _S<O<"(7S# =:<6,J48QZN(;E\:(KL^;/$>\C
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MP!&W<S7;4'[&;ESUK73UV\_,Y*YS4?+QU=W?^-?O/OC_:"27"_\&4$L#!!0
M   (  $^=U:I2UVQZ\0  -':   8    8V=T>"TR,#(R,3(S,7@Q,&LP,3@N
M:G!GS+H'5%/?MBX>FD@7I E(5(H( DJ1(A ;(" @(D5:%)06>@T8$@'I34!
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M!HCZ*/QS! ;R#/_YKNTQA*Q<.P;O<JB_P:7E")'J9G_]5JG\###;42KV"\P
M$_,Y U!'$B10]\+L)*IWS.QI]:#^&?T: 47.2GC:9X<J5?LL&Q4D4>CJZ36R
M-A%)0)% IY=U>>V6516]DDFXZO+K5*5NZC=$'O!]NCS3<.FT U1Y&'(*7$,
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MH%Z@R>6)\< S;X43L:Z&J_B*@X]#,*,<<PB(0V;:2DTK?V9G=!(P<-&AKE3
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M-7W_;CS]4T%<D"'.#]*G(@<#$&C;D)<PD%->8FPI5/I%56"7L;B0NP-Y6<@
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M]619WML[L^J4)AJ$'0&V?;I[KZX;+;P)>%.V56$R;F??5L'8RQU7V%EY<[>
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M2!'9"@:)(]@^>:D<Z8[BL=T"[*LQRUU4-B2(>G"VC/2:+&CPI>V-H=3SEK<
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M;YB2%-O52?!23+T !"ZV!LA&]"/Z'RAKA%4@2,ENU<],%=[:J81/;#AH +>
M."ZXUZH1O"::0-P"[O\@K'#+,.TT&8>UCO. H=24@;P+<XJ5/6LBJU_BO4^+
M=98$X#>;5=P)CF4[2;NC :7EL<="&5(5P77^V@CI-E6Z77H\Z96D"F26@BM9
M48&7!UI)7PY5]660/1>-&8S4[:=CN<DZ'0X!5D@'!E@?D.M.IL) :3'-9U-Y
MTY6FSDS[C8\.>P 8K$5]/PAG\1V[J(!A'PTN]"9*3TL$GRIWG^[AO<\,=GW,
M;LQS1VXX39O''>W/<$5EMP^Y+/3-G'<I%;!;A5KX#=]<F_G/!CQ"4WLU;")
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M@ V@MZR!9+?:\LS2M[=":\*S=TQX6Z?VN?ZH#,'S,O^>RO!_Y<9Q\D3F)B?
M1GJN5P.9NL83@F8:13&O0+ 7JG4,+"8;JFOGWTA11F9]S0ER[=&[MTQ?X'[I
M[GW-[_5:F@YE/.'_V'_T&,G?$6J>U8VF&H^EF['4,,5O(J"TT&9R>"G?-\Q
M-[["@V1[FW:Q+P@&?6@99Y!B&U6R.9E]SH$W#<)TW@8WBIPS1L+!FN?)-T7^
M][RHVP*H4;[@';JG<-8(QV>Q1YT)AI@I<Y3:>2\?J$,C&>-?M;V_]TMPE0X+
MSIW_1_/9@$PH-IQOF)6.!#N,^RL<9Z_&OJ3L00P!(#D!#I#/8@3U=S^:0%K@
MAV5C+?842'VM@7>M?M\/>GVIYL(;3>^"XP.X.)HS6Y..A0;$!!!(48$D$6^E
M"*$(@AA?B&H9M46FG+SI"6/,&Z<?:TG3"4:W@%!I>T<B^AD/1SK; 4<_Q"._
MUP%X-NJSA1AJ$Q+C>"I%XTDG9@4 3XCI5(#Y, ;*$JD-WWJ'.$\2:&@-=XNR
M\^(IY=ZHK@]L"E%04Z#4F9OWUNS%J(.D"9[#_4,1*N='KT<QI7%:K<!"2E]+
MN2@JE^R(N>\?F7KRK5ND2\3[JN$L+#]PRR+:#L!#B5K!;K2A$!+F-*%\D!9;
MH@=U%L!-30%CYM$NS[KU1V[S-^%ZLX&G#%272N?^-Q4HX[6CR!8J.# .A6NW
MJ@\"KH[" @B-;"YZU@7K^XX+L&3[[A=)_\26\=,M#OC%=X2N:T4'66,<GYP[
M(*P.U*^U(=%0>@(0L&KD8[6RJ;'XK^8*@L&XKX^UW-KO-S.>.]SDM?!Y\9QW
M-R$Q$'8&XQ+FQW/5YPT_,ZA*7K^5M>#Z1/B[B=3A53L.35;*W9V9?6)RD].$
MC_#4A]=V27JVHQG'!1L_?_Q8ZF#"(5YT/_R^<?0#5G%/O+7@X&A=:$ [4^LJ
M1GB/%/^XX"+Q^?!:YO>Q7C\_L/&WC4RN:W,B#H"9Q8=P'%>:X+J@EX!3R-T#
M#!K>'1!Q1S#=A]N&/^&:?2BR46HT0)!EDYT&4RQAOP+@MYG?5]B)M4M&AB-R
MS[-NPLZX"+L"GKC',,(".J.NJZN:,X>6^]-&YUG+1G1#Q168%2@8:*S(SXT0
M0AEP1_0C)43J2T1HAW5J"Z/KS3?FV5G:]L4F++/VA8(X(WK%TUL DB.\ZPA?
M#_U;TTMB5V=:B@E!D&M;0P7BIM/1R]>G4\Z-_P&H/W,2'\&9EZ) T(9'2XCF
M[S5HP;;>31R8-=5\Q7.,E<$KH*U[UO)D1,!8VN0N)FGU.I_7+*^9L.\-A#F3
M+G"P8]__A1&&:94TW.P'O.;Q<K@%=-!7U7:"Z;4B?DQPN2EI9;)>CU9$$Q<L
M6.'L .__I93C^1]*.=N:_U+*T?T+I=PN%[1:2&?4<+XKWK K2 06\;J8C>(1
M8 4@TJWTUX N+#V4T)\!7<SY?<Y"Z7\5&92F?J2RBJ1($>!^":C0IF2X]QW.
M\>-?9 9@_L]!%O#4]L&G[H0DNQ4SG-^.W],+C!/-/G:Q6Q\FN[M&><CA(5-4
MNPE6RB[ *=4GJH+K%O!QC?Y:T'OF>R=^" AJ!;%?7O'6:QK'"0)!"R 6)=<)
M%\JDE[,?[AC+0V25G=2-7+N8UOGR0EC_YMT!6Z+*;SCF6DCN#OU*@GQ-O.[T
MB$1_<.5 X;/Q-.&F(=GIR8M'=]3]T]6T(.<:CH%1TY2_[3*<0(P2?;_IB^BE
MX6$:RD.J*">GIC[R?.GY2H)ED#9!XM/^<LD'@ER^<B/_8_"E\BI/B##Z(3*B
M%*BW_':)='),KK[<O9,S_*=DO>#J'*1=-6+NS2)24S;3;OB1T=#O.)K=I^RJ
M.H<$O/$B)9DL63VMU>01((6;I,(H0OSM_38Y)C"-E]&Y>HIKK<0IJNBU5R+]
M[$"'_[-1GG>$N8L+1BIH&_T'? W1'N_Y7![N[ &C85O!/<\[DJD2\K%$9=63
MZU,%M":TLQK!:&/"1;@; DGY.O^CC*AVX4Z'^A?' 6Y],0=EP:,=^X8SJ0PX
M3ICT*A[<,B&'4F*J\I/L\*Y/UD3:-D<&TANF@X@+$K"WF.!,3=EC_/1"V$VZ
M4'!4=^^KJL69CW_ORH;.:4U6(/(G_]R-):06>9DE##Y#O?XS?2OZ'X8A!)S'
M-M]\KU8F5*M$^L((/W,5&2E@&"+]61(..@KMCT(_8GQ_=-F)?K#HYHC& +VJ
MYQ7 =J0VEC<-:/H&A8I(K0E>+((H[YR[_RT@D0O!@^YM7+YAJ?F32BI.28,F
MWW1/-H/7R9_,E2M]SHGG?]MEC@U %="LC&*#+=S]G"WPUXF7#$/Y#?,^]3V6
M%&83I3Q( ]3*:!D;])T)CZ<<8T\0/^4W>(B35I'T:<,UHWY-DLW>H$^0:7SN
M&*O5C0]<%.]=&ER"-21_\0/735OAS([#\-J.$L(0>;[.&S2[?E_A=72%-BLK
M1IF8NG>)WLX%6;FQR2M[R?%+)SG.8C"'F;C6DQ,:#Y)[#I%% 24S.[(+)DN&
M<]01F"\B-K1.F"1)7;Q91]2+=L_%N,KK)GBX]M]S5T0X6.A-5(A@,*TQP;$
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M230PRHX;*]*]843CG/EHAO!H:K+T0^7O2V&1U8T4"JUZKRJOO,$.HYVB-"Y
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M(OQ**'Q).(QMW?_ATGP'\-@7M'Q/2\PP*]<O&=Y2>+6='>Z(C%YD#KT.XEN
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M4=5J[CC=1"15[/C'4U\!@3@Y!(?S*;)K1Q[%;B'!^?U76NO#C7>>_G@L_OQ
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MYFUL!;HB0OH$4 <+*8*XX,>=K]\607K@M'%IR@#'/.?)P,,JW27S#;I($>P
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MRNR.F^7F [K:% C>N!MWQJWOUV%)J\,)UZYPJ31Y]-WTZE;_)+Y2<8$\=<\
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MOGC&7-2KV?U,26WJ7\2%=SM^(P><B=?"*62AC^^93EZ9K@V4?[-H*I.>9/[
MM+C2_.>AC@TR""\&(!V=<DF^=OP#,%Q#3:4?,:3B%1LZ(D ^ 60DHD)P<6,G
M@.BB@1. ]B%.Y 0 H)1'%ZVG[*AP*O#.!_M COIH>7NT&?9AK:W7]P'\106!
MX^](CT$2*$,9TS9Y*EZW4_$2GEKS6B\A$'*5/OQ1P+J>3X=5?#'-87,+W9G_
MYOP07?(HI%KX.5&O;^G'=*V!_ET^KLGE*??VZ@2'P305\1VSP]#7&ON;]ZFP
MPN\I-'T4KUN9@R<N2?>HBBM=^"+9VUN4I#3A]^31.X"Z@:(^!>]JZPW_"XLN
MBV<TKD!F#)L_--;6L>KP[YL]X$?DA^3B'-"#B-[%J!PAK%FAC[=3X<84ZW<C
M;^?[^MPJ2VES],/JG1_;S[:QNRQ2DSD(/AU-6O.3^*SWJ)#,<_%C!2Z<WD\I
M7ACJT6%,UP_YEX30_9,03:3I3VMP&EA@L8&C2*H?;YZ^N*:P[G>TYNP<'S.0
MMEW3K:_M#/E;)MWF,48Z)O-S_$=7JQ=DA4F49:O^[TL60D[)<;VU][>^%>X\
MQBJ_ V;!T>NR)X#1-IC>":!#X 30,^61_\>$?=V(EWEO4X9:PM/S>WY^[3=]
MG@R)Z_2)%F=65WC.[_/5'IVS4\5%XQ^/:-P@F1 <EK/-*=98"P(L? FQ]WSB
M<&%.M>7N7\VOWCYA)^;YR5']#OAG<@U.4WI6P>T4Z2[0-$6F1)Y.;8HFHQ&<
MM2/A!RO;C3"&*WI]=L#\T/#II- )9#5G] G =8=J+90-QU=<[*)@%5K&4<DS
M:YF@.Z;#5AFI.ADU)NPPKDQ-,:#V?S8YT-]'<N=*K^2I'"A\3;S1Z^\9\ '&
MBENH=$WAR@FF3_<U![#FO[Q 3\/C]^/O:8.B0* /I>X%,<.=(!==VB2P"Q7H
M$&U/COFY/I?2[P,N-WK<W=ET6;5,[Z<]Y#KO:)0?4GD3A#2F5**V>ZA$_Q!6
M:8H#9EB&R\@U/?NK *-$Z*Z!SG&NV.GV?5-WT_]GXPP10)\ *,F#W=E2Q4 2
ML:Z9KW*N3M>\&"T<_R%SG**4L4EX3!6P32&\8:G.MSG?OM/TF2K[!W@,F^\F
M3@?5(//(2'A*M2%=N"&5_VG"]<M9@EZR@>SY?T_H% *.*.L, I$,L*O64Q2E
M&#5@-<J;!A/\::^G?N4304G]=*B_7C'?^>.W7?=-$)4K$FOF%L+:Y;:ELZ33
MPZOQ]>R\Y.#DIR2EOKL4ZZ.;RBZD]-GBPV3IP]9*PCD<,W[(E_6VMZ>K8)*6
M^B4+*7J-#VT]A&ELK@'A)[:ZQXYF<GN[5&[>8\[:R/OQ?0/N';.OVS1.8BH1
MYAIL)-5*@@YVNEOCW+B'A[3<,6T7K\:Y^*H"2U9YQDOX,-F;JP!CNL__ZHV*
M6O\HJ02MT\<TZ F_[W.,<3DIF$@LW(_XJ##B7U^Y<BH6N!.8,L;'F64MMLP1
M%*UD$C+,4RT;56(37N=[AY\:W-&/?U=/N<G] 76T//$"B07W?>INJ-=X2SY1
M)^/X!"!]N8ZXS'ZJ#Q%*PN@1#?MP+>N9+W&L+J#OW4:TX*I &])W5'L >*&O
M%@";_Y<,:S_-,'314JHYI08:O"8E>*%KNE+BJA[P+],.Q]9H^:-S$'9*ZT8P
M2O$-@NJCU32XL"ME&.72%B=W/S^^5 ?)<4UZ'5H=EN+9"($5)3:JYY0F3/];
M$^_:*4/SJ2_?TB@P&'L1(Y2=1_\X$Q-LG/PY['&UC V S@<"2PIO1,3Q :H(
M)=CEG@6F"0^1FD_3-6M[,ZNU8D*)0K<2OC2PO 1>HC&FZU4Q)[%_0-F.H]O'
M0VE(FA,23RY3C+&>M9=_2+;TH^8/OC3/OU';!ZN*YGN#!:&-HEO.YB[8+JXU
M24B>5U3LO3O$K?W,VIE:V6>$<;N(^O?&G7^XWM;D?EW6:6HE]K[(,9A32):H
M\#@4>/I<4W3&C$M)#73GW[H_B>DTOL(6;A R, :@^Q.UY]KY7+=*(;TP!QG4
MU\>9!I7NQOXK_B 9D>>#P>P43S#Z4ZM(^J%"6#TI2HVV;$@89,X6O%//^FX^
MW:)_3N?KW'/$JR/N?]L:- MOCST!Q(%=%AE(G@V3\J(M6NA!H;WX$ T!T(Q@
M8F2_Q%+Y\>*:T6C8H7E2(UX%0* VIW2O=A8*-\PRGM0X"[LY_O1*7Y9?H,?5
M6-F;E]^\HE2+/_:O%E11CJH0SG<Z.U_8 8[),$O]7-6MII U]I=]FN/#!OYP
M>H&R$$\<<:DMC7@;)H"CZ][RP/\V'-M/BWS2^$E4V$@*NG(YH$1:DHN.'VO@
M"V*&773!3J,/HM0$[-6F%51HW[CG:ZI_X7N:W,G:4TH >%S15 (X4:AI^W=J
M^DJ?4A.3Y>+A"Z&,S^06YF6WX!2+Q*\4 ,.M^Q>XSC"K[)X6<@%X^S^% Z2S
M:3J*I$K155E!<<E Z8!4@8.L8)4.FZ/YHZ)9FCN!E[ZH_3MQK8"9R2CIPM#%
M'%$"Q=$8*WI_U[U'YXV#T9>24"HOE#@6VQS[YHZG;>#<TYLAL =H$("0@R(S
M5BS#.0;1@U;2C'-0654+O[[*5Q8#USD"$YW$/[7W+XHJ'QJ]?P>$'&> 716/
M\[=(.N)0ZIY0&G*?,Z=GS,/=P>%,067$\^PV"'B'\3<$A<(_PK;WP*FA[1B1
MF'(_IEL;FMB]98.QP6[)/-GG2-6':NV'*VT=Y>>6IY_+ V,7:6$.: -A?6BM
MI(-!^M#\]ESIG<WKYRXP4/]B L!"L*%'RP84)&^Z<G*DJ-TH?.%G6Z6MZSA@
MR$#CJR22B5N\"'6[ \)JPYGLSG&Q;MZ1IEE_!\[&SYB'!JTZ4_\2WP;/+.-]
MFK#2FX@"&#^NV1)RQW>@3-%$Q3=14)IG4/A6M5CJ;KL?S_17,SC64#HQ]=<4
MB*$6$GMD,-T1+ZEKE_^AJ]O8EY5SMW\7JX(\=$E(\;X)\B>=;6N<(#,2^-8W
MTQLS=.J<)*[K[4XUS^9_6%.8I44X%E@69K@Y,5KWM,5\!!R?M?U_O$7'>00'
MM%X;*QV](S]\P=5L5COY28YC[\^YYP*)(7KR/23!X_S02R2_QM9:+#A^;RMT
M>_#VL+NG](X)0X=[87;C#D02WFFQ;[FM=@V;VF4@D CJR9&(FC9.Y*IXPW5M
M%X=:E>^#00C!Z/:983(C'5%AGD"G%]U=N3'2EE9D-<.4;*/MPV$9_%:7X4!+
M70L0FCSZ/]R@65GD!#LO1IT SB1F$E9[FP*B5UJ^U-<W9AQ4B2Y]TARB*_-;
M8,(51./.=?M;G0"B]O7=G71:#+!V5KI\BGP]YC^,>J1!.A@@BKBL-52/[3I8
M%BXL_'QDEO9!*SWN\RQ_T>_DB 2JY^2)GOW>D#\K!TZ%@ESA5-OO"7#W$A<S
M_.RKDB+GIA[RTSI%D<NO>,Y?Z^-AC@K3J/UW&S:5W\9X]K8SP'A',%-J]F4H
MY_2+ANFC U[?%P5XQ(K6#?SV#TTHGG:=< [C?I4RJ>_-46J93M_H?3G[RXK5
M4=)W0$$PL@\'_BH;,@@(S8%&?&[BC%23!L?L9YNB]$>67MCHA?CQ)\G=DF40
M;CE 1V^Y8%.7I6,@M[#12;YE#A:,0W4F!K&/'ZQ_!2Y0"^2;$:J)ZH0 ?!I!
M\3W!J)>3$^MR)WWZ;MV-0,<9XX>*13]P$"!,G^"Y9,1!GE\\VP+"@K3KQW=(
MYWSP%1RN32KL]5'T/V+3E7F\;,3N%DY\8UM]"PC-_7= F5]TQ.5V!F7TBK='
MFS4=E_4EE$DR[1W==W]S-5I,4='^8!H1E(59C6[1PPQ'!TTEHWF]H)X]BEZ'
M9DW%% T^>:1MP[QZJ6*H?>8<6H9PC3)$RCC/R+QI:9B>'_"%8\[J_8G+OM,7
M=?'EFW!6+U'JG<5X9(UY-_*YOLL)@&$XGI+^P(& ;Q=LOA!G $N?3(;4-SX0
M@G$BW2#V%D7:=K2DQ[#=F+"@T.3;Y],"11HO@KA)\\=U'B1I;#.>-*)FOSS(
MI"$(A9MB?X4#SZ- *NNCH[8!ATK@*^#K(L5.RS\K3HWBCHM"7R><5>UVP9S5
MK//14-MO2T+0Y0C!)BNF[TE:8-\E1+GHO_]<10D<#^*%T6%5[]:WXX9C-]54
MSPZPA=E^I?ZF8UPR,='.2)8G@)8]$J6*EQ"L%M"X(<[=%3?EVW(&">B,C\BR
MP.'/BS,^:#B"++#6SDZ^*M,4W:T@58 R;: V3!(ZCYH'\G!(YOP WCGTQ-./
M^;I5S%HO1_>VGYVICVIC5 ,[5LI>BUH(,$@4C"E,?)>7N+5"M743Y$.Z1YA?
M0H;79;H/)^P3;9G5M>'55H&K;_+VC)75=59M>YY)5)84?_U$ S*!Q"W6P6-@
M6L2_(&L0;H\G.<,=H]!T:2#!KG/BN9KH3,H/!/ZUEXX)I,8J@!2Q!=](.0%<
MN<GA_"_+C[Y,"!>E[H=Y$VU@_ 3O92%L10PI.,\E".=H7I/IW71UGCHG'AFT
M!V:!+G>36;'9P['[B8^&#;''+5<QMG<";W55YB0V%S!KA<+(<Z!JQ><:0)@@
MCOS^ PP\"7/ >'+9J&_UQ93K-9 _/R)FFA*$C#W4 - C\TM$LSY6\F=DM718
M&>RNFLX[-ZNRM'Q\OI,XE6\1NQ?#*O6@Q^7W)FLW0>\H=(*[>$;!>;;+MV#
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MXGP"T)8X0=8K::F2S2RK88DE*VAIK F(F^G,,FVG-TE'03.3IK'9ST7:M_(
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MZ)7RA6,S&+R4^=RX[_;64SP",0P[.^V*L[NVMMWY[B0NA*2:SS8%L878>*W
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MIRJVK[HP?$_35:\^N/QX__>L1Z8%4[X_;VWS@2G\H01:)V*[97R>.BOYX,O
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MP/S*=-Q'')'$G2)*?3SQ4[X'K,?17_A?5I$!VR"+?\6:Z=AU^(DA+IM*G>;
M*E"A6[SNX670J.F9Y#WR$\#,P>7A%1L.14"%6JDU&>>ZP$S]$^"#GS&QALG7
M^?_W7Y__*Q3 ] 1 C5!Y M301"#U!:C9C#]49T,H+;R@>WH1TN2J,CC?V*Y
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M!49H>KFE_!>WE'ZAT> ;7]WSQ#2S=\5CP;/2JH_Z_'<I:EO8)^+*N\Y<WFU
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M4?.&^8=U(=,M_8?D X1H-CC[W4RG8,P/1V&\7:[%&2Y:"@B;=^V42[,I/2P
M1Y<M3L(KPO^:6^R\3\71>W^7H?#+NMM.5MXFV _&_*(7<3Z\;N?1\.<N8)KB
M:=4(LYORIB)-%!--5*6$CEIM,OE;RH'!G:+B))]E4\>+.6?CYNH;P?=UV)/B
MAV$0R20M5,T_JHUC_;5FK_IDG\K%9K[XU*SRK[JYLRXJ;[T*PYHAK$5JQFKM
M,KWW (SJQ8LKM\WQ3TX;>OHVV\:EY/GM*<;,9^5-5A75CVU^*CP9&[[BA$R'
M(LI:K/T(W;< UQ-T#%R\U7I,U'_GEM67>>-,'[[,W>6GS/M*?<UV_J::VO;
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M4XA;=(N$9<,5!CQ<MZAQ:$-9U2\A,ZJ:1E\Y/;N-6_KDH%P@MMRE*T#-$Y<
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MTC[&-V;\&7TJ13ROPP,C@]*^V#^1ZQ4%CD_J]^:[D@I_B>J_^\J7=5&;5X#
M[>&T1Z"W5=.9#MJ_+SC&<@^Y:]^2:IJ]UP.Q:UQ>3^]L*W6N&64\!L\T \<'
M-78$+J8$5OFV[U.$2'YD60T]23Q5.F-K"L&NA[KOD;X%,TG&OQ,XFF$ S\\#
M^ELE=#^(M<=_W'+8U#]Q:*U$#? _S$+^I[>&_?_T_V8BNIKZ/U!+ P04
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M/\-/RSB6Q>T85R;=D2F*_\YKS1%_10CZNEJ^6NZ&CF;"B$1HD_13RT:4L?+
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MXSE,2E=?3QI?N; T-RDPD%>[>;E&.BXZ-BO!J% !<^E6_'OAE+&B 1R%-0C
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MCGWTZO AE37^GV%1IO'*PU)0Y42LSEK.^82JQ]2)UY\5G_<<5\4F([6%JZ+
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MSE((VY[Y6#6_L>R0;U"SZ+2?I/]UAOP)?M=7YRZ_N&'KB]G'# +('VIECCW
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MZS4CV1$SAHAYXNC*"WC>YSPF321M.%R+ CU]'4TX=1U=L+KV*%E+^R&6GR5
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MIC3*-(7?\XZ#OI^3!V_9I&<V98.PKH9SY KK%R$[+^%GO(_$9^&K3Q9G%$F
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MB;I79FUW:&FI#L!^)J]( "!>^^/&J45&-X%:>MMSN2;"L4VB\[*$1=^9B3C
ME'9,"=S3PK%"R&_F7<1=GL _1!-.,'+1,H?:B^C(RX&"[@V!N1AT@)/+78VC
M\C,B)VR'#,1U>SI( -PM,FP6&:')_3L]./'JP?KAEHLAB^:8QR!^)?G23<MG
M5G/J:!L.^1M#?1%G^K0**G<#E\?JF7$6B]7Z!&X@,PF 9,G%IUYC^UL&<;-E
M.-8#-^^)X=KJWL!4Z?(1AC(S[Z0 :<33'U@SO*0ZT[?O/,C<X$=&[;!\-<0M
M(_',IRGL)$"**^6Z#1H^"R,:>Z"X">%9)[$'S*^JB".+/%#Y+^Y;F/".TX>5
M4W+5N>)$EHG4@)G?\GO#"!I5)[6=/=M%EA878"*0'<__%>?H@)OY:/QIT_2=
M%QLSC8@7>*9YA$QF-X#_/LUX /84?J("C"8!L+1DLG:]_,4X4GSGO),;8S5(
M0$NGXD8<'^72ZR4*,JR1TYE,6!Z>65[.[4RBW5S@G2*JK#_?L"ELL+4KU:&_
M]3S^ZK-%5S6=0XI#[K]N7 [9>+?M(>@-Q\N>>C:KKM-[>[+=Y/&FRA>RN!&?
M6WUZ 4D4LR..M#!!398N7FR^"@D]([*5/7;3<44_$I^I8N]K ;IJ-O^6[[$!
MG'$U^^&\20#Q8HP+L97/A!BE?%>'FSA*2_1((L]9=+0)T;#<\3;A?;.*ZX+.
M%-[9 P._9>]K5?-J;%</_8CGIP^79$WH:-O)K+C6".VDR]]V15.)G %_,99I
M>:<S1?S3\6:AS1R5\&6':.4=O6X9C4#F<);NAPEQ$N>QB4Q6!YF T_+8DW7\
M5<)'@ C>!TVVX2.1?SS.B\Z9QD;B\I$E9=:A"I#0CKX)KVTM..[&Z,%*_^CN
M,(+6_D?/TQ':@/]D9Y7S@+O39*9J&=8E1[> \W D#ZU1X8+G@25Y9+WWOSV,
M/+O><PE\D[L]%\%'EZ*$0R+1T?G72(#70AIDJN&H1+'=\I]%S^27004)^?XA
M@J?=)@D+@BF:[P2Y;BY],FU[^TI!EDGCJ*T\":G??D8"D*=FU?0K*/M7!UO'
MQ?4%X\9IE;#79D"M6O.KM#P/IUYJ?_O?B(K_5WV*,W#KXL5F!J@GIGB',< O
MTS)#)N(X4CF87]O1^$?#XU>JIL*Q9J.O8^_/F+^94?>B#CDRC 7@@MM::!K-
M2 #:9I$%=S!1%"VBZ%I[GJYJ?Z=</-B6*]%UQ;# =S5]^1)C1YK:[^:/?]J;
M="<!NEF3_MT=F?_!I1G_A6+??7LNW2NM"LFOZ'HO9^L"(."8YO-;"^>F9:'W
MT8G8BPJ;+Q06<3:8)*Q77D^*N<NQ JSZNV!U#@\!#A4**"V.;#2AR4>">$NW
MW&3C_-T/4B675U(N]?<'LR=*S9?\]/=^&<0$QU3=P:7*TA0ZNS_8UZJ("HV3
M?'IDT2L ?F\682-C=&$[:U*[;+)\>%S_UQE4S"WLI^10>@BW.(_.[>0Q+\/@
M;ZE59G&(_;OWQL9JH\3/["\N".)>Z,/X_R&G\_H_OI0*?@<7-GFQYS0&- _J
M__1O=[,G+,%.. Z'3U%7:O;P28@ 0J 1"9!_H>H_+@9L?/Z?FUTI+[7N8]\F
M8N!$KD;%]G0CU"RL^A:&*\5D;K#*R84^_,.*P!GXZQ91<EQ+GL/[\]!#-MK'
MYU2>WY#]K44YXNO@=J9' @RJD5?4^G'R=#1V2$"9T%E!RH1L]U19I:.UBF<[
MH^]5X=CORWH$-V1S:,=];FHZ"9J%;:Z"<-9\-#.U\P8[YPDK;I155Y!W48"A
M.8T/9P3W#T!NJ+*O6HRL;!VOUK?!AVIV)\V6S^_S+(;EPFZ[XT5'/[:\.N5/
MT$-@)3F[NIIF]7[F<S)X)GZ^(:;_>=AN8A0O/7KY$7CG4KK,SYF5GV*'1-SP
MAE7H6>]169IH(QG"Y)I\+_Z$MQMS&<M+-;6-"[E>$(.8HE=?E?OMXI9$=R?\
M2H?4!Q9?RS5<&7(VE"\X53Q3:#]ES/*-O)Y/&GW:R;VDP<3<VSGCR.94UZE.
M[8G<)WX>,(6G)[<+8_.6TP8$?^C@+Q1[H)-T:YP?*N/C*\]S%M;+7J=;IS%8
MHQ=F>A[8U_<[8V^[5I($>-QO%GJZ4W<"R]U\ZM:L,GH4_%UF>Y=OM=B^%].Y
MJK/93.]TX47]!P$7+3^UH7#4BS=+TJ..U^7342 )ZSY%"OI*S;ITGBNKD+[=
M*]Y,4,WQ1JG/-5.YOC ^)4EV&^5Q):JO$4SWBW:^%NC,*QA*-^+<"A9D4*D!
MW A+9R?&#B%'%1/Y_N21W;7Q.N%8^,)LX4^9#,F:P.<;Y1E;,-G%@)M !]S7
M$O?]=?G9Q4#+5 <#+YZOK!Q9%RGL\*V[:U0^N*G(A.5)Q[KK)484377?'^\_
M??#N31AKY4V&#^=94GX KU(JX9HYURMNBCPL_V5(-;5K TVWMFM82RQ,<I@4
M'>XP5EB[9W14/^$)M_0!Y7KZC59!H^.C!#B=$Q1 ,U2/BB;AOOG#TCY8-Z6:
M:7@:"6#+T0C",,D$Z#:E;Y1Y>LD<B7]+/M=8\5*6P8"?,O(!+6W1D@E-F5NS
M*KHFDT>:3]/_B:7!QUKY\]8#8=4LE )=XH1]D]M))CC#/#=?^P'W#):FU?9Y
MN[0,@E^)7&;IW/.; 8< /\"%^K7V]5EC@^K U5?.KFF- U'QU:[[:A<VSULR
M"JDC.N)9YX#-ABIO%K&>AOWR;U.\C5,<&G;*:F8KZILU1C^-^@U:2KID#M^_
M4ALI99B]*FK$<,F^8Y5J7^/","PV$YCKE5P]IG>@I?!3&%&[^O"@!<+\4^$U
MBWQ.X+GJ,KPXNUNF;LWVOIUA\45,[VL]HZ>/UUR![=MJ/65.,W@@^J@\%RO)
MM;L_MW+UQP\7:0;!ZU3HP"3*Z?@UK4F0^XZ'P.&4S8^F@@Q;F_GY>IFTW*QU
M#RO<GG[+9&0&QZXR0ZWGIYADM,8'UMYC7DIAM=[R<,X^6ZCBN).]B-V"NT;R
MN,C!@^"S7/7C^!W/%2^J<_K]>OJ,R?;^;DS!P6M,H@_''<&>Y77$%F3#MT^%
M'ZO5VE/_N+/Y4;S9Z)_B_.B"P$E0%C),2L4T$+L_PPZG71S:_UYV3;#KSQ'K
M#?U+.RTK/]P=L;(($F#CSB'%PK_(KT:FOSE4HFB%"I( 28Y_:$GV?28!UA&'
M%PY(@/!%S!:JY8Q7&4C@=PC[MWJ(2;K^(Y2;"6:%"T,.,WL 9VQRR%/R<TBD
MO='V,=MK[ZI;UU(<8!$!##DSG&%.F /D[R_PC5/.C'B_X"9OTTK[&\-W8W?N
M'+,H>.M;; ;(_:0U4]^PT]\Q/E-;@(:,X[64$MRT0%^L[/JH)V<EQ3Q5D S@
M]&7*DGP>G:\:_N5LH%_#IM]P6_XHH^"FRWOM[)M8Q(IE7>JBS&!")U<[W1A/
M0=J#!^=D+TZ\H9>E4Z(8^T4<=Z0C RLJ2&E-8MEGW"-Q#-NZ*O@J_1EM1(Z\
M)#56F$'0Z($7;[?'Z&]"GA:E9_EUY G4I+ X5JR2>W0=]#1^OI('WYI/L1J[
M$I:C+YSHL?;PC!&7"(I"Z(4)UN3W!'@L[?AV5-U)-O@BVG74WI]"F-LQ9=H^
MR$F;@@1@'V%:(J!N7[(N>G>PX< 6+7'@AN!YY;6)Y>^VHK6N#Y.;S>/?,HCP
M^%-]IE6BV-!A(WP.%81D74-;Y@>@^.68'2#U\UY^35*6/Q*EOG#4CJA$"HN@
MU=NTF#RF/)"SS+_8.U\8(PUVE4/HP95)-\8/[=W']CUO2%1X/-LO?2/"IB<Z
M1 (TR%UHO7H(KWN<T#S4Q__4\[NE%NJEE$?09'&47_".V<E/RQ?/FCJ'."K,
M30W5!'*H(<4=P[.4[3D:WSQ-3$>/X'20( _=YHIIY5^/;.E[^:[S)2N9:72O
MOH<%"(';-MJZ05%$+OR=FJGJZ\&!EPF9,K<UYZW]A<@S*?O7=;^I(97Z+MY+
M>CZOK@'",O>_DP!.\R[M?-YQ-;ELB/6/W5L=TQK.NVGH:8-LT>FU5'ZOW]72
MEZW-$UIOZ1RP-_!P4!RZXK+1P4N?^(HRH;K(O0LWF3Z1*6'8+I>H[<S;H;8J
M$D#FXG/<IGM2+ G@#F+<J', 5J!SLK[@;T\J#ZA.E.YH7;G\CO^6D$U BOXM
M\[D;\;5&SV@\>HALQ/X%F69<,+K8'&,Q68FK'W> <>"2E26JI*NTJZ[S,?Z@
M&-7*'P:46$:1&8 S*!I$IQ^IO$BS1>1+[=((22.FPCQ*KJM_^U&3@]EUDAA%
MCAG,1#WB3R8C]5-^)+A+AGV9]K40ANFUE]E\43HBV/;7'56N.M8*ZX=IS//^
M#U^I"[Z.7=41)8Y:ZIS#O,+=-T+713?ZH"2V6ZIWM[4TO0427#P:7%-NBD0K
M=+)\_E3U8,DRBHS3T+'>X:$TN7=:)L:MIFID]-:L)N4>1?7%&GU9##YQ2[&@
M!9PS;/W] Q@-I,$'.F&\37'AZ&&;D:='VDZ&2083GEJ&WDK)EQ)F/GZ/[O1M
M,KHJL2A%.6%*):A$*&..4':\8#,+5<1$5C#':E6/E0LE(A:'WA>X7*WVO9/$
M_[7DL498SWU3CY9J<'L+"_Y&AN[4X4RY/YS:+0D5G/6^['7RAH)>OL/5)631
M/3$ZXU87^.6Z1ENT;6>SS&0HB[M&5/33(YF;;:=O6B:]G6OW&0\"F?EYEN]\
M91O^P!Y_(2 ^E'H1E[O,.1W'M76'SX[(63_"F#;_(TMAX(H.]BYG*OTKA?.#
M@ ?K)$#MQ>)H/.B+@QN(J=$II,0-A4!YTEU_F@%SRN9%-O 7T3T2NAOJV0^Y
M9&F>6P>+],1+(>>?PV@AY3PUP=9'7'4JZ,#TVGL&PAY1/_,4TA]&Q%>Q]O*4
MZ[>2$9=<#%04?882C>?KCOJ$B^JR5$'<3I!>4,YN*K5F:"L.>*-9PL)Q\3.
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M-J%D% UB)W?V_(IJ[XN_BWB7*MU+-TQ)J5-=01P/VFZ^G'7#)%Q07:-4I2]
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M/QSLK1(,M]QP% >LRIE"E=Z+E)?S RY)Q@_R7TK00,T(-NS$-&(;332,&Z;
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M37OH?<!#F,7?F4&E*=8WCX6-IJ*U39MB?Y\[B)RL,!EL4WV 3P7W=&OAB?S
M3RJ^;WG@[86_^3BW.L"73P=JN"\LW;C/13%YKINE-+1>^B5N=Y\&\>3R_5F0
MQ56?@VC]W;<2+*YABS/VE&;1 GT6V-,*8ORJA$QE1 JMMODY<T&0&!#Q(\!&
MX=-]A' ::91PE.9]U34.N^W%^IN\CD= 7+5(=7^/&183/&C F1P)<ICQ]JX:
MMK5VQ"Y9:&QHCJ]TW:_@LTV)N:;]BG)P^>]#[?]'*^#_R_;?FQGQ3W<*B.NA
M#G7?VZM.90D>_E5DI$94>^SRNV$J&Y[SK2O1@P!7,_,E<1_X;?_2!E\#XB-8
M!Q_*H4RY2//6B:A2S4V;_KSH2O2)C4I1(AT,9AX8_7G:LWMII4R$-6;SN )9
M&UL)3!S>8Q&-TPS!"KUL>C6^O4B+G7E2,V;Z\*2!!*G57GT01Q1D*N956Q 1
MDF.@61LG@-C%PK:Y+5W?GM/M&9'/I,-IIZZ)\;O&)8^.+K$']+;ZCI@?>623
M-.2?OF[/$\O0H9GXBR.N,F\%[O1G3D_^)*@.2%$E[BO %TZSKH7)LL*=7X]2
ME]=F<**L=E!L5W.$M2,Y$'3##YC(F)^'0E)<RI5_<(E-FFH7B?X$-;[@*VA+
M)&WOL>6DVET?);E1A_!@V=.BP^_S8@H,2G*+P?2)5, QW@]_+%3N5*I\ 7^)
MH?I13?E)^>2!&&M 9[4ECVS\YR92=96??1-S!6-E7LBBM[YAS/R:LT-/_^)N
M8?9A.'P0SCIH150$##,2G>2[W:LI9HFQB=G^ C/7V4IV"1AF;#O#O1.%;X9+
M"+I"[NF46^IF3BGULV9YO49F]\>Y4E6XTE(UGA8\ 80!W!R(,D'R^ A'2'CZ
M%-MG>967?L[<?]<J].!>Q\Y@(]TI@TED'C:C(O'!'AXWD)%/+,A#BO1^/_\)
MSA,G(>GBK^(@& ]7XS'GV8D(259I5ZMVZ=PN([GJCNCD*$*R]B^*T49\POM>
MM#R\:VQD',^LDK.%_]Y!_R7*^=0=<9#,PAW[K8ALT3&8N_3'Y^2CEGK)O(I/
M@D4%IEHCO5:ZS(1K^O.7_Y(1\W^8@?V7[9]3?O]LZ&/^2_#B!][Y/Z)+R9<"
MC5$%/_!0_R4VH9]_]_]("_X/^]K\9XPC![%T%UKU"#@^Q;\GYRBL=A\V.\=N
M>034M$I?FO_ B_[/5\_\_[+_UB2D_UW[[X;@)H28O>,#-;#$@#4#;#5[^OU5
MJ&*B\K+< ']]LD[8"/V.)J:Z@G_W5H 2E#6,JQO"1O .C%>#']78H<XZX+O3
MXB8X7_^MVED^3#BCDK6ESVE_U$)7U>JJ69I2PK 29^HDZ(5]^^@<]UECE>RG
MA53AQ!L<,SY"0I#-!0N57#(Y<PRK6BS@JIVCM_$,S*2+D&EMAN_%. 3]:FHN
M='>T+E-_E?M:L+Q9&WW _5>C&T9K?TJ;SA=S ]ZGSXT,7JIL*O6[IWHOQOCD
M8,6R5;\SM[EEV7<G]*PVG(91 '+ROZM0:V)V?C 5"!3YK#>-5-EMG+%]!(0W
M&CX"+.^SM2#QS;.3MW&_0J6]2/E+KR,Z+'/5C:%[Q9 @%*2&UE+CRWH$1EOY
MRL&L@=%Z7(6?ZO>]\QC[KX /[]^[YD"  BA':- ,D"G"-M'3.996&NX<+L@A
MPB7P74*WPBZK*=9$7"&(FM(_K0^2]J)3P#D^M)Y^/]@!A,Q&Q#X"(&$.>NV!
ML5E5S1%%1B86#DL.%>6VN5N1+&A$[RV8._B8:[=%!5!.//0S@?G;]K..3?(E
M3[+4J BL/O[!S''&*45-[=8J8ZT>OPD-4&<0QX<:[*M'FG0KLVX&#%.:W9A3
M:]<@/!1J>:#KGCNU O(4<Y*>2N>2!(?SJ\RYRJUH:CZM^1''7I?T52$"Q>TZ
MCW9.:D* \A&P MZX,NDSX8=L_[UF74_1H175/N+H;D5.2)CRM#QIW&7'GQEG
MFBUU+7GVR_0\]BQC3G\#KQA?_Z!5Q2\&^%:17$3L#]*H]CX"7C;ARAL9RWM+
MQ?TTZ"H&_30:XB@_*PU/3[F*=^H9!>0 '+1-D(70!(KJ)G7M/K!N=5OI ;AK
M@"#!<%>+/HNF(-[\5PQ!(8&LE83;\Q_X?C\[YR U S#C03)3EN;%RU4.48%6
M6/5/!YRH%*M(8)8";I?^BPYED1$)6C']#.#F]L"&$-+.<?.]GW'02Z"2YI+
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M%ID Y8FA%&B^&8S,+@IHZ"\TF3OU&%LQ-?;YFHX>QQB/@=U/HZ@;0C$E^[2
M\7-K_KQ([>I-8[GVI 3I!HAC]5L"%<F&]_M>8A9"NH<95C0'J(MV-2\0K,,3
MWKU&PY$>76;R<]S.@C3::K-.CX#ZF@T[F%6[ST).78(+V9CZCX2)3(@,>K[#
MK8P#9>3W4HU/$&>8^%@7J]9\QM#DMD?U8DOMZE_72 "?=7HV6J(.C_\T9NL'
M4]Q/MXJ;R)+%(QYL^RS3C@HCPX3WQN(),H<G7 ^;@AV5,2X5S/R*&><^(7//
M&9ZG2EF> 78TG\W\(XCYK^&5_TIN2$?V*D? NTD_U5:F]J9<2G;S[ZA%T?TO
M*DM#L9@)'"+_5>Q+#YU1'07A29$@XP:RI+(\C>^E-B>4>95UUPIVS46M$U25
M97;"F>*G,;4V:&=7->KK'(6F5PP%U!V^F&M38S"^4" CUXK0J18SMR2O]O 7
MA7--)32I?[&CY 2QM389.%>'$V9_9S#7]9_<X=7JB![%B=\R]U&L0Q1JPT$%
M/\?P$R[IB)"V.MFZRG\B6A+TA!)G11W-^8OR/J8Z$^6G*.XR>(6&YQ,O2K$<
MDUD.@82:Y_6&/\QW\L%/H:=7P]>NE>Y'^CB>86EU0BILK-)L4TQHTYC+OBV]
MF^@.< .%7T#;]_.#"5.K7!OGA&^*EK'-_*QC7O\J9=YY'=8#<.H.OU1AO<A6
MJK4'+5R=\:XR.#?Z!)KEY@15GC^HKWLA<O0GO<T:I:.'XW;@.^W5224;=,1'
M-WI+S1AV58QS16T-R05?W<8K+J@Q38,]?[5T4X 8Y(4C/9;O5"#9*G>R!?U0
M'$E;@T> 8F.>$E\,IWD"D;R(@GCSF2%^5C@?M@+ S_N.S2S*LN]Z@YH69R:H
M]LP)=^V*SE*#O6020D_^UU#CM3Y54!3)[#I0^FT7_.B ^% OU>Y7'.6R#[U<
M;!$)N#"D,5B6!@O-C6/B@>SNW>*=+()L (Q1?]"WO*9AR9(<ZR>ZI5H23O(=
MRVY'#6LG4G=]#_/UH")98O95E!E224*V6CCARY>G@Q37)?;TEF+::C<>,QO1
M%E[]'(K8A)F9?"W?$K%_U9KC QO@-F'F7RAI:$>M:U/VFK[U5#'SMW]-57##
MP?2T>;$RYB3*^NH7,@VR&>G_R:7!P9<FHYP^OB]P <L%\6>Y!_X;GUY(1B*>
MUF%OPN&J ,$:=5FFYGVCNVSR9@!V55&V,)Z9P478$-WXI6QRE(GH%^8W,K?@
MUPO#, 5H@+1,U_R<FKKOX:5@YUR:\HI@]EI5N+!6OPL9?R]C#,WPAE*2.9HT
M&NJAPR, VUXL+P$CW=WR908!&L'@[[_&&"\+T$B8J ED:9M"G+<Z)(4'P8[K
M@[ <+R'71DK:%)I*%QQ]/JA</-['$]Q@ ."-%2T60KPFD99[3D(H:QJ!&=6I
M6J3B[BJ="XEKK3XU;S"P^/1JA8BE@_"-\JP2@8J0A+GUU[,_&C$W]Y/YT*1G
M\@Z"Z77S3LZ,*F=<I"H,KI\D8F<RZ"O\OS&5:_7' HZ-(=<167P4\(VT6JZ^
MB-L7!L^V3EM1=[?'67GNMT<GS-7A^)"%H2BA))XP 7N!OP6QSQD==%EFF=IY
MC<_\BW:H=RC/L1[$D&G][8+5Q97 T,GS*:TY#XZ_U7J+;(6S%NU?!UVET3(2
M@*+^$1)I+?1?CJ6D$0$Y=24QVS32@Q9<>-=&L5S2:DD3\Z IMP)&.69S[Z)0
M(0_3=Z<R';4 R3 ]I#V$R^]]6^V\_YLB4\,U,$OXM+HU%6?&@5L*8>('%68>
M&1_R4H,[47AS;D%_H2QDG4^@U=%TE OWIX %YA!RA'[7&-5%VH]Z#^0]^R -
M3#WN17R^-N6'KX_[5B;GBGJ($AE:>C5FZ8?:ERAO1Y\E*,LET*,D[WXW4"AX
MF,_C[( GIE?3O.;R/=.$GP@W9V01JE@$*#1>N"UF$EX(O!BOUE*K)T&G<DB4
MD2IHF+Z<X';X#A.X555Q>O9\)Y)$\2LCS&0 SRL1PQ>[?U8"96NWMH,R,*YX
M[%,@C76B2*HRL]Z7]HA=N0;KV)#0%6;;5ZW=(0^"",S$.^'*SUE)T4\/\&2=
M>NGHC]]+<BNF7)-IHHF"S,(*8 I]E!B)?-H.Y.BVY)M^M^84* V5>FQ_G[?8
MLH%'6;C6%.XC($-%$_F<,17KHWFJ+&LRRED^B13>X2. Z&E]WOIZ5G-O=[0:
M=_%Q_VQGJRQC,1EYOQ:I14Z@XP5-PKS#A7='W F7VFL=-K=46+$0GB:$V]6;
MCQ)QB*?@$#R/^9XI<46^]R#IK[UP1\P342D TU"&7S@D"3#I+.[:F<=:AW?:
M[_EHT3.'G==2-:>C$7%0]F\K19_XN_XX%%LL_MF<_FM%GOA(SZN^R.4SZ$-0
M?2 BY)FU^)S+6H%<RG>":<P6UHA+NV)[;94Z0\IMF/5@_3,;,-GXI-3#-)GW
M1P 'G192>VO=3'=6D*/[A;VVF3W>N<%'P9\8+;;,S;.8%):MB=EM1V_,>(WO
M?)'Y#EL'=S)9>]D5J^L'8E5KDQ[+LURO]V8AJ<*.-1F&(G+Q;GA8$M17R7=:
MB-W2@33(\SLER 'S7-ZBNU2]0M=0@Z/0GE?DAL@R02>]=;+C:]50K!_X[MU(
M3TBN(I5!R?2)G-$8,SRZ@/#;AIQ://96PFVV]W4+]?ZK:I4B.Z.V4+ JE]CU
M+;<N[\",$NL*,\XYC%R<G'V;7$3P0L>L42-N>Y;!.'IBJ!#MF L&RG$L3MU;
M'?'QAXEIWV:'.W9TEO+])N ]CI1$CQKT:T2P#);-PP1636Q-FQL>YBF-!B7K
MQRSW!E+#DEEXZE!5YX#DAS*T^\7 -_TW+Q<O[-M)LTLGG'%6^UFJ<EP%/HB?
M>6C]^&388X&)=NY3] @(9^W?\,Z^#ROQZ;;W^\>,EB3OO,/=SK;A3:N_JIY,
M\5"0;^8V71+K]!^<BEQCC9F].8'CBA,<MK4-EBY(A/7?'%BL3B^]6Y=N,&.7
M-M0YB:=1FA"IK=C<;L+8_]%^^CB>R2/Q;40>6^1)]3Y3?*(,O9L"@+,;"T2"
MM'P7I9C6+T4U6^GLO+A'I13)IJ?ZPZV$U_4"SX6L5(3&H6): @62C]V[<W"#
MD5TR7*\\TM3T]G?'F><(#07(0CS/8;\[LGWW>F SR<@08=U4=9.$(3C=;"=L
M]'>LC#$N.E5]U3M<'Y,Y6$GP#PW 78\.MY.C9)6EDY9NKO/;;J+=K*IGLN),
M\T'L*:93GXHF[\O[-5V'S7 IS'D;%2=_AH+Q Q9L8XVX),$6U3OI@;5\[=&]
M]B.V9U6)F;8EST'#]N@U.0]6(+5/PLW/3K_@O7_Y(J_'5_?7DRS^YV!;N]B^
MA.<C@+XBZ.8V[,F;80,.(EQ U(^ U#KHV<U%_1.Q3E__U^1$-M1&4&WS N=>
M8V=+[.FB-3LG\0\/3TE9[5[:H=J:.S+(,U*.=1P%1JA(%0DW%\,]E&'<U3Q1
M+B7==#W"YLX&D5&Z11<)7NPH7*91?)BE1_2];)8RQR$0BT#+[^O,,B,_ I_%
MI:G-GYK/>W0)#[3;7KVOMW@K;/KY37MHJR+[^7DK9"A &;/Z,.C%'?:UT4:A
M)62=U-[SI[96ECAPQ[B3FI!5<RU1J6R_V'!>BA0IKXN0S(^ND1 N^7CLE4QE
MQU/4K,VH$/]E4@QE3E+<HI/T8INTHQ1I]!OWC2'\-,I;[+,BIKN]XXM,S;5T
M'8\,!2KE4<=25\DA!U^ZN W6CHX4BX4OB@66%<;V[H<6ZQ1.CKLQ&JM,X@VC
MG+_E7_81/$G*>08DQY:X@9ZX\W-[TFR^.EB5'JL:=4)EZZ>I@JI!N%G4C XN
M_OL>K,)[(JEHM]SN\'-)7']$$$)ZF/<@ZH,9Q0HWC,CQPP>/$:^,T/W?#&[#
MNYZ[#3E>C"D@"6#+@"G#XO;<G2RDBDB2RVQBSDEU"F@A=,SL7FEJE-#&NL__
ME=XR3(8V#:&Z19J/(#U=F#_46XRNCZFLOK2KMDQ92YB-U$M\FQ9O)87OXE#9
MCC2#3)CU+(*(%AM'!"=(L6;YG,MXLJ0TV@,ME)GJ)I6J?# B$'X#-[9Q_I+V
M%4>6 V(VA;@Y]5.%QGVTLZKIZ*1V&I.?MB(R7EF4GB6FSP"'H8'EF(/?[UX)
MKN)C#J,7=^W&WR2T?ON\FD^L&&NH2D).+I]L0*OT$N4@#K[9=UAF9/8JS#Q3
M+X638"09G8/R/&X8C7T'-8=6\?4<DK6_NL-8=DYYO)3.*BF)U^+]YI"(L^F?
M"]TDF'2E K2;R)C&]GWG;.5E89F2J_M+U[].+:$49)^E/NCB,XQ^21@&0-OI
MB/U]%T^MVSJF!7&H[BG'##,F=R^_<^VTJ[K4_76KU&HEIN?T_F+]Q:UMB UU
MO@B)"S]U?F&$]-) /ZBW:VZX_X7#VJ"5HIIS]O$<OQ4V_&[3# 5IS<+/$^61
MPII+TNMJ2>J_/,3D#[L=$=&>Q_M60X_413@/@,21:=[V0@T02*F1NJ>M3\'0
MG%"A$R)_O2V^#V3 A);AI3?UVUW'_P.">""#\JK@I[TI1^3LS?&@IOUJ#7WL
M+HQK]_TSI?1AIEU./)]C&=J%TCL)."B5[B209A;6XM/&!U9\LY?S6\S#_3HJ
M\,^0$D0CS$BP<5!@"L-0GGGT137I JH*X5KLQ'KR.<J.GWZZ$N),>UY"]Q?2
M2=UM4V^N:.8/G^!X\Z@=?,(IW)5</$TBK?-B089D_+.Z(VU!S7BSD>Z:UR,
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MA&*ZY^P%2Z7.!A(#>>1 BSP"CP <>Z%,RHX8G@T. 3I[<_=,\EY1P&V>[^)
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MLIS>"&!M[<'T>5-6,M>\!M.Y11_\B] !2/0Z\<I3D+N%0GOW^MFWYD#K<=S
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MB-=]S[IP.28\<(0H:N5S=Q)G^I#@S"2R&![Y#I<Z\1,);UYU&EPP^)X#;93
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M^-+RG9=LSZ847QSSQ9P#OOV=3.QWOY"[J6_19AHHCEI-03B]9-6[5H /TSO
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M@(9>IK0B@S)G^PH![8I72AV/)KH+)^&RM_'(I<SX9Z.I750TF(ZJ?A+\+O.
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MBO85)+$_D!<\E^!DWD&(N1$,XC6O8$9>PE _%][/5FY-FRA5+KDD=]VT^C5
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MR7C*?U8G0I[TZ/GAU[U@;&W,]298U7P:YG$_I?7J_C=8I(LS/.RH4<CLKF!
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M[X?C+V.S&71LMGP(?2W$>+>4KCUM;ZX \K[R^=*O0;Y3"_AZVZ4!P'LP^@=
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MFD>*&"_':Q*#J2C6D&TZP.SWIB;G-IO-+<:V*ZHUK@:B)R[\Q68@:$>=RA\
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M7U6OCWU[K[.J7\T[FEO5J?J]KWI '/X)4$L#!!0    (  $^=U93D[@H@0D
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MXHS?LG34X'#G91U H^ W_28Y-<>42*CP"+ G#EP:+7)NF(43BPNY4+3T[EA
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M&3_MC+0'UA@J7D#PT/H?"+J4E8E2?L.2<8/7G9?U!!H%O\F3Q-0<0R*FPD/
M+ARX-%YDW#"+)Q85<J%HZ=VQ@/#SZOT9].!JF31=:I^_O>"/]=8=8D/@E,JI
M&#>YTQ=!Z).,SAE1;,[9 M2'R;@FM"@J*J"PE,J ("%OP9P,^L&O1*;D7,X*
M>^4DDXS!:%D%TZ*[Y*J(>^3 9(Q@S W[8\5F7!O0'\86#,:'ZS#$20AQ<4*[
MFE\-7O>PV$,N-WO(/6O(#7<-<F^HMC*?Y$MR#=X+!OE UR'/0RZ1T'$A(9&
M!B@O )%+4A5&50P\A33!9AF 14IR.%(<T)K2&(H4D3E(/B.=W2V#@L5,:ZJ6
M:)+3:T80L*LV-90EX QT*=!K[ ,-8JX@M0$S2'8T> ++36 1XHSH"C_6]1=,
M,=\(#B#G&A0X3K=+AA33)8NM@]AN":[)!(8)*PV3,ETVIV'/%GNV^-9L,7HV
M;,%(R@O (T*[@3]:@#6<58W3O$BQ.7O-YD4LJ@2:!(@WL-8%>N!*+$D)"(6&
M+ 50(=;TX9&K-_L&BDJL'.BB227 !R -"<BV'8(]NA13G9%4R(6N*66M#@C%
M0F<'CG8;S*!K?VXYO">'/3E\:W(XVC5RF+1PA,$R>#G6'O\^A<5+KTQ3#H<6
M85>$*F;1#.#D&$N .<(TK@O7&9JC60ZR Z4''B=<QT+J"NJA(%%2.)XIE8Q9
M L6:' "&$P:LX(!Z>1-GM)@Q\AJN]9\J 1:#$0T&QP?LT%8='"?NR!URW$XH
M')M@^P0%08-D'.;1EZT[2EL=I= 1CG.3>< "$Z#H.[/)R][1+3YQ97M&^8J,
MTD!ZYVP3V]^=;@[HX8[QS073,!I GE7]7Z:%+B8D,:WT]E4P,Y@R@+COR>4:
MLE+0 &@"#&F4&F#%"ML.[M"M54I3ZKB-?> ,GVRL<=_U,@A/<A LX(N6@B?V
M!HRNIIHGG"J. ^ N);+:J\"6*HUIBJ58;7,:JTND9N"0 2&$E4J*JU\)BHH*
MAF6=6*<[4,,E3\V<#_Z;,C0$Q0/U(8AW7.&0^K?&S\/(R1?9OOI[LGKV9#7=
M;;+:6F'<XJSMM<G6U 5T-^<),A+5LK 1336P&6ZO($U1E=24 23&J<,%9DYW
M=8L$:MG%$H?C/I]DW9DB6KUWXP=55JH$\M(VWXMCB#_KA-VLF;$"LC@!' 9G
M6(GDB"9581Q/ 8GR$B37GJGV3/6,F"K>-::ZG%-16>V!F&5IRF)\(*%@^H[=
MDE66MX66<H=W;Z!88H**H(.0E\!X"@M]OP?;J#VZLF:X#95^>8^73.O]+<NU
MS,T$^#/&QO>\LN>5Y\,KR:[QRH6#[&WHX^TDOV]BS]S)+P_0/9B"R3BN% *\
MD>_<T6HNM8%R?( $VM(PY^2_%:1+T/3!/5528"I0(QO6WO$8^,/>"2O:MZT/
MG5<9U:OD$'6,93:66)%GY\,+L"41_)H)?UMLP[[[?T_1]V&S_;,E/]+N]/&?
M8W?:/H^2U,S570L$U"M-]EAK!<3_ _*[6]M!*]=HE7 CE5ZE5+8 FLQS;@QC
M?Z#&WDA(VO#\!0?_L)']GO(/R0,[+E)V;D_YM1 $-TPXD #>DL&;.S%G@%J?
MP*SV=A>,7F-&XC8K;$YBMUKL4R_U_>8'<8'?AG4WQ.Y0 C2!BIJMA,"]O.$W
M:* *@!^"H^O2(@TYD:YRB"V8%7>#VRNP.V_.[W.>/9T\,SK9N5W?UY#:I JN
MVUT -[-2 ^C!/HKF>:3K,@->S*68,TP/"CKS3]0IKTY87@JY9'!VD4DG26B+
MI8!5GB1WZOT(28%]V<=!>"M<NCXQVKSC^.H.SB3XW&(06AE9%[C7@FQ)B]'Z
MZZ#U-EC20%^'6 "\ZKB7&BP":S_KB?/(7 7Y)G9DC9%C:+ QHQM@:+R8U&@9
M8P,?C:KGL#X.$'O1%*Y,U\$")NR++SNMSM.IEJ(R;%SS3W.X7_<="S<A_ZDT
MJOMV</7(/WZU\>#>_O*?;?;83^PC)O8^U&Z/T%LK8IFH?25ZY-)\CQ=Z6A/2
MO)Z5BMG%Q\TQN!Q$A+RC"A3@<-0E^+YE:TX>$)F>SVIN+&^(?9Z _-2W/SLV
M/:$.-UYX(NL1[]+*[\H%[!&A@ 2QZW'0CH%]"#Q5".S6*E^AJN$Y.<\X2\G;
ME0;]X+?=]NO^YUSW@X_N 0U8ZEN+?KBQZ'7.X13 +LB81PB7;"7;IS2^GBE9
M%0FF&%)%-?\VO@Z@?<+[N1EU_5:ZX;]SH)5PM,M6WW%00DH9.(5)4\!?1.>2
MUTG_RY/>T6!UI7!E?9O>N^].L%_&</8[4$L#!!0    (  $^=U;G;$6J+@8
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M? ]_D20LHJH3JN[&I6+8F6'O@_%BAW\W?F___DM'J1^+'R;SO&SP>/#*?QU
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M2P$"% ,4    "  !/G=6W4Z5A3D0  "B\P  %0              @ %<$@
M8V=T>"TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @  3YW5K#YKPC[+@
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M2P$"% ,4    "  !/G=6QJD-<7&1  "NG   &               @ $9\@4
M8V=T>"TR,#(R,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @  3YW5I:WIE2^
M/@$ S5@! !@              ( !P(,& &-G='@M,C R,C$R,S%X,3!K,# S
M+FIP9U!+ 0(4 Q0    (  $^=U8Y R!DF>L  ,'W   8              "
M ;3"!P!C9W1X+3(P,C(Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    "  !/G=6
MZLT:7_D8 0 *)0$ &               @ &#K@@ 8V=T>"TR,#(R,3(S,7@Q
M,&LP,#4N:G!G4$L! A0#%     @  3YW5L& &$:1CP  &K<  !@
M     ( !LL<) &-G='@M,C R,C$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    (
M  $^=U9G*Q*R^)   &JC   8              "  7E7"@!C9W1X+3(P,C(Q
M,C,Q>#$P:S P-RYJ<&=02P$"% ,4    "  !/G=69#7\U /P  #2%P$ &
M            @ &GZ H 8V=T>"TR,#(R,3(S,7@Q,&LP,#@N:G!G4$L! A0#
M%     @  3YW5L4%4U-6.@$ $F0! !@              ( !X-@+ &-G='@M
M,C R,C$R,S%X,3!K,# Y+FIP9U!+ 0(4 Q0    (  $^=U8XY+*1:V   #)[
M   8              "  6P3#0!C9W1X+3(P,C(Q,C,Q>#$P:S Q,"YJ<&=0
M2P$"% ,4    "  !/G=6.TY&7".>  #5I@  &               @ $-= T
M8V=T>"TR,#(R,3(S,7@Q,&LP,3$N:G!G4$L! A0#%     @  3YW5NZC[RY*
MJ0$ 6;@! !@              ( !9A(. &-G='@M,C R,C$R,S%X,3!K,#$R
M+FIP9U!+ 0(4 Q0    (  $^=U;4? L'=U0  (]9   8              "
M >:[#P!C9W1X+3(P,C(Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4    "  !/G=6
M9>Q_7A:-  #XL   &               @ &3$!  8V=T>"TR,#(R,3(S,7@Q
M,&LP,30N:G!G4$L! A0#%     @  3YW5A]1^*3A_P  NA ! !@
M     ( !WYT0 &-G='@M,C R,C$R,S%X,3!K,#$U+FIP9U!+ 0(4 Q0    (
M  $^=U;?3W$VX8L! /_( 0 8              "  ?:=$0!C9W1X+3(P,C(Q
M,C,Q>#$P:S Q-BYJ<&=02P$"% ,4    "  !/G=6&T66<LKJ  #)^   &
M            @ $-*A, 8V=T>"TR,#(R,3(S,7@Q,&LP,3<N:G!G4$L! A0#
M%     @  3YW5JE+7;'KQ   T=H  !@              ( !#144 &-G='@M
M,C R,C$R,S%X,3!K,#$X+FIP9U!+ 0(4 Q0    (  $^=U:FOX<?<:L  #:S
M   8              "  2[:% !C9W1X+3(P,C(Q,C,Q>#$P:S Q.2YJ<&=0
M2P$"% ,4    "  !/G=6I'(ZU!$( 0#@-0$ &               @ '5A14
M8V=T>"TR,#(R,3(S,7@Q,&LP,C N:G!G4$L! A0#%     @  3YW5OLPV!H3
M!   JA8  !@              ( !'(X6 &-G='@M,C R,C$R,S%X97@R,60Q
M+FAT;5!+ 0(4 Q0    (  $^=U9H-"&"A 0  !05   8              "
M 662%@!C9W1X+3(P,C(Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    "  !/G=6
M4Y.X*($)  ""0P  &               @ $?EQ8 8V=T>"TR,#(R,3(S,7AE
M>#,Q9#$N:'1M4$L! A0#%     @  3YW5N)M^]@\"0  8$(  !@
M     ( !UJ 6 &-G='@M,C R,C$R,S%X97@S,60R+FAT;5!+ 0(4 Q0    (
M  $^=U;G;$6J+@8  *0>   8              "  4BJ%@!C9W1X+3(P,C(Q
M,C,Q>&5X,S)D,2YH=&U02P$"% ,4    "  !/G=6428,+3T&  "-(   &
M            @ &LL!8 8V=T>"TR,#(R,3(S,7AE>#,R9#(N:'1M4$L%!@
0   @ "  J@@  !^W%@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
